PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Montzka, SA; Spivakovsky, CM; Butler, JH; Elkins, JW; Lock, LT; Mondeel, DJ				Montzka, SA; Spivakovsky, CM; Butler, JH; Elkins, JW; Lock, LT; Mondeel, DJ			New observational constraints for atmospheric hydroxyl on global and hemispheric scales	SCIENCE			English	Article							METHYL CHLOROFORM; TROPOSPHERIC OH; HYDROCARBONS; HALOCARBONS; ABUNDANCE; EMISSIONS; LIFETIME; CH3CCL3; OZONE	Dramatic declines in emissions of methyl chloroform (1,1,1 -trichloroethane) resulting from the Montreal Protocol provide an unprecedented opportunity to improve our understanding of the oxidizing power of Earth's atmosphere. Atmospheric observations of this industrial gas during the late 1990s yield new insights into the global burden and distribution of the hydroxyl radical. Our results set firm upper limits on the global and Southern Hemispheric lifetimes of methyl chloroform and confirm the predominance of hydroxyl in the tropics. Our analysis suggests a global lifetime for methyl chloroform of 5.2 (+0.2, -0.3) years, a Southern Hemispheric Lifetime of 4.9 (+0.2, -0.3) years, and mean annual concentrations of OH that are 15 +/- 10% higher south of the intertropical convergence zone than those north of this natural mixing boundary between the hemispheres.	NOAA, Climate Monitoring & Diagnost Lab, Boulder, CO 80303 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80303 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Harvard University; Harvard University; University of Colorado System; University of Colorado Boulder	Montzka, SA (corresponding author), NOAA, Climate Monitoring & Diagnost Lab, 325 Broadway, Boulder, CO 80303 USA.		montzka, stephen/V-6162-2019	montzka, stephen/0000-0002-9396-0400				BUTLER JH, 1991, J GEOPHYS RES-ATMOS, V96, P22347, DOI 10.1029/91JD02126; Gupta ML, 1998, J GEOPHYS RES-ATMOS, V103, P28219, DOI 10.1029/98JD02645; Houweling S, 1998, J GEOPHYS RES-ATMOS, V103, P10673, DOI 10.1029/97JD03582; Jockel P, 1999, J GEOPHYS RES-ATMOS, V104, P11733, DOI 10.1029/1999JD900061; LEVY H, 1971, SCIENCE, V173, P141, DOI 10.1126/science.173.3992.141; LOVELOCK JE, 1977, NATURE, V267, P32, DOI 10.1038/267032a0; MIDGLEY PM, 1995, ATMOS ENVIRON, V29, P1601, DOI 10.1016/1352-2310(95)00078-D; Miller BR, 1998, J GEOPHYS RES-ATMOS, V103, P13237, DOI 10.1029/98JD00771; Montzka SA, 1999, NATURE, V398, P690, DOI 10.1038/19499; Montzka SA, 1996, SCIENCE, V272, P1318, DOI 10.1126/science.272.5266.1318; PRINN R, 1992, J GEOPHYS RES-ATMOS, V97, P2445, DOI 10.1029/91JD02755; PRINN RG, 1995, SCIENCE, V269, P187, DOI 10.1126/science.269.5221.187; RAVISHANKARA AR, 1995, SCIENCE, V269, P183, DOI 10.1126/science.269.5221.183; RUDOLPH J, 1995, J ATMOS CHEM, V22, P67, DOI 10.1007/BF00708182; RUDOLPH J, COMMUNICATION; SINGH HB, 1977, GEOPHYS RES LETT, V4, P453, DOI 10.1029/GL004i010p00453; Spivakovsky CM, 2000, J GEOPHYS RES-ATMOS, V105, P8931, DOI 10.1029/1999JD901006; SPIVAKOVSKY CM, 1990, J GEOPHYS RES-ATMOS, V95, P18441, DOI 10.1029/JD095iD11p18441; TIE X, 1992, J GEOPHYS RES-ATMOS, V97, P20751, DOI 10.1029/92JD02085; *UN ENV PROGR, 1999, PROD CONS OZ DEPL SU; Wang YH, 1998, J GEOPHYS RES-ATMOS, V103, P10757, DOI 10.1029/98JD00156; WEINSTOCK B, 1972, SCIENCE, V176, P290, DOI 10.1126/science.176.4032.290; *WORLD MET ORG, 1999, 44 WORLD MET ORG, pCH1; YVONLEWIS SA, 1997, EOS, V78, pF93	24	111	112	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					500	503		10.1126/science.288.5465.500	http://dx.doi.org/10.1126/science.288.5465.500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775106				2022-12-28	WOS:000086626000041
J	Omer, AD; Lowe, TM; Russell, AG; Ebhardt, H; Eddy, SR; Dennis, PP				Omer, AD; Lowe, TM; Russell, AG; Ebhardt, H; Eddy, SR; Dennis, PP			Homologs of small nucleolar RNAs in archaea	SCIENCE			English	Article							ARCHAEBACTERIUM SULFOLOBUS-ACIDOCALDARIUS; EUKARYOTIC RIBOSOMAL-RNA; PRERIBOSOMAL RNA; GUIDE SNORNAS; METHYLATION; SOLFATARICUS; SEQUENCES; PROTEIN; 16S; IDENTIFICATION	In eukaryotes, dozens of posttranscriptional modifications are directed to specific nucleotides in ribosomal RNAs (rRNAs) by small nucleolar RNAs (snoRNAs). We identified homologs of snoRNA genes in both branches of the Archaea. Eighteen small sno-like RNAs (sRNAs) were cloned from the archaeon Sulfolobus acidocaldarius by coimmunoprecipitation with archaeal fibrillarin and NOP56, the homologs of eukaryotic snoRNA-associated proteins. We trained a probabilistic model on these sRNAs to search for more sRNAs in archaeal genomic sequences. Over 200 additional sRNAs were identified in seven archaeal genomes representing both the Crenarchaeota and the Euryarchaeota, snoRNA-based rRNA processing was therefore probably present in, the Last common ancestor of Archaea and Eukarya, predating the evolution of a morphologically distinct nucleolus.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	University of British Columbia; Washington University (WUSTL)	Dennis, PP (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Omer, Arina/AAS-7960-2021; Lowe, Todd Michael/ABJ-5261-2022	Eddy, Sean/0000-0001-6676-4706	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001363] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01363] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMIRI KA, 1994, J BACTERIOL, V176, P2124, DOI 10.1128/jb.176.7.2124-2127.1994; Armbruster DW, 1997, J BIOL CHEM, V272, P19758, DOI 10.1074/jbc.272.32.19758; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BousquetAntonelli C, 1997, EMBO J, V16, P4770, DOI 10.1093/emboj/16.15.4770; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Chamberlain JR, 1998, GENE DEV, V12, P1678, DOI 10.1101/gad.12.11.1678; DAMS E, 1983, NUCLEIC ACIDS RES, V11, P4667, DOI 10.1093/nar/11.14.4667; DANIELS CJ, COMMUNICATION; DUROVIC P, 1994, MOL MICROBIOL, V13, P229, DOI 10.1111/j.1365-2958.1994.tb00418.x; DUROVIC P, 1994, J BACTERIOL, V176, P514, DOI 10.1128/JB.176.2.514-517.1994; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GUPTA R, 1984, J BIOL CHEM, V259, P9461; Kiss-Laszlo Z, 1998, EMBO J, V17, P797, DOI 10.1093/emboj/17.3.797; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Michot B, 1999, NUCLEIC ACIDS RES, V27, P2271, DOI 10.1093/nar/27.11.2271; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Noon KR, 1998, J BACTERIOL, V180, P2883, DOI 10.1128/JB.180.11.2883-2888.1998; OLSEN GJ, 1985, J MOL EVOL, V22, P301, DOI 10.1007/BF02115685; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; STAHL DA, 1981, NUCLEIC ACIDS RES, V9, P6129, DOI 10.1093/nar/9.22.6129; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453	34	264	277	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					517	522		10.1126/science.288.5465.517	http://dx.doi.org/10.1126/science.288.5465.517			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775111				2022-12-28	WOS:000086626000046
J	Georges, B; Beguin, C; Jadoul, M				Georges, B; Beguin, C; Jadoul, M			Spironolactone and congestive heart-failure	LANCET			English	Letter									Catholic Univ Louvain, Clin Univ St Luc, Dept Nephrol, B-1200 Brussels, Belgium; Catholic Univ Louvain, Clin Univ St Luc, Dept Med Informat, B-1200 Brussels, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Georges, B (corresponding author), Catholic Univ Louvain, Clin Univ St Luc, Dept Nephrol, B-1200 Brussels, Belgium.		Jadoul, Michel/B-8779-2008					Ghali WA, 2000, LANCET, V355, P579, DOI 10.1016/S0140-6736(05)73234-7; Pitt B, 1996, AM J CARDIOL, V78, P902; Pitt B, 1995, EUR HEART J, V16, P107, DOI 10.1093/eurheartj/16.suppl_N.107; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Stolear JC, 1999, NEPHROL DIAL TRANSPL, V14, P1961, DOI 10.1093/ndt/14.8.1961	5	14	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2000	355	9212					1369	1370		10.1016/S0140-6736(05)72606-4	http://dx.doi.org/10.1016/S0140-6736(05)72606-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776778				2022-12-28	WOS:000086829400060
J	Venning, P; Durie, A; Roland, M; Roberts, C; Leese, B				Venning, P; Durie, A; Roland, M; Roberts, C; Leese, B			Randomised controlled trial comparing cost effectiveness of general practitioners and nurse practitioners in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OUTCOME MEASURE; QUESTIONNAIRE; SATISFACTION	Objective To compare the cost effectiveness of general practitioners and nurse practitioners as first point of contact in primary care. Design Multicentre randomised controlled trial of patients requesting an appointment the same day. Setting 20 general practices in England and Wales. Participants 1716 patients were eligible for randomisation, of whom 1316 agreed to randomisation and 1303 subsequently attended the clinic. Data were available for analysis on 1292 patients (651 general practitioner consultations and 641 nurse practitioner consultations). Main outcome measures Consultation process (length of consultation, examinations, prescriptions, referrals), patient satisfaction, health status, return clinic visits over two weeks, and costs. Results Nurse practitioner consultations were significantly longer than those of the general practitioners (11.57 v 7.28 min; adjusted difference 4.20, 95% confidence interval 2.98 to 5.41), and nurses carried out more tests (8.7% v 5.6% of patients; odds ratio 1.66, 95% confidence interval 1.04 to 2.66) and asked patients to return more often (31.2% v 24.8%; 1.93, 1.36 to 2.73). There was no significant difference in patterns of prescribing or health status outcome for the two groups. Patients were more satisfied with nurse practitioner consultations (mean score 4.40 v 4.24 for general practitioners; adjusted difference 0.18, 0.092 to 0.257). This difference remained after consultation length was controlled for, There was no significant difference in health service costs (nurse practitioner pound 18.11 v general practitioner pound 20.70; adjusted difference pound 2.33, -pound 1.62 to pound 6.28). Conclusions The clinical care and health service costs of nurse practitioners and general practitioners were similar. Lf nurse practitioners were able to maintain the benefits while reducing their return consultation rate or shortening consultation times, they could be more cost effective than general practitioners.	Univ Manchester, Sch Primary Care, Rusholme Hlth Ctr, Manchester, Lancs, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ Manchester, Sch Epidemiol & Hlth Sci, Hlth Care Trials Unit, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester; University of Manchester	Venning, P (corresponding author), 12 Kingston Rd, Manchester M20 2RZ, Lancs, England.	pamelavenning@gofree.co.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Brown SA, 1995, NURS RES, V44, P332; DIERS D, 1986, NURS RES, V35, P310; Howie JGR, 1998, FAM PRACT, V15, P165, DOI 10.1093/fampra/15.2.165; Landgraf JM, 1998, QUAL LIFE RES, V7, P433, DOI 10.1023/A:1008810004694; LEWIS CC, 1986, MED CARE, V24, P209, DOI 10.1097/00005650-198603000-00003; Mayes M, 1996, Nurs Stand, V10, P34; McKinley RK, 1997, BMJ-BRIT MED J, V314, P190, DOI 10.1136/bmj.314.7075.190; Netten A., 1998, READY RECKONER STAFF; *NHS EX, 1996, NURS PRACT EV PROJ F; *OFF TECHN ASS, 1986, OTAHCS37; Reveley S, 1998, J ADV NURS, V28, P584, DOI 10.1046/j.1365-2648.1998.00685.x; RICHARDSON G, 1995, FEWER DOCTORS MORE N; ROBERTS C, IN PRESS STAT MED; *ROYAL COLL NURS, 1989, NURS PRACT PRIM HLTH; *S THAM REG HLTH A, 1994, EV NURS PRACT PIL PR; SPITZER WO, 1974, NEW ENGL J MED, V290, P251, DOI 10.1056/NEJM197401312900506; *STAT CORP, 1997, STAT STAT SOFTW REL; *U NEWC UP TYN CTR, 1998, EV NURS PRACT GEN PR; Ware JE, 1993, SF36 HLTH SURVEY MAN; Wolf M H, 1978, J Behav Med, V1, P391, DOI 10.1007/BF00846695; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	23	275	278	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 15	2000	320	7241					1048	1053		10.1136/bmj.320.7241.1048	http://dx.doi.org/10.1136/bmj.320.7241.1048			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	307VW	10764367	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086675700026
J	Willems, PJ				Willems, PJ			Mechanism of disease: Genetic causes of hearing loss.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MYOSIN-VIIA GENE; SYNDROMIC RECESSIVE DEAFNESS; PENDRED-SYNDROME; NONSYNDROMIC DEAFNESS; SENSORINEURAL DEAFNESS; MUTATIONS; IMPAIRMENT; EXPRESSION; EAR; LOCALIZATION		Erasmus Univ, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands; Univ Antwerp, Dept Biochem Physiol & Genet, B-2020 Antwerp, Belgium	Erasmus University Rotterdam; University of Antwerp	Willems, PJ (corresponding author), Erasmus Univ, Dept Clin Genet, Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.							Bruzzone R, 1996, BIOESSAYS, V18, P709, DOI 10.1002/bies.950180906; Casano RAMS, 1999, AM J OTOLARYNG, V20, P151, DOI 10.1016/S0196-0709(99)90062-5; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; COUCKE P, 1994, NEW ENGL J MED, V331, P425, DOI 10.1056/NEJM199408183310702; Coucke PJ, 1999, HUM MOL GENET, V8, P1321, DOI 10.1093/hmg/8.7.1321; Coyle B, 1998, HUM MOL GENET, V7, P1105, DOI 10.1093/hmg/7.7.1105; Davis A., 1993, J AUDIOL MED, V3, P35; DAVIS AC, 1989, INT J EPIDEMIOL, V18, P911, DOI 10.1093/ije/18.4.911; deKok YJM, 1996, HUM MOL GENET, V5, P1229, DOI 10.1093/hmg/5.9.1229; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; FISCHELGHODSIAN N, 1995, AM J OTOLARYNG, V16, P403, DOI 10.1016/0196-0709(95)90078-0; FISCHELGHODSIAN N, 1993, AM J OTOLARYNG, V14, P399, DOI 10.1016/0196-0709(93)90113-L; Fransen E, 1999, HUM MOL GENET, V8, P1425, DOI 10.1093/hmg/8.8.1425; Fraser G. R, 1976, BIG 4 CAUSES POVERTY; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GORLIN RJ, 1995, OXFORD MONOGRAPHS ME, V28, P337; Greinwald JH, 1998, AM J MED GENET, V78, P107, DOI 10.1002/(SICI)1096-8628(19980630)78:2<107::AID-AJMG2>3.3.CO;2-9; Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868; Hasson T, 1997, CELL MOTIL CYTOSKEL, V37, P127, DOI 10.1002/(SICI)1097-0169(1997)37:2<127::AID-CM5>3.0.CO;2-5; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; Huizing E H, 1966, Acta Otolaryngol, V61, P35, DOI 10.3109/00016486609127040; Jacobs HT, 1997, ANN MED, V29, P483, DOI 10.3109/07853899709007472; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; KHETARPAL U, 1991, ARCH OTOLARYNGOL, V117, P1032; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Manolis EN, 1996, HUM MOL GENET, V5, P1047, DOI 10.1093/hmg/5.7.1047; MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504; MARKIN VS, 1995, ANNU REV BIOPH BIOM, V24, P59, DOI 10.1146/annurev.bb.24.060195.000423; Martini A., 1996, GENETICS HEARING IMP; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Morell RJ, 1998, NEW ENGL J MED, V339, P1500, DOI 10.1056/NEJM199811193392103; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Nobili R, 1998, TRENDS NEUROSCI, V21, P159, DOI 10.1016/S0166-2236(97)01192-2; PARVING A., 1995, J AUDIOL MED, V4, P2; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Phelps PD, 1998, CLIN RADIOL, V53, P268, DOI 10.1016/S0009-9260(98)80125-6; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; Reardon W, 1996, J MED GENET, V33, P1037, DOI 10.1136/jmg.33.12.1037; REARDON W, 1995, J AUDIOL MED, V4, P40; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Robertson NG, 1998, NAT GENET, V20, P299, DOI 10.1038/3118; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; Sevior KB, 1998, AM J MED GENET, V75, P179, DOI 10.1002/(SICI)1096-8628(19980113)75:2<179::AID-AJMG11>3.3.CO;2-1; Skvorak AB, 1999, HUM MOL GENET, V8, P439, DOI 10.1093/hmg/8.3.439; Steel KP, 1995, ANNU REV GENET, V29, P675; Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905; Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x; Tong KA, 1997, AM J ROENTGENOL, V168, P1097, DOI 10.2214/ajr.168.4.9124122; Usami S, 1999, HUM GENET, V104, P188, DOI 10.1007/s004390050933; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; Van Hauwe P, 1998, HUM MOL GENET, V7, P1099, DOI 10.1093/hmg/7.7.1099; Van Laer L, 1998, NAT GENET, V20, P194; VanCamp G, 1997, AM J HUM GENET, V60, P758; VANCAMP G, 1995, HUM MOL GENET, V4, P2159; VANCAMP G, 1998, J AUDIOL MED, V7, P120; Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; Verhoeven K, 1999, NAT GENET, V21, P449; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Xia JH, 1999, NAT GENET, V21, P241, DOI 10.1038/6067; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	80	110	121	2	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1101	1109		10.1056/NEJM200004133421506	http://dx.doi.org/10.1056/NEJM200004133421506			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10760311				2022-12-28	WOS:000086406700006
J	Straus, SE; McAlister, FA; Sackett, DL; Deeks, JJ				Straus, SE; McAlister, FA; Sackett, DL; Deeks, JJ		CARE-COAD1 Grp	The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL EXAMINATION; RESEARCH NETWORKS	Context The accuracy of the clinical examination in detecting obstructive airway disease (OAD) is largely unknown because of a paucity of methodologically rigorous studies. Objective To determine the accuracy of patient history, wheezing, laryngeal height, and laryngeal descent in the diagnosis of OAD. Design Comparison study conducted from November 3, 1998, to December 4, 1998, evaluating 4 clinical examination elements for diagnosis of OAD vs the gold standard of forced expiratory volume in 1 second (FEV1) and FEV1-forced vital capacity (FVC) ratio less than the fifth percentile (adjusted for patient height, age, and sex). Setting Twenty-five sites, including primary care and referral practices, in 14 countries. Participants A total of 309 consecutive patients were recruited (mean age, 56 years; 43% female), 76 (25%) with known chronic OAD, 1 14 (37%) with suspected chronic OAD, and 119 (39%) with neither known nor suspected OAD. Main Outcome Measures Sensitivity, specificity, and likelihood ratios (LRs) for each of the 4 elements of the clinical examination compared with the gold standard. Results Mean FEV1 and FVC values were 2.1 L/s and 2.9 L; 52% had an FEV1 and FEV1-FVC ratio less than the fifth percentile. The LR for wheezing was 2.7 (95% confidence interval [CI], 1.7-4.2) and was not statistically significant in the multivariate model. The LR for laryngeal descent ranged from 0.9 (95% CI, 0.5-1.4) to 1.2 (95% CI, 0.4-3.4), depending on the cut point chosen, and did not enter the multivariate model. Only 4 of the history or physical examination elements we tested were significantly associated with the diagnosis of OAD on multivariate analysis: smoking for more than 40 pack-years (LR, 8.3), self-reported history of chron ic OAD (LR, 7.3), maximum laryngeal height of at least 4 cm (LR, 2.8), and age at least 45 years (LR, 1.3). Patients having all 4 findings had an LR of 220 (ruling in OAD); those with none had an LK of 0.13 (ruling out OAD). The area under the receiver operating characteristic curve for the model incorporating these 4 factors was 0.86. Conclusions Further research is needed to validate our model, but in the meantime, our data suggest that less emphasis should be placed on the presence of individual symptoms or signs (such as wheezing or laryngeal descent) in the diagnosis of OAD.	Ctr Evidence Based Med, Nuffield Dept Med, Oxford, England; Univ Hlth Network, Mt Sinai Hosp, Div Gen Internal Med, Toronto, ON, Canada; Univ Alberta, Div Gen Internal Med, Edmonton, AB, Canada; Imperial Canc Res Fund, Natl Hlth Serv, Ctr Stat Med, Inst Hlth Sci, Oxford, England	University of Oxford; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto; University of Alberta; NHS Blood & Transplant (NHSBT); University of Oxford	McAlister, FA (corresponding author), Univ Alberta Hosp, Div Gen Internal Med, Walter Mackenzie Ctr 2E3 24, 8440 112 St, Edmonton, AB T6G 2R7, Canada.	Finlay.McAlister@ualberta.ca	McAlister, Finlay/C-4151-2013; Deeks, Jon/AAV-5745-2020	McAlister, Finlay/0000-0001-7435-3341; Deeks, Jon/0000-0002-8850-1971				[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; CAMPBELL EJ, 1969, THORAX, V24, P1, DOI 10.1136/thx.24.1.1; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; FEINSTEIN AR, 1977, CLIN PHARMACOL THER, V21, P482; GODFREY S, 1969, THORAX, V24, P4, DOI 10.1136/thx.24.1.4; GREEN LA, 1994, J FAM PRACTICE, V38, P400; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P63, DOI 10.1007/BF02599985; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; McAlister FA, 1999, LANCET, V354, P1721, DOI 10.1016/S0140-6736(99)01174-5; Nutting PA, 1996, J FAM PRACTICE, V42, P199; SACKETT DL, 1997, EVIDENCE BASED MED; Sapira JD, 1990, ART SCI BEDSIDE DIAG; Simel DL, 1997, JAMA-J AM MED ASSOC, V277, P572, DOI 10.1001/jama.277.7.572; SPIEGELHALTER DJ, 1984, J R STAT SOC A STAT, V147, P35, DOI 10.2307/2981737; *STATC, 1997, STATA STAT SOFTW REL; STUBBING DG, 1982, AM REV RESPIR DIS, V125, P549, DOI 10.1164/arrd.1982.125.5.549	18	64	65	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1853	1857		10.1001/jama.283.14.1853	http://dx.doi.org/10.1001/jama.283.14.1853			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770147	Bronze			2022-12-28	WOS:000086248600031
J	Young, RK				Young, RK			The old man's friend	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1793	1794		10.1001/jama.283.14.1793	http://dx.doi.org/10.1001/jama.283.14.1793			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770128				2022-12-28	WOS:000086248600001
J	Agalarov, SC; Prasad, GS; Funke, PM; Stout, CD; Williamson, JR				Agalarov, SC; Prasad, GS; Funke, PM; Stout, CD; Williamson, JR			Structure of the S15,S18-rRNA complex: Assembly of the 30S ribosome central domain	SCIENCE			English	Article							ESCHERICHIA-COLI; PROTEIN S15; THERMUS-THERMOPHILUS; RIBONUCLEOPROTEIN PARTICLE; BINDING-SITE; RNA; 16S; SUBUNIT; S6	The crystal structure of a 70-kilodalton ribonucleoprotein complex from the central domain of the Thermus thermophilus 30S ribosomal subunit was solved at 2.6 angstrom resolution. The complex consists of a 104-nucleotide RNA fragment composed of two three-helix junctions that Lie at the end of a central helix, and the ribosomal proteins S15, S6, and S18. S15 binds the ribosomal RNA early in the assembly of the 30S ribosomal subunit, stabilizing a conformational reorganization of the two three-helix junctions that creates the RNA fold necessary for subsequent binding of S6 and S18. The structure of the complex demonstrates the central role of S15-induced reorganization of central domain RNA for the subsequent steps of ribosome assembly.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Russian Acad Sci, Inst Prot Res, Pushchino 142292, Russia; MIT, Dept Chem, Cambridge, MA 02139 USA	Scripps Research Institute; Scripps Research Institute; Russian Academy of Sciences; Massachusetts Institute of Technology (MIT)	Stout, CD (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.		Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009; Agalarov, Sultan/L-1969-2015	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X; Agalarov, Sultan/0000-0002-2567-447X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053757, R01GM053757] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53757] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGALAROV AS, UNPUB; Agalarov SC, 2000, RNA, V6, P402, DOI 10.1017/S1355838200991945; Agalarov SC, 1998, P NATL ACAD SCI USA, V95, P999, DOI 10.1073/pnas.95.3.999; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Batey RT, 1996, J MOL BIOL, V261, P550, DOI 10.1006/jmbi.1996.0482; Batey RT, 1998, RNA, V4, P984, DOI 10.1017/S1355838298980426; Batey RT, 1996, J MOL BIOL, V261, P536, DOI 10.1006/jmbi.1996.0481; Berglund H, 1997, NAT STRUCT BIOL, V4, P20, DOI 10.1038/nsb0197-20; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPEL MS, 1988, J MOL BIOL, V200, P65, DOI 10.1016/0022-2836(88)90334-8; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Clemons WM, 1998, STRUCT FOLD DES, V6, P429, DOI 10.1016/S0969-2126(98)00045-8; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; GREGORY RJ, 1984, J MOL BIOL, V178, P287, DOI 10.1016/0022-2836(84)90145-1; GUTELL RR, 1994, NUCLEIC ACIDS RES, V22, P3502, DOI 10.1093/nar/22.17.3502; HELD WA, 1974, J BIOL CHEM, V249, P3103; LESLIE AGW, 1994, ACTA CRYSTALLOGR D, V50, P760; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; Orr JW, 1998, J MOL BIOL, V275, P453, DOI 10.1006/jmbi.1997.1489; OTWINOWSKI Z, 1994, ACTA CRYSTALLOGR D, V50, P760; Otzen DE, 1999, BIOCHEMISTRY-US, V38, P6499, DOI 10.1021/bi982819j; POWERS T, 1995, RNA, V1, P194; SAMAHA RR, 1994, P NATL ACAD SCI USA, V91, P7884, DOI 10.1073/pnas.91.17.7884; Serganov AA, 1996, RNA, V2, P1124; SVENSSON P, 1988, J MOL BIOL, V200, P301, DOI 10.1016/0022-2836(88)90242-2; Tocilj A, 1999, P NATL ACAD SCI USA, V96, P14252, DOI 10.1073/pnas.96.25.14252; WEITZMANN CJ, 1993, FASEB J, V7, P177, DOI 10.1096/fasebj.7.1.7916699; ZWIEB C, 1992, NUCLEIC ACIDS RES, V20, P4397, DOI 10.1093/nar/20.17.4397	33	177	198	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					107	112		10.1126/science.288.5463.107	http://dx.doi.org/10.1126/science.288.5463.107			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753109				2022-12-28	WOS:000086387700043
J	Friedman, JM				Friedman, JM			Obesity in the new millennium	NATURE			English	Editorial Material							EARLY-ONSET OBESITY; BODY-WEIGHT; FRAMESHIFT MUTATION; LEPTIN LEVELS; OB/OB MICE; HUMANS; GENE; OVERWEIGHT; MC4R	Obesity has increased at ale alarming rate in recent years and is now a worldwide public health problem. In addition to suffering poor health and an increased risk of illnesses such as hypertension and heart disease, obese people are often stigmatized socially. But major advances have now been made in identifying the components of the homeostatic system that regulates body weight, including several of the genes responsible for animal and human obesity. A key element of the physiological system is the hormone leptin, which acts on nerve cells in the brain (and elsewhere) to regulate food intake and body weight. The identification of additional molecules that comprise this homeostatic system will provide further insights into the molecular basis of obesity end possibilities for new treatments.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Friedman, JM (corresponding author), Rockefeller Univ, Box 305,1230 York Ave, New York, NY 10021 USA.		Friedman, Jeffrey M/E-5784-2011					Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; James WPT, 1996, CIBA F SYMP, V201, P1; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RAVUSSIN E, 1995, METABOLISM S3, V9, P12; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; Troiano RP, 1998, PEDIATRICS, V101, P497; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	25	536	583	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					632	634		10.1038/35007504	http://dx.doi.org/10.1038/35007504			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766249	Bronze			2022-12-28	WOS:000086400100062
J	Ledesma, D; Pearce, WH				Ledesma, D; Pearce, WH			Septic (Aspergillus) embolus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Northwestern Univ, Sch Med, Chicago, IL 60611 USA	Northwestern University	Ledesma, D (corresponding author), Northwestern Univ, Sch Med, Chicago, IL 60611 USA.								0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	2000	342	14					1015	1015		10.1056/NEJM200004063421404	http://dx.doi.org/10.1056/NEJM200004063421404			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300JB	10749963				2022-12-28	WOS:000086248900004
J	Schoonjans, K; Auwerx, J				Schoonjans, K; Auwerx, J			Thiazolidinediones: an update	LANCET			English	Article							ACTIVATED RECEPTOR-GAMMA; II DIABETES-MELLITUS; PPAR-GAMMA; INSULIN SENSITIZER; TROGLITAZONE; MICE; ADIPOGENESIS; BINDING; OBESITY; TISSUE	Thiazolidinediones, which are being developed for the treatment of insulin resistance and type 2 diabetes mellitus bind and activate peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates the expression of several genes involved in metabolism. This receptor controls adipocyte differentation, lipid storage, and insulin sensitisation. Besides metabolic activities, thiazolidinediones have effects as diverse as the control of host defence :ell proliferation, and tumorigenesis.	Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,Parc Innovat, F-67404 Illkirch Graffenstaden, France.	auwerx@igbmc.u-strasbg.fr	Auwerx, Johan/ABE-9307-2021	Schoonjans, Kristina/0000-0003-1247-4265; Auwerx, Johan/0000-0002-5065-5393				Al-Salman J, 2000, ANN INTERN MED, V132, P121, DOI 10.7326/0003-4819-132-2-200001180-00006; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Balfour JAB, 1999, DRUGS, V57, P921; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Freid J, 2000, ANN INTERN MED, V132, P164, DOI 10.7326/0003-4819-132-2-200001180-00015; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oakes ND, 1997, METABOLISM, V46, P935, DOI 10.1016/S0026-0495(97)90083-4; Pill J, 1999, METABOLISM, V48, P34, DOI 10.1016/S0026-0495(99)90007-0; Plosker GL, 1999, DRUGS, V57, P409, DOI 10.2165/00003495-199957030-00014; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Shibata T, 1999, EUR J PHARMACOL, V364, P211, DOI 10.1016/S0014-2999(98)00832-2; Shibuya A, 1998, DIABETES CARE, V21, P2140, DOI 10.2337/diacare.21.12.2140; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; Watkins PB, 1998, NEW ENGL J MED, V338, P916, DOI 10.1056/NEJM199803263381314; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a	34	166	173	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					1008	1010		10.1016/S0140-6736(00)90002-3	http://dx.doi.org/10.1016/S0140-6736(00)90002-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768450				2022-12-28	WOS:000086054000041
J	Gershon, D				Gershon, D			Pushing the frontiers of interdisciplinary research: an idea whose time has come	NATURE			English	Article																			0	9	11	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					313	316		10.1038/35005213	http://dx.doi.org/10.1038/35005213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749218				2022-12-28	WOS:000086022200056
J	Hubert-Ferrari, A; Barka, A; Jacques, E; Nalbant, SS; Meyer, B; Armijo, R; Tapponnier, P; King, GCP				Hubert-Ferrari, A; Barka, A; Jacques, E; Nalbant, SS; Meyer, B; Armijo, R; Tapponnier, P; King, GCP			Seismic hazard in the Marmara Sea region following the 17 August 1999 Izmit earthquake	NATURE			English	Article							FAULT; ZONE; CALIFORNIA; GPS	On 17 August 1999, a destructive magnitude 7.4 earthquake occurred 100 km east of Istanbul, near the city of Izmit, on the North Anatolian fault. This 1,600-km-long plate boundary(1,2) slips at an average rate of 2-3 cm yr(-1) (refs 3-5), and historically has been the site of many devastating earthquakes(6,7). This century alone it has ruptured over 900 km of its length(6). Models of earthquake-induced stress change(8) combined with active fault maps(9) had been used to forecast that the epicentral area of the 1999 Izmit event was indeed a likely location for the occurrence of a large earthquake(9,10). Here we show that the 1999 event itself significantly modifies the stress distribution resulting from previous fault interactions(9,10). Our new stress models take into account all events in the region with magnitudes greater than 6 having occurred since 1700 (ref. 7) as well as secular interseismic stress change, constrained by GPS data(11). These models provide a consistent picture of the long term spatio-temporal behaviour of the North Anatolian fault and indicate that two events of magnitude equal to, or greater than, the Izmit earthquake are likely to occur within the next decades beneath the Marmara Sea, south of Istanbul.	Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; ITU, Maden Fak, Jeoloji Bolumu, Istanbul, Turkey; Istanbul Univ, Fac Engn, Dept Geophys, Istanbul, Turkey; Inst Phys Globe Strasbourg, Lab Tecton & Mecan Lithosphere, CNRS, UMR 7578, Paris, France; Observ Sci Terre Strasbourg, CNRS, UMS 830, Strasbourg, France	Princeton University; Istanbul Technical University; Istanbul University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hubert-Ferrari, A (corresponding author), Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA.	ferrari@princeton.edu	Armijo, Rolando/P-5123-2019; Meyer, Bertrand/E-6903-2011; Armijo, Rolando/A-5715-2011; Tapponnier, .Paul E/B-7033-2011; Jacques, Eric/E-6650-2017	Tapponnier, .Paul E/0000-0002-7135-1962; Jacques, Eric/0000-0002-0989-0359; Nalbant, Suleyman Sami/0000-0002-7944-5912; Armijo, Rolando/0000-0002-8258-2862				Ambraseys N.N, 1988, HIST SEISMOGRAMS EAR, P173; AMBRASEYS NN, 1970, TECTONOPHYSICS, V9, P143, DOI 10.1016/0040-1951(70)90014-4; AMBRASEYS NN, 1991, TERRA NOVA, V3, P527, DOI 10.1111/j.1365-3121.1991.tb00188.x; Armijo R, 1999, GEOLOGY, V27, P267, DOI 10.1130/0091-7613(1999)027<0267:WPOTNA>2.3.CO;2; Barka A, 1999, SCIENCE, V285, P1858, DOI 10.1126/science.285.5435.1858; BARKA AA, 1988, TECTONICS, V7, P663, DOI 10.1029/TC007i003p00663; Barka AA, 1992, ANN TECTONICAE, P164; Bowman DD, 1998, J GEOPHYS RES-SOL EA, V103, P24359, DOI 10.1029/98JB00792; DIETERICH J, 1994, J GEOPHYS RES-SOL EA, V99, P2601, DOI 10.1029/93JB02581; Harris RA, 1996, GEOPHYS RES LETT, V23, P229, DOI 10.1029/96GL00015; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24347, DOI 10.1029/98JB01576; HUBERT A, 1998, THESIS D DIDEROT U P; KANAMORI H, 1975, B SEISMOL SOC AM, V65, P1073; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; Nalbant SS, 1998, J GEOPHYS RES-SOL EA, V103, P24469, DOI 10.1029/98JB01491; OKADA Y, 1992, B SEISMOL SOC AM, V82, P1018; Pollitz FF, 1998, GEOPHYS RES LETT, V25, P2233, DOI 10.1029/98GL00645; Reilinger RE, 1997, J GEOPHYS RES-SOL EA, V102, P9983, DOI 10.1029/96JB03736; SEGALL P, 1986, SCIENCE, V233, P1409, DOI 10.1126/science.233.4771.1409; SORNETTE A, 1989, EUROPHYS LETT, V9, P197, DOI 10.1209/0295-5075/9/3/002; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Straub C, 1997, J GEOPHYS RES-SOL EA, V102, P27587, DOI 10.1029/97JB02563; Wittlinger G, 1998, SCIENCE, V282, P74, DOI 10.1126/science.282.5386.74	23	210	218	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					269	273		10.1038/35005054	http://dx.doi.org/10.1038/35005054			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749206	Green Published			2022-12-28	WOS:000086022200044
J	O'Brien, E; Coats, A; Owens, P; Petrie, J; Padfield, PL; Littler, WA; de Swiet, M; Mee, F				O'Brien, E; Coats, A; Owens, P; Petrie, J; Padfield, PL; Littler, WA; de Swiet, M; Mee, F			Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WHITE-COAT HYPERTENSION; SYSTOLIC HYPERTENSION; OLDER PATIENTS; GUIDELINES; POPULATION; MANAGEMENT; PREGNANCY; PREDICTOR		Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland; Royal Brompton Hosp, London SW3 6LY, England; Royal Cornwall Hosp, Dept Cardiol, Truro TR1 3LJ, England; Aberdeen Royal Infirm, Dept Med & Therapeut, Clin Pharmacol Unit, Aberdeen AB9 2ZB, Scotland; Western Gen Hosp, Dept Med Sci, Edinburgh EH4 2XU, Midlothian, Scotland; Queen Elizabeth Hosp, Dept Cardiovasc Med, Birmingham B15 2TH, W Midlands, England; Univ London Imperial Coll Sci Technol & Med, Queen Charlottes & Chelsea Hosp, Sch Med, Inst Obstet & Gynaecol, London W6 0XG, England	Royal Brompton Hospital; Royal Cornwall Hospital; University of Aberdeen; University of Edinburgh; University of Birmingham; Imperial College London	O'Brien, E (corresponding author), Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland.	eobrien@iol.ie	Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				Association for the Advancement of Medical Instrumentation, 1993, ANSI AAMI SP, P40; ATKINS N, 1998, J HYPERTENS S2, V16; Ayman D, 1940, AM J MED SCI, V200, P462; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; ELLOMO G, 1999, JAMA-J AM MED ASSOC, V282, P1447; Fagard, 1997, Blood Press Monit, V2, P315; Glen SK, 1996, LANCET, V348, P654, DOI 10.1016/S0140-6736(96)02303-3; HALLIGAN A, 1993, J HYPERTENS, V11, P869, DOI 10.1097/00004872-199308000-00014; Halligan AWF, 1997, BRIT J OBSTET GYNAEC, V104, P559, DOI 10.1111/j.1471-0528.1997.tb11532.x; Higgins JR, 1997, BRIT J OBSTET GYNAEC, V104, P356, DOI 10.1111/j.1471-0528.1997.tb11468.x; Inden Y, 1998, CLIN CARDIOL, V21, P801, DOI 10.1002/clc.4960211104; Mallion JM, 1999, J HYPERTENS, V17, P585, DOI 10.1097/00004872-199917050-00001; MCLEOD MJ, 1998, BLOOD PRESSURE MEASU; Moser M, 1998, AM J HYPERTENS, V11, p120S, DOI 10.1016/S0895-7061(98)00106-X; Myers MG, 1999, AM J HYPERTENS, V12, P1149, DOI 10.1016/S0895-7061(99)00199-5; O'Brien, 1998, Blood Press Monit, V3, P131; O'Brien, 1998, Blood Press Monit, V3, P205; O'Brien E, 1993, J HYPERTENS, V11, pS43; O'Brien Eoin, 1995, Blood Pressure, V4, P266; OBRIEN E, 1991, J HUM HYPERTENS, V5, P7; OBrien E, 1996, J HUM HYPERTENS, V10, P565; OBRIEN E, 1988, LANCET, V2, P397; OBRIEN E, IN PRESS HDB HYPERTE; Owens P, 1999, HEART, V82, P477, DOI 10.1136/hrt.82.4.477; Owens P, 1999, HYPERTENSION, V34, P267, DOI 10.1161/01.HYP.34.2.267; Owens P, 1998, J HYPERTENS, V16, P1735, DOI 10.1097/00004872-199816120-00005; Owens PE, 1998, J HUM HYPERTENS, V12, P743, DOI 10.1038/sj.jhh.1000721; OWENS PE, 1996, BLOOD PRESS MONIT, V2, P3; Penny JA, 1998, AM J OBSTET GYNECOL, V178, P521, DOI 10.1016/S0002-9378(98)70432-6; Pickering T, 1996, AM J HYPERTENS, V9, P1, DOI 10.1016/0895-7061(95)00341-X; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1994, J HYPERTENS, V12, pS29; Pickering TG., 1991, AMBULATORY MONITORIN; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; STAESSEN J, 1991, J HYPERTENS, V9, pS13; Staessen JA, 1997, JAMA-J AM MED ASSOC, V278, P1065, DOI 10.1001/jama.278.13.1065; Staessen JA, 1999, JAMA-J AM MED ASSOC, V282, P539, DOI 10.1001/jama.282.6.539; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Verdecchia P, 2000, HYPERTENSION, V35, P844, DOI 10.1161/01.HYP.35.3.844; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; White, 1998, Blood Press Monit, V3, P181	43	320	331	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	2000	320	7242					1128	1134		10.1136/bmj.320.7242.1128	http://dx.doi.org/10.1136/bmj.320.7242.1128			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775227	Green Published			2022-12-28	WOS:000086782800024
J	MacNeilage, PF; Davis, BL				MacNeilage, PF; Davis, BL			On the origin of internal structure of word forms	SCIENCE			English	Article							SPEECH	This study shows that a corpus of proto-word forms shares four sequential sound patterns with words of modern languages and the first words of infants. Three of the patterns involve intrasyllabic consonant-vowel (CV) co-occurrence: labial (Lip) consonants with central vowels, coronal (tongue front) consonants with front vowels, and dorsal (tongue back) consonants with back vowels. The fourth pattern is an intersyllabic preference for initiating words with a labial consonant-vowel-coronal consonant sequence (LC). The CV effects may be primarily biomechanically motivated. The LC effect may be self-organizational, with multivariate causality. The findings support the hypothesis that these four patterns were basic to the origin of words.	Univ Texas, Dept Psychol, Austin, TX 78712 USA; Univ Texas, Dept Commun Sci & Disorders, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	MacNeilage, PF (corresponding author), Univ Texas, Dept Psychol, Austin, TX 78712 USA.	macneilage@psy.utexas.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027733] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD 27733-07] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bengtson J. D., 1994, ORIGIN LANGUAGES STU, P277; Boe L.-J., 1999, P 14 INT C PHON SCI, P2501; Boysson-Bardies B.de., 1992, PHONOLOGICAL DEV MOD, P369; CHOMSKY N, 1968, LANGUAGE PROBLEMS KN; Clark A., 1998, BEING THERE PUTTING; DAVIS BD, UNPUB; DAVIS BL, 1995, J SPEECH HEAR RES, V38, P1199, DOI 10.1044/jshr.3806.1199; DAVIS BL, 1999, 20 ANN CHILD PHON C; DEBOYSSONBARDIES B, 1993, NATO ADV SCI INST SE, V69, P353; Dixon R. M. W., 1980, LANGUAGES AUSTR; GILDERSLEEVE C, THESIS U TEXAS; GODDARD I, 1987, CURR ANTHROPOL, V28, P657; Greenberg J. H, 1987, LANGUAGE AM; GREENBERG JH, 1963, LANGUAGES AFRICA; Hockett C.F., 1960, ANIMAL SOUNDS COMMUN, P392; Ingram D., 1974, J CHILD LANG, V1, P49; Janson T., 1986, PHONOLOGY YB, V3, P179, DOI DOI 10.1017/S0952675700000634; KORNHUBER HH, 1987, ENCY NEUROSCIENCE, P1302; Langsdale, 1996, FIRST LANG, V16, P159, DOI 10.1177/014272379601604702; LIEBERMAN PH, 1969, SCIENCE, V164, P1185, DOI 10.1126/science.164.3884.1185; LOCKE JL, 1990, J CHILD LANG, V17, P1, DOI 10.1017/S0305000900013076; LOCKE JL, 1993, PHONOLOGICAL ACQUISI; LOEB GE, 1987, ENCY NEUROSCIENCE, P690; MACKEN M, 1987, LINGUA, V44, P219; MacNeilage PF, 1997, SPEECH COMMUN, V22, P269, DOI 10.1016/S0167-6393(97)00022-8; MacNeilage PF, 1998, BEHAV BRAIN SCI, V21, P499, DOI 10.1017/S0140525X98001265; MacNeilage PF, 1999, PSYCHOL SCI, V10, P459, DOI 10.1111/1467-9280.00187; MacNeilage PF, 2000, CHILD DEV, V71, P153, DOI 10.1111/1467-8624.00129; MACNEILAGE PF, 1993, DEV NEUROCOGNITION S, P123; MACNEILAGE PF, IN PRESS EVOLUTIONAR; Maddieson Ian, 1992, PHONOLOGY, V9.1, P45; MENSTOWICZ M, 1994, PHONOLOGY GEN GRAMMA; Oller DK, 1993, 1 2 LANGUAGE PHONOLO, P45; Ruhlen Merritt, 1994, ORIGIN LANGUAGES STU; TEIXERA E, UNPUB; Vihman M. M, 1992, PHONOLOGICAL DEV MOD, P393	36	194	196	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					527	531		10.1126/science.288.5465.527	http://dx.doi.org/10.1126/science.288.5465.527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	306YJ	10775113				2022-12-28	WOS:000086626000048
J	Fletcher, M				Fletcher, M			Doctors have become more caring than nurses	BRITISH MEDICAL JOURNAL			English	Editorial Material														Fletcher, Monica/0000-0002-9700-3552					0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1083	1083		10.1136/bmj.320.7241.1083	http://dx.doi.org/10.1136/bmj.320.7241.1083			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764388	Green Published			2022-12-28	WOS:000086675700065
J	Gurney, ME; Tomasselli, AG; Heinrikson, RL				Gurney, ME; Tomasselli, AG; Heinrikson, RL			Neurobiology - Stay the executioner's hand	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MITOCHONDRIA; DEGENERATION; MUTATION; MICE; ALS		Pharmacia Corp, Genom, Kalamazoo, MI 49007 USA; Pharmacia Corp, Prot Sci, Kalamazoo, MI 49007 USA	Pfizer; Pfizer	Gurney, ME (corresponding author), Pharmacia Corp, Genom, 301 Henrietta St, Kalamazoo, MI 49007 USA.							Cleveland DW, 1999, NEURON, V24, P515, DOI 10.1016/S0896-6273(00)81108-3; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7	11	13	16	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					283	284		10.1126/science.288.5464.283	http://dx.doi.org/10.1126/science.288.5464.283			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10777410				2022-12-28	WOS:000086454300025
J	McKeganey, N; Norrie, J				McKeganey, N; Norrie, J			Association between illegal drugs and weapon carrying in young people in Scotland: schools' survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SCOTTISH SCHOOLCHILDREN; VIOLENT BEHAVIOR; SAMPLE; ADOLESCENTS; STUDENTS	Objectives To identify the type and extent of weapons being carried among young people in Scotland, and to determine the relation between use of illegal drugs and weapon carrying. Design Questionnaire school survey. Setting Independent schools in central Scotland and schools in Lanarkshire and Perth and Kinross. Participants 3121 students aged 11 to 16 in 20 schools. Main outcome measures Self completion questionnaire reporting history of drug use and weapon carrying. Results Overall, 34.1% of males and 8.6% of females reported having carried a weapon (P < 0.0001), ranging From 29.2% of boys aged 11-13 (classes S1 to S2) to 39.3% of boys aged 13-15 (S3 to S4). These values are higher than those in a recent survey of young people in England. Weapon carrying in Lanarkshire was 70% higher for males than in the rural area of Perth and Kinross. Both males and females who had taken drugs were more likely to carry weapons (63.5% of male drug users versus 20.5%, of non-users and 22.8% of female drug users versus 3.7% of non-users; both P < 0.0001). The proportions of males carrying weapons who used none, one, two, three or four, or five or more illegal drugs were 21%, 52%, 68% 74%, and 92% respectively. A similar trend was found among females. Conclusions Better information is needed on the nature and extent of weapon carrying by young people in the United Kingdom, and better educational campaigns are needed warning of the dangers of carrying weapons.	Univ Glasgow, Ctr Drug Misuse Res, Glasgow G12 8SQ, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	McKeganey, N (corresponding author), Univ Glasgow, Ctr Drug Misuse Res, Glasgow G12 8SQ, Lanark, Scotland.	gkua27@udcf.gla.ac.uk						BALDING J, 1996, CASH CARRY YOUNG PEO; Barnard M, 1996, DRUG-EDUC PREV POLIC, V3, P81, DOI 10.3109/09687639609019313; Barnard M, 1998, ADDICT RES, V6, P421, DOI 10.3109/16066359809026060; DuRant RH, 1997, ARCH PEDIAT ADOL MED, V151, P360, DOI 10.1001/archpedi.1997.02170410034004; Forsyth A, 1998, DRUG-EDUC PREV POLIC, V5, P157, DOI 10.3109/09687639809006681; Friedman AS, 1998, AGGRESS VIOLENT BEH, V3, P339, DOI 10.1016/S1359-1789(97)00012-8; Komro KA, 1998, J CHILD ADOLES SUBST, V8, P77; Lowry R, 1998, AM J PREV MED, V14, P122, DOI 10.1016/S0749-3797(97)00020-2; McKeganey N, 1996, BRIT MED J, V313, P401; McKeganey N, 1999, ADDICT RES, V7, P493, DOI 10.3109/16066359909004402; Presley CA, 1997, J AM COLL HEALTH, V46, P3, DOI 10.1080/07448489709595580; VALOIS RF, 1995, J ADOLESCENT HEALTH, V16, P26, DOI 10.1016/1054-139X(95)94070-O; Wagner EF, 1996, AGGRESS VIOLENT BEH, V1, P375, DOI 10.1016/S1359-1789(96)00008-0	13	30	30	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2000	320	7240					982	984		10.1136/bmj.320.7240.982	http://dx.doi.org/10.1136/bmj.320.7240.982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303XP	10753152	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000086453100024
J	Kennett, JP; Cannariato, KG; Hendy, IL; Behl, RJ				Kennett, JP; Cannariato, KG; Hendy, IL; Behl, RJ			Carbon isotopic evidence for methane hydrate instability during quaternary interstadials	SCIENCE			English	Article							SANTA-BARBARA BASIN; ICE-CORE RECORD; GAS-HYDRATE; CONTINENTAL-MARGIN; CLIMATE-CHANGE; ENVIRONMENTAL-CONTROL; NORTHERN CALIFORNIA; ATMOSPHERIC METHANE; MARINE-SEDIMENTS; SEA	Large (about 5 per mil) millennial-scale benthic foraminiferal carbon isotopic oscillations in the Santa Barbara Basin during the last 60,000 years reflect widespread shoaling of sedimentary methane gradients and increased outgassing from gas hydrate dissociation during interstadials. Furthermore, several Large, brief, negative excursions (up to -6 per mil) coinciding with smaller shifts (up to -3 per mil) in depth-stratified planktonic foraminiferal species indicate massive releases of methane from basin sediments. Gas hydrate stability was modulated by intermediate-water temperature changes induced by switches in thermohaline circulation. These oscillations were Likely widespread along the California margin and elsewhere, affecting gas hydrate instability and contributing to millennial-scale atmospheric methane oscillations.	Univ Calif Santa Barbara, Geol Sci & Marine Sci Inst, Santa Barbara, CA 93106 USA; Calif State Univ Long Beach, Dept Geol Sci, Long Beach, CA 90840 USA	University of California System; University of California Santa Barbara; California State University System; California State University Long Beach	Kennett, JP (corresponding author), Univ Calif Santa Barbara, Geol Sci & Marine Sci Inst, Santa Barbara, CA 93106 USA.		, Ingrid/AAT-1279-2021; Behl, Richard/AAJ-6379-2020	hendy, Ingrid/0000-0001-8305-6752; Behl, Richard/0000-0002-1011-7419				BARNES RO, 1976, GEOLOGY, V4, P297, DOI 10.1130/0091-7613(1976)4<297:MPACIA>2.0.CO;2; Behl RJ, 1996, NATURE, V379, P243, DOI 10.1038/379243a0; Behling H, 1999, J PALEOLIMNOL, V21, P461, DOI 10.1023/A:1008051720473; BERGER WH, 1986, GEOL RUNDSCH, V75, P249, DOI 10.1007/BF01770192; Bernhard JM, 1997, J FORAMIN RES, V27, P301, DOI 10.2113/gsjfr.27.4.301; BONNEFILLE MG, IN PRESS GLOBAL PLAN; Borowski WS, 1996, GEOLOGY, V24, P655, DOI 10.1130/0091-7613(1996)024<0655:MPWSPI>2.3.CO;2; Brewer PG, 1997, GEOLOGY, V25, P407, DOI 10.1130/0091-7613(1997)025<0407:DOFTOM>2.3.CO;2; BREWER PG, 1997, EOS, V78, P340; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; BROOKS JM, 1991, MAR GEOL, V96, P103, DOI 10.1016/0025-3227(91)90204-H; Cannariato KG, 1999, GEOLOGY, V27, P63, DOI 10.1130/0091-7613(1999)027<0063:BRTLQR>2.3.CO;2; Cannariato KG, 1999, GEOLOGY, V27, P975, DOI 10.1130/0091-7613(1999)027<0975:CRMSFI>2.3.CO;2; Chappell J, 1996, EARTH PLANET SC LETT, V141, P227, DOI 10.1016/0012-821X(96)00062-3; CHAPPELLAZ J, 1990, NATURE, V345, P127, DOI 10.1038/345127a0; Cicerone RJ, 1988, GLOBAL BIOGEOCHEM CY, V2, P299, DOI 10.1029/GB002i004p00299; CYNAR FJ, 1992, J GEOPHYS RES-OCEANS, V97, P11269, DOI 10.1029/92JC00865; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; DICKENS GR, 1994, GEOPHYS RES LETT, V21, P2115, DOI 10.1029/94GL01858; Dickens GR, 1997, NATURE, V385, P426, DOI 10.1038/385426a0; Evans D, 1996, MAR GEOL, V130, P281, DOI 10.1016/0025-3227(95)00135-2; FIELD ME, 1985, GEOLOGY, V13, P517, DOI 10.1130/0091-7613(1985)13<517:GHOTNC>2.0.CO;2; GORNITZ V, 1994, GLOBAL BIOGEOCHEM CY, V8, P335, DOI 10.1029/94GB00766; Haq BU, 1998, GEOL SOC SPEC PUBL, V137, P303, DOI 10.1144/GSL.SP.1998.137.01.24; Harms S, 1998, J GEOPHYS RES-OCEANS, V103, P3041, DOI 10.1029/97JC02393; HENDERSCOTT MC, 1999, 5 CAL ISL S 29 MARCH, P21; Hendy IL, 2000, PALEOCEANOGRAPHY, V15, P30, DOI 10.1029/1999PA000413; Hendy IL, 1999, GEOLOGY, V27, P291, DOI 10.1130/0091-7613(1999)027<0291:LQNPSW>2.3.CO;2; HENDY IL, UNPUB; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Katz ME, 1999, SCIENCE, V286, P1531, DOI 10.1126/science.286.5444.1531; Kayen R.E., 1991, MAR GEOTECHNOL, V10, P125, DOI [DOI 10.1080/10641199109379886, 10.1080/10641199109379886]; Kennett J.P., 1983, NEOGENE PLANKTONIC F; KENNETT JP, 1995, NATURE, V377, P510, DOI 10.1038/377510a0; KENNETT JP, IN PRESS OCEAN DRILL, P167; KENNETT JP, 1998, AAPG BULL, V83, P692; KENNETT JP, UNPUB; KENNETT JP, 1994, P OCEAN DRILL PROG 2, V146; KHALIL MAK, 1995, COMPOSITION CHEM CLI, P50; KVENVOLDEN KA, 1988, CHEM GEOL, V71, P41, DOI 10.1016/0009-2541(88)90104-0; Kvenvolden KA, 1995, ORG GEOCHEM, V23, P997, DOI 10.1016/0146-6380(96)00002-2; Kvenvolden KA, 1988, GLOBAL BIOGEOCHEM CY, V2, P221, DOI 10.1029/GB002i003p00221; Ledru MP, 1998, REV PALAEOBOT PALYNO, V99, P131, DOI 10.1016/S0034-6667(97)00049-3; Liu K.B., 1994, TERR ATMOS OCEAN SCI, V5, P393; LONSDALE P, 1985, AAPG BULL, V69, P1160; LORIUS C, 1990, NATURE, V347, P139, DOI 10.1038/347139a0; MACDONALD GT, 1990, ANNU REV ENERG ENV, V15, P5; MACDONALD IR, 1994, GEOLOGY, V22, P699, DOI 10.1130/0091-7613(1994)022<0699:GHTBTS>2.3.CO;2; Maslin M, 1998, GEOLOGY, V26, P1107, DOI 10.1130/0091-7613(1998)026<1107:SLAGHC>2.3.CO;2; MASLIN M, 1998, P OCEAN DRILL PROGRA, V155, P305; McCorkle DC, 1990, PALEOCEANOGRAPHY, V5, P161, DOI 10.1029/PA005i002p00161; MCCORKLE DC, 1988, GEOCHIM COSMOCHIM AC, V52, P1169, DOI 10.1016/0016-7037(88)90270-0; MCCORKLE DC, 1991, GEOCHIM COSMOCHIM AC, V55, P161, DOI 10.1016/0016-7037(91)90408-W; NISBET EG, 1992, J GEOPHYS RES-ATMOS, V97, P12859, DOI 10.1029/92JD00743; Nisbet EG, 1998, NATURE, V392, P329, DOI 10.1038/32765; NISBET EG, 1990, CAN J EARTH SCI, V27, P148, DOI 10.1139/e90-012; Ortiz JD, 1996, GEOCHIM COSMOCHIM AC, V60, P4509, DOI 10.1016/S0016-7037(96)00256-6; ORTIZ JD, 1995, PALEOCEANOGRAPHY, V10, P987, DOI 10.1029/95PA02088; PAK D, 1997, EOS, V78, P359; PAULL CK, 1991, GEOPHYS RES LETT, V18, P432, DOI 10.1029/91GL00351; Paull CK, 1996, GEOLOGY, V24, P143, DOI 10.1130/0091-7613(1996)024<0143:ICMSFD>2.3.CO;2; PRATT LM, 1994, P OCEAN DRILL PROG 2, V146, P213; Raynaud D, 1998, GEOL SOC SPEC PUBL, V137, P327, DOI 10.1144/GSL.SP.1998.137.01.26; Reeburgh W. S., 1993, P1; Rothwell RG, 1998, NATURE, V392, P377, DOI 10.1038/32871; Salgado-Labouriau ML, 1998, REV PALAEOBOT PALYNO, V99, P115, DOI 10.1016/S0034-6667(97)00045-6; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Stauffer B, 1998, NATURE, V392, P59, DOI 10.1038/32133; Van der Zwaan GJ, 1999, EARTH-SCI REV, V46, P213, DOI 10.1016/S0012-8252(99)00011-2; vanGeen A, 1996, PALEOCEANOGRAPHY, V11, P519, DOI 10.1029/96PA01860; WARFORD AL, 1979, GEOMICROBIOL J, V1, P117, DOI 10.1080/01490457909377728; WEFER G, 1994, NATURE, V369, P282, DOI 10.1038/369282a0; WINKLER MG, IN PRESS B AM PALEON; Yun JW, 1999, MAR GEOL, V154, P357, DOI 10.1016/S0025-3227(98)00123-6; Zahn R, 1986, PALEOCEANOGRAPHY, V1, P27, DOI 10.1029/PA001i001p00027; Zhang Y., COMMUNICATION	77	394	451	2	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					128	133		10.1126/science.288.5463.128	http://dx.doi.org/10.1126/science.288.5463.128			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753115				2022-12-28	WOS:000086387700049
J	Shi, YQ; Zhang, C; Zhang, H; Bechtel, JH; Dalton, LR; Robinson, BH; Steier, WH				Shi, YQ; Zhang, C; Zhang, H; Bechtel, JH; Dalton, LR; Robinson, BH; Steier, WH			Low (sub-1-volt) halfwave voltage polymeric electro-optic modulators achieved by controlling chromophore shape	SCIENCE			English	Article							GHZ; HYPERPOLARIZABILITY; DEVICE; LINKS	Electro-optic (EO) modulators encode electrical signals onto fiber optic transmissions. High drive voltages Limit gain and noise levels, Typical polymeric and Lithium niobate modulators operate with halfwave voltages of 5 volts. Sterically modified organic chromophores have been used to reduce the attenuation of electric field poling-induced electro-optic activity caused by strong intermolecular electrostatic interactions, Such modified chromophores, incorporated into polymer hosts, were used to fabricate EO modulators with halfwave voltages of 0.8 volts (at a telecommunications wavelength of 1318 nanometers) and to achieve a halfwave voltage-interaction Length product of 2.2 volt-centimeters. Optical push-pull poling and driving were also used to reduce halfwave voltage. This study, together with recent demonstrations of exceptional bandwidths (more than 110 gigahertz) and ease of integration (with very large scale integration semiconductor circuitry and ultra-law-loss passive optical circuitry) demonstrates the potential of polymeric materials for next generation telecommunications, information processing, and radio frequency distribution.	TACAN Corp, Carlsbad, CA 92008 USA; Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; Univ So Calif, Loker Hydrocarbon Res Inst, Los Angeles, CA 90089 USA; Univ So Calif, Ctr Photon Technol, Dept Elect Engn, Los Angeles, CA 90089 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Southern California; University of Southern California; University of Southern California; University of Washington; University of Washington Seattle	Shi, YQ (corresponding author), TACAN Corp, 2330 Faraday Ave, Carlsbad, CA 92008 USA.							Albert IDL, 1997, J AM CHEM SOC, V119, P6575, DOI 10.1021/ja962968u; Burns WK, 1998, IEEE PHOTONIC TECH L, V10, P805, DOI 10.1109/68.681490; Chen DT, 1997, APPL PHYS LETT, V70, P3335, DOI 10.1063/1.119162; Chen DT, 1999, IEEE PHOTONIC TECH L, V11, P54, DOI 10.1109/68.736388; COX CH, 1990, IEEE T MICROW THEORY, V38, P501, DOI 10.1109/22.54917; Dalton LR, 1999, J MATER CHEM, V9, P1905, DOI 10.1039/a902659b; Dalton LR, 1997, P NATL ACAD SCI USA, V94, P4842, DOI 10.1073/pnas.94.10.4842; ERMER S, IN PRESS P SPIE; FETTERMAN H, 1998, ORGANIC OPTICS OPTOE, P9; Garner SM, 1999, IEEE J QUANTUM ELECT, V35, P1146, DOI 10.1109/3.777214; HAHN KH, 1994, ELECTRON LETT, V30, P1220, DOI 10.1049/el:19940809; JANSON HR, 1978, AEU-ARCH ELEKTRON UB, V32, P485; Kalluri S, 1996, IEEE PHOTONIC TECH L, V8, P644, DOI 10.1109/68.491566; KANIS DR, 1994, CHEM REV, V94, P195, DOI 10.1021/cr00025a007; Lee HM, 1997, APPL PHYS LETT, V71, P3779, DOI 10.1063/1.120541; Liakatas I, 2000, APPL PHYS LETT, V76, P1368, DOI 10.1063/1.126034; MARDER SR, 1994, SCIENCE, V263, P1706, DOI 10.1126/science.263.5154.1706; MARDER SR, 1991, SCIENCE, V252, P103, DOI 10.1126/science.252.5002.103; MARDER SR, 1994, SCIENCE, V265, P632, DOI 10.1126/science.265.5172.632; NALWA HS, 1998, NONLINEAR OPTICS ORG; Noguchi K, 1998, J LIGHTWAVE TECHNOL, V16, P615, DOI 10.1109/50.664072; Park H, 1997, APPL PHYS LETT, V70, P2796, DOI 10.1063/1.119062; Prasad P.N., 1991, INTRO NONLINEAR OPTI; Robinson BH, 1999, CHEM PHYS, V245, P35, DOI 10.1016/S0301-0104(99)00079-8; Shi YQ, 1999, P SOC PHOTO-OPT INS, V3632, P144, DOI 10.1117/12.344602; Shi YQ, 1997, APPL PHYS LETT, V71, P2236, DOI 10.1063/1.120067; Shi YQ, 1996, IEEE J SEL TOP QUANT, V2, P289, DOI 10.1109/2944.577380; SINGER KD, 1987, J OPT SOC AM B, V4, P968, DOI 10.1364/JOSAB.4.000968; Steier WH, 1999, CHEM PHYS, V245, P487, DOI 10.1016/S0301-0104(99)00042-7; STEPHENS WE, 1987, J LIGHTWAVE TECHNOL, V5, P380, DOI 10.1109/JLT.1987.1075509; TENG CC, 1992, APPL PHYS LETT, V60, P1538, DOI 10.1063/1.107482; TENG CC, 1993, APPL OPTICS, V32, P1051, DOI 10.1364/AO.32.001051; TUMOLILLO TA, 1992, IEEE PHOTONIC TECH L, V4, P142, DOI 10.1109/68.122342; Wang WS, 1999, IEEE PHOTONIC TECH L, V11, P51, DOI 10.1109/68.736387; WANG WS, 1995, APPL PHYS LETT, V67, P1806, DOI 10.1063/1.115065; Wise D.L., 1998, ELECT OPTICAL POLYM; ZHANG C, 1999, POLYM PREPR, V40, P49; Zyss J., 1994, MOL NONLINEAR OPTICS	38	942	981	10	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	2000	288	5463					119	122		10.1126/science.288.5463.119	http://dx.doi.org/10.1126/science.288.5463.119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753112				2022-12-28	WOS:000086387700046
J	Bray, GA; Tartaglia, LA				Bray, GA; Tartaglia, LA			Medicinal strategies in the treatment of obesity	NATURE			English	Article							UNCOUPLING PROTEIN HOMOLOG; LEPTIN RECEPTOR; FEEDING-BEHAVIOR; FOOD-INTAKE; BODY-COMPOSITION; CONTROLLED TRIAL; WEIGHT-LOSS; HUMANS; GENE; IDENTIFICATION	When prevention fails, medicinal treatment of obesity may become a necessity Any strategic medicinal development must recognize that obesity is a chronic, stigmatized and costly disease that is increasing in prevalence. Because obesity can rarely be cured, treatment strategies are effective only as long as they are used, and combined therapy may be more effective than monotherapy. For a drug to have significant impact on body weight it must ultimately reduce energy intake, Increase energy expenditure, or both, Currently approved drugs for long-term treatment of obesity include sibutramine, which inhibits food intake, and orlistat, which blocks fat digestion.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Bray, GA (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	BrayGA@pbrc.edu						Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Apfelbaum M, 1999, AM J MED, V106, P179, DOI 10.1016/S0002-9343(98)00411-2; ASTRUP A, 1992, INT J OBESITY, V16, P269; ASTRUP A, 1992, METABOLISM, V41, P686, DOI 10.1016/0026-0495(92)90304-S; ASTRUP A, 1985, AM J CLIN NUTR, V42, P83, DOI 10.1093/ajcn/42.1.83; Barton C, 1996, PEPTIDES, V17, P237, DOI 10.1016/0196-9781(95)02103-5; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bray G, 1998, AM J CLIN NUTR, V67, P1; Bray GA, 1999, OBES RES, V7, P189, DOI 10.1002/j.1550-8528.1999.tb00701.x; Bray GA, 1999, ENDOCR REV, V20, P805, DOI 10.1210/er.20.6.805; BRAY GA, 1998, CURRENT CONT MANAGEM; Bujalska IJ, 1999, ENDOCRINOLOGY, V140, P3188, DOI 10.1210/en.140.7.3188; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cone RD, 1999, TRENDS ENDOCRIN MET, V10, P211, DOI 10.1016/S1043-2760(99)00153-8; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; CONWVATCHED W, 1997, DIABETOLOGIA, V40, pA196; Danforth E, 1997, EUR J ENDOCRINOL, V136, P362, DOI 10.1530/eje.0.1360362; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; ErlansonAlbertsson C, 1997, OBES RES, V5, P360, DOI 10.1002/j.1550-8528.1997.tb00565.x; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flint A, 1998, J CLIN INVEST, V101, P515, DOI 10.1172/JCI990; Gietzen DW, 1998, J NUTR, V128, P771, DOI 10.1093/jn/128.4.771; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Greenway FL, 1995, OBES RES, V3, pS561, DOI 10.1002/j.1550-8528.1995.tb00228.x; Guerciolini R, 1997, INT J OBESITY, V21, pS12; GUTZWILLER JP, 1994, GASTROENTEROLOGY, V106, P1168, DOI 10.1016/0016-5085(94)90006-X; Gutzwiller JP, 1999, AM J PHYSIOL-REG I, V276, pR1541, DOI 10.1152/ajpregu.1999.276.5.R1541; Hansen DL, 1998, AM J CLIN NUTR, V68, P1180, DOI 10.1093/ajcn/68.6.1180; HAUPTMAN JB, 1992, AM J CLIN NUTR, V55, P309; Heinonen P, 1999, J CLIN ENDOCR METAB, V84, P2429, DOI 10.1210/jc.84.7.2429; Heymsfield SB, 1998, JAMA-J AM MED ASSOC, V280, P1596, DOI 10.1001/jama.280.18.1596; HEYMSFIELD SB, J AM MED ASS, V282, P1568; Hill JO, 1999, AM J CLIN NUTR, V69, P1108; Hollander PA, 1998, DIABETES CARE, V21, P1288, DOI 10.2337/diacare.21.8.1288; Holst JJ, 1999, TRENDS ENDOCRIN MET, V10, P229, DOI 10.1016/S1043-2760(99)00157-5; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jequier E, 1999, PHYSIOL REV, V79, P451, DOI 10.1152/physrev.1999.79.2.451; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Karolyi IJ, 1999, P NATL ACAD SCI USA, V96, P11595, DOI 10.1073/pnas.96.20.11595; KIN KR, 1999, HORM RES, V51, P78; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Kurose Y, 1999, BRAIN RES, V828, P115, DOI 10.1016/S0006-8993(99)01339-6; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lembo PMC, 1999, NAT CELL BIOL, V1, P267, DOI 10.1038/12978; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; LOVEJOY JC, 1995, INT J OBESITY, V19, P614; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Mantzoros CS, 1999, ANN INTERN MED, V130, P671, DOI 10.7326/0003-4819-130-8-199904200-00014; MARIN P, 1992, INT J OBESITY, V16, P991; MORLEY JE, 1994, AM J PHYSIOL, V267, pR178, DOI 10.1152/ajpregu.1994.267.1.R178; Nagase H, 1996, PHYSIOL BEHAV, V59, P555, DOI 10.1016/0031-9384(95)02109-4; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; Organization WH, 1998, WELLB MEAS PRIM HLTH; PALMITER RD, 1999, PENNINGTON CTR NUTR, P269; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rokaeus A, 1998, ANN NY ACAD SCI, V863, P1, DOI 10.1111/j.1749-6632.1998.tb10679.x; Rolls BJ, 1998, OBES RES, V6, P1; Rosmond R, 1996, OBES RES, V4, P245, DOI 10.1002/j.1550-8528.1996.tb00542.x; Rothman RB, 1999, CIRCULATION, V100, P869, DOI 10.1161/01.CIR.100.8.869; Ryan DH, 1999, OBES RES, V7, P313, DOI 10.1002/j.1550-8528.1999.tb00414.x; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Sakata T, 1997, NUTRITION, V13, P403, DOI 10.1016/S0899-9007(97)91277-6; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Scharrer E, 1999, NUTRITION, V15, P704, DOI 10.1016/S0899-9007(99)00125-2; Seagle HM, 1998, OBES RES, V6, P115, DOI 10.1002/j.1550-8528.1998.tb00324.x; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; Smeets M, 1999, FASEB J, V13, pA871; Smith BK, 1999, AM J PHYSIOL-REG I, V277, pR802, DOI 10.1152/ajpregu.1999.277.3.R802; SMITH GP, 1998, SATIATION GUT BRAIN, P291; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; SULLIVAN AC, 1974, LIPIDS, V9, P129, DOI 10.1007/BF02532137; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Terry P, 1995, OBES RES, V3, pS515, DOI 10.1002/j.1550-8528.1995.tb00221.x; TOUBRO S, 1993, INT J OBESITY, V17, pS73; Tso P, 1999, J NUTR, V129, P1503, DOI 10.1093/jn/129.8.1503; Vickers SP, 1999, PSYCHOPHARMACOLOGY, V143, P309, DOI 10.1007/s002130050952; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WEATHERFORD SC, 1992, APPETITE, V19, P225, DOI 10.1016/0195-6663(92)90155-Y; Wilson BD, 1999, MOL MED TODAY, V5, P250, DOI 10.1016/S1357-4310(99)01471-9; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zimanyi IA, 1998, CURR PHARM DESIGN, V4, P349; [No title captured]	93	304	321	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					672	677		10.1038/35007544	http://dx.doi.org/10.1038/35007544			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766254				2022-12-28	WOS:000086400100067
J	Lowell, BB; Spiegelman, BM				Lowell, BB; Spiegelman, BM			Towards a molecular understanding of adaptive thermogenesis	NATURE			English	Article							BROWN ADIPOSE-TISSUE; MITOCHONDRIAL UNCOUPLING PROTEIN; RESTING ENERGY-EXPENDITURE; THYROID-HORMONE; METABOLIC-RATE; BODY-WEIGHT; OXIDATIVE-PHOSPHORYLATION; TARGETED DISRUPTION; GENE-EXPRESSION; TRANSGENIC MICE	Obesity results when energy In lake exceeds energy expenditure. Naturally occurring genetic mutations, as well as ablative lesions, have shown that the brain regulates both aspects of energy balance and that abnormalities in energy expenditure contribute to the development of obesity. Energy can be expended by performing work or producing heat (thermogenesis). Adaptive thermogenesis, or the regulated production of heat, is influenced by environmental temperature and diet. Mitochondria, the organelles that convert food to carbon dioxide, water and ATP are fundamental in mediating effects on energy dissipation. Recently there have been significant advances in understanding the molecular regulation of energy expenditure in mitochondria and the mechanisms of transcriptional control of mitochondrial genes. Here we explore these developments in relation to classical physiological views of adaptive thermogenesis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Lowell, BB (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, 99 Brookline Ave, Boston, MA 02215 USA.	blowell@caregroup.harvard.edu; bruce_spiegelman@dfci.harvard.edu						Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; AlAdsani H, 1997, J CLIN ENDOCR METAB, V82, P1118, DOI 10.1210/jc.82.4.1118; Almeida NG, 1996, AM J PHYSIOL-REG I, V271, pR1380, DOI 10.1152/ajpregu.1996.271.5.R1380; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; BALABAN RS, 1990, AM J PHYSIOL, V258, pC377, DOI 10.1152/ajpcell.1990.258.3.C377; Bartha T, 2000, ENDOCRINOLOGY, V141, P229, DOI 10.1210/en.141.1.229; Blaxter K, 1989, ENERGY METABOLISM AN; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; BROWN GC, 1992, BIOCHEM J, V284, P1; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CHAMPIGNY O, 1990, J NUTR, V120, P1730, DOI 10.1093/jn/120.12.1730; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; CHANCE B, 1955, J BIOL CHEM, V217, P409; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Cusin I, 1998, DIABETES, V47, P1014, DOI 10.2337/diabetes.47.7.1014; DAUNCEY MJ, 1981, BRIT J NUTR, V45, P257, DOI 10.1079/BJN19810102; DAVIS TRA, 1960, AM J PHYSIOL, V198, P471, DOI 10.1152/ajplegacy.1960.198.3.471; Demonacos CV, 1996, STEROIDS, V61, P226, DOI 10.1016/0039-128X(96)00019-0; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; DUMONTEIL E, 1995, AM J PHYSIOL-CELL PH, V269, pC955, DOI 10.1152/ajpcell.1995.269.4.C955; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Encke D, 1997, BBA-MOL CELL RES, V1357, P339, DOI 10.1016/S0167-4889(97)00045-1; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fisher MH, 1998, J CLIN INVEST, V101, P2387, DOI 10.1172/JCI2496; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; GARRUTI G, 1992, INT J OBESITY, V16, P383; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; HART JS, 1956, J APPL PHYSIOL, V9, P404, DOI 10.1152/jappl.1956.9.3.404; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; Hinz W, 1999, FEBS LETT, V448, P57, DOI 10.1016/S0014-5793(99)00331-2; Hochachka PW, 1999, P NATL ACAD SCI USA, V96, P12233, DOI 10.1073/pnas.96.22.12233; Hosoi Y, 1999, J CLIN ENDOCR METAB, V84, P3293, DOI 10.1210/jc.84.9.3293; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Kadenbach B, 1998, J BIOENERG BIOMEMBR, V30, P25, DOI 10.1023/A:1020599209468; KEVONIAN AV, 1984, J NUTR, V114, P543, DOI 10.1093/jn/114.3.543; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; LANDSBERG L, 1984, AM J PHYSIOL, V247, pE181, DOI 10.1152/ajpendo.1984.247.2.E181; Legradi G, 1997, ENDOCRINOLOGY, V138, P2569, DOI 10.1210/en.138.6.2569; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Melnyk A, 1998, AM J PHYSIOL-REG I, V274, pR1131, DOI 10.1152/ajpregu.1998.274.4.R1131; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OBrien J, 1996, J EXP BIOL, V199, P2679; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; PRUSINER SB, 1968, EUR J BIOCHEM, V7, P51, DOI 10.1111/j.1432-1033.1968.tb19572.x; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; ROBERTS SB, 1988, NEW ENGL J MED, V318, P461, DOI 10.1056/NEJM198802253180801; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; ROTHWELL NJ, 1987, J NUTR, V117, P833, DOI 10.1093/jn/117.5.833; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; Satoh N, 1998, NEUROSCI LETT, V249, P107, DOI 10.1016/S0304-3940(98)00401-7; Scarpace PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE226, DOI 10.1152/ajpendo.1997.273.1.E226; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SHIBATA H, 1987, J APPL PHYSIOL, V63, P465, DOI 10.1152/jappl.1987.63.2.465; Silva JE, 1995, THYROID, V5, P481, DOI 10.1089/thy.1995.5.481; SIMONSEN L, 1992, AM J PHYSIOL, V263, pE850, DOI 10.1152/ajpendo.1992.263.5.E850; SIMS EAH, 1987, J CLIN INVEST, V79, P1019, DOI 10.1172/JCI112913; Strosberg AD, 1996, TRENDS PHARMACOL SCI, V17, P373, DOI 10.1016/S0165-6147(96)80011-3; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Villena JA, 1998, BIOCHEM J, V331, P121, DOI 10.1042/bj3310121; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	93	1216	1263	3	177	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					652	660		10.1038/35007527	http://dx.doi.org/10.1038/35007527			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766252				2022-12-28	WOS:000086400100065
J	Matsunami, H; Montmayeur, JP; Buck, LB				Matsunami, H; Montmayeur, JP; Buck, LB			A family of candidate taste receptors in human and mouse	NATURE			English	Article							PUTATIVE PHEROMONE RECEPTORS; MULTIGENE FAMILY; MAMMALS; TRANSDUCTION; GENETICS; MICE	The gustatory system of mammals can sense four basic taste qualities, bitter, sweet, salty and sour, as well as umami, the taste of glutamate(1-6). Previous studies suggested that the detection of bitter and sweet tastants by taste receptor cells in the mouth is likely to involve G-protein-coupled receptors(2,7,8). Although two putative G-protein-coupled bitter/sweet taste receptors have been identified(9), the chemical diversity of bitter and sweet compounds leads one to expect that there is a larger number of different receptors(8,10,11). Here we report the identification of a family of candidate taste receptors (the TRBs) that are members of the G-protein-coupled receptor superfamily and that are specifically expressed by taste receptor cells. A cluster of genes encoding human TRBs is located adjacent to a Prp gene locus(12), which in mouse is tightly linked to the SOA genetic locus that is involved in detecting the bitter compound sucrose octaacetate(13-15). Another TRB gene is found on a human contig assigned to chromosome 5p15, the location of a genetic locus (PROP) that controls the detection of the bitter compound 6-n-propyl-2-thiouracil in humans(16,17).	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Buck, LB (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02215 USA.	lbuck@hms.harvard.edu	Montmayeur, Jean-Pierre R/A-5723-2009	Montmayeur, Jean-Pierre/0000-0002-0942-1114				AZEN E, 1984, P NATL ACAD SCI-BIOL, V81, P5561, DOI 10.1073/pnas.81.17.5561; BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1; BARTOSHUK LM, 1994, ANNU REV PSYCHOL, V45, P419, DOI 10.1146/annurev.ps.45.020194.002223; Berghard A, 1996, J NEUROSCI, V16, P909; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAPELESS CG, 1992, BEHAV GENET, V22, P655, DOI 10.1007/BF01066636; Chaudhari N, 1998, ANN NY ACAD SCI, V855, P398, DOI 10.1111/j.1749-6632.1998.tb10598.x; Chaudhari N, 2000, NAT NEUROSCI, V3, P113, DOI 10.1038/72053; Chaudhari N, 1996, J NEUROSCI, V16, P3817; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Herness MS, 1999, ANNU REV PHYSIOL, V61, P873, DOI 10.1146/annurev.physiol.61.1.873; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; Lindemann B, 1999, NAT MED, V5, P381, DOI 10.1038/7377; Lindemann B, 2000, NAT NEUROSCI, V3, P99, DOI 10.1038/72153; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; LUSH IE, 1995, GENET RES, V66, P167, DOI 10.1017/S0016672300034510; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Reed DR, 1999, AM J HUM GENET, V64, P1478, DOI 10.1086/302367; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; ROPER SD, 1989, ANNU REV NEUROSCI, V12, P329, DOI 10.1146/annurev.ne.12.030189.001553; ROUX KH, 1995, PCR PRIMER LAB MANUA; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Smith DV, 1999, CURR BIOL, V9, pR453, DOI 10.1016/S0960-9822(99)80280-2; SPIELMAN AI, 1992, SOC GEN PHY, V47, P307; WHITNEY G, 1994, PHYSIOL BEHAV, V56, P1141, DOI 10.1016/0031-9384(94)90358-1; Wong GT, 1999, J NEUROSCI, V19, P5802, DOI 10.1523/JNEUROSCI.19-14-05802.1999	29	539	582	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					601	+		10.1038/35007072	http://dx.doi.org/10.1038/35007072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766242				2022-12-28	WOS:000086400100053
J	Yamamoto, A; Lucas, JJ; Hen, R				Yamamoto, A; Lucas, JJ; Hen, R			Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease	CELL			English	Article							INTRANUCLEAR NEURONAL INCLUSIONS; EXPANDED CAG REPEAT; TRANSGENIC MICE; GENE-EXPRESSION; EMBRYONIC LETHALITY; TETRACYCLINE; BRAIN; INACTIVATION; PATHOGENESIS; AGGREGATION	Neurodegenerative disorders like Huntington's disease (HD) are characterized by progressive and putative irreversible clinical and neuropathological symptoms, including neuronal protein aggregates. Conditional transgenic models of neurodegenerative diseases therefore could be a powerful means to explore the relationship between mutant protein expression and progression of the disease. We have created a conditional model of HD by using the tet-regulatable system. Mice expressing a mutated huntingtin fragment demonstrate neuronal inclusions, characteristic neuropathology, and progressive motor dysfunction. Blockade of expression in symptomatic mice leads to a disappearance of inclusions and an amelioration of the behavioral phenotype. We thus demonstrate that a continuous influx of the mutant protein is required to maintain inclusions and symptoms, raising the possibility that HD may be reversible.	Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University	Hen, R (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA.		Yamamoto, Ai/D-1100-2011; Lucas, Jose J./U-6543-2019	Lucas, Jose J./0000-0003-1597-3916				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; Augood SJ, 1997, ANN NEUROL, V42, P215, DOI 10.1002/ana.410420213; AYLWARD EH, 1994, NEUROLOGY, V44, P823, DOI 10.1212/WNL.44.5.823; Backman L, 1997, BRAIN, V120, P2207, DOI 10.1093/brain/120.12.2207; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Carter RJ, 1999, J NEUROSCI, V19, P3248; Cha JHJ, 1999, PHILOS T R SOC B, V354, P981, DOI 10.1098/rstb.1999.0449; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DAVIES SW, 1999, PHILOS T R SOC LON B, V354, P81; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Ghavami A, 1999, J CELL SCI, V112, P967; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gusella JF, 1996, ANNU REV MED, V47, P201; Halliday GM, 1998, EXP NEUROL, V154, P663, DOI 10.1006/exnr.1998.6919; Hansson O, 1999, P NATL ACAD SCI USA, V96, P8727, DOI 10.1073/pnas.96.15.8727; HEDREEN JC, 1995, J NEUROPATH EXP NEUR, V54, P105, DOI 10.1097/00005072-199501000-00013; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Koshy BT, 1997, BRAIN PATHOL, V7, P927, DOI 10.1111/j.1750-3639.1997.tb00894.x; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Levine MS, 1999, J NEUROSCI RES, V58, P515, DOI 10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Lucas JJ, 1998, J NEUROSCI, V18, P5537, DOI 10.1523/JNEUROSCI.18-14-05537.1998; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MYERS RH, 1991, J NEUROPATH EXP NEUR, V50, P729, DOI 10.1097/00005072-199111000-00005; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; RUBINSZTEIN DC, 1994, NAT GENET, V7, P525, DOI 10.1038/ng0894-525; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; TURJANSKI N, 1995, BRAIN, V118, P689, DOI 10.1093/brain/118.3.689; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; Wheeler VC, 1999, HUM MOL GENET, V8, P115, DOI 10.1093/hmg/8.1.115; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	53	842	881	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 31	2000	101	1					57	66		10.1016/S0092-8674(00)80623-6	http://dx.doi.org/10.1016/S0092-8674(00)80623-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778856	Bronze			2022-12-28	WOS:000086249900008
J	Mitchell, SJ; Silver, RA				Mitchell, SJ; Silver, RA			Glutamate spillover suppresses inhibition by activating presynaptic mGluRs	NATURE			English	Article							PURKINJE-CELL SYNAPSES; RAT CEREBELLUM; SYNAPTIC INHIBITION; GABA(A) RECEPTORS; GRANULE CELLS; MODULATION; TRANSMISSION; PROBABILITY; DEPRESSION; CURRENTS	Metabotropic glutamate receptors (mGluRs) found on synaptic terminals throughout the brain are thought to be important in modulating neurotransmission(1,2). Activation of mGluRs by synaptically released glutamate depresses glutamate release from excitatory terminals(3-5) but the physiological role of mGluRs on inhibitory terminals is unclear. We have investigated activation of mGluRs on inhibitory terminals within the cerebellar glomerulus, a structure in which GABA (gamma-aminobutyric acid)-releasing inhibitory terminals and glutamatergic excitatory terminals are in close apposition and make axo-dendritic synapses onto granule cells(6). Here we show that 'spillover' of glutamate, which is released from excitatory mossy fibres, inhibits GABA release from Golgi cell terminals by activating presynaptic mGluRs under physiological conditions. The magnitude of the depression of the inhibitory postsynaptic current is dependent on the frequency of mossy fibre stimulation, reaching 50% at 100 Hz. Furthermore, the duration of inhibitory postsynaptic current depression mirrors the time course of mossy fibre activity. Our results establish that mGluRs on inhibitory interneuron axons(7) sense the activity of neighbouring excitatory synapses. This heterosynaptic mechanism is likely to boost the efficacy of active excitatory fibres by locally reducing the level of inhibition.	UCL, Dept Physiol, London WC1E 6BT, England	University of London; University College London	Silver, RA (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	a.silver@ucl.ac.uk		Silver, Robin/0000-0002-5480-6638				Barbour B, 1997, TRENDS NEUROSCI, V20, P377; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; Clements JD, 2000, TRENDS NEUROSCI, V23, P105, DOI 10.1016/S0166-2236(99)01520-9; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; Glitsch M, 1996, J PHYSIOL-LONDON, V497, P531, DOI 10.1113/jphysiol.1996.sp021786; HAMORI J, 1983, J COMP NEUROL, V220, P365, DOI 10.1002/cne.902200402; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Ito M, 1984, CEREBELLUM NEURAL CO; Jaarsma D, 1998, J NEUROCYTOL, V27, P303, DOI 10.1023/A:1006982023657; JAKAB RL, 1988, ANAT EMBRYOL, V179, P81, DOI 10.1007/BF00305102; Knoflach F, 1998, J PHYSIOL-LONDON, V509, P347, DOI 10.1111/j.1469-7793.1998.347bn.x; LLANO I, 1995, J PHYSIOL-LONDON, V486, P163, DOI 10.1113/jphysiol.1995.sp020800; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; Morishita W, 1998, J NEUROSCI, V18, P4870; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Neki A, 1996, NEUROSCIENCE, V75, P815, DOI 10.1016/0306-4522(96)00316-8; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; PONCER JC, 1995, J PHYSIOL-LONDON, V485, P121, DOI 10.1113/jphysiol.1995.sp020717; Rossi DJ, 1998, NEURON, V20, P783, DOI 10.1016/S0896-6273(00)81016-8; Scanziani M, 1997, NATURE, V385, P630, DOI 10.1038/385630a0; Silver RA, 1998, J PHYSIOL-LONDON, V510, P881, DOI 10.1111/j.1469-7793.1998.881bj.x; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; Tia S, 1996, J NEUROSCI, V16, P3630; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P74, DOI 10.1152/jn.1993.69.1.74; Vetter P, 1999, NEUROPHARMACOLOGY, V38, P805, DOI 10.1016/S0028-3908(99)00003-9; Vogt KE, 1999, P NATL ACAD SCI USA, V96, P1118, DOI 10.1073/pnas.96.3.1118; vonGersdorff H, 1997, J NEUROSCI, V17, P8137; Wall MJ, 1997, EUR J NEUROSCI, V9, P533, DOI 10.1111/j.1460-9568.1997.tb01630.x	30	195	198	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					498	502		10.1038/35006649	http://dx.doi.org/10.1038/35006649			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761918				2022-12-28	WOS:000086257700049
J	Reich, MR				Reich, MR			The global drug cap	SCIENCE			English	Article							COMMUNITY; HEALTH	Global inequities in access to pharmaceutical products exist between rich and poor countries because of market and government failures as well as huge income differences. Multiple policies are required to address this global drug gap for three categories of pharmaceutical products: essential drugs, new drugs, and yet-to-be-developed drugs. Policies should combine "push" approaches of financial subsidies to support targeted drug development, "pull" approaches of financial incentives such as market guarantees, and "process" approaches aimed at improved institutional-capacity. Constructive solutions are needed that can both protect the incentives for research and development and reduce the inequities of access.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Reich, MR (corresponding author), Harvard Univ, Sch Publ Hlth, 667 Huntington Ave, Boston, MA 02115 USA.							[Anonymous], 1993, WORLD DEV REP 1993 I; Bond P, 1999, INT J HEALTH SERV, V29, P765, DOI 10.2190/4MA6-53E3-LE1X-C1YY; Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406; FUJISAKI T, 1997, ASSESSMENT TDRS CONT; *IMS, 1999, IMS HLTH; Kremer M, 1998, Q J ECON, V113, P1137, DOI 10.1162/003355398555865; KREMER M, 1999, PURCHASE PRECOMMITME; Lanjouw J.O., 1999, 6366 NAT BUR EC RES; Management Sciences for Health, 1997, MAN DRUG SUPPL; MCPAKE B, 1993, SOC SCI MED, V36, P1383, DOI 10.1016/0277-9536(93)90381-D; Milstien JB, 1998, DRUG INF J, V32, P175, DOI 10.1177/009286159803200125; Olliaro P, 1996, JAMA-J AM MED ASSOC, V275, P230, DOI 10.1001/jama.275.3.230; Parry E, 1997, THORAX, V52, P589, DOI 10.1136/thx.52.7.589; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Reich M.R., 1998, DAP RES SERIES; REICH MR, 1987, HEALTH POLICY, V8, P39, DOI 10.1016/0168-8510(87)90129-1; Reich MR, 1999, B WORLD HEALTH ORGAN, V77, P675; Trouiller P, 1999, TROP MED INT HEALTH, V4, P412, DOI 10.1046/j.1365-3156.1999.00420.x; *UNDP WORLD BANK W, 1995, TROP DIS RES PROGR 1; Wehrwein P, 1999, HARV PUBLIC HLTH SUM, P32; *WHO EXP COMM, 1998, WHO TECHN REP SER, V882; 1999, GUIDELINES DRUG DONA; 1999, SUPPLY DIVISION ANN; 1998, AIDS EPIDEMIC UPDATE	24	50	51	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1979	1981		10.1126/science.287.5460.1979	http://dx.doi.org/10.1126/science.287.5460.1979			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10755953				2022-12-28	WOS:000085902800051
J	Reichhardt, T				Reichhardt, T			New form of hydrogen power provokes scepticism	NATURE			English	News Item																			0	4	4	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					218	218		10.1038/35005254	http://dx.doi.org/10.1038/35005254			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749181	Bronze			2022-12-28	WOS:000086022200012
J	Savaglio, S; Carbone, V				Savaglio, S; Carbone, V			Human performance - Scaling in athletic world records	NATURE			English	Article									Space Telescope Sci Inst, Baltimore, MD 21218 USA; Univ Calabria, Dipartimento Fis, I-87036 Arcavacata Di Rende, CS, Italy; Univ Calabria, Ist Nazl Fis Mat, Unita Cosenza, I-87036 Arcavacata Di Rende, CS, Italy	Space Telescope Science Institute; University of Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Calabria	Savaglio, S (corresponding author), Space Telescope Sci Inst, 3700 San Martin Dr, Baltimore, MD 21218 USA.	savaglio@stsci.edu	Carbone, Vincenzo/AAD-8557-2020	Carbone, Vincenzo/0000-0002-3182-6679; Savaglio, Sandra/0000-0003-2354-3238				di Prampero P E, 1981, Rev Physiol Biochem Pharmacol, V89, P143; Henry FM, 1955, RES QUART, V26, P147, DOI 10.1080/10671188.1955.10612815; Katz JS, 1999, J SPORT SCI, V17, P467; Kennelly AE, 1906, P AM ACAD ARTS SCI, V42, P273; MOGNONI P, 1982, EUR J APPL PHYSIOL O, V49, P287, DOI 10.1007/BF00441290	5	26	26	1	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					244	244		10.1038/35005165	http://dx.doi.org/10.1038/35005165			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749198	Bronze, Green Submitted			2022-12-28	WOS:000086022200036
J	Ghosh, S; Shand, A; Ferguson, A				Ghosh, S; Shand, A; Ferguson, A			Regular review - Ulcerative colitis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PRIMARY SCLEROSING CHOLANGITIS; INFLAMMATORY BOWEL-DISEASE; QUALITY-OF-LIFE; CROHNS-DISEASE; ACTIVITY INDEX; CYCLOSPORINE; MESALAZINE; POUCHITIS; THERAPY; RISK		Univ Edinburgh, Dept Med Sci, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Ghosh, S (corresponding author), Univ Edinburgh, Dept Med Sci, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	sg@srv0.med.ed.ac.uk	Eckhardt, Erik/G-1567-2010					Acciuffi S, 1996, ALIMENT PHARM THER, V10, P321, DOI 10.1111/j.0953-0673.1996.00321.x; Allan R.N., 1997, INFLAMMATORY BOWEL D; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Brentnall TA, 1996, GASTROENTEROLOGY, V110, P331, DOI 10.1053/gast.1996.v110.pm8566577; *BRIT SOC GASTR, 1996, GUID GASTR, V4; CANTRELL M, 1990, J AUTOIMMUN, V3, P307, DOI 10.1016/0896-8411(90)90149-M; Cohen RD, 1999, INFLAMM BOWEL DIS, V5, P1; COURTNEY MG, 1992, LANCET, V339, P1279, DOI 10.1016/0140-6736(92)91601-4; DAS KM, 1993, J IMMUNOL, V150, P2487; Dijkstra B, 1999, DIS COLON RECTUM, V42, P334, DOI 10.1007/BF02236349; Evans RC, 1997, ALIMENT PHARM THERAP, V11, P1037, DOI 10.1046/j.1365-2036.1997.00252.x; GAFFNEY PR, 1995, AM J GASTROENTEROL, V90, P220; Gionchetti P, 1999, ALIMENT PHARM THERAP, V13, P381; Green JR, 1999, GUT, V44, P455, DOI 10.1136/gut.44.4.455; HENDRIKSEN C, 1985, GUT, V26, P158, DOI 10.1136/gut.26.2.158; Holzmann K, 1998, INT J CANCER, V76, P1; KELLY KA, 1992, AM J SURG, V163, P5, DOI 10.1016/0002-9610(92)90244-L; KORELITZ BI, 1992, MANAGEMENT INFLAMMAT; Kornbluth A, 1997, AM J GASTROENTEROL, V92, P204; Lashner BA, 1999, AM J GASTROENTEROL, V94, P456, DOI 10.1016/S0002-9270(98)00758-8; LEE JG, 1995, HEPATOLOGY, V21, P661, DOI 10.1002/hep.1840210310; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; Loftus EV, 1998, HEPATOLOGY, V27, P685, DOI 10.1002/hep.510270308; LUUKKONEN P, 1994, GUT, V35, P243, DOI 10.1136/gut.35.2.243; MACHIDA HM, 1994, J PEDIATR GASTR NUTR, V19, P22, DOI 10.1097/00005176-199407000-00004; Marshall JK, 1997, GUT, V40, P775, DOI 10.1136/gut.40.6.775; MIGNON M, 1995, DIS COLON RECTUM, V38, P100, DOI 10.1007/BF02053868; Mitchell SA, 1997, ALIMENT PHARM THERAP, V11, P33, DOI 10.1046/j.1365-2036.1997.91263000.x; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; NARVIN S, 1995, HEPATOLOGY, V22, P451; NILSSON A, 1995, AM J GASTROENTEROL, V90, P381; Olsen KO, 1999, BRIT J SURG, V86, P493, DOI 10.1046/j.1365-2168.1999.01076.x; OLSSON R, 1991, GASTROENTEROLOGY, V100, P1319; Pitcher MCL, 1996, GUT, V39, P1, DOI 10.1136/gut.39.1.1; POWELLTUCK J, 1978, SCAND J GASTROENTERO, V13, P833, DOI 10.3109/00365527809182199; PROBERT CSJ, 1992, GUT, V33, P687, DOI 10.1136/gut.33.5.687; PULLAN RD, 1994, GUT, V35, P353, DOI 10.1136/gut.35.3.353; Roozendaal C, 1998, AM J MED, V105, P393, DOI 10.1016/S0002-9343(98)00294-0; RUTGEERTS P, 1994, GASTROENTEROLOGY, V106, P1251, DOI 10.1016/0016-5085(94)90016-7; Schreiber S, 1996, NEW ENGL J MED, V334, P619, DOI 10.1056/NEJM199603073341002; Seidel SA, 1999, AM SURGEON, V65, P40; SOMERVILLE KW, 1985, BRIT MED J, V291, P866, DOI 10.1136/bmj.291.6499.866; Stack WA, 1998, ALIMENT PHARM THERAP, V12, P973; Stack WA, 1999, ALIMENT PHARM THERAP, V13, P569; Stahlberg D, 1996, DIS COLON RECTUM, V39, P1012, DOI 10.1007/BF02054692; THULUVATH PJ, 1994, GUT, V35, P1493, DOI 10.1136/gut.35.10.1493; TREEM WR, 1995, DIS COLON RECTUM, V38, P474, DOI 10.1007/BF02148846; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; TSAI HH, 1995, GUT, V36, P570, DOI 10.1136/gut.36.4.570; TYSK C, 1991, GASTROENTEROLOGY, V100, P419, DOI 10.1016/0016-5085(91)90211-3; [No title captured]	51	55	68	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	2000	320	7242					1119	1123		10.1136/bmj.320.7242.1119	http://dx.doi.org/10.1136/bmj.320.7242.1119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775225	Green Published			2022-12-28	WOS:000086782800022
J	Grant, J; Cottrell, R; Cluzeau, F; Fawcett, G				Grant, J; Cottrell, R; Cluzeau, F; Fawcett, G			Evaluating "payback" on biomedical research from papers cited in clinical guidelines: applied bibliometric study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SCIENCE	Objectives To develop a methodology for evaluating the impact of research on health care, and to characterise the papers cited on clinical guidelines. Design The bibliographic details of the papers cited in 15 clinical guidelines, developed in and for the United Kingdom, were collated and analysed with applied bibliometric techniques. Results The median age of papers cited in clinical guidelines was eight years; most papers were published by authors living in either the United States (36%) or the United Kingdom (25%)-this is two and a half times more than expected as about 10% of all biomedical outputs are published in the United Kingdom; and clinical guidelines do not cite basic research papers. Conclusion Analysis of the evidence base of clinical guidelines may be one way of tracking the flow of knowledge from the laboratory to the clinic. Moreover, such analysis provides a useful, clinically relevant method for evaluating research outcomes and different strategies in research and development.	Wellcome Trust Res Labs, Policy Unit, London NW1 2BE, England; St George Hosp, Sch Med, Hlth Care Evaluat Unit, London SW17 0RE, England	St Georges University London	Grant, J (corresponding author), Wellcome Trust Res Labs, Policy Unit, London NW1 2BE, England.	j.grant@wellcome.ac.uk	Grant, Jonathan C/K-4282-2012	Grant, Jonathan C/0000-0002-1646-3486	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson J, 1996, TECHNOL ANAL STRATEG, V8, P135, DOI 10.1080/09537329608524240; Buxton M, 1996, J Health Serv Res Policy, V1, P35; Cluzeau F A, 1999, Jt Comm J Qual Improv, V25, P514; Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21; COMROE JH, 1976, SCIENCE, V192, P105, DOI 10.1126/science.769161; DAVIES E, 1997, IMPROVING CARE PATIE; Dawson G., 1998, MAPPING LANDSCAPE NA; ENDERBY P, 1998, CLIN GUID CONS SPEEC; Grant J, 1997, SCIENCE, V278, P878; Grant J., 1999, RES EVALUAT, V8, P33, DOI DOI 10.3152/147154499781777658; *N ENGL EV BAS GUI, 1998, PRIM CAR MAN DEM; *N ENGL EV BAS GUI, 1998, ASP SEC PROPH VASC D; *N ENGL EV BAS GUI, 1998, ACE INH PRIM CAR MAN; *N ENGL EV BAS GUI, 1998, NONST ANT DRUGS NSAI; *N ENGL EV BAS GUI, 1996, PRIM CAR MAN STABL A; *N ENGL EV BAS GUI, 1998, CHOIC ANT DEPR PRIM; *N ENGL EV BAS GUI, 1996, PRIM CAR MAN ASTHM A; NARIN F, 1976, J AM SOC INFORM SCI, V27, P25, DOI 10.1002/asi.4630270104; O'Donoghue, 1997, ADULTS POORLY CONTRO; *ROYAL COLL OBST G, 1998, IN MAN MEN; *ROYAL COLL PHYS, 1998, CLIN GUID STRAT PREV; *ROYAL COLL PSYCH, 1998, MAN IMM VIOL; Royal College of Obstetricians and Gynaecologists, 1998, MAN INF SEC CAR; SMITH R, 1987, BRIT MED J, V295, P1404, DOI 10.1136/bmj.295.6610.1404; WADDELL G, 1996, LOW BACK PAIN EVIDEN	25	124	127	2	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	2000	320	7242					1107	1111		10.1136/bmj.320.7242.1107	http://dx.doi.org/10.1136/bmj.320.7242.1107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775218	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086782800016
J	Finette, BA; Homans, AC; Albertini, RJ				Finette, BA; Homans, AC; Albertini, RJ			Emergence of genetic instability in children treated for leukemia	SCIENCE			English	Article							T-LYMPHOCYTES; HPRT LOCUS; MUTATIONS; CANCER; POPULATION; EXPOSURE; DELETION; MUTATORS; P53	T cells from patients who had received chemotherapy for B-lineage acute lymphocytic Leukemia were studied to determine whether genetic instability, a principal characteristic of cancer cells, can also occur in nonmalignant cells. Consistent with expectations for a genetic instability phenotype, multiple mutations were detected in the hypoxanthine-guanine phosphoribosyltransferase (HPRT) reporter gene in independently isolated mutant T cells expressing identical rearranged T cell receptor beta (TCR beta) gene hypervariable regions. These results indicate that cancer treatment can lead to genetic instability in nonmalignant cells in some individuals. They also suggest a mechanistic paradigm for the induction of second malignancies and drug resistance.	Univ Vermont, Dept Pediat, Burlington, VT 05405 USA; Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Vermont Canc Ctr, Burlington, VT 05405 USA; Univ Vermont, Dept Med, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont; University of Vermont	Finette, BA (corresponding author), Univ Vermont, Dept Pediat, Med Alumni Bldg, Burlington, VT 05405 USA.	finette@salus.med.uvm.edu			NCI NIH HHS [1K01CA77737, P30CA22435] Funding Source: Medline; NICHD NIH HHS [1R29HD35309] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD035309] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA022435, K01CA077737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertini RJ, 1998, MUTAT RES-FUND MOL M, V400, P381, DOI 10.1016/S0027-5107(98)00063-3; BRANDA RF, 1991, CANCER RES, V51, P6603; Cariello NF, 1998, NUCLEIC ACIDS RES, V26, P198, DOI 10.1093/nar/26.1.198; Finette BA, 1998, NAT MED, V4, P1144, DOI 10.1038/2640; FINETTE BA, 1994, MUTAT RES, V308, P223, DOI 10.1016/0027-5107(94)90157-0; FUSCOE JC, 1991, CANCER RES, V51, P6001; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; HIROTA H, 1994, MUTAT RES-DNA REPAIR, V315, P95, DOI 10.1016/0921-8777(94)90010-8; Hunt CR, 1998, CANCER RES, V58, P3986; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KOSHI S, 1998, MUTAT RES, V422, P213; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strauss BS, 1997, CARCINOGENESIS, V18, P1445, DOI 10.1093/carcin/18.8.1445; Strauss BS, 1998, SEMIN CANCER BIOL, V8, P431, DOI 10.1006/scbi.1998.0092; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600	23	45	46	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					514	517		10.1126/science.288.5465.514	http://dx.doi.org/10.1126/science.288.5465.514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775110				2022-12-28	WOS:000086626000045
J	LaCombe, MA; Davidoff, F				LaCombe, MA; Davidoff, F			On being a doctor 2	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											LaCombe, MA (corresponding author), 1303 Naples Rd, Harrison, ME 04040 USA.							BEKAS S, 1999, BEING DOCTOR, V2, P301; CASANO AA, 1999, BEING DOCTOR, V2, P31; FITZGERALD FT, 1999, BEING DOCTOR, V2, P5; FOURNLER AM, 1999, BEING DOCTOR, V2, P23; GENSHEIMER KF, 1999, BEING DOCTOR, V2, P92; GRUBB BP, 1999, BEING DOCTOR, V2, P13; IEZZONI LI, 1999, BEING DOCTOR, V2, P277; KLEIN MD, 1999, BEING DOCTOR, V2, P54; LACOMBE MA, 1999, BEING DOCTOR, V2; SMITH L, 1999, BEING DOCTOR, V2, P115	10	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					671	672		10.7326/0003-4819-132-8-200004180-00011	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766687				2022-12-28	WOS:000086497500010
J	Sors, H; Meyer, G				Sors, H; Meyer, G			Place of aspirin in prophylaxis of venous thromboembolism	LANCET			English	Editorial Material							TOTAL HIP-REPLACEMENT; DOUBLE-BLIND; THROMBOPROPHYLAXIS; ENOXAPARIN		Univ Paris 05, Laennec Hosp, Dept Lung Dis, F-75007 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Sors, H (corresponding author), Univ Paris 05, Laennec Hosp, Dept Lung Dis, F-75007 Paris, France.							Bergqvist D, 1996, NEW ENGL J MED, V335, P696, DOI 10.1056/NEJM199609053351002; COHEN AT, 1994, BRIT MED J, V309, P1213, DOI 10.1136/bmj.309.6963.1213; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; COLLINS R, 1994, BMJ-BRIT MED J, V309, P1215, DOI 10.1136/bmj.309.6963.1215; Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26; GLAGETT GP, 1998, CHEST, V114, pS531; Hirsh J, 1998, Chest, V114, p113S, DOI 10.1378/chest.114.2_Supplement.113S; Planes A, 1996, LANCET, V348, P224, DOI 10.1016/S0140-6736(96)01453-5; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904	9	25	25	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1288	1289		10.1016/S0140-6736(00)02104-8	http://dx.doi.org/10.1016/S0140-6736(00)02104-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776735				2022-12-28	WOS:000086829400002
J	Brocklehurst, P; Elbourne, D; Alfirevic, Z				Brocklehurst, P; Elbourne, D; Alfirevic, Z			Role of external evidence in monitoring clinical trials: experience from a perinatal trial	BRITISH MEDICAL JOURNAL			English	Article							THYROTROPIN-RELEASING-HORMONE		Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Perinatal Trials Serv, Oxford OX3 7LF, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Med Stat Unit, London WC1E 7HT, England; Liverpool Womens Hosp, Dept Obstet & Gynaecol, Liverpool L8 7SS, Merseyside, England	University of Oxford; University of London; London School of Hygiene & Tropical Medicine; University of Liverpool	Brocklehurst, P (corresponding author), Inst Hlth Sci, Natl Perinatal Epidemiol Unit, Perinatal Trials Serv, Oxford OX3 7LF, England.		Brocklehurst, Peter/B-5804-2011					Alfirevic Z, 1999, BRIT J OBSTET GYNAEC, V106, P898, DOI 10.1111/j.1471-0528.1999.tb08427.x; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; CHALMERS I, 1978, EFFECTIVE CARE PREGN; CROWTHER C, 1996, COCHRANE LIB; Crowther CA, 1997, PEDIATRICS, V99, P311, DOI 10.1542/peds.99.3.311; CROWTHER CA, 1995, LANCET, V345, P877; Medical Research Council, 1998, MRC GUID GOOD CLIN P; Meinert CL, 1998, CONTROL CLIN TRIALS, V19, P515, DOI 10.1016/S0197-2456(98)00027-0; MEINERT CL, 1986, MONOGRAPHS EPIDEMIOL, V8; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pocock SJ, 1996, STAT MED, V15, P1285, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1285::AID-SIM309>3.3.CO;2-S; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527	12	11	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					995	998		10.1136/bmj.320.7240.995	http://dx.doi.org/10.1136/bmj.320.7240.995			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753158	Green Published, Green Submitted			2022-12-28	WOS:000086453100031
J	Lees, KR; Bath, PMW; Naylor, AR				Lees, KR; Bath, PMW; Naylor, AR			ABC of arterial and venous disease - Secondary prevention of transient ischaemic attack and stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Leicester Royal Infirm, Dept Surg, Leicester, Leics, England; Univ Nottingham Hosp, Nottingham NG7 2UH, England	University of Glasgow; University of Leicester; University of Nottingham	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.	k.r.lees@clinmed.gla.ac.uk	Bath, Philip/F-9020-2011	Bath, Philip/0000-0003-2734-5132				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; KOUDSTAAL PJ, 1993, LANCET, V342, P1255	5	26	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2000	320	7240					991	994		10.1136/bmj.320.7240.991	http://dx.doi.org/10.1136/bmj.320.7240.991			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753157	Green Published, Green Accepted			2022-12-28	WOS:000086453100030
J	Powles, R; Mehta, J; Kulkarni, S; Treleaven, J; Millar, B; Marsden, J; Shepherd, V; Rowland, A; Sirohi, B; Tait, D; Horton, C; Long, S; Singhal, S				Powles, R; Mehta, J; Kulkarni, S; Treleaven, J; Millar, B; Marsden, J; Shepherd, V; Rowland, A; Sirohi, B; Tait, D; Horton, C; Long, S; Singhal, S			Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial	LANCET			English	Article							VERSUS-HOST DISEASE; HEMATOLOGIC MALIGNANCIES; ACUTE-LEUKEMIA; GRAFT; RISK; IMMUNOTHERAPY; IDENTIFICATION; CYCLOSPORINE; PROPHYLAXIS; LYMPHOMA	Background Autologous transplantation with peripheral blood stem cells (PBSC) results in faster haematopoietic-cell repopulation than with bone marrow. We prospectively compared bone marrow and PBSC for allogeneic transplantation. Methods Adult HLA-identical sibling donors provided bone marrow and lenograstim-mobilised PBSC. 39 patients with malignant haematological disorders were infused with either bone marrow (n=19) or PBSC (n=20) after standard conditioning regimens in a double-blind, randomised fashion. The identity of the infused products for all patients remained mashed until 1 year after the last patient had received transplantation. Findings The PBSC group had significantly faster neutrophil recovery to 0.5x10(9)/L (median 17.5 vs 23 days, p=0.002), and platelet recovery to 20x10(9)/L (median 11 vs 18 days, p<0.0001) and to 50x10(9)/L (median 20.5 vs 27 days, p=0.02) than the bone-marrow group. PBSC patients were discharged from hospital earlier than were bone-marrow patients (median 26 vs 31 days, p=0.01). At 4 weeks after transplantation, absolute lymphocytes (0.48 vs 0.63, p=0.08) and CD25 cells (0.04 vs 0.08, p=0.007) were higher in the PBSC group, and the proportion of patients with absolute lymphopenia (74% vs 33%, p=0.03) and CD4 lymphopenia (59% vs 24%, p=0.05) was significantly higher in the bone-marrow group. There was no significant difference in the occurrence of acute or chronic graft-versus-host disease and overall survival. The probability of relapse was significantly higher in the bone-marrow group than in the PBSC group (p=0.01); all five relapses occurred among bone-marrow recipients. Interpretation Our small study indicates that PBSCs are better than bone marrow for allogeneic transplantation from HLA-identical siblings in terms of faster haematopoietic and immune recovery, and have the potential to reduce disease recurrence.	Royal Marsden Hosp, Leukaemia Unit, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp, Myeloma Unit, Sutton SM2 5PT, Surrey, England; Inst Canc Res, Sutton, Surrey, England; Chugal Pharma UK, London, England; Palmetto Richland Mem Hosp, S Carolina Canc Ctr, Div Transplant Med, Myeloma & Lymphoma Program, Columbia, SC USA	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Roche Holding	Powles, R (corresponding author), Royal Marsden Hosp, Leukaemia Unit, Downs Rd, Sutton SM2 5PT, Surrey, England.							Appelbaum FR, 1999, BLOOD, V94, P381, DOI 10.1182/blood.V94.2.381.414a48_381_383; ATKINSON K, 1988, BONE MARROW TRANSPL, V3, P5; Bensinger W, 1999, BLOOD, V94, p368A; BENSINGER WI, 1995, BLOOD, V85, P1655, DOI 10.1182/blood.V85.6.1655.bloodjournal8561655; Bensinger WI, 1996, BLOOD, V88, P2794, DOI 10.1182/blood.V88.7.2794.bloodjournal8872794; Brown RA, 1999, J CLIN ONCOL, V17, P806, DOI 10.1200/JCO.1999.17.3.806; Deeg HJ, 1997, BLOOD, V89, P3880, DOI 10.1182/blood.V89.10.3880.3880_3880_3887; Duncan N, 1996, BONE MARROW TRANSPL, V18, P1175; Elmaagacli AH, 1999, BLOOD, V94, P384, DOI 10.1182/blood.V94.2.384.414k06_384_389; Glass B, 1997, BLOOD, V90, P1694, DOI 10.1182/blood.V90.4.1694.1694_1694_1700; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; KORBLING M, 1995, BLOOD, V85, P1659, DOI 10.1182/blood.V85.6.1659.bloodjournal8561659; Kulkarni S, 1998, BLOOD, V92, p141A; Majolino I, 1996, BONE MARROW TRANSPL, V17, P555; Mehta J, 1997, BONE MARROW TRANSPL, V19, P349, DOI 10.1038/sj.bmt.1700657; Mehta J, 1997, BONE MARROW TRANSPL, V20, P129, DOI 10.1038/sj.bmt.1700859; Mehta J, 1997, BONE MARROW TRANSPL, V19, P709, DOI 10.1038/sj.bmt.1700720; MEHTA J, 1993, LEUKEMIA LYMPHOMA, V10, P427, DOI 10.3109/10428199309148199; MEHTA J, 1998, LEUKAEMIA ASS DIS, P455; Miflin G, 1997, BONE MARROW TRANSPL, V19, P9, DOI 10.1038/sj.bmt.1700603; NASH RA, 1992, BLOOD, V80, P1838; Powles R, 1998, BLOOD, V91, P3481, DOI 10.1182/blood.V91.9.3481.3481_3481_3486; POWLES RL, 1983, LANCET, V1, P612; POWLES RL, 1990, LANCET, V335, P999, DOI 10.1016/0140-6736(90)91065-I; POWLES RL, 1994, CLIN BONE MARROW TRA, P736; Przepiorka D, 1997, BONE MARROW TRANSPL, V19, P455, DOI 10.1038/sj.bmt.1700692; Russell JA, 1999, BONE MARROW TRANSPL, V24, P1177, DOI 10.1038/sj.bmt.1702051; Russell JA, 1996, BONE MARROW TRANSPL, V17, P703; Schmitz N, 1996, LANCET, V347, P353, DOI 10.1016/S0140-6736(96)90536-X; SCHMITZ N, 1995, BLOOD, V85, P1666, DOI 10.1182/blood.V85.6.1666.bloodjournal8561666; Schmitz N, 1998, BONE MARROW TRANSPL, V21, P995, DOI 10.1038/sj.bmt.1701234; Singhal S, 2000, BONE MARROW TRANSPL, V25, P501, DOI 10.1038/sj.bmt.1702173; SINGHAL S, 1997, BLOOD S1, V90, pS235; Storek J, 1997, BLOOD, V90, P4705, DOI 10.1182/blood.V90.12.4705.4705_4705_4709; Treleaven J G, 1992, J Hematother, V1, P215, DOI 10.1089/scd.1.1992.1.215	35	284	295	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1231	1237		10.1016/S0140-6736(00)02090-0	http://dx.doi.org/10.1016/S0140-6736(00)02090-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770306				2022-12-28	WOS:000086448000013
J	Maiorano, D; Moreau, J; Mechali, M				Maiorano, D; Moreau, J; Mechali, M			XCDT1 is required for the assembly of pre-replicative complexes in Xenopus laevis	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; CELL-CYCLE; LICENSING SYSTEM; MCM PROTEINS; CDC6 PROTEIN; S-PHASE; CHROMATIN; INITIATION; EXTRACTS	In eukaryotic cells, chromosomal DNA replication begins with the formation of pre-replication complexes at replication origins. Formation and maintenance of pre-replication complexes is dependent upon CDC6 (ref. 1), a protein which allows assembly of MCM2-7 proteins(2-4), which are putative replicative helicases(5). The functional assembly of MCM proteins into chromatin corresponds to replication licensing. Removal of these proteins from chromatin in S phase is crucial in origins firing regulation(6). We have identified a protein that is required for the assembly of prereplication complexes, in a screen for maternally expressed genes in Xenopus. This factor (XCDT1) is a relative of fission yeast cdt1, a protein proposed to function in DNA replication(7), and is the first to be identified in vertebrates. Here we show, using Xenopus in vitro systems, that XCDT1 is required for chromosomal DNA replication. XCDT1 associates with pre-replicative chromatin in a manner dependent on ORC protein and is removed from chromatin at the time of initiation of DNA synthesis. Immunodepletion and reconstitution experiments show that XCDT1 is required to load MCM2-7 proteins onto pre-replicative chromatin. These findings indicate that XCDT1 is an essential component of the system that regulates origins firing during S phase.	CNRS, Inst Human Genet, F-34396 Montpellier 5, France; Univ Paris 07, Inst Jacques Monod, Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; Universite Paris Cite	Mechali, M (corresponding author), CNRS, Inst Human Genet, 141 Rue Cardonille, F-34396 Montpellier 5, France.	mechali@igh.cnrs.fr	Maiorano, Domenico/N-5755-2017	Maiorano, Domenico/0000-0003-4229-5903				ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1998, EXP CELL RES, V245, P282, DOI 10.1006/excr.1998.4271; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; MAIORANO D, IN PRESS J BIOL CHEM; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; Menut S, 1999, ADV MOLEC BIOL, P196; MOREAU J, 1995, MOL REPROD DEV, V41, P1, DOI 10.1002/mrd.1080410102; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Rowles A, 1999, J CELL SCI, V112, P2011; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Vuillard L, 1998, EUR J BIOCHEM, V256, P128, DOI 10.1046/j.1432-1327.1998.2560128.x	25	290	292	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					622	625		10.1038/35007104	http://dx.doi.org/10.1038/35007104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766247				2022-12-28	WOS:000086400100058
J	von Hippel, PH; Jing, DH				von Hippel, PH; Jing, DH			Structural biology - Bit players in the trombone orchestra	SCIENCE			English	Editorial Material							POLYMERASES		Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	von Hippel, PH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.			von Hippel, Peter H./0000-0003-2512-8097				ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Hiasa H, 1999, J BIOL CHEM, V274, P27244, DOI 10.1074/jbc.274.38.27244; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Jing DH, 1999, J BIOL CHEM, V274, P27287, DOI 10.1074/jbc.274.38.27287; Johnson SK, 2000, BIOCHEMISTRY-US, V39, P736, DOI 10.1021/bi991554l; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; KORNBERG A, 1992, DNA REPLICATION, VB; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	10	3	3	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2435	2436		10.1126/science.287.5462.2435	http://dx.doi.org/10.1126/science.287.5462.2435			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10766621				2022-12-28	WOS:000086202200032
J	Ferner, RE; Aronson, JK				Ferner, RE; Aronson, JK			Medication errors, worse than a crime	LANCET			English	Editorial Material									City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England; Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX1 2JD, England	University of Birmingham; Radcliffe Infirmary; University of Oxford	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England.			Ferner, Robin/0000-0003-3769-1346				Ashraf H, 2000, LANCET, V355, P471, DOI 10.1016/S0140-6736(00)82021-8; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Ferner RE, 1999, BRIT J CLIN PHARMACO, V47, P581; FERNER RE, 1999, SIDE EFFECTS DRUGS A, P22; Firth-Cozens J, 1993, MED ACCIDENTS, P131; Kohn LT., 2000, ERR IS HUMAN BUILDIN; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; RUNCIMAN WB, 1993, ANAESTH INTENS CARE, V21, P506, DOI 10.1177/0310057X9302100506; TEAHON K, 1993, BRIT MED J, V307, P605, DOI 10.1136/bmj.307.6904.605; Walley T, 1997, BRIT J CLIN PHARMACO, V44, P171, DOI 10.1046/j.1365-2125.1997.00668.x	11	46	48	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					947	948		10.1016/S0140-6736(00)99025-1	http://dx.doi.org/10.1016/S0140-6736(00)99025-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YH	10768430				2022-12-28	WOS:000086054000006
J	Barton, JH				Barton, JH			Policy forum: Intellectual property rights - Reforming the patent system	SCIENCE			English	Article									Stanford Univ, Stanford Law Sch, Stanford, CA 94305 USA	Stanford University	Barton, JH (corresponding author), Stanford Univ, Stanford Law Sch, Stanford, CA 94305 USA.							*AIPLA, 1999, REP EC SURV 1999; DICKINSON QT, 2000, GOV EXEC         FEB, P39; EISENBERG RS, 1989, U CHICAGO LAW REV, V56, P1017, DOI 10.2307/1599761; HALL B, 1999, NBER PAT SYST INN C; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; *NAT SCI FDN, 1998, SCI ENG IND 1998; *NIH WORK GROUP, 1998, REP NIH WORK GROUP R; Skolnick J, 1999, US Patent, Patent No. 5933819; Voss D, 1999, SCIENCE, V284, P1252, DOI 10.1126/science.284.5418.1252; WARSHOFSKY F, 1994, PATENT WARS BATTLE O, P122; 1999, FED REG         1221, V64, P71440	11	106	106	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1933	1934		10.1126/science.287.5460.1933	http://dx.doi.org/10.1126/science.287.5460.1933			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	294GE	10755943				2022-12-28	WOS:000085902800027
J	Saikkonen, K				Saikkonen, K			Kentucky 31, Far from Home	SCIENCE			English	Editorial Material							TALL-FESCUE; ENDOPHYTE; LIMITATION; PLANT		Univ Turku, Sect Ecol, Dept Biol, Turku, Finland	University of Turku	Saikkonen, K (corresponding author), Univ Turku, Sect Ecol, Dept Biol, Turku, Finland.	karisaik@utu.fi						[Anonymous], 1958, ECOLOGY INVASION ANI; BACON CW, 1995, J ANIM SCI, V73, P861; BALL DM, 1993, AM SCI, V81, P370; BARRETT JA, 1981, GENETIC CONSEQUENCES, P209; Clay K, 1999, SCIENCE, V285, P1742, DOI 10.1126/science.285.5434.1742; HOVELAND CS, 1993, AGR ECOSYST ENVIRON, V44, P3, DOI 10.1016/0167-8809(93)90036-O; Saikkonen K, 1998, ANNU REV ECOL SYST, V29, P319, DOI 10.1146/annurev.ecolsys.29.1.319; SAIKKONEN K, ECOGRAPHY IN PRESS; Salaman RN, 1949, HIST SOCIAL INFLUENC; TILMAN D, 1993, ECOLOGY, V74, P2179, DOI 10.2307/1939572; Tilman D, 1997, ECOLOGY, V78, P81, DOI 10.1890/0012-9658(1997)078[0081:CIRLAG]2.0.CO;2; TUTIN TG, 1980, FLORA EUROPAEA, V5, P132	12	41	43	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2000	287	5460					1887	1887						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10755931				2022-12-28	WOS:000085902800069
J	Sander, C				Sander, C			Genomic medicine and the future of health care	SCIENCE			English	Article								Genomic technologies and computational advances are Leading to an information revolution in biology and medicine. Simulations of molecular processes in cells and predictions of drug effects in humans will advance pharmaceutical research and speed up clinical trials. Computational prognostics and diagnostics that combine clinical data with genotyping and molecular profiling may soon cause fundamental changes in the practice of health care.	Millennium Pharmaceut & Millennium Predict Med, Cambridge, MA 02139 USA; MIT, Ctr Genome Res, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Massachusetts Institute of Technology (MIT)	Sander, C (corresponding author), Millennium Pharmaceut & Millennium Predict Med, 640 Mem Dr, Cambridge, MA 02139 USA.							Abbott A, 1999, NATURE, V402, P219, DOI 10.1038/46111; Arkin A, 1998, GENETICS, V149, P1633; BRAZMA A, COMMUNICATION; Brent R, 2000, CELL, V100, P169, DOI 10.1016/S0092-8674(00)81693-1; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Clark DE, 2000, DRUG DISCOV TODAY, V5, P49, DOI 10.1016/S1359-6446(99)01451-8; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; MUIR CS, COMMUNICATION; Schaff J, 1999, Pac Symp Biocomput, P228; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; Service RF, 1999, SCIENCE, V284, P80; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tomita M, 1999, BIOINFORMATICS, V15, P72, DOI 10.1093/bioinformatics/15.1.72; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WEINSTEIN JN, 1999, NAT GENET, V23, P81; Yates JR, 2000, TRENDS GENET, V16, P5, DOI 10.1016/S0168-9525(99)01879-X	17	119	156	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1977	1978		10.1126/science.287.5460.1977	http://dx.doi.org/10.1126/science.287.5460.1977			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10755952				2022-12-28	WOS:000085902800050
J	Bennett, CH; DiVincenzo, DP				Bennett, CH; DiVincenzo, DP			Quantum information and computation	NATURE			English	Review							NUCLEAR-MAGNETIC-RESONANCE; ERROR-CORRECTING CODES; MIXED-STATE ENTANGLEMENT; PODOLSKY-ROSEN CHANNELS; NOISY CHANNELS; EXPERIMENTAL REALIZATION; BIT COMMITMENT; TRAPPED IONS; IMPLEMENTATION; TELEPORTATION	In information processing, as in physics, our classical world view provides an incomplete approximation to an underlying quantum reality. Quantum effects like interference and entanglement play no direct role in conventional information processing, but they can-in principle now, but probably eventually in practice-be harnessed to break codes, create unbreakable codes, and speed up otherwise intractable computations.	IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	Bennett, CH (corresponding author), IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA.	bennetc@watson.ibm.com	Bennett, Charles H. H/G-9082-2013; DiVincenzo, David P/H-5952-2013; qiong, angel/ABG-8344-2020	Bennett, Charles H. H/0000-0003-0921-2643; DiVincenzo, David P/0000-0003-4332-645X; 				Abrams DS, 1997, PHYS REV LETT, V79, P2586, DOI 10.1103/PhysRevLett.79.2586; BARENCO A, 1995, PHYS REV A, V52, P3457, DOI 10.1103/PhysRevA.52.3457; Beals R, 1998, ANN IEEE SYMP FOUND, P352, DOI 10.1109/SFCS.1998.743485; BENNETT CH, 1992, PHYS REV LETT, V69, P2881, DOI 10.1103/PhysRevLett.69.2881; BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Bennett CH, 1996, PHYS REV A, V54, P3824, DOI 10.1103/PhysRevA.54.3824; Bennett CH, 1999, PHYS REV LETT, V83, P3081, DOI 10.1103/PhysRevLett.83.3081; Bennett CH, 1996, PHYS REV LETT, V76, P722, DOI 10.1103/PhysRevLett.76.722; Bennett CH, 1996, PHYS REV A, V53, P2046, DOI 10.1103/PhysRevA.53.2046; BENNETT CH, 1995, NATURE, V377, P389, DOI 10.1038/377389a0; Bennett CH., 1984, P IEEE INT C COMP SY, P175; Biham E, 1997, PHYS REV LETT, V78, P2256, DOI 10.1103/PhysRevLett.78.2256; Boschi D, 1998, PHYS REV LETT, V80, P1121, DOI 10.1103/PhysRevLett.80.1121; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Buhrman H., 1998, Proceedings of the Thirtieth Annual ACM Symposium on Theory of Computing, P63, DOI 10.1145/276698.276713; Calderbank AR, 1996, PHYS REV A, V54, P1098, DOI 10.1103/PhysRevA.54.1098; Chuang IL, 1998, NATURE, V393, P143, DOI 10.1038/30181; Chuang IL, 1998, PHYS REV LETT, V80, P3408, DOI 10.1103/PhysRevLett.80.3408; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; Cleve R, 1997, PHYS REV A, V56, P1201, DOI 10.1103/PhysRevA.56.1201; Cory DG, 1998, PHYSICA D, V120, P82, DOI 10.1016/S0167-2789(98)00046-3; Cory DG, 1998, PHYS REV LETT, V81, P2152, DOI 10.1103/PhysRevLett.81.2152; Cory DG, 1997, P NATL ACAD SCI USA, V94, P1634, DOI 10.1073/pnas.94.5.1634; Deutsch D, 1996, PHYS REV LETT, V77, P2818, DOI 10.1103/PhysRevLett.77.2818; DiVincenzo DP, 1998, SUPERLATTICE MICROST, V23, P419, DOI 10.1006/spmi.1997.0520; Dur W, 1999, PHYS REV A, V59, P169, DOI 10.1103/PhysRevA.59.169; Ekert A, 1996, REV MOD PHYS, V68, P733, DOI 10.1103/RevModPhys.68.733; Farhi E, 1998, PHYS REV LETT, V81, P5442, DOI 10.1103/PhysRevLett.81.5442; Fuchs CA, 1997, PHYS REV LETT, V79, P1162, DOI 10.1103/PhysRevLett.79.1162; Furusawa A, 1998, SCIENCE, V282, P706, DOI 10.1126/science.282.5389.706; Gershenfeld NA, 1997, SCIENCE, V275, P350, DOI 10.1126/science.275.5298.350; Gottesman D, 1996, PHYS REV A, V54, P1862, DOI 10.1103/PhysRevA.54.1862; Griffiths RB, 1997, PHYS REV A, V56, P1173, DOI 10.1103/PhysRevA.56.1173; Grover LK, 1997, PHYS REV LETT, V79, P325, DOI 10.1103/PhysRevLett.79.325; Haroche S, 1997, PHILOS T R SOC A, V355, P2367, DOI 10.1098/rsta.1997.0133; Helstrom CW, 1976, QUANTUM DETECTION ES; Holevo A. S., 1977, Reports on Mathematical Physics, V12, P273, DOI 10.1016/0034-4877(77)90010-6; Holevo AS, 1998, IEEE T INFORM THEORY, V44, P269, DOI 10.1109/18.651037; Horodecki M, 1998, PHYS REV LETT, V80, P5239, DOI 10.1103/PhysRevLett.80.5239; Jones JA, 1999, PHYS REV LETT, V83, P1050, DOI 10.1103/PhysRevLett.83.1050; Jones JA, 1998, J CHEM PHYS, V109, P1648, DOI 10.1063/1.476739; JOZSA R, 1994, J MOD OPTIC, V41, P2343, DOI 10.1080/09500349414552191; Kempe J, 1999, PHYS REV A, V60, P910, DOI 10.1103/PhysRevA.60.910; Kholevo A. S., 1973, Problems of Information Transmission, V9, P177; Kholevo A. S., 1979, Problems of Information Transmission, V15, P247; Laflamme R, 1998, PHILOS T R SOC A, V356, P1941, DOI 10.1098/rsta.1998.0257; Linden N, 1999, PHYS REV LETT, V83, P243, DOI 10.1103/PhysRevLett.83.243; Linden N, 1998, CHEM PHYS LETT, V296, P61, DOI 10.1016/S0009-2614(98)01015-X; LLOYD S, 1993, SCIENCE, V261, P1569, DOI 10.1126/science.261.5128.1569; LLOYD S, 1994, SCIENCE, V263, P695, DOI 10.1126/science.263.5147.695; LO H, 1997, QUANTPH9707038; Lo HK, 1999, SCIENCE, V283, P2050, DOI 10.1126/science.283.5410.2050; Lo HK, 1997, PHYS REV LETT, V78, P3410, DOI 10.1103/PhysRevLett.78.3410; Mabuchi H, 1996, OPT LETT, V21, P1393, DOI 10.1364/OL.21.001393; Mattle K, 1996, PHYS REV LETT, V76, P4656, DOI 10.1103/PhysRevLett.76.4656; Mayers D, 1997, PHYS REV LETT, V78, P3414, DOI 10.1103/PhysRevLett.78.3414; MAYERS D, 1998, QUANTPH9802025; Muller A, 1997, APPL PHYS LETT, V70, P793, DOI 10.1063/1.118224; Nielsen MA, 1998, NATURE, V396, P52, DOI 10.1038/23891; OZHIGOV Y, 1997, QUANTPH9712051; Preskill J, 1998, P ROY SOC A-MATH PHY, V454, P385, DOI 10.1098/rspa.1998.0167; Sasaki M, 1998, PHYS REV A, V58, P146, DOI 10.1103/PhysRevA.58.146; Schumacher B, 1996, PHYS REV LETT, V76, P3452, DOI 10.1103/PhysRevLett.76.3452; SHOR PW, 1995, PHYS REV A, V52, pR2493, DOI 10.1103/PhysRevA.52.R2493; SHOR PW, 1994, AN S FDN CO, P124; Steane A, 1996, P ROY SOC A-MATH PHY, V452, P2551, DOI 10.1098/rspa.1996.0136; Terhal B. M., 1999, THESIS U AMSTERDAM; Thapliyal AV, 1999, PHYS REV A, V59, P3336, DOI 10.1103/PhysRevA.59.3336; Turchette QA, 1998, PHYS REV LETT, V81, P3631, DOI 10.1103/PhysRevLett.81.3631; VAIDMAN L, 1994, PHYS REV A, V49, P1473, DOI 10.1103/PhysRevA.49.1473; van Enk SJ, 1999, PHYS REV A, V59, P2659, DOI 10.1103/PhysRevA.59.2659; vanEnk SJ, 1997, PHYS REV LETT, V78, P4293, DOI 10.1103/PhysRevLett.78.4293; VIDAL G, 1998, QUANTPH9807077; WIESNER S, 1996, QUANTPH9603028	79	1882	1985	16	475	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					247	255		10.1038/35005001	http://dx.doi.org/10.1038/35005001			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749200				2022-12-28	WOS:000086022200038
J	Hemley, RJ				Hemley, RJ			High-pressure physics - The element of uncertainty	NATURE			English	Editorial Material							SOLID HYDROGEN; DENSE HYDROGEN; POLARIZATION; GPA		Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Carnegie Inst Washington, Ctr High Pressure Res, Washington, DC 20015 USA	Carnegie Institution for Science; Carnegie Institution for Science	Hemley, RJ (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.							Benoit M, 1998, NATURE, V392, P258, DOI 10.1038/32609; DIXON DA, 1977, FARADAY DISCUSS, P110; Edwards B, 1997, NATURE, V388, P652, DOI 10.1038/41645; FRIEDLI C, 1977, PHYS REV B, V16, P662, DOI 10.1103/PhysRevB.16.662; HEMLEY RJ, 1994, NATURE, V369, P384, DOI 10.1038/369384a0; Johnson KA, 2000, NATURE, V403, P632, DOI 10.1038/35001024; Kitamura H, 2000, NATURE, V404, P259, DOI 10.1038/35005027; Kohanoff J, 1999, PHYS REV LETT, V83, P4097, DOI 10.1103/PhysRevLett.83.4097; Mazin II, 1997, PHYS REV LETT, V78, P1066, DOI 10.1103/PhysRevLett.78.1066; Nagao K, 1999, PHYS REV B, V59, P13741, DOI 10.1103/PhysRevB.59.13741; Richardson CF, 1997, PHYS REV LETT, V78, P118, DOI 10.1103/PhysRevLett.78.118; Souza I, 1998, PHYS REV LETT, V81, P4452, DOI 10.1103/PhysRevLett.81.4452; TSE JS, 1995, NATURE, V378, P595, DOI 10.1038/378595a0; Weir ST, 1996, PHYS REV LETT, V76, P1860, DOI 10.1103/PhysRevLett.76.1860; Wigner E, 1935, J CHEM PHYS, V3, P764, DOI 10.1063/1.1749590	15	4	4	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					240	241		10.1038/35005205	http://dx.doi.org/10.1038/35005205			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749195				2022-12-28	WOS:000086022200032
J	Pagola, S; Stephens, PW; Bohle, DS; Kosar, AD; Madsen, SK				Pagola, S; Stephens, PW; Bohle, DS; Kosar, AD; Madsen, SK			The structure of malaria pigment beta-haematin	NATURE			English	Article							FALCIPARUM HEMOGLOBIN DEGRADATION; PLASMODIUM-FALCIPARUM; HEME POLYMERIZATION; POWDER DIFFRACTION; IRON ENVIRONMENT; HEMATIN; CHLOROQUINE; MECHANISM; TROPHOZOITES; INHIBITION	Despite the worldwide public health impact of malaria, neither the mechanism by which the Plasmodium parasite detoxifies and sequesters haem, nor the action of current antimalarial drugs is well understood. The haem groups released from the digestion of the haemoglobin of infected red blood cells are aggregated into an insoluble material called haemozoin or malaria pigment. Synthetic beta-haematin (Fe-III-protoporphyrin-IX)(2) is chemically(1,2). spectroscopically(2,3) and crystallographically(4) identical to haemozoin and is believed to consist of strands of Fe-III-porphyrin units, linked into a polymer by propionate oxygen-iron bonds. Here we report the crystal structure of beta-haematin determined using simulated annealing techniques to analyse powder diffraction data obtained with synchrotron radiation. The molecules are linked into dimers through reciprocal iron-carboxylate bonds to one of the propionic side chains of each porphyrin, and the dimers form chains linked by hydrogen bonds in the crystal. This result has implications for understanding the action of current antimalarial drugs and possibly for the design of new therapeutic agents.	SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA; Univ Wyoming, Dept Chem, Laramie, WY 82071 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wyoming	Stephens, PW (corresponding author), SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA.			PAGOLA, SILVINA/0000-0003-2083-7599				Adams PA, 1996, J INORG BIOCHEM, V63, P69, DOI 10.1016/0162-0134(95)00212-X; Andreev YG, 1998, J CHEM SOC DALTON, P4071, DOI 10.1039/a805437a; BENDRAT K, 1995, NATURE, V378, P138, DOI 10.1038/378138a0; Bohle DS, 1997, J BIOL CHEM, V272, P713, DOI 10.1074/jbc.272.2.713; BOHLE DS, 1993, BIOCHEM BIOPH RES CO, V193, P504, DOI 10.1006/bbrc.1993.1652; Bohle DS, 1998, J AM CHEM SOC, V120, P8255, DOI 10.1021/ja980962u; BOHLE DS, 1994, ACS SYM SER, V572, P497; BOMINAAR EL, 1992, INORG CHEM, V31, P1845, DOI 10.1021/ic00036a023; David WIF, 1998, CHEM COMMUN, P931, DOI 10.1039/a800855h; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; Dorn A, 1998, BIOCHEM PHARMACOL, V55, P727, DOI 10.1016/S0006-2952(97)00510-8; Egan TJ, 1999, J INORG BIOCHEM, V73, P101, DOI 10.1016/S0162-0134(98)10095-8; FITCH CD, 1987, J BIOL CHEM, V262, P15552; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; KOENIG DF, 1965, ACTA CRYSTALLOGR, V18, P663, DOI 10.1107/S0365110X65001536; LARSON AC, 1987, LAUR86748 LOS AL LAB; LE BAIL A, 1988, MATER RES BULL, V23, P447, DOI 10.1016/0025-5408(88)90019-0; LEMBERG R, 1949, HAEMATIN COMPOUNDS B; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; RIDLEY RG, 1995, NATURE, V378, P138, DOI 10.1038/378138b0; Scheidt W.R., 1987, METAL COMPLEXES TETR, V64, P1, DOI DOI 10.1007/BFB0036789; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; Sullivan DJ, 1998, J BIOL CHEM, V273, P31103, DOI 10.1074/jbc.273.47.31103; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784	30	707	732	0	100	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					307	310		10.1038/35005132	http://dx.doi.org/10.1038/35005132			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749217				2022-12-28	WOS:000086022200055
J	Park, SD; Vohs, JM; Gorte, RJ				Park, SD; Vohs, JM; Gorte, RJ			Direct oxidation of hydrocarbons in a solid-oxide fuel cell	NATURE			English	Article							METHANE; CERIA	The direct electrochemical oxidation of dry hydrocarbon fuels to generate electrical power has the potential to accelerate substantially the use of fuel cells in transportation and distributed-power applications(1). Most fuel-cell research has involved the use of hydrogen as the fuel, although the practical generation and storage of hydrogen remains an important technological hurdle(2). Methane has been successfully oxidized electrochemically(3-6), but the susceptibility to carbon formation from other hydrocarbons that may be present or poor power densities have prevented the application of this simple fuel in practical applications(1). Here we report the direct, electrochemical oxidation of various hydrocarbons (methane, ethane, 1-butene, n-butane and toluene) using a solid-oxide fuel cell at 973 and 1,073 K with a composite anode of copper and ceria (or samaria-doped ceria). We demonstrate that the final products of the oxidation are CO2 and water, and that reasonable power densities can be achieved. The observation that a solid-oxide fuel cell can be operated on dry hydrocarbons, including liquid fuels, without reforming suggests that this type of fuel cell could provide an alternative to hydrogen-based fuel-cell technologies.	Univ Penn, Dept Chem Engn, Philadelphia, PA 19104 USA	University of Pennsylvania	Gorte, RJ (corresponding author), Univ Penn, Dept Chem Engn, Philadelphia, PA 19104 USA.	gorte@seas.upenn.edu	Vohs, John M/C-8246-2019	Vohs, John/0000-0002-8283-5241				CHRISTENSEN H, 1999, 1999010472 SOC AUT E, P1; Craciun R, 1999, J ELECTROCHEM SOC, V146, P4019, DOI 10.1149/1.1392586; Lloyd AC, 1999, SCI AM, V281, P80, DOI 10.1038/scientificamerican0799-80; Marina OA, 1999, APPL CATAL A-GEN, V189, P117, DOI 10.1016/S0926-860X(99)00259-8; Murray EP, 1999, NATURE, V400, P649, DOI 10.1038/23220; Park S, 1999, J ELECTROCHEM SOC, V146, P3603, DOI 10.1149/1.1392521; Putna ES, 1995, LANGMUIR, V11, P4832, DOI 10.1021/la00012a040; Service RF, 1999, SCIENCE, V285, P682, DOI 10.1126/science.285.5428.682; STEELE BCH, 1988, SOLID STATE IONICS, V28, P1547, DOI 10.1016/0167-2738(88)90417-1; Steele BCH, 1999, NATURE, V400, P619, DOI 10.1038/23144; Trovarelli A, 1996, CATAL REV, V38, P439, DOI 10.1080/01614949608006464; YAMANAKA I, 1995, J MOL CATAL A-CHEM, V95, P115, DOI 10.1016/1381-1169(94)00015-8	12	1618	1675	21	755	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					265	267		10.1038/35005040	http://dx.doi.org/10.1038/35005040			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749204				2022-12-28	WOS:000086022200042
J	Messerli, FH				Messerli, FH			Implications of discontinuation of doxazosin arm of ALLHAT	LANCET			English	Editorial Material									Ochsner Med Inst, Dept Hypertens, New Orleans, LA 70121 USA	Ochsner Health System	Messerli, FH (corresponding author), Ochsner Med Inst, Dept Hypertens, New Orleans, LA 70121 USA.		Messerli, Franz/AAR-4783-2021					Black HR, 1997, ARCH INTERN MED, V157, P2413; Chalmers J, 1999, J HYPERTENS, V17, P151; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; Feldman RD, 1999, CAN MED ASSOC J, V161, pS1; Grimm RH, 1996, JAMA-J AM MED ASSOC, V275, P1549, DOI 10.1001/jama.275.20.1549; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; KAPLAN NM, 2000, ABCS ANTIHYPERTENSIV, P99; PLOUIN PF, 1997, DIAGNOSTIC TRAITMENT, P241; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; *UK PROSP DIAB GRO, 1998, BRIT MED J, V291, P97; White WB, 2000, AM J MED, V108, P238, DOI 10.1016/S0002-9343(99)00444-1	12	56	56	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					863	864		10.1016/S0140-6736(00)00092-1	http://dx.doi.org/10.1016/S0140-6736(00)00092-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752699				2022-12-28	WOS:000085896000005
J	Sherertz, RJ; Ely, EW; Westbrook, DM; Gledhill, KS; Streed, SA; Kiger, B; Flynn, L; Hayes, S; Strong, S; Cruz, J; Bowton, DL; Hulgan, T; Haponik, EF				Sherertz, RJ; Ely, EW; Westbrook, DM; Gledhill, KS; Streed, SA; Kiger, B; Flynn, L; Hayes, S; Strong, S; Cruz, J; Bowton, DL; Hulgan, T; Haponik, EF			Education of physicians-in-training can decrease the risk for vascular catheter infection	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; TEST-ORDERING BEHAVIOR; INTRAVENOUS THERAPY TEAM; BLOOD-STREAM INFECTIONS; PROCEDURAL SKILLS; NOSOCOMIAL INFECTIONS; VEIN CATHETERIZATION; COMPUTER REMINDERS; PREVENTIVE CARE; COST-EDUCATION	Background: Procedure instruction for physicians-in-training is usually nonstandardized. The authors observed that during insertion of central Venous catheters (CVCs), few physicians used full-size sterile drapes (an intervention proven to reduce the risk for CVC-related infection). Objective: To improve standardization of infection control practices and techniques during invasive procedures. Design: Nonrandomized pre-post observational trial. Setting: Six intensive care units and one step-down unit at Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina. Participants: Third-year medical students and physicians completing their first postgraduate year. Intervention: Al-day course on infection control practices and procedures given in June 1996 and June 1997. Measurements: Surveys assessing physician attitudes toward use of sterile techniques during insertion of CVCs were administered during the baseline year and just before, immediately after, and 6 months after the first course. Preintervention and postintervention use of full size sterile drapes was measured, and surveillance for vascular catheter-related infection was performed. Results: The perceived need for full-size sterile drapes was 22% in the year before the course and 73% 6 months after the course (P < 0.001). The perceived need for small sterile towels at the insertion site decreased reciprocally (P < 0.001). Documented use of full-size sterile drapes increased from 44% to 65% (P < 0.001). The rate of catheter-related infection decreased from 4.51 infections per 1000 patient-days before the first course to 2.92 infections per 1000 patient-days 18 months after the first course (average decrease, 3.23 infections per 1000 patient-days; P < 0.01). The estimated cost savings of this 28% decrease was at least $63 000 and may have exceeded $800 000. Conclusions: Standardization of infection control practices through a course is a cost-effective way to decrease related adverse outcomes. If these findings can be reproduced, this approach may serve as a model for physicians-in-training.	N Carolina Baptist Hosp, Winston Salem, NC 27103 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University	Sherertz, RJ (corresponding author), Wake Forest Univ, Baptist Med Ctr, Dept Internal Med, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.	sherertz@wfubmc.edu	Hulgan, Todd/B-3947-2014; Ely, E. Wesley/Z-2018-2019; Bowton, David/AAZ-2916-2020; Hulgan, Todd/AAG-7491-2019	Hulgan, Todd/0000-0002-3339-067X; Ely, E. Wesley/0000-0003-3957-2172; 				AMIRAV I, 1995, J ALLERGY CLIN IMMUN, V95, P818, DOI 10.1016/S0091-6749(95)70124-9; ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; Baldwin PJ, 1998, LANCET, V351, P804, DOI 10.1016/S0140-6736(05)78931-5; BARTTER T, 1993, CHEST, V103, P1873, DOI 10.1378/chest.103.6.1873; BILLI JE, 1987, J GEN INTERN MED, V2, P306, DOI 10.1007/BF02596163; BOLINN GW, 1982, CATHETER CARDIO DIAG, V8, P23, DOI 10.1002/ccd.1810080105; CHANDLER JR, 1983, OTOLARYNG HEAD NECK, V91, P239, DOI 10.1177/019459988309100307; CHENEY C, 1987, AM J MED, V83, P129, DOI 10.1016/0002-9343(87)90507-9; COHEN DI, 1982, MED CARE, V20, P286, DOI 10.1097/00005650-198203000-00005; COHEN SJ, 1985, SOC SCI MED, V21, P909, DOI 10.1016/0277-9536(85)90147-9; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; Elliott RL, 1996, ACAD MED, V71, P243, DOI 10.1097/00001888-199603000-00012; EVERETT GD, 1983, ARCH INTERN MED, V143, P942, DOI 10.1001/archinte.143.5.942; FARES LG, 1986, AM SURGEON, V52, P108; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GEHLBACH SH, 1984, MED CARE, V22, P193, DOI 10.1097/00005650-198403000-00002; HALEY RW, 1985, AM J EPIDEMIOL, V121, P182, DOI 10.1093/oxfordjournals.aje.a113990; HAWES R, 1986, AM J MED, V80, P465, DOI 10.1016/0002-9343(86)90721-7; HEADRICK LA, 1992, ARCH INTERN MED, V152, P2490, DOI 10.1001/archinte.152.12.2490; HELMS LB, 1991, ACAD MED, V66, P718, DOI 10.1097/00001888-199112000-00002; HERSHEY CO, 1987, MED CARE, V25, P72, DOI 10.1097/00005650-198701000-00008; HERSHEY CO, 1986, MED CARE, V24, P472, DOI 10.1097/00005650-198606000-00002; JARVIS WR, 1991, AM J MED, V91, pS185, DOI 10.1016/0002-9343(91)90367-7; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P285; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; LAVIES NG, 1988, AM J GASTROENTEROL, V83, P618; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; MAIN DS, 1995, AM J PREV MED, V11, P54, DOI 10.1016/S0749-3797(18)30501-4; Maki Dennis G., 1994, P155; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1990, 3 INT C NOS INF ATL; MANDEL JH, 1988, ARCH INTERN MED, V148, P853, DOI 10.1001/archinte.148.4.853; MANHEIM LM, 1990, MED CARE, V28, P29, DOI 10.1097/00005650-199001000-00005; MANU P, 1990, MED TEACH, V12, P367, DOI 10.3109/01421599009006645; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; MARTON KI, 1985, ARCH INTERN MED, V145, P816, DOI 10.1001/archinte.145.5.816; MAZZUCA SA, 1988, J GEN INTERN MED, V3, P1, DOI 10.1007/BF02595748; MCCORMICK R, 1989, 29 INT C ANT AG CHEM; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; NYSTROM B, 1983, J HOSP INFECT, V4, P338, DOI 10.1016/0195-6701(83)90004-X; PHELPS KA, 1996, ED RES METH, V28, P565; PITTET D, 1994, JAMA-J AM MED ASSOC, V272, P1820; PUGH JA, 1989, ARCH INTERN MED, V149, P426, DOI 10.1001/archinte.149.2.426; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; RICHET H, 1990, J CLIN MICROBIOL, V28, P2520, DOI 10.1128/JCM.28.11.2520-2525.1990; ROTER DL, 1990, J GEN INTERN MED, V5, P347, DOI 10.1007/BF02600404; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; SIMPSON ET, 1982, J TRAUMA, V22, P781, DOI 10.1097/00005373-198209000-00011; SMITH RL, 1991, CHEST, V100, P164, DOI 10.1378/chest.100.1.164; Soifer NE, 1998, ARCH INTERN MED, V158, P473, DOI 10.1001/archinte.158.5.473; STEELE MA, 1989, DICP ANN PHARMAC, V23, P497, DOI 10.1177/106002808902300612; SULMASY DP, 1993, J MED ETHICS, V19, P157, DOI 10.1136/jme.19.3.157; SULMASY DP, 1992, JAMA-J AM MED ASSOC, V267, P682; SZNAJDER JI, 1986, ARCH INTERN MED, V146, P259, DOI 10.1001/archinte.146.2.259; Taylor DM, 1997, MED J AUSTRALIA, V166, P251, DOI 10.5694/j.1326-5377.1997.tb140106.x; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; TOMFORD JW, 1984, ARCH INTERN MED, V144, P1191, DOI 10.1001/archinte.144.6.1191; TURNER RC, 1990, ARCH INTERN MED, V150, P645, DOI 10.1001/archinte.150.3.645; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; WIDMER AF, 1997, CATHETER RELATED INF, P183; WIGTON RS, 1989, ANN INTERN MED, V111, P932, DOI 10.7326/0003-4819-111-11-932; WIGTON RS, 1992, ANN INTERN MED, V116, P1091, DOI 10.7326/0003-4819-116-12-1091; 1992, MMWR MORB MORT WKLY, V41, P783	72	250	259	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					641	648		10.7326/0003-4819-132-8-200004180-00007	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766683				2022-12-28	WOS:000086497500006
J	O'Brien, J; Duncan, H; Kirsh, G; Allen, V; King, P; Hargraves, R; Mendes, L; Perera, T; Catto, P; Schofield, S; Ploschke, H; Hefner, T; Churchland, M; Woolnough, S; Wuttke, R; Manning, M; Jeffries, T; Hensley, L; Bath, P; Bainbridge, D; Guinane, F; McMahon, L; Zavattaro, D; Wilson, D; Blake, K; Morton, J; Sharman, D; Locke, R; Ghabrial, J; McNeil, S; Rehfisch, P; van der Merwe, S; Einoder, B; Douglas, D; Ashwell, J; Morrissey, A; Brown, A; Simm, R; Fisch, G; Crawford, W; Everding, T; Tanham, D; Hooper, J; Aldana, C; Goldwasser, M; Mibus, M; Rowden, N; Mills, J; Johnson, P; Stilwell, J; Williams, R; Stevenson, T; Zwar, J; Bauze, R; Nyunt, B; Russell, R; Day, G; Cameron, M; Clements, P; Beck, T; Ellis, A; Phipps, S; Quaill, W; Skirving, A; McGuiness, M; Gray, P; Rankin, J; Wood, D; Senior, J; Courtenay, B; Green, M; Harris, I; Rush, J; Kilgour, M; Davies, J; Newcombe, J; Lewis, C; Leitl, S; Chilcott, R; Pianta, R; Aguila, A; Hawe, C; Nade, S; Smith, M; Robertson, P; Rothwell, A; May, S; Williams, S; Rothwell, A; Shamy, S; Martin, G; Steele, V; Jeffery, K; Kelman, I; McKillan, J; Dayaram, P; Culling, J; Lawson, D; Winfield, P; Kuzel, R; Milburn, C; Palmer, N; Pitts, A; Lamb, G; Prodan, L; Gray, H; Walker, K; Smith, K; Newton, C; Atkinson, D; Fail, B; Panting, A; Menzies, J; Watkiss, A; Robertson, P; Outhred, J; Clay, D; Lander, R; Fou, R; Clarke, DS; Murrell, T; Rolleston, B; Clarke, DS; Keyworth, S; Medlicott, P; Woods, T; Dawe, C; Waldron, R; Taine, W; Le Roy, L; Smith, A; Cowley, G; Campbell, C; Maxwell, R; Elvy, M; Thurston, A; Newth, S; Cousins, L; Sanderson, M; MacMillan, C; Golele, R; Walters, J; Kruger, S; Ramsden, T; Joseph, H; Gantz, D; Steyn, S; Hadjichristofis, S; Nojoko, L; Snowdowne, R; Botha, M; Knebel, R; Sernbo, I; Ferris, B; Tello, E; Nevelos, A; Dunn, C; Warwick, D; Sudhakar, J; Tuite, JD; Francis, J; Wallace, ME; Jordan, A; Baird, P; Fowler, W; Ainscow, DAP; Harrison, A; Butler-Manuel, A; Palmer, N; Broome, G; Swailes, P; Stahl, TJ; Randall, AM; Forester, AJ; Hucker, J; Redden, J; Logan, L; Howard, PW; Brownlee, D; Angus, P; Boyce, A; Porter, BB; Arbid, M; Youll, J; Ogden, AS; MacDowell, C; Beverly, M; Ramdeholl, P; Nelson, I; Howlett, I; Warwick, D; Weeber, A; Peacock, A; Hubbard, MJS; Flanagan, M; Crawshaw, C; Kinninmonth, A; Campbell, T; Tibrewal, S; Lennox, CME; Clifford, I; Gillham, N; Hunt, M; Bulstrode, C; Handley, R; Iyer, V; Lawton, J; Robbins, J; Harper, WM; Davison, J; Hope, P; Smallbones, K; Jones, W; Ratnam, KR; Upton, J; Hirst, P; Knox, S; Sadique, T; Khan, M; Umar, M; Anderson, J; Frank, J; Briggs, P; Sanderson, P; McBride, D; Leese, K; Bayliss, NC; El-Deen, M; Banan, H; Williams, S; Parker, MJ; Minhas, H; Best, A; Blakeway, C; Salter, T; Foy, MA; Pollitt, A; Blayney, JDM; Davis, S; Parnell, E; Ko, C; Grover, ML; Howells, S; Williams, D; Saunders, C; Brenkel, I; Mani, G; Grizzle, M; Henderson, A; Board, T; Chadwick, CJ; Overton, M; Hodkinson, S; Macdonald, DA; Lewis, V; McDonald, RJM; Adamson, J; Bradley, J; Hodgson, E; Plewes, JL; Clarke, D; Hullin, M; Smith, J; Lemon, GJ; Greatrex, K; Miles, C; Bannister, G; Dare, J; Carden, DG; Aughton, J; Stirrat, A; Fishburn, J; Ebizie, AO; Mason, M; Irvine, G; Facey, T; Spratt, C; Briggs, P; Kanagavel, N; Gerrard, T; Reissis, N; Tzanetos, P; Stefanotti, M; Greiss, M; Wright, V; Rahmaty, A; Archer, J; Bedford, A; Taylor, D; Griffith, M; Evans, J; Heron, K; Livingstone, B; O'Dwyer, K; Wheatley, D; Lemon, GJ; Miles, C; Campbell, P; Dixon, P; McSweeney, L; Shanahan, MDG; Griffith, I; MacMahon, S; Rodgers, A; Collins, R; Prentice, C; Gray, H; MacMahon, S; Norton, R; Ockleford, P; Rodgers, A; Rutland, M; Collins, R; Prentice, C; Dickinson, J; Gregg, P; Macdonald, D; Mollan, RAB; Douglas, J; Beaumont, D; Broad, J; Clark, T; Henderson, M; McCulloch, A; Neal, B; Prasad, R; Walker, N; Wood, M; Beighton, A; Bell, P; Farrell, B; Murch, K; Sharpe, N; Gordon, G; Doughty, R; Ratnasabapathy, Y; Danesh, J; Sleight, P; Peto, R; Simes, J; Keech, A; Rodgers, A; MacMahon, S; Collins, R; Prentice, C				O'Brien, J; Duncan, H; Kirsh, G; Allen, V; King, P; Hargraves, R; Mendes, L; Perera, T; Catto, P; Schofield, S; Ploschke, H; Hefner, T; Churchland, M; Woolnough, S; Wuttke, R; Manning, M; Jeffries, T; Hensley, L; Bath, P; Bainbridge, D; Guinane, F; McMahon, L; Zavattaro, D; Wilson, D; Blake, K; Morton, J; Sharman, D; Locke, R; Ghabrial, J; McNeil, S; Rehfisch, P; van der Merwe, S; Einoder, B; Douglas, D; Ashwell, J; Morrissey, A; Brown, A; Simm, R; Fisch, G; Crawford, W; Everding, T; Tanham, D; Hooper, J; Aldana, C; Goldwasser, M; Mibus, M; Rowden, N; Mills, J; Johnson, P; Stilwell, J; Williams, R; Stevenson, T; Zwar, J; Bauze, R; Nyunt, B; Russell, R; Day, G; Cameron, M; Clements, P; Beck, T; Ellis, A; Phipps, S; Quaill, W; Skirving, A; McGuiness, M; Gray, P; Rankin, J; Wood, D; Senior, J; Courtenay, B; Green, M; Harris, I; Rush, J; Kilgour, M; Davies, J; Newcombe, J; Lewis, C; Leitl, S; Chilcott, R; Pianta, R; Aguila, A; Hawe, C; Nade, S; Smith, M; Robertson, P; Rothwell, A; May, S; Williams, S; Rothwell, A; Shamy, S; Martin, G; Steele, V; Jeffery, K; Kelman, I; McKillan, J; Dayaram, P; Culling, J; Lawson, D; Winfield, P; Kuzel, R; Milburn, C; Palmer, N; Pitts, A; Lamb, G; Prodan, L; Gray, H; Walker, K; Smith, K; Newton, C; Atkinson, D; Fail, B; Panting, A; Menzies, J; Watkiss, A; Robertson, P; Outhred, J; Clay, D; Lander, R; Fou, R; Clarke, DS; Murrell, T; Rolleston, B; Clarke, DS; Keyworth, S; Medlicott, P; Woods, T; Dawe, C; Waldron, R; Taine, W; Le Roy, L; Smith, A; Cowley, G; Campbell, C; Maxwell, R; Elvy, M; Thurston, A; Newth, S; Cousins, L; Sanderson, M; MacMillan, C; Golele, R; Walters, J; Kruger, S; Ramsden, T; Joseph, H; Gantz, D; Steyn, S; Hadjichristofis, S; Nojoko, L; Snowdowne, R; Botha, M; Knebel, R; Sernbo, I; Ferris, B; Tello, E; Nevelos, A; Dunn, C; Warwick, D; Sudhakar, J; Tuite, JD; Francis, J; Wallace, ME; Jordan, A; Baird, P; Fowler, W; Ainscow, DAP; Harrison, A; Butler-Manuel, A; Palmer, N; Broome, G; Swailes, P; Stahl, TJ; Randall, AM; Forester, AJ; Hucker, J; Redden, J; Logan, L; Howard, PW; Brownlee, D; Angus, P; Boyce, A; Porter, BB; Arbid, M; Youll, J; Ogden, AS; MacDowell, C; Beverly, M; Ramdeholl, P; Nelson, I; Howlett, I; Warwick, D; Weeber, A; Peacock, A; Hubbard, MJS; Flanagan, M; Crawshaw, C; Kinninmonth, A; Campbell, T; Tibrewal, S; Lennox, CME; Clifford, I; Gillham, N; Hunt, M; Bulstrode, C; Handley, R; Iyer, V; Lawton, J; Robbins, J; Harper, WM; Davison, J; Hope, P; Smallbones, K; Jones, W; Ratnam, KR; Upton, J; Hirst, P; Knox, S; Sadique, T; Khan, M; Umar, M; Anderson, J; Frank, J; Briggs, P; Sanderson, P; McBride, D; Leese, K; Bayliss, NC; El-Deen, M; Banan, H; Williams, S; Parker, MJ; Minhas, H; Best, A; Blakeway, C; Salter, T; Foy, MA; Pollitt, A; Blayney, JDM; Davis, S; Parnell, E; Ko, C; Grover, ML; Howells, S; Williams, D; Saunders, C; Brenkel, I; Mani, G; Grizzle, M; Henderson, A; Board, T; Chadwick, CJ; Overton, M; Hodkinson, S; Macdonald, DA; Lewis, V; McDonald, RJM; Adamson, J; Bradley, J; Hodgson, E; Plewes, JL; Clarke, D; Hullin, M; Smith, J; Lemon, GJ; Greatrex, K; Miles, C; Bannister, G; Dare, J; Carden, DG; Aughton, J; Stirrat, A; Fishburn, J; Ebizie, AO; Mason, M; Irvine, G; Facey, T; Spratt, C; Briggs, P; Kanagavel, N; Gerrard, T; Reissis, N; Tzanetos, P; Stefanotti, M; Greiss, M; Wright, V; Rahmaty, A; Archer, J; Bedford, A; Taylor, D; Griffith, M; Evans, J; Heron, K; Livingstone, B; O'Dwyer, K; Wheatley, D; Lemon, GJ; Miles, C; Campbell, P; Dixon, P; McSweeney, L; Shanahan, MDG; Griffith, I; MacMahon, S; Rodgers, A; Collins, R; Prentice, C; Gray, H; MacMahon, S; Norton, R; Ockleford, P; Rodgers, A; Rutland, M; Collins, R; Prentice, C; Dickinson, J; Gregg, P; Macdonald, D; Mollan, RAB; Douglas, J; Beaumont, D; Broad, J; Clark, T; Henderson, M; McCulloch, A; Neal, B; Prasad, R; Walker, N; Wood, M; Beighton, A; Bell, P; Farrell, B; Murch, K; Sharpe, N; Gordon, G; Doughty, R; Ratnasabapathy, Y; Danesh, J; Sleight, P; Peto, R; Simes, J; Keech, A; Rodgers, A; MacMahon, S; Collins, R; Prentice, C		Pulmonary Embolism Prevention Tri	Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; ENTERIC-COATED ASPIRIN; VENOUS THROMBOSIS; ORTHOPEDIC SURGEONS; RANDOMIZED TRIALS; THROMBOPROPHYLAXIS; MORTALITY; RISK		Univ Auckland, Dept Med, Clin Trial Res Unit, Auckland, New Zealand; Prince Wales Hosp, Sydney, NSW, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; Queen Elizabeth Hosp, Adelaide, SA, Australia; Royal Hobart Hosp, Hobart, Tas, Australia; Geelong Hosp, Geelong, Vic, Australia; Box Hill Hosp, Box Hill, Vic, Australia; Bathurst Hosp, Bathurst, NSW, Australia; Coffs Harbour Hosp, Coffs Harbour, NSW, Australia; Gold Coast Hosp, Gold Coast, Qld, Australia; Gosford Hosp, Gosford, NSW, Australia; John Hunter Hosp, Newcastle, NSW, Australia; Latrobe Hosp, Traralgon, Vic, Australia; Launceston Hosp, Launceston, Tas, Australia; Maroondah Hosp, Ringwood, Vic, Australia; Monash Hosp, Clayton, Vic, Australia; Royal Perth Hosp, Perth, WA, Australia; Royal Brisbane Hosp, Brisbane, Qld 4029, Australia; Rockhampton Hosp, Rockhampton, Qld, Australia; Royal Hobart Hosp, Hobart, Tas, Australia; Royal N Shore Hosp, St Leonards, NSW 2065, Australia; Royal Perth Hosp, Perth, WA, Australia; Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia; St Vincents Hosp, Sydney, NSW 2010, Australia; St Vincents Hosp, Melbourne, Vic, Australia; Austin Hosp, Melbourne, Vic 3084, Australia; Hosp Bankstown, Bankstown, NSW, Australia; Bendigo Hosp, Bendigo, Vic, Australia; Tamworth Hosp, Tamworth, NSW, Australia; Wangaratta Hosp, Wangaratta, Vic, Australia; Western Hosp, Parkville, Vic, Australia; Westmead Hosp, Westmead, NSW 2145, Australia; Auckland Hosp, Auckland, New Zealand; Burwood Hosp, Christchurch, New Zealand; Christchurch Hosp, Christchurch, New Zealand; Dunedin Publ Hosp, Dunedin, New Zealand; Gisborne Hosp, Gisborne, New Zealand; Greymouth Hosp, Greymouth, New Zealand; Hastings Hosp, Hastings, New Zealand; Hutt Hosp, Lower Hutt, New Zealand; Kenepuru Hosp, Wellington, New Zealand; Mercy Hosp, Auckland, New Zealand; Middlemore Hosp, Auckland 6, New Zealand; Napier Hosp, Napier, New Zealand; N Shore Hosp, Auckland, New Zealand; Palmerston N Hosp, Palmerston North, New Zealand; Queen Elizabeth Hosp, Rotorua, New Zealand; Rotorua Hosp, Rotorua, New Zealand; Taranaki Base Hosp, New Plymouth, New Zealand; Tauranga Hosp, Tauranga, New Zealand; Timaru Hosp, Timaru, New Zealand; Waikato Hosp, Hamilton, New Zealand; Wairau Hosp, Blenheim, New Zealand; Wellington Hosp, Wellington, New Zealand; Whangarei Hosp, Whangarei, New Zealand; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; Helen Joseph Hosp, Johannesburg, South Africa; Johannesburg Hosp, Johannesburg, South Africa; Natl Hosp, Bloemfontein, South Africa; Malmo Hosp, Malmo, Sweden; Kristianstad Hosp, Kristianstad, Sweden; Barnet Gen Hosp, Barnet, England; Bradford Royal Hosp, Bradford, W Yorkshire, England; Bristol Royal Hosp, Bristol, Avon, England; Broomfield Hosp, Colchester, Essex, England; Burton Hosp, Burton Upon Trent, England; Chelsea & Westminster Hosp, London, England; Cheltenham Gen Hosp, Cheltenham, Glos, England; Conquest Hosp, St Leonards On Sea, England; Cumberland Hosp, Carlisle, England; Darlington Mem Hosp, Darlington, Durham, England; Charing Cross Hosp, London, England; Doncaster Royal Hosp, Doncaster, England; Derbyshire Royal Hosp, Derby, England; Dewsbury Dist Hosp, Dewsbury, England; Dryburn & Shotley Bridge Hosp, Durham, England; Dumfries & Galloway Royal Hosp, Dumfries, Scotland; Ealing Gen Hosp, London, England; Frenchay Hosp, Bristol BS16 1LE, Avon, England; Bristol Hosp, Bristol, Avon, England; Friarage Hosp, Northallerton, England; Glan Clwyd Gen Hosp, Rhyl, Wales; Gloucestershire Royal Hosp, Gloucester GL1 3NN, England; Glasgow Royal Hosp, Glasgow, Lanark, Scotland; Greenwich Dist Hosp, Greenwich, England; Hartlepool Gen Hosp, Hartlepool, England; Horton Gen Hosp, Banbury, England; John Radcliffe Hosp, Oxford OX3 9DU, England; Leeds Gen Hosp, Leeds, W Yorkshire, England; Leicester Royal Infirm, Leicester, Leics, England; Stevenage Hosp, Stevenage, Herts, England; Liverpool Royal & Broadgreen Hosp, Liverpool, Merseyside, England; Macclesfield Hosp, Macclesfield, Cheshire, England; Manchester Royal Infirm, Manchester M13 9WL, Lancs, England; Manor Hosp, Walsall, W Midlands, England; Middlesbrough Gen Hosp, Middlesbrough, Cleveland, England; Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; N Staffordshire Royal Hosp, Stoke On Trent, Staffs, England; N Tees Gen Hosp, Stockton On Tees, England; Oldchurch Hosp, Romford RM7 0BE, Essex, England; Peterborough Dist Gen Hosp, Peterborough, Cambs, England; Pilgrim Hosp, Boston, England; Poole Hosp, Poole, Dorset, England; Princess Margaret Hosp, Swindon, Wilts, England; Prince Wales Hosp, Bridgend, Wales; Princess Royal Hosp, Haywards Heath, England; Queen Alexandra Hosp, Portsmouth, Hants, England; Queen Elizabeth II Hosp, Welwyn Garden City, Herts, England; Queen Margaret Hosp, Dunfermline, Fife, Scotland; Queen Marys Hosp, Sidcup, England; Royal Bolton Hosp, Bolton, England; Royal Hosp Haslar, Gosport, Hants, England; St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England; St Johns Hosp, Howden, England; Scarborough Gen Hosp, Scarborough, England; S Birmingham Hosp, Trauma Unit, Birmingham, W Midlands, England; So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland; S Manchester Hosp, Manchester, Lancs, England; Southmead Gen Hosp, Bristol BS10 5NB, Avon, England; Southport & Formby Dist Gen Hosp, Southport, England; Sunderland Dist Gen, Sunderland, England; Tameside Gen Hosp, Ashton Under Lyne, England; Wansbeck Gen Hosp, Ashington, England; Warrington Dist Gen Hosp, Warrington, Cheshire, England; Watford Dist Gen Hosp, Watford, England; W Cumberland Dist Gen Hosp, Whitehaven, England; W Middlesex Univ Hosp, Isleworth, Middx, England; W Suffolk Hosp, Bury St Edmunds, Suffolk, England; W Wales Gen Hosp, Carmarthen, Dyfed, Wales; Wigan & Leigh Hosp, Wigan, England; Worcester Royal Hosp, Worcester, England; Wythenshawe Hosp, Manchester M23 9LT, Lancs, England; York Dist Gen Hosp, York, N Yorkshire, England; Ysbyty Gwynedd Hosp, Bangor, Gwynedd, Wales	University of Auckland; Royal Hobart Hospital; Geelong Hospital; Box Hill Hospital; Gold Coast University Hospital; John Hunter Hospital; Royal Perth Hospital; University of Western Australia; Royal Brisbane & Women's Hospital; Royal Hobart Hospital; Royal North Shore Hospital; Royal Perth Hospital; University of Western Australia; University of Western Australia; St Vincents Hospital Sydney; St Vincent's Hospital Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Western Hospital; University of Sydney; Auckland City Hospital; Christchurch Hospital New Zealand; Dunedin Public Hospital; Waikato Hospital; University of Cape Town; University of Witwatersrand; Bradford Royal Infirmary; Bristol Royal Hospital For Children; Mid Essex Hospital Services NHS Trust; Broomfield Hospital; Imperial College London; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; Imperial College London; Imperial College London; Gloucestershire Royal Hospital; University of Oxford; Leeds General Infirmary; University of Leicester; University of Manchester; Newcastle General Hospital; University Hospital of North Staffordshire NHS Trust; University Hospital of North Tees; Poole Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Royal Bolton Hospital; Saint James's University Hospital; University of Glasgow; Southmead Hospital; Watford General Hospital; Imperial College London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Prentice, C (corresponding author), Univ Auckland, Dept Med, Clin Trial Res Unit, Private Bag 92019, Auckland, New Zealand.		warwick, david/I-1061-2019; Broad, Joanna B/D-1194-2010; Fisch, Gilberto F./E-5906-2011; Clark, Taane G./AAM-2570-2020; Schofield, Steven R/I-7943-2016; Board, Tim/I-9296-2019; Williams, Richard P/B-2029-2012; Simes, Robert John/P-1497-2014	warwick, david/0000-0003-3030-442X; Broad, Joanna B/0000-0003-0157-7031; Clark, Taane G./0000-0001-8985-9265; Schofield, Steven R/0000-0002-0727-3015; Board, Tim/0000-0002-3295-2087; Neal, Bruce/0000-0002-0490-7465; Rodgers, Anthony/0000-0003-1282-1896; MacMahon, Stephen/0000-0003-2064-7699; Ellis, Andrew/0000-0002-2539-7994				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON FA, 1991, ANN INTERN MED, V115, P591, DOI 10.7326/0003-4819-591; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; COHEN AT, 1994, BRIT MED J, V309, P1213, DOI 10.1136/bmj.309.6963.1213; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COLLINS R, 1994, BMJ-BRIT MED J, V309, P1215, DOI 10.1136/bmj.309.6963.1215; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; *INT CONS STAT, 1997, ANGIOLOGY, V16, P3; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; JIMENEZ AH, 1992, AM J CARDIOL, V69, P258, DOI 10.1016/0002-9149(92)91316-V; Koch A, 1997, BRIT J SURG, V84, P750, DOI 10.1002/bjs.1800840605; LAVERICK MD, 1991, BRIT MED J, V303, P549, DOI 10.1136/bmj.303.6802.549; LOWE GDO, 1992, BMJ-BRIT MED J, V305, P567; MACMAHON S, 1994, J BONE JOINT SURG BR, V76B, P521, DOI 10.1302/0301-620X.76B4.8027132; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167; RODGERS A, 1994, AUST NZ J SURG, V64, P167, DOI 10.1111/j.1445-2197.1994.tb02170.x; Sandercock P, 1997, LANCET, V349, P1569; *SCOTT INT GUID NE, 1995, PROPH VEN THROMB; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124; 1999, DRUG THER B, V37, P89	29	750	762	1	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2000	355	9212					1295	1302						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776741				2022-12-28	WOS:000086829400008
J	Utzinger, J; N'Goran, NK; N'Dri, A; Lengeler, C; Shuhua, X; Tanner, M				Utzinger, J; N'Goran, NK; N'Dri, A; Lengeler, C; Shuhua, X; Tanner, M			Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial	LANCET			English	Article							PRAZIQUANTEL; CHEMOTHERAPY; RESISTANCE; SENEGAL; FOCUS; DRUG	Background Chemotherapy with praziquantel is the current strategy of choice to control schistosomiasis, However, in view of concern about praziquantel tolerance or resistance, new drugs are needed. Artemether, a derivative of the antimalarial drug artemisinin, kills immature schistosomes of Schistosoma japonicum, and reduces the incidence of infection in field trials. Laboratory studies have also showed activity by this drug against S mansoni. We report a randomised double-blind placebo-controlled clinical trial of artemether to prevent S mansoni infection. Methods The trial was done in an area of western Cote d'Ivoire endemic for S mansoni. 354 schoolchildren were enrolled. Stool specimens were screened over four consecutive days, followed by two mass treatments with praziquantel 4 weeks apart. All S mansoni negative children were randomly assigned to placebo (n=151) or artemether 6 mg/kg (n=138) orally six times once every 3 weeks. Adverse events were assessed 24 h after treatment. Perceived illness episodes were recorded once a week by interviewing the children with a standardised questionnaire. 3 weeks after the final medication S mansoni infections were assessed by screening stool samples. Blood samples were examined for Plasmodium falciparum before the first and after the last artemether treatment. Findings Oral artemether showed no adverse reactions. The group that received artemether had a significantly lower incidence of S mansoni infection (31/128 versus 68/140, relative risk: 0.50 [95% CI 0.35-0.71], p=0.00006). The geometric mean egg output among positive children in the artemether group was significantly lower than in placebo recipients (19 vs 32 eggs/g stool, p=0.017). There was also a significant reduction in the prevalence of P falciparum. Interpretation Oral artemether is safe and shows a prophylatic effect against S mansoni. The use of artemether may be recommended in appropriated situations as an additional tool for more effective schistosomiasis control measures. However the application needs to be carefully assessed especially in view of the concern that it could select for resistant plasmodia.	Swiss Trop Inst, CH-4002 Basel, Switzerland; Ctr Suisse Rech Sci, Abidjan, Cote Ivoire; Univ Cocody, UFR Biosci, Abidjan, Cote Ivoire; Chinese Acad Prevent Med, Inst Parasit Dis, Shanghai 200025, Peoples R China	University of Basel; Swiss Tropical & Public Health Institute; Chinese Center for Disease Control & Prevention; National Institute of Parasitic Diseases, Chinese Center for Disease Control & Prevention	Tanner, M (corresponding author), Swiss Trop Inst, CH-4002 Basel, Switzerland.	marcel.tanner@unibas.ch						Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; BOUT DT, 1984, AM J TROP MED HYG, V33, P185, DOI 10.4269/ajtmh.1984.33.185; Capron A, 1998, PARASITOL TODAY, V14, P379, DOI 10.1016/S0169-4758(98)01322-2; Cioli D, 1998, PARASITOL TODAY, V14, P418, DOI 10.1016/S0169-4758(98)01323-4; CONAWAY MR, 1990, BIOMETRICS, V46, P317, DOI 10.2307/2531437; DEVLAS SJ, 1992, PARASITOL TODAY, V8, P274, DOI 10.1016/0169-4758(92)90144-Q; Doumenge J, 1987, ATLAS GLOBAL DISTRIB; FALLON PG, 1994, AM J TROP MED HYG, V51, P83, DOI 10.4269/ajtmh.1994.51.83; GRYSEELS B, 1994, TROP GEOGR MED, V46, P209; Guisse F, 1997, AM J TROP MED HYG, V56, P511, DOI 10.4269/ajtmh.1997.56.511; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; KING CH, 1989, AM J TROP MED HYG, V40, P507, DOI 10.4269/ajtmh.1989.40.507; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; KUMAR V, 1994, INT J ANTIMICROB AG, V4, P313, DOI 10.1016/0924-8579(94)90032-9; Kusel J, 1999, PARASITOL TODAY, V15, P352, DOI 10.1016/S0169-4758(99)01510-0; Li SW, 1996, CHINESE MED J-PEKING, V109, P848; MARTI H, 1990, SCHWEIZ MED WSCHR, V120, P1473; MCINTOSH HM, 1999, COCHRANE LIB; NGORAN KE, 1989, B MED PHARM, V3, P117; SABAH AA, 1986, EXP PARASITOL, V61, P294, DOI 10.1016/0014-4894(86)90184-0; Schoen O, 1998, MRS INTERNET J N S R, V3, part. no.; SHUHUA X, 1989, ANTIMICROB AGENTS CH, V33, P1557, DOI 10.1128/AAC.33.9.1557; STELMA FF, 1995, AM J TROP MED HYG, V53, P167, DOI 10.4269/ajtmh.1995.53.167; Utzinger J, 2000, B WORLD HEALTH ORGAN, V78, P389; UTZINGER J, SCHISTOSOMA MANSONI; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; WILKINS HA, 1989, PARASITOL TODAY, V5, P83, DOI 10.1016/0169-4758(89)90008-2; World Health Organization, 1993, WHO TECHN REP SER; Xiao SH, 2000, PARASITOL INT, V49, P19, DOI 10.1016/S1383-5769(00)00028-3; Xiao SH, 1998, ACTA PHARMACOL SIN, V19, P63; Xiao SH, 2000, PARASITOL TODAY, V16, P122, DOI 10.1016/S0169-4758(99)01601-4; Xiao Shu-Hua, 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P306	32	157	162	2	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2000	355	9212					1320	1325		10.1016/S0140-6736(00)02114-0	http://dx.doi.org/10.1016/S0140-6736(00)02114-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776745				2022-12-28	WOS:000086829400012
J	Ornstein, DL; Frederickson, K				Ornstein, DL; Frederickson, K			Meningeal carcinomatosis in breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Dartmouth College; Harvard University; Beth Israel Deaconess Medical Center	Ornstein, DL (corresponding author), Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA.								0	3	3	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1093	1093		10.1056/NEJM200004133421504	http://dx.doi.org/10.1056/NEJM200004133421504			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10760309				2022-12-28	WOS:000086406700004
J	Davies, HTO; Nutley, SM				Davies, HTO; Nutley, SM			Developing learning organisations in the new NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ St Andrews, Dept Management, St Andrews KY16 9AL, Fife, Scotland	University of St Andrews	Davies, HTO (corresponding author), Univ St Andrews, Dept Management, St Andrews KY16 9AL, Fife, Scotland.							Argyris C., 1978, ORG LEARNING THEORY; Argyris C., 1996, ORG LEARNING; CALVIN RS, 1998, INTEGRATED HEALTHCAR, V125, P1; Cavaleri S.A., 1996, MANAGING ORG LEARN; Davies HTO, 1998, QUAL HEALTH CARE, V7, P159, DOI 10.1136/qshc.7.3.159; Davies HTO, 1999, PUBLIC MONEY MANAGE, V19, P55; DAVIES HTO, 1999, REFORMING MARKETS HL; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DEAL T, 1992, CORPORATE CULTURES R; DODGSON M, 1993, ORGAN STUD, V14, P375, DOI 10.1177/017084069301400303; Garside P, 1998, QUAL HEALTH CARE, V7, pS8; GARVIN DA, 1993, HARVARD BUS REV, V71, P78; Hedberg B., 1981, HDB ORG DESIGN; Hopkins A, 1996, J ROY COLL PHYS LOND, V30, P415; MARQUARDT M, 1996, BUILDING LEARNING OR; Mintzberg H, 1998, STRATEGY SAFARI; Moingeon B., 1996, ORG LEARNING COMPETI; *NHS EX, 1998, NEW NHS MOD DEP NAT; PEDLAR M, 1998, CONCISE GUIDE LEARNI; Sackett D. L., 1997, EVIDENCE BASED MED P; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Secretary of State for Health, 1998, 1 CLASS SERV QUAL NE; Senge P. M., 1994, 5 DISCIPLINE ART PRA; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; STARKEY K, 1996, ORG LEARN; [No title captured]	26	86	88	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					998	1001		10.1136/bmj.320.7240.998	http://dx.doi.org/10.1136/bmj.320.7240.998			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753159	Green Published			2022-12-28	WOS:000086453100032
J	Schiller, LR				Schiller, LR			Pathophysiology and treatment ed microscopic-colitis syndrome	LANCET			English	Editorial Material							COLLAGENOUS-COLITIS; CHRONIC DIARRHEA		Baylor Univ, Med Ctr, Dept Gastroenterol, Dallas, TX 75246 USA	Baylor University; Baylor University Medical Center	Schiller, LR (corresponding author), Baylor Univ, Med Ctr, Dept Gastroenterol, Dallas, TX 75246 USA.							Bohr J, 1996, GUT, V39, P846, DOI 10.1136/gut.39.6.846; Fine K, 1999, GASTROENTEROLOGY, V116, pA880; Fine KD, 1999, GASTROENTEROLOGY, V116, pA879; Fine KD, 1998, GASTROENTEROLOGY, V114, P29, DOI 10.1016/S0016-5085(98)70629-8; Fine KD, 2000, GASTROINTEST ENDOSC, V51, P318, DOI 10.1016/S0016-5107(00)70362-2; LAZENBY AJ, 1989, HUM PATHOL, V20, P18, DOI 10.1016/0046-8177(89)90198-6; LEE E, 1988, GASTROENTEROLOGY, V94, P409, DOI 10.1016/0016-5085(88)90430-1; LEE E, 1992, GASTROENTEROLOGY, V103, P1790, DOI 10.1016/0016-5085(92)91436-8; LINDSTROM CG, 1976, PATHOL EUR, V11, P87; NELSON RW, 1988, J VET INTERN MED, V2, P133, DOI 10.1111/j.1939-1676.1988.tb02809.x; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; READ NW, 1980, GASTROENTEROLOGY, V78, P264; Schiller L R, 1999, Semin Gastrointest Dis, V10, P145; SCHILLER LR, 1990, GASTROENTEROLOGY, V98, P1036, DOI 10.1016/0016-5085(90)90031-U; Ung KA, 2000, GUT, V46, P170, DOI 10.1136/gut.46.2.170	15	19	19	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1198	1199		10.1016/S0140-6736(00)02079-1	http://dx.doi.org/10.1016/S0140-6736(00)02079-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770295				2022-12-28	WOS:000086448000002
J	Bodenheimer, T				Bodenheimer, T			California's beleaguered physician groups - Will they survive?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE MARKETPLACE; LARGE EMPLOYERS											Alexander J. O., 1999, INTERPERSONAL COMPUT, V7, P1; BERNSTEIN S, 1999, LOS ANGELES TIM 0914, pC1; Bodenheimer T, 1998, NEW ENGL J MED, V338, P1084, DOI 10.1056/NEJM199804093381525; Bodenheimer T, 1998, NEW ENGL J MED, V338, P1003, DOI 10.1056/NEJM199804023381422; *CA MED ASS, 1999, MED GROUP SOLV PROBL; *CA MED ASS, 1999, COM MED GROUP FAIL E; CASALINO LP, 1997, EVOLUTION MED GROUPS; Cross M, 1999, Manag Care, V8, P25; CROSS MA, 1999, MANAGED CARE, V8, P28; CROSS MA, 1999, MANAGED CARE, V8, P31; GLABMAN M, 1998, PHYSICIANS FINA 1115, P1; HAGLAND M, 1999, CALIF MED, V10, P52; HEIMOFF SH, 1999, MODERN PHYSICIAN SEP; JACOB JA, 2000, AM MED NEWS     0313, P20; JACOB JA, 2000, AM MED NEWS     0207, P17; JAKLEVIC MC, 1998, MODERN HEALTHCA 1116, P6; JAKLEVIC MC, 1998, MODERN HEALTHCA 0713, P18; JAKLEVIC MC, 1998, MODERN HEALTHCA 1116, P2; Levit K, 2000, HEALTH AFFAIR, V19, P124, DOI 10.1377/hlthaff.19.1.124; ORBACH NF, 1999, BUS HLTH, V17, P27; *PAC BUS GROUP HLT, 1999, PACIFIC CURRENTS, V5, P10; PAGE L, 1999, AM MED NEWS     1108, P26; PAGE L, 1999, AM MED NEWS     0920, P1; PAGE L, 1999, AM MED NEWS     1108, P24; PAGE L, 1999, AM MED NEWS     1025, P14; PAGE L, 1999, AM MED NEWS     0920, P27; PAGE L, 1999, AM MED NEWS     1025, P13; Pear Robert, 1999, N Y Times Web, P27; *PRIC, 1999, HEALTHC IND ER; Reese S, 1999, Bus Health, V17, P28; REINHARDT U, 1999, MANAGED CARE     NOV, pB38; Robinson JC, 1998, JAMA-J AM MED ASSOC, V279, P144, DOI 10.1001/jama.279.2.144; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; RUNDLE RL, 1999, WALL STREET J   0809; RUPPERT D, 1999, MANAGED HLTHCARE JUL, P1; SHINKMAN R, 1999, MODERN HEALTHCA 0726, P22; STERNGOLD J, 1999, NY TIMES        0517, P1; STEWART GM, 1998, CALIF MED, V9, P70; [No title captured]; 1999, PHYSICIANS FINA 0930, pS7	41	18	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	2000	342	14					1064	1068		10.1056/NEJM200004063421422	http://dx.doi.org/10.1056/NEJM200004063421422			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300JB	10749972				2022-12-28	WOS:000086248900029
J	McCabe, H				McCabe, H			Reshuffle lifts French synchrotron hopes	NATURE			English	News Item																		2000, NATURE, V404, P323; 1999, NATURE, V400, P489	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					533	533		10.1038/35007224	http://dx.doi.org/10.1038/35007224			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766205	Bronze			2022-12-28	WOS:000086400100011
J	Reichhardt, T				Reichhardt, T			NASA pays the price of its dash for Mars	NATURE			English	News Item																		1999, NATURE, V382, P565	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					535	535		10.1038/35007232	http://dx.doi.org/10.1038/35007232			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766207	Bronze			2022-12-28	WOS:000086400100014
J	Sims, DW; Andrews, PLR; Young, JZ				Sims, DW; Andrews, PLR; Young, JZ			Fish behaviour - Stomach rinsing in rays	NATURE			English	Article									Univ Aberdeen, Dept Zool, Aberdeen AB24 2TZ, Scotland; St George Hosp, Sch Med, Dept Physiol, London SW17 0RE, England; Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	University of Aberdeen; St Georges University London; University of Oxford	Sims, DW (corresponding author), Univ Aberdeen, Dept Zool, Tillydrone Ave, Aberdeen AB24 2TZ, Scotland.			Sims, David/0000-0002-0916-7363				Andrews PLR, 1998, J MAR BIOL ASSOC UK, V78, P1269, DOI 10.1017/S0025315400044489; ANDREWS PLR, IN PRESS J EXP BIOL; BEINTEMA AJ, 1991, NATURE, V352, P480, DOI 10.1038/352480b0; BORISON HL, 1952, J PHARMACOL EXP THER, V105, P317; Budker P., 1971, LIFE SHARKS; CROW G L, 1990, Copeia, P226; NAITOH T, 1991, COMP BIOCHEM PHYS C, V100, P353; Naitoh T, 1996, NATURE, V380, P30, DOI 10.1038/380030b0; NAITOH T, 1989, PHYSIOL ZOOL, V62, P819, DOI 10.1086/physzool.62.3.30157929; Wake M. H, 1979, HYMANS COMP VERTEBRA, VThird	10	25	27	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					566	566		10.1038/35007149	http://dx.doi.org/10.1038/35007149			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766231	Bronze			2022-12-28	WOS:000086400100042
J	Walker, P				Walker, P			Nuclear physics - Doubly magic nickel	NATURE			English	Editorial Material									Univ Surrey, Dept Phys, Guildford GU2 7XH, Surrey, England	University of Surrey	Walker, P (corresponding author), Univ Surrey, Dept Phys, Guildford GU2 7XH, Surrey, England.							Blank B, 2000, PHYS REV LETT, V84, P1116, DOI 10.1103/PhysRevLett.84.1116; Blank B, 1996, PHYS REV LETT, V77, P2893, DOI 10.1103/PhysRevLett.77.2893	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					447	+		10.1038/35006537	http://dx.doi.org/10.1038/35006537			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761897				2022-12-28	WOS:000086257700028
J	Lewis, KA; Gray, PC; Blount, AL; MacConnell, LA; Wiater, E; Bilezikjian, LM; Vale, W				Lewis, KA; Gray, PC; Blount, AL; MacConnell, LA; Wiater, E; Bilezikjian, LM; Vale, W			Betaglycan binds inhibin and can mediate functional antagonism of activin signalling	NATURE			English	Article							RECEPTOR COMPLEX; CLONING; KINASE; GROWTH	Activins and inhibins(1), structurally related members of the TGF-beta superfamily of growth and differentiation factors(2), are mutually antagonistic regulators of reproductive and other functions(1,3). Activins bind specific type II receptor serine kinases (ActRII or IIB)(4-6) to promote the recruitment and phosphorylation of the type I receptor serine kinase, ALK4 (refs 7-9), which then regulates gene expression by activating Smad proteins(2). Inhibins also bind type II activin receptors but do not recruit ALK4, providing a competitive model for the antagonism of activin by inhibing(9-11). Inhibins fail to antagonize activin in some tissues and cells, however, suggesting that additional components are required for inhibin action(9,12,13). Here we show that the type III TGF-beta receptor, betaglycan(14,15), can function as an inhibin coreceptor with ActRII. Betaglycan binds inhibin with high affinity and enhances binding in cells co-expressing ActRII and betaglycan. Inhibin also forms crosslinked complexes with both recombinant and endogenously expressed betaglycan and ActRII. Finally, betaglycan confers inhibin sensitivity to cell lines that otherwise respond poorly to this hormone. The ability of betaglycan to facilitate inhibin antagonism of activin provides a variation on the emerging roles of proteoglycans as co-receptors modulating ligand-receptor sensitivity, selectivity and function(16-19).	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	Salk Institute	Vale, W (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vale@salk.edu			PHS HHS [13527] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Draper LB, 1998, J BIOL CHEM, V273, P398, DOI 10.1074/jbc.273.1.398; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; Martens JWM, 1997, ENDOCRINOLOGY, V138, P2928, DOI 10.1210/en.138.7.2928; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1996, RECENT PROG HORM RES, V51, P155; VALE W, 1988, RECENT PROG HORM RES, V44, P1; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308	13	464	486	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					411	414		10.1038/35006129	http://dx.doi.org/10.1038/35006129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746731				2022-12-28	WOS:000086119000056
J	Rademann, J; Jung, G				Rademann, J; Jung, G			Drug discovery - Integrating combinatorial synthesis and bioassays	SCIENCE			English	Article							LIBRARY; SPECIFICITY; CRUZIPAIN; ASSAY		Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Rademann, J (corresponding author), Univ Tubingen, Inst Organ Chem, Morgenstelle 18, D-72076 Tubingen, Germany.		Rademann, Jörg/F-4893-2017	Rademann, Jörg/0000-0001-6678-3165				Bianco A, 1998, J PEPT SCI, V4, P471, DOI 10.1002/(SICI)1099-1387(199812)4:8<471::AID-PSC166>3.0.CO;2-8; BUCHARDT J, 1999, 16 AM PEPT S MINN MN; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; Fleckenstein B, 1999, SEMIN IMMUNOL, V11, P405, DOI 10.1006/smim.1999.0198; FLECKENSTEIN B, 1999, COMBINATORIAL CHEM S, P355; FRANK R, 1996, PEPTIDE NONPEPTIDE L; Hemmer B, 1999, NAT MED, V5, P1375; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; Jung G., 1999, COMBINATORIAL CHEM S; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Lebl M, 1999, J COMB CHEM, V1, P3, DOI 10.1021/cc9800327; Leipert D, 1999, ANAL CHIM ACTA, V392, P213, DOI 10.1016/S0003-2670(99)00178-6; Leipert D, 1998, ANGEW CHEM INT EDIT, V37, P3308, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3308::AID-ANIE3308>3.0.CO;2-#; MacBeath G, 1999, J AM CHEM SOC, V121, P7967, DOI 10.1021/ja991083q; Meldal M, 1998, J PEPT SCI, V4, P83, DOI 10.1002/(SICI)1099-1387(199804)4:2<83::AID-PSC124>3.0.CO;2-Z; MELDAL M, 1994, P NATL ACAD SCI USA, V91, P3314, DOI 10.1073/pnas.91.8.3314; MELDAL M, 1992, TETRAHEDRON LETT, V33, P3077, DOI 10.1016/S0040-4039(00)79604-3; Piehler J, 1996, ANAL CHEM, V68, P139, DOI 10.1021/ac9504878; Rademann J, 1999, J AM CHEM SOC, V121, P5459, DOI 10.1021/ja984355i; Rothmund M, 1997, FRESEN J ANAL CHEM, V359, P15, DOI 10.1007/s002160050529; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Walk TB, 1999, ANGEW CHEM INT EDIT, V38, P1763, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1763::AID-ANIE1763>3.0.CO;2-#	22	37	38	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1947	1948		10.1126/science.287.5460.1947	http://dx.doi.org/10.1126/science.287.5460.1947			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10755947				2022-12-28	WOS:000085902800036
J	Kitamura, H; Tsuneyuki, S; Ogitsu, T; Miyake, T				Kitamura, H; Tsuneyuki, S; Ogitsu, T; Miyake, T			Quantum distribution of protons in solid molecular hydrogen at megabar pressures	NATURE			English	Article							DENSE HYDROGEN; DYNAMICS; EFFICIENT	Solid hydrogen, a simple system consisting only of protons and electrons, exhibits a variety of structural phase transitions at high pressures. Experimental studies' based on static compression up to about 230 GPa revealed three relevant phases of solid molecular hydrogen: phase I (high-temperature, low-pressure phase), phase II (low-temperature phase) and phase III (high-pressure phase). Spectroscopic data suggest that symmetry breaking; possibly related to orientational ordering(1,2), accompanies the transition into phases II and III. The boundaries dividing the three phases exhibit a strong isotope effect(3), indicating that the quantum-mechanical properties of hydrogen nuclei are important. Here we report the quantum distributions of protons in the three phases of solid hydrogen, obtained by a first-principles path-integral molecular dynamics method. We show that quantum fluctuations of protons effectively hinder molecular rotation-that is, a quantum localization occurs. The obtained crystal structures have entirely different symmetries from those predicted by the conventional simulations which treat protons classically.	Univ Tokyo, Inst Solid State Phys, Tokyo 1068666, Japan; Rice Univ, Dept Space Phys & Astron, Houston, TX 77251 USA; Univ Calif Los Alamos Natl Lab, Appl Theoret & Computat Phys Div, Los Alamos, NM 87545 USA; Univ Illinois, Natl Ctr Supercomp Applicat, Urbana, IL 61801 USA; Joint Res Ctr Atom Technol, Tsukuba, Ibaraki 3050046, Japan	University of Tokyo; Rice University; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Illinois System; University of Illinois Urbana-Champaign; National Institute of Advanced Industrial Science & Technology (AIST)	Tsuneyuki, S (corresponding author), Univ Tokyo, Inst Solid State Phys, Tokyo 1068666, Japan.		Tsuneyuki, Shinji/B-3409-2009; Miyake, Takashi/M-6767-2018	Miyake, Takashi/0000-0003-2658-3470				ASHCROFT NW, 1990, PHYS REV B, V41, P10963, DOI 10.1103/PhysRevB.41.10963; Biermann S, 1998, J LOW TEMP PHYS, V110, P97, DOI 10.1023/A:1022566818119; Biermann S, 1998, SOLID STATE COMMUN, V108, P337, DOI 10.1016/S0038-1098(98)00388-3; CHANDLER D, 1981, J CHEM PHYS, V74, P4078, DOI 10.1063/1.441588; Edwards B, 1997, NATURE, V388, P652, DOI 10.1038/41645; HEMLEY RJ, 1995, ELEMENTARY PROCESSES, P271; HOHL D, 1993, PHYS REV LETT, V71, P541, DOI 10.1103/PhysRevLett.71.541; Kohanoff J, 1997, PHYS REV LETT, V78, P2783, DOI 10.1103/PhysRevLett.78.2783; Loubeyre P, 1996, NATURE, V383, P702, DOI 10.1038/383702a0; MAO HK, 1994, REV MOD PHYS, V66, P671, DOI 10.1103/RevModPhys.66.671; Marx D, 1996, J CHEM PHYS, V104, P4077, DOI 10.1063/1.471221; MARX D, 1994, Z PHYS B CON MAT, V95, P143, DOI 10.1007/BF01312185; Mazin II, 1997, PHYS REV LETT, V78, P1066, DOI 10.1103/PhysRevLett.78.1066; MAZIN II, 1995, PHYS REV B, V52, pR8597, DOI 10.1103/PhysRevB.52.R8597; Miyake T, 1996, SURF SCI, V363, P403, DOI 10.1016/0039-6028(96)00168-9; Miyake T, 1998, PHYS REV LETT, V81, P1873, DOI 10.1103/PhysRevLett.81.1873; Nagao K, 1998, PHYS REV LETT, V80, P548, DOI 10.1103/PhysRevLett.80.548; Nagao K, 1999, PHYS REV B, V59, P13741, DOI 10.1103/PhysRevB.59.13741; NAGARA H, 1992, PHYS REV LETT, V68, P2468, DOI 10.1103/PhysRevLett.68.2468; NATOLI V, 1995, PHYS REV LETT, V74, P1601, DOI 10.1103/PhysRevLett.74.1601; PAYNE MC, 1992, REV MOD PHYS, V64, P1045, DOI 10.1103/RevModPhys.64.1045; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; Tuckerman ME, 1996, J CHEM PHYS, V104, P5579, DOI 10.1063/1.471771	24	91	94	2	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					259	262		10.1038/35005027	http://dx.doi.org/10.1038/35005027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749202				2022-12-28	WOS:000086022200040
J	Loder, M				Loder, M			Uproar at Oxford as suspended professor returns to work	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					214	214		10.1038/35005232	http://dx.doi.org/10.1038/35005232			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10766597	Bronze			2022-12-28	WOS:000086022200004
J	Poulin, EC; Schlachta, CM; Mamazza, J				Poulin, EC; Schlachta, CM; Mamazza, J			Early laparoscopy to help diagnose acute non-specific abdominal pain	LANCET			English	Editorial Material							ACUTE ABDOMEN		Univ Toronto, St Michaels Hosp, Ctr Minimally Invas Surg, Toronto, ON M46 1J3, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Poulin, EC (corresponding author), Univ Toronto, St Michaels Hosp, Ctr Minimally Invas Surg, Toronto, ON M46 1J3, Canada.							ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; Allemann F, 1999, EUR J SURG, V165, P966; Decadt B, 1999, BRIT J SURG, V86, P1383, DOI 10.1046/j.1365-2168.1999.01239.x; Gupta H, 1997, SURG CLIN N AM, V77, P1245, DOI 10.1016/S0039-6109(05)70616-2; Hawthorn I E, 1992, J R Coll Surg Edinb, V37, P389; IRVIN TT, 1989, BRIT J SURG, V76, P1121, DOI 10.1002/bjs.1800761105; RAHEJA SK, 1990, J ROY SOC MED, V88, P10; Rao PM, 1998, NEW ENGL J MED, V338, P141, DOI 10.1056/NEJM199801153380301; Salky BA, 1998, SURG ENDOSC-ULTRAS, V12, P911, DOI 10.1007/s004649900744; VIPOND MN, 1990, BRIT J SURG, V77, P86, DOI 10.1002/bjs.1800770130	10	22	24	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					861	863		10.1016/S0140-6736(99)00432-8	http://dx.doi.org/10.1016/S0140-6736(99)00432-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752698				2022-12-28	WOS:000085896000004
J	Staessen, JA; Gasowski, J; Wang, JG; Thijs, L; Den Hond, E; Boissel, JP; Coope, J; Ekbom, T; Gueyffier, F; Liu, LS; Kerlikowske, K; Pocock, S; Fagard, RH				Staessen, JA; Gasowski, J; Wang, JG; Thijs, L; Den Hond, E; Boissel, JP; Coope, J; Ekbom, T; Gueyffier, F; Liu, LS; Kerlikowske, K; Pocock, S; Fagard, RH			Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials	LANCET			English	Article							CORONARY HEART-DISEASE; HIGH BLOOD-PRESSURE; EUROPEAN-WORKING-PARTY; RANDOMIZED TRIAL; ACTIVE TREATMENT; DRUG-TREATMENT; MORTALITY; METAANALYSIS; STROKE; MORBIDITY	Background Previous meta-analysis of outcome trials in hypertension have not specifically focused on isolated systolic hypertension or they have explained treatment benefit mainly in function of the achieved diastolic blood pressure reduction. We therefore undertook a quantitative overview of the trials to further evaluate the risks associated with systolic blood pressure in treated and untreated older patients with isolated systolic hypertension. Methods Patients were 60 years old or more. Systolic blood pressure was 160 mm Hg or greater and diastolic blood pressure was less than 95 mm Hg. We used non-parametric methods and Cox regression to model the risks associated with blood pressure and to correct for regression dilution bias. We calculated pooled effects of treatment from stratified 2 x 2 contingency tables after application of Zelen's test of heterogeneity. Findings In eight trials 15 693 patients with isolated systolic hypertension were followed up for 3.8 years (median). After correction for regression dilution bias, sex, age, and diastolic blood pressure, the relative hazard rates associated with a 10 mm Hg higher initial systolic blood pressure were 1.26 (p=0.0001) for total mortality, 1.22 (p=0.02) for stroke, but only 1.07 (p=0.37) for coronary events. Independent of systolic blood pressure, diastolic blood pressure was inversely correlated with total mortality, highlighting the role of pulse pressure as risk factor. Active treatment reduced total mortality by 13% (95% CI 2-22, p=0.02), cardiovascular mortality by 18%, all cardiovascular complications by 26%, stroke by 30%, and coronary events by 23%. The number of patients to treat for 5 years to prevent one major cardiovascular event was lower in men (18 vs 38), at or above age 70 (19 vs 39), and in patients with previous cardiovascular complications (16 vs 37). Interpretation Drug treatment is justified in older patients with isolated systolic hypertension whose systolic blood pressure is 160 mm Hg or higher. Absolute benefit is larger in men, in patients aged 70 or more and in those with previous cardiovascular complications or wider pulse pressure. Treatment prevented stroke more effectively than coronary events. However, the absence of a relation between coronary events and systolic blood pressure in untreated, patients suggests that the coronary protection may have been underestimated.	Univ Louvain, Dept Mol & Cardiovasc Res, Hypertens & Cardiovasc Rehabil Unit, Louvain, Belgium; Jagiellonian Univ, Sch Med, Dept Gerontol & Family Med, Krakow, Poland; Chinese Acad Med Sci, Cardiovasc Inst, Beijing 100037, Peoples R China; Chinese Acad Med Sci, Fuwai Hosp, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Univ Lyon 1, Lyon Hosp, Dept Clin Pharmacol, Lyon, France; Lund Univ, Dept Community Med, Malmo, Sweden; Dept Vet Affairs Med Ctr, San Francisco, CA USA; London Sch Hyg & Trop Med, London WC1, England	Jagiellonian University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Lund University; University of London; London School of Hygiene & Tropical Medicine	Staessen, JA (corresponding author), Studiecoordinatiectr, Lab Hypertensie, Campus Gasthuisberg,Gebouw Onderwijs & Navorsing, B-3000 Louvain, Belgium.	jan.staessen@med.kuleuven.ac.be	Gąsowski, Jerzy/CAF-0671-2022; Gueyffier, François/B-8545-2008; Staessen, Jan A/A-1065-2011; Gąsowski, Jerzy/GPC-8774-2022	Gueyffier, François/0000-0002-9921-0977; Staessen, Jan A/0000-0002-3026-1637; Gąsowski, Jerzy/0000-0002-8025-5323; Thijs, Lutgarde/0000-0002-8108-2356				AMERY A, 1985, LANCET, V1, P1349; AMERY A, 1988, J HYPERTENS, V6, P925, DOI 10.1097/00004872-198811000-00012; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409; [Anonymous], 1981, MED J AUSTRALIA, V2, P398; BLACHER J, 2000, IN PRESS ARCH INTERM; Chalmers J, 1999, J HYPERTENS, V17, P151; Chalmers J, 1996, J HYPERTENS, V14, pS41; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DUCHIER J, 1987, AM J CARDIOL, V60, P99, DOI 10.1016/0002-9149(87)90993-3; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; FLEISS JL, 1981, STATISTICAL METHODS, P13; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; GUEYFFIER F, 1995, THERAPIE, V50, P353; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HEIKINHEIMO RJ, 1990, J HYPERTENS, V8, P361, DOI 10.1097/00004872-199004000-00010; Hosmer DW, 1989, APPL LOGISTIC REGRES, P47; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; KURAMOTO K, 1981, JPN HEART J, V22, P75; LEVER AF, 1995, J HYPERTENS, V13, P571, DOI 10.1097/00004872-199506000-00001; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MEHTA C, 1998, STATXACT 4 WINDOWS S, P469; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; Millar JA, 1999, J HYPERTENS, V17, P1065, DOI 10.1097/00004872-199917080-00004; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; PERRY HM, 1986, J HYPERTENS, V4, pS21; Prineas R., 1982, MINNESOTA CODE MANUA; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; SELMER R, 1992, AM J EPIDEMIOL, V136, P428, DOI 10.1093/oxfordjournals.aje.a116516; Sever PS, 1999, J HUM HYPERTENS, V13, P725, DOI 10.1038/sj.jhh.1000923; Somes GW, 1999, ARCH INTERN MED, V159, P2004, DOI 10.1001/archinte.159.17.2004; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STAESSEN J, 1983, HYPERTENSION, P1069; Staessen JA, 1998, ARCH INTERN MED, V158, P1681, DOI 10.1001/archinte.158.15.1681; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; THIJS L, 1994, J HYPERTENS, V12, pS25; WHO Int Soc Hyperten Blood Press Lower, 1998, J HYPERTENS, V16, P127; 1979, JAMA-J AM MED ASSOC, V242, P2572	48	825	892	0	40	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	2000	355	9207					865	872		10.1016/S0140-6736(99)07330-4	http://dx.doi.org/10.1016/S0140-6736(99)07330-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752701				2022-12-28	WOS:000085896000007
J	Ong, KKL; Ahmed, ML; Emmett, PM; Preece, MA; Dunger, DB				Ong, KKL; Ahmed, ML; Emmett, PM; Preece, MA; Dunger, DB		Avon Longitudinal Study Pregnancy	Association between postnatal catch-up growth and obesity in childhood: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							PREGNANT-WOMEN; WEIGHT-GAIN; SOUTH-WEST; POPULATION; CHILDREN; INFANTS; ENGLAND; BIRTH; DIET	Objective To identify predictors of postnatal catch-up growth from birth to two years and its relation to size and obesity at five years. Design Regional prospective cohort study. Setting Avon longitudinal study of pregnancy and childhood, United Kingdom. Subjects 848 full term singletons from a 10% random sample of the Avon longitudinal study of pregnancy and childhood. Main outcome measures Maternal birth weight, prepregnancy weight pregnancy weight gain, height, smoking, and parity, and paternal height, Weight and length of infants at birth, two years, and five years expressed as standard deviation (SD) scores fr om the UK reference scores for 1990, Percentage fat mass and total fat mass (estimated from skinfolds) and waist circumference at five years. Results Size at birth was representative of die national reference. Overall, 30.7% (260 of 848) of infants showed a gain in SD score for weight greater than 0.67 SD scores between zero and two years, indicating clinically significant catch-up growth. These children had lower weight, length, and ponderal index at birth than other children, and were more often from primiparous pregnancies. They also had taller fathers than other children, and their mothers had lower birth weights and were more likely to smoke during pregnancy. Children who showed catch-up growth between zero and two years were heavier, taller, and fatter (body mass index, percentage body fat, and waist circumference) at five years than other children. Conclusions Tn this contemporary well nourished cohort, catch-up growth was predicted by factors relating to intrauterine restraint of fetal growth. Children who showed catch-up growth between zero and two years were fatter and had more central fat distribution at five years than other children. Mechanisms that signal and regulate early catch-up growth in the postnatal period may influence associations between small size at birth and risks for disease in adulthood.	Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ Bristol, Unit Paediat & Perinatal Epidemiol, Bristol BS8 1TQ, Avon, England; Inst Child Hlth, Biochem Endocrinol & Metab Unit, London WC1N 1AH, England	University of Oxford; University of Bristol; University of London; University College London	Dunger, DB (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.		Emmett, Pauline/AAL-6815-2021	Emmett, Pauline/0000-0003-1076-4779; Dunger, Professor David/0000-0002-2566-9304; Golding, Jean/0000-0003-2826-3307	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROOK CGD, 1971, ARCH DIS CHILD, V46, P182, DOI 10.1136/adc.46.246.182; Casteels K, 1999, LANCET, V353, P1499, DOI 10.1016/S0140-6736(98)05817-6; Crowther NJ, 1998, DIABETOLOGIA, V41, P1163, DOI 10.1007/s001250051046; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Freedman DS, 1999, AM J CLIN NUTR, V69, P308; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Haig D, 1996, AM J REPROD IMMUNOL, V35, P226; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; OBRIEN PM, 1999, P 36 ROYAL COLL OBST; Ong KKL, 1999, J CLIN ENDOCR METAB, V84, P1145, DOI 10.1210/jc.84.3.1145; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; OUNSTED M, 1975, LANCET, V1, P1393, DOI 10.1016/S0140-6736(75)92605-7; Reilly JJ, 1999, BRIT MED J, V319, P1039, DOI 10.1136/bmj.319.7216.1039; Rogers I, 1998, EUR J CLIN NUTR, V52, P251, DOI 10.1038/sj.ejcn.1600544; Rogers I, 1998, EUR J CLIN NUTR, V52, P246, DOI 10.1038/sj.ejcn.1600543; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Siri W E, 1993, Nutrition, V9, P480; Tanner J. M., 1994, Acta Medica Auxologica (Milan), V26, P7; Tanner J. M., 1986, HUMAN GROWTH, P167; TANNER JM, 1956, ARCH DIS CHILD, V31, P372, DOI 10.1136/adc.31.159.372; Vanhala M, 1998, BRIT MED J, V317, P319, DOI 10.1136/bmj.317.7154.319; Walton A, 1938, PROC R SOC SER B-BIO, V125, P311, DOI 10.1098/rspb.1938.0029; 1999, AVON LONGITUDINAL ST	25	1182	1245	0	68	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					967	971		10.1136/bmj.320.7240.967	http://dx.doi.org/10.1136/bmj.320.7240.967			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753147	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086453100020
J	Loo, LS; Cohen, RE; Gleason, KK				Loo, LS; Cohen, RE; Gleason, KK			Chain mobility in the amorphous region of nylon 6 observed under active uniaxial deformation	SCIENCE			English	Article							PLASTIC-DEFORMATION; NMR; POLYMERS; DYNAMICS; PHASE	A specially designed solid-state deuterium nuclear magnetic resonance probe was used to examine the effect of uniaxial elongation on the chain mobility in the amorphous region of semicrystalline nylon 6. In measurements conducted near the glass transition temperature, there was measurable deformation-induced enhancement of the mobility of the amorphous chains up to the yield point. This enhanced mobility decayed once deformation was stopped. Enhanced mobility was not observed in deformation at room temperature. The mechanics of deformation can be explained by the Robertson model for glassy polymers near the glass transition temperature, which states that applied stress induces liquid-like behavior in the polymer chains.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Gleason, KK (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.		Gleason, Karen/G-1471-2013; Loo, Leslie/G-6225-2010	Gleason, Karen/0000-0001-6127-1056; 				ARGON AS, 1993, MAT SCI TECHNOLOGY, V6; Bartczak Z, 1996, POLYMER, V37, P2113, DOI 10.1016/0032-3861(96)85856-3; Crist B., 1997, PHYS GLASSY POLYM, P155; DENG D, 1989, PHILOS T R SOC A, V329, P613, DOI 10.1098/rsta.1989.0092; HANSEN MT, 1993, COLLOID POLYM SCI, V271, P446, DOI 10.1007/BF00657388; HIRSCHINGER J, 1990, MACROMOLECULES, V23, P2153, DOI 10.1021/ma00210a009; HOULT DI, 1975, P ROY SOC LOND A MAT, V344, P311, DOI 10.1098/rspa.1975.0104; Hutchison JL, 1996, MACROMOLECULES, V29, P5551, DOI 10.1021/ma9514840; KELLER A, 1971, J MATER SCI, V6, P453, DOI 10.1007/BF00550302; Loo LS, 1999, MACROMOLECULES, V32, P4359, DOI 10.1021/ma990080v; MURTHY NS, 1989, MACROMOLECULES, V22, P1261, DOI 10.1021/ma00193a043; POPE DP, 1975, J POLYM SCI POL PHYS, V13, P533, DOI 10.1002/pol.1975.180130307; ROBERTSON RE, 1966, J CHEM PHYS, V44, P3950, DOI 10.1063/1.1726558; Scharfetter C, 1995, PSYCHOPATHOLOGY, V28, P1; SPIESS HW, 1985, ADV POLYM SCI, V66, P23; STEJSKAL EO, 1974, J MAGN RESON, V14, P160, DOI 10.1016/0022-2364(74)90270-4; Utz M, 1999, MACROMOLECULES, V32, P6191, DOI 10.1021/ma990061l	17	120	120	2	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					116	119		10.1126/science.288.5463.116	http://dx.doi.org/10.1126/science.288.5463.116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753111				2022-12-28	WOS:000086387700045
J	Antman, K; Chang, Y				Antman, K; Chang, Y			Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PHASE-II TRIAL; ACQUIRED IMMUNODEFICIENCY SYNDROME; PEGYLATED-LIPOSOMAL DOXORUBICIN; RECOMBINANT INTERFERON-ALPHA; RENAL-TRANSPLANT RECIPIENTS; HUMAN HERPESVIRUS-8; HUMAN-HERPESVIRUS-8 INFECTION; SEXUAL TRANSMISSION; RANDOMIZED TRIAL; VIRUS INFECTION		Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Chang, Y (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, P&S14-442,630 W 168th St, New York, NY 10032 USA.		Chang, Yuan/F-4146-2011	Chang, Yuan/0000-0003-1125-4041; /0000-0002-1093-8356	NATIONAL CANCER INSTITUTE [F32CA066244] Funding Source: NIH RePORTER; NCI NIH HHS [CA167391, P20CA66244-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS DI, 1986, SEMIN ONCOL, V13, P43; ARCHIBALD CP, 1990, J ACQUIR IMMUNE D S1, V3, P18; ATHALE UH, 1995, J ACQ IMMUN DEF SYND, V8, P96; Bais C, 1998, NATURE, V392, P210, DOI 10.1038/32472; BAYLEY AC, 1984, LANCET, V1, P1318; Belotti D, 1996, CLIN CANCER RES, V2, P1843; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Biggar RJ, 1996, HEMATOL ONCOL CLIN N, V10, P997, DOI 10.1016/S0889-8588(05)70380-4; Bower M, 1997, INT J STD AIDS, V8, P518, DOI 10.1258/0956462971920686; BRAMBILLA L, 1994, CANCER-AM CANCER SOC, V74, P2873, DOI 10.1002/1097-0142(19941115)74:10<2873::AID-CNCR2820741021>3.0.CO;2-1; Brenner B, 1999, INT J ONCOL, V14, P1097; CDC, 1981, MMWR MORB MORTAL WKL, V30, P305; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; DEWIT R, 1988, LANCET, V2, P1214; DEWIT R, 1991, J INTERN MED, V229, P35; DIGIOVANNA JJ, 1981, AM J MED, V71, P779, DOI 10.1016/0002-9343(81)90364-8; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Farge D, 1999, TRANSPLANTATION, V67, P1236, DOI 10.1097/00007890-199905150-00007; Farge D, 1993, Eur J Med, V2, P339; Fife K, 1998, INT J STD AIDS, V9, P751, DOI 10.1258/0956462981921512; FISCHL MA, 1993, J ACQ IMMUN DEF SYND, V6, P259; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujii T, 1999, J MED VIROL, V57, P159, DOI 10.1002/(SICI)1096-9071(199902)57:2&lt;159::AID-JMV12&gt;3.0.CO;2-A; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Gill PS, 1999, J CLIN ONCOL, V17, P1876, DOI 10.1200/JCO.1999.17.6.1876; GILL PS, 1994, LEUKEMIA, V8, pS26; GILL PS, 1991, AM J MED, V90, P427, DOI 10.1016/0002-9343(91)80081-V; Gill PS, 1996, J CLIN ONCOL, V14, P2353, DOI 10.1200/JCO.1996.14.8.2353; Gill PS, 1997, NEW ENGL J MED, V336, P670; GROOPMAN JE, 1984, ANN INTERN MED, V100, P671, DOI 10.7326/0003-4819-100-5-671; GUO WX, 1995, CANCER RES, V55, P823; HAUSCHILD A, 1992, HAUTARZT, V43, P789; Hayward GS, 1999, SEMIN CANCER BIOL, V9, P187, DOI 10.1006/scbi.1998.0116; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Joffe MM, 1997, CLIN INFECT DIS, V25, P1125, DOI 10.1086/516108; Kaposi M, 1872, CA-CANCER J CLIN, V32, P342; Kedes DH, 1996, NAT MED, V2, P1041; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kedes DH, 1997, J CLIN INVEST, V99, P2082, DOI 10.1172/JCI119380; KLEIN E, 1980, CANCER, V45, P427, DOI 10.1002/1097-0142(19800201)45:3<427::AID-CNCR2820450304>3.0.CO;2-1; Koelle DM, 1997, J INFECT DIS, V176, P94, DOI 10.1086/514045; KROWN SE, 1992, J CLIN ONCOL, V10, P1344, DOI 10.1200/JCO.1992.10.8.1344; Krown SE, 1996, NEW ENGL J MED, V335, P1309, DOI 10.1056/NEJM199610243351709; LANE HC, 1990, ANN INTERN MED, V112, P388, DOI 10.7326/0003-4819-112-5-388_2; LANE HC, 1988, LANCET, V2, P1218; LANE HC, 1989, ANN INTERN MED, V111, P41, DOI 10.7326/0003-4819-111-1-41; LaParola IL, 1997, DERMATOLOGY, V194, P229, DOI 10.1159/000246107; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Lev-Chelouche D, 1999, ARCH SURG-CHICAGO, V134, P177, DOI 10.1001/archsurg.134.2.177; LO TCM, 1980, CANCER, V45, P684, DOI 10.1002/1097-0142(19800215)45:4<684::AID-CNCR2820450411>3.0.CO;2-U; LUNARDIISKANDAR Y, 1995, NATURE, V376, P447, DOI 10.1038/376447a0; MALEKZADEH MH, 1987, NEPHRON, V47, P62, DOI 10.1159/000184458; MARGOLIUS L, 1994, S AFR MED J, V84, P16; Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Mayama S, 1998, INT J CANCER, V77, P817, DOI 10.1002/(SICI)1097-0215(19980911)77:6&lt;817::AID-IJC2&gt;3.0.CO;2-X; Melbye M, 1998, INT J CANCER, V77, P543, DOI 10.1002/(SICI)1097-0215(19980812)77:4&lt;543::AID-IJC12&gt;3.0.CO;2-7; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Money-Kyrle J F, 1993, Clin Oncol (R Coll Radiol), V5, P367, DOI 10.1016/S0936-6555(05)80088-3; MONTAGNINO G, 1994, AM J NEPHROL, V14, P121, DOI 10.1159/000168700; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Moore PS, 1996, J VIROL, V70, P9083; Nagpal S, 1997, MOL CELL BIOL, V17, P4159, DOI 10.1128/MCB.17.7.4159; Neyts J, 1997, ANTIMICROB AGENTS CH, V41, P2754, DOI 10.1128/AAC.41.12.2754; NISCE LZ, 1981, CANCER, V47, P640, DOI 10.1002/1097-0142(19810215)47:4<640::AID-CNCR2820470403>3.0.CO;2-S; Northfelt DW, 1998, J CLIN ONCOL, V16, P2445, DOI 10.1200/JCO.1998.16.7.2445; Olsen SJ, 1998, AIDS, V12, P1921, DOI 10.1097/00002030-199814000-00024; Opravil M, 1999, INT J STD AIDS, V10, P369, DOI 10.1258/0956462991914285; Osman M, 1999, J VIROL, V73, P6136, DOI 10.1128/JVI.73.7.6136-6140.1999; PAREDES J, 1995, J ACQ IMMUN DEF SYND, V9, P138; Parravicini C, 1997, BLOOD, V90, P2826; Pellett PE, 1999, J CLIN MICROBIOL, V37, P1298, DOI 10.1128/JCM.37.5.1298-1301.1999; PRESANT CA, 1993, LANCET, V341, P1242, DOI 10.1016/0140-6736(93)91147-E; QUNIBI W, 1988, AM J MED, V84, P225, DOI 10.1016/0002-9343(88)90418-4; Qunibi W, 1998, TRANSPLANTATION, V65, P583, DOI 10.1097/00007890-199802270-00024; Regamey N, 1998, NEW ENGL J MED, V339, P1358, DOI 10.1056/NEJM199811053391903; Rivero J, 1997, BIOTHERAPY, V10, P107, DOI 10.1007/BF02678537; Robles R, 1999, J ACQ IMMUN DEF SYND, V20, P34, DOI 10.1097/00042560-199901010-00005; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Saiag P, 1998, AIDS, V12, P2169, DOI 10.1097/00002030-199816000-00012; SANTAMBROGIO S, 1998, P 12 WORLD AIDS C GE; SAVILLE MW, 1995, LANCET, V346, P26, DOI 10.1016/S0140-6736(95)92654-2; Shepherd FA, 1998, J CLIN ONCOL, V16, P1736, DOI 10.1200/JCO.1998.16.5.1736; Shepherd FA, 1997, J CLIN ONCOL, V15, P2371, DOI 10.1200/JCO.1997.15.6.2371; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Sitas F, 1999, NEW ENGL J MED, V340, P1863, DOI 10.1056/NEJM199906173402403; Soler RA, 1996, CLIN INFECT DIS, V23, P501, DOI 10.1093/clinids/23.3.501; STEIN ME, 1994, ONCOLOGY, V51, P63; STELZER KJ, 1993, INT J RADIAT ONCOL, V27, P1057, DOI 10.1016/0360-3016(93)90523-X; Stewart S, 1998, J CLIN ONCOL, V16, P683, DOI 10.1200/JCO.1998.16.2.683; Stine JT, 2000, BLOOD, V95, P1151, DOI 10.1182/blood.V95.4.1151.004k37_1151_1157; Strauchen JA, 1996, ANN INTERN MED, V125, P822, DOI 10.7326/0003-4819-125-10-199611150-00006; Szende Bela, 1997, General and Diagnostic Pathology, V143, P209; TAYLOR JF, 1971, INT J CANCER, V8, P122, DOI 10.1002/ijc.2910080116; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tur E, 1998, DERMATOLOGY, V197, P37, DOI 10.1159/000017973; Uthayakumar S, 1996, AIDS, V10, P515, DOI 10.1097/00002030-199605000-00010; VOLBERDING PA, 1985, ANN INTERN MED, V103, P335, DOI 10.7326/0003-4819-103-3-335; VOLBERDING PA, 1985, SEMIN ONCOL, V12, P2; VOLM MD, 1997, P AN M AM SOC CLIN, V16, pA46; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Wang AYM, 1998, TRANSPLANTATION, V66, P115, DOI 10.1097/00007890-199807150-00018; Welles L, 1998, J CLIN ONCOL, V16, P1112, DOI 10.1200/JCO.1998.16.3.1112; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Winceslaus J, 1998, INT J STD AIDS, V9, P368; Wit FWNM, 1998, AIDS, V12, P218; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	114	649	682	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	2000	342	14					1027	1038		10.1056/NEJM200004063421407	http://dx.doi.org/10.1056/NEJM200004063421407			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300JB	10749966				2022-12-28	WOS:000086248900007
J	Bianchi, E; Denti, S; Granata, A; Bossi, G; Geginat, J; Villa, A; Rogge, L; Pardi, R				Bianchi, E; Denti, S; Granata, A; Bossi, G; Geginat, J; Villa, A; Rogge, L; Pardi, R			Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity	NATURE			English	Article							COMPLEX; KINASE; CYTOSKELETAL; REQUIRES; SUBUNIT; SIGNALS	Integrin adhesion receptors transduce signals that control complex cell functions which require the regulation of gene expression, such as proliferation, differentiation and survival(1). Their intracellular domain has no catalytic function, indicating that interaction with other transducing molecules is crucial for integrin-mediated signalling. Here we have identified a protein that interacts with the cytoplasmic domain of the beta 2 subunit of the alpha L/beta 2 integrin LFA-1. This protein is JAB1 (Jun activation domain-binding protein 1), a coactivator of the c-Jun transcription factor(2). We found that JAB1 is present both in the nucleus and in the cytoplasm of cells and that a fraction of JAB1 colocalizes with LFA-1 at the cell membrane. LFA-1 engagement is followed by an increase of the nuclear pool of JAB1, paralleled by enhanced binding of c-Jun-containing AP-1 complexes to their DNA consensus site and increased transactivation of an AP-1-dependent promoter. We suggest that signalling through the LFA-1 integrin may affect c-Jun-driven transcription by regulating JAB1 nuclear localization. This represents a new pathway for integrin-dependent modulation of gene expression.	San Raffaele Sci Inst, DIBIT, I-20132 Milan, Italy; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Milan Bicocca, Fac Med, MIA, I-20052 Monza, Italy; Roche Milano Ric, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, I-20132 Milan, Italy	University of Oxford; University of Milano-Bicocca; Roche Holding; Vita-Salute San Raffaele University	Bianchi, E (corresponding author), San Raffaele Sci Inst, DIBIT, I-20132 Milan, Italy.		Villa, Antonello/B-4781-2012; Rogge, Lars/GYJ-6142-2022; Geginat, Jens/AAA-5818-2019	Geginat, Jens/0000-0003-4813-0384; Rogge, Lars/0000-0003-1262-9204; Villa, Antonello/0000-0002-3820-8072	Telethon [E.0492] Funding Source: Medline	Telethon(Fondazione Telethon)		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fabbri M, 1999, EMBO J, V18, P4915, DOI 10.1093/emboj/18.18.4915; Geginat J, 1999, J IMMUNOL, V162, P5085; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PARDI R, 1995, J IMMUNOL, V155, P1252; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7	21	180	188	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					617	+		10.1038/35007098	http://dx.doi.org/10.1038/35007098			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766246				2022-12-28	WOS:000086400100057
J	Fuentes-Prior, P; Iwanaga, Y; Huber, R; Pagila, R; Rumennik, G; Seto, M; Morser, J; Light, DR; Bode, W				Fuentes-Prior, P; Iwanaga, Y; Huber, R; Pagila, R; Rumennik, G; Seto, M; Morser, J; Light, DR; Bode, W			Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex	NATURE			English	Article							RAY CRYSTAL-STRUCTURE; FACTOR-LIKE DOMAINS; EGF-LIKE DOMAIN; PROTEIN-C; MOLECULAR MECHANISMS; COFACTOR ACTIVITY; BINDING-SITE; COAGULATION; ACTIVATION; SURFACE	The serine proteinase alpha-thrombin causes blood clotting through proteolytic cleavage of fibrinogen and protease-activated receptors and amplifies its own generation by activating the essential clotting factors V and VIII1, Thrombomodulin(2), a transmembrane thrombin receptor with six contiguous epidermal growth factor-like domains (TME1-6), profoundly alters the substrate specificity of thrombin from pro- to anticoagulant by activating protein C (see, for example, reference 2). Activated protein C then deactivates the coagulation cascade by degrading activated factors V and VIII2. The thrombin-thrombomodulin complex inhibits fibrinolysis by activating the procarboxypeptidase thrombin-activatable fibrinolysis inhibitor(3). Here we present the 2.3 Angstrom crystal structure of human alpha-thrombin bound to the smallest thrombomodulin fragment required for full protein-C co-factor activity, TME456. The Y-shaped thrombomodulin fragment binds to thrombin's anion-binding exosite-I, preventing binding of procoagulant substrates. Thrombomodulin binding does not seem to induce marked allosteric structural rearrangements at the thrombin active site. Rather, docking of a protein C model to thrombin-TME456 indicates that TME45 may bind substrates in such a manner that their zymogen-activation cleavage sites are presented optimally to the unaltered thrombin active site.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Berlex Biosci, Richmond, CA 94804 USA	Max Planck Society	Fuentes-Prior, P (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.	fuentes@biochem.mpg.de; bode@biochem.mpg.de		Fuentes-Prior, Pablo/0000-0002-6618-3204				ADLER M, 1995, J BIOL CHEM, V270, P23366, DOI 10.1074/jbc.270.40.23366; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; Benitez BAS, 1997, J MOL BIOL, V273, P913, DOI 10.1006/jmbi.1997.1356; BODE W, 1992, PROTEIN SCI, V1, P426; BRUNGER GJ, 1993, XPLOR VERSION 3 1 SY; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; Gerlitz B, 1996, J BIOL CHEM, V271, P22285, DOI 10.1074/jbc.271.37.22285; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GRINNELL BW, 1994, BIOCHEM J, V303, P929, DOI 10.1042/bj3030929; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HOGG PJ, 1992, J BIOL CHEM, V267, P703; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; Light DR, 1999, EUR J BIOCHEM, V262, P522, DOI 10.1046/j.1432-1327.1999.00398.x; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MEININGER DP, 1995, PROTEIN SCI, V4, P1683, DOI 10.1002/pro.5560040904; MUSCI G, 1988, BIOCHEMISTRY-US, V27, P769, DOI 10.1021/bi00402a042; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; VINCENOT A, 1995, FEBS LETT, V367, P153, DOI 10.1016/0014-5793(95)00552-K; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Weisel JW, 1996, J BIOL CHEM, V271, P31485, DOI 10.1074/jbc.271.49.31485; YE J, 1991, J BIOL CHEM, V266, P23016; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	37	259	288	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	2000	404	6777					518	525		10.1038/35006683	http://dx.doi.org/10.1038/35006683			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761923				2022-12-28	WOS:000086257700054
J	Harms, KE; Wright, SJ; Calderon, O; Hernandez, A; Herre, EA				Harms, KE; Wright, SJ; Calderon, O; Hernandez, A; Herre, EA			Pervasive density-dependent recruitment enhances seedling diversity in a tropical forest	NATURE			English	Article							JANZEN-CONNELL MODEL; NEOTROPICAL FOREST; TREE; SPECIFICITY; HERBIVORY; SURVIVAL; DISTANCE	Negative density-dependent recruitment of seedlings, that is, seeds of a given species are less likely to become established seedlings if the density of that species is high, has been proposed to be an important mechanism contributing to the extraordinary diversity of tropical tree communities(1-3) because it can potentially prevent any particular species from usurping all available space, either in close proximity to seed sources or at relatively larger spatial scales(1-18). However, density-dependent recruitment does not necessarily enhance community diversity(14). Furthermore, although density-dependent effects have been found at some life stages in some species(3-13), no study has shown that density-dependent recruitment affects community diversity(14,15). Here we report the results of observations in a lowland, moist forest in the Republic of Panama in which the species identities of 386,027 seeds that arrived at 200 seed traps were compared with the species identities of 13,068 seedlings that recruited into adjacent plots over a 4-year period. Across the 200 sites, recruit seedling diversity was significantly higher than seed diversity. Part of this difference was explained by interspecies differences in average recruitment success. Even after accounting for these differences, however, negative density-dependent recruitment contributes significantly to the increase in diversity from Seeds to seedling recruits.	Smithsonian Trop Res Inst, Balboa, Panama	Smithsonian Institution; Smithsonian Tropical Research Institute	Wright, SJ (corresponding author), Smithsonian Trop Res Inst, Apartado 2072, Balboa, Panama.	wrightj@tivoli.si.edu	Wright, Stuart Joseph/M-3311-2013	Wright, Stuart Joseph/0000-0003-4260-5676				AUGSPURGER CK, 1984, ECOLOGY, V65, P1705, DOI 10.2307/1937766; Barone JA, 1998, J ANIM ECOL, V67, P400, DOI 10.1046/j.1365-2656.1998.00197.x; CLARK DA, 1984, AM NAT, V124, P769, DOI 10.1086/284316; Coley P.D., 1991, PLANT ANIMAL INTERAC, P25; Coley PD, 1996, ANNU REV ECOL SYST, V27, P305, DOI 10.1146/annurev.ecolsys.27.1.305; Condit R, 1996, J TROP ECOL, V12, P231, DOI 10.1017/S0266467400009433; CONDIT R, 1992, AM NAT, V140, P261, DOI 10.1086/285412; CONNELL J H, 1971, P298; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; GILBERT GS, 1994, OECOLOGIA, V98, P100, DOI 10.1007/BF00326095; HAMMERSTEIN B, 1995, CD-ROM PROF, V8, P76; Hammond D. S., 1998, Dynamics of tropical communities : the 37th symposium of the British Ecological Society, Cambridge University, 1996., P51; HOWE HF, 1990, J TROP ECOL, V6, P259, DOI 10.1017/S0266467400004508; Hubbell SP, 1999, SCIENCE, V283, P554, DOI 10.1126/science.283.5401.554; HUBBELL SP, 1990, PHILOS T R SOC B, V330, P269, DOI 10.1098/rstb.1990.0198; HUBBELL SP, 1980, OIKOS, V35, P214, DOI 10.2307/3544429; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; JANZEN DH, 1980, J ECOL, V68, P929, DOI 10.2307/2259466; KITAJIMA K, 1994, OECOLOGIA, V98, P419, DOI 10.1007/BF00324232; Leigh EG, 1999, TROPICAL FOREST ECOL; Ridley H., 1930, J ECOL, DOI DOI 10.2307/2255951; SCHUPP EW, 1992, AM NAT, V140, P526, DOI 10.1086/285426; Webb CO, 1999, ECOLOGY, V80, P2006, DOI 10.1890/0012-9658(1999)080[2006:SDDPCO]2.0.CO;2; Wills C, 1997, P NATL ACAD SCI USA, V94, P1252, DOI 10.1073/pnas.94.4.1252; Wills C, 1999, P ROY SOC B-BIOL SCI, V266, P1445, DOI 10.1098/rspb.1999.0799; Wright SJ, 1999, HANDBOOK OF FUNCTIONAL PLANT ECOLOGY, P449; Wright SJ, 1999, ECOLOGY, V80, P1632, DOI 10.2307/176552	27	720	808	8	280	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 30	2000	404	6777					493	495		10.1038/35006630	http://dx.doi.org/10.1038/35006630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761916				2022-12-28	WOS:000086257700047
J	Thomas, SL; Ellertson, C				Thomas, SL; Ellertson, C			Nuisance or natural and healthy: should monthly menstruation be optional for women?	LANCET			English	Article									Populat Council, Latin Amer & Caribbean Reg Off, Mexico City 04000, DF, Mexico		Ellertson, C (corresponding author), Populat Council, Latin Amer & Caribbean Reg Off, Escondrida 110,Col Villa Coyoacan, Mexico City 04000, DF, Mexico.							Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96; COUTINHO EM, 1999, REPROD MED MILLENNIU; COUTINHO EM, 1996, IS MENSTRUATION OBSO; EATON SB, 1994, Q REV BIOL, V69, P353, DOI 10.1086/418650; Kjerulff KH, 1996, AM J PUBLIC HEALTH, V86, P195, DOI 10.2105/AJPH.86.2.195; LOUDON NB, 1977, BRIT MED J, V2, P487, DOI 10.1136/bmj.2.6085.487; Sulak PJ, 1997, OBSTET GYNECOL, V89, P179, DOI 10.1016/S0029-7844(96)00488-7; World Health Organization, 1996, IMPR ACC QUAL CAR FA	8	114	125	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					922	924		10.1016/S0140-6736(99)11159-0	http://dx.doi.org/10.1016/S0140-6736(99)11159-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752720				2022-12-28	WOS:000085896000043
J	Teplitsky, V; Virag, I; Halabe, A				Teplitsky, V; Virag, I; Halabe, A			Drug points - Immune complex haemolytic anaemia associated with sulfasalazine	BRITISH MEDICAL JOURNAL			English	Article									Tel Aviv Univ, Wolfson Med Ctr, Inst Hematol, Dept Internal Med E, IL-69978 Tel Aviv, Israel	Tel Aviv University	Teplitsky, V (corresponding author), Tel Aviv Univ, Wolfson Med Ctr, Inst Hematol, Dept Internal Med E, IL-69978 Tel Aviv, Israel.							BALINT JA, 1963, AM J DIG DIS, V8, P537, DOI 10.1007/BF02232036; BELL DW, 1981, SOUTHERN MED J, V74, P359, DOI 10.1097/00007611-198103000-00029; Giannadaki E, 1997, AM J GASTROENTEROL, V92, P1872; MECHANICK JI, 1985, MT SINAI J MED, V52, P667; Petz LD, 1985, METHODS HEMATOLOGY I, P47	5	6	6	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1113	1113						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775222				2022-12-28	WOS:000086782800019
J	Turley, SJ; Inaba, K; Garrett, WS; Ebersold, M; Unternaehrer, J; Steinman, RM; Mellman, I				Turley, SJ; Inaba, K; Garrett, WS; Ebersold, M; Unternaehrer, J; Steinman, RM; Mellman, I			Transport of peptide-MHC class II complexes in developing dendritic cells	SCIENCE			English	Article							BONE-MARROW CULTURES; DEVELOPMENTAL REGULATION; B-LYMPHOCYTES; LARGE NUMBERS; T-CELLS; MOLECULES; ACCUMULATION; COMPARTMENT; GENERATION; LYSOSOMES	Major histocompatibility complex class II (MHC II) molecules capture peptides within the endocytic pathway to generate T cell receptor (TCR) ligands. Immature dendritic cells (DCs) sequester intact antigens in Lysosomes, processing and converting antigens into peptide-MHC II complexes upon induction of DC maturation. The complexes then accumulate in distinctive, nonlysosomal MHC II+ vesicles that appear to migrate to the cell surface. Although the vesicles exclude soluble lysosomal contents and antigen-processing machinery, many contain MHC I and B7 costimulatory molecules. After arrival at the cell surface, the MHC and costimulatory molecules remain clustered. Thus, transport of peptide-MHC II complexes by DCs not only accomplishes transfer from late endocytic compartments to the plasma membrane, but does so in a manner that selectively concentrates TCR ligands and costimulatory molecules for T cell contact.	Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, Immunobiol Sect, New Haven, CT 06520 USA; Kyoto Univ, Grad Sch Biostudies, Immunobiol Lab, Kyoto 6068502, Japan; Rockefeller Univ, Cellular Physiol & Immunol Lab, Lab Cellular Immunol & Physiol, New York, NY 10021 USA	Ludwig Institute for Cancer Research; Yale University; Ludwig Institute for Cancer Research; Yale University; Kyoto University; Rockefeller University	Mellman, I (corresponding author), Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, 333 Cedar St,POB 208002, New Haven, CT 06520 USA.		Mellman, Ira/ABG-5896-2020; Steinman, Ralph/F-7729-2012	Garrett, Wendy/0000-0002-5092-0150; Unternaehrer-Hamm, Julia/0000-0001-5864-4704	NIAID NIH HHS [AI-13013, AI-34098, AI-39672] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013013, R01AI034098, R37AI034098, R37AI013013, P01AI039672] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; GARRETT WR, UNPUB; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HARDING CV, 1992, J CELL BIOL, V119, P531, DOI 10.1083/jcb.119.3.531; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rescigno M, 1998, P NATL ACAD SCI USA, V95, P5229, DOI 10.1073/pnas.95.9.5229; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1; Talmor M, 1998, EUR J IMMUNOL, V28, P811, DOI 10.1002/(SICI)1521-4141(199803)28:03<811::AID-IMMU811>3.3.CO;2-J; UNTERMAEHRER J, UNPUB; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Zhong GM, 1997, P NATL ACAD SCI USA, V94, P13856, DOI 10.1073/pnas.94.25.13856	28	385	396	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					522	527		10.1126/science.288.5465.522	http://dx.doi.org/10.1126/science.288.5465.522			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775112				2022-12-28	WOS:000086626000047
J	O'Cathain, A; Munro, JF; Nicholls, JP; Knowles, E				O'Cathain, A; Munro, JF; Nicholls, JP; Knowles, E			How helpful is NHS direct? Postal survey of callers	BRITISH MEDICAL JOURNAL			English	Article							TELEPHONE		Sch Hlth & Related Res, Med Care Res Unit, Sheffield, S Yorkshire, England	University of Sheffield	O'Cathain, A (corresponding author), Sch Hlth & Related Res, Med Care Res Unit, Sheffield, S Yorkshire, England.		Nicholl, Jon/B-8257-2008					*DEP HLTH, 1997, CMD3807; Fareed A, 1996, J ADV NURS, V23, P272, DOI 10.1111/j.1365-2648.1996.tb02667.x; MUNRO J, 1998, EVALUATION NHS DIREC; NAGLE JP, 1992, BRIT J GEN PRACT, V42, P190; POOLE SR, 1993, PEDIATRICS, V92, P670	5	56	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1035	1035		10.1136/bmj.320.7241.1035	http://dx.doi.org/10.1136/bmj.320.7241.1035			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764361	Green Published, Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000086675700020
J	Reed, JL; Lyne, R				Reed, JL; Lyne, R			Inpatient care of mentally ill people in prison: results of a year's programme of semistructured inspections	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; DISORDER	Objective To investigate the facilities for inpatient care of mentally disordered people in prison. Design Semistructured inspections conducted by doctor and nurse. Expected standards were based on healthcare quality standards published by the Prison Service or the NHS. Setting 13 prisons with inpatient beds in England and Wales subject to the prison inspectorate's routine inspection programme during 1997-8. Main outcomes measures Appraisals of quality of care against published standards. Results The 13 prisons had 348 beds, 20% of all beds in prisons. Inpatient units had between 3 and 75 beds. No doctor in charge of inpatients had completed specialist psychiatric training. 24% of nursing staff had mental health training; 32% were non-nursing trained healthcare officers. Only one prison had occupational therapy input; two had input from a clinical psychologist Most patients were unlocked for about 3.5 hours a day and none for more than nine hours a day. Four prisons provided statistics on the use of seclusion. The average length of an episode of seclusion was 50 hours. Conclusion The quality of services for mentally ill prisoners fell far below the standards in the NHS. Patients' lives were unacceptably restricted and therapy limited. The present policy dividing inpatient care of mentally disordered prisoners between the prison service and the NHS needs reconsideration.	HM Inspectorate Prisons, Home Off, London SW1H 9AT, England		Reed, JL (corresponding author), HM Inspectorate Prisons, Home Off, London SW1H 9AT, England.							Birmingham L, 1996, BRIT MED J, V313, P1521, DOI 10.1136/bmj.313.7071.1521; Brooke D, 1996, BRIT MED J, V313, P1524, DOI 10.1136/bmj.313.7071.1524; *DEP HLTH, 1998, IN PAT FORM DET HOSP; GUNN J, 1991, BRIT MED J, V303, P338, DOI 10.1136/bmj.303.6798.338; Hargreaves D, 1997, J FORENSIC PSYCHIATR, V8, P62, DOI 10.1080/09585189708411994; Health Advisory Committee for the Prison Service, 1997, PROV MENT HLTH CAR P; *HER MAJ INSP PRIS, 1999, REP FULL INSP HMYOI; *HER MAJ PRIS SERV, 1993, HLTH CAR STAND PRIS; *HER MAJ PRIS SERV, 1999, FUT ORG PRIS HLTH CA; *HER MAJ PRIS SERV, 1991, STAND ORD 13 HLTH CA; *HOM OFF, 1991, CUST CAR JUST WAY AH; MELTZER H, 1994, PREVALENCE PSYCHIAT; *PRIS SERV, 1997, REP DIR HLTH CAR 199; *PRIS SERV, 1998, REP DIR HLTH CAR 199; Reed J, 1997, BRIT MED J, V315, P1420, DOI 10.1136/bmj.315.7120.1420; Singleton N., 1998, PSYCHIAT MORBIDITY P; Smith Richard, 1984, PRISON HLTH CARE; THOMLINSON L, 1998, BMA NEWS REV     OCT; WILLIAMS J, 1999, PHARM J, V263, P634	19	38	38	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1031	1034		10.1136/bmj.320.7241.1031	http://dx.doi.org/10.1136/bmj.320.7241.1031			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764360	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086675700018
J	Scott, JAG; Hall, AJ; Muyodi, C; Lowe, B; Ross, M; Chohan, B; Mandaliya, K; Getambu, E; Gleeson, F; Drobniewski, F; Marsh, K				Scott, JAG; Hall, AJ; Muyodi, C; Lowe, B; Ross, M; Chohan, B; Mandaliya, K; Getambu, E; Gleeson, F; Drobniewski, F; Marsh, K			Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya	LANCET			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY COMPLICATIONS; BACTERIAL PNEUMONIA; ETIOLOGY; ADMISSIONS; INFECTION; GUINEA	Background Despite a substantial disease burden, there is little descriptive epidemiology of acute pneumonia in sub-Saharan Africa. We did this study to define the aetiology of acute pneumonia, to estimate mortality at convalescence, and to analyse mortality risk-factors. Methods We studied 281 Kenyan adults who presented to two public hospitals (one urban and one rural) with acute radiologically confirmed pneumonia during 1994-96. We did blood and lung-aspirate cultures, mycobacterial cultures, serotype-specific pneumococcal antigen detection, and serology for viral and atypical agents. Findings Aetiology was defined in 182 (65%) patients. Streptococcus pneumoniae was the most common causative agent, being found in 129 (46%) cases; Mycobacterium tuberculosis was found in 26 (9%). Of 255 patients followed up for at least 3 weeks, 25 (10%) died at a median age of 33 years. In multivariate analyses, risk or protective factors for mortality were age (odds ratio 1.51 per decade [95% CI 1.04-2.19]), unemployment (4.42 [1.21-16.1]), visiting a traditional healer (5.26 [1.67-16.5]), visiting a pharmacy (0.30 [0.10-0.91]), heart rate (1.64 per 10 beats [1.24-2.16]), and herpes labialis (1.54 [2.22-107]). HIV-1 seropositivity, found in 52%, was not associated with mortality. Death or failure to recover after 3 weeks was more common in patients with pneumococci of intermediate resistance to benzylpenicillin, which comprised 28% of pneumococcal isolates, than in those infected with susceptible pneumococci (5.60 [1.33-23.6]). Interpretation We suggest that tuberculosis is a sufficiently common cause of acute pneumonia in Kenyan adults to justify routine sputum culture, and that treatment with benzylpenicillin remains appropriate for clinical failure due to M tuberculosis, intermediate-resistant pneumococci, and other bacterial pathogens. However, interventions restricted to hospital management will fail to decrease mortality associated with socioeconomic, educational, and behavioural factors.	London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England; Coast Prov Gen Hosp, Mombasa, Kenya; Royal Berkshire Hosp, Publ Hlth Lab, Reading RG1 5AN, Berks, England; Churchill Hosp, Dept Radiol, Oxford OX3 7LJ, England; Publ Hlth Lab Serv, Mycobacterium Reference Unit, London, England; Publ Hlth Lab Serv, Reg Ctr Mycobacteriol, London, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of London; London School of Hygiene & Tropical Medicine; Royal Berkshire Hospital; University of Oxford; Public Health England; Public Health England; University of Oxford	Scott, JAG (corresponding author), Wellcome Trust Res Labs, Kenya Med Res Inst, Ctr Geog Med Res Coast, POB 230, Kilifi, Kenya.	ascott@kilifi.mimcom.net			Wellcome Trust [061089, 081835] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; ADERAYE G, 1994, ETHIOPIAN MED J, V32, P115; ALLEN SC, 1984, THORAX, V39, P612, DOI 10.1136/thx.39.8.612; ANDREWS BE, 1987, Q J MED, V62, P195; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; Daley CL, 1996, AM J RESP CRIT CARE, V154, P105, DOI 10.1164/ajrccm.154.1.8680664; DAVIDSON M, 1976, JAMA-J AM MED ASSOC, V235, P158, DOI 10.1001/jama.235.2.158; Drobniewski FA, 1998, METH MOL B, V101, P323, DOI 10.1385/0-89603-471-2:323; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FINE MJ, 1990, AM J MED, V88, pN1; HARRIES AD, 1990, TROP GEOGR MED, V42, P274; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; KAMANFU G, 1993, AM REV RESPIR DIS, V147, P658, DOI 10.1164/ajrccm/147.3.658; Klugman KP, 1996, J ANTIMICROB CHEMOTH, V38, P133, DOI 10.1093/jac/38.suppl_A.133; KoullaShiro S, 1996, TUBERCLE LUNG DIS, V77, P47, DOI 10.1016/S0962-8479(96)90075-1; LIND K, 1988, EPIDEMIOL INFECT, V101, P377, DOI 10.1017/S0950268800054327; MACFARLANE JT, 1979, THORAX, V34, P713, DOI 10.1136/thx.34.6.713; MACFARLANE JT, 1982, LANCET, V2, P255; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MUNDY LM, 1995, AM J RESP CRIT CARE, V152, P1309, DOI 10.1164/ajrccm.152.4.7551387; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; Scott JAG, 1999, CHEST, V116, P1716, DOI 10.1378/chest.116.6.1716; Scott JAG, 1998, CLIN INFECT DIS, V27, P1442, DOI 10.1086/515013; Scott JAG, 1999, CLIN INFECT DIS, V28, P764, DOI 10.1086/515198; SHANN F, 1984, LANCET, V2, P537; Sofowora E O, 1973, Niger Med J, V3, P144; Sow O, 1996, THORAX, V51, P385, DOI 10.1136/thx.51.4.385; WALLACE RJ, 1978, AM J MED, V64, P87, DOI 10.1016/0002-9343(78)90182-1; WILLIAMS EH, 1986, J TROP MED HYG, V89, P193	30	138	140	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2000	355	9211					1225	1230		10.1016/S0140-6736(00)02089-4	http://dx.doi.org/10.1016/S0140-6736(00)02089-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770305				2022-12-28	WOS:000086448000012
J	Aldhous, P				Aldhous, P			Global warming could be bad news for Arctic ozone layer	NATURE			English	News Item																			0	14	14	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					531	531		10.1038/35007212	http://dx.doi.org/10.1038/35007212			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766201	Bronze			2022-12-28	WOS:000086400100007
J	Wickware, P				Wickware, P			Next-generation biologists must straddle computation and biology	NATURE			English	Editorial Material																		[No title captured]	1	12	13	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					683	684		10.1038/35007262	http://dx.doi.org/10.1038/35007262			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766255				2022-12-28	WOS:000086400100068
J	Fiscella, K; Frankel, R				Fiscella, K; Frankel, R			Overcoming cultural barriers: International medical graduates in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE		Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Fiscella, K (corresponding author), Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA.							Cohen-Cole SA, 1991, MED INTERVIEW 3 FUNC; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Fiscella K, 1997, FAM PRACT, V14, P112, DOI 10.1093/fampra/14.2.112; FORESST DV, 1978, J PSYCHATR ED, V2, P68; Haveliwala Y A, 1979, Psychiatr Q, V51, P307, DOI 10.1007/BF01082834; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Mick SS, 1997, MED CARE RES REV, V54, P379, DOI 10.1177/107755879705400401; PAJAK GG, 1990, DISS ABSTR INT, V50, P3872; ROSNER F, 1993, J GEN INTERN MED, V8, P264, DOI 10.1007/BF02600094; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423	10	43	44	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1751	1751		10.1001/jama.283.13.1751	http://dx.doi.org/10.1001/jama.283.13.1751			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	298BK	10755508				2022-12-28	WOS:000086119300042
J	Chen, P; Luo, C; Deng, YL; Ryan, K; Register, J; Margosiak, S; Tempczyk-Russell, A; Nguyen, B; Myers, P; Lundgren, K; Kan, CC; O'Connor, PM				Chen, P; Luo, C; Deng, YL; Ryan, K; Register, J; Margosiak, S; Tempczyk-Russell, A; Nguyen, B; Myers, P; Lundgren, K; Kan, CC; O'Connor, PM			The 1.7 angstrom crystal structure of human cell cycle checkpoint kinase Chk1: Implications for Chk1 regulation	CELL			English	Article							DNA-DAMAGE CHECKPOINT; DEPENDENT PROTEIN-KINASE; REPLICATION CHECKPOINT; TYROSINE KINASE; FISSION YEAST; PEPTIDE SUBSTRATE; CATALYTIC SUBUNIT; PHOSPHORYLATION; ACTIVATION; CDC2	The checkpoint kinase Chk1 is an important mediator of cell cycle arrest following DNA damage. The 1.7 Angstrom resolution crystal structures of the human Chk1 kinase domain and its binary complex with an ATP analog has revealed an identical open kinase conformation. The secondary structure and side chain interactions stabilize the activation loop of Chk1 and enable kinase activity without phosphorylation of the catalytic domain. Molecular modeling of the interaction of a Cdc25C peptide with Chk1 has uncovered several conserved residues that are important for substrate selectivity. In addition, we found that the less conserved C-terminal region negatively impacts Chk1 kinase activity.	Agouron Pharmaceut Inc, San Diego, CA 92121 USA	Pfizer	Chen, P (corresponding author), Agouron Pharmaceut Inc, 3565 Gen Atom Court, San Diego, CA 92121 USA.							Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR V3 1 SYSTEM XR; Chen P, 1999, ONCOGENE, V18, P249, DOI 10.1038/sj.onc.1202257; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; FAN SJ, 1995, CANCER RES, V55, P1649; Francesconi S, 1997, EMBO J, V16, P1332, DOI 10.1093/emboj/16.6.1332; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRAVES PR, 2000, IN PRESS J BIOL CHEM; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; LEE YY, 1992, APPL BIOCHEM BIOTECH, V34-5, P3, DOI 10.1007/BF02920529; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OConnor PM, 1997, CANCER SURV, V29, P151; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sarkaria JN, 1999, CANCER RES, V59, P4375; Suganuma M, 1999, CANCER RES, V59, P5887; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	59	176	186	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 17	2000	100	6					681	692		10.1016/S0092-8674(00)80704-7	http://dx.doi.org/10.1016/S0092-8674(00)80704-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761933	Bronze			2022-12-28	WOS:000085983800010
J	Carby, M; Smith, SR				Carby, M; Smith, SR			A hazard of paint spraying	LANCET			English	Article									Horton Hosp, Dept Med, Banbury OX16 9AL, Oxon, England		Smith, SR (corresponding author), Horton Hosp, Dept Med, Oxford Rd, Banbury OX16 9AL, Oxon, England.							HARI PR, 1999, PAEDIATRICS, V103, pE19; STERN EJ, 1992, CHEST, V102, P263, DOI 10.1378/chest.102.1.263	2	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					896	896		10.1016/S0140-6736(99)12151-2	http://dx.doi.org/10.1016/S0140-6736(99)12151-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752707				2022-12-28	WOS:000085896000013
J	Abboud, P; Quereux, C; Mansour, G; Allag, F; Zanardi, M				Abboud, P; Quereux, C; Mansour, G; Allag, F; Zanardi, M			Stronger campaign needed to end female genital mutilation	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Hosp Reims, Reims, France; Hosp Soissons, Soissons, France	CHU de Reims	Abboud, P (corresponding author), Univ Hosp Reims, Reims, France.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1153	1153		10.1136/bmj.320.7242.1153	http://dx.doi.org/10.1136/bmj.320.7242.1153			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775250	Green Published			2022-12-28	WOS:000086782800066
J	Pope, JH; Aufderheide, TP; Ruthazer, R; Woolard, RH; Feldman, JA; Beshansky, JR; Griffith, JL; Selker, HP				Pope, JH; Aufderheide, TP; Ruthazer, R; Woolard, RH; Feldman, JA; Beshansky, JR; Griffith, JL; Selker, HP			Missed diagnoses of acute cardiac ischemia in the emergency department	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; INSENSITIVE PREDICTIVE INSTRUMENT; CHEST PAIN; HEART-DISEASE; FOLLOW-UP; PROSPECTIVE MULTICENTER; CLINICAL-FEATURES; WOMEN; MORTALITY; TIME	Background: Discharging patients with acute myocardial infarction or unstable angina from the emergency department because of missed diagnoses can have dire consequences. We studied the incidence of, factors related to, and clinical outcomes of failure to hospitalize patients with acute cardiac ischemia. Methods: We analyzed clinical data from a multicenter, prospective clinical trial of all patients with chest pain or other symptoms suggesting acute cardiac ischemia who presented to the emergency departments of 10 U.S. hospitals. Results: Of 10,689 patients, 17 percent ultimately met the criteria for acute cardiac ischemia (8 percent had acute myocardial infarction and 9 percent had unstable angina), 6 percent had stable angina, 21 percent had other cardiac problems, and 55 percent had noncardiac problems. Among the 889 patients with acute myocardial infarction, 19 (2.1 percent) were mistakenly discharged from the emergency department (95 percent confidence interval, 1.1 to 3.1 percent); among the 966 patients with unstable angina, 22 (2.3 percent) were mistakenly discharged (95 percent confidence interval, 1.3 to 3.2 percent). Multivariable analysis showed that patients who presented to the emergency department with acute cardiac ischemia were more likely not to be hospitalized if they were women less than 55 years old (odds ratio for discharge, 6.7; 95 percent confidence interval, 1.4 to 32.5), were nonwhite (odds ratio, 2.2; 1.1 to 4.3), reported shortness of breath as their chief symptom (odds ratio, 2.7; 1.1 to 6.5), or had a normal or nondiagnostic electrocardiogram (odds ratio, 3.3; 1.7 to 6.3). Patients with acute infarction were more likely not to be hospitalized if they were nonwhite (odds ratio for discharge, 4.5; 95 percent confidence interval, 1.8 to 11.8) or had a normal or nondiagnostic electrocardiogram (odds ratio, 7.7; 95 percent confidence interval, 2.9 to 20.2). For the patients with acute infarction, the risk-adjusted mortality ratio for those who were not hospitalized, as compared with those who were, was 1.9 (95 percent confidence interval, 0.7 to 5.2), and for the patients with unstable angina, it was 1.7 (95 percent confidence interval, 0.2 to 17.0). Conclusions: The percentage of patients who present to the emergency department with acute myocardial infarction or unstable angina who are not hospitalized is low, but the discharge of such patients may be associated with increased mortality. Failure to hospitalize is related to race, sex, and the absence of typical features of cardiac ischemia. Efforts to reduce the number of missed diagnoses are warranted. (N Engl J Med 2000;342:1163-70.) (C) 2000, Massachusetts Medical Society.	New England Med Ctr, Dept Med, Div Clin Care Res, Ctr Cardiovasc Hlth Serv Res, Boston, MA 02111 USA; Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA; Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; Rhode Isl Hosp, Dept Emergency Med, Providence, RI USA; Boston Med Ctr, Dept Emergency Med, Boston, MA USA	Tufts Medical Center; Baystate Medical Center; Medical College of Wisconsin; Lifespan Health Rhode Island; Rhode Island Hospital; Boston Medical Center	Selker, HP (corresponding author), New England Med Ctr, Dept Med, Div Clin Care Res, Ctr Cardiovasc Hlth Serv Res, 63,750 Washington St, Boston, MA 02111 USA.		woolard, robert h/A-7860-2011	Feldman, James/0000-0003-3962-0189	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007360] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS07360] Funding Source: Medline; NCRR NIH HHS [M01 RR00054] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AM HEART ASS, 1995, CARD DIS STAT HEART, P1; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Cooper R S, 1992, Ann Epidemiol, V2, P637; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LIAO YL, 1987, CIRCULATION, V75, P347, DOI 10.1161/01.CIR.75.2.347; LUSIANI L, 1994, ANGIOLOGY, V45, P49, DOI 10.1177/000331979404500107; MAYNARD C, 1986, CIRCULATION, V74, P64, DOI 10.1161/01.CIR.74.1.64; Maynard C, 1997, J NATL MED ASSOC, V89, P665; Maynard C, 1996, CIRCULATION, V94, P93; MAYNARD C, 1992, J MYOCARD ISCHEMIA, V4, P27; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; Pope JH, 1998, J THROMB THROMBOLYS, V6, P63, DOI 10.1023/A:1008876322599; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; SCHOR S, 1976, JAMA-J AM MED ASSOC, V236, P941; Selker HP, 1997, ANN EMERG MED, V29, P1, DOI 10.1016/S0196-0644(97)70297-X; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002; SELKER HP, 1992, MED CARE, V30, P188; SHARPE PA, 1991, WOMEN HEALTH, V17, P25, DOI 10.1300/J013v17n02_02; SULLIVAN AK, 1994, BRIT MED J, V308, P883, DOI 10.1136/bmj.308.6933.883; ZALENSKI RJ, IN PRESS ANN EMERG M; Zucker DR, 1997, J GEN INTERN MED, V12, P79, DOI 10.1046/j.1525-1497.1997.00011.x	29	1279	1316	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	2000	342	16					1163	1170		10.1056/NEJM200004203421603	http://dx.doi.org/10.1056/NEJM200004203421603			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305DG	10770981				2022-12-28	WOS:000086523700003
J	Alhasso, A; Bryden, AA; Neilson, D				Alhasso, A; Bryden, AA; Neilson, D			Drug points - Lithium toxicity after urinary diversion with ileal conduit	BRITISH MEDICAL JOURNAL			English	Article									Blackburn Royal Infirm, Blackburn BB2 3LR, Lancs, England		Alhasso, A (corresponding author), Blackburn Royal Infirm, Blackburn BB2 3LR, Lancs, England.							BOWYER GW, 1987, BRIT J UROL, V60, P592, DOI 10.1111/j.1464-410X.1987.tb05050.x; DEKERNION J, 1997, ADULT PAEDIAT UROLOG, P1465; HALLWORTH M, 1993, THER DRUG MONIT, P65; Mills RD, 1999, J UROLOGY, V161, P1057, DOI 10.1016/S0022-5347(01)61590-8; SAVARIRA.F, 1969, J UROLOGY, V101, P844, DOI 10.1016/S0022-5347(17)62438-8	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1037	1037						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764364				2022-12-28	WOS:000086675700023
J	Lockwood, CJ				Lockwood, CJ			Prediction of pregnancy loss	LANCET			English	Editorial Material							RECURRENT SPONTANEOUS-ABORTION; PREIMPLANTATION EMBRYOS; WOMEN; FERTILIZATION; MISCARRIAGE; PREVENTION; OOCYTES; TRIAL		NYU, Sch Med, Dept Obstet & Gynecol, New York, NY 10016 USA	New York University	Lockwood, CJ (corresponding author), NYU, Sch Med, Dept Obstet & Gynecol, New York, NY 10016 USA.							Be C, 1997, REV MED CHILE, V125, P317; Daniely M, 1998, HUM REPROD, V13, P805, DOI 10.1093/humrep/13.4.805; KARAMARDIAN LM, 1992, AM J OBSTET GYNECOL, V167, P1391, DOI 10.1016/S0002-9378(11)91724-4; Laskin CA, 1997, NEW ENGL J MED, V337, P148, DOI 10.1056/NEJM199707173370302; MICHAELI G, 1990, J IN VITRO FERTIL EM, V7, P341, DOI 10.1007/BF01130587; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; Ober C, 1999, LANCET, V354, P365, DOI 10.1016/S0140-6736(98)12055-X; Olliaro P, 1991, Boll Ist Sieroter Milan, V70, P467; SCOTT JR, 2000, COCHRANE LIB; Simon C, 1998, REPROD FERT DEVELOP, V10, P87, DOI 10.1071/R98030; SORENSEN SS, 1987, AM J OBSTET GYNECOL, V156, P1112, DOI 10.1016/0002-9378(87)90121-9; Stephenson MD, 1998, AM J REPROD IMMUNOL, V39, P82; STIRRAT GM, 1990, LANCET, V336, P728, DOI 10.1016/0140-6736(90)92215-4; STROM CM, 1992, J ASSIST REPROD GEN, V9, P458, DOI 10.1007/BF01204052; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Zhang J, 1999, FERTIL STERIL, V71, P726, DOI 10.1016/S0015-0282(98)00549-4	16	26	27	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1292	1293		10.1016/S0140-6736(00)02108-5	http://dx.doi.org/10.1016/S0140-6736(00)02108-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776739				2022-12-28	WOS:000086829400006
J	Pouyanne, P; Haramburu, F; Imbs, JL; Begaud, B				Pouyanne, P; Haramburu, F; Imbs, JL; Begaud, B		French Pharmacovigliance Centres	Admissions to hospital caused by adverse drug reactions: cross sectional incidence study	BRITISH MEDICAL JOURNAL			English	Article									Univ Victor Segalen, CHU, Ctr Pharmacovigilance, Dept Pharmacol, F-33076 Bordeaux, France; Hop Univ, Serv Pharmacol Clin, Ctr Reg Pharmacovigilance Alsace, F-67091 Strasbourg, France	CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; CHU Strasbourg	Haramburu, F (corresponding author), Univ Victor Segalen, CHU, Ctr Pharmacovigilance, Dept Pharmacol, F-33076 Bordeaux, France.							EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Imbs JL, 1999, THERAPIE, V54, P21; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Roughead EE, 1998, MED J AUSTRALIA, V168, P405, DOI 10.5694/j.1326-5377.1998.tb138996.x; *WHO, 1996, WHO TECHN REP SER, V425	5	281	296	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1036	1036		10.1136/bmj.320.7241.1036	http://dx.doi.org/10.1136/bmj.320.7241.1036			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764362	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086675700021
J	Stock, W; Hoffman, R				Stock, W; Hoffman, R			White blood cells 1: non-malignant disorders	LANCET			English	Article							ADENOSINE-DEAMINASE DEFICIENCY; LINKED DYSKERATOSIS-CONGENITA; SEVERE CHRONIC NEUTROPENIA; CHEDIAK-HIGASHI-SYNDROME; GENE; LEUKEMIA; ACTIVATION; DISEASES; PATHOPHYSIOLOGY; LYMPHOCYTES	Disorders of white cells are very common in clinical practice. White-cell development and numbers are controlled by a mixture of external stimuli including cytokines, matrix proteins, and accessory cells. Several different white-cell lineages are recognised; each has a role in host defence. Both white-cell deficiency and overproduction can lead to disease. Some forms of inherited white-cell deficiency are potentially treatable with gene therapy.	Univ Illinois, Sch Med, Dept Med, Hematol Oncol Sect, Chicago, IL 60614 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hoffman, R (corresponding author), Univ Illinois, Sch Med, Dept Med, Hematol Oncol Sect, Room 3150,Mol Biol Res Bldg,M-C 734,900 S Ashland, Chicago, IL 60614 USA.	ronhoff@uic.edu						Barrat FJ, 1996, AM J HUM GENET, V59, P625; Barrat FJ, 1999, P NATL ACAD SCI USA, V96, P8645, DOI 10.1073/pnas.96.15.8645; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Bernini JC, 1996, PEDIATR CLIN N AM, V43, P773, DOI 10.1016/S0031-3955(05)70432-6; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BONILLA MA, 1994, BRIT J HAEMATOL, V88, P723, DOI 10.1111/j.1365-2141.1994.tb05110.x; Cavazzana-Calvo M, 1999, BLOOD, V94, p367A; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; DALE DC, 1975, J CLIN INVEST, V56, P808, DOI 10.1172/JCI108159; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; DENBURG JA, 1992, BLOOD, V79, P846; Durandy A, 1997, J IMMUNOL, V158, P2576; Foucar K, 1999, MODERN PATHOL, V12, P141; Freedman M H, 1997, Curr Opin Hematol, V4, P217; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; HERRING WB, 1974, AM J MED, V56, P729, DOI 10.1016/0002-9343(74)90642-1; HERSHFIELD MS, 1995, HUM MUTAT, V5, P107, DOI 10.1002/humu.1380050202; Hess JL, 1996, AM J CLIN PATHOL, V105, P238; Horwitz M, 1999, BLOOD, V94, p650A; Knight SW, 1999, AM J HUM GENET, V65, P50, DOI 10.1086/302446; Knight SW, 1998, J MED GENET, V35, P993, DOI 10.1136/jmg.35.12.993; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; LEONARD WJ, 1996, ANNU REV MED, V18, P325; LOUGHRAN TP, 1993, BLOOD, V82, P1; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MARSH JC, 1967, J CLIN INVEST, V46, P1943, DOI 10.1172/JCI105684; METCALF D, 1993, BLOOD, V82, P3515; Misumi DJ, 1997, GENOMICS, V40, P147, DOI 10.1006/geno.1996.4549; OGAWA M, 1993, BLOOD, V81, P2844; Palmer SE, 1996, AM J MED GENET, V66, P413, DOI 10.1002/(SICI)1096-8628(19961230)66:4<413::AID-AJMG5>3.0.CO;2-L; Resta R, 1997, IMMUNOL TODAY, V18, P371, DOI 10.1016/S0167-5699(97)01047-5; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Semenzato G, 1997, BLOOD, V89, P256; SEYMOUR JF, 1994, BLOOD, V83, P2906, DOI 10.1182/blood.V83.10.2906.2906; SHANNON KM, 1992, BLOOD, V79, P1311; SHASTRI KA, 1993, BLOOD, V81, P1984; Spickett GP, 1997, IMMUNOL TODAY, V18, P325, DOI 10.1016/S0167-5699(97)01086-4; STITES DP, 1971, SEMIN HEMATOL, V8, P243; Stroncek David F., 1993, Transfusion Medicine Reviews, V7, P268, DOI 10.1016/S0887-7963(93)70146-7; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; TODD RF, 1988, HEMATOL ONCOL CLIN N, V2, P13; URBA WJ, 1989, BLOOD, V73, P38; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; WARD HN, 1971, ANN INTERN MED, V75, P193, DOI 10.7326/0003-4819-75-2-193; Welte K, 1996, ANN HEMATOL, V72, P158, DOI 10.1007/s002770050156; Welte K, 1997, SEMIN HEMATOL, V34, P267	47	39	39	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2000	355	9212					1351	1357		10.1016/S0140-6736(00)02125-5	http://dx.doi.org/10.1016/S0140-6736(00)02125-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776761				2022-12-28	WOS:000086829400041
J	von Helden, G; Tielens, ACGM; van Heijnsbergen, D; Duncan, MA; Hony, S; Waters, LBFM; Meijer, G				von Helden, G; Tielens, ACGM; van Heijnsbergen, D; Duncan, MA; Hony, S; Waters, LBFM; Meijer, G			Titanium carbide nanocrystals in circumstellar environments	SCIENCE			English	Article							RICH PROTOPLANETARY NEBULAE; MASS-LOSS; EMISSION; STARS; EVOLUTION; GRAPHITE; SHELLS; SIS2; DUST	Meteorites contain micrometer-sized graphite grains with embedded titanium carbide grains. Although isotopic analysis identifies asymptotic giant branch stars as the birth sites of these grains, there is no direct observational identification of these grains in astronomical sources. We report that infrared wavelength spectra of gas-phase titanium carbide nanocrystals derived in the laboratory show a prominent feature at a wavelength of 20.1 micrometers, which compares well to a similar feature in observed spectra of postasymptotic giant branch stars. It is concluded that titanium carbide forms during a short (approximately 100 years) phase of catastrophic mass Loss (>0.001 solar masses per year) in dying, Low-mass stars.	EURATOM, FOM, Inst Plasma Phys Rijnhuizen, NL-3430 BE Nieuwegein, Netherlands; Catholic Univ Nijmegen, Dept Mol & Laser Phys, NL-6525 ED Nijmegen, Netherlands; Univ Groningen, SRON Kapteyn Inst, NL-9700 AV Groningen, Netherlands; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Amsterdam, Astron Inst, NL-1098 SJ Amsterdam, Netherlands; Katholieke Univ Leuven, Sterrekundig Inst, B-3001 Heverlee, Belgium	Euratom; Radboud University Nijmegen; University of Groningen; University System of Georgia; University of Georgia; University of Amsterdam; KU Leuven	von Helden, G (corresponding author), EURATOM, FOM, Inst Plasma Phys Rijnhuizen, Edisonbaan 14, NL-3430 BE Nieuwegein, Netherlands.	gertvh@rijnh.nl	von Helden, Gert/H-9357-2012; Meijer, Gerard/D-2141-2009	von Helden, Gert/0000-0001-7611-8740; Meijer, Gerard/0000-0001-9669-8340				ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; Begemann B, 1996, ASTROPHYS J, V464, pL195, DOI 10.1086/310110; Bernatowicz TJ, 1996, ASTROPHYS J, V472, P760, DOI 10.1086/178105; BUSS RH, 1993, ASTROPHYS J, V415, P250, DOI 10.1086/173160; Cherchneff I, 1999, IAU SYMP, P251; Crovisier J., 1999, UNIVERSE SEEN ISO ES, V427, P161; DANCE I, COMMUNICATION; Dayal A, 1998, ASTROPHYS J, V492, P603, DOI 10.1086/305051; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; DEMUIZON MJ, 1992, LES HOUCHES, P489; GOEBEL JH, 1993, ASTRON ASTROPHYS, V278, P226; GUO BC, 1992, SCIENCE, V255, P1411, DOI 10.1126/science.255.5050.1411; Hill HGM, 1998, ASTRON ASTROPHYS, V336, pL41; Hofner S, 1998, ASTRON ASTROPHYS, V340, P497; HRIVNAK BJ, 1995, ASTROPHYS J, V438, P341, DOI 10.1086/175078; JURA M, 1997, AIP C P, V402, P379; JUSTTANONT K, 1992, ASTROPHYS J, V389, P400, DOI 10.1086/171215; JUSTTANONT K, 1996, ASTROPHYS J, V476, P319; KWOK S, 1989, ASTROPHYS J, V345, pL51, DOI 10.1086/185550; Meixner M, 1997, ASTROPHYS J, V482, P897, DOI 10.1086/304174; Molster FJ, 1996, ASTRON ASTROPHYS, V315, pL373; OEPTS D, 1995, INFRARED PHYS TECHN, V36, P297, DOI 10.1016/1350-4495(94)00074-U; OSHLMA C, 1987, PHYS REV B, V36, P7510; PILGRIM JS, 1993, J AM CHEM SOC, V115, P9724, DOI 10.1021/ja00074a044; Renzini A., 1981, PHYS PROCESSES RED G, P431; SOURISSEAU C, 1992, ASTRON ASTROPHYS, V254, pL1; Tielens AGGM, 1999, NATO ADV SCI I C-MAT, V523, P331; van Heijnsbergen D, 1999, PHYS REV LETT, V83, P4983, DOI 10.1103/PhysRevLett.83.4983; Van Winckel H, 1999, IAU SYMP, P465; van Winckel H, 2000, ASTRON ASTROPHYS, V354, P135; Volk K, 1999, ASTROPHYS J, V516, pL99, DOI 10.1086/312007	32	132	133	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	2000	288	5464					313	316						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764639				2022-12-28	WOS:000086454300030
J	Appleby, L				Appleby, L			Suicide in women	LANCET			English	Editorial Material							PREVENTION; IMMIGRANTS; MORTALITY; TRENDS		Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England	University of Manchester	Appleby, L (corresponding author), Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England.							ALLEBECK P, 1986, ARCH GEN PSYCHIAT, V43, P650; APPLEBY L, 1991, BRIT MED J, V302, P137, DOI 10.1136/bmj.302.6769.137; Appleby L., 1999, SAFER SERVICES REPOR; Burr JA, 1997, SOC SCI MED, V44, P1847, DOI 10.1016/S0277-9536(96)00294-8; Gunnell D, 1999, BRIT J PSYCHIAT, V175, P263, DOI 10.1192/bjp.175.3.263; Haste F, 1998, BRIT J GEN PRACT, V48, P1759; Hawton K, 1998, Crisis, V19, P119, DOI 10.1027/0227-5910.19.3.119; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Isometsa ET, 1998, BRIT J PSYCHIAT, V173, P531, DOI 10.1192/bjp.173.6.531; LAVECCHIA C, 1994, ACTA PSYCHIAT SCAND, V90, P53; Patel SP, 1996, PSYCHIATR SERV, V47, P517; Pritchard C, 1996, ACTA PSYCHIAT SCAND, V93, P362, DOI 10.1111/j.1600-0447.1996.tb10661.x; RALEIGH VS, 1990, BRIT J PSYCHIAT, V156, P46, DOI 10.1192/bjp.156.1.46	13	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1203	1204		10.1016/S0140-6736(00)02083-3	http://dx.doi.org/10.1016/S0140-6736(00)02083-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770299				2022-12-28	WOS:000086448000006
J	Wolf, CR; Smith, G; Smith, RL				Wolf, CR; Smith, G; Smith, RL			Science, medicine, and the future - Pharmacogenetics	BRITISH MEDICAL JOURNAL			English	Review									Univ Dundee, Ninewells Hosp & Med Sch, Imperial Canc Res Fund, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, Sect Mol Toxicol, London SW7 2AZ, England	University of Dundee; University of Dundee; Imperial College London	Wolf, CR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Imperial Canc Res Fund, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland.			Smith, Gillian/0000-0001-9288-7566; Wolf, Charles Roland/0000-0002-6969-0113				Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; BERTILSSON L, 1993, LANCET, V341, P363; CHOU WH, IN PRESS J CLIN PSYC; *DAT, 1999, ABPI COMP DAT SHEETS; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; Krynetski EY, 1996, PHARMACOGENETICS, V6, P279, DOI 10.1097/00008571-199608000-00001; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; *MED EC, 1999, PHYS DESK REF 2000; Vogel F., 1959, ERG INN MED KINDERHK, V12, P52, DOI 10.1007/978-3-642-94744-5_2; WEBER WW, 1997, PHARMACOGENETICS; Wolf CR, 1999, BRIT MED BULL, V55, P366, DOI 10.1258/0007142991902439; 1997, ADVERSE DRUG REACT T, V16, P75	13	167	180	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					987	990		10.1136/bmj.320.7240.987	http://dx.doi.org/10.1136/bmj.320.7240.987			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753155	Green Published			2022-12-28	WOS:000086453100029
J	Gloeckler, G; Geiss, J; Schwadron, NA; Fisk, LA; Zurbuchen, TH; Ipavich, FM; von Steiger, R; Balsiger, H; Wilken, B				Gloeckler, G; Geiss, J; Schwadron, NA; Fisk, LA; Zurbuchen, TH; Ipavich, FM; von Steiger, R; Balsiger, H; Wilken, B			Interception of comet Hyakutake's ion tail at a distance of 500 million kilometres	NATURE			English	Article							GIACOBINI-ZINNER; SOLAR-WIND; HALLEY; P/HALLEY; DENSITY	Remote sensing observations(1-5) and the direct sampling of material(6-8) from a few comets have established the characteristic composition of cometary gas. This gas is ionized by solar ultraviolet radiation and the solar wind to form 'pick-up' ions(9-11), ions in a low ionization state that retain the same compositional signatures as the original gas. The pick-up ions are carried outward by the solar wind, and they could in principle be detected far from the coma. (Sampling of pick-up ions has also been used to study interplanetary dust(12,13), Venus' tail(14) and the interstellar medium(15,16).) Here we report the serendipitous detection of cometary pick-up ions, most probably associated with the tail of comet Hyakutake, at a distance of 3.4 AU from the nucleus. Previous observations have provided a wealth of physical and chemical information about a small sample of comets(6-9), but this detection suggests that remote sampling of comet compositions, and the discovery of otherwise invisible comets, may be possible.	Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Univ Maryland, Inst Phys Sci & Technol, College Pk, MD 20742 USA; Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA; Int Space Sci Inst, CH-3012 Bern, Switzerland; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Max Planck Inst Aeron, D-37189 Katlenburg Lindau, Germany	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; University of Michigan System; University of Michigan; University of Bern; Max Planck Society	Gloeckler, G (corresponding author), Univ Maryland, Dept Phys, College Pk, MD 20742 USA.		von Steiger, Rudolf/F-6822-2011	von Steiger, Rudolf/0000-0002-3350-0023				ALTWEGG K, 1993, ASTRON ASTROPHYS, V279, P260; Altwegg K, 1999, SPACE SCI REV, V90, P3, DOI 10.1023/A:1005256607402; BALSIGER H, 1986, NATURE, V321, P330, DOI 10.1038/321330a0; BIERMANN L, 1952, Z NATURFORSCH A, V7, P127; Biver N, 1999, ASTRON J, V118, P1850, DOI 10.1086/301033; Combi MR, 1998, ASTROPHYS J, V494, P816, DOI 10.1086/305228; Crovisier J, 1999, SPACE SCI REV, V90, P19, DOI 10.1023/A:1005217224240; GEISS J, 1995, J GEOPHYS RES-SPACE, V100, P23373, DOI 10.1029/95JA03051; Geiss J, 1999, SPACE SCI REV, V90, P253, DOI 10.1023/A:1005266619214; Gloeckler G, 2000, J GEOPHYS RES-SPACE, V105, P7459, DOI 10.1029/1999JA000224; Gloeckler G, 1998, SPACE SCI REV, V86, P127, DOI 10.1023/A:1005019628054; GLOECKLER G, 1993, SCIENCE, V261, P70, DOI 10.1126/science.261.5117.70; GLOECKLER G, 1992, ASTRON ASTROPHYS SUP, V92, P267; GLOECKLER G, 1986, GEOPHYS RES LETT, V13, P251, DOI 10.1029/GL013i003p00251; Grevesse N, 1998, SPACE SCI REV, V85, P161, DOI 10.1023/A:1005161325181; Grunwaldt H, 1997, GEOPHYS RES LETT, V24, P1163, DOI 10.1029/97GL01159; Huebner W, 1999, SPACE SCI REV, V90, P117, DOI 10.1023/A:1005289829692; IP WH, 1987, NATURE, V325, P418, DOI 10.1038/325418a0; IPAVICH FM, 1986, SCIENCE, V232, P366, DOI 10.1126/science.232.4748.366; JOKIPII JR, 1968, PHYS REV LETT, V21, P44, DOI 10.1103/PhysRevLett.21.44; Jones GH, 2000, NATURE, V404, P574, DOI 10.1038/35007011; KISSEL J, 1986, NATURE, V321, P336, DOI 10.1038/321336a0; Lisse CM, 1999, ICARUS, V140, P189, DOI 10.1006/icar.1999.6131; NEUGEBAUER M, 1989, J GEOPHYS RES, V94, P1261, DOI 10.1029/JA094iA02p01261; NEUGEBAUER M, 1991, ASTROPHYS J, V372, P291, DOI 10.1086/169975; Riley P, 1998, J GEOPHYS RES-SPACE, V103, P1933, DOI 10.1029/97JA02142; Schmidt H. U, 1982, COMETS, P538; VONROSENVINGE TT, 1986, SCIENCE, V232, P353, DOI 10.1126/science.232.4748.353; 1986, NATURE S, V321, P259	30	34	34	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					576	578		10.1038/35007015	http://dx.doi.org/10.1038/35007015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766234	Green Published			2022-12-28	WOS:000086400100045
J	Hvidberg, CS				Hvidberg, CS			When Greenland ice melts	NATURE			English	Editorial Material							TEMPERATURE; SHEET		Univ Copenhagen, Dept Geophys, DK-2100 Copenhagen, Denmark	University of Copenhagen	Hvidberg, CS (corresponding author), Univ Copenhagen, Dept Geophys, Juliane Maries Vej 30, DK-2100 Copenhagen, Denmark.		Hvidberg, Christine S./E-8934-2015	Hvidberg, Christine S./0000-0002-9665-1339				Cuffey KM, 2000, NATURE, V404, P591, DOI 10.1038/35007053; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; DahlJensen D, 1997, J GLACIOL, V43, P300, DOI 10.3189/S0022143000003245; DahlJensen D, 1998, SCIENCE, V282, P268, DOI 10.1126/science.282.5387.268; FABRE A, 1995, ANN GLACIOL, V21, P1; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; LETREGUILLY A, 1991, GLOBAL PLANET CHANGE, V90, P385, DOI 10.1016/0921-8181(91)90004-G; Oppenheimer M, 1998, NATURE, V393, P325, DOI 10.1038/30661	9	9	9	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					551	552		10.1038/35007164	http://dx.doi.org/10.1038/35007164			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766220				2022-12-28	WOS:000086400100029
J	Stender, IM; Na, RH; Fogh, H; Gluud, C; Wulf, HC				Stender, IM; Na, RH; Fogh, H; Gluud, C; Wulf, HC			Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial	LANCET			English	Article							5-AMINOLEVULINIC ACID; VIRAL WARTS; TOPICAL APPLICATION; PROTOPORPHYRIN; CRYOTHERAPY; CONDYLOMATA; COMMON; TUMORS	Background Photodynamic therapy (PDT) with topical 5-aminolaevulinic acid (ALA) followed by irradiation with incoherent light (ALA-PDT) for recalcitrant warts have had beneficial results, Therefore, we undertook a randomised, parallel, double-blind clinical trial of ALA-PDT versus placebo-PDT for recalcitrant foot and hand warts. Methods Recalcitrant foot and hand warts were randomly assigned to six repetitive ALA-PDT or placebo-PDT interventions combined with standard treatment encompassing paring followed by a keratolytic (Verucid), Standardised photographs of each wart were taken before, during (week 7) and after treatment (weeks 14 and 18). The area of each wart compared with entry area was the primary outcome variable, measured from photographs by arl evaluator unaware of treatment allocation for intervention. Pain intensity immediately and 24 h after each intervention was assessed by a five-point scale. Findings A total of 232 foot and hand warts in 45 patients were entered into the trial: 117 warts were allocated to ALA-PDT and 115 warts to placebo-PDT. In week 14, the median relative reduction in wart area was 98% in the ALA-PDT group (interquartile range 100%, 55%) versus 52% (100%, 0) in the placebo group (p = 0.0006,), In week 18, the median relative reduction in wart area wa!; 100% in the ALA-PDT group (100%, 57%) versus 71% (100%, 0) in the placebo-PDT arm (p = 0.008). Both the number of vanishing warts and the difference in relative wart area of persisting warts at week 14 and 18 were significant (p < 0.05) in favour of ALA-PDT, Significantly more ALA-PDT warts were graded at a higher pain intensity after treatment than placebo-PDT warts. Interpretation ALA-PDT is superior to placebo-PDT when both wart area and number of vanishing warts are considered.	Bispebjerg Hosp, Dept Dermatol, Copenhagen NV, Denmark; Copenhagen Univ Hosp, Kommunehosp, Inst Prevent Med, Ctr Clin Intervent Res,Copenhagen Trial Unit, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	Stender, IM (corresponding author), Bispebjerg Hosp, Dept Dermatol, Copenhagen NV, Denmark.		Gluud, Christian/AAY-1027-2021; Gluud, Christian/HGB-3191-2022	Gluud, Christian/0000-0002-8861-0799; 				BOURKE JF, 1995, BRIT J DERMATOL, V132, P433, DOI 10.1111/j.1365-2133.1995.tb08678.x; BUNNEY MH, 1976, BRIT J DERMATOL, V94, P667, DOI 10.1111/j.1365-2133.1976.tb05167.x; Fehr MK, 1996, AM J OBSTET GYNECOL, V174, P951, DOI 10.1016/S0002-9378(96)70332-0; Frank RGJ, 1996, GENITOURIN MED, V72, P70; Fritsch C, 1998, ARCH DERMATOL, V134, P207, DOI 10.1001/archderm.134.2.207; JETTE C, 1993, BEADV C COP DENM, P28; KEEFE M, 1990, CLIN EXP DERMATOL, V15, P260, DOI 10.1111/j.1365-2230.1990.tb02085.x; KENNEDY JC, 1990, J PHOTOCH PHOTOBIO B, V6, P143, DOI 10.1016/1011-1344(90)85083-9; Kilkenny M, 1998, BRIT J DERMATOL, V138, P840; Kloek J, 1998, PHOTOCHEM PHOTOBIOL, V67, P150; Morton CA, 1996, BRIT J DERMATOL, V135, P766, DOI 10.1111/j.1365-2133.1996.tb03887.x; OHNHAUS EE, 1975, PAIN, V1, P379, DOI 10.1016/0304-3959(75)90075-5; ORENSTEIN A, 1995, CANCER LETT, V93, P227, DOI 10.1016/0304-3835(95)03814-D; PENQ Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235; PENQ Q, 1997, CANCER, V79, P2282; Ross EV, 1997, BRIT J DERMATOL, V137, P736; Smetana Z, 1997, LASER SURG MED, V21, P351, DOI 10.1002/(SICI)1096-9101(1997)21:4<351::AID-LSM6>3.0.CO;2-P; Stender IM, 1999, CLIN EXP DERMATOL, V24, P154, DOI 10.1046/j.1365-2230.1999.00441.x; Stender IM, 1999, ACTA DERM-VENEREOL, V79, P400, DOI 10.1080/000155599750010463; SVANBERG K, 1994, BRIT J DERMATOL, V130, P743, DOI 10.1111/j.1365-2133.1994.tb03412.x	20	170	175	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					963	966		10.1016/S0140-6736(00)90013-8	http://dx.doi.org/10.1016/S0140-6736(00)90013-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768434				2022-12-28	WOS:000086054000010
J	Chandrashekar, J; Mueller, KL; Hoon, MA; Adler, E; Feng, LX; Guo, W; Zuker, CS; Ryba, NJP				Chandrashekar, J; Mueller, KL; Hoon, MA; Adler, E; Feng, LX; Guo, W; Zuker, CS; Ryba, NJP			T2Rs function as bitter taste receptors	CELL			English	Article							G-PROTEIN; SUCROSE OCTAACETATE; EXPRESSION; GUSTDUCIN; NERVE; MICE; RAT; TRANSDUCTION; COUPLE; SWEET	Bitter taste perception provides animals with critical protection against ingestion of poisonous compounds. In the accompanying paper, we report the characterization of a large family of putative mammalian taste receptors (T2Rs). Here we use a heterologous expression system to show that specific T2Rs function as bitter taste receptors. A mouse T2R (mT2R-5) responds to the bitter tastant cycloheximide, and a human and a mouse receptor (hT2R-4 and mT2R-8) responded to denatonium and 6-n-propyl-2-thiouracil. Mice strains deficient in their ability to detect cycloheximide have amino acid substitutions in the mT2R-5 gene; these changes render the receptor significantly less responsive to cycloheximide. We also expressed mT2R-5 in insect cells and demonstrate specific tastant-dependent activation of gustducin, a G protein implicated in bitter signaling. Since a single taste receptor cell expresses a large repertoire of T2Rs, these findings provide a plausible explanation for the uniform bitter taste that is evoked by many structurally unrelated toxic compounds.	NIH, Natl Inst Dent & Craniofacial Res, Bethesda, MD 20892 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, Dept Neurosci, La Jolla, CA 92093 USA; Aurora Biosci, San Diego, CA 92121 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Zuker, CS (corresponding author), NIH, Natl Inst Dent & Craniofacial Res, Bldg 10, Bethesda, MD 20892 USA.			Chandrashekar, jayaram/0000-0001-6412-0114	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000561] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABE K, 1993, J BIOL CHEM, V268, P12033; Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263; CAPELESS CG, 1992, BEHAV GENET, V22, P655, DOI 10.1007/BF01066636; Chaudhari N, 2000, NAT NEUROSCI, V3, P113, DOI 10.1038/72053; CONNEALLY PM, 1976, HUM HERED, V26, P267, DOI 10.1159/000152813; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; FRANK ME, 1991, J NEUROPHYSIOL, V65, P1452, DOI 10.1152/jn.1991.65.6.1452; FRANK ME, 1983, J NEUROPHYSIOL, V50, P941, DOI 10.1152/jn.1983.50.4.941; Garcia J., 1975, OLFACTION TASTE, P39, DOI DOI 10.1016/B978-0-12-209750-8.50014-7; GLENDINNING JI, 1994, PHYSIOL BEHAV, V56, P1217, DOI 10.1016/0031-9384(94)90369-7; Glendinning JI, 1999, BEHAV NEUROSCI, V113, P840, DOI 10.1037/0735-7044.113.4.840; HARGRAVE PA, 1986, EXP EYE RES, V42, P363, DOI 10.1016/0014-4835(86)90030-8; HOON MA, 1995, BIOCHEM J, V309, P629, DOI 10.1042/bj3090629; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; KINNAMON SC, 1992, ANNU REV PHYSIOL, V54, P715, DOI 10.1146/annurev.physiol.54.1.715; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; KUSANO T, 1971, Applied Entomology and Zoology, V6, P40; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; Lindemann B, 1996, CURR BIOL, V6, P1234, DOI 10.1016/S0960-9822(96)00704-X; LINDEMANN B, 1996, GENET RES, V44, P151; LUSH IE, 1986, GENET RES, V47, P117, DOI 10.1017/S0016672300022941; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MATSUOKA I, 1993, BIOCHEM BIOPH RES CO, V194, P504, DOI 10.1006/bbrc.1993.1848; MCBURNEY DH, 1979, PSYCHOL BULL, V86, P151, DOI 10.1037/0033-2909.86.1.151; Mehta RK, 1999, BIOTECHNIQUES, V26, P1082, DOI 10.2144/99266bm17; Ming D, 1998, P NATL ACAD SCI USA, V95, P8933, DOI 10.1073/pnas.95.15.8933; NEJAD MS, 1986, CHEM SENSES, V11, P283, DOI 10.1093/chemse/11.3.283; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Reed DR, 1999, AM J HUM GENET, V64, P1478, DOI 10.1086/302367; REISINE T, 1995, NEUROPHARMACOLOGY, V34, P463, DOI 10.1016/0028-3908(95)00025-2; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SAROLI A, 1984, NATURWISSENSCHAFTEN, V71, P428, DOI 10.1007/BF00365895; Stewart RE, 1997, AM J PHYSIOL-CELL PH, V272, pC1, DOI 10.1152/ajpcell.1997.272.1.C1; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; WARREN RP, 1970, NATURE, V227, P77, DOI 10.1038/227077a0; WHITNEY G, 1986, BEHAV GENET, V16, P559, DOI 10.1007/BF01066342; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0	41	1017	1125	7	282	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 17	2000	100	6					703	711		10.1016/S0092-8674(00)80706-0	http://dx.doi.org/10.1016/S0092-8674(00)80706-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761935	Bronze			2022-12-28	WOS:000085983800012
J	Brin, D				Brin, D			Reality check - Do you sometimes get the feeling that everything's too bad to be true?	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					229	229		10.1038/35005182	http://dx.doi.org/10.1038/35005182			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749189	Bronze			2022-12-28	WOS:000086022200025
J	Hirotsu, T; Saeki, S; Yamamoto, M; Ilno, Y				Hirotsu, T; Saeki, S; Yamamoto, M; Ilno, Y			The Ras-MAPK pathway is important for olfaction in Caenorhabditis elegans	NATURE			English	Article							NUCLEOTIDE-GATED CHANNEL; KSR-1 GENE ENCODES; C-ELEGANS; SENSORY NEURONS; CHEMOTAXIS; PROTEIN; TRANSDUCTION; MAINTENANCE; ACTIVATION; MECHANISMS	The Ras-MAPK (mitogen-activated protein kinase) signal transduction pathway is well known to control cellular proliferation and differentiation in response to extracellular signals, but its other functions are less understood. In Caenorhabditis elegans this pathway regulates several developmental events, such as vulval induction and progression of meiosis(1), but its function in the nervous system is unknown. Here we report that the Ras-MAPK pathway is involved in olfaction in this organism. Mutational inactivation and hyperactivation of this pathway impairs efficiency of chemotaxis to a set of odorants. Experiments in which let-60 ras was expressed using a heat-shock promoter and a cell-specific promoter show that a normal activity of LET-60 Ras is required in mature olfactory neurons. Application of the odorant isoamylalcohol to wild-type animals leads to the activation of MAP kinase in olfactory neurons within 10 seconds. This induction is dependent on the function of the nucleotide-gated channel TAX-2/TAX-4 and the voltage-activated calcium channel subunit UNC-2. These results suggest a dynamic regulatory role for the Ras-MAPK pathway in perception and transmission of sensory signals in olfactory neurons.	Univ Tokyo, Mol Genet Res Lab, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Ilno, Y (corresponding author), Univ Tokyo, Mol Genet Res Lab, Tokyo 1130033, Japan.	iino@ims.u-tokyo.ac.jp	Hirotsu, Takaaki/G-9358-2013; IINO, YUICHI/G-4962-2014	Hirotsu, Takaaki/0000-0003-3936-8382; 				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Coburn CM, 1998, DEVELOPMENT, V125, P249; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; DUSENBERY DB, 1975, GENETICS, V80, P297; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nonet ML, 1997, J NEUROSCI, V17, P8061; Peckol EL, 1999, DEVELOPMENT, V126, P1891; Prasad BC, 1999, TRENDS GENET, V15, P150, DOI 10.1016/S0168-9525(99)01695-9; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Schild D, 1998, PHYSIOL REV, V78, P429, DOI 10.1152/physrev.1998.78.2.429; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0	29	59	76	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					289	293		10.1038/35005101	http://dx.doi.org/10.1038/35005101			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749212				2022-12-28	WOS:000086022200050
J	Bateman, DN				Bateman, DN			Triptans and migraine	LANCET			English	Editorial Material							SUMATRIPTAN; EXTRAVASATION		Royal Infirm, Scottish Poisons Informat Bur, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh	Bateman, DN (corresponding author), Royal Infirm, Scottish Poisons Informat Bur, Edinburgh EH3 9YW, Midlothian, Scotland.			Bateman, David Nicholas/0000-0002-8971-862X				Ahrens SP, 1999, CEPHALALGIA, V19, P525, DOI 10.1046/j.1468-2982.1999.019005525.x; BATEMAN DN, 1993, LANCET, V341, P221, DOI 10.1016/0140-6736(93)90079-V; Dulli DA, 1999, ANN PHARMACOTHER, V33, P704, DOI 10.1345/aph.18300; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; Goadsby PJ, 2000, NEUROLOGY, V54, P156, DOI 10.1212/WNL.54.1.156; Limmroth V, 1999, LANCET, V353, P378, DOI 10.1016/S0140-6736(05)74950-3; Mathew NT, 1997, NEUROLOGY, V49, P1485, DOI 10.1212/WNL.49.6.1485; May A, 1998, BRAIN, V121, P1231, DOI 10.1093/brain/121.7.1231; Perry CM, 1998, DRUGS, V55, P889, DOI 10.2165/00003495-199855060-00020; Rose A., 1997, INPHARMA, V1101, P3; SAXENA PR, 1995, PHARMACOL THERAPEUT, V66, P339, DOI 10.1016/0163-7258(94)00005-N; Spencer CM, 1999, DRUGS, V58, P347, DOI 10.2165/00003495-199958020-00016; Tfelt-Hansen P, 1998, CEPHALALGIA, V18, P532, DOI 10.1046/j.1468-2982.1998.1808532.x; VanDenBrink AM, 1998, CIRCULATION, V98, P25, DOI 10.1161/01.CIR.98.1.25; VISTER WH, 1996, ARCH NEUROL-CHICAGO, V53, P1132; Wainscott DB, 1998, EUR J PHARMACOL, V352, P117, DOI 10.1016/S0014-2999(98)00336-7	16	29	30	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					860	861		10.1016/S0140-6736(00)90028-X	http://dx.doi.org/10.1016/S0140-6736(00)90028-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752697				2022-12-28	WOS:000085896000003
J	Brown, BH; Tidy, JA; Boston, K; Blackett, AD; Smallwood, RH; Sharp, F				Brown, BH; Tidy, JA; Boston, K; Blackett, AD; Smallwood, RH; Sharp, F			Relation between tissue structure and imposed electrical current flow in cervical neoplasia	LANCET			English	Article							UTERINE CERVIX; CANCER	Background When an electrical potential is applied to human tissue, the pattern of the resulting current flow is determined by the shapes, arrangements, and internal structure of the tissue cells. By measurement of the electrical current patterns over a range of frequencies, and use of an inverse modelling procedure, electrical variables describing the tissue structure can be calculated, We used this method to develop a screening technique for the detection of cervical precancers. Methods We used a pencil probe (diameter 5 mm) to measure electrical impedance spectra from eight points on the cervix in 124 women with abnormal cervical smears. Variables that should be sensitive to the expected tissue changes were calculated. These were compared with the colposcopic results. Findings The measured electrical impedance changes were those predicted on the basis of the expected tissue structures. Measurements made on normal squamous tissues were well separated from those made on precancerous tissues. We constructed receiver-operating-characteristic curves, comparing measurements made on normal tissue and that showing cervical intraepithelial neoplasia grade 2/3; the area under the curve was 0.951. These groups of women could be separated with a sensitivity of 0.92 and a specificity of 0.92. Interpretation Characteristics of the electrical impedance spectra of tissues can be explained by changes in cell arrangements (layering) and in the size of the nuclei. This relation opens the way to deriving tissue structure from electrical impedance spectral measurements. We show that this approach can be used to give good separation of normal and precancerous cervical tissues.	Univ Sheffield, Royal Hallamshire Hosp, Dept Med Phys, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, No Gen Hosp Trust, Ctr Clin Sci, Dept Obstet & Gynaecol, Sheffield, S Yorkshire, England	University of Sheffield; Northern General Hospital; University of Sheffield	Brown, BH (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Dept Med Phys, Sheffield S10 2JF, S Yorkshire, England.		Smallwood, Rod/C-5583-2011	Smallwood, Rod/0000-0003-0134-0632				ANDERSON MC, 1992, TEXT ATLAS INTEGRATE; BOON ME, 1985, HISTOPATHOLOGY, V9, P751, DOI 10.1111/j.1365-2559.1985.tb02861.x; BROWN BH, 1995, PHYSIOL MEAS, V16, P57; Cole KS, 1941, J CHEM PHYS, V9, P341, DOI 10.1063/1.1750906; COPPLESON M, 1994, INT J GYNECOL CANCER, V4, P79, DOI 10.1046/j.1525-1438.1994.04020079.x; DUCK FA, 1990, PHYSICAL PROPERTIES; FOSTER KR, 1989, CRIT REV BIOMED ENG, V17, P25; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Mitchell MF, 1999, OBSTET GYNECOL, V93, P462, DOI 10.1016/S0029-7844(98)00385-8; PRITCHARD DA, 1996, NHS CERVICAL SCREENI, V3; SASIENI P, 1995, LANCET, V346, P1566, DOI 10.1016/S0140-6736(95)92099-4; SCHWAN H P, 1957, Adv Biol Med Phys, V5, P147; SORENSEN FB, 1991, VIRCHOWS ARCH A, V418, P225, DOI 10.1007/BF01606060	13	136	156	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					892	895		10.1016/S0140-6736(99)09095-9	http://dx.doi.org/10.1016/S0140-6736(99)09095-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752706				2022-12-28	WOS:000085896000012
J	Lederberg, J				Lederberg, J			Infectious history	SCIENCE			English	Article									Rockefeller Univ, Lab Mol Genet & Informat, New York, NY 10021 USA	Rockefeller University	Lederberg, J (corresponding author), Rockefeller Univ, Lab Mol Genet & Informat, 1230 York Ave, New York, NY 10021 USA.							[Anonymous], 1993, HIST PUBLIC HLTH; Barbujani G., 1999, EVOLUTION HLTH DIS; Brock TD., 1990, EMERGENCE BACTERIAL; Bulloch W., 1938, HIST BACTERIOLOGY; Dubos R. J., 1987, MIRAGE HLTH UTOPIAS; Ewald P., 2000, ENCY MICROBIOLOGY; Joklik W K, 1999, MICROBIOLOGY CENTENA; Lederberg J., 1992, I MED US COMMITTEE; MANDELL GL, 2000, PRINCIPLES PRACTICE; Morse Stephen S., 1993, EMERGING VIRUSES; 1996, J AM MED ASS     AUG	11	408	470	4	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					287	293		10.1126/science.288.5464.287	http://dx.doi.org/10.1126/science.288.5464.287			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10777411				2022-12-28	WOS:000086454300027
J	Wotawa, G; Trainer, M				Wotawa, G; Trainer, M			The influence of Canadian forest fires on pollutant concentrations in the United States	SCIENCE			English	Article							TRANS-SIBERIAN RAILROAD; CARBON-MONOXIDE; TROPOSPHERIC OZONE; EMISSIONS; TROPICS; IMPACT; CH4; CO	High carbon monoxide (CO) concentrations from uncertain origins occurred episodically in the southeastern United States during the summer of 1995. We show that these episodes were caused by Large forest fires in Canada. Over a period of 2 weeks, these natural emissions increased CO concentrations in the southeastern United States as well as along the eastern seaboard, a region with one of the world's highest rates of anthropogenic emissions. Within the forest fire plumes, there were abo high concentrations of ozone, volatile organic compounds, and aerosols. These results suggest that the impact of boreal forest fire emissions on air quality in the mid-latitudes of the Northern Hemisphere, where anthropogenic pollutant sources have been considered predominant, needs to be reevaluated.	Univ Agr Sci, Inst Meteorol & Phys, A-1180 Vienna, Austria; NOAA, Aeron Lab, Boulder, CO 80303 USA	University of Natural Resources & Life Sciences, Vienna; National Oceanic Atmospheric Admin (NOAA) - USA	Wotawa, G (corresponding author), Univ Colorado, CIRES, Boulder, CO 80309 USA.		Trainer, Michael/H-5168-2013	Trainer, Michael/0000-0002-1668-2961				BANTA RM, 1992, J APPL METEOROL, V31, P1328, DOI 10.1175/1520-0450(1992)031&lt;1328:SCOFTF&gt;2.0.CO;2; Bergamaschi P, 1998, J GEOPHYS RES-ATMOS, V103, P8227, DOI 10.1029/97JD03738; Cheng L, 1998, ATMOS ENVIRON, V32, P673, DOI 10.1016/S1352-2310(97)00319-1; CHIN M, 1994, J GEOPHYS RES-ATMOS, V99, P14565, DOI 10.1029/94JD00907; Cofer WR, 1998, GEOPHYS RES LETT, V25, P3919, DOI 10.1029/1998GL900042; CRUTZEN PJ, 1990, SCIENCE, V250, P1669, DOI 10.1126/science.250.4988.1669; Crutzen PJ, 1998, J ATMOS CHEM, V29, P179, DOI 10.1023/A:1005848202970; *EUR CTR MED RANG, 1995, US GUID ECMWF PROD V; HARRISS RC, 1994, J GEOPHYS RES-ATMOS, V99, P1635, DOI 10.1029/93JD01788; HARRISS RC, 1992, J GEOPHYS RES-ATMOS, V97, P16383, DOI 10.1029/91JD02109; HARRISS RC, 1992, J GEOPHYS RES-ATMOS, V97, P16589, DOI 10.1029/91JD02037; JACOB DJ, 1992, J GEOPHYS RES-ATMOS, V97, P16421, DOI 10.1029/91JD01968; Jonquieres I, 1998, J GEOPHYS RES-ATMOS, V103, P19059, DOI 10.1029/98JD00819; Mauzerall DL, 1996, J GEOPHYS RES-ATMOS, V101, P4175, DOI 10.1029/95JD03224; Meagher JF, 1998, J GEOPHYS RES-ATMOS, V103, P22213, DOI 10.1029/98JD01693; Moody JL, 1998, J GEOPHYS RES-ATMOS, V103, P13181, DOI 10.1029/98JD00526; Novelli PC, 1998, J GEOPHYS RES-ATMOS, V103, P19015, DOI 10.1029/98JD01366; Olszyna KJ, 1998, J GEOPHYS RES-ATMOS, V103, P31143, DOI 10.1029/1998JD100038; SEILER W, 1976, 10 WMO; Skinner WR, 1999, THEOR APPL CLIMATOL, V63, P89, DOI 10.1007/s007040050095; Stohl A, 1996, ATMOS ENVIRON, V30, P579, DOI 10.1016/1352-2310(95)00314-2; Stohl A, 1999, BOUND-LAY METEOROL, V90, P155, DOI 10.1023/A:1001741110696; STOHL A, 1995, J APPL METEOROL, V34, P2149, DOI 10.1175/1520-0450(1995)034<2149:IEIWFA>2.0.CO;2; U.S. Environmental Protection Agency, 1997, EPA454R97011; *US EPA, 1989, EPA600789012A; WATSON CE, 1990, J GEOPHYS RES-ATMOS, V95, P16443, DOI 10.1029/JD095iD10p16443; Weber MG, 1998, AMBIO, V27, P545; WOFSY SC, 1994, J GEOPHYS RES-ATMOS, V99, P1887, DOI 10.1029/93JD02256; WOFSY SC, 1992, J GEOPHYS RES-ATMOS, V97, P16731, DOI 10.1029/92JD00622	29	217	221	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					324	328		10.1126/science.288.5464.324	http://dx.doi.org/10.1126/science.288.5464.324			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764643				2022-12-28	WOS:000086454300034
J	Dickinson, MH; Farley, CT; Full, RJ; Koehl, MAR; Kram, R; Lehman, S				Dickinson, MH; Farley, CT; Full, RJ; Koehl, MAR; Kram, R; Lehman, S			How animals move: An integrative view	SCIENCE			English	Review							BLOWFLY CALLIPHORA-VICINA; HOVERING INSECT FLIGHT; POWER OUTPUT; PEDESTRIAN LOCOMOTION; HEXAPEDAL RUNNERS; DIFFERENT MODES; NERVOUS-SYSTEM; FLUID-DYNAMICS; COLUMBA-LIVIA; MUSCLE FORCE	Recent advances in integrative studies of Locomotion have revealed several general principles. Energy storage and exchange mechanisms discovered in walking and running bipeds apply to multilegged Locomotion and even to flying and swimming. Nonpropulsive lateral forces can be sizable, but they may benefit stability, maneuverability, or other criteria that become apparent in natural environments. Locomotor control systems combine rapid mechanical preflexes with multimodal sensory feedback and feedforward commands. Muscles have a surprising variety of functions in locomotion, serving as motors, brakes, springs, and struts. Integrative approaches reveal not only how each component within a Locomotor system operates but how they function as a collective whole.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Dickinson, MH (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.	flymanmd@socrates.berkeley.edu	Sikandar, Usama/F-6586-2016		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044688, R29AR044008] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44688, AR44008A] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDER RM, 1989, PHYSIOL REV, V69, P1199, DOI 10.1152/physrev.1989.69.4.1199; ALEXANDER RM, 1975, J ZOOL, V177, P265, DOI 10.1111/j.1469-7998.1975.tb05983.x; Alexander RM., 1988, ELASTIC MECH ANIMAL; Altringham JD, 1999, J EXP BIOL, V202, P3397; ALTRINGHAM JD, 1993, J EXP BIOL, V182, P191; Andersen JB, 1999, MOTOR CONTROL, V3, P151, DOI 10.1123/mcj.3.2.151; Biewener AA, 1998, J EXP BIOL, V201, P1681; Biewener AA, 1999, J EXP BIOL, V202, P3387; BLEWENER AA, 1998, J EXP BIOL, V201, P3293; BLICKHAN R, 1985, J COMP PHYSIOL A, V157, P115, DOI 10.1007/BF00611101; BLICKHAN R, 1987, J EXP BIOL, V130, P155; BLICKHAN R, 1993, J COMP PHYSIOL A, V173, P509; BLICKHAN R, 1989, J BIOMECH, V22, P1217, DOI 10.1016/0021-9290(89)90224-8; BRODSKY AK, 1991, J EXP BIOL, V161, P77; CAPADAY C, 1987, J PHYSIOL-LONDON, V392, P513, DOI 10.1113/jphysiol.1987.sp016794; CAVAGNA GA, 1976, J PHYSIOL-LONDON, V262, P639, DOI 10.1113/jphysiol.1976.sp011613; CAVAGNA GA, 1977, AM J PHYSIOL, V233, pR243, DOI 10.1152/ajpregu.1977.233.5.R243; CAVAGNA GA, 1964, J APPL PHYSIOL, V19, P249, DOI 10.1152/jappl.1964.19.2.249; CHAI P, 1995, NATURE, V377, P722, DOI 10.1038/377722a0; Chan WP, 1998, SCIENCE, V280, P289, DOI 10.1126/science.280.5361.289; Cheng JY, 1996, CAN J ZOOL, V74, P1734, DOI 10.1139/z96-192; Chiel HJ, 1997, TRENDS NEUROSCI, V20, P553, DOI 10.1016/S0166-2236(97)01149-1; CHILDRESS S, 1987, J FLUID MECH, V177, P407, DOI 10.1017/S0022112087001022; CLARAC F, 1982, BIOL CYBERN, V43, P109, DOI 10.1007/BF00336973; Costello JH, 1995, MAR BIOL, V124, P399, DOI 10.1007/BF00363913; CRUSE H, 1976, J COMP PHYSIOL, V112, P235, DOI 10.1007/BF00606541; DANIEL TL, 1983, CAN J ZOOL, V61, P1406, DOI 10.1139/z83-190; DIAL KP, 1993, J EXP BIOL, V176, P31; DIAL KP, 1992, J EXP ZOOL, V262, P357, DOI 10.1002/jez.1402620402; Dickinson MH, 1999, SCIENCE, V284, P1954, DOI 10.1126/science.284.5422.1954; Dickinson MH, 1997, BIOPHYS J, V73, P3122, DOI 10.1016/S0006-3495(97)78338-3; Dickinson MH, 1997, COMP BIOCHEM PHYS A, V116, P223, DOI 10.1016/S0300-9629(96)00162-4; Domenici P, 1999, J EXP BIOL, V202, P3069; Drucker EG, 1999, J EXP BIOL, V202, P2393; Duysens J, 2000, PHYSIOL REV, V80, P83, DOI 10.1152/physrev.2000.80.1.83; Ellington CP, 1996, NATURE, V384, P626, DOI 10.1038/384626a0; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P1, DOI 10.1098/rstb.1984.0049; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P115, DOI 10.1098/rstb.1984.0053; EMERSON SB, 1990, EVOLUTION, V44, P1931, DOI 10.1111/j.1558-5646.1990.tb04300.x; Farley CT, 1998, EXERCISE SPORT SCI R, V26, P253; FARLEY CT, 1991, SCIENCE, V253, P306, DOI 10.1126/science.1857965; Farley CT, 1997, J EXP BIOL, V200, P2177; FARLEY CT, 1993, J EXP BIOL, V185, P71; Fauci LJ, 1996, AM ZOOL, V36, P599; FEINSINGER P, 1979, AM NAT, V113, P481, DOI 10.1086/283408; Ferris DP, 1998, P ROY SOC B-BIOL SCI, V265, P989, DOI 10.1098/rspb.1998.0388; Full R.J., 1989, ENERGY TRANSFORMATIO, P175; Full R.J., 1997, HDB PHYSL 13, P853; Full RJ, 1998, J EXP BIOL, V201, P997; FULL RJ, 1995, J EXP BIOL, V198, P2441; FULL RJ, 1991, J EXP BIOL, V156, P215; FULL RJ, 1991, J EXP BIOL, V158, P369; Full RJ, 1999, J EXP BIOL, V202, P3325; FULL RJ, BIOMECHANICS NEURAL; Gandevia SC., 1994, MOVEMENT CONTROL, P12, DOI [10.1017/CBO9780511529788.003, DOI 10.1017/CBO9780511529788.003]; Gans C., 1997, HDB PHYSL COMP PHYSL, VVolume 13, P55; GILBERT C, 1995, J COMP NEUROL, V361, P285, DOI 10.1002/cne.903610207; Gillis GB, 1998, J EXP BIOL, V201, P3245; GRIFFITHS RI, 1991, J PHYSIOL-LONDON, V436, P219, DOI 10.1113/jphysiol.1991.sp018547; GUERON S, 1993, BIOPHYS J, V65, P499, DOI 10.1016/S0006-3495(93)81062-2; Hengstenberg R., 1991, Seminars in the Neurosciences, V3, P19, DOI 10.1016/1044-5765(91)90063-T; Jindrich DL, 1999, J EXP BIOL, V202, P1603; Josephson RK, 1999, J EXP BIOL, V202, P3369; JOSEPHSON RK, 1985, J EXP BIOL, V114, P493; JOYCE GC, 1974, J PHYSL, V240, P331; Kearney RE, 1999, J NEUROPHYSIOL, V81, P2893, DOI 10.1152/jn.1999.81.6.2893; KLARNER D, 1986, J EXP BIOL, V122, P161; Koehl M.A.R., 1995, Symposia of the Society for Experimental Biology, V49, P157; KOKSHAYSKY NV, 1979, NATURE, V279, P146, DOI 10.1038/279146a0; Kubow TM, 1999, PHILOS T ROY SOC B, V354, P849, DOI 10.1098/rstb.1999.0437; Lauder G., UNPUB; Lejeune TM, 1998, J EXP BIOL, V201, P2071; LIEBER RL, 1992, J EXP BIOL, V169, P251; Liu H, 1996, J EXP BIOL, V199, P1245; Loeb GE, 1999, EXP BRAIN RES, V126, P1, DOI 10.1007/s002210050712; LUTZ GJ, 1994, SCIENCE, V263, P370, DOI 10.1126/science.8278808; Marden JH, 1998, AM ZOOL, V38, P528; Marder E, 1996, PHYSIOL REV, V76, P687, DOI 10.1152/physrev.1996.76.3.687; MARSH RL, 1994, J EXP BIOL, V193, P139; Martinez MM, 1996, AM ZOOL, V36, P619; Martinez MM, 1998, J EXP BIOL, V201, P2609; Maughan DW, 1999, NEWS PHYSIOL SCI, V14, P87; MCMAHON TA, 1990, J BIOMECH, V23, P65, DOI 10.1016/0021-9290(90)90042-2; MEYHOFER E, 1990, J EXP BIOL, V151, P435; MOCHON S, 1980, J BIOMECH, V13, P49, DOI 10.1016/0021-9290(80)90007-X; Muller UK, 1997, J EXP BIOL, V200, P2893; Nichols TR, 1999, PROG BRAIN RES, V123, P369, DOI 10.1016/S0079-6123(08)62871-X; Orlovsky G, 1999, NEURAL CONTROL LOCOM; Pearson KG, 1998, ANN NY ACAD SCI, V860, P203, DOI 10.1111/j.1749-6632.1998.tb09050.x; Pearson KG, 1995, CURR OPIN NEUROBIOL, V5, P786, DOI 10.1016/0959-4388(95)80107-3; PEPLOWSKI MM, 1999, J EXP BIOL, V201, P2861; Powers RK, 2000, J NEUROPHYSIOL, V83, P483, DOI 10.1152/jn.2000.83.1.483; RACK PM, 1969, J PHYSL, V204, P461; Raffel M., 1998, EXP FLUID MECH; RAIBERT MH, 1993, BIOL NEURAL NETWORKS, P319; RAYNER JMV, 1986, NATURE, V321, P162, DOI 10.1038/321162a0; RAYNER JMV, 1979, J EXP BIOL, V80, P17; Roberts TJ, 1997, SCIENCE, V275, P1113, DOI 10.1126/science.275.5303.1113; Rome LC, 1998, COMP BIOCHEM PHYS B, V120, P51, DOI 10.1016/S0305-0491(98)00023-6; ROSEN MW, 1959, THESIS U CALIFORNIA; SCHMITT J, UNPUB; Shadwick RE, 1998, AM ZOOL, V38, P755; SPEDDING G R, 1992, P51; SPEDDING GR, 1986, J FLUID MECH, V165, P247, DOI 10.1017/S0022112086003087; SPEDDING GR, 1987, J EXP BIOL, V127, P59; STEIN RB, 1982, BEHAV BRAIN SCI, V5, P535, DOI 10.1017/S0140525X00013327; TING LH, 1994, J EXP BIOL, V197, P251; Tobalske BW, 1999, J EXP BIOL, V202, P1725; TU MS, 1994, J EXP BIOL, V192, P207; Tu MS, 1996, J COMP PHYSIOL A, V178, P813, DOI 10.1007/BF00225830; Videler J. J, 1993, FISH SWIMMING, V10; Videler JJ, 1999, J EXP BIOL, V202, P3423; VOGEL S, 1985, BIOL BULL, V169, P624, DOI 10.2307/1541304; Wagner H, 1999, J THEOR BIOL, V199, P163, DOI 10.1006/jtbi.1999.0949; WEBB PW, 1994, CAN J ZOOL, V72, P1149, DOI 10.1139/z94-153; WEINSTEIN RB, IN PRESS BIOMECHANIC; Wilga CD, 1999, J EXP BIOL, V202, P2413; WILLIAMS TL, 1995, BIOL FLUID DYNAMICS, V49, P49; Willmott AP, 1997, PHILOS T ROY SOC B, V352, P303, DOI 10.1098/rstb.1997.0022; Zehr EP, 1999, PROG NEUROBIOL, V58, P185, DOI 10.1016/S0301-0082(98)00081-1; Zill SN, 1996, SCI AM, V275, P86, DOI 10.1038/scientificamerican0796-86	121	1064	1103	9	358	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	2000	288	5463					100	106		10.1126/science.288.5463.100	http://dx.doi.org/10.1126/science.288.5463.100			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753108				2022-12-28	WOS:000086387700042
J	Oesterhelt, F; Oesterhelt, D; Pfeiffer, M; Engel, A; Gaub, HE; Muller, DJ				Oesterhelt, F; Oesterhelt, D; Pfeiffer, M; Engel, A; Gaub, HE; Muller, DJ			Unfolding pathways of individual bacteriorhodopsins	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPE; PROTEIN-COUPLED RECEPTORS; SCANNING PROBE MICROSCOPY; PROTON PUMPS; RESOLUTION; MEMBRANES; MECHANISM; MOLECULES; MODEL; DNA	Atomic force microscopy and single-molecule force spectroscopy were combined to image and manipulate purple membrane patches from Halobacterium salinarum. Individual bacteriorhodopsin molecules were first localized and then extracted from the membrane; the remaining vacancies were imaged again. Anchoring forces between 100 and 200 piconewtons for the different helices were found. Upon extraction, the helices were found to unfold. The force spectra revealed the individuality of the unfolding pathways. Helices G and F as well as helices E and D always unfolded pairwise, whereas helices B and C occasionally unfolded one after the other. Experiments with cleaved Loops revealed the origin of the individuality: stabilization of helix B by neighboring helices.	Univ Munich, CeNS, D-80799 Munich, Germany; Univ Munich, Lehrstuhl Angew Phys, D-80799 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Basel, Bioctr, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	University of Munich; University of Munich; Max Planck Society; University of Basel; Max Planck Society	Gaub, HE (corresponding author), Univ Munich, CeNS, Arnalienstr 54, D-80799 Munich, Germany.		Müller, Daniel J./A-5967-2010	Müller, Daniel J./0000-0003-3075-0665				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; Engel A, 1999, CURR BIOL, V9, pR133, DOI 10.1016/S0960-9822(99)80081-5; Engel A, 1997, CURR OPIN STRUC BIOL, V7, P279, DOI 10.1016/S0959-440X(97)80037-1; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; EVANS E, 1999, J PHYS-CONDENS MAT, V11, P1; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; Hargrave PA, 1991, CURR OPIN STRUC BIOL, V1, P575, DOI 10.1016/S0959-440X(05)80080-6; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; HENDERSON R, 1990, PHILOS T ROY SOC B, V326, P379, DOI 10.1098/rstb.1990.0019; HEYMANN JB, IN PRESS STRUCTURE; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; LANYI JK, 1995, NATURE, V375, P461, DOI 10.1038/375461a0; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Muller DJ, 1999, P NATL ACAD SCI USA, V96, P13170, DOI 10.1073/pnas.96.23.13170; Muller DJ, 1999, BIOPHYS J, V76, P1101, DOI 10.1016/S0006-3495(99)77275-9; Muller DJ, 1999, J MOL BIOL, V285, P1903, DOI 10.1006/jmbi.1998.2441; Muller DJ, 1997, J STRUCT BIOL, V119, P172, DOI 10.1006/jsbi.1997.3875; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Pfeiffer M, 1999, J MOL BIOL, V287, P163, DOI 10.1006/jmbi.1998.2593; PFEIFFER M, 2000, THESIS L MAXIMILIANS; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; SHAO ZF, 1995, Q REV BIOPHYS, V28, P195, DOI 10.1017/S0033583500003061; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Zhang YY, 1996, BIOPHYS J, V71, P2168, DOI 10.1016/S0006-3495(96)79418-3	48	578	600	8	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					143	146		10.1126/science.288.5463.143	http://dx.doi.org/10.1126/science.288.5463.143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753119				2022-12-28	WOS:000086387700053
J	Yeh, C; Shimabukuro, F; Stanton, P; Jamnejad, V; Imbriale, W; Manshadi, F				Yeh, C; Shimabukuro, F; Stanton, P; Jamnejad, V; Imbriale, W; Manshadi, F			Communication at millimetre-submillimetre wavelengths using a ceramic ribbon	NATURE			English	Article							POLYMERS	Following the discovery by Kao and Hockman(1-3) that ultra-low-loss optical fibres could be made from pure silica through the elimination of impurities, the ability to guide signals effectively at optical wavelengths has been assured. But there remains an important region of the spectrum-from 30 to 3,000 GHz (the millimetre-submillimetre band)-where low-loss waveguides are unknown. The main problem here in finding low-loss solids is no longer one of eliminating impurities, but is due to the presence of intrinsic vibration absorption bands(4-6). And the use of highly conducting materials is also precluded owing to high skin-depth losses(7,8) in this part of the spectrum. Here we show that a combination of material and waveguide geometry can circumvent these difficulties. We adopt a ribbon-like structure with an aspect ratio of 10:1, fabricated from ceramic alumina (Coors' 998 Alumina), and the resulting waveguide has an attenuation factor of less than 10 dB km(-1) in the millimetre-submillimetre band. This attenuation is more than 100 times smaller than that of a typical ceramic (or other dielectric) circular rod waveguide and is sufficient for immediate application.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Aerosp Corp, Los Angeles, CA 90009 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Aerospace Corporation - USA	Yeh, C (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	cavour.yeh@jpl.nasa.gov						AFSAR MN, 1985, P IEEE, V73, P131, DOI 10.1109/PROC.1985.13114; AFSAR MN, 1985, IEEE T MICROW THEORY, V33, P1410, DOI 10.1109/TMTT.1985.1133232; Agrawal G. P., 1997, FIBER OPTIC COMMUNIC; BIRCH JR, 1981, INFRARED PHYS, V21, P225, DOI 10.1016/0020-0891(81)90053-1; KAO KC, 1966, P I ELECTR ENG, V133, P1151; Koul S. K., 1997, WILEY SERIES MICROWA; Marcuse D., 1972, LIGHT TRANSMISSION O; Ramo S., 1984, FIELDS WAVES COMMUNI; SHIMABUKURO FI, 1988, IEEE T MICROW THEORY, V36, P1160, DOI 10.1109/22.3651; Taflove A., 1995, COMPUTATIONAL ELECTR; YEH C, 1989, APPL PHYS LETT, V54, P1183, DOI 10.1063/1.101485; YEH C, 1979, APPL OPTICS, V18, P1490, DOI 10.1364/AO.18.001490; YEH C, 1962, J APPL PHYS, V33, P3235, DOI 10.1063/1.1931144; YEH C, 1962, P IRE, V50, P2145; YEH C, 1978, J OPT SOC AM, V68, P989, DOI 10.1364/JOSA.68.000989; Yeh C., 1963, IEEE T ANTENN PROPAG, V11, P177; YEH C, 1972, AM I PHYSICS HDB	17	24	28	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					584	+		10.1038/35007036	http://dx.doi.org/10.1038/35007036			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766237				2022-12-28	WOS:000086400100048
J	Parkhill, J; Achtman, M; James, KD; Bentley, SD; Churcher, C; Klee, SR; Morelli, G; Basham, D; Brown, D; Chillingworth, T; Davies, RM; Davis, P; Devlin, K; Feltwell, T; Hamlin, N; Holroyd, S; Jagels, K; Leather, S; Moule, S; Mungall, K; Quail, MA; Rajandream, MA; Rutherford, KM; Simmonds, M; Skelton, J; Whitehead, S; Spratt, BG; Barrell, BG				Parkhill, J; Achtman, M; James, KD; Bentley, SD; Churcher, C; Klee, SR; Morelli, G; Basham, D; Brown, D; Chillingworth, T; Davies, RM; Davis, P; Devlin, K; Feltwell, T; Hamlin, N; Holroyd, S; Jagels, K; Leather, S; Moule, S; Mungall, K; Quail, MA; Rajandream, MA; Rutherford, KM; Simmonds, M; Skelton, J; Whitehead, S; Spratt, BG; Barrell, BG			Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491	NATURE			English	Article							PILIN ANTIGENIC VARIATION; OUTER-MEMBRANE PROTEIN; MOLECULAR CHARACTERIZATION; VARIABLE EXPRESSION; GONORRHOEAE; GENE; RECOMBINATION; IDENTIFICATION; TRANSFORMATION; BIOSYNTHESIS	Neisseria meningitidis causes bacterial meningitis and is therefore responsible for considerable morbidity and mortality in both the developed and the developing world. Meningococci are opportunistic pathogens that colonize the nasopharynges and oropharynges of asymptomatic carriers. For reasons that are still mostly unknown, they occasionally gain access to the blood, and subsequently to the cerebrospinal fluid, to cause septicaemia and meningitis. N. meningitidis strains are divided into a number of serogroups on the basis of the immunochemistry of their capsular polysaccharides; serogroup A strains are responsible for major epidemics and pandemics of meningococcal disease, and therefore most of the morbidity and mortality associated with this disease. Here we have determined the complete genome sequence of a serogroup A strain of Neisseria meningitidis, Z2491 (ref. 1). The sequence is 2,184,406 base pairs in length, with an overall G+C content of 51.8%, and contains 2,121 predicted coding sequences. The most notable feature of the genome is the presence of many hundreds of repetitive elements, ranging from short repeats, positioned either singly or in large multiple arrays, to insertion sequences and gene duplications of one kilobase or more. Many of these repeats appear to be involved in genome fluidity and antigenic variation in this important human pathogen.	Sanger Ctr, Cambridge CB10 1SA, England; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England	Wellcome Trust Sanger Institute; Max Planck Society; University of Oxford	Parkhill, J (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.		Spratt, Brian G/A-1676-2009; Quail, michael/ABE-6131-2020; Parkhill, Julian/G-4703-2011; Rutherford, Kim/Y-7995-2018	Parkhill, Julian/0000-0002-7069-5958; Rutherford, Kim/0000-0001-6277-726X; Davies, Robert/0000-0002-9983-1378; Achtman, Mark/0000-0001-6815-0070; Davis, Paul/0000-0001-5545-0824				Adhikari P, 1996, J BACTERIOL, V178, P2145, DOI 10.1128/jb.178.7.2145-2149.1996; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; CORREIA FF, 1988, J BIOL CHEM, V263, P12194; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; DEMPSEY JAF, 1995, J BACTERIOL, V177, P6390, DOI 10.1128/jb.177.22.6390-6400.1995; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; Frishman D, 1998, NUCLEIC ACIDS RES, V26, P2941, DOI 10.1093/nar/26.12.2941; GOODMAN SD, 1988, P NATL ACAD SCI USA, V85, P6982, DOI 10.1073/pnas.85.18.6982; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; Henderson IR, 1999, MOL MICROBIOL, V33, P919, DOI 10.1046/j.1365-2958.1999.01555.x; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HowellAdams B, 1996, MOL MICROBIOL, V22, P509, DOI 10.1046/j.1365-2958.1996.00128.x; KLEE SR, IN PRESS INFECT IMMU; Lewis LA, 1997, MOL MICROBIOL, V23, P737, DOI 10.1046/j.1365-2958.1997.2501619.x; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mehr IJ, 1998, MOL MICROBIOL, V30, P697, DOI 10.1046/j.1365-2958.1998.01089.x; Pettersson A, 1998, MOL MICROBIOL, V27, P599, DOI 10.1046/j.1365-2958.1998.00707.x; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; SARKARI J, 1994, MOL MICROBIOL, V13, P207, DOI 10.1111/j.1365-2958.1994.tb00416.x; Smith NH, 1999, MOL BIOL EVOL, V16, P773, DOI 10.1093/oxfordjournals.molbev.a026162; STOJILJKOVIC I, 1995, MOL MICROBIOL, V15, P531, DOI 10.1111/j.1365-2958.1995.tb02266.x; Swartley JS, 1998, J BACTERIOL, V180, P1533, DOI 10.1128/JB.180.6.1533-1539.1998; VANDERENDE A, 1995, J BACTERIOL, V177, P2475, DOI 10.1128/jb.177.9.2475-2480.1995; VONDERHAAR RA, 1994, J BACTERIOL, V176, P6207, DOI 10.1128/jb.176.20.6207-6213.1994; WAINWRIGHT LA, 1994, MOL MICROBIOL, V13, P75, DOI 10.1111/j.1365-2958.1994.tb00403.x; ZHOU JJ, 1992, MOL MICROBIOL, V6, P2135, DOI 10.1111/j.1365-2958.1992.tb01387.x	30	573	1193	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					502	506		10.1038/35006655	http://dx.doi.org/10.1038/35006655			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761919				2022-12-28	WOS:000086257700050
J	Segre, G				Segre, G			The Big Bang and the genetic code	NATURE			English	Editorial Material									Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Segre, G (corresponding author), Univ Penn, 209 S 33rd St, Philadelphia, PA 19104 USA.								0	4	4	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					437	437		10.1038/35006517	http://dx.doi.org/10.1038/35006517			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761891	Bronze			2022-12-28	WOS:000086257700022
J	Tharun, S; He, WH; Mayes, AE; Lennertz, P; Beggs, JD; Parker, R				Tharun, S; He, WH; Mayes, AE; Lennertz, P; Beggs, JD; Parker, R			Yeast Sm-like proteins function in mRNA decapping and decay	NATURE			English	Article							MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; IDENTIFICATION; DEADENYLATION; DEGRADATION; TURNOVER; U6	One of the main mechanisms of messenger RNA degradation in eukaryotes occurs by deadenylation-dependent decapping which leads to 5'-to-3' decay(1,2). A family of Sm-like (Lsm) proteins has been identified, members of which contain the 'Sm' sequence motif, form a complex with U6 small nuclear RNA and are required for pre-mRNA splicing(3-9). Here we show that mutations in seven yeast Lsm proteins (Lsm1-Lsm7) also lead to inhibition of mRNA decapping. In addition, the Lsm1-Lsm7 proteins coimmunoprecipitate with the mRNA decapping enzyme (Dcp1), a decapping activator (Pat1/Mrt1) and with mRNA. This indicates that the Lsm proteins may promote decapping by interactions with the mRNA and the decapping machinery. In addition, the Lsm complex that functions in mRNA decay appears to be distinct from the U6-associated Lsm complex, indicating that Lsm proteins form specific complexes that affect different aspects of mRNA metabolism.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Howard Hughes Med Inst, Tucson, AZ 85721 USA; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Unilever Res Colworth, Sharnbrook MK44 1LQ, Beds, England	University of Arizona; Howard Hughes Medical Institute; University of Arizona; University of Edinburgh; Unilever	Parker, R (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.	rrparker@u.arizona.edu	Beggs, Jean/H-4861-2011; , jbeggs/N-9551-2019	Beggs, Jean/0000-0002-8179-6519; 				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; Boeck R, 1998, MOL CELL BIOL, V18, P5062, DOI 10.1128/MCB.18.9.5062; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dix I, 1999, RNA, V5, P360, DOI 10.1017/S1355838299981396; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; FROMONTRACINE M, UNPUB P NATL ACAD SC; Hatfield L, 1996, MOL CELL BIOL, V16, P5830; He WH, 1999, METHODS, V17, P3, DOI 10.1006/meth.1998.0701; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schwartz DC, 1999, MOL CELL BIOL, V19, P5247; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; Tharun S, 1999, GENETICS, V151, P1273; Wang XQ, 1996, NUCLEIC ACIDS RES, V24, P4791, DOI 10.1093/nar/24.23.4791	23	329	345	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					515	518		10.1038/35006676	http://dx.doi.org/10.1038/35006676			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761922	Green Published			2022-12-28	WOS:000086257700053
J	Dalton, R				Dalton, R			Older women scientists fight USGS over layoffs	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					219	219		10.1038/35005260	http://dx.doi.org/10.1038/35005260			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749183	Bronze			2022-12-28	WOS:000086022200014
J	McLaughlin, K; Jardine, AG; Moss, JG				McLaughlin, K; Jardine, AG; Moss, JG			ABC of arterial and venous disease - Renal artery stenosis	BRITISH MEDICAL JOURNAL			English	Review							VASCULAR-DISEASE; RANDOMIZED TRIAL; ANGIOPLASTY		Univ Calgary, Calgary, AB T2N 1N4, Canada; Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland; Gartnavel Gen Hosp, Glasgow, Lanark, Scotland	University of Calgary; University of Glasgow	McLaughlin, K (corresponding author), Univ Calgary, Calgary, AB T2N 1N4, Canada.		Jardine, Alan/L-5770-2019	Jardine, Alan/0000-0001-5815-9370				Conlon PJ, 1998, J AM SOC NEPHROL, V9, P252; MAILLOUX LU, 1994, AM J KIDNEY DIS, V24, P622, DOI 10.1016/S0272-6386(12)80223-X; Plouin PF, 1998, HYPERTENSION, V31, P823, DOI 10.1161/01.HYP.31.3.823; Textor SC, 1998, KIDNEY INT, V53, P799, DOI 10.1038/ki.1998.37; van de Ven PJG, 1999, LANCET, V353, P282, DOI 10.1016/S0140-6736(98)04432-8	5	35	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1124	1127		10.1136/bmj.320.7242.1124	http://dx.doi.org/10.1136/bmj.320.7242.1124			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775226	Green Published			2022-12-28	WOS:000086782800023
J	Crossley, T; Abedin, L				Crossley, T; Abedin, L			For and against - Doctors and nurses should monitor each other's performance	BRITISH MEDICAL JOURNAL			English	Article									Thornley St Surg, Wolverhampton WV1 1JP, W Midlands, England		Crossley, T (corresponding author), Thornley St Surg, Wolverhampton WV1 1JP, W Midlands, England.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1070	1071		10.1136/bmj.320.7241.1070	http://dx.doi.org/10.1136/bmj.320.7241.1070			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764373	Green Published			2022-12-28	WOS:000086675700031
J	Feldman, RD; Hegele, RA				Feldman, RD; Hegele, RA			G-protein polymorphisms and maternal/neonatal metabolism: still a weight for the answer	LANCET			English	Editorial Material							BETA-3 SUBUNIT VARIANT; HYPERTENSION		Univ Western Ontario, Robarts Res Inst, London, ON N6A 5A5, Canada	Western University (University of Western Ontario)	Feldman, RD (corresponding author), Univ Western Ontario, Robarts Res Inst, London, ON N6A 5A5, Canada.		Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020; Feldman, Ross/G-3293-2011	Hegele, Robert/0000-0003-2861-5325; 				Beige J, 1999, HYPERTENSION, V33, P1049, DOI 10.1161/01.HYP.33.4.1049; Brand E, 1999, HYPERTENSION, V33, P1175, DOI 10.1161/01.HYP.33.5.1175; Carel JC, 1999, J CLIN ENDOCR METAB, V84, P4127, DOI 10.1210/jc.84.11.4127; Dong YB, 1999, HYPERTENSION, V34, P1193, DOI 10.1161/01.HYP.34.6.1193; Feldman RD, 1998, TRENDS CARDIOVAS MED, V8, P297, DOI 10.1016/S1050-1738(98)00022-X; Hegele RA, 1999, GENOME RES, V9, P972, DOI 10.1101/gr.9.10.972; Ishikawa K, 2000, AM J HYPERTENS, V13, P140, DOI 10.1016/S0895-7061(99)00118-1; Jacobi J, 1999, J HYPERTENS, V17, P1457, DOI 10.1097/00004872-199917100-00014; Kato N, 1998, HYPERTENSION, V32, P935, DOI 10.1161/01.HYP.32.5.935; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Poch E, 2000, HYPERTENSION, V35, P214, DOI 10.1161/01.HYP.35.1.214; Siffert W, 1999, J AM SOC NEPHROL, V10, P1921; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; SU HL, 1993, AM J PHYSIOL, V265, pC1729, DOI 10.1152/ajpcell.1993.265.6.C1729; Varani K, 1999, BRIT J CLIN PHARMACO, V47, P167, DOI 10.1046/j.1365-2125.1999.00866.x	15	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2000	355	9211					1201	1202		10.1016/S0140-6736(00)02081-X	http://dx.doi.org/10.1016/S0140-6736(00)02081-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770297				2022-12-28	WOS:000086448000004
J	Unger, MA; Chou, HP; Thorsen, T; Scherer, A; Quake, SR				Unger, MA; Chou, HP; Thorsen, T; Scherer, A; Quake, SR			Monolithic microfabricated valves and pumps by multilayer soft lithography	SCIENCE			English	Article							CAPILLARY ELECTROPHORESIS; ELECTROOSMOTIC FLOW; SYSTEMS; CHIP; DIELECTROPHORESIS	Soft Lithography is an alternative to silicon-based micromachining that uses replica molding of nontraditional elastomeric materials to fabricate stamps and microfluidic channels. We describe here an extension to the soft Lithography. paradigm. multilayer soft lithography, with which devices consisting of multiple Layers may be fabricated from soft materials. We used this technique to build active microfluidic systems containing on-off valves, switching valves, and pumps entirely out of elastomer. The softness of these materials allows the device areas to be reduced by more than two orders of magnitude compared with silicon-based devices. The other advantages of soft Lithography, such as rapid prototyping, ease of fabrication, and biocompatibility, are retained.	CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA	California Institute of Technology	Quake, SR (corresponding author), CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA.				NIDA NIH HHS [DA-9121] Funding Source: Medline; NINDS NIH HHS [NS-11756] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009121] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BRECHTEL R, 1995, J CHROMATOGR A, V716, P97, DOI 10.1016/0021-9673(95)00717-2; Buchaillot L, 1997, JPN J APPL PHYS 2, V36, pL794, DOI 10.1143/JJAP.36.L794; Delamarche E, 1997, SCIENCE, V276, P779, DOI 10.1126/science.276.5313.779; Duffy DC, 1999, J MICROMECH MICROENG, V9, P211, DOI 10.1088/0960-1317/9/3/301; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; Effenhauser CS, 1997, ELECTROPHORESIS, V18, P2203, DOI 10.1002/elps.1150181211; Effenhauser CS, 1997, ANAL CHEM, V69, P3451, DOI 10.1021/ac9703919; FAHRENBERG J, 1995, J MICROMECH MICROENG, V5, P77; Fu AY, 1999, NAT BIOTECHNOL, V17, P1109, DOI 10.1038/15095; Goll C, 1996, J MICROMECH MICROENG, V6, P77, DOI 10.1088/0960-1317/6/1/017; Gravesen P., 1993, Journal of Micromechanics and Microengineering, V3, P168, DOI 10.1088/0960-1317/3/4/002; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; Hosokawa K, 1999, ANAL CHEM, V71, P4781, DOI 10.1021/ac990571d; Ikuta K., 1994, Proceedings IEEE Micro Electro Mechanical Systems. An Investigation of Micro Structures, Sensors, Actuators, Machines and Robotic Systems (Cat. No.94CH3404-1), P1, DOI 10.1109/MEMSYS.1994.555588; Jacobson SC, 1999, ANAL CHEM, V71, P4455, DOI 10.1021/ac990576a; JACOBSON SC, 1994, ANAL CHEM, V66, P1114, DOI 10.1021/ac00079a029; Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046; KUHN L, 1978, IEEE T ELECTRON DEV, V25, P1257, DOI 10.1109/T-ED.1978.19261; Lin LY, 1999, IEEE J SEL TOP QUANT, V5, P4, DOI 10.1109/2944.748098; Lotters JC, 1997, J MICROMECH MICROENG, V7, P145, DOI 10.1088/0960-1317/7/3/017; Lucy CA, 1996, ANAL CHEM, V68, P300, DOI 10.1021/ac950632h; Muller RS, 1998, P IEEE, V86, P1705, DOI 10.1109/5.704276; Pethig R, 1997, TRENDS BIOTECHNOL, V15, P426, DOI 10.1016/S0167-7799(97)01096-2; PJA, 1999, SCIENCE, V285, P83; ROYLANCE LM, 1979, IEEE T ELECTRON DEV, V26, P1911, DOI 10.1109/T-ED.1979.19795; Schasfoort RBM, 1999, SCIENCE, V286, P942, DOI 10.1126/science.286.5441.942; Shoji S, 1998, TOP CURR CHEM, V194, P163; TUFTE ON, 1962, J APPL PHYS, V33, P3322, DOI 10.1063/1.1931164; WASHIZU M, 1994, IEEE T IND APPL, V30, P835, DOI 10.1109/28.297897; Xia YN, 1996, SCIENCE, V273, P347, DOI 10.1126/science.273.5273.347; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Yang X, 1998, SENSOR ACTUAT A-PHYS, V64, P101, DOI 10.1016/S0924-4247(97)01660-9; Yazdi N, 1998, P IEEE, V86, P1640, DOI 10.1109/5.704269; Young A. M., 1999, Transactions of the ASME. Journal of Biomechanical Engineering, V121, P2, DOI 10.1115/1.2798039; [No title captured]	35	3092	3543	35	1274	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					113	116		10.1126/science.288.5463.113	http://dx.doi.org/10.1126/science.288.5463.113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753110				2022-12-28	WOS:000086387700044
J	Vale, RD; Milligan, RA				Vale, RD; Milligan, RA			The way things move: Looking under the hood of molecular motor proteins	SCIENCE			English	Review							SINGLE KINESIN MOLECULES; X-RAY STRUCTURE; CRYSTAL-STRUCTURE; UNCONVENTIONAL MYOSINS; MUSCLE-CONTRACTION; LIGHT-CHAIN; NECK REGION; DOMAIN; NCD; MECHANISM	The microtubule-based kinesin motors and actin-based myosin motors generate motions associated with intracellular trafficking, cell division, and muscle contraction. Early studies suggested that these molecular motors work by very different mechanisms. Recently, however, it has become clear that kinesin and myosin share a common core structure and convert energy from adenosine triphosphate into protein motion using a similar conformational change strategy. Many different types of mechanical amplifiers have evolved that operate in conjunction with the conserved core. This modular design has given rise to a remarkable diversity of kinesin and myosin motors whose motile properties are optimized for performing distinct biological functions.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Scripps Research Institute	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.							Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Burgess SA, 1997, J CELL BIOL, V139, P675, DOI 10.1083/jcb.139.3.675; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Cooke R, 1999, CURR BIOL, V9, pR773, DOI 10.1016/S0960-9822(00)80010-X; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Heintzelman MB, 1997, J MOL BIOL, V271, P139, DOI 10.1006/jmbi.1997.1167; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; McMahon T.A., 1984, MUSCLES REFLEXES LOC; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Pechatnikova E, 1999, BIOPHYS J, V77, P1003, DOI 10.1016/S0006-3495(99)76951-1; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; RIEF M, UNPUB; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Stewart RJ, 1998, EUR BIOPHYS J BIOPHY, V27, P353, DOI 10.1007/s002490050142; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Taylor KA, 1999, CELL, V99, P421, DOI 10.1016/S0092-8674(00)81528-7; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	60	1166	1218	4	338	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					88	95		10.1126/science.288.5463.88	http://dx.doi.org/10.1126/science.288.5463.88			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753125				2022-12-28	WOS:000086387700040
J	Barsh, GS; Farooqi, IS; O'Rahilly, S				Barsh, GS; Farooqi, IS; O'Rahilly, S			Genetics of body-weight regulation	NATURE			English	Review							QUANTITATIVE TRAIT LOCI; BETA(3)-ADRENERGIC RECEPTOR GENE; MULTIFACTORIAL MOUSE MODEL; AGOUTI-RELATED PROTEIN; BARDET-BIEDL-SYNDROME; HUMAN OBESITY GENES; EARLY-ONSET OBESITY; TWINS REARED APART; MASS INDEX; LEPTIN RECEPTOR	The role of genetics in obesity is twofold. Studying rare mutations in humans and model organisms provides fundamental insight into a complex physiological process, and complements population-based studies that seek to reveal primary causes. Remarkable progress has been made on both fronts, and the pace of advance is likely to accelerate as functional genomics and the human genome project expand and mature. Approaches based on mendelian and quantitative genetics may well converge, and lead ultimately to more rational and selective therapies.	Beckman Ctr, Dept Pediat, Stanford, CA 94305 USA; Beckman Ctr, Dept Genet, Stanford, CA 94305 USA; Beckman Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England	Howard Hughes Medical Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Barsh, GS (corresponding author), Beckman Ctr, Dept Pediat, Stanford, CA 94305 USA.		O'Rahilly, Stephen/ABF-6509-2020; Farooqi, Ismaa Sadaf/AAZ-3046-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Farooqi, Sadaf/0000-0001-7609-3504				Ahima RS, 1999, ENDOCRINOLOGY, V140, P4923, DOI 10.1210/en.140.11.4923; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Allison DB, 1999, AM J HUM GENET, V65, P531, DOI 10.1086/302487; Allison DB, 1996, INT J OBESITY, V20, P501; Allison DB, 1998, INT J OBESITY, V22, P559, DOI 10.1038/sj.ijo.0800625; Allison DB, 1997, BEHAV GENET, V27, P401, DOI 10.1023/A:1025696232582; Beales PL, 1997, J MED GENET, V34, P92, DOI 10.1136/jmg.34.2.92; Boggon TJ, 1999, SCIENCE, V286, P2119, DOI 10.1126/science.286.5447.2119; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; Brennan J, 1999, METH MOL B, V97, P123, DOI 10.1385/1-59259-270-8:123; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; Brockmann GA, 1998, GENETICS, V150, P369; Brown SDM, 1998, HUM MOL GENET, V7, P1627, DOI 10.1093/hmg/7.10.1627; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Chagnon YC, 1996, TRENDS GENET, V12, P441, DOI 10.1016/0168-9525(96)30103-0; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; CHEVERUD JM, 1995, GENETICS, V139, P1455; Cheverud JM, 1996, GENETICS, V142, P1305; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLLINS AC, 1993, MAMM GENOME, V4, P454, DOI 10.1007/BF00296821; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Comuzzie AG, 1996, J CLIN ENDOCR METAB, V81, P597, DOI 10.1210/jc.81.2.597; Comuzzie AG, 1998, SCIENCE, V280, P1374, DOI 10.1126/science.280.5368.1374; de Angelis MH, 1998, MUTAT RES-FUND MOL M, V400, P25, DOI 10.1016/S0027-5107(98)00061-X; DRAGANI TA, 1995, MAMM GENOME, V6, P778, DOI 10.1007/BF00539002; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; FALCONE DS, 1995, INTRO QUANTITATIVE G; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Fisler JS, 1997, J NUTR, V127, pS1909, DOI 10.1093/jn/127.9.1909S; Frankel WN, 1996, NAT GENET, V14, P371, DOI 10.1038/ng1296-371; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fujisawa T, 1998, J CLIN ENDOCR METAB, V83, P2441, DOI 10.1210/jc.83.7.2441; Good DJ, 1997, NAT GENET, V15, P397, DOI 10.1038/ng0497-397; Goodale HD, 1938, J HERED, V29, P101, DOI 10.1093/oxfordjournals.jhered.a104463; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Gu W, 1999, DIABETES, V48, P635, DOI 10.2337/diabetes.48.3.635; GunayAygun M, 1997, BEHAV GENET, V27, P307, DOI 10.1023/A:1025683829856; Gunn TM, 1999, NATURE, V398, P152, DOI 10.1038/18217; Hager J, 1998, NAT GENET, V20, P304, DOI 10.1038/3123; Hahm S, 1999, NEURON, V23, P537, DOI 10.1016/S0896-6273(00)80806-5; Hanson RL, 1998, AM J HUM GENET, V63, P1130, DOI 10.1086/302061; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Hixson JE, 1999, J CLIN ENDOCR METAB, V84, P3187, DOI 10.1210/jc.84.9.3187; Ho GY, 1999, J BIOL CHEM, V274, P35816, DOI 10.1074/jbc.274.50.35816; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Keightley PD, 1996, GENETICS, V142, P227; KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761; Kolehmainen J, 1997, EUR J HUM GENET, V5, P206, DOI 10.1159/000484765; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lee JH, 1999, AM J HUM GENET, V64, P196, DOI 10.1086/302195; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; Li LS, 1996, DIABETOLOGIA, V39, P857, DOI 10.1007/s001250050521; Long AD, 1999, GENOME RES, V9, P720; Lowell BB, 1997, ANNU REV MED, V48, P307; MacArthur JW, 1944, AM NAT, V78, P142, DOI 10.1086/281181; Maes HHM, 1997, BEHAV GENET, V27, P325, DOI 10.1023/A:1025635913927; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; MATHEWS KD, 1989, AM J MED GENET, V34, P470, DOI 10.1002/ajmg.1320340403; Mehrabian M, 1998, J CLIN INVEST, V101, P2485, DOI 10.1172/JCI1748; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; Miller KA, 1997, GENETICS, V146, P1407; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P814, DOI 10.1210/en.140.2.814; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Moody DE, 1999, GENETICS, V152, P699; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Norman RA, 1997, AM J HUM GENET, V60, P166; Odunsi K, 1999, P NATL ACAD SCI USA, V96, P8315, DOI 10.1073/pnas.96.15.8315; Ohta T, 1999, AM J HUM GENET, V64, P397, DOI 10.1086/302233; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Perusse L, 1999, OBES RES, V7, P111, DOI 10.1002/j.1550-8528.1999.tb00398.x; PietriRouxel F, 1997, EUR J BIOCHEM, V247, P1174, DOI 10.1111/j.1432-1033.1997.01174.x; Pomp D, 1999, OBES RES, V7, P106, DOI 10.1002/j.1550-8528.1999.tb00397.x; PRICE RA, 1991, BEHAV GENET, V21, P1, DOI 10.1007/BF01067662; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; Rotimi CN, 1999, DIABETES, V48, P643, DOI 10.2337/diabetes.48.3.643; Russell-Eggitt IM, 1998, OPHTHALMOLOGY, V105, P1274, DOI 10.1016/S0161-6420(98)97033-6; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Sina M, 1999, AM J HUM GENET, V65, P1501, DOI 10.1086/302660; SIRACUSA LD, 1994, TRENDS GENET, V10, P423, DOI 10.1016/0168-9525(94)90112-0; Spielman RS, 1996, AM J HUM GENET, V59, P983; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; Suto J, 1998, MAMM GENOME, V9, P506, DOI 10.1007/s003359900809; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; Taylor BA, 1999, MAMM GENOME, V10, P963, DOI 10.1007/s003359901141; Taylor BA, 1997, GENOMICS, V43, P249, DOI 10.1006/geno.1997.4835; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; THOMSON G, 1995, AM J HUM GENET, V57, P487; Urbanek M, 1999, P NATL ACAD SCI USA, V96, P8573, DOI 10.1073/pnas.96.15.8573; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; WEST DB, 1995, AM J PHYSIOL-REG I, V268, pR658, DOI 10.1152/ajpregu.1995.268.3.R658; West DB, 1996, ENDOCRIN METAB CLIN, V25, P801, DOI 10.1016/S0889-8529(05)70355-8; WEST DB, 1994, MAMM GENOME, V5, P546, DOI 10.1007/BF00354928; WEST DB, 1994, J CLIN INVEST, V94, P1410, DOI 10.1172/JCI117477; *WHO, 1998, OB PREV MART GLOB EP; Wilson BD, 1999, MOL MED TODAY, V5, P250, DOI 10.1016/S1357-4310(99)01471-9; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; York B, 1996, MAMM GENOME, V7, P677, DOI 10.1007/s003359900204; York B, 1999, MAMM GENOME, V10, P457, DOI 10.1007/s003359901023; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	125	544	579	1	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					644	651		10.1038/35007519	http://dx.doi.org/10.1038/35007519			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766251				2022-12-28	WOS:000086400100064
J	Beebe, DJ; Moore, JS; Bauer, JM; Yu, Q; Liu, RH; Devadoss, C; Jo, BH				Beebe, DJ; Moore, JS; Bauer, JM; Yu, Q; Liu, RH; Devadoss, C; Jo, BH			Functional hydrogel structures for autonomous flow control inside microfluidic channels	NATURE			English	Article							POLYMER GELS	Hydrogels have been developed to respond to a wide variety of stimuli(1-6), but their use in macroscopic systems has been hindered by slow response times (diffusion being the rate-limiting factor governing the swelling process). However, there are many natural examples of chemically driven actuation that rely on short diffusion paths to produce a rapid response(7). It is therefore expected that scaling down hydrogel objects to the micrometre scale should greatly improve response times. At these scales, stimuli-responsive hydrogels could enhance the capabilities of microfluidic systems by allowing self-regulated flow control. Here we report the fabrication of active hydrogel components inside microchannels via direct photopatterning of a liquid phase. Our approach greatly simplifies system construction and assembly as the functional components are fabricated in situ, and the stimuli-responsive hydrogel components perform both sensing and actuation functions. We demonstrate significantly improved response times (less than 10 seconds) in hydrogel valves capable of autonomous control of local flow.	Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Wisconsin System; University of Wisconsin Madison	Beebe, DJ (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA.			Moore, Jeffrey/0000-0001-5841-6269				Breen TL, 1999, SCIENCE, V284, P948, DOI 10.1126/science.284.5416.948; Cumpston BH, 1999, NATURE, V398, P51, DOI 10.1038/17989; HU ZB, 1995, SCIENCE, V269, P525, DOI 10.1126/science.269.5223.525; Jackman RJ, 1998, SCIENCE, V280, P2089, DOI 10.1126/science.280.5372.2089; Jo BH, 2000, J MICROELECTROMECH S, V9, P76, DOI 10.1109/84.825780; Kataoka K, 1998, J AM CHEM SOC, V120, P12694, DOI 10.1021/ja982975d; Kenis PJA, 1999, SCIENCE, V285, P83, DOI 10.1126/science.285.5424.83; Kovacs GTA., 1998, MICROMACHINED TRANSD; Miyata T, 1999, NATURE, V399, P766, DOI 10.1038/21619; SCHMIDTNIELSEN K, 1975, ANIMAL PHYSL; SMELA E, 1995, SCIENCE, V268, P1735, DOI 10.1126/science.268.5218.1735; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TANAKA T, 1980, PHYS REV LETT, V45, P1636, DOI 10.1103/PhysRevLett.45.1636; TRIMMER WSN, 1989, SENSOR ACTUATOR, V19, P267, DOI 10.1016/0250-6874(89)87079-9	15	1618	1764	38	1134	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					588	+		10.1038/35007047	http://dx.doi.org/10.1038/35007047			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766238				2022-12-28	WOS:000086400100049
J	Nakanishi-Matsui, M; Zheng, YW; Sulciner, DJ; Weiss, EJ; Ludeman, MJ; Coughlin, SR				Nakanishi-Matsui, M; Zheng, YW; Sulciner, DJ; Weiss, EJ; Ludeman, MJ; Coughlin, SR			PAR3 is a cofactor for PAR4 activation by thrombin	NATURE			English	Article							RECEPTOR ACTIVATION; SPECIFICITY; CLEAVAGE; CLONING	Identification of the mechanisms by which the coagulation protease thrombin activates platelets is critical for understanding haemostasis and thrombosis. Thrombin activates cells at least in part by cleaving protease-activated G-protein-coupled receptors (PARs)(1). PAR3 and PAR4 are thrombin receptors expressed in mouse platelets(2,3). Inhibition of thrombin binding to mPAR3 (ref. 4) and knockout of the mPAR3 gene 3 inhibited mouse platelet activation at low but not high concentrations of thrombin. Thus PAR3 is important for thrombin signalling in mouse platelets. Expression of human PAR3 in heterologous expression systems reliably resulted in responsiveness to thrombin(2). Curiously, despite its importance for the activation of mouse platelets by thrombin 3,4, mouse PAR3 (mPAR3) did not lead to thrombin signalling even when overexpressed. We now report that mPAR3 and mPAR4 interact in a novel way: mPAR3 does not itself mediate transmembrane signalling but instead functions as a cofactor for the cleavage and activation of mPAR4 by thrombin. This establishes a paradigm for cofactor-assisted PAR activation and for a G-protein-coupled receptor's acting as an accessory molecule to present ligand to another receptor.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Daiichi Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 505 Parnassus Ave, San Francisco, CA 94143 USA.			Nakanishi-Matsui, Mayumi/0000-0001-9219-7442				CHEN J, 1994, J BIOL CHEM, V269, P16041; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ishihara H, 1998, BLOOD, V91, P4152, DOI 10.1182/blood.V91.11.4152.411k22_4152_4157; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Klagsbrun M, 1992, Semin Cancer Biol, V3, P81; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LIU LW, 1991, J BIOL CHEM, V266, P16977; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; OKAMURA T, 1978, J BIOL CHEM, V253, P3435; Sage S.O., 1996, PRACT APPROACH SER, P67; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	25	437	453	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					609	+		10.1038/35007085	http://dx.doi.org/10.1038/35007085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766244				2022-12-28	WOS:000086400100055
J	Wickware, P				Wickware, P			Training - United States gives priority to skills shortage	NATURE			English	Editorial Material																		Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	1	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					686	+		10.1038/35007274	http://dx.doi.org/10.1038/35007274			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766257				2022-12-28	WOS:000086400100070
J	Orr, HT; Zoghbi, HY				Orr, HT; Zoghbi, HY			Reversing neurodegeneration: A promise unfolds	CELL			English	Review							LOCALIZATION; AGGREGATION; UBIQUITIN; DISEASE; SCA1		Univ Minnesota, Dept Lab Med & Pathol, Inst Human Genet, Minneapolis, MN 55455 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Howard Hughes Medical Institute	Orr, HT (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Inst Human Genet, Minneapolis, MN 55455 USA.			Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Chai YH, 1999, J NEUROSCI, V19, P10338; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lin X, 1999, NEURON, V24, P499, DOI 10.1016/S0896-6273(00)81104-6; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MacDonald ME, 1999, NAT GENET, V23, P10, DOI 10.1038/12602; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	19	57	58	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 31	2000	101	1					1	4		10.1016/S0092-8674(00)80617-0	http://dx.doi.org/10.1016/S0092-8674(00)80617-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778849	Bronze			2022-12-28	WOS:000086249900001
J	Reichhardt, T				Reichhardt, T			Safety concerns force NASA to condemn satellite to fiery end	NATURE			English	News Item																		2000, NATURE, V403, P583; 2000, NATURE, V403, P232	2	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					423	423		10.1038/35006700	http://dx.doi.org/10.1038/35006700			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761881	Bronze			2022-12-28	WOS:000086257700002
J	Stark, J; Gallivan, S; Lovegrove, J; Hamilton, JRL; Monro, JL; Pollock, JCS; Watterson, KG				Stark, J; Gallivan, S; Lovegrove, J; Hamilton, JRL; Monro, JL; Pollock, JCS; Watterson, KG			Mortality rates after surgery for congenital heart defects in children and surgeons' performance	LANCET			English	Article							CARDIAC-SURGERY; LIFE	Background A public inquiry into surgery for paediatric congenital heart defects in Bristol, UK, underscored the need for reliable data on overall mortality rates, which would allow assessment of individual surgeons' performance. We aimed to gather and report such data for 1 year to provide information for clinicians, researchers, policy makers, and the general public. Methods We collected data on all operations (1378) for congenital heart defects done by 11 surgeons in five departments in the UK between April 1, 1997, and March 31, 1998, These operations represented about 36% of all operations done in the UK during that time. Clearly defined criteria were agreed to classify operations into subgroups. Findings The overall mortality rate for all operations was 4.0% (95% CI 3.0-5.2). No deaths occurred for 67 arterial-switch operations, Mortality rates for coarctation, ventricular septal defect, atrioventricular septal defect, Fallot, and truncus arteriosus operations were 1.1%, 0.6%, 3.6%, 2.3%, and 28.6%, respectively. Although overall mortality rates between surgeons varied (1.6-6.9%), no surgeon's were higher than the 95% CI, The numbers of operations done by individual surgeons were small, which led to wide confidence intervals and made the detection of differences in performance difficult. Interpretation The participating departments seemed to reach high standards of care for children with congenital heart defects, although more data would be needed to assess performance of individual surgeons. The development of quality standards will be difficult because of the complexity of defects, the different types of operations, and few patients in each subgroup. Collection of larger sets of data for more patients and centres are needed.	Inst Child Hlth, London, England; UCL, Ctr Math & Phys Life Sci & Expt Biol, London, England; UCL, Dept Math, Clin Operat Res Unit, London, England; Freeman Rd Hosp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Southampton Gen Hosp, Wessex Cardiothorac Ctr, Southampton SO9 4XY, Hants, England; Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland; United Leeds Teaching Hosp, Yorkshire Heart Ctr, Leeds, W Yorkshire, England	University of London; University College London; University of London; University College London; University of London; University College London; Newcastle Freeman Hospital; Newcastle University - UK; University of Southampton; University of Glasgow	Stark, J (corresponding author), Great Ormond St Hosp Sick Children, Great Ormond St, London WC1N 3JH, England.	jarda@freeuk.com						Armitage P., 1987, STAT METHODS MED RES; DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; DELEVAL MR, IN PRESS J THORAC CA; EBERT PA, 1984, ANN SURG, V200, P451, DOI 10.1097/00000658-198410000-00006; ENGLISH TAH, 1984, BRIT MED J, V289, P1205, DOI 10.1136/bmj.289.6453.1205; EYPASCH E, 1995, BRIT MED J, V311, P619, DOI 10.1136/bmj.311.7005.619; General Medical Council (UK), 1998, SEEK PAT CONS ETH CO; Hannan EL, 1998, PEDIATRICS, V101, P963, DOI 10.1542/peds.101.6.963; Keogh BE, 1998, BMJ-BRIT MED J, V316, P1759, DOI 10.1136/bmj.316.7147.1759; KEOGH BE, 1999, NATL ADULT AUDIT CAR; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; MOLLER J, 1998, PAEDIAT CARDIAC CARE; Parsonnet V., 1989, CIRCULATION S1, V779, P1; QUAGEBEUR JM, 1986, J THORAC CARDIOVASC, V92, P361; Rothwell PM, 1999, LANCET, V353, P1325, DOI 10.1016/S0140-6736(99)01000-4; *SEN SURG GB IR, 1998, RESP GEN MED COUNC D; SPIEGELHALTER DJ, 1992, BRIT MED J, V305, P1500, DOI 10.1136/bmj.305.6867.1500-a; Stark J, 1996, CIRCULATION, V94, P1; STARK JF, IN PRESS SEM THOR CA	19	83	87	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					1004	1007		10.1016/S0140-6736(00)90001-1	http://dx.doi.org/10.1016/S0140-6736(00)90001-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768449				2022-12-28	WOS:000086054000040
J	Kendall, K				Kendall, K			Hydrocarbon fuels - Hopes for a flame-free future	NATURE			English	Editorial Material									Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Kendall, K (corresponding author), Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.							BUCHI FN, 1999, PORT FUEL CELLS C BO; DAVY H, 1817, PHIL T R SOC LOND, V107, P45; Grove WR., 1839, PHILOS MAG, V14, P127, DOI [10.1080/14786443908649684, DOI 10.1080/14786443908649684]; HOUGHTON J, 1994, GLOBAL WARMING, pCH3; KENDALL K, 1998, Patent No. 5827620; Murray EP, 1999, NATURE, V400, P649, DOI 10.1038/23220; Park SD, 2000, NATURE, V404, P265, DOI 10.1038/35005040; 2000, J POWER SOURCES  MAR	8	22	23	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					233	+		10.1038/35005191	http://dx.doi.org/10.1038/35005191			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749192				2022-12-28	WOS:000086022200028
J	Thomas, GA; Shraiman, BI; Glodis, PF; Stephen, MJ				Thomas, GA; Shraiman, BI; Glodis, PF; Stephen, MJ			Towards the clarity limit in optical fibre	NATURE			English	Article								An important scientific and technological goal(1-4) in the held of optical communications is the achievement of the clarity limit in optical fibres-that is, ensuring that the SiO2 glass from which fibres are made is as transparent as possible. The clarity of the wavelength transmission window (and the width of that window) in existing fibres is already sufficient to form the basis of a world-wide optical communication system(3,4), yet it is still limited by contamination of the fibre by water. Here we measure the spatial distribution of water in the glass rods from which optical fibres are drawn and explain the distribution quantitatively with a mathematical model of diffusion(5,6) in a medium with essentially perfect cylindrical symmetry. Our analysis shows that the water enters from the outside of the rod and diffuses into the molten, flowing glass much faster than is expected from extrapolation of low-temperature measurements(6,7). Our elucidation of the physics underlying the contamination process has already led to the fabrication of dry fibres(8,9), which have a clarified and broadened communications window. The improved operational range of wavelengths should yield applications for new lasers, optical amplifiers and detectors, and should substantially increase the information-carrying capacity of optical communications systems.	Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; Lucent Technol, Network Prod, Norcross, GA 30071 USA; Rutgers State Univ, Piscataway, NJ 08854 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Alcatel-Lucent; Lucent Technologies; Rutgers State University New Brunswick	Thomas, GA (corresponding author), MIT, George R Harrison Spect Lab, Room 6-008,77 Massachusetts Ave, Cambridge, MA 02139 USA.							CHANG K, 1999, P OPT FIB COMM C, P1; Doremus RH., 1994, GLASS SCI, V2nd ed; KECK DB, 1973, APPL PHYS LETT, V22, P307, DOI 10.1063/1.1654649; KECK DB, 1973, Patent No. 3737292; KEISER G, 1983, OPTICAL FIBER COMMUN, P1; LIMOGE Y, 1990, NATO ADV SCI I E-APP, V179, P601; MACCHESNEY JB, 1990, J AM CERAM SOC, V73, P3537, DOI 10.1111/j.1151-2916.1990.tb04256.x; MOLSON AJ, 1960, P CHEM SOC LOND, V59, P388; PARTUS F, 1995, Patent No. 5692087; SHELBY JE, 1982, J AM CERAM SOC, V65, pC59, DOI 10.1111/j.1151-2916.1982.tb10420.x; STONE J, 1982, J CHEM PHYS, V76, P1712, DOI 10.1063/1.443210	11	106	110	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					262	264		10.1038/35005034	http://dx.doi.org/10.1038/35005034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749203				2022-12-28	WOS:000086022200041
J	Alcolado, J				Alcolado, J			Nurse practitioners and the future of general practice	BRITISH MEDICAL JOURNAL			English	Editorial Material													Alcolado, John/B-4999-2009	Alcolado, John/0000-0003-0666-0352					0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1084	1084		10.1136/bmj.320.7241.1084	http://dx.doi.org/10.1136/bmj.320.7241.1084			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764390	Green Published			2022-12-28	WOS:000086675700066
J	Lattimer, V; Sassi, F; George, S; Moore, M; Turnbull, J; Mullee, M; Smith, H				Lattimer, V; Sassi, F; George, S; Moore, M; Turnbull, J; Mullee, M; Smith, H			Cost analysis of nurse telephone consultation in out of hours primary care: evidence from a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To undertake an economic evaluation of nurse telephone consultation using decision support software in comparison with usual general practice care provided by a general practice cooperative. Design Cost analysis from an NHS perspective using stochastic data from a randomised controlled trial. Setting General practice cooperative with 55 general practitioners serving 97 000 registered patients in Wiltshire, England. Subjects All patients contacting the service, or about whom the service was contacted during the trial year (January 1997 to January 1998). Main outcome measures Costs and savings to the NHS during the trial year. Results The cost of providing nurse telephone consultation was pound 81 237 per annum. This, however, determined a pound 94 422 reduction of other costs for the NHS arising from reduced emergency admissions to hospital. Using point estimates for savings, the cost analysis, combined with the analysis of outcomes, showed a dominance situation for the intervention over general practice cooperative care alone. If a larger improvement in outcomes is assumed (upper 95% confidence limit) NHS savings increase to pound 123 824 per annum. Savings of only pound 3728 would, however, arise in a scenario where lower 95% confidence limits for outcome differences were observed. To break even, the intervention would have needed to save 138 emergency hospital admissions per year, around 90% of the effect achieved in the trial. Additional savings of pound 16 928 for general practice arose from reduced travel to visit patients at home and fewer surgery appointments within three days of a call. Conclusions Nurse telephone consultation in out of hours primary care may reduce NHS costs in the long term by reducing demand for emergency admission to hospital. General practitioners currently bear most of the cost of nurse telephone consultation and benefit least from the savings associated with it This indicates that the service produces benefits in terms of service quality, which are beyond the reach of this cost analysis.	Univ Southampton, Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Univ London London Sch Econ & Polit Sci, Dept Social Policy, London WC2A 2AE, England; Three Swans Surg, Salisbury SP1 1DX, England; Univ Southampton, Aldermoor Hlth Ctr, Acad Dept Primary Med Care, Southampton SO9 5NH, Hants, England	University of Southampton; University of London; London School Economics & Political Science; University of Southampton	Lattimer, V (corresponding author), Univ Southampton, Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England.	val@soton.ac.uk	Moore, Michael/C-3447-2011; Smith, Helen E/M-2449-2016	Moore, Michael/0000-0002-5127-4509; Smith, Helen E/0000-0003-1883-6124; Turnbull, Joanne/0000-0002-5006-4438				Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Christensen MB, 1998, BMJ-BRIT MED J, V316, P1502, DOI 10.1136/bmj.316.7143.1502; *COLL HLTH, 1998, DEV NHS DIR; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Drummond MF, 2015, METHODS EC EVALUATIO; JANOWSKI R, 1999, BMJ-BRIT MED J, V319, P67; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Lattimer V, 1997, BRIT MED J, V314, P198; Lattimer V, 1996, PRIMARY CARE MANAGEM, V6, P3; Levin H. M., 1983, COST EFFECTIVENESS P; *NAT ASS GP COOP, 1998, BRIT MED J, V317, P1054; *NAT HLTH MAN EV, 1994, COST ALL GEN PRINC A; Netten A, 1998, UNIT COSTS HLTH SOCI; NICHOL J, 1998, EVALUATION NHS DIREC; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Reid FDA, 1999, BRIT MED J, V319, P98, DOI 10.1136/bmj.319.7202.98; Thompson F, 1999, BMJ-BRIT MED J, V319, P1408, DOI 10.1136/bmj.319.7222.1408	19	62	63	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 15	2000	320	7241					1053	+		10.1136/bmj.320.7241.1053	http://dx.doi.org/10.1136/bmj.320.7241.1053			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764368	Green Published, Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000086675700027
J	Radcliffe, M				Radcliffe, M			Doctors and nurses: new game, same result	BRITISH MEDICAL JOURNAL			English	Editorial Material									Nursing Times, London, England		Radcliffe, M (corresponding author), Nursing Times, London, England.								0	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1085	1085		10.1136/bmj.320.7241.1085	http://dx.doi.org/10.1136/bmj.320.7241.1085			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764392	Green Published			2022-12-28	WOS:000086675700067
J	Roses, AD				Roses, AD			Pharmacogenetics and future drug development and delivery	LANCET			English	Editorial Material							DISEASE; POLYMORPHISM; DEMENTIA		Glaxo Wellcome plc, Genet Directorate, Greenford, Middx, England; Duke Univ, Med Ctr, Durham, NC USA	GlaxoSmithKline; Duke University	Roses, AD (corresponding author), Glaxo Wellcome Res & Dev Ltd, 5 Moore Dr,5-5616, Res Triangle Pk, NC 27709 USA.							AITMAN TJ, 1995, BAILLIERE CLIN ENDOC, V9, P631, DOI 10.1016/S0950-351X(95)80655-5; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Fijal BA, 2000, CONTROL CLIN TRIALS, V21, P7, DOI 10.1016/S0197-2456(99)00039-2; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; Lai E, 1998, GENOMICS, V54, P31, DOI 10.1006/geno.1998.5581; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Mather DB, 1999, AM J MANAG CARE, V5, P277; Murrell JR, 1997, AM J HUM GENET, V61, P1131, DOI 10.1086/301594; *NHS, 1999, FAST ACC MOD TREATM; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; ROSES AD, 1994, CURR NEUROL, V14, P111; Scott WK, 1999, JAMA-J AM MED ASSOC, V281, P513, DOI 10.1001/jama.281.6.513; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Wood AJJ, 1998, NEW ENGL J MED, V339, P1851, DOI 10.1056/NEJM199812173392512	15	149	155	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1358	1361		10.1016/S0140-6736(00)02126-7	http://dx.doi.org/10.1016/S0140-6736(00)02126-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776762				2022-12-28	WOS:000086829400042
J	Ong, EK; Glantz, SA				Ong, EK; Glantz, SA			Tobacco industry efforts subverting international Agency for Research on Cancer's second-hand smoke study	LANCET			English	Article							RESPIRABLE SUSPENDED PARTICLES; PASSIVE SMOKING; LUNG-CANCER; NONSMOKING WOMEN; AIR-QUALITY; EXPOSURE; MISCLASSIFICATION; MULTICENTER; HEALTH; RISK	Scientific reports on second-hand smoke have stimulated legislation on clean indoor air in the USA, but less so in Europe. Recently, the largest European study, by the International Agency for Research on Cancer (IARC), demonstrated a 16% increase in the point estimate of risk in lung cancer for nonsmokers, a result consistent with earlier studies. However, the study was described by newspapers and the tobacco industry as demonstrating no increase in risk. To understand the tobacco industry's strategy on the IARC study we analysed industry documents released in US litigation and interviewed IARC investigators, The Philip Morris tobacco company feared that the study (and a possible IARC monograph on second-hand smoke) would lead to increased restrictions in Europe so they spearheaded an inter-industry, three-prong strategy to subvert IARC's work. The scientific strategy attempted to undercut IARC's research and to develop industry-directed research to counter the anticipated findings. The communications strategy planned to shape opinion by manipulating the media and the public. The government strategy sought to prevent increased smoking restrictions. The IARC study cost $2 million over ten years; Philip Morris planned to spend $2 million in one year alone and up to $4 million on research. The documents and Interviews suggest that the tobacco industry continues to conduct a sophisticated campaign against conclusions that secondhand smoke causes lung cancer and other diseases, subverting normal scientific processes.	Univ Calif San Francisco, Inst Hlth Policy Studies, Cardiovasc Res Inst, Dept Med,Div Cardiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Cardiovasc Res Inst, Dept Med,Div Cardiol, Box 0130, San Francisco, CA 94143 USA.	glantz@medicine.ucsf.edu			NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES D, 1995, JAMA-J AM MED ASSOC, P248; Barnes D E, 1997, Tob Control, V6, P19; Barnes DE, 1996, J HEALTH POLIT POLIC, V21, P515, DOI 10.1215/03616878-21-3-515; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188, DOI 10.1093/oxfordjournals.epirev.a017925; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1993, TOB CONTROL, V2, P103; Blot WJ, 1998, J NATL CANCER I, V90, P1416, DOI 10.1093/jnci/90.19.1416; Boffetta P, 1998, J NATL CANCER I, V90, P1440, DOI 10.1093/jnci/90.19.1440; Chapman S, 1998, BRIT MED J, V316, P727; DYER C, 1998, GUARDIAN        0707; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; GARFINKEL L, 1981, JNCI-J NATL CANCER I, V66, P1061, DOI 10.1093/jnci/66.6.1061; GARFINKEL L, 1984, NY TIMES        0605; Gelbspan R., 1997, HEAT IS HIGH STAKES; GLANTZ S, 1983, P 12 WORLD C TOB HLT, P287; Glantz S A, 1997, Tob Control, V6, P164; Glantz S.A., 1996, CIGARETTE PAPERS; *IMP TOB, 1999, IMP TOB POS SMOK REL; *INT AG RES CANC, 1998, PASS SMOK LUNG CANC; Jenkins RA, 1996, LUNG CANCER-J IASLC, V14, pS195; Jenkins RA, 1996, J EXPO ANAL ENV EPID, V6, P473; Korea Ministry of Health and Welfare, 2016, DEV NAT BIOM PROGR E; Lash TL, 1999, AM J EPIDEMIOL, V149, P5; LEGRAND C, 1998, AUSTRALIAN      0310; MACDONALD V, 1998, SUNDAY TELEGRAP 0308; Manley M W, 1997, Tob Control, V6 Suppl 2, pS12, DOI 10.1136/tc.6.suppl_2.S12; MATANOSKI G, 1995, AM J EPIDEMIOL, V142, P149, DOI 10.1093/oxfordjournals.aje.a117613; MATTHEWS R, 1998, SUNDAY TELEGRAP 0816; MOONEY L, 1998, WALL STREET J   0319, pA18; *NAT HLTH MRC, 1986, EFF PASS SMOK HLTH; *NAT HLTH MRC, 1997, HLTH EFF PASS SMOK; National Research Council Committee on Passive Smoking, 1986, ENV TOB SMOK MEAS EX; *NZ DEP HLTH, 1998, CREAT SMOK ENV; [Office of Research and Development Office of Health Environmental Assessment United States Environmental Protection Agency], 1992, RESP HLTH EFF PASS S; Phillips K, 1997, ENVIRON INT, V23, P173, DOI 10.1016/S0160-4120(97)00004-4; PHILLIPS K, 1994, ENVIRON INT, V20, P693, DOI 10.1016/0160-4120(94)90303-4; Phillips K, 1997, ENVIRON INT, V23, P851, DOI 10.1016/S0160-4120(97)00097-4; Phillips K, 1999, ATMOS ENVIRON, V33, P1889, DOI 10.1016/S1352-2310(98)00205-2; Phillips K, 1996, SCAND J WORK ENV HEA, V22, P1; Phillips K, 1998, ENVIRON INT, V24, P405, DOI 10.1016/S0160-4120(98)00020-8; Phillips K, 1998, INT ARCH OCC ENV HEA, V71, P379, DOI 10.1007/s004200050296; Phillips K, 1998, ENVIRON INT, V24, P301, DOI 10.1016/S0160-4120(98)00009-9; Phillips K, 1998, INT ARCH OCC ENV HEA, V71, P201, DOI 10.1007/s004200050271; Proctor CJ, 1998, BRIT MED J, V317, P349; REPACE J, 1998, NAT TOX PROGR BOARD; REPACE JL, 1985, ENVIRON INT, V11, P3, DOI 10.1016/0160-4120(85)90098-4; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; RIBOLI E, 1995, EUR RESPIR J, V8, P285, DOI 10.1183/09031936.95.08020285; *ROP ORG, 1978, STUD PUBL ATT CIG SM, V1; SCHLESINGER J, 1998, WALL STREET J   0720; Simpson D, 1998, TOB CONTROL, V7, P117; SIMPSON D, 1998, TOB CONTROL, V7, P228; Smith GD, 1996, BRIT MED J, V313, P929; Stead LF, 2006, REP SCI COMM TOB HLT, DOI 10.1002/14651858.CD002850.pub2; SWEET M, 1998, SYDNEY MORNING  0203; TEINKEN J, 1990, SMOKESCREEN CRITIQUE; THOMAS H, 1999, S CHINA MORNING 0118; *TOB I SO AFR, 1998, TISA SUBM IND PORTF; *TRONDH EUR WORK P, 1996, ENV TOB SMOK LUNG CA; *US DEP HHS, 1986, DHHS PUB; Wells AJ, 1998, AM J PUBLIC HEALTH, V88, P1503, DOI 10.2105/AJPH.88.10.1503; *WHO, 1998, PASS SMOK DOES CAUS; *WHO, 1998, ZIMBABWE INDEPE 1023; 1997, PR NEWSWIRE     1203; 1999, EUR SCI ENV FOR APR	66	144	144	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2000	355	9211					1253	1259		10.1016/S0140-6736(00)02098-5	http://dx.doi.org/10.1016/S0140-6736(00)02098-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770318				2022-12-28	WOS:000086448000039
J	Blaauwgeers, R; Eltsov, VB; Krusius, M; Ruohio, JJ; Schanen, R; Volovik, GE				Blaauwgeers, R; Eltsov, VB; Krusius, M; Ruohio, JJ; Schanen, R; Volovik, GE			Double-quantum vortex in superfluid He-3-A	NATURE			English	Article							ROTATING HE-3-A; PHASE; VORTICES	Linear defects are generic in continuous media(1). In quantum systems they appear as topological line defects which are associated with a circulating persistent current. In relativistic quantum field theories they are known as cosmic strings(2), in superconductors as quantized flux lines(3), and in superfluids(3,4) and low-density Bose-Einstein condensates(5) as quantized vortex lines. A conventional quantized vortex Line consists of a central core around which the phase of the order parameter winds by 2 pi n, while within the core the order parameter vanishes or is depleted from the bulk value. Usually vortices are singly quantized (that is, have n = 1). But it has been theoretically predicted that, in superfluid He-3-A, vortex lines are possible that have n = 2 and continuous structure, so that the orientation of the multicomponent order parameter changes smoothly throughout the vortex while the amplitude remains constant. Here we report direct proof, based on high-resolution nuclear magnetic resonance measurements, that the most common vortex line in He-3-A has n = 2. One vortex line after another is observed to form in a regular periodic process, similar to a phase-slip in the Josephson effect.	Aalto Univ, Low Temp Lab, FIN-02015 Espoo, Finland; Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands; PL Kapitza Phys Problems Inst, Moscow 117334, Russia; CNRS, Ctr Rech Tres Basses Temp, F-38042 Grenoble 09, France; LD Landau Theoret Phys Inst, Moscow 117334, Russia	Aalto University; Leiden University; Leiden University - Excl LUMC; PL Kapitza Institute for Physical Problems of Russian Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); Russian Academy of Sciences; Landau Institute for Theoretical Physics	Eltsov, VB (corresponding author), Aalto Univ, Low Temp Lab, POB 2200, FIN-02015 Espoo, Finland.	ve@boojum.hut.fi	Krusius, Matti/F-8896-2013; Eltsov, Vladimir/M-8767-2015; Volovik, Grigory E/F-6396-2015	Eltsov, Vladimir/0000-0002-6949-5334; 				ACHUCARRO A, IN PRESS PHYS REP; ANDERSON PW, 1977, PHYS REV LETT, V38, P508, DOI 10.1103/PhysRevLett.38.508; [Anonymous], 1990, SUPERFLUIDITY SUPERC; Feynman R. P., 1955, PROG LOW TEMP PHYS, V1, P17; HAKONEN PJ, 1982, PHYS REV LETT, V49, P1258, DOI 10.1103/PhysRevLett.49.1258; HINDMARSH MB, 1995, REP PROG PHYS, V58, P477, DOI 10.1088/0034-4885/58/5/001; Ho TL, 1998, PHYS REV LETT, V81, P742, DOI 10.1103/PhysRevLett.81.742; Kleman M., 1983, POINTS LINES WALLS L; Matthews MR, 1999, PHYS REV LETT, V83, P2498, DOI 10.1103/PhysRevLett.83.2498; MERMIN ND, 1976, PHYS REV LETT, V36, P594, DOI 10.1103/PhysRevLett.36.594; Onsager L., 1949, NUOVO CIMENTO, V6, P249, DOI DOI 10.1007/BF02780991; Packard RE, 1998, REV MOD PHYS, V70, P641, DOI 10.1103/RevModPhys.70.641; PARTS U, 1995, PHYS REV LETT, V75, P3320, DOI 10.1103/PhysRevLett.75.3320; Ruutu VMH, 1997, J LOW TEMP PHYS, V107, P93, DOI 10.1007/BF02396838; SEPPALA HK, 1983, J LOW TEMP PHYS, V51, P279, DOI 10.1007/BF00683557; Vollhardt D., 1990, SUPERFLUID PHASES 3H; VOLOVIK GE, 1977, JETP LETT+, V25, P22	17	78	79	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	2000	404	6777					471	473		10.1038/35006583	http://dx.doi.org/10.1038/35006583			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761908				2022-12-28	WOS:000086257700039
J	Goldberg, J				Goldberg, J			Decoding of sorting signals by coatomer through a GTPase switch in the COPI coat complex	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ADP-RIBOSYLATION FACTOR; EARLY SECRETORY PATHWAY; HUMAN KDEL RECEPTOR; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GOLGI TRANSPORT; BINDING-PROTEIN; ACTIVATING PROTEIN; ARF GTPASE	Sorting signals on cargo proteins are recognized by coatomer for selective uptake into COPI (coatomer)-coated vesicles. This study shows that coatomer couples sorting signal recognition to the GTP hydrolysis reaction on ARF1. Coatomer responds differently to different signals. The cytoplasmic signal sequence of hp24a inhibits coatomer-dependent GTP hydrolysis. By contrast, the dilysine retrieval signal, which competes for the same binding site on coatomer, has no effect on GTPase activity. It is inferred that, in vivo, sorting signal selection is under kinetic control, with coatomer governing a GTPase discard pathway that excludes dilysine-tagged proteins from one class of COPI-coated vesicles. The concept of competing sets of sorting signals that act positively and negatively during vesicle budding through a GTPase switch in the COPI coat complex suggests mechanisms for cargo segregation in which specificity is conferred by GTP hydrolysis.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	jonathan@ximpact4.ski.mskcc.org						Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Aoe T, 1998, P NATL ACAD SCI USA, V95, P1624, DOI 10.1073/pnas.95.4.1624; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1994, J BIOL CHEM, V269, P24486; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Wen CH, 1999, J CELL BIOL, V145, P1165, DOI 10.1083/jcb.145.6.1165; YARUS M, 1992, TRENDS BIOCHEM SCI, V17, P171, DOI 10.1016/0968-0004(92)90257-A; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	58	106	110	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 17	2000	100	6					671	679		10.1016/S0092-8674(00)80703-5	http://dx.doi.org/10.1016/S0092-8674(00)80703-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761932	Bronze			2022-12-28	WOS:000085983800009
J	Lander, ES; Weinberg, RA				Lander, ES; Weinberg, RA			Genomics: Journey to the center of biology	SCIENCE			English	Article							SIMIAN SARCOMA-VIRUS; GROWTH-FACTOR; DNA; GENE; SEQUENCES; DISEASE		Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Clayton RA, 1997, NATURE, V387, P459, DOI 10.1038/387459a0; Correns C. J., 1900, BERICHTE DTSCH BOT G, V18, P158, DOI DOI 10.1111/J.1438-8677.1900.TB04893.X; Creighton HB, 1931, P NATL ACAD SCI USA, V17, P492, DOI 10.1073/pnas.17.8.492; De Vries H. M., 1900, BER DEUT BOT GES, V18, P83; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mendel G., 1866, VERHAND NATURF VER B, V4, P3, DOI DOI 10.5962/BHL.TITLE.61004; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; NIRENBERG M, 1961, P NATL ACAD SCI USA, V47, P1588, DOI 10.1073/pnas.47.10.1588; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; Schrodinger E., 1945, WHAT IS LIFE; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sturtevant AH, 1913, J EXP ZOOL, V14, P43, DOI 10.1002/jez.1400140104; Sturtevant Alfred, 1965, HIST GENETICS; Ting CT, 1998, SCIENCE, V282, P1501, DOI 10.1126/science.282.5393.1501; Tschermak-Seysenegg Ev, 1900, BERICHTE DTSCH BOTAN, V18, P232; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Watson J. D., 1992, RECOMBINANT DNA; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	30	98	121	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2000	287	5459					1777	1782		10.1126/science.287.5459.1777	http://dx.doi.org/10.1126/science.287.5459.1777			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BY	10755930				2022-12-28	WOS:000085775300031
J	Pockley, P				Pockley, P			Australian jailed for removal of fossilized footprints	NATURE			English	News Item																		LONG, 2000, NATURE, V403, P689; LONG, 2000, NATURE, V403, P687	2	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					4	4		10.1038/35003708	http://dx.doi.org/10.1038/35003708			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10755904	Bronze			2022-12-28	WOS:000085775100006
J	Bishop, KM; Goudreau, G; O'Leary, DDM				Bishop, KM; Goudreau, G; O'Leary, DDM			Regulation of area identity in the mammalian neocortex by Emx2 and Pax6	SCIENCE			English	Article							EMBRYONIC CEREBRAL-CORTEX; DROSOPHILA EMBRYO; VISUAL-CORTEX; CORTICAL-NEURONS; MOUSE; EXPRESSION; GENE; MICE; DIFFERENTIATION; PROJECTIONS	The contribution of extrinsic and genetic mechanisms in determining areas of the mammalian neocortex has been a contested issue. This study analyzes the roles of the regulatory genes Emx2 and Pax6, which are expressed in opposing gradients in the neocortical ventricular zone, in specifying areas. Changes in the patterning of molecular markers and area-specific connections between the colter and thalamus suggest that arealization of the neocortex is disproportionately altered in Emx2 and Pax6 mutant mice in opposing manners predicted from their countergradients of expression: rostral areas expand and caudal areas contract in Emx2 mutants, whereas the opposite effect is seen in Pax6 mutants. These findings suggest that Emx2 and Pax6 cooperate to regulate arealization of the neocortex and to confer area identity to cortical cells.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany	Salk Institute; Max Planck Society	O'Leary, DDM (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	doleary@salk.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031558, R37NS031558] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31558] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1988, J COMP NEUROL, V275, P346, DOI 10.1002/cne.902750304; BISHOP KM, UNPUB; CHENN A, 1997, MOL CELLULAR APPROAC, P440; CRANDALL JE, 1984, J COMP NEUROL, V228, P542, DOI 10.1002/cne.902280407; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DEHAY C, 1989, NATURE, V337, P265, DOI 10.1038/337265a0; Donoghue MJ, 1999, J NEUROSCI, V19, P5967, DOI 10.1523/JNEUROSCI.19-14-05967.1999; Gao PP, 1998, P NATL ACAD SCI USA, V95, P5329, DOI 10.1073/pnas.95.9.5329; Grove EA, 1998, DEVELOPMENT, V125, P2315; Gulisano M, 1996, EUR J NEUROSCI, V8, P1037, DOI 10.1111/j.1460-9568.1996.tb01590.x; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Livy DJ, 1997, HIPPOCAMPUS, V7, P2, DOI 10.1002/(SICI)1098-1063(1997)7:1<2::AID-HIPO2>3.0.CO;2-R; Mackarehtschian K, 1999, CEREB CORTEX, V9, P601, DOI 10.1093/cercor/9.6.601; Mallamaci A, 1998, MECH DEVELOP, V77, P165, DOI 10.1016/S0925-4773(98)00141-5; MILLER B, 1993, J COMP NEUROL, V335, P16, DOI 10.1002/cne.903350103; Miyashita-Lin EM, 1999, SCIENCE, V285, P906, DOI 10.1126/science.285.5429.906; Nakagawa Y, 1999, J NEUROSCI, V19, P10877, DOI 10.1523/JNEUROSCI.19-24-10877.1999; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; Pellegrini M, 1996, DEVELOPMENT, V122, P3893; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1991, P NATL ACAD SCI USA, V88, P2083, DOI 10.1073/pnas.88.6.2083; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; Rubenstein JLR, 1999, CEREB CORTEX, V9, P524, DOI 10.1093/cercor/9.6.524; Rusch J, 1996, CURR OPIN GENET DEV, V6, P416, DOI 10.1016/S0959-437X(96)80062-1; SCHLAGGAR BL, 1993, DEV BRAIN RES, V75, P19, DOI 10.1016/0165-3806(93)90061-E; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; STANFIELD BB, 1985, NATURE, V313, P135, DOI 10.1038/313135a0; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; Stoykova A, 1996, DEVELOPMENT, V122, P3453; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Theil T, 1999, DEVELOPMENT, V126, P3561; Tuttle R, 1999, DEVELOPMENT, V126, P1903; TUTTLE R, 1999, J COMP NEUROL, V408, P147; WALTHER C, 1991, DEVELOPMENT, V113, P1435	40	440	445	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	2000	288	5464					344	349		10.1126/science.288.5464.344	http://dx.doi.org/10.1126/science.288.5464.344			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764649				2022-12-28	WOS:000086454300040
J	Davis, BM; Lawson, EH; Sandkvist, M; Ali, A; Sozhamannan, S; Waldor, MK				Davis, BM; Lawson, EH; Sandkvist, M; Ali, A; Sozhamannan, S; Waldor, MK			Convergence of the secretory pathways for cholera toxin and the filamentous phage, CTX phi	SCIENCE			English	Article							PROTEIN SECRETION; VIBRIO-CHOLERAE; MEMBRANE; GENES	Virulence of Vibrio cholerae depends on secretion of cholera toxin (CT), which is encoded within the genome of a filamentous phage, CTX phi. Release of CT is mediated by the extracellular protein secretion (eps) type II secretion system. Here. the outer membrane component of this system, EpsD, was shown to be required for secretion of the phage as well. Thus, EpsD plays a role both in pathogenicity and in horizontal transfer of a key virulence gene. Genomic analysis suggests that additional filamentous phages also exploit chromosome-encoded outer membrane channels.	Tufts Univ, Sch Med, Div Geog Med & Infect Dis, Boston, MA 02111 USA; Amer Red Cross, Holland Lab, Dept Biochem, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Med, Div Hosp Epidemiol, Baltimore, MD 21201 USA	Tufts University; American Red Cross; University System of Maryland; University of Maryland Baltimore	Waldor, MK (corresponding author), Tufts Univ, Sch Med, Div Geog Med & Infect Dis, Boston, MA 02111 USA.		Sozhamannan, Shanmuga/AAN-7809-2020; Sozhamannan, Shanmuga/AGF-2410-2022	Sozhamannan, Shanmuga/0000-0002-6762-7874; 	NIAID NIH HHS [AI-42347] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042347, R37AI042347] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali A, 2000, INFECT IMMUN, V68, P1967, DOI 10.1128/IAI.68.4.1967-1974.2000; Binet R, 1997, GENE, V192, P7, DOI 10.1016/S0378-1119(96)00829-3; Christie PJ, 1997, J BACTERIOL, V179, P3085, DOI 10.1128/jb.179.10.3085-3094.1997; DAVIS BD, UNPUB; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Fullner KJ, 1999, INFECT IMMUN, V67, P1393, DOI 10.1128/IAI.67.3.1393-1404.1999; HASE CC, 1991, J BACTERIOL, V173, P3311; JUDSON M, UNPUB; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; KOONIN EV, 1992, FEBS LETT, V312, P3, DOI 10.1016/0014-5793(92)81398-6; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; Lindeberg M, 1996, MOL MICROBIOL, V20, P175, DOI 10.1111/j.1365-2958.1996.tb02499.x; Marciano DK, 1999, SCIENCE, V284, P1516, DOI 10.1126/science.284.5419.1516; PEARSON GDN, 1993, P NATL ACAD SCI USA, V90, P3750, DOI 10.1073/pnas.90.8.3750; Pugsley AP, 1998, CELL MOL LIFE SCI, V54, P347, DOI 10.1007/s000180050162; RUSSEL M, 1995, TRENDS MICROBIOL, V3, P223, DOI 10.1016/S0966-842X(00)88929-5; RUSSEL M, 1993, J MOL BIOL, V231, P689, DOI 10.1006/jmbi.1993.1320; Russel M, 1998, J MOL BIOL, V279, P485, DOI 10.1006/jmbi.1998.1791; Sandkvist M, 1999, J BACTERIOL, V181, P3129, DOI 10.1128/JB.181.10.3129-3135.1999; Sandkvist M, 1997, J BACTERIOL, V179, P6994, DOI 10.1128/jb.179.22.6994-7003.1997; SANDKVIST M, 1995, EMBO J, V14, P1664, DOI 10.1002/j.1460-2075.1995.tb07155.x; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	22	86	96	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					333	335		10.1126/science.288.5464.333	http://dx.doi.org/10.1126/science.288.5464.333			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764646				2022-12-28	WOS:000086454300037
J	Bensinger, WI; Deeg, HJ				Bensinger, WI; Deeg, HJ			Blood or marrow?	LANCET			English	Editorial Material							STEM-CELL TRANSPLANTATION; COLONY-STIMULATING FACTOR; ENGRAFTMENT; LEUKEMIA; RISK		Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Washington, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Deeg, HJ (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.							BENSINGER W, 1995, J CLIN ONCOL, V13, P2547, DOI 10.1200/JCO.1995.13.10.2547; Bensinger W, 1999, BLOOD, V94, p368A; BENSINGER WI, 1995, BLOOD, V85, P1655, DOI 10.1182/blood.V85.6.1655.bloodjournal8561655; Blaise D, 2000, J CLIN ONCOL, V18, P537, DOI 10.1200/JCO.2000.18.3.537; Champlin R, 1998, BLOOD, V92, p657A; Elmaagacli AH, 1999, BLOOD, V94, P384, DOI 10.1182/blood.V94.2.384.414k06_384_389; KORBLING M, 1995, BLOOD, V85, P1659, DOI 10.1182/blood.V85.6.1659.bloodjournal8561659; Miflin G, 1997, BONE MARROW TRANSPL, V19, P9, DOI 10.1038/sj.bmt.1700603; SCHMITZ N, 1995, BLOOD, V85, P1666, DOI 10.1182/blood.V85.6.1666.bloodjournal8561666; Schmitz N, 1998, BONE MARROW TRANSPL, V21, P995, DOI 10.1038/sj.bmt.1701234; Solano C, 1998, BONE MARROW TRANSPL, V22, P1129, DOI 10.1038/sj.bmt.1701500; Storek J, 1997, BLOOD, V90, P4705, DOI 10.1182/blood.V90.12.4705.4705_4705_4709; Vigorito AC, 1998, BONE MARROW TRANSPL, V22, P1145, DOI 10.1038/sj.bmt.1701510; WEAVER CH, 1994, BONE MARROW TRANSPL, V13, P411	14	26	27	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1199	1200		10.1016/S0140-6736(00)02080-8	http://dx.doi.org/10.1016/S0140-6736(00)02080-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770296				2022-12-28	WOS:000086448000003
J	Manyala, N; Sidis, Y; DiTusa, JF; Aeppli, G; Young, DP; Fisk, Z				Manyala, N; Sidis, Y; DiTusa, JF; Aeppli, G; Young, DP; Fisk, Z			Magnetoresistance from quantum interference effects in ferromagnets	NATURE			English	Article							SPIN; CHARGE; SEMICONDUCTORS; FE1-XCOXSI; PYROCHLORE; PEROVSKITE; TRANSITION; TL2MN2O7; FESI; MNSI	The desire to maximize the sensitivity of read/write heads (and thus the information density) of magnetic storage devices has stimulated interest in the discovery and design of new magnetic materials exhibiting magnetoresistance. Recent discoveries include the 'colossal' magnetoresistance in the manganites(1-4) and the enhanced magnetoresistance in low-carrier-density ferromagnets(4-6). An important feature of these systems is that the electrons involved in electrical conduction are different from those responsible for the magnetism. The latter are localized and act as scattering sites for the mobile electrons, and it is the field tuning of the scattering strength that ultimately gives rise to the observed magnetoresistance. Here we argue that magnetoresistance can arise by a different mechanism in certain ferromagnets-quantum interference effects rather than simple scattering. The ferromagnets in question are disordered, low-carrier-density magnets where the same electrons are responsible for both the magnetic properties and electrical conduction. The resulting magnetoresistance is positive (that is, the resistance increases in response to an applied magnetic field) and only weakly temperature-dependent below the Curie point.	Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA; NEC, Princeton, NJ 08540 USA; Florida State Univ, Natl High Magnet Field Facil, Tallahassee, FL 32306 USA	Louisiana State University System; Louisiana State University; State University System of Florida; Florida State University	DiTusa, JF (corresponding author), Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA.		Manyala, Ncholu/F-1250-2011	Manyala, Ncholu/0000-0003-2990-4284				Aeppli G., 1992, COMMENTS COND MAT PH, V16, P155; Al'tshuler BL, 1987, SOV SCI REV A, V9, P223; BEILLE J, 1983, SOLID STATE COMMUN, V47, P399, DOI 10.1016/0038-1098(83)90928-6; CAMPBELL IA, 1982, FERROMAGNETIC MATERI, V3, P751; Chernikov MA, 1997, PHYS REV B, V56, P1366, DOI 10.1103/PhysRevB.56.1366; DiTusa JF, 1997, PHYS REV LETT, V78, P2831, DOI 10.1103/PhysRevLett.78.2831; Hwang HY, 1996, PHYS REV LETT, V77, P2041, DOI 10.1103/PhysRevLett.77.2041; ISHIKAWA Y, 1976, SOLID STATE COMMUN, V19, P525, DOI 10.1016/0038-1098(76)90057-0; ISHIMOTO K, 1992, J PHYS SOC JPN, V61, P2503, DOI 10.1143/JPSJ.61.2503; JACCARINO V, 1967, PHYS REV, V160, P476, DOI 10.1103/PhysRev.160.476; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; KADOWAKI K, 1982, J PHYS SOC JPN, V51, P2433, DOI 10.1143/JPSJ.51.2433; KAWARAZAKI S, 1976, J PHYS SOC JPN, V41, P1171, DOI 10.1143/JPSJ.41.1171; LEE PA, 1985, REV MOD PHYS, V57, P287, DOI 10.1103/RevModPhys.57.287; Majumdar P, 1998, NATURE, V395, P479, DOI 10.1038/26703; MILLIS AJ, 1984, PHYS REV B, V30, P6170, DOI 10.1103/PhysRevB.30.6170; Moriya T., 1985, SPIN FLUCTUATIONS IT; Paschen S, 1999, PHYSICA B, V259-61, P864, DOI 10.1016/S0921-4526(98)00970-3; ROSENBAUM TF, 1983, PHYS REV B, V27, P7509, DOI 10.1103/PhysRevB.27.7509; SCHLESINGER Z, 1993, PHYS REV LETT, V71, P1748, DOI 10.1103/PhysRevLett.71.1748; SEARLE CW, 1969, CAN J PHYS, V47, P2703, DOI 10.1139/p69-329; Shimakawa Y, 1996, NATURE, V379, P53, DOI 10.1038/379053a0; Tokura Y, 1996, J APPL PHYS, V79, P5288, DOI 10.1063/1.361353; UEDA K, 1976, SOLID STATE COMMUN, V19, P965, DOI 10.1016/0038-1098(76)90631-1; van der Marel D, 1998, PHYSICA B, V244, P138, DOI 10.1016/S0921-4526(97)00476-6; WERNICK JH, 1972, MATER RES BULL, V7, P1431, DOI 10.1016/0025-5408(72)90180-8; Xu R, 1997, NATURE, V390, P57, DOI 10.1038/36306	28	193	198	4	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					581	+		10.1038/35007030	http://dx.doi.org/10.1038/35007030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766236				2022-12-28	WOS:000086400100047
J	Aronson, RD				Aronson, RD			National interest waiver eligibility for international medical graduates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Immigrat & Natl Lawyers, Minneapolis, MN USA		Aronson, RD (corresponding author), Immigrat & Natl Lawyers, Minneapolis, MN USA.							*COUNC GRAD MED ED, 1997, REC C SECR HLTH HUM; *I MED, 1996, NAT PHYS WORKF; YANNI PR, 1998, AILA IMMIGRATION NAT, V2; 1991, FED REG, V56, P54928	4	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1747	1747		10.1001/jama.283.13.1747	http://dx.doi.org/10.1001/jama.283.13.1747			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BK	10755505	hybrid			2022-12-28	WOS:000086119300039
J	Perutz, M				Perutz, M			Paul Sigler (1934-2000) - Obituary	CELL			English	Biographical-Item									MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Perutz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.								0	0	0	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 31	2000	101	1					23	24		10.1016/S0092-8674(02)71111-2	http://dx.doi.org/10.1016/S0092-8674(02)71111-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778852	Bronze			2022-12-28	WOS:000086249900004
J	Bova, B				Bova, B			Eternal verities, eternal questions	NATURE			English	Editorial Material									Natl Space Soc, Washington, DC 20003 USA		Bova, B (corresponding author), Natl Space Soc, Washington, DC 20003 USA.								0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					439	439		10.1038/35006520	http://dx.doi.org/10.1038/35006520			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761892	Bronze			2022-12-28	WOS:000086257700023
J	Sackett, CA; Kielpinski, D; King, BE; Langer, C; Meyer, V; Myatt, CJ; Rowe, M; Turchette, QA; Itano, WM; Wineland, DJ; Monroe, C				Sackett, CA; Kielpinski, D; King, BE; Langer, C; Meyer, V; Myatt, CJ; Rowe, M; Turchette, QA; Itano, WM; Wineland, DJ; Monroe, C			Experimental entanglement of four particles	NATURE			English	Article							COLD TRAPPED IONS; QUANTUM; GENERATION; STATES; PAIRS	Quantum mechanics allows for many-particle wavefunctions that cannot be factorized into a product of single-particle wavefunctions, even when the constituent particles are entirely distinct Such 'entangled' states explicitly demonstrate the non-local character of quantum theory(1), having potential applications in high-precision spectroscopy(2), quantum communication, cryptography and computation(3). In general, the more particles that can be entangled, the more dearly nonclassical effects are exhibited(4,5)-and the more useful the states are for quantum applications. Here we implement a recently proposed entanglement technique(6) to generate entangled states of two and four trapped ions. Coupling between the ions is provided through their collective motional degrees of freedom, but actual motional excitation is minimized. Entanglement is achieved using a single laser pulse, and the method can in principle be applied to any number of ions.	Natl Inst Stand & Technol, Div Time & Frequency, Boulder, CO 80303 USA; NIST, Atom Phys Div, Gaithersburg, MD 20899 USA; Res Electroopt, Boulder, CO 80301 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA	Monroe, C (corresponding author), Natl Inst Stand & Technol, Div Time & Frequency, Boulder, CO 80303 USA.	monroe@boulder.nist.gov	Itano, Wayne/AAV-8781-2020; Sackett, Charles/AAD-1452-2019; Monroe, Christopher R/G-8105-2011	Sackett, Charles/0000-0001-6741-0571; Kielpinski, David/0000-0002-2816-6892				Bell J. S., 1987, SPEAKABLE UNSPEAKABL; Bennett CH, 1996, PHYS REV LETT, V76, P722, DOI 10.1103/PhysRevLett.76.722; Bollinger JJ, 1996, PHYS REV A, V54, pR4649, DOI 10.1103/PhysRevA.54.R4649; Bouwmeester D, 1999, PHYS REV LETT, V82, P1345, DOI 10.1103/PhysRevLett.82.1345; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; EBERHARD PH, 1993, PHYS REV A, V47, pR747, DOI 10.1103/PhysRevA.47.R747; Fitzgerald R, 2000, PHYS TODAY, V53, P20, DOI 10.1063/1.882932; Grover LK, 1997, PHYS REV LETT, V79, P325, DOI 10.1103/PhysRevLett.79.325; Hagley E, 1997, PHYS REV LETT, V79, P1, DOI 10.1103/PhysRevLett.79.1; James DFV, 1998, APPL PHYS B-LASERS O, V66, P181, DOI 10.1007/s003400050373; King BE, 1998, PHYS REV LETT, V81, P1525, DOI 10.1103/PhysRevLett.81.1525; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Law CK, 1997, J MOD OPTIC, V44, P2067, DOI 10.1080/095003497152357; Lewenstein M, 1998, PHYS REV LETT, V80, P2261, DOI 10.1103/PhysRevLett.80.2261; LO HK, 1997, INTRO QUANTUM COMPUT; MAILBURN G, 1999, QUANTPH9908037; MERMIN ND, 1990, PHYS REV LETT, V65, P1838, DOI 10.1103/PhysRevLett.65.1838; Molmer K, 1999, PHYS REV LETT, V82, P1835, DOI 10.1103/PhysRevLett.82.1835; MOLMER K, 2000, QUANTPH0002024; Nagerl HC, 1999, PHYS REV A, V60, P145, DOI 10.1103/PhysRevA.60.145; Preskill J, 1999, PHYS TODAY, V52, P24, DOI 10.1063/1.882692; Shor PW, 1997, SIAM J COMPUT, V26, P1484, DOI [10.1137/S0097539795293172, 10.1137/S0036144598347011]; TITTLE W, 1998, PHYS REV LETT, V81, P3565; Turchette QA, 1998, PHYS REV LETT, V81, P3631, DOI 10.1103/PhysRevLett.81.3631; TURCHETTE QA, 2000, QUANTPH0002040; Vaidman L, 1996, PHYS REV A, V54, pR1745, DOI 10.1103/PhysRevA.54.R1745; Vedral V, 1997, PHYS REV LETT, V78, P2275, DOI 10.1103/PhysRevLett.78.2275; Wootters WK, 1998, PHYS REV LETT, V80, P2245, DOI 10.1103/PhysRevLett.80.2245	30	1158	1184	4	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					256	259		10.1038/35005011	http://dx.doi.org/10.1038/35005011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749201				2022-12-28	WOS:000086022200039
J	Fuhrer, MS; Nygard, J; Shih, L; Forero, M; Yoon, YG; Mazzoni, MSC; Choi, HJ; Ihm, J; Louie, SG; Zettl, A; McEuen, PL				Fuhrer, MS; Nygard, J; Shih, L; Forero, M; Yoon, YG; Mazzoni, MSC; Choi, HJ; Ihm, J; Louie, SG; Zettl, A; McEuen, PL			Crossed nanotube junctions	SCIENCE			English	Article							CARBON NANOTUBES; SINGLE-WALL	Junctions consisting of two crossed single-walled carbon nanotubes were fabricated with electrical contacts at each end of each nanotube. The individual nanotubes were identified as metallic (M) or semiconducting (S), based on their two-terminal conductances; MM, MS, and SS four-terminal devices were studied. The MM and SS junctions had high conductances, on the order of 0.1 e(2)/h (where e is the electron charge and h is Planck's constant). For an MS junction, the semiconducting nanotube was depleted at the junction by the metallic nanotube, forming a rectifying Schottky barrier. We used two- and three-terminal experiments to fully characterize this junction.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Seoul Natl Univ, Dept Phys, Seoul 151742, South Korea; Seoul Natl Univ, Ctr Theoret Phys, Seoul 151742, South Korea	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Seoul National University (SNU); Seoul National University (SNU)	McEuen, PL (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	mceuen@socrates.berkeley.edu	Nygård, Jesper/F-5113-2014; Dee, Chang Fu/G-4842-2010; Zettl, Alex K/O-4925-2016; Mazzoni, Mario S. C./C-5137-2018; Choi, Hyoung Joon/N-8933-2015; Fuhrer, Michael S/E-7634-2010; Yoon, Young-Gui/C-2978-2008	Nygård, Jesper/0000-0002-4639-5314; Dee, Chang Fu/0000-0003-1015-9181; Zettl, Alex K/0000-0001-6330-136X; Mazzoni, Mario S. C./0000-0001-5897-6936; Choi, Hyoung Joon/0000-0001-8565-8597; Fuhrer, Michael S/0000-0001-6183-2773; Yoon, Young-Gui/0000-0002-1071-8628; Forero-Shelton, Manu/0000-0002-7989-0311				Bockrath M, 1999, NATURE, V397, P598, DOI 10.1038/17569; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Chico L, 1996, PHYS REV LETT, V76, P971, DOI 10.1103/PhysRevLett.76.971; Collins PG, 1997, SCIENCE, V278, P100, DOI 10.1126/science.278.5335.100; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Hertel T, 1998, PHYS REV B, V58, P13870, DOI 10.1103/PhysRevB.58.13870; LAMBIN P, 1995, CHEM PHYS LETT, V245, P85, DOI 10.1016/0009-2614(95)00961-3; LANDAUER R, 1957, IBM J RES DEV, V1, P223, DOI 10.1147/rd.13.0223; Leonard F, 1999, PHYS REV LETT, V83, P5174, DOI 10.1103/PhysRevLett.83.5174; Liu J, 1999, CHEM PHYS LETT, V303, P125, DOI 10.1016/S0009-2614(99)00209-2; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; ODINTSOV AA, 1999, PREPRINT; Saito R, 1996, PHYS REV B, V53, P2044, DOI 10.1103/PhysRevB.53.2044; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	17	1075	1116	2	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					494	497		10.1126/science.288.5465.494	http://dx.doi.org/10.1126/science.288.5465.494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775104				2022-12-28	WOS:000086626000039
J	Lee, TH; Goldman, L				Lee, TH; Goldman, L			Primary care: Evaluation of the patient with acute chest pain.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; CARDIAC TROPONIN-T; ACUTE CORONARY SYNDROMES; ISCHEMIC-HEART-DISEASE; LOW-RISK PATIENTS; SHORT-STAY UNIT; PREDICTIVE INSTRUMENT; EMERGENCY ROOM; COST-EFFECTIVENESS; CLINICAL-TRIAL		Partners Community Healthcare, Boston, MA 02199 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco	Lee, TH (corresponding author), Partners Community Healthcare, Prudential Tower Suite 1150,800 Boylston St, Boston, MA 02199 USA.	thlee@partners.org						ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; ANTMAN EM, 1995, JAMA-J AM MED ASSOC, V273, P1279, DOI 10.1001/jama.273.16.1279; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; Cohon PJ, 1998, AM J CARDIOL, V81, P545, DOI 10.1016/S0002-9149(97)00987-9; COREY GA, 1987, J FAM PRACTICE, V25, P127; Farkouh ME, 1998, NEW ENGL J MED, V339, P1882, DOI 10.1056/NEJM199812243392603; Garber AM, 1999, ANN INTERN MED, V130, P719, DOI 10.7326/0003-4819-130-9-199905040-00003; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GASPOZ JM, 1991, AM J CARDIOL, V68, P145, DOI 10.1016/0002-9149(91)90734-3; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Goldman L, 1996, NEW ENGL J MED, V334, P1498, DOI 10.1056/NEJM199606063342303; Gomez MA, 1996, J AM COLL CARDIOL, V28, P25, DOI 10.1016/0735-1097(96)00093-9; Goyal RK, 1996, ANN INTERN MED, V124, P1008, DOI 10.7326/0003-4819-124-11-199606010-00010; GRAFF L, 1995, AM J CARDIOL, V76, P1036, DOI 10.1016/S0002-9149(99)80291-4; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Kontos MC, 1999, CIRCULATION, V99, P2073, DOI 10.1161/01.CIR.99.16.2073; Kuntz KM, 1999, ANN INTERN MED, V130, P709, DOI 10.7326/0003-4819-130-9-199905040-00002; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; Lewis WR, 1999, J AM COLL CARDIOL, V33, P1843, DOI 10.1016/S0735-1097(99)00098-4; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; Luscher MS, 1997, CIRCULATION, V96, P2578, DOI 10.1161/01.CIR.96.8.2578; National Heart Attack Alert Program, 1993, NIH PUBLICATION, V93-3278; Newby LK, 1998, CIRCULATION, V98, P1853, DOI 10.1161/01.CIR.98.18.1853; Nichol G, 1997, ANN INTERN MED, V127, P996, DOI 10.7326/0003-4819-127-11-199712010-00009; Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; *PLAT REC INH ISCH, 1998, NEW ENGL J MED, V339, P415; Polanczyk CA, 1999, AM J CARDIOL, V83, P1175, DOI 10.1016/S0002-9149(99)00055-7; Polanczyk CA, 1998, AM J CARDIOL, V81, P288, DOI 10.1016/S0002-9149(97)00897-7; Polanczyk CA, 1998, J AM COLL CARDIOL, V32, P8, DOI 10.1016/S0735-1097(98)00176-4; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; Pretre R, 1997, LANCET, V349, P1461, DOI 10.1016/S0140-6736(96)09372-5; PULCO PR, 1994, NEW ENGL J MED, V331, P561; Roberts RR, 1997, JAMA-J AM MED ASSOC, V278, P1670, DOI 10.1001/jama.278.20.1670; RUSNAK RA, 1989, ANN EMERG MED, V18, P1029, DOI 10.1016/S0196-0644(89)80924-2; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002; SMITH EE, 1995, ANN EMERG MED, V25, P274, DOI 10.1016/S0196-0644(95)70342-X; Tosteson ANA, 1996, CIRCULATION, V94, P143, DOI 10.1161/01.CIR.94.2.143; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; Zimmerman J, 1999, CIRCULATION, V99, P1671, DOI 10.1161/01.CIR.99.13.1671	48	317	333	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 20	2000	342	16					1187	1195		10.1056/NEJM200004203421607	http://dx.doi.org/10.1056/NEJM200004203421607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305DG	10770985				2022-12-28	WOS:000086523700007
J	Trainer, PJ; Drake, WM; Katznelson, L; Freda, PU; Herman-Bonert, V; van der Lely, AJ; Dimaraki, EV; Stewart, PM; Friend, KE; Vance, ML; Besser, GM; Scarlett, JA; Thorner, MO; Parkinson, C; Klibanski, A; Powell, JS; Barkan, AL; Sheppard, MC; Maldonado, M; Rose, DR; Clemmons, DR; Johannson, G; Bengtsson, BA; Stavrou, S; Kleinberg, DL; Cook, DM; Phillips, LS; Bidlingmaier, M; Strasburger, CJ; Hackett, S; Zib, K; Bennett, WF; Davis, RJ				Trainer, PJ; Drake, WM; Katznelson, L; Freda, PU; Herman-Bonert, V; van der Lely, AJ; Dimaraki, EV; Stewart, PM; Friend, KE; Vance, ML; Besser, GM; Scarlett, JA; Thorner, MO; Parkinson, C; Klibanski, A; Powell, JS; Barkan, AL; Sheppard, MC; Maldonado, M; Rose, DR; Clemmons, DR; Johannson, G; Bengtsson, BA; Stavrou, S; Kleinberg, DL; Cook, DM; Phillips, LS; Bidlingmaier, M; Strasburger, CJ; Hackett, S; Zib, K; Bennett, WF; Davis, RJ			Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM TREATMENT; TRANSSPHENOIDAL SURGERY; FOLLOW-UP; OCTREOTIDE; THERAPY; CABERGOLINE	Background: Patients with acromegaly are treated with surgery, radiation therapy, and drugs to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have adverse effects. Pegvisomant is a genetically engineered growth hormone-receptor antagonist that blocks the action of growth hormone. Methods: We conducted a 12-week, randomized, double-blind study of three different daily doses of pegvisomant (10 mg, 15 mg, and 20 mg) and placebo, given subcutaneously, in 112 patients with acromegaly. Results: The mean (+/-SD) serum concentration of insulin-like growth factor I (IGF-I) decreased from base line by 4.0+/-16.8 percent in the placebo group, 26.7+/-27.9 percent in the group that received 10 mg of pegvisomant per day, 50.1+/-26.7 percent in the group that received 15 mg of pegvisomant per day, and 62.5+/-21.3 percent in the group that received 20 mg of pegvisomant per day (P<0.001 for the comparison of each pegvisomant group with placebo), and the concentrations became normal in 10 percent, 54 percent, 81 percent, and 89 percent of patients, respectively (P<0.001 for each comparison with placebo). Among patients treated with 15 mg or 20 mg of pegvisomant per day, there were significant decreases in ring size, soft-tissue swelling, the degree of excessive perspiration, and fatigue. The score for total symptoms and signs of acromegaly decreased significantly in all groups receiving pegvisomant (P less/equal 0.05). The incidence of adverse effects was similar in all groups. Conclusions: On the basis of these preliminary results, treatment of patients who have acromegaly with a growth hormone-receptor antagonist results in a reduction in serum IGF-I concentrations and in clinical improvement. (N Engl J Med 2000;342:1171-7.) (C) 2000, Massachusetts Medical Society.	Christie Univ Hosp, Manchester, Lancs, England; Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England; St Bartholomews Hosp, London, England; Massachusetts Gen Hosp, Boston, MA 02114 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Acad Hosp Dijkzigt, NL-3000 DR Rotterdam, Netherlands; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Univ Birmingham, Birmingham, W Midlands, England; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA; Sensus Drug Dev, Austin, TX 78701 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; NYU, Med Ctr, New York, NY 10016 USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Emory Univ, Sch Med, Atlanta, GA USA; Univ Munich, Klinikum Innenstadt, D-8000 Munich, Germany; Statworks, Chapel Hill, NC USA	Christie NHS Foundation Trust; Christie Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; Queen Mary University London; Harvard University; Massachusetts General Hospital; Columbia University; Cedars Sinai Medical Center; Erasmus University Rotterdam; Erasmus MC; University of Michigan System; University of Michigan; University of Birmingham; University of Texas System; UTMD Anderson Cancer Center; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Sahlgrenska University Hospital; New York University; Oregon Health & Science University; Emory University; University of Munich	Scarlett, JA (corresponding author), Sensus Drug Dev, 98 San Jacinto Blvd,Suite 430, Austin, TX 78701 USA.		Davis, Roger/GWR-3631-2022	Davis, Roger/0000-0002-4926-3413; Johannsson, Gudmundur/0000-0003-3484-8440; Katznelson, Laurence/0000-0001-8115-5714; Trainer, Peter/0000-0003-0146-3835				Abs R, 1998, J CLIN ENDOCR METAB, V83, P374, DOI 10.1210/jc.83.2.374; Ahmed S, 1999, CLIN ENDOCRINOL, V50, P561; BARKAN AL, 1989, ENDOCRIN METAB CLIN, V18, P277, DOI 10.1016/S0889-8529(18)30372-4; Barkan AL, 1997, J CLIN ENDOCR METAB, V82, P3187, DOI 10.1210/jc.82.10.3187; Caron P, 1997, J CLIN ENDOCR METAB, V82, P18, DOI 10.1210/jc.82.1.18; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; Clark R, 1996, J BIOL CHEM, V271, P21969, DOI 10.1074/jbc.271.36.21969; Cozzi R, 1998, EUR J ENDOCRINOL, V139, P516, DOI 10.1530/eje.0.1390516; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; EZZAT S, 1995, J ENDOCRINOL INVEST, V18, P364, DOI 10.1007/BF03347839; Flogstad AK, 1997, J CLIN ENDOCR METAB, V82, P23, DOI 10.1210/jc.82.1.23; FRANCIS GE, 1992, IN VIVO PATHWAYS DEG, P235; Freda PU, 1998, J NEUROSURG, V89, P353, DOI 10.3171/jns.1998.89.3.0353; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Goffin V, 1999, ENDOCRINOLOGY, V140, P3853, DOI 10.1210/en.140.8.3853; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; Lancranjan I, 1996, METABOLISM, V45, P67, DOI 10.1016/S0026-0495(96)90087-6; Lancranjan I, 1999, Pituitary, V1, P105; LUNDIN P, 1992, J COMPUT ASSIST TOMO, V16, P519, DOI 10.1097/00004728-199207000-00004; NEWMAN CB, 1995, J CLIN ENDOCR METAB, V80, P2768, DOI 10.1210/jc.80.9.2768; NEWMAN CB, 1995, J CLIN ENDOCR METAB, V80, P3238; OLSEN K, 1997, POLYETHYLENE GLYCOL, P170; Sheaves R, 1996, CLIN ENDOCRINOL, V45, P407, DOI 10.1046/j.1365-2265.1996.8370847.x; Swearingen B, 1998, J CLIN ENDOCR METAB, V83, P3419, DOI 10.1210/jc.83.10.3419; VANCE ML, 1991, ARCH INTERN MED, V151, P1573; vanderLely AJ, 1997, J CLIN ENDOCR METAB, V82, P3185, DOI 10.1210/jc.82.10.3185; Zalipsky S., 1992, POLYETHYLENE GLYCOL, P347	27	583	609	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	2000	342	16					1171	1177		10.1056/NEJM200004203421604	http://dx.doi.org/10.1056/NEJM200004203421604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305DG	10770982	Bronze			2022-12-28	WOS:000086523700004
J	Ryder, OA; McLaren, A; Brenner, S; Zhang, YP; Benirschke, K				Ryder, OA; McLaren, A; Brenner, S; Zhang, YP; Benirschke, K			Ecology - DNA banks for endangered animal species	SCIENCE			English	Article							FLORIDA PANTHER; GENETIC DIVERSITY; IDENTIFICATION; CONSERVATION; WHALE		Zool Soc San Diego, Ctr Reprod Endangered Species, San Diego, CA 92112 USA; Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Chinese Acad Sci, Kunming Inst Zool, Key Lab Cellular & Mol Evolut, Kunming, Peoples R China; Mol Sci Lab, Berkeley, CA 94720 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Zoological Society of San Diego; University of Cambridge; Chinese Academy of Sciences; Kunming Institute of Zoology; The Molecular Sciences Institute; University of California System; University of California San Diego	Ryder, OA (corresponding author), Zool Soc San Diego, Ctr Reprod Endangered Species, San Diego, CA 92112 USA.							Amato George, 1998, P177; Baker CS, 1996, MOL ECOL, V5, P671, DOI 10.1111/j.1365-294X.1996.tb00362.x; BENFORD G, 1992, P NATL ACAD SCI USA, V89, P11098, DOI 10.1073/pnas.89.22.11098; BOWEN BW, 1994, EVOLUTION, V48, P1820, DOI 10.1111/j.1558-5646.1994.tb02217.x; Cipriano F, 1999, NATURE, V397, P307, DOI 10.1038/16823; Gagneux P, 1999, P NATL ACAD SCI USA, V96, P5077, DOI 10.1073/pnas.96.9.5077; GEYER CJ, 1993, MOL BIOL EVOL, V10, P571; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; HEDRICK PW, 1995, CONSERV BIOL, V9, P996, DOI 10.1046/j.1523-1739.1995.9050988.x-i1; *IUCN, 1997, LIST THREAT AN; JAMA M, UNPUB; Kirchner JW, 2000, NATURE, V404, P177, DOI 10.1038/35004564; Mayer WE, 1998, HEREDITY, V80, P702, DOI 10.1046/j.1365-2540.1998.00347.x; MENOTTIRAYMOND M, 1993, P NATL ACAD SCI USA, V90, P3172, DOI 10.1073/pnas.90.8.3172; OBRIEN SJ, 1990, NATL GEOGR RES, V6, P485; Palumbi SR, 1998, J HERED, V89, P459; RALLS K, IN PRESS ANIM CONSER; ROELKE ME, 1993, CURR BIOL, V3, P340, DOI 10.1016/0960-9822(93)90197-V; Ruvolo M, 1997, ANNU REV ANTHROPOL, V26, P515, DOI 10.1146/annurev.anthro.26.1.515; RYDER OA, 1988, NATURE, V331, P396, DOI 10.1038/331396a0; Ryder OA, 1997, ZOO BIOL, V16, P295, DOI 10.1002/(SICI)1098-2361(1997)16:4<295::AID-ZOO1>3.0.CO;2-5; SAARENMAA H, 1999, 34 EUR ENV AG; Shimamura M, 1997, NATURE, V388, P666, DOI 10.1038/41759; Zhang YP, 1997, SCI CHINA SER C, V40, P210, DOI 10.1007/BF02882050	24	47	53	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					275	+		10.1126/science.288.5464.275	http://dx.doi.org/10.1126/science.288.5464.275			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10777408				2022-12-28	WOS:000086454300022
J	Brennan, TA				Brennan, TA			The Institute of Medicine Report on medical errors - Could it do harm?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY; EVENTS		Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							Ashton CM, 1999, MED CARE, V37, P798, DOI 10.1097/00005650-199908000-00009; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BOOTH B, 2000, AM MED NEWS     0124, P14; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 1999, JAMA-J AM MED ASSOC, V282, P381, DOI 10.1001/jama.282.4.381; *CAL MED ASS CAL H, 1977, REP MED INS FEAS STU; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; Kohn KT, 2000, ERR IS HUMAN BUILDIN; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; MILAMED DR, 1994, ANN SURG, V219, P94, DOI 10.1097/00000658-199401000-00015; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; Peterson L M, 1990, J Clin Ethics, V1, P207; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; Weiler PC, 1993, MEASURE MALPRACTICE	14	213	218	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1123	1125		10.1056/NEJM200004133421510	http://dx.doi.org/10.1056/NEJM200004133421510			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10760315				2022-12-28	WOS:000086406700010
J	Barton, JH				Barton, JH			Financing of vaccines	LANCET			English	Editorial Material									Stanford Univ, Sch Law, Stanford, CA 94305 USA	Stanford University	Barton, JH (corresponding author), Stanford Univ, Sch Law, Stanford, CA 94305 USA.							Bloom BR, 1998, NAT MED, V4, P480, DOI 10.1038/nm0598supp-480; *CONS GROUP INT AG, 1998, CONS GROUP INT AGR R; *GLOB PROGR VACC, 1996, STAT WORLDS VACC IMM; Keohane Robert O., 1996, I ENV AID PITFALLS P; Mahoney RT, 1999, VACCINE, V17, P646, DOI 10.1016/S0264-410X(98)00246-1; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; MURASKIN W, 1995, WAR HEPATITIS B; SACHS J, 1999, ECONOMIST       0814, P17; *WORLD BANK, 1998, HLTH NUTR POP SECT S, P61; *WORLD BANK, 1993, WORLD DEV REP	10	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1269	1270		10.1016/S0140-6736(00)02100-0	http://dx.doi.org/10.1016/S0140-6736(00)02100-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770320				2022-12-28	WOS:000086448000041
J	Rolla, G; Brussino, L; Carra, R; Garbella, E; Bucca, C				Rolla, G; Brussino, L; Carra, R; Garbella, E; Bucca, C			Hypertension and ascorbic acid	LANCET			English	Letter							ENDOTHELIUM-DEPENDENT VASODILATION; NITRIC-OXIDE		Univ Turin, Dipartimento Sci Biomed & Oncol Umana, I-10126 Turin, Italy	University of Turin	Rolla, G (corresponding author), Univ Turin, Dipartimento Sci Biomed & Oncol Umana, Via Genova 3, I-10126 Turin, Italy.		Rolla, Giovanni/C-9901-2009; Bucca, Caterina/C-9886-2009; brussino, luisa/J-2486-2012	Rolla, Giovanni/0000-0001-5997-7172; Bucca, Caterina/0000-0002-9941-9236; brussino, luisa/0000-0001-7249-7616				Duffy SJ, 1999, LANCET, V354, P2048, DOI 10.1016/S0140-6736(99)04410-4; Hornig B, 1998, CIRCULATION, V97, P363; SCHILLING J, 1994, EUR RESPIR J, V7, P467, DOI 10.1183/09031936.94.07030467; Taddei S, 1998, CIRCULATION, V97, P2222, DOI 10.1161/01.CIR.97.22.2222; Ting HH, 1997, CIRCULATION, V95, P2617, DOI 10.1161/01.CIR.95.12.2617	5	5	5	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1271	1272		10.1016/S0140-6736(05)74698-5	http://dx.doi.org/10.1016/S0140-6736(05)74698-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770322				2022-12-28	WOS:000086448000043
J	Weitoft, GR; Haglund, B; Rosen, M				Weitoft, GR; Haglund, B; Rosen, M			Mortality among lone mothers in Sweden: a population study	LANCET			English	Article							EMPLOYMENT STATUS; HEALTH; INEQUALITIES	Background An increasing number of lone mothers are experiencing financial and health disadvantages. Our aim was to assess mortality among lone mothers compared with mothers with partners. Methods In this population-based study, overall and cause-specific mortality, between 1991 and 1995, was estimated for 90 111 lone mothers and 622 368 mothers with partners from data collected in the Swedish Population and Housing Census 1990. We estimated relative risks by Poisson regression, adjusted for socioeconomic status, and, to handle health-selection effects, we adjusted for previous inpatient history from 1987 to 1990. Findings Lone mothers showed an almost 70% higher premature risk of death than mothers with partners. The excess risk remained significantly increased (relative risk 1.2 [95% CI 1.1-1.4]) after adjustments for socioeconomic status and previous severe somatic and psychiatric inpatient history. Increased mortality was especially pronounced for suicides (2.2 [1.5-3.1]), violence (3.0 [0.9-10.6]), and alcohol-related mortality (2.4 [1.4-4.1]) among mothers who were without a partner in 1985 and in 1990. Interpretation The increase of lone mothers in society shows financial, social, and health disadvantages. Nevertheless, the increased mortality risk of lone mothers seems to be partly independent of socioeconomic status and health selection into lone motherhood. For long-term lone mothers the risks may be underestimated when adjusting for selection bias by taking hospital discharge history into account, since these events may be part of the consequences of the stress of lone motherhood.	Natl Board Hlth & Welf, Ctr Epidemiol, S-10630 Stockholm, Sweden; Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden	National Board of Health & Welfare; Umea University	Weitoft, GR (corresponding author), Natl Board Hlth & Welf, Ctr Epidemiol, S-10630 Stockholm, Sweden.	gunilla.ringback@sos.se						Benzeval M, 1998, SOC SCI MED, V46, P1337, DOI 10.1016/S0277-9536(97)10083-1; BERKMAN PL, 1969, J HEALTH SOC BEHAV, V10, P323, DOI 10.2307/2948439; Bradshaw J., 1991, 6 DEP SOC SEC; Burstrom B, 1999, J EPIDEMIOL COMMUN H, V53, P750, DOI 10.1136/jech.53.12.750; Elstad JI, 1996, SOC SCI MED, V42, P75, DOI 10.1016/0277-9536(95)00078-X; FORSSEN A, 1991, ALLMANMEDICIN, V12, P72; GAHLER M, 1998, THESIS SWEDISH I SOC; KOTLER P, 1989, AM J PUBLIC HEALTH, V79, P607, DOI 10.2105/AJPH.79.5.607; Lynch JW, 1997, NEW ENGL J MED, V337, P1889, DOI 10.1056/NEJM199712253372606; MACINTYRE S, 1992, SOC SCI MED, V35, P453, DOI 10.1016/0277-9536(92)90338-Q; Macran S, 1996, SOC SCI MED, V42, P1203, DOI 10.1016/0277-9536(95)00432-7; MARMOT MG, 1984, LANCET, V1, P1003; MARTIKAINEN P, 1995, SOC SCI MED, V40, P199, DOI 10.1016/0277-9536(94)E0065-Z; NYMAN H, 1998, THESIS GOTEBORG U GO; POPEY J, 1990, J SOC POLICY, V19, P499; Power C, 1997, LANCET, V350, P1584, DOI 10.1016/S0140-6736(97)07474-6; Shouls S, 1999, Popul Trends, P41; SOGAARD AJ, 1994, INT J EPIDEMIOL, V23, P82, DOI 10.1093/ije/23.1.82; *STAT SWED, 1992, BE43SM9201 STAT SWED; *STAT SWED, 1995, MEDD SAM FRAG 1982, V4; VAGERO D, 1994, LANCET, V343, P1224, DOI 10.1016/S0140-6736(94)92432-5; VOGEL J, 1997, LEVNADSFORHALLANDEN; Whitehead M, 2000, SOC SCI MED, V50, P255, DOI 10.1016/S0277-9536(99)00280-4; 1998, REPORT INDEPENDENT I	24	61	61	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2000	355	9211					1215	1219		10.1016/S0140-6736(00)02087-0	http://dx.doi.org/10.1016/S0140-6736(00)02087-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303VX	10770303				2022-12-28	WOS:000086448000010
J	Milligan, G				Milligan, G			Neurobiology - Receptors as kissing cousins	SCIENCE			English	Editorial Material							PROTEIN		Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg,Univ Ave, Glasgow G12 8QQ, Lanark, Scotland.		Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	15	18	20	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					65	+		10.1126/science.288.5463.65	http://dx.doi.org/10.1126/science.288.5463.65			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10766637				2022-12-28	WOS:000086387700030
J	Schwartz, MW; Woods, SC; Porte, D; Seeley, RJ; Baskin, DG				Schwartz, MW; Woods, SC; Porte, D; Seeley, RJ; Baskin, DG			Central nervous system control of food intake	NATURE			English	Review							PROOPIOMELANOCORTIN MESSENGER-RNA; HYPOTHALAMIC NEUROPEPTIDE-Y; AGOUTI-RELATED PROTEIN; LEPTIN RECEPTOR; BODY-WEIGHT; MELANOCORTIN RECEPTORS; GENE-EXPRESSION; OB/OB MICE; IN-VIVO; PARAVENTRICULAR NUCLEUS	New information regarding neuronal circuits that control food intake and their hormonal regulation has extended our understanding of energy homeostasis, the process whereby energy intake is matched to energy expenditure over time. The profound obesity that results in rodents (and in the rare human case as well) from mutation of key signalling molecules involved in this regulatory system highlights its Importance to human health, Although each new signalling pathway discovered in the hypothalamus is a potential target for drug development in the treatment of obesity the growing number of such signalling molecules indicates that food intake is controlled by a highly complex process. Se better understand how energy homeostasis can be achieved, we describe a model that delineates the roles of individual hormonal and neuropeptide signalling pathways in the control of food Intake and the means by which obesity can arise from Inherited or acquired defects in their function.	Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Biol Struct, Seattle, WA 98104 USA; Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98104 USA; Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45267 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University System of Ohio; University of Cincinnati	Schwartz, MW (corresponding author), Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA.		Schwartz, Michael W/H-9950-2012; sheng, jian/E-9474-2012	Seeley, Randy/0000-0002-3721-5625				BAGDADE JD, 1967, J CLIN INVEST, V46, P1549, DOI 10.1172/JCI105646; BASKIN DG, 1994, ENDOCRINOLOGY, V134, P1952, DOI 10.1210/en.134.4.1952; Baskin DG, 1999, DIABETES, V48, P828, DOI 10.2337/diabetes.48.4.828; BASKIN DG, 1988, TRENDS NEUROSCI, V11, P107, DOI 10.1016/0166-2236(88)90155-5; BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; BILLINGTON CJ, 1991, AM J PHYSIOL, V260, pR321, DOI 10.1152/ajpregu.1991.260.2.R321; Bjorbaek C, 1998, ENDOCRINOLOGY, V139, P3485, DOI 10.1210/en.139.8.3485; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; BRAY GA, 1990, FRONT NEUROENDOCRIN, V11, P128; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; BRONSTEIN DM, 1992, BRAIN RES, V587, P269, DOI 10.1016/0006-8993(92)91007-2; Brunetti L, 1999, EUR J PHARMACOL, V372, P237, DOI 10.1016/S0014-2999(99)00255-1; Calapi G, 1999, J CLIN INVEST, V104, P975, DOI 10.1172/JCI5867; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; Dawson R, 1997, AM J PHYSIOL-ENDOC M, V273, pE202, DOI 10.1152/ajpendo.1997.273.1.E202; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; EDHOLM OG, 1977, J HUM NUTR, V31, P413; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Emond M, 1999, AM J PHYSIOL-REG I, V276, pR1545, DOI 10.1152/ajpregu.1999.276.5.R1545; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; FIGLEWICZ DP, 1986, AM J PHYSIOL, V250, pR856, DOI 10.1152/ajpregu.1986.250.5.R856; Figlewicz DP, 1999, EPILEPSY RES, V37, P203, DOI 10.1016/S0920-1211(99)00072-8; Flynn MC, 1998, AM J PHYSIOL-REG I, V275, pR174, DOI 10.1152/ajpregu.1998.275.1.R174; Friedman MI, 1999, AM J PHYSIOL-REG I, V276, pR1046, DOI 10.1152/ajpregu.1999.276.4.R1046; GIBBS J, 1973, J COMP PHYSIOL PSYCH, V84, P488, DOI 10.1037/h0034870; GRILL HJ, 1988, AM J PHYSIOL, V254, pR853, DOI 10.1152/ajpregu.1988.254.6.R853; Grill HJ, 1998, J NEUROSCI, V18, P10128; Hagan JJ, 1999, P NATL ACAD SCI USA, V96, P10911, DOI 10.1073/pnas.96.19.10911; Hagan MM, 1999, J NEUROSCI, V19, P2362; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; HARRIS RBS, 1986, J NUTR, V116, P2536, DOI 10.1093/jn/116.12.2536; Hathout EH, 1999, J CLIN ENDOCR METAB, V84, P4545, DOI 10.1210/jc.84.12.4545; Havel PJ, 1998, AM J PHYSIOL-REG I, V274, pR1482, DOI 10.1152/ajpregu.1998.274.5.R1482; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; KENNEDY GC, 1953, P ROY SOC LOND B BIO, V140, P579; KOW LM, 1991, PHARMACOL BIOCHEM BE, V38, P359, DOI 10.1016/0091-3057(91)90291-9; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; LEEDOM LJ, 1989, PSYCHONEUROENDOCRINO, V14, P275, DOI 10.1016/0306-4530(89)90030-9; LEIBOWITZ SF, 1991, PEPTIDES, V12, P1251, DOI 10.1016/0196-9781(91)90203-2; Leibowitz SF, 1998, BIOL PSYCHIAT, V44, P851, DOI 10.1016/S0006-3223(98)00186-3; LEIBOWITZ SF, 1984, PHARMACOL BIOCHEM BE, V21, P801, DOI 10.1016/S0091-3057(84)80022-2; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; MAGA, IN PRESS AM J PHYSL; Mantzoros CS, 1998, DIABETES, V47, P230, DOI 10.2337/diabetes.47.2.230; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Matson CA, 1999, AM J PHYSIOL-REG I, V276, pR1038, DOI 10.1152/ajpregu.1999.276.4.R1038; Mercer JG, 1998, ENDOCRINOLOGY, V139, P29, DOI 10.1210/en.139.1.29; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MORAN TP, 1994, HUM-COMPUT INTERACT, V9, P1, DOI 10.1207/s15327051hci0901_1; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Mueller WM, 1998, ENDOCRINOLOGY, V139, P551, DOI 10.1210/en.139.2.551; Nonogaki K, 1998, NAT MED, V4, P1152, DOI 10.1038/2647; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; OLTMANS GA, 1983, BRAIN RES, V273, P369, DOI 10.1016/0006-8993(83)90865-X; Patterson TA, 1998, NEUROENDOCRINOLOGY, V68, P11, DOI 10.1159/000054345; POLONSKY KS, 1988, J CLIN INVEST, V81, P442, DOI 10.1172/JCI113339; Porte D, 1998, DIABETOLOGIA, V41, P863, DOI 10.1007/s001250051002; POTHOS EN, 1995, J NEUROSCI, V15, P6640; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; RITTER S, 1994, BRAIN RES, V646, P53, DOI 10.1016/0006-8993(94)90057-4; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SALAMONE JD, 1993, PHARMACOL BIOCHEM BE, V44, P605, DOI 10.1016/0091-3057(93)90174-R; Satoh N, 1997, NEUROSCI LETT, V224, P149, DOI 10.1016/S0304-3940(97)00163-8; Schwartz MW, 1997, DIABETES CARE, V20, P1476, DOI 10.2337/diacare.20.9.1476; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1997, DIABETES, V46, P2119, DOI 10.2337/diabetes.46.12.2119; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Sindelar DK, 1999, DIABETES, V48, P1275, DOI 10.2337/diabetes.48.6.1275; SIPOLS AJ, 1995, DIABETES, V44, P147, DOI 10.2337/diabetes.44.2.147; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; STANLEY BG, 1986, PEPTIDES, V7, P1189; STANLEY BG, 1993, BRAIN RES, V630, P41; STELLAR E, 1954, PSYCHOL REV, V61, P5, DOI 10.1037/0033-295X.101.2.301; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Szczypka MS, 1999, P NATL ACAD SCI USA, V96, P12138, DOI 10.1073/pnas.96.21.12138; Tang-Christensen M, 1999, NEUROREPORT, V10, P1183, DOI 10.1097/00001756-199904260-00005; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TERHORST GJ, 1989, NEUROSCIENCE, V31, P785; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; TRAVERS JB, 1987, ANNU REV NEUROSCI, V10, P595, DOI 10.1146/annurev.ne.10.030187.003115; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Verbalis JG, 1995, ADV EXP MED BIOL, V395, P209; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; WHITE J D, 1990, Molecular and Cellular Neuroscience, V1, P41; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; WILLIAMS G, 1989, DIABETES, V38, P321, DOI 10.2337/diabetes.38.3.321; Wilson BD, 1999, ENDOCRINOLOGY, V140, P2387, DOI 10.1210/en.140.5.2387; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; WOODS SC, 1994, PSYCHON B REV, V1, P141, DOI 10.3758/BF03200770; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	121	4443	4608	17	599	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					661	671		10.1038/35007534	http://dx.doi.org/10.1038/35007534			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766253				2022-12-28	WOS:000086400100066
J	Sheffield, C				Sheffield, C			The new laureate speaks - The response of this year's Nobelist in full	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					549	549		10.1038/35007161	http://dx.doi.org/10.1038/35007161			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766219	Bronze			2022-12-28	WOS:000086400100028
J	Capdevila, J; Vogan, KJ; Tabin, CJ; Belmonte, JCI				Capdevila, J; Vogan, KJ; Tabin, CJ; Belmonte, JCI			Mechanisms of left-right determination in vertebrates	CELL			English	Review							LEFT-RIGHT ASYMMETRY; NODAL-RELATED GENES; SIGNALING PATHWAY; SITUS-INVERSUS; CHICK EMBRYOGENESIS; MESODERM FORMATION; EMBRYONIC HEART; MOUSE EMBRYO; EXPRESSION; PITX2		Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Salk Institute; Harvard University; Harvard Medical School	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu		Vogan, Kyle/0000-0001-9565-9665				Adachi H, 1999, GENE DEV, V13, P1589, DOI 10.1101/gad.13.12.1589; AFZELIUS B A, 1976, Science (Washington D C), V193, P317; Bisgrove BW, 1999, DEVELOPMENT, V126, P3253; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Brown N, 1999, HEART DEV, P447; BROWN NA, 1990, DEVELOPMENT, V127, P1081; Campione M, 1999, DEVELOPMENT, V126, P1225; Casey B, 1998, HUM MOL GENET, V7, P1565, DOI 10.1093/hmg/7.10.1565; Chang H, 2000, DEV BIOL, V219, P71, DOI 10.1006/dbio.1999.9594; Chazaud C, 1999, DEVELOPMENT, V126, P2589; Chen JN, 1997, DEVELOPMENT, V124, P4373; Cheng AMS, 2000, DEVELOPMENT, V127, P1049; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Constam DB, 2000, DEVELOPMENT, V127, P245; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; DERSCH H, 1993, DEV BIOL, V160, P424, DOI 10.1006/dbio.1993.1318; Dufort D, 1998, DEVELOPMENT, V125, P3015; Essner JJ, 2000, DEVELOPMENT, V127, P1081; Esteban CR, 1999, NATURE, V401, P243, DOI 10.1038/45738; FUJINAGA M, 1991, DEV BIOL, V143, P203, DOI 10.1016/0012-1606(91)90067-D; Fujinaga M, 1997, INT J DEV BIOL, V41, P153; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gaio U, 1999, CURR BIOL, V9, P1339, DOI 10.1016/S0960-9822(00)80059-7; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Guglielmotti V, 1999, J COMP NEUROL, V411, P441, DOI 10.1002/(SICI)1096-9861(19990830)411:3<441::AID-CNE7>3.0.CO;2-N; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heyer J, 1999, P NATL ACAD SCI USA, V96, P12595, DOI 10.1073/pnas.96.22.12595; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Ishimaru Y, 2000, MECH DEVELOP, V90, P115, DOI 10.1016/S0925-4773(99)00232-4; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; Kennedy DN, 1999, NEUROLOGY, V53, P1260, DOI 10.1212/WNL.53.6.1260; King T, 1998, MECH DEVELOP, V79, P29, DOI 10.1016/S0925-4773(98)00166-X; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Kosaki K, 1999, AM J HUM GENET, V64, P712, DOI 10.1086/302289; Kosaki R, 1999, AM J MED GENET, V82, P70, DOI 10.1002/(SICI)1096-8628(19990101)82:1<70::AID-AJMG14>3.0.CO;2-Y; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1998, GENE DEV, V12, P763, DOI 10.1101/gad.12.6.763; Levin M, 1999, DEVELOPMENT, V126, P4703; Levin M, 1998, DEV BIOL, V203, P90, DOI 10.1006/dbio.1998.9024; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Mochizuki T, 1998, NATURE, V395, P177, DOI 10.1038/26006; Morgan D, 1998, NAT GENET, V20, P149, DOI 10.1038/2450; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Norris DP, 1999, GENE DEV, V13, P1575, DOI 10.1101/gad.13.12.1575; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Patel K, 1999, CURR BIOL, V9, P609, DOI 10.1016/S0960-9822(99)80267-X; Patterson KD, 2000, DEVELOPMENT, V127, P167; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ramsdell AF, 1999, DEVELOPMENT, V126, P5195; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Saijoh Y, 1999, GENE DEV, V13, P259, DOI 10.1101/gad.13.3.259; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; Sampath K, 1997, DEVELOPMENT, V124, P3293; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schilling TF, 1999, DEV BIOL, V210, P277, DOI 10.1006/dbio.1999.9214; Schneider A, 1999, CURR BIOL, V9, P911, DOI 10.1016/S0960-9822(99)80397-2; Schweickert A, 2000, MECH DEVELOP, V90, P41, DOI 10.1016/S0925-4773(99)00227-0; Sefton M, 1998, DEVELOPMENT, V125, P3111; Shamim H, 1999, MECH DEVELOP, V85, P189, DOI 10.1016/S0925-4773(99)00093-3; Smith SM, 1997, DEV BIOL, V182, P162, DOI 10.1006/dbio.1996.8474; St Amand TR, 1998, BIOCHEM BIOPH RES CO, V247, P100; Supp DM, 2000, TRENDS CELL BIOL, V10, P41, DOI 10.1016/S0962-8924(99)01701-8; Supp DM, 1999, DEVELOPMENT, V126, P5495; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Tanaka S, 1999, NEUROPSYCHOLOGIA, V37, P869, DOI 10.1016/S0028-3932(98)00144-4; Thisse C, 1999, DEVELOPMENT, V126, P229; Toyoizumi R, 1997, DEV GROWTH DIFFER, V39, P505; Tsuda T, 1998, DEV GENET, V23, P203, DOI 10.1002/(SICI)1520-6408(1998)23:3<203::AID-DVG6>3.0.CO;2-6; Tsukui T, 1999, P NATL ACAD SCI USA, V96, P11376, DOI 10.1073/pnas.96.20.11376; Vogan KJ, 1999, NATURE, V397, P295, DOI 10.1038/16796; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wasiak S, 1999, DEV BIOL, V215, P332, DOI 10.1006/dbio.1999.9465; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yasui K, 2000, DEVELOPMENT, V127, P187; Yokouchi Y, 1999, CELL, V98, P573, DOI 10.1016/S0092-8674(00)80045-8; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Yost HJ, 1999, CURR OPIN GENET DEV, V9, P422; Zhu L, 1999, CURR BIOL, V9, P931, DOI 10.1016/S0960-9822(99)80419-9	103	262	267	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 31	2000	101	1					9	21		10.1016/S0092-8674(00)80619-4	http://dx.doi.org/10.1016/S0092-8674(00)80619-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778851	Bronze			2022-12-28	WOS:000086249900003
J	Zhang, HS; Gavin, M; Dahiya, A; Postigo, AA; Ma, DD; Luo, RX; Harbour, JW; Dean, DC				Zhang, HS; Gavin, M; Dahiya, A; Postigo, AA; Ma, DD; Luo, RX; Harbour, JW; Dean, DC			Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF	CELL			English	Article							CHROMATIN-REMODELING COMPLEX; SWI-SNF COMPLEX; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; GROWTH SUPPRESSION; PRB-FAMILY; E2F; INHIBITION; BINDING	We present evidence that Rb forms a repressor containing histone deacetylase (HDAC) and the hSWI/SNF nucleosome remodeling complex, which inhibits transcription of genes for cyclins E and A and arrests cells in the G1 phase of the cell cycle. Phosphorylation of Rb by cyclin D/cdk4 disrupts association with HDAC, relieving repression of the cyclin E gene and G1 arrest. However, the Rb-hSWI/SNF complex persists and is sufficient to maintain repression of the cyclin A and cdc2 genes, inhibiting exit from S phase. HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF then appear to maintain the order of cyclin E and A expression during the cell cycle, which in turn regulates exit from G1 and from S phase, respectively.	Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.	ddean@im.wustl.edu	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809; Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; NEVINS JR, 1992, SCIENCE, V258, P424; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Wade PA, 1999, CURR BIOL, V9, pR221, DOI 10.1016/S0960-9822(99)80134-1; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	524	533	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 31	2000	101	1					79	89		10.1016/S0092-8674(00)80625-X	http://dx.doi.org/10.1016/S0092-8674(00)80625-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778858	Bronze			2022-12-28	WOS:000086249900010
J	Pienitz, R; Vincent, WF				Pienitz, R; Vincent, WF			Effect of climate change relative to ozone depletion on UV exposure in subarctic lakes	NATURE			English	Article							ULTRAVIOLET-RADIATION; NORTHWEST-TERRITORIES; BOREAL FOREST; B PENETRATION; VEGETATION; TREELINE; CANADA; ACIDIFICATION; YELLOWKNIFE	The effect of stratospheric ozone depletion on increases in ambient levels of solar ultraviolet (UV) radiation in high-latitude regions' has raised concerns about the response of northern ecosystems to environmental change. The concentration of coloured dissolved organic material, which is derived from terrestrial vegetation and acts as a screen for ultraviolet radiation, is low in high-latitude lakes(2). The underwater light environment in these lakes is therefore likely to be sensitive to small variations in the supply of this material, in addition to the effects of ozone depletion(2-5). Here we use fossil diatom assemblages in combination with bio-optical models to estimate the magnitude of past variations in the underwater light regime of a lake at the boreal tree line. We find large shifts in underwater UV-B, UV-A and photosynthetically available radiation associated with changes in the input of coloured dissolved organic material into subarctic lakes during the Holocene. The inferred changes in biological exposure to UV radiation were at least two orders of magnitude greater than those associated with moderate (30%) ozone depletion. Our findings indicate that freshwater ecosystems at present located across vegetation gradients will experience significant shifts in underwater spectral irradiance through the effects of climate change on catchment vegetation and the export of coloured dissolved organic material.	Univ Laval, Ctr Etud Nord, Quebec City, PQ G1K 7P4, Canada	Laval University	Pienitz, R (corresponding author), Univ Laval, Ctr Etud Nord, Quebec City, PQ G1K 7P4, Canada.	reinhard.pienitz@cen.ulaval.ca; warwick.vincent@bio.ulaval.ca	Vincent, Warwick/AAH-6152-2019; Vincent, Warwick F/C-9522-2009	Vincent, Warwick/0000-0001-9055-1938; 				Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Battarbee RW, 1997, HYDROBIOLOGIA, V348, P69, DOI 10.1023/A:1003085116632; CULLEN JJ, 1992, SCIENCE, V258, P646, DOI 10.1126/science.258.5082.646; ENGSTROM DR, 1987, CAN J FISH AQUAT SCI, V44, P1306, DOI 10.1139/f87-154; Fallu MA, 1999, ECOSCIENCE, V6, P603, DOI 10.1080/11956860.1999.11682553; FOLEY JA, 1994, NATURE, V371, P52, DOI 10.1038/371052a0; FREDERICK JE, 1988, SCIENCE, V241, P438, DOI 10.1126/science.241.4864.438; Hansen G, 1999, J GEOPHYS RES-ATMOS, V104, P1837, DOI 10.1029/1998JD100021; *INT ARCT SCI COMM, 1995, EFF INCR ULTR RAD AR, V2; Korsman T., 1994, Holocene, V4, P132, DOI 10.1177/095968369400400203; Laurion I, 1997, PHOTOCHEM PHOTOBIOL, V65, P107; Leavitt PR, 1997, NATURE, V388, P457, DOI 10.1038/41296; MACDONALD GM, 1993, NATURE, V361, P243, DOI 10.1038/361243a0; MacDonald GM, 1998, ANN ASSOC AM GEOGR, V88, P183, DOI 10.1111/1467-8306.00090; MOSER KA, 1990, QUATERNARY RES, V34, P227, DOI 10.1016/0033-5894(90)90033-H; Pielke RA, 1995, J GEOPHYS RES-ATMOS, V100, P25755, DOI 10.1029/95JD02418; Pienitz R, 1999, ARCT ANTARCT ALP RES, V31, P82, DOI 10.2307/1552625; PIENITZ R, 1993, HYDROBIOLOGIA, V269, P391, DOI 10.1007/BF00028037; PLENITZ R, 1997, CAN J FISH AQUAT SCI, V54, P347; Schindler DW, 1996, NATURE, V379, P705, DOI 10.1038/379705a0; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SMITH TM, 1992, ADV ECOL RES, V22, P93, DOI 10.1016/S0065-2504(08)60134-8; URBAN NR, 1989, WATER RESOUR RES, V25, P1619, DOI 10.1029/WR025i007p01619; Vincent WF, 1996, GEOSCI CAN, V23, P231; Vincent WF, 1998, ANN GLACIOL, V27, P691; Vinebrooke RD, 1996, LIMNOL OCEANOGR, V41, P1035, DOI 10.4319/lo.1996.41.5.1035; Williamson CE, 1996, LIMNOL OCEANOGR, V41, P1024, DOI 10.4319/lo.1996.41.5.1024; Wolfe BB, 1996, J PALEOLIMNOL, V15, P171; Yan ND, 1996, NATURE, V381, P141, DOI 10.1038/381141a0	29	155	161	1	68	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 30	2000	404	6777					484	487		10.1038/35006616	http://dx.doi.org/10.1038/35006616			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761913				2022-12-28	WOS:000086257700044
J	Eddleston, M; Rajapakse, S; Rajakanthan; Jayalath, S; Sjostrom, L; Santharaj, W; Thenabadu, PN; Sheriff, MHR; Warrell, DA				Eddleston, M; Rajapakse, S; Rajakanthan; Jayalath, S; Sjostrom, L; Santharaj, W; Thenabadu, PN; Sheriff, MHR; Warrell, DA			Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial	LANCET			English	Article							DIGITALIS INTOXICATION; TOXICITY; MANAGEMENT	Background Severe cardiac glycoside cardiotoxicity after ingestion of yellow oleander seeds is an important problem in rural areas of Sri Lanka. Currently, patients must be transferred to the capital for temporary cardiac pacing. We did a randomised controlled trial to investigate whether antidigoxin Fat, could reverse serious oleander-induced arrhythmias. Methods After a preliminary dose-finding study, 66 patients who presented to hospital with a serious cardiac arrhythmia were randomised to rea:ive either 1200 mg of anti-digoxin Fab or a saline placebo. A 12-lead electrocardiogram, 3 min rhythm strip, and blood sample for measurement of electrolytes and cardiac glycosides were taken before treatment and at 12 timepoints thereafter. Findings 34 patients received anti-digoxin Fab and 32 received placebo, The presenting arrhythmia had resolved completely after 2 h in 15 antibody-treated patients and two controls (p < 0.001); 24 and five patients, respectively, were in sinus rhythm at 8 h (p < 0.001). Kaplan-Meier analysis of time to first reversal showed a significant response to antidigoxin Fab. The heart rate increased in cases, from 49.1 per min at baseline to 66.8 at 2 h, but not in controls (50.6 per min at baseline to 51.5; p < 0.001). Mean serum potassium concentrations decreased from 4.9 mmol/L to 4.1 mmol/L at 2 h in cases; no such decrease occurred in controls. Interpretation Anti-digoxin Fab fragments are a safe and effective treatment for serious cardiac arrhythmias induced by yellow oleander. Their use in small rural hospitals in Sri Lanka should minimise costly transfer of patients and reduce the numbers of deaths; however, further study will be required to confirm this reduction.	Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England; Univ Colombo, Dept Clin Med, Colombo, Sri Lanka; Natl Hosp Sri Lanka, Inst Cardiol, Colombo, Sri Lanka; Protherics, London EC1 7HN, England	University of Oxford; University of Colombo	Warrell, DA (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.		Rajapakse, Senaka/A-8404-2011	Rajapakse, Senaka/0000-0003-1965-6678				ANSFORD AJ, 1981, MED J AUSTRALIA, V1, P360, DOI 10.5694/j.1326-5377.1981.tb135633.x; ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; BARTELL S, 1996, NACCT; BISMUTH C, 1973, CLIN TOXICOL, V6, P153, DOI 10.3109/15563657308990513; BLUM LM, 1987, J ANAL TOXICOL, V11, P219, DOI 10.1093/jat/11.5.219; BRESTER D, 1986, ANN TROP PAEDIATR, V6, P289; Brubacher JR, 1996, CHEST, V110, P1282, DOI 10.1378/chest.110.5.1282; *CDCP, 1995, MMWR-MORBID MORTAL W, V77, P853; Chyka P A, 1997, J Toxicol Clin Toxicol, V35, P721; CLARK RF, 1991, ANN EMERG MED, V20, P1073, DOI 10.1016/S0196-0644(05)81355-1; Eddleston M, 1999, TROP MED INT HEALTH, V4, P266, DOI 10.1046/j.1365-3156.1999.00397.x; Eddleston M, 1998, BRIT MED J, V317, P133, DOI 10.1136/bmj.317.7151.133; Eddleston M, 2000, HEART, V83, P301, DOI 10.1136/heart.83.3.301; Gaultier M, 1968, Bull Mem Soc Med Hop Paris, V119, P247; HAYNES BE, 1985, ANN EMERG MED, V14, P350, DOI 10.1016/S0196-0644(85)80103-7; HICKEY AR, 1991, J AM COLL CARDIOL, V17, P590, DOI 10.1016/S0735-1097(10)80170-6; KELLY RA, 1992, AM J CARDIOL, V69, pG108, DOI 10.1016/0002-9149(92)91259-7; LALONDE RL, 1985, CLIN PHARMACOL THER, V37, P367, DOI 10.1038/clpt.1985.55; Langford SD, 1996, TOXICOLOGY, V109, P1, DOI 10.1016/0300-483X(95)03296-R; MISRA A, 1990, POSTGRAD MED J, V66, P492, DOI 10.1136/pgmj.66.776.492-a; OSTERLOH J, 1982, JAMA-J AM MED ASSOC, V247, P1596, DOI 10.1001/jama.247.11.1596; Pearn J., 1989, TOXIC PLANTS ANIMALS, P37; RICH SA, 1993, ANN EMERG MED, V22, P1904, DOI 10.1016/S0196-0644(05)80420-2; SAFADI R, 1995, ARCH INTERN MED, V155, P2121, DOI 10.1001/archinte.155.19.2121; Saraswat D K, 1992, J Assoc Physicians India, V40, P628; SARAVANAPAVANANTHAN N, 1988, FORENSIC SCI INT, V36, P247, DOI 10.1016/0379-0738(88)90150-8; SCHAUMANN W, 1986, EUR J CLIN PHARMACOL, V30, P527, DOI 10.1007/BF00542410; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SHAW D, 1979, MED J AUSTRALIA, V2, P267, DOI 10.5694/j.1326-5377.1979.tb127135.x; SHUMAIK GM, 1988, ANN EMERG MED, V17, P732, DOI 10.1016/S0196-0644(88)80625-5; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; SPIEGEL A, 1985, AM HEART J, V109, P1397, DOI 10.1016/0002-8703(85)90376-X; URTIZBEREA M, 1991, ARCH TOXICOL, V8, P132; WOOLF AD, 1992, NEW ENGL J MED, V326, P1739, DOI 10.1056/NEJM199206253262604	34	85	87	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					967	972		10.1016/S0140-6736(00)90014-X	http://dx.doi.org/10.1016/S0140-6736(00)90014-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768435				2022-12-28	WOS:000086054000011
J	Goshima, G; Yanagida, M				Goshima, G; Yanagida, M			Establishing biorientation occurs with precocious separation of the sister kinetochores, but not the arms, in the early spindle of budding yeast	CELL			English	Article							FISSION YEAST; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; MITOTIC SPINDLE; CENTROMERE; PROTEIN; CHROMOSOMES; ANAPHASE; MITOSIS	Sister kinetochores are bioriented toward the spindle poles in higher eukaryotic prometaphase before chromosome segregation. We show that, in budding yeast, the sister kinetochores are separated in the very early spindle, while the sister arms remain associated. Biorientation of the separated kinetochores is achieved already after replication. Mtw1p, a homolog of fission yeast Mis12 required for biorientation, locates at the centromeres in an Ndc10p-dependent manner. Mtw1p and the sequences 1.8 and 3.8 kb from CEN3 and CEN15, respectively, behave like the precociously separated kinetochores, whereas the sequences 23 and 35 kb distant from CEN3 and CEN5 previously used as the centromere markers behave like a part of the arm. Mtw1p and Ndc10p are identically located except for additional spindle localization of Ndc10p. A model explaining small centromeres and early spindle formation in budding yeast is proposed.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, CREST Res Proj, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Gene Mechanisms, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University; Kyoto University; Kyoto University	Yanagida, M (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.	yanagida@kozo.biophys.kyoto-u.ac.jp						ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Allshire RC, 1997, CURR OPIN GENET DEV, V7, P264, DOI 10.1016/S0959-437X(97)80137-2; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; Chibana H, 1996, GENES CELLS, V1, P727, DOI 10.1111/j.1365-2443.1996.tb00013.x; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; DING R, 1993, J CELL BIOL, V120, P141, DOI 10.1083/jcb.120.1.141; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Goshima G, 1999, GENE DEV, V13, P1664, DOI 10.1101/gad.13.13.1664; HAGAN IM, 1988, J CELL SCI, V89, P343; Haraguchi T, 1999, CELL STRUCT FUNCT, V24, P291, DOI 10.1247/csf.24.291; Hyland KM, 1999, J CELL BIOL, V145, P15, DOI 10.1083/jcb.145.1.15; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; IMIGER S, 1995, CELL, V81, P269; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; MASUDA H, 1992, J CELL BIOL, V117, P1055, DOI 10.1083/jcb.117.5.1055; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; O'Toole ET, 1999, MOL BIOL CELL, V10, P2017, DOI 10.1091/mbc.10.6.2017; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; Pereira G, 1997, J CELL SCI, V110, P295; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; Sorger PK, 1995, P NATL ACAD SCI USA, V92, P12026, DOI 10.1073/pnas.92.26.12026; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Waters JC, 1996, J CELL SCI, V109, P2823; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; WOODS A, 1989, J CELL SCI, V93, P491	46	252	255	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 17	2000	100	6					619	633		10.1016/S0092-8674(00)80699-6	http://dx.doi.org/10.1016/S0092-8674(00)80699-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761928	Bronze			2022-12-28	WOS:000085983800005
J	Ajayan, PM; Nugent, JM; Siegel, RW; Wei, B; Kohler-Redlich, P				Ajayan, PM; Nugent, JM; Siegel, RW; Wei, B; Kohler-Redlich, P			Growth of carbon micro-trees - Carbon deposition under extreme conditions causes tree-like structures to spring up.	NATURE			English	Article									Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA; Max Planck Inst Met Forsch, D-70174 Stuttgart, Germany	Rensselaer Polytechnic Institute; Max Planck Society	Ajayan, PM (corresponding author), Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA.		Wei, Bingqing/A-4525-2008	Wei, Bingqing/0000-0002-9416-1731				Dresselhaus M.S., 1996, SCI FULLERENES CARBO; ENDO M, 1997, CARBON NANOTUBES PRE, P35; HARVEY J, 1963, SPECIAL CERAMICS, P181	3	122	125	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					243	243		10.1038/35005161	http://dx.doi.org/10.1038/35005161			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749197	Bronze			2022-12-28	WOS:000086022200035
J	Vidale, JE; Earle, PS				Vidale, JE; Earle, PS			Fine-scale heterogeneity in the Earth's inner core	NATURE			English	Article							ANISOTROPY; IRON; ATTENUATION; BOUNDARY; DENSITY	The seismological properties of the Earth's inner core have become of particular interest as we understand more about its composition and thermal state(1,2). Observations of anisotropy and velocity heterogeneity in the inner core are beginning to reveal how it has grown and whether it convects(3,4). The attenuation of seismic waves in the inner core is strong, and studies of seismic body waves(5,6) have found that this high attenuation is consistent with either scattering or intrinsic attenuations, The outermost portion of the inner core has been inferred to possess layering and to be less anisotropic than at greater depths(7-10). Here we present observations of seismic waves scattered in the inner core which follow the expected arrival time of the body-wave reflection from the inner-core boundary. The amplitude of these scattered waves can be explained by stiffness variations of 1.2% with a scale length of 2 kilometres across the outermost 300 km of the inner core. These variations might be caused by variations in composition, by pods of partial melt in a mostly solid matrix or by variations in the orientation or strength of seismic anisotropy.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Vidale, JE (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.		Vidale, John/H-4965-2011	Vidale, John/0000-0002-3658-818X				Aki K., 1980, QUANTITATIVE SEISMOL, V842; Aki K., 1980, QUANTITATIVE SEISMOL, VI and II, DOI [10.1002/gj.3350160110, DOI 10.1002/GJ.3350160110]; ANDERSON OL, 1995, REV GEOPHYS, V33, P429, DOI 10.1029/95RG00877; BHATTACHARYYA J, 1993, GEOPHYS J INT, V114, P1, DOI 10.1111/j.1365-246X.1993.tb01461.x; BOEHLER R, 1993, NATURE, V363, P534, DOI 10.1038/363534a0; BUCHBINDER GG, 1973, B SEISMOL SOC AM, V63, P1699; CAPON J, 1970, B SEISMOL SOC AM, V60, P1701; Cormier VF, 1998, GEOPHYS RES LETT, V25, P4019, DOI 10.1029/1998GL900074; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; ENGDAHL ER, 1970, NATURE, V228, P852, DOI 10.1038/228852a0; GREEN PE, 1965, PR INST ELECTR ELECT, V53, P1821, DOI 10.1109/PROC.1965.4453; JEANLOZ R, 1990, ANNU REV EARTH PL SC, V18, P357; JEPHCOAT A, 1987, NATURE, V325, P332, DOI 10.1038/325332a0; Mao HK, 1998, NATURE, V396, P741, DOI 10.1038/25506; Mao HK, 1999, NATURE, V399, P280, DOI 10.1038/20472; Romanowicz B, 1996, SCIENCE, V274, P963, DOI 10.1126/science.274.5289.963; SHEARER P, 1990, GEOPHYS J INT, V102, P491, DOI 10.1111/j.1365-246X.1990.tb04481.x; SHEARER PM, 1994, J GEOPHYS RES-SOL EA, V99, P19647, DOI 10.1029/94JB01470; SONG XD, 1995, J GEOPHYS RES-SOL EA, V100, P9805, DOI 10.1029/95JB00244; Song XD, 1998, SCIENCE, V282, P924, DOI 10.1126/science.282.5390.924; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; SOURIAU A, 1989, GEOPHYS J INT, V98, P39, DOI 10.1111/j.1365-246X.1989.tb05512.x; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; Tanaka S, 1997, J GEOPHYS RES-SOL EA, V102, P2925, DOI 10.1029/96JB03187; WIDMER R, 1991, GEOPHYS J INT, V104, P541, DOI 10.1111/j.1365-246X.1991.tb05700.x; WU RS, 1985, J GEOPHYS RES-SOLID, V90, P261, DOI 10.1029/JB090iB12p10261	26	122	126	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					273	275		10.1038/35005059	http://dx.doi.org/10.1038/35005059			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749207				2022-12-28	WOS:000086022200045
J	Butler, D				Butler, D			Biology back issues free as publishers walk HighWire	NATURE			English	News Item																		1999, NATURE, V401, P6; 1999, NATURE, V401, P626	2	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					117	117		10.1038/35004746	http://dx.doi.org/10.1038/35004746			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10755906	Bronze			2022-12-28	WOS:000085870900015
J	Tokura, Y; Nagaosa, N				Tokura, Y; Nagaosa, N			Orbital physics in transition-metal oxides	SCIENCE			English	Review							DOUBLE-EXCHANGE FERROMAGNET; INSULATOR-TRANSITION; ELECTRONIC-STRUCTURE; SPIN-LIQUID; LA1-XSRXMNO3; MANGANITES; PHASE; SYSTEMS; LATTICE; CHARGE	An electron in a solid, that is, bound to or nearly localized on the specific atomic site, has three attributes: charge. spin, and orbital. The orbital represents the shape of the electron cloud in solid. In transition-metal oxides with anisotropic-shaped d-orbital electrons, the Coulomb interaction between the electrons (strong electron correlation effect) is of importance for understanding their metal-insulator transitions and properties such as high-temperature superconductivity and colossal magnetoresistance. The orbital degree of freedom occasionally plays an important role in these phenomena, and its correlation and/or order-disorder transition causes a variety of phenomena through strong coupling with charge, spin, and lattice dynamics. An overview is given here on this "orbital physics," which wilt be a key concept for the science and technology of correlated electrons.	Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo 1138656, Japan; Joint Res Ctr Atom Technol, Tsukuba, Ibaraki 3050046, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Tokura, Y (corresponding author), Univ Tokyo, Dept Appl Phys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.		Nagaosa, Naoto/G-7057-2012; Tokura, Yoshinori/C-7352-2009	Tokura, Yoshinori/0000-0002-2732-4983				ANDERSON PW, 1955, PHYS REV, V100, P675, DOI 10.1103/PhysRev.100.675; ANDERSON PW, 1963, SOLID STATE PHYS, V14, P99; Anisimov VI, 1997, PHYS REV B, V55, P15494, DOI 10.1103/PhysRevB.55.15494; Azaria P, 1999, PHYS REV LETT, V83, P624, DOI 10.1103/PhysRevLett.83.624; Bao W, 1997, PHYS REV LETT, V78, P507, DOI 10.1103/PhysRevLett.78.507; BRINK J, 1999, PHYS REV LETT, V83, P5118; CASTELLANI C, 1978, PHYS REV B, V18, P4945, DOI 10.1103/PhysRevB.18.4945; Damay F, 1997, J APPL PHYS, V82, P6181, DOI 10.1063/1.366543; Dessau DS, 1998, PHYS REV LETT, V81, P192, DOI 10.1103/PhysRevLett.81.192; Feiner LF, 1997, PHYS REV LETT, V78, P2799, DOI 10.1103/PhysRevLett.78.2799; Fiebig M, 1998, SCIENCE, V280, P1925, DOI 10.1126/science.280.5371.1925; Frischmuth B, 1999, PHYS REV LETT, V82, P835, DOI 10.1103/PhysRevLett.82.835; GEHRING GA, 1975, REP PROG PHYS, V38, P1, DOI 10.1088/0034-4885/38/1/001; Goodenough J.B., 1963, MAGNETISM CHEM BOND; GOODENOUGH JB, 1955, PHYS REV, V100, P564, DOI 10.1103/PhysRev.100.564; Ishihara S, 1997, PHYS REV B, V55, P8280, DOI 10.1103/PhysRevB.55.8280; Ishikawa T, 1999, PHYS REV B, V59, P8367, DOI 10.1103/PhysRevB.59.8367; Jahn HA, 1937, PROC R SOC LON SER-A, V161, P220, DOI 10.1098/rspa.1937.0142; Kajimoto R, 1999, PHYS REV B, V60, P9506, DOI 10.1103/PhysRevB.60.9506; KANAMORI J, 1959, J PHYS CHEM SOLIDS, V10, P87, DOI 10.1016/0022-3697(59)90061-7; KANAMORI J, 1960, J APPL PHYS, V31, pS14, DOI 10.1063/1.1984590; Kawano H, 1997, PHYS REV LETT, V78, P4253, DOI 10.1103/PhysRevLett.78.4253; Kiryukhin V, 1997, NATURE, V386, P813, DOI 10.1038/386813a0; Kolezhuk AK, 1998, PHYS REV LETT, V80, P2709, DOI 10.1103/PhysRevLett.80.2709; Konishi Y, 1999, J PHYS SOC JPN, V68, P3790, DOI 10.1143/JPSJ.68.3790; Korotin MA, 1996, PHYS REV B, V54, P5309, DOI 10.1103/PhysRevB.54.5309; Kramers HA, 1934, PHYSICA, V1, P182, DOI 10.1016/S0031-8914(34)90023-9; KUGEL KI, 1980, SOV PHYS JETP, V52, P501; Kuwahara H, 1999, PHYS REV LETT, V82, P4316, DOI 10.1103/PhysRevLett.82.4316; KUWAHARA H, 1995, SCIENCE, V270, P961, DOI 10.1126/science.270.5238.961; Li YQ, 1998, PHYS REV LETT, V81, P3527, DOI 10.1103/PhysRevLett.81.3527; Maezono R, 1998, PHYS REV B, V58, P11583, DOI 10.1103/PhysRevB.58.11583; Millis AJ, 2000, ADV COND MAT SCI, V2, P53; Mizokawa T, 1996, PHYS REV B, V54, P5368, DOI 10.1103/PhysRevB.54.5368; Murakami Y, 1998, PHYS REV LETT, V80, P1932, DOI 10.1103/PhysRevLett.80.1932; Nagaev EL, 1998, PHYS REV B, V58, P2415, DOI 10.1103/PhysRevB.58.2415; Nersesyan AA, 1997, PHYS REV LETT, V78, P3939, DOI 10.1103/PhysRevLett.78.3939; OKIMOTO Y, 1995, PHYS REV LETT, V75, P109, DOI 10.1103/PhysRevLett.75.109; Okuda T, 1998, PHYS REV LETT, V81, P3203, DOI 10.1103/PhysRevLett.81.3203; Pen HF, 1997, PHYS REV LETT, V78, P1323, DOI 10.1103/PhysRevLett.78.1323; Ren Y, 1998, NATURE, V396, P441, DOI 10.1038/24802; Sarma DD, 1996, PHYS REV B, V53, P6873, DOI 10.1103/PhysRevB.53.6873; Sawada H, 1998, PHYS REV B, V58, P6831, DOI 10.1103/PhysRevB.58.6831; Shiba H, 1997, J PHYS SOC JPN, V66, P941, DOI 10.1143/JPSJ.66.941; Solovyev I, 1996, PHYS REV LETT, V76, P4825, DOI 10.1103/PhysRevLett.76.4825; Solovyev IV, 1999, PHYS REV LETT, V83, P2825, DOI 10.1103/PhysRevLett.83.2825; Tokura Y, 1996, PHYS REV LETT, V76, P3184, DOI 10.1103/PhysRevLett.76.3184; Tokura Y., 2000, COLOSSAL MAGNETORESI; Tomioka Y, 1997, APPL PHYS LETT, V70, P3609, DOI 10.1063/1.119248; von Zimmermann M, 1999, PHYS REV LETT, V83, P4872, DOI 10.1103/PhysRevLett.83.4872; Woodfield BF, 1997, PHYS REV LETT, V78, P3201, DOI 10.1103/PhysRevLett.78.3201; Yamashita Y, 1998, PHYS REV B, V58, P9114, DOI 10.1103/PhysRevB.58.9114; ZENER C, 1951, PHYS REV, V82, P403, DOI 10.1103/PhysRev.82.403	53	2005	2028	28	821	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					462	468		10.1126/science.288.5465.462	http://dx.doi.org/10.1126/science.288.5465.462			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775098				2022-12-28	WOS:000086626000033
J	Albelda, SM; Wiewrodt, R; Zuckerman, JB				Albelda, SM; Wiewrodt, R; Zuckerman, JB			Gene therapy for lung disease: Hype or hope?	ANNALS OF INTERNAL MEDICINE			English	Review							ADENOASSOCIATED VIRUS VECTORS; ADENOVIRUS-MEDIATED TRANSFER; I CLINICAL-TRIAL; TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN ALPHA-1-ANTITRYPSIN GENE; COLONY-STIMULATING FACTOR; AIRWAY EPITHELIAL-CELLS; CYSTIC-FIBROSIS; PHASE-I; NASAL EPITHELIUM	Gene therapy, the treatment of any disorder or pathphysiologic state on the basis of the transfer of genetic information, was a high-priority goal in the 1990s. The lung is a major target of gene therapy for genetic disorders, such as cystic fibrosis and alpha(1)-antitrypsin deficiency, and for other diseases, including lung cancer, malignant mesothelioma, pulmonary inflammation, surfactant deficiency, and pulmonary hypertension. This paper examines general concepts in gene therapy, summarizes the results of published clinical trials, and highlights areas of research aimed at overcoming challenges in the field. Although progress has been slower than anticipated, gene transfer has been safely achieved in patients with lung diseases. Recent advancements in understanding of the molecular basis of lung disease and the development of improved vector systems make it likely that gene therapy will be an important tool for the 21st-century clinician.	Univ Penn, Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania	Albelda, SM (corresponding author), 856 BRBII III,421 Curie Blvd, Philadelphia, PA 19104 USA.	albelda@mail.med.upenn.edu	Zuckerman, Jonathan/AAU-1857-2020	Zuckerman, Jonathan/0000-0002-8190-9210	PHS HHS [P01 66726] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; ANDERSON WF, 1999, HUM GENE THER, V10, P2037; Bellon G, 1997, HUM GENE THER, V8, P15, DOI 10.1089/hum.1997.8.1-15; BILBAO G, 1998, TUMOR TARGET, V3, P59; Boasquevisque CHR, 1999, J THORAC CARDIOV SUR, V117, P8; Boucher RC, 1999, J CLIN INVEST, V103, P441, DOI 10.1172/JCI6330; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CARBONE DP, 1992, ADV INTERNAL MED, V37, P153; CHEN SH, 1995, P NATL ACAD SCI USA, V92, P2577, DOI 10.1073/pnas.92.7.2577; Chillon M, 1998, GENE THER, V5, P995, DOI 10.1038/sj.gt.3300665; CONARY JT, 1994, J CLIN INVEST, V93, P1834, DOI 10.1172/JCI117169; Conrad CK, 1996, GENE THER, V3, P658; CRYSTAL RG, 1989, CHEST, V95, P196, DOI 10.1378/chest.95.1.196; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; Curiel DT, 1996, AM J RESP CELL MOL, V14, P1; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; Dow SW, 1999, HUM GENE THER, V10, P1905, DOI 10.1089/10430349950017266; Dow SW, 1999, J IMMUNOL, V163, P1552; Dubinett SM, 1998, HEMATOL ONCOL CLIN N, V12, P569, DOI 10.1016/S0889-8588(05)70009-5; Eastman SJ, 1997, HUM GENE THER, V8, P765, DOI 10.1089/hum.1997.8.6-765; Elshami AA, 1996, GENE THER, V3, P85; Engelhardt JF, 1999, ANTIOXID REDOX SIGN, V1, P5, DOI 10.1089/ars.1999.1.1-5; Epperly M, 1998, GENE THER, V5, P196, DOI 10.1038/sj.gt.3300580; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; Esandi MC, 1998, GENE THER, V5, P778, DOI 10.1038/sj.gt.3300662; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Ferrari FK, 1997, NAT MED, V3, P1295, DOI 10.1038/nm1197-1295; Flotte T, 1996, HUM GENE THER, V7, P1145, DOI 10.1089/hum.1996.7.9-1145; Flotte T R, 1997, Adv Pharmacol, V40, P85, DOI 10.1016/S1054-3589(08)60138-6; Fouty B, 1999, AM J RESP CELL MOL, V21, P555, DOI 10.1165/ajrcmb.21.5.f170; Frederiksen KS, 1999, LUNG CANCER, V23, P191, DOI 10.1016/S0169-5002(99)00012-4; Freeman SM, 1997, LANCET, V349, P2, DOI 10.1016/S0140-6736(97)22001-5; FUJIWARA T, 1994, CANCER RES, V54, P2287; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Gahery-Segard H, 1998, J VIROL, V72, P2388; GaherySegard H, 1997, J CLIN INVEST, V100, P2218, DOI 10.1172/JCI119759; GARVER RI, 1987, SCIENCE, V237, P762, DOI 10.1126/science.3497452; Gill DR, 1997, GENE THER, V4, P199, DOI 10.1038/sj.gt.3300391; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; HALBERT CL, 1995, J VIROL, V69, P1473, DOI 10.1128/JVI.69.3.1473-1479.1995; Harvey BG, 1999, J VIROL, V73, P6729, DOI 10.1128/JVI.73.8.6729-6742.1999; HAY JG, 1995, HUM GENE THER, V6, P1487, DOI 10.1089/hum.1995.6.11-1487; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Hogan SP, 1998, EUR J IMMUNOL, V28, P413; Huang M, 1998, CANCER RES, V58, P1208; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; JOHNSON LG, 1995, J CLIN INVEST, V95, P1377, DOI 10.1172/JCI117789; Jooss K, 1996, HUM GENE THER, V7, P1555, DOI 10.1089/hum.1996.7.13-1555; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; Kearns WG, 1996, GENE THER, V3, P748; KNOELL DL, 1995, CHEST, V107, P535, DOI 10.1378/chest.107.2.535; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; Knowles MR, 1998, HUM GENE THER, V9, P249, DOI 10.1089/hum.1998.9.2-249; Kolls J, 1998, AM J RESP CRIT CARE, V157, pA563; Kong HL, 1998, J NATL CANCER I, V90, P273, DOI 10.1093/jnci/90.4.273; KORST RJ, 1995, HUM GENE THER, V6, P277, DOI 10.1089/hum.1995.6.3-277; Kucharczuk JC, 1997, CANCER RES, V57, P466; Lee CT, 1997, HUM GENE THER, V8, P187, DOI 10.1089/hum.1997.8.2-187; LORENCE RM, 1994, CANCER RES, V54, P6017; Mansoura MK, 1999, HUM GENE THER, V10, P861, DOI 10.1089/10430349950018274; Mathieu M, 1999, GENE THER, V6, P245, DOI 10.1038/sj.gt.3300814; Miller PW, 2000, HUM GENE THER, V11, P53, DOI 10.1089/10430340050016157; Molnar-Kimber KL, 1998, HUM GENE THER, V9, P2121, DOI 10.1089/hum.1998.9.14-2121; MOOLTEN FL, 1994, CANCER GENE THER, V1, P279; MUKHERJEE S, 1997, LUNG CANCER S1, V18, P236; Muzykantov VR, 1998, PATHOPHYSIOLOGY, V5, P15; O'Riordan CR, 1999, HUM GENE THER, V10, P1349, DOI 10.1089/10430349950018021; OHIRA T, 1994, GENE THER, V1, P269; Pope IM, 1997, EUR J CANCER, V33, P1005, DOI 10.1016/S0959-8049(96)00483-2; Porteous DJ, 1997, GENE THER, V4, P210, DOI 10.1038/sj.gt.3300390; Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307; Rizk NP, 1999, CANCER GENE THER, V6, P291, DOI 10.1038/sj.cgt.7700059; Robinson BWS, 1998, J IMMUNOTHER, V21, P211, DOI 10.1097/00002371-199805000-00007; Rodman DM, 1997, AM J RESP CELL MOL, V16, P640, DOI 10.1165/ajrcmb.16.6.9191465; Rodriguez R, 1997, CANCER RES, V57, P2559; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Roth Jack A., 1998, Current Opinion in Oncology, V10, P127, DOI 10.1097/00001622-199803000-00008; Rubenstein RC, 1997, GENE THER, V4, P384, DOI 10.1038/sj.gt.3300417; RUSSELL SJ, 1994, EUR J CANCER, V30A, P1165, DOI 10.1016/0959-8049(94)90477-4; Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689; Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180; Schuler M, 1998, HUM GENE THER, V9, P2075, DOI 10.1089/hum.1998.9.14-2075; Schwarzenberger P, 1998, J La State Med Soc, V150, P168; Sharma S, 1996, CANCER GENE THER, V3, P302; Simons JW, 1997, CANCER RES, V57, P1537; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Smith TAG, 1996, GENE THER, V3, P496; Song S, 1998, P NATL ACAD SCI USA, V95, P14384, DOI 10.1073/pnas.95.24.14384; SORSCHER EJ, 1994, HUM GENE THER, V5, P1259, DOI 10.1089/hum.1994.5.10-1259; Sterman DH, 1998, HUM GENE THER, V9, P1083, DOI 10.1089/hum.1998.9.7-1083; Stoller JK, 1997, CHEST, V111, pS123, DOI 10.1378/chest.111.6_Supplement.123S; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Teramoto S, 1998, J VIROL, V72, P8904, DOI 10.1128/JVI.72.11.8904-8912.1998; Tursz T, 1996, J NATL CANCER I, V88, P1857, DOI 10.1093/jnci/88.24.1857; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; VILQUIN JT, 1995, HUM GENE THER, V6, P1391, DOI 10.1089/hum.1995.6.11-1391; Wagner JA, 1998, HUM GENE THER, V9, P889, DOI 10.1089/hum.1998.9.6-889; Wagner JA, 1998, LANCET, V351, P1702, DOI 10.1016/S0140-6736(05)77740-0; Wang GS, 1999, J CLIN INVEST, V104, pR55, DOI 10.1172/JCI8390; Wivel NA, 1998, HEMATOL ONCOL CLIN N, V12, P483, DOI 10.1016/S0889-8588(05)70004-6; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; Xiao WD, 1998, J VIROL, V72, P10222, DOI 10.1128/JVI.72.12.10222-10226.1998; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Yeh P, 1997, FASEB J, V11, P615, DOI 10.1096/fasebj.11.8.9240963; YEI SP, 1994, AM J RESP CELL MOL, V11, P329, DOI 10.1165/ajrcmb.11.3.8086169; Yew NS, 1999, HUM GENE THER, V10, P223, DOI 10.1089/10430349950019011; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; Zabner J, 1996, J CLIN INVEST, V97, P1504, DOI 10.1172/JCI118573; ZHANG G, 1994, IEEE PHOTONIC TECH L, V6, P1, DOI 10.1109/68.265870; Zuckerman JB, 1999, HUM GENE THER, V10, P2973, DOI 10.1089/10430349950016384	116	56	60	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					649	660		10.7326/0003-4819-132-8-200004180-00008	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766684				2022-12-28	WOS:000086497500007
J	Berkman, LF				Berkman, LF			Which influences cognitive function: living alone or being alone?	LANCET			English	Editorial Material							DEMENTIA; HEALTH		Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Berkman, LF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, 665 Huntington Ave, Boston, MA 02115 USA.							Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002; BERKMAN LF, 1995, PSYCHOSOM MED, V57, P245, DOI 10.1097/00006842-199505000-00006; FABRIGOULE C, 1995, J AM GERIATR SOC, V43, P485, DOI 10.1111/j.1532-5415.1995.tb06093.x; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; Schaie, 1987, COGNITIVE FUNCTIONIN, P24; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488	8	59	61	3	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1291	1292		10.1016/S0140-6736(00)02107-3	http://dx.doi.org/10.1016/S0140-6736(00)02107-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310LJ	10776738				2022-12-28	WOS:000086829400005
J	Morris, AAM; Lightowlers, RN				Morris, AAM; Lightowlers, RN			Can paternal mtDNA be inherited?	LANCET			English	Editorial Material							MITOCHONDRIAL-DNA; RECOMBINATION		Newcastle Univ, Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Univ, Royal Victoria Infirm, Dept Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Morris, AAM (corresponding author), Newcastle Univ, Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.							Awadalla P, 1999, SCIENCE, V286, P2524, DOI 10.1126/science.286.5449.2524; Eyre-Walker A, 1999, P ROY SOC B-BIOL SCI, V266, P477, DOI 10.1098/rspb.1999.0662; Hagelberg E, 1999, P ROY SOC B-BIOL SCI, V266, P485, DOI 10.1098/rspb.1999.0663; KAMIMURA N, 1989, J MOL BIOL, V210, P703, DOI 10.1016/0022-2836(89)90103-4; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Macaulay V, 1999, P ROY SOC B-BIOL SCI, V266, P2037, DOI 10.1098/rspb.1999.0883; Sutovsky P, 1999, NATURE, V402, P371, DOI 10.1038/46466; THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2000	355	9212					1290	1291						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776737				2022-12-28	WOS:000086829400004
J	Volmink, J; Matchaba, P; Garner, P				Volmink, J; Matchaba, P; Garner, P			Directly observed therapy and treatment adherence	LANCET			English	Review							RURAL SOUTH-AFRICA; TUBERCULOSIS TREATMENT PROGRAM; RANDOMIZED CONTROLLED TRIAL; PULMONARY TUBERCULOSIS; TREATMENT COMPLETION; DRUG-RESISTANCE; UNITED-STATES; COMMUNITY; DOTS; IMPLEMENTATION	Direct observation of patients taking their medication is a strategy to improve completion rates for tuberculosis treatment, but the programmes to implement this approach consist of a complex array of inputs aimed at influencing adherence. Policy makers need a clear understanding of these inputs to succeed. We systematically identified and reviewed published reports of direct observation therapy (DOT) programmes and compared inputs with WHO's short-course DOT programme. DOT programmes frequently consist of more than the five elements of WHO's strategy, including incentives, tracing of defaulters, legal sanctions, patient-centred approaches, staff motivation, supervision, and additional external funds. Focusing on direct observation as a key factor in the promotion of adherence seems inappropriate. Multiple components might account for the success of DOT programmes, and WHO should make these explicit.	S African MRC, S African Cochrane Ctr, ZA-7505 Tygerberg, Cape Town, South Africa; Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Div, Liverpool L3 5QA, Merseyside, England	South African Medical Research Council; Liverpool School of Tropical Medicine; University of Liverpool	Volmink, J (corresponding author), S African MRC, S African Cochrane Ctr, POB 1907, ZA-7505 Tygerberg, Cape Town, South Africa.		Garner, Paul/Y-8385-2019; Garner, Paul/HII-5856-2022; Walley, John D/AAY-1375-2021	Garner, Paul/0000-0002-0607-6941; Walley, John D/0000-0001-7290-0989				Agutu WO, 1997, E AFR MED J, V74, P348; Alvarez-Gordillo GD, 1998, SALUD PUBLICA MEXICO, V40, P272, DOI 10.1590/S0036-36341998000300008; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1997, WHOTB97220; BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; Bayer R, 1998, AM J PUBLIC HEALTH, V88, P1052, DOI 10.2105/AJPH.88.7.1052; Bechan S, 1997, T ROY SOC TROP MED H, V91, P704, DOI 10.1016/S0035-9203(97)90532-0; Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168; Caminero JA, 1996, THORAX, V51, P1130, DOI 10.1136/thx.51.11.1130; Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; CHOWDHURY AM, 1997, LANCET, V350, P157; Coninx R, 1999, LANCET, V353, P969, DOI 10.1016/S0140-6736(98)08341-X; Davidson BL, 1998, CHEST, V114, P1239, DOI 10.1378/chest.114.5.1239; Davies GR, 1999, AIDS, V13, P811, DOI 10.1097/00002030-199905070-00010; Dick J, 1996, TUBERCLE LUNG DIS, V77, P274, DOI 10.1016/S0962-8479(96)90013-1; ElSadr W, 1996, AM J PUBLIC HEALTH, V86, P1146, DOI 10.2105/AJPH.86.8_Pt_1.1146; FREIDEN TR, 1995, NEW ENGL J MED, V333, P229; Fujiwara PI, 1997, CLIN CHEST MED, V18, P135, DOI 10.1016/S0272-5231(05)70363-4; Garner P, 1997, LANCET, V350, P666, DOI 10.1016/S0140-6736(05)63361-2; Kamolratanakul P, 1999, T ROY SOC TROP MED H, V93, P552, DOI 10.1016/S0035-9203(99)90379-6; Kumaresan JA, 1998, INT J TUBERC LUNG D, V2, P992; MANALO F, 1990, AM REV RESPIR DIS, V142, P1301, DOI 10.1164/ajrccm/142.6_Pt_1.1301; MILES SH, 1984, AM REV RESPIR DIS, V130, P827; Morris K, 1997, LANCET, V349, P857, DOI 10.1016/S0140-6736(05)61765-5; Neher A, 1996, TUBERCLE LUNG DIS, V77, P302, DOI 10.1016/S0962-8479(96)90093-3; Norval PY, 1998, INT J TUBERC LUNG D, V2, P44; POZSIK C, 1993, MMWR-MORBID MORTAL W, V42, P74; Ruben F L, 1996, Pa Med, V99, P26; SCHLUGER N, 1995, AM J RESP CRIT CARE, V151, P1486, DOI 10.1164/ajrccm.151.5.7735604; Smirnoff M, 1998, INT J TUBERC LUNG D, V2, P134; VOLMINK J, 2000, PROMOTING ADHERENCE; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1996, AM J PUBLIC HEALTH, V86, P1094, DOI 10.2105/AJPH.86.8_Pt_1.1094; Wilkinson D, 1998, J TROP PEDIATRICS, V44, P266, DOI 10.1093/tropej/44.5.266; Zalesky R, 1999, INT J TUBERC LUNG D, V3, P394; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	39	123	132	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1345	1350		10.1016/S0140-6736(00)02124-3	http://dx.doi.org/10.1016/S0140-6736(00)02124-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310LJ	10776760				2022-12-28	WOS:000086829400040
J	Li, MW; Ona, VO; Guegan, C; Chen, MH; Jackson-Lewis, V; Andrews, LJ; Olszewski, AJ; Stieg, PE; Lee, JP; Przedborski, S; Friedlander, RM				Li, MW; Ona, VO; Guegan, C; Chen, MH; Jackson-Lewis, V; Andrews, LJ; Olszewski, AJ; Stieg, PE; Lee, JP; Przedborski, S; Friedlander, RM			Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; CU,ZN SUPEROXIDE-DISMUTASE; TROPHIC FACTOR WITHDRAWAL; MEDIATED APOPTOSIS; NEURONAL APOPTOSIS; FAMILY PROTEASES; BRAIN INJURY; CELL-DEATH; MICE	Mutations in the copper/zinc superoxide dismutase (SOD1) gene produce an animal model of familiar amyotrophic Lateral sclerosis (ALS), a fatal neurodegenerative disorder., To test a new therapeutic strategy for ALS, we examined the effect of caspase inhibition in transgenic mice expressing mutant human SOD1 with a substitution of glycine to alanine in position 93 (mSOD1(G93A)). Intracerebroventricular administration of zVAD-fmk, a broad caspase inhibitor. delays disease onset and mortality. Moreover, zVAD-fmk inhibits caspase-1 activity as well as caspase-1 and caspase-3 mRNA up-regulation, providing evidence for a non-cell-autonomous pathway regulating caspase expression. Caspases play an instrumental role in neurodegeneration in transgenic mSOD1(G93A) mice, which suggests that caspase inhibition may have a protective role in ALS.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Neuroapoptosis Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Neurosurg Serv, Boston, MA 02115 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Columbia University; Columbia University; University of Chicago	Friedlander, RM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Neuroapoptosis Lab, Boston, MA 02115 USA.		Olszewski, Adam J/F-8449-2013; Guegan, Christelle/AAD-5377-2020; Friedlander, Robert M/A-2845-2016	Olszewski, Adam J/0000-0002-6472-6658; Friedlander, Robert M/0000-0003-4423-9219	NINDS NIH HHS [R01 NS38586, R29 NS37345, P50 NS38370] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038586, R29NS037345, P50NS038370] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali A, 1999, J HEMATOTH STEM CELL, V8, P343, DOI 10.1089/152581699320108; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Gurney ME, 1998, NEUROLOGY, V50, P62, DOI 10.1212/WNL.50.1.62; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Liberatore GT, 1999, NAT MED, V5, P1403; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Martin LJ, 2000, INT J MOL MED, V5, P3; Namura S, 1998, J NEUROSCI, V18, P3659; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland L. P., 1995, MERRITTS TXB NEUROLO, P742; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; Vukosavic Slobodanka, 1999, Society for Neuroscience Abstracts, V25, P1304; WILLIAMS DB, 1993, PERIPHERAL NEUROPATH; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	30	576	602	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					335	339		10.1126/science.288.5464.335	http://dx.doi.org/10.1126/science.288.5464.335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764647				2022-12-28	WOS:000086454300038
J	Ritala, M; Kukli, K; Rahtu, A; Raisanen, PI; Leskela, M; Sajavaara, T; Keinonen, J				Ritala, M; Kukli, K; Rahtu, A; Raisanen, PI; Leskela, M; Sajavaara, T; Keinonen, J			Atomic layer deposition of oxide thin films with metal alkoxides as oxygen sources	SCIENCE			English	Article							SILICON	A chemical approach to atomic Layer deposition (ALD) of oxide thin films is reported here. Instead of using water or other compounds for an oxygen source, oxygen is obtained from a metal alkoxide, which serves as both an oxygen and a metal source when it reacts with another metal compound such as a metal chloride or a metal alkyl. These reactions generally enable deposition of oxides of many metals. With this approach, an alumina film has been deposited on silicon without creating an interfacial silicon oxide Layer that otherwise forms easily. This finding adds to the other benefits of the ALD method, especially the atomic-level thickness control and excellent uniformity, and takes a major step toward the scientifically challenging and technologically important task of replacing silica as the gate dielectric in the future generations of metal oxide semiconductor field effect transistors.	Univ Helsinki, Dept Chem, FIN-00014 Helsinki, Finland; Univ Helsinki, Accelerator Lab, FIN-00014 Helsinki, Finland; Univ Tartu, Inst Expt Phys & Technol, EE-51010 Tartu, Estonia	University of Helsinki; University of Helsinki; University of Tartu	Ritala, M (corresponding author), Univ Helsinki, Dept Chem, POB 55, FIN-00014 Helsinki, Finland.		Kukli, Kaupo/I-4525-2015; Sajavaara, Timo/ABC-6106-2020; Sajavaara, Timo/A-4340-2013; Ritala, Mikko/N-7268-2013; Leskelä, Markku Antero/K-8389-2018; Keinonen, Juhani/D-4347-2013	Kukli, Kaupo/0000-0002-5821-0364; Sajavaara, Timo/0000-0003-2235-7441; Sajavaara, Timo/0000-0003-2235-7441; Ritala, Mikko/0000-0002-6210-2980; Leskelä, Markku Antero/0000-0001-5830-2800; 				Bourget L, 1998, J NON-CRYST SOLIDS, V242, P81, DOI 10.1016/S0022-3093(98)00789-3; CORRIU R, 1992, CHEM MATER, V4, P961, DOI 10.1021/cm00023a001; Hubbard KJ, 1996, J MATER RES, V11, P2757, DOI 10.1557/JMR.1996.0350; Klaus JW, 1999, SURF REV LETT, V6, P435, DOI 10.1142/S0218625X99000433; Klaus JW, 1997, SCIENCE, V278, P1934, DOI 10.1126/science.278.5345.1934; McKee RA, 1998, PHYS REV LETT, V81, P3014, DOI 10.1103/PhysRevLett.81.3014; Moore G. E., 1965, IEDM, V38, P11; Muller DA, 1999, NATURE, V399, P758, DOI 10.1038/21602; Niinisto L, 1996, MAT SCI ENG B-SOLID, V41, P23, DOI 10.1016/S0921-5107(96)01617-0; *OUT RES OY, OUT HSC CHEM WIND PR; Packan PA, 1999, SCIENCE, V285, P2079, DOI 10.1126/science.285.5436.2079; Ritala M, 1997, APPL SURF SCI, V112, P223, DOI 10.1016/S0169-4332(96)01004-5; Ritala M, 1999, CHEM VAPOR DEPOS, V5, P7, DOI 10.1002/(SICI)1521-3862(199901)5:1<7::AID-CVDE7>3.0.CO;2-J; Schulz M, 1999, NATURE, V399, P729, DOI 10.1038/21526; *SEM IND ASS, 1997, NAT TECHN ROADM SEM; Trentler TJ, 1999, J AM CHEM SOC, V121, P1613, DOI 10.1021/ja983361b; Vioux A, 1997, CHEM MATER, V9, P2292, DOI 10.1021/cm970322a; Wilk GD, 1999, APPL PHYS LETT, V74, P2854, DOI 10.1063/1.124036	18	426	528	4	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					319	321		10.1126/science.288.5464.319	http://dx.doi.org/10.1126/science.288.5464.319			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764641				2022-12-28	WOS:000086454300032
J	Felker, GM; Thompson, RE; Hare, JM; Hruban, RH; Clemetson, DE; Howard, DL; Baughman, KL; Kasper, EK				Felker, GM; Thompson, RE; Hare, JM; Hruban, RH; Clemetson, DE; Howard, DL; Baughman, KL; Kasper, EK			Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; PERIPARTUM CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; MORTALITY; MORBIDITY	Background: Previous studies of the prognosis of patients with heart failure due to cardiomyopathy categorized patients according to whether they had ischemic or nonischemic disease. The prognostic value of identifying more specific underlying causes of cardiomyopathy is unknown. Methods: We evaluated the outcomes of 1230 patients with cardiomyopathy. The patients were grouped into the following categories according to underlying cause: idiopathic cardiomyopathy (616 patients); peripartum cardiomyopathy (51); and cardiomyopathy due to myocarditis (111), ischemic heart disease (91), infiltrative myocardial disease (59), hypertension (49), human immunodeficiency virus (HIV) infection (45), connective-tissue disease (39), substance abuse (37), therapy with doxorubicin (15), and other causes (117). Cox proportional-hazards analysis was used to assess the association between the underlying cause of cardiomyopathy and survival. Results: During a mean follow-up of 4.4 years, 417 patients died and 57 underwent cardiac transplantation. As compared with the patients with idiopathic cardiomyopathy, the patients with peripartum cardiomyopathy had better survival (adjusted hazard ratio for death, 0.31; 95 percent confidence interval, 0.09 to 0.98), and survival was significantly worse among the patients with cardiomyopathy due to infiltrative myocardial disease (adjusted hazard ratio, 4.40; 95 percent confidence interval, 3.04 to 6.39), HIV infection (adjusted hazard ratio, 5.86; 95 percent confidence interval, 3.92 to 8.77), therapy with doxorubicin (adjusted hazard ratio, 3.46; 95 percent confidence interval, 1.67 to 7.18), and ischemic heart disease (adjusted hazard ratio, 1.52; 95 percent confidence interval, 1.07 to 2.17). Conclusions: The underlying cause of heart failure has prognostic value in patients with unexplained cardiomyopathy. Patients with peripartum cardiomyopathy appear to have a better prognosis than those with other forms of cardiomyopathy. Patients with cardiomyopathy due to infiltrative myocardial diseases, HIV infection, or doxorubicin therapy have an especially poor prognosis. (N Engl J Med 2000;342:1077-84.) (C) 2000, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kasper, EK (corresponding author), Johns Hopkins Univ Hosp, Div Cardiol, Carnegie 568,600 N Wolfe St, Baltimore, MD 21287 USA.	ekasper@jhmi.edu	Felker, Michael/AAX-2288-2021; Howard, David L/H-8288-2019	Howard, David L/0000-0002-4907-4292; Felker, Gary/0000-0002-5931-1239				Adams KF, 1999, CIRCULATION, V99, P1816, DOI 10.1161/01.CIR.99.14.1816; Adams KF, 1996, J AM COLL CARDIOL, V28, P1781, DOI 10.1016/S0735-1097(96)00380-4; *AM COLL CARD AM H, 1995, CIRCULATION, V92, P2794; BILGRAD R, 1995, NATL DEATH INDEX USE; BOURASSA MG, 1993, J AM COLL CARDIOL, V22, pA14, DOI 10.1016/0735-1097(93)90456-B; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; Cooper LT, 1997, NEW ENGL J MED, V336, P1860, DOI 10.1056/NEJM199706263362603; DEMAKIS JG, 1971, CIRCULATION, V44, P1053, DOI 10.1161/01.CIR.44.6.1053; Felker GM, 1999, MEDICINE, V78, P270, DOI 10.1097/00005792-199907000-00005; FRANCIOSA JA, 1983, AM J CARDIOL, V51, P831, DOI 10.1016/S0002-9149(83)80141-6; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GARG R, 1995, JAMA-J AM MED ASSOC, V274, P462; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; HOMANS DC, 1985, NEW ENGL J MED, V312, P1432, DOI 10.1056/NEJM198505303122206; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; OAKLEY CM, 1980, BRIT HEART J, V44, P672; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Packer M, 1999, AM J CARDIOL, V83, p1A; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4	26	1049	1096	2	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1077	1084		10.1056/NEJM200004133421502	http://dx.doi.org/10.1056/NEJM200004133421502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10760308				2022-12-28	WOS:000086406700002
J	Hoerauf, A; Volkmann, L; Hamelmann, C; Adjei, O; Autenrieth, IB; Fleischer, B; Buttner, DW				Hoerauf, A; Volkmann, L; Hamelmann, C; Adjei, O; Autenrieth, IB; Fleischer, B; Buttner, DW			Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis	LANCET			English	Article								Endosymbiotic bacteria living in plasmodia or worm parasites are required for the homoeostasis of their host and should be excellent targets for chemotherapy of certain parasitic diseases. We show that targeting of Wolbachia spp bacteria in Onchocerca volvulus filariae by doxycycline leads to sterility of adult worms to an extent not seen with drugs used against onchocerciasis, a reading cause of blindness in African countries.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Kumasi Ctr Collaborat Res, Kumasi, Ghana; Univ Sci & Technol, Kumasi, Ghana; Univ Munich, Max Von Pettenkofer Inst, D-80336 Munich, Germany	Bernhard Nocht Institut fur Tropenmedizin; Kumasi Center for Collaborative Research; Kwame Nkrumah University Science & Technology; University of Munich	Hoerauf, A (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.							Hoerauf A, 1999, J CLIN INVEST, V103, P11, DOI 10.1172/JCI4768; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Plasari E, 1997, CHEM ENG RES DES, V75, P237, DOI 10.1205/026387697523507; Taylor MJ, 1999, PARASITOL TODAY, V15, P437, DOI 10.1016/S0169-4758(99)01533-1; *WHO, 1997, TOB HLTH GLOB STAT R, P1	5	228	234	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1242	1243		10.1016/S0140-6736(00)02095-X	http://dx.doi.org/10.1016/S0140-6736(00)02095-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770311				2022-12-28	WOS:000086448000018
J	Rocheville, M; Lange, DC; Kumar, U; Patel, SC; Patel, RC; Patel, YC				Rocheville, M; Lange, DC; Kumar, U; Patel, SC; Patel, RC; Patel, YC			Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity	SCIENCE			English	Article							ADENYLYL-CYCLASE; RAT-BRAIN; INTERNALIZATION; SYSTEM; CELLS; D1	Somatostatin and dopamine are two major neurotransmitter systems that share a number of structural and functional characteristics. Somatostatin receptors and dopamine receptors are colocalized in neuronal subgroups, and somatostatin is involved in modulating dopamine-mediated control of motor activity. However, the molecular basis for such interaction between the two systems is unclear. Here, we show that dopamine receptor D2R and somatostatin receptor SSTR5 interact physically through hetero-oligomerization to create a novel receptor with enhanced functional activity. Our results provide evidence that receptors from different G protein (heterotrimeric guanine nucleotide binding protein)-coupled receptor families interact through oligomerization. Such direct intramembrane association defines a new level of molecular crosstalk between related G protein-coupled receptor subfamilies.	McGill Univ, Dept Med, Fraser Labs, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Pharmacol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Therapeut, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Neurol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Clarkson Univ, Dept Phys, Potsdam, NY 13699 USA; Clarkson Univ, Dept Chem, Potsdam, NY 13699 USA; VA Connecticut Healthcare Syst, Newington, CT 06111 USA; New England Biomed Res Ctr, Newington, CT 06111 USA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; Royal Victoria Hospital; Clarkson University; Clarkson University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Patel, YC (corresponding author), McGill Univ, Dept Med, Fraser Labs, Montreal, PQ H3A 1A1, Canada.				NINDS NIH HHS [NS32160-05, NS34339] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032160, R01NS034339] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHNEIWEISS H, 1985, J NEUROCHEM, V44, P1825, DOI 10.1111/j.1471-4159.1985.tb07175.x; Clegg R.M., 1996, FLUORESCENCE IMAGING; COHN L, 1975, BRAIN RES, V96, P138; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; Forster T, 1948, NATURWISSENSCHAFTEN, V6, P166; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; HAVLICEK V, 1976, PHARMACOL BIOCHEM BE, V4, P455, DOI 10.1016/0091-3057(76)90063-0; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; HOYER D, 1994, ARCH PHARM, V350, P1; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; IzquierdoClaros RM, 1997, MOL BRAIN RES, V47, P99, DOI 10.1016/S0169-328X(97)00063-6; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; JOVIN TM, 1989, CELL STRUCTURE FUNCT; KASTIN AJ, 1978, METABOLISM, V27, P1247, DOI 10.1016/0026-0495(78)90053-7; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; LEBLANC R, 1988, NEUROLOGY, V38, P1887, DOI 10.1212/WNL.38.12.1887; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; MARTINIVERSON MT, 1986, PHARM BIOCH BEHAV, V24, P17; Marzullo P, 1999, Pituitary, V1, P115, DOI 10.1023/A:1009932521242; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PATEL YC, 1992, BASIC CLIN ASPECTS N, V4, P1; Picetti R, 1997, CRIT REV NEUROBIOL, V11, P121, DOI 10.1615/CritRevNeurobiol.v11.i2-3.20; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; RodriguezSanchez MN, 1997, J NEUROSCI RES, V48, P238, DOI 10.1002/(SICI)1097-4547(19970501)48:3<238::AID-JNR6>3.0.CO;2-G; SRIKANT CB, 1981, P NATL ACAD SCI-BIOL, V78, P3930, DOI 10.1073/pnas.78.6.3930; WEINER DM, 1991, P NATL ACAD SCI USA, V88, P1859, DOI 10.1073/pnas.88.5.1859; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	31	704	724	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					154	157		10.1126/science.288.5463.154	http://dx.doi.org/10.1126/science.288.5463.154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753124				2022-12-28	WOS:000086387700056
J	de Waal, FBM; Berger, ML				de Waal, FBM; Berger, ML			Payment for labour in monkeys	NATURE			English	Article							FOOD; CHIMPANZEES; CEBUS		Emory Univ, Yerkes Reg Primate Res Ctr, Atlanta, GA 30329 USA; Emory Univ, Dept Psychol, Atlanta, GA 30329 USA	Emory University; Emory University	de Waal, FBM (corresponding author), Emory Univ, Yerkes Reg Primate Res Ctr, Atlanta, GA 30329 USA.			Berger, Michelle/0000-0002-6679-6756				BOESCH C, 1989, AM J PHYS ANTHROPOL, V78, P547, DOI 10.1002/ajpa.1330780410; Crawford M.P., 1937, COMP PSYCHOL MONOGR, V14, P1; De Waal F., 1996, GOOD NATURED; de Waal FBM, 1997, J COMP PSYCHOL, V111, P370, DOI 10.1037/0735-7036.111.4.370; de Waal FBM, 1997, EVOL HUM BEHAV, V18, P375, DOI 10.1016/S1090-5138(97)00085-8; DEWAAL FBM, IN PRESS ANIM BEHAV; Dugatkin L.A., 1997, COOPERATION ANIMALS; Goodall J., 1965, P425; PERRY S, 1994, PRIMATES, V35, P409, DOI 10.1007/BF02381950; Rose LM, 1997, INT J PRIMATOL, V18, P727, DOI 10.1023/A:1026343812980; Stanford CB, 1999, HUNTING APES; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; [No title captured]	13	145	150	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					563	563		10.1038/35007138	http://dx.doi.org/10.1038/35007138			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766228	Bronze			2022-12-28	WOS:000086400100039
J	Polleux, F; Morrow, T; Ghosh, A				Polleux, F; Morrow, T; Ghosh, A			Semaphorin 3A is a chemoattractant for cortical apical dendrites	NATURE			English	Article							VISUAL-CORTEX; GROWTH; PROJECTIONS; EXPRESSION; NEUROPILIN; RECEPTOR; CELLS; IV	The apical dendrites of pyramidal neurons integrate inputs from various cortical layers and are central to information processing. Here we show that the growth of apical dendrites towards the pial surface is regulated by a diffusible chemoattractant present at high levels near the marginal zone. A major component of this signal is semaphorin 3A (Sema3A), which was previously characterized as a chemorepellant for cortical axons. Soluble guanylate cyclase is asymmetrically localized to the developing apical dendrite, and is required for the chemoattractive effect of Sema3A. Thus the asymmetric localization of soluble guanylate cyclase confers distinct Sema3A responses to axons and dendrites. These observations reveal a mechanism by which a single chemotropic signal can pattern both axons and dendrites during development.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Ghosh, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Polleux, Franck/H-9948-2014	Polleux, Franck/0000-0003-4313-0481				Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BUTTS NK, 1994, J STRENGTH COND RES, V8, P265; Catalano SM, 1998, MOL CELL NEUROSCI, V11, P173, DOI 10.1006/mcne.1998.0687; Chedotal A, 1998, DEVELOPMENT, V125, P4313; FISHELL G, 1995, DEVELOPMENT, V121, P803; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GILBERT CD, 1983, ANNU REV NEUROSCI, V6, P217, DOI 10.1146/annurev.ne.06.030183.001245; HARRIS DN, 1979, J CYCLIC NUCL PROT, V5, P125; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Kolodkin AL, 1998, PROG BRAIN RES, V117, P115; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Larkum ME, 1999, NATURE, V398, P338, DOI 10.1038/18686; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; MILLER MW, 1988, CEREB CORTEX, V7, P133; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Polleux F, 1998, SCIENCE, V282, P1904, DOI 10.1126/science.282.5395.1904; Robinson KR, 1997, DEV BIOL, V187, P125, DOI 10.1006/dbio.1997.8600; Skaliora I, 1998, EUR J NEUROSCI, V10, P1215, DOI 10.1046/j.1460-9568.1998.00128.x; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222	30	553	565	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					567	573		10.1038/35007001	http://dx.doi.org/10.1038/35007001			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766232				2022-12-28	WOS:000086400100043
J	Arbeitman, MN; Hogness, DS				Arbeitman, MN; Hogness, DS			Molecular chaperones activate the Drosophila ecdysone receptor, an RXR heterodimer	CELL			English	Article							RETINOID-X-RECEPTOR; NUCLEAR RECEPTORS; STEROID-RECEPTORS; DNA-BINDING; ULTRASPIRACLE; MELANOGASTER; HSP90; PROTEINS; COMPLEX; LOCALIZATION	The steroid hormone 20-hydroxyecdysone coordinates the stages of Drosophila development by activating a nuclear receptor heterodimer consisting of the ecdysone receptor, EcR, and the Drosophila RXR receptor, USP. We show that EcR/USP DNA binding activity requires activation by a chaperone heterocomplex like that required for activation of the vertebrate steroid receptors, but not previously shown to be required far activation of RXR heterodimers. Six proteins normally present in the chaperone complex were individually purified and shown to be sufficient for this activation. We also show that two of the six (Hsp90 and Hsc70) are required in vivo for ecdysone receptor activity, and that EcR is the primary target of the chaperone complex.	Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA	Stanford University	Hogness, DS (corresponding author), Stanford Univ, Dept Dev Biol, Sch Med, Stanford, CA 94305 USA.			Arbeitman, Michelle/0000-0002-2437-4352				ARBEITMAN MN, 1998, THESIS STANFORD U ST; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; Craig TA, 1999, BIOCHEM BIOPH RES CO, V260, P446, DOI 10.1006/bbrc.1999.0931; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DeFranco DB, 1998, J STEROID BIOCHEM, V65, P51, DOI 10.1016/S0960-0760(97)00177-5; DING D, 1993, MOL CELL BIOL, V13, P3773, DOI 10.1128/MCB.13.6.3773; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; HENRICH VC, 1994, DEV BIOL, V165, P38, DOI 10.1006/dbio.1994.1232; Hing HK, 1999, EUR J CELL BIOL, V78, P690, DOI 10.1016/S0171-9335(99)80037-5; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KISS I, 1988, GENETICS, V118, P247; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, THESIS STANFORD U ST; Li C, 1997, P NATL ACAD SCI USA, V94, P2278, DOI 10.1073/pnas.94.6.2278; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAROY P, 1978, P NATL ACAD SCI USA, V75, P6035, DOI 10.1073/pnas.75.12.6035; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PALTER KB, 1986, MOL CELL BIOL, V6, P1187, DOI 10.1128/MCB.6.4.1187; PERRIMON N, 1985, GENETICS, V111, P23; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RIDDIFORD LM, 1993, HORMONES DROSOPHILA; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; Ylikomi T, 1998, CRIT REV BIOCHEM MOL, V33, P437, DOI 10.1080/10409239891204279; YUND MA, 1978, P NATL ACAD SCI USA, V75, P6039, DOI 10.1073/pnas.75.12.6039	38	116	131	2	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 31	2000	101	1					67	77		10.1016/S0092-8674(00)80624-8	http://dx.doi.org/10.1016/S0092-8674(00)80624-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778857	Bronze			2022-12-28	WOS:000086249900009
J	Bartsiokas, A				Bartsiokas, A			The eye injury of King Philip II and the skeletal evidence from the Royal Tomb II at Vergina	SCIENCE			English	Article								The Royal Tomb II was discovered in Vergina, Greece, in 1977. It contained a male skeleton and a rich array of grave goods. Evidence of trauma supposedly in the orbital bones of the skull has been thought to correspond to an eye injury that King Philip II is historically known to have suffered. However, reexamination of the orbital morphology showed no evidence of such pathology. Therefore, the skeleton does not belong to Philip II. New skeletal evidence shows that the skeleton belongs to King Philip III Arrhidaeus. In this case, the tomb may well contain some of the paraphernalia of Alexander the Great.	Anaximandrian Inst Human Evolut, GR-16673 Voula, Greece		Bartsiokas, A (corresponding author), Anaximandrian Inst Human Evolut, 6 Aeginis St, GR-16673 Voula, Greece.							ADAMS WL, 1991, ANCIENT WORLD, V22, P27; ANDRONICOS M, 1994, VERGINA ROYAL TOMBS; BERKOVITZ BKB, 1989, COLOR ATLAS SKULL; BORZA EN, 1987, PHOENIX-J CLASS ASSN, V41, P105, DOI 10.2307/1088739; BORZA EN, 1992, SHADOW OLYMPUS EMERG; Bosworth A. B., 2000, ALEXANDER GREAT FACT; Hare P.E., 1980, P208; Hauser G., 1989, EPIGENETIC VARIANTS; Herrmann NP, 1999, J FORENSIC SCI, V44, P461; MUSGRAVE J. H., 1990, ANNU BRIT SCH ATHENS, V85, P271; MUSGRAVE JH, 1984, J HELLENIC STUD, V104, P60, DOI 10.2307/630280; Musgrave JH, 1985, CURRENT TOPICS ORAL, P1; PRAG AJNW, 1990, AM J ARCHAEOL, V94, P237, DOI 10.2307/505951; PRAG J, 1997, MAKING FACES USING F, P53; RIGINOS AS, 1994, J HELLENIC STUD, V114, P103, DOI 10.2307/632736; Shipman P., 1981, LIFE HIST FOSSIL INT; Stewart T.D., 1979, ESSENTIALS FORENSIC, P59; THEMELIS P, 1997, PUBLICATION TAPA, V59; Ubelaker D. H., 1991, HUMAN SKELETAL REMAI; VONENDT DW, 1984, J ARCHAEOL SCI, V11, P247, DOI 10.1016/0305-4403(84)90005-0; White T.D., 1991, HUMAN OSTEOLOGY; Xirotiris N.I., 1981, ARCHEPH, P142	22	20	21	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					511	514		10.1126/science.288.5465.511	http://dx.doi.org/10.1126/science.288.5465.511			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775109				2022-12-28	WOS:000086626000044
J	Johnson-Laird, PN; Legrenzi, P; Girotto, V; Legrenzi, MS				Johnson-Laird, PN; Legrenzi, P; Girotto, V; Legrenzi, MS			Illusions in reasoning about consistency	SCIENCE			English	Article								Reasoners succumb to predictable illusions in evaluating whether sets of assertions are consistent. We report two studies of this computationally intractable task of "satisfiability." The results show that as the number of possibilities compatible with the assertions increases, the difficulty of the task increases, and that reasoners represent what is true according to assertions, not what is false. This procedure avoids overloading memory, but it yields illusions of consistency and of inconsistency. These illusions modify our picture of human rationality.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; Univ Milan, Dept Philosophy, I-20122 Milan, Italy; Univ Aix Marseille 1, CNRS, LPC, F-13100 Aix En Provence, France; Univ Trieste, Dept Psychol, I-34100 Trieste, Italy; Univ Padua, Dept Psychol, I-35100 Padua, Italy	Princeton University; University of Milan; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Trieste; University of Padua	Johnson-Laird, PN (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	phil@princeton.edu						Braine M. D. S., 1998, MENTAL LOGIC, DOI [10.4324/9781410603005, DOI 10.4324/9781410603005]; BRAINE MDS, 1991, PSYCHOL REV, V98, P182, DOI 10.1037/0033-295X.98.2.182; Cook SA, 1971, P 3 ANN ACM S THEOR, P151, DOI DOI 10.1145/800157.805047; Garey M.R., 1979, COMPUTERS INTRACTABI; Johnson-Laird P. N., 1991, DEDUCTION; Johnson-Laird PN, 1999, PSYCHOL REV, V106, P62, DOI 10.1037/0033-295X.106.1.62; Johnson-Laird PN, 1999, COGNITION, V71, P191, DOI 10.1016/S0010-0277(99)00015-3; Rips L. J, 1994, PSYCHOL PROOF	8	54	58	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					531	532		10.1126/science.288.5465.531	http://dx.doi.org/10.1126/science.288.5465.531			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	306YJ	10775114				2022-12-28	WOS:000086626000049
J	Lowrey, PL; Shimomura, K; Antoch, MP; Yamazaki, S; Zemenides, PD; Ralph, MR; Menaker, M; Takahashi, JS				Lowrey, PL; Shimomura, K; Antoch, MP; Yamazaki, S; Zemenides, PD; Ralph, MR; Menaker, M; Takahashi, JS			Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau	SCIENCE			English	Article							CASEIN KINASE-I; REPRESENTATIONAL DIFFERENCE ANALYSIS; DROSOPHILA PERIOD GENE; DIRECTED PROTEIN-KINASE; CLOCK GENE; SUPRACHIASMATIC NUCLEUS; SUBSTRATE DETERMINANTS; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; DOUBLE-TIME	The tau mutation is a semidominant autosomal allele that dramatically shortens period Length of circadian rhythms in Syrian hamsters. We report the molecular identification of the tau Locus using genetically directed representational difference analysis to define a region of conserved synteny in hamsters with both the mouse and human genomes. The tau Locus is encoded by casein kinase I epsilon (CKl epsilon), a homolog of the Drosophila circadian gene double-time. in vitro expression and functional studies of wild-type and tau mutant CKl epsilon enzyme reveal that the mutant enzyme has a markedly reduced maximal velocity and autophosphorylation state. In addition, in vitro CKl epsilon can interact with mammalian PERIOD proteins, and the mutant enzyme is deficient in its ability to phosphorylate PERIOD. We conclude that tau is an allele of hamster CKl epsilon and propose a mechanism by which the mutation Leads to the observed aberrant circadian phenotype in mutant animals.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA; Univ Virginia, Dept Biol, Natl Sci Fdn, Ctr Biol Timing, Charlottesville, VA 22903 USA; Univ Toronto, Dept Psychol, Toronto, ON M5S 3G3, Canada	Northwestern University; Howard Hughes Medical Institute; Northwestern University; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; University of Toronto	Takahashi, JS (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA.	j-takahashi@northwestern.edu	Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; Antoch, mantoch/0000-0003-3001-8511; Yamazaki, Shin/0000-0002-6691-1531	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056647, R37MH039592] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIMH NIH HHS [R01MH56647, R37MH39592] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADLER S, 1948, NATURE, V162, P256, DOI 10.1038/162256b0; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Anderson SL, 1997, ADV GENET, V35, P1, DOI 10.1016/S0065-2660(08)60446-0; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Aschoff J., 1981, HDB BEHAV NEUROBIOLO, V4; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Bae K, 2000, J NEUROSCI, V20, P1746; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DIETRICH W, 1992, GENETICS, V131, P423; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Hastings M H, 1999, J Neurosci, V19, pRC11; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Johnson CH, 1999, ANNU REV MICROBIOL, V53, P389, DOI 10.1146/annurev.micro.53.1.389; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Koike N, 1998, FEBS LETT, V441, P427, DOI 10.1016/S0014-5793(98)01597-X; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LANDER ES, 1993, NAT GENET, V4, P5, DOI 10.1038/ng0593-5; Lee C, 1999, MOL CELL BIOL, V19, P5316; LISITSYN N, 1995, METHOD ENZYMOL, V254, P291; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LISITSYN NA, 1994, NAT GENET, V6, P57, DOI 10.1038/ng0194-57; LISITSYN NA, 1995, TRENDS GENET, V11, P303, DOI 10.1016/S0168-9525(00)89087-3; Longenecker KL, 1998, ACTA CRYSTALLOGR D, V54, P473, DOI 10.1107/S0907444997011724; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; Murphy M.R., 1985, P3; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; Okuizumi H, 1997, MAMM GENOME, V8, P121, DOI 10.1007/s003359900370; Ott J., 1991, ANAL HUMAN GENETIC L; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tischkau S A, 1999, J Neurosci, V19, pRC15; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	80	645	667	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					483	491		10.1126/science.288.5465.483	http://dx.doi.org/10.1126/science.288.5465.483			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775102	Green Accepted			2022-12-28	WOS:000086626000037
J	Orenstein, J; Millis, AJ				Orenstein, J; Millis, AJ			Advances in the physics of high-temperature superconductivity	SCIENCE			English	Review							2-DIMENSIONAL HUBBARD-MODEL; A-B PLANE; NORMAL-STATE; CUPRATE SUPERCONDUCTORS; SURFACE IMPEDANCE; FLUX-QUANTIZATION; PENETRATION DEPTH; DOPING DEPENDENCE; PHASE-SEPARATION; GAP ANISOTROPY	The high-temperature copper oxide superconductors are of fundamental and enduring interest. They not only manifest superconducting transition temperatures inconceivable 15 years ago, but also exhibit many other properties apparently incompatible with conventional metal physics. The materials expand our notions of what is possible, and compel us to develop new experimental techniques and theoretical concepts, This article provides a perspective on recent developments and their implications for our understanding of interacting electrons in metals.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Rutgers State University New Brunswick	Orenstein, J (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.		Orenstein, Joseph W/I-3451-2015					Aeppli G, 1997, SCIENCE, V278, P1432, DOI 10.1126/science.278.5342.1432; AMBEGAOKAR V, 1980, PHYS REV B, V21, P1806, DOI 10.1103/PhysRevB.21.1806; Andersen OK, 1995, J PHYS CHEM SOLIDS, V56, P1573, DOI 10.1016/0022-3697(95)00269-3; Anderson P. W., 1997, THEORY SUPERCONDUCTI; ANDERSON PW, 1959, PHYS REV, V115, P2, DOI 10.1103/PhysRev.115.2; ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; ANNETT J, 1991, PHYS REV B, V43, P2778, DOI 10.1103/PhysRevB.43.2778; Balatsky AV, 1999, PHYS REV LETT, V82, P5337, DOI 10.1103/PhysRevLett.82.5337; BASOV DN, 1994, PHYS REV B, V50, P3511, DOI 10.1103/PhysRevB.50.3511; BATLOGG B, 1994, PHYSICA C, V235, P130, DOI 10.1016/0921-4534(94)91330-7; Boebinger GS, 1996, PHYS REV LETT, V77, P5417, DOI 10.1103/PhysRevLett.77.5417; Bonn DA, 1996, CZECH J PHYS, V46, P3195, DOI 10.1007/BF02548130; Campuzano JC, 1998, NATO ADV SCI I B-PHY, V371, P229; CASTELLANI C, 1995, PHYS REV LETT, V75, P4650, DOI 10.1103/PhysRevLett.75.4650; CHAKRAVARTY S, 1993, SCIENCE, V261, P337, DOI 10.1126/science.261.5119.337; CHEONG SW, 1991, PHYS REV LETT, V67, P1791, DOI 10.1103/PhysRevLett.67.1791; CHIEN TR, 1991, PHYS REV LETT, V67, P2088, DOI 10.1103/PhysRevLett.67.2088; Corson J, 1999, NATURE, V398, P221, DOI 10.1038/18402; CRAWFORD MK, 1991, PHYS REV B, V44, P7749, DOI 10.1103/PhysRevB.44.7749; Ding H, 1996, PHYS REV B, V54, pR9678, DOI 10.1103/PhysRevB.54.R9678; DING H, 1995, PHYS REV LETT, V75, P1425, DOI 10.1103/PhysRevLett.75.1425; Ding H, 1996, PHYS REV LETT, V76, P1533, DOI 10.1103/PhysRevLett.76.1533; EMERY VJ, 1990, PHYS REV LETT, V64, P475, DOI 10.1103/PhysRevLett.64.475; Emery VJ, 1997, PHYS REV B, V56, P6120, DOI 10.1103/PhysRevB.56.6120; EMERY VJ, 1990, PHYSICA B, V163, P306, DOI 10.1016/0921-4526(90)90196-2; Fedorov AV, 1999, PHYS REV LETT, V82, P2179, DOI 10.1103/PhysRevLett.82.2179; FRADKIN E, 1986, PHYS REV B, V33, P3263, DOI 10.1103/PhysRevB.33.3263; GOUGH CE, 1987, NATURE, V326, P855, DOI 10.1038/326855a0; HARDY WN, 1993, PHYS REV LETT, V70, P3999, DOI 10.1103/PhysRevLett.70.3999; HIRSCHFELD PJ, 1993, PHYS REV LETT, V71, P3705, DOI 10.1103/PhysRevLett.71.3705; HIRSCHFELD PJ, 1994, PHYS REV B, V50, P10250, DOI 10.1103/PhysRevB.50.10250; HLUBINA R, 1995, PHYS REV B, V51, P9253, DOI 10.1103/PhysRevB.51.9253; HOMES CC, 1995, PHYSICA C, V254, P265, DOI 10.1016/0921-4534(95)00579-X; Hosseini A, 1999, PHYS REV B, V60, P1349, DOI 10.1103/PhysRevB.60.1349; Imada M, 1998, REV MOD PHYS, V70, P1039, DOI 10.1103/RevModPhys.70.1039; Ioffe LB, 1998, PHYS REV B, V58, P11631, DOI 10.1103/PhysRevB.58.11631; JACOBS T, 1995, PHYS REV LETT, V75, P4516, DOI 10.1103/PhysRevLett.75.4516; Kaminski A, 2000, PHYS REV LETT, V84, P1788, DOI 10.1103/PhysRevLett.84.1788; KELLEY RJ, 1994, PHYS REV B, V50, P590, DOI 10.1103/PhysRevB.50.590; Kimura H, 1999, PHYS REV B, V59, P6517, DOI 10.1103/PhysRevB.59.6517; KOTLIAR G, 1988, PHYS REV B, V38, P5142, DOI 10.1103/PhysRevB.38.5142; Krishana K, 1997, SCIENCE, V277, P83, DOI 10.1126/science.277.5322.83; Lee PA, 1999, PHYSICA C, V317, P194, DOI 10.1016/S0921-4534(99)00059-3; LEE PA, 1993, PHYS REV LETT, V71, P1887, DOI 10.1103/PhysRevLett.71.1887; Lee PA, 1997, PHYS REV LETT, V78, P4111, DOI 10.1103/PhysRevLett.78.4111; Lee SF, 1996, PHYS REV LETT, V77, P735, DOI 10.1103/PhysRevLett.77.735; Loeser AG, 1997, PHYS REV B, V56, P14185, DOI 10.1103/PhysRevB.56.14185; LOW U, 1994, PHYS REV LETT, V72, P1918, DOI 10.1103/PhysRevLett.72.1918; MAGGIOAPRILE I, 1995, PHYS REV LETT, V75, P2754, DOI 10.1103/PhysRevLett.75.2754; MASON TE, 1992, PHYS REV LETT, V68, P1414, DOI 10.1103/PhysRevLett.68.1414; Millis AJ, 1998, J PHYS CHEM SOLIDS, V59, P1742, DOI 10.1016/S0022-3697(98)00094-8; Millis AJ, 1999, NATURE, V398, P193, DOI 10.1038/18311; MONTHOUX P, 1992, PHYS REV B, V46, P14803, DOI 10.1103/PhysRevB.46.14803; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; Niedermayer C, 1998, PHYS REV LETT, V80, P3843, DOI 10.1103/PhysRevLett.80.3843; Noda T, 1999, SCIENCE, V286, P265, DOI 10.1126/science.286.5438.265; Ong NP, 1997, PHYS REV LETT, V78, P977, DOI 10.1103/PhysRevLett.78.977; ORENSTEIN J, 1990, PHYS REV B, V42, P6342, DOI 10.1103/PhysRevB.42.6342; Pan SH, 2000, NATURE, V403, P746, DOI 10.1038/35001534; Panagopoulos C, 1999, PHYS REV B, V60, P14617, DOI 10.1103/PhysRevB.60.14617; Sachdev S, 2000, SCIENCE, V288, P475, DOI 10.1126/science.288.5465.475; Salkola MI, 1996, PHYS REV LETT, V77, P155, DOI 10.1103/PhysRevLett.77.155; Schiffer P., 1996, Comments on Condensed Matter Physics, V18, P21; SCHULZ HJ, 1990, PHYS REV LETT, V64, P1445, DOI 10.1103/PhysRevLett.64.1445; Seibold G, 1998, PHYS REV B, V58, P13506, DOI 10.1103/PhysRevB.58.13506; SHEN ZX, 1993, PHYS REV LETT, V70, P1553, DOI 10.1103/PhysRevLett.70.1553; SHEN ZX, 1995, PHYS REP, V253, P2; SPIELMAN S, 1990, PHYS REV LETT, V65, P123, DOI 10.1103/PhysRevLett.65.123; Stojkovic BP, 1997, PHYS REV B, V56, P11931, DOI 10.1103/PhysRevB.56.11931; Stojkovic BP, 1996, PHYS REV LETT, V76, P811, DOI 10.1103/PhysRevLett.76.811; Suzuki T, 1998, PHYS REV B, V57, pR3229, DOI 10.1103/PhysRevB.57.R3229; SUZUMURA Y, 1988, J PHYS SOC JPN, V57, P2768, DOI 10.1143/JPSJ.57.2768; TALLON JL, 1995, PHYS REV LETT, V74, P1008, DOI 10.1103/PhysRevLett.74.1008; THURSTON TR, 1989, PHYS REV B, V40, P4585, DOI 10.1103/PhysRevB.40.4585; THURSTON TR, 1992, PHYS REV B, V46, P9128, DOI 10.1103/PhysRevB.46.9128; Tokura Y, 2000, SCIENCE, V288, P462, DOI 10.1126/science.288.5465.462; Tranquada JM, 1997, PHYSICA B, V241, P745, DOI 10.1016/S0921-4526(97)00711-4; Tranquada JM, 1997, PHYS REV LETT, V78, P338, DOI 10.1103/PhysRevLett.78.338; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; TSUEI CC, 1994, PHYS REV LETT, V73, P593, DOI 10.1103/PhysRevLett.73.593; UEMURA YJ, 1989, PHYS REV LETT, V62, P2317, DOI 10.1103/PhysRevLett.62.2317; Valla T, 1999, SCIENCE, V285, P2110, DOI 10.1126/science.285.5436.2110; Varma CM, 1996, PHYSICA C, V263, P39, DOI 10.1016/0921-4534(96)00070-6; VARMA CM, 1989, PHYS REV LETT, V63, P1996, DOI 10.1103/PhysRevLett.63.1996; Varma CM, 1999, PHYS REV LETT, V83, P3538, DOI 10.1103/PhysRevLett.83.3538; White SR, 2000, PHYS REV B, V61, P6320, DOI 10.1103/PhysRevB.61.6320; WOLLMAN DA, 1993, PHYS REV LETT, V71, P2134, DOI 10.1103/PhysRevLett.71.2134; Yamada K, 1998, PHYS REV B, V57, P6165, DOI 10.1103/PhysRevB.57.6165; YOSHIZAWA H, 1988, J PHYS SOC JPN, V57, P3686, DOI 10.1143/JPSJ.57.3686; Zaanen J, 1999, SCIENCE, V286, P251, DOI 10.1126/science.286.5438.251; Zaanen J, 1998, J PHYS CHEM SOLIDS, V59, P1769, DOI 10.1016/S0022-3697(98)00106-1; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391; Zhang SC, 1997, SCIENCE, V275, P1089, DOI 10.1126/science.275.5303.1089; Zhou XJ, 1999, SCIENCE, V286, P268, DOI 10.1126/science.286.5438.268	96	726	738	7	315	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					468	474		10.1126/science.288.5465.468	http://dx.doi.org/10.1126/science.288.5465.468			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775099				2022-12-28	WOS:000086626000034
J	Hwang, SL; Shen, PY; Chu, HT; Yui, TF				Hwang, SL; Shen, PY; Chu, HT; Yui, TF			Nanometer-size alpha-PbO2-type TiO2 in garnet: A thermobarometer for ultrahigh-pressure metamorphism	SCIENCE			English	Article							PHASE-TRANSITION; ROCKS; DIAMOND	A high-pressure phase of titanium dioxide (TiO2) with an alpha-PbO2-type structure has been identified in garnet of diamondiferous quartzofeldspathic rocks from the Saxonian Erzgebirge, Germany. Analytical electron microscopy indicates that this alpha-PbO2-type TiO2 occurred as an epitaxial nanometer-thick slab between twinned rutile bicrystals. Given a V-shaped curve for the equilibrium phase boundary of alpha-PbO2-type TiO2 to rutile, the stabilization pressure of alpha-PbO2-type TiO2 should be 4 to 5 gigapascals at 900 degrees to 1000 degrees C. This suggests a burial of continental crustal rocks to depths of at Least 130 kilometers. The alpha-PbO2-type TiO2 may be a useful pressure and temperature indicator in the diamond stability field.	Natl Sun Yat Sen Univ, Inst Mat Sci & Engn, Kaohsiung 80424, Taiwan; I Shou Univ, Dept Mat Sci & Engn, Kaohsiung, Taiwan; Cent Geol Survey, Taipei, Taiwan; Acad Sinica, Inst Earth Sci, Taipei 115, Taiwan	National Sun Yat Sen University; I Shou University; Academia Sinica - Taiwan	Shen, PY (corresponding author), Natl Sun Yat Sen Univ, Inst Mat Sci & Engn, Kaohsiung 80424, Taiwan.	pshen@mail.nsysu.edu.tw	Yui, Tzen-Fu/B-9271-2009					AKAOGI M, 1989, 30 HIGH PRESS C JAP, P111; Berman R. G., 1979, PROPERTIES DIAMOND, P4; CHOPIN C, 1984, CONTRIB MINERAL PETR, V86, P107, DOI 10.1007/BF00381838; DOBRZHINETSKAYA LF, 1995, GEOLOGY, V23, P597, DOI 10.1130/0091-7613(1995)023<0597:MIHGMR>2.3.CO;2; HAHN T, 1987, INT TABLES CRYSTALLO, VA, P190; Hyde B. G., 1989, INORGANIC CRYSTAL ST, P67; Isaak DG, 1998, PHYS CHEM MINER, V26, P31, DOI 10.1007/s002690050158; KRINER A, 1998, MINER PETROL, V132, P1; KUSABA K, 1988, PHYS CHEM MINER, V15, P238, DOI 10.1007/BF00307512; Liou JG, 1998, REV MINERAL, V37, P33; Massonne HJ, 1998, EUR J MINERAL, V10, P497; MASSONNE HJ, 1998, IN PRESS P 7 INT KIM; Olsen JS, 1999, J PHYS CHEM SOLIDS, V60, P229, DOI 10.1016/S0022-3697(98)00274-1; REED SJB, 1982, ULTRAMICROSCOPY, V7, P405, DOI 10.1016/0304-3991(82)90263-7; SIMONS PY, 1967, ACTA CRYSTALLOGR, V23, P334, DOI 10.1107/S0365110X67002713; SOBOLEV NV, 1990, NATURE, V343, P742, DOI 10.1038/343742a0; TANG J, 1993, J AM CERAM SOC, V76, P796, DOI 10.1111/j.1151-2916.1993.tb03683.x; TOLBERT SH, 1994, SCIENCE, V265, P373, DOI 10.1126/science.265.5170.373; WILLIAMS DB, 1996, TRANSMISSION ELECT M, V4, P623; WINCHELL AN, 1961, ELEMENTS OPTICAL MIN, P66; XU ST, 1992, SCIENCE, V256, P80, DOI 10.1126/science.256.5053.80	21	147	219	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	2000	288	5464					321	324		10.1126/science.288.5464.321	http://dx.doi.org/10.1126/science.288.5464.321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764642				2022-12-28	WOS:000086454300033
J	Knipping, EM; Lakin, MJ; Foster, KL; Jungwirth, P; Tobias, DJ; Gerber, RB; Dabdub, D; Finlayson-Pitts, BJ				Knipping, EM; Lakin, MJ; Foster, KL; Jungwirth, P; Tobias, DJ; Gerber, RB; Dabdub, D; Finlayson-Pitts, BJ			Experiments and simulations of ion-enhanced interfacial chemistry on aqueous NaCl aerosols	SCIENCE			English	Article							MOLECULAR-DYNAMICS; CHEMICAL-REACTION; WATER; SURFACES; CHLORINE; CLUSTERS; OZONE; ATOM	A combination of experimental, molecular dynamics, and kinetics modeling studies is applied to a system of concentrated aqueous sodium chloride particles suspended in air at room temperature with ozone. irradiated at 254 nanometers to generate hydroxyl radicals. Measurements of the observed gaseous molecular chlorine product are explainable only if reactions at the air-water interface are dominant. Molecular dynamics simulations show the availability of substantial amounts of chloride ions for reaction at the interface, and quantum chemical calculations predict that in the gas phase chloride ions will strongly attract hydroxl radicals. Model extrapolation to the marine boundary Layer yields daytime chlorine atom concentrations that are in good agreement with estimates based on field measurements of the decay of selected organics over the Southern Ocean and the North Atlantic. Thus, ion-enhanced interactions with gases at aqueous interfaces may play a more generalized and important role in the chemistry of concentrated inorganic salt solutions than was previously recognized.	Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Mech & Aerosp Engn, Irvine, CA 92697 USA; Acad Sci Czech Republ, J Heyrovsky Inst Phys Chem, CR-18223 Prague 8, Czech Republic; Hebrew Univ Jerusalem, Dept Phys Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Fritz Haber Res Ctr, IL-91904 Jerusalem, Israel	University of California System; University of California Irvine; University of California System; University of California Irvine; Czech Academy of Sciences; J. Heyrovsky Institute of Physical Chemistry of the Czech Academy of Sciences; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Finlayson-Pitts, BJ (corresponding author), Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.	bjfinlay@uci.edu	Jungwirth, Pavel/D-9290-2011; Knipping, Eladio/GWR-2070-2022; Tobias, Douglas J/B-6799-2015	Jungwirth, Pavel/0000-0002-6892-3288; Knipping, Eladio/0000-0002-9654-9019; Finlayson-Pitts, Barbara/0000-0003-4650-168X				Barrie L, 1997, TELLUS B, V49, P450, DOI 10.1034/j.1600-0889.49.issue5.2.x; Behnke W, 1995, ENVIRON CHEM, V1, P375; CHAMEIDES WL, 1992, J GEOPHYS RES-ATMOS, V97, P20565, DOI 10.1029/92JD01923; Dabdub D, 1996, PARALLEL COMPUT, V22, P111, DOI 10.1016/0167-8191(95)00063-1; DAVIS MJ, 1994, J CHEM PHYS, V101, P4708, DOI 10.1063/1.468463; De Haan DO, 1999, INT REV PHYS CHEM, V18, P343, DOI 10.1080/014423599229910; Degreve L, 1999, J CHEM PHYS, V110, P3070, DOI 10.1063/1.477903; DONALDSON DJ, 1995, J PHYS CHEM-US, V99, P9313, DOI 10.1021/j100023a002; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FRISCH MJ, 1998, GAUSSIAN98 COMPUTER; Griffiths FB, 1999, J GEOPHYS RES-ATMOS, V104, P21649, DOI 10.1029/1999JD900386; Hanson DR, 1997, J PHYS CHEM B, V101, P4998, DOI 10.1021/jp970461f; HU JH, 1995, J PHYS CHEM-US, V99, P8768, DOI 10.1021/j100021a050; Jacobi HW, 1999, INT J CHEM KINET, V31, P169, DOI 10.1002/(SICI)1097-4601(1999)31:3<169::AID-KIN2>3.0.CO;2-K; JARVIS NL, 1968, J PHYS CHEM-US, V72, P74, DOI 10.1021/j100847a014; JAYNE JT, 1990, J PHYS CHEM-US, V94, P6041, DOI 10.1021/j100378a076; JAYSON GG, 1973, J CHEM SOC FARAD T 1, P1597; Jungwirth P, 2000, J PHYS CHEM A, V104, P145, DOI 10.1021/jp993010z; KESTER DR, 1967, LIMNOL OCEANOGR, V12, P176, DOI 10.4319/lo.1967.12.1.0176; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Magi L, 1997, J PHYS CHEM A, V101, P4943, DOI 10.1021/jp970646m; MARTYNA GJ, UNPUB PINY MD PROGRA; Oum KW, 1998, GEOPHYS RES LETT, V25, P3923, DOI 10.1029/1998GL900078; Oum KW, 1998, SCIENCE, V279, P74, DOI 10.1126/science.279.5347.74; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PERERA L, 1991, J CHEM PHYS, V95, P1954, DOI 10.1063/1.460992; Petersen CP, 1999, J PHYS CHEM A, V103, P4162, DOI 10.1021/jp984806l; Pitts Jr J. N., 2000, CHEM UPPER LOWER ATM; Pitzer K.S, 1991, ION INTERACTION APPR, Vsecond; Ramaniah LM, 1998, J CHEM PHYS, V109, P6839, DOI 10.1063/1.477250; Sander R, 1996, J GEOPHYS RES-ATMOS, V101, P9121, DOI 10.1029/95JD03793; Schwartz S.E., 1986, MASS TRANSPORT CONSI, P415, DOI DOI 10.1007/978-3-642-70627-1_16; Sevilla MD, 1997, J PHYS CHEM A, V101, P2910, DOI 10.1021/jp964097g; Snoeyink VL., 1980, WATER CHEM; Tang IN, 1997, J GEOPHYS RES-ATMOS, V102, P23269, DOI 10.1029/97JD01806; Taube H, 1942, J AM CHEM SOC, V64, P2468, DOI 10.1021/ja01262a072; WILSON MA, 1991, J CHEM PHYS, V95, P6005, DOI 10.1063/1.461592; Wingenter OW, 1999, J GEOPHYS RES-ATMOS, V104, P21819, DOI 10.1029/1999JD900203; Wingenter OW, 1996, J GEOPHYS RES-ATMOS, V101, P4331, DOI 10.1029/95JD02457	39	633	637	7	276	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	2000	288	5464					301	306		10.1126/science.288.5464.301	http://dx.doi.org/10.1126/science.288.5464.301			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764637				2022-12-28	WOS:000086454300028
J	Kostis, JB; Wilson, AC; Lacy, CR				Kostis, JB; Wilson, AC; Lacy, CR			Hypertension and ascorbic acid	LANCET			English	Letter									Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Kostis, JB (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.							Duffy SJ, 1999, LANCET, V354, P2048, DOI 10.1016/S0140-6736(99)04410-4; Egan DA, 1999, AM J CARDIOL, V83, P569, DOI 10.1016/S0002-9149(98)00915-1; Galley HF, 1997, CLIN SCI, V92, P361, DOI 10.1042/cs0920361; Mark SD, 1998, EPIDEMIOLOGY, V9, P9, DOI 10.1097/00001648-199801000-00005; Miller E R 3rd, 1997, J Cardiovasc Risk, V4, P19	5	4	4	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1272	1272		10.1016/S0140-6736(05)74699-7	http://dx.doi.org/10.1016/S0140-6736(05)74699-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770323	Bronze			2022-12-28	WOS:000086448000044
J	Kuhn, NJ				Kuhn, NJ			Learn lateral thinking first and specialize later	NATURE			English	Letter									Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Kuhn, NJ (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.							Seitz F, 2000, NATURE, V403, P483, DOI 10.1038/35000668	1	0	0	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					542	542		10.1038/35007249	http://dx.doi.org/10.1038/35007249			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766216	Bronze			2022-12-28	WOS:000086400100021
J	Rosenbaum, TF				Rosenbaum, TF			Magnetoresistance - A new spin on magnets	NATURE			English	Editorial Material							METAL		Univ Chicago, Dept Phys, Chicago, IL 60637 USA; Univ Chicago, James Franck Inst, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Rosenbaum, TF (corresponding author), Univ Chicago, Dept Phys, 5640 Ellis Ave, Chicago, IL 60637 USA.							Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; DiTusa JF, 1997, PHYS REV LETT, V78, P2831, DOI 10.1103/PhysRevLett.78.2831; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; Kikkawa JM, 1997, SCIENCE, V277, P1284, DOI 10.1126/science.277.5330.1284; LEE PA, 1985, REV MOD PHYS, V57, P287, DOI 10.1103/RevModPhys.57.287; Manyala N, 2000, NATURE, V404, P581, DOI 10.1038/35007030; ROSENBAUM TF, 1981, PHYS REV LETT, V47, P1758, DOI 10.1103/PhysRevLett.47.1758; Tokura Y, 1996, J APPL PHYS, V79, P5288, DOI 10.1063/1.361353	8	3	3	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					556	557		10.1038/35007178	http://dx.doi.org/10.1038/35007178			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766223				2022-12-28	WOS:000086400100033
J	Charlesworth, B				Charlesworth, B			No pie in the sky, thanks	NATURE			English	Letter									Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Charlesworth, B (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Kings Bldg,W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.							Cantor G, 2000, NATURE, V403, P831, DOI 10.1038/35002681	1	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					431	431		10.1038/35006736	http://dx.doi.org/10.1038/35006736			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761890	Bronze			2022-12-28	WOS:000086257700016
J	Nowak, MA; Plotkin, JB; Jansen, VAA				Nowak, MA; Plotkin, JB; Jansen, VAA			The evolution of syntactic communication	NATURE			English	Article							LANGUAGE	Animal communication is typically non-syntactic, which means that signals refer to whole situations(1-7). Human language is syntactic, and signals consist of discrete components that have their own meaning(8). Syntax is a prerequisite for taking advantage of combinatorics, that is, "making infinite use of finite means"(9-11) The vast expressive power of human language would be impossible without syntax, and the transition from non-syntactic to syntactic communication was an essential step in the evolution of human language(12-16). We aim to understand the evolutionary dynamics of this transition and to analyse how natural selection can guide it. Here we present a model for the population dynamics of language evolution, define the basic reproductive ratio of words and calculate the maximum size of a lexicon. Syntax allows larger repertoires and the possibility to formulate messages that have not been learned beforehand. Nevertheless, according to our model natural selection can only favour the emergence of syntax if the number of required signals exceeds a threshold value. This result might explain why only humans evolved syntactic communication and hence complex language.	Inst Adv Study, Princeton, NJ 08540 USA; Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England	Institute for Advanced Study - USA; University of London; Royal Holloway University London	Nowak, MA (corresponding author), Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA.		Nowak, Martin A/A-6977-2008; Plotkin, Joshua B/E-6947-2013; Galantucci, Bruno/E-5770-2010; Jansen, Vincent A A/C-8353-2009	Jansen, Vincent A.A./0000-0002-6518-2090				Batali J., 1998, APPROACHES EVOLUTION; BATES E, 1991, BIOL BEHAV DETERMINA; BICKERTON D, 1990, SPECIES LANGUAGE; BURLING R, 1993, CURR ANTHROPOL, V34, P25, DOI 10.1086/204132; Cheney D. L., 1990, MONKEYS SEE WORLD IN; CHOMSKY N., 1972, LANGUAGE MIND; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; Chomsky Noam, 1988, LANGUAGE PROBLEMS KN; Dunbar R., 1996, GROOMING GOSSIP EVOL; GOULD JL, 1987, SCI AM, V256, P74, DOI 10.1038/scientificamerican0187-74; Hauser, 1996, EVOL COMMUN; Jackendoff R, 1997, ARCHITECTURE LANGUAG; Lieberman P., 1984, BIOL EVOLUTION LANGU; MARLER P, 1970, AM SCI, V58, P669; Miller George A., 1963, HDB MATH PSYCHOL, P419; Nowak MA, 1999, P NATL ACAD SCI USA, V96, P8028, DOI 10.1073/pnas.96.14.8028; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; Pinker Steven, 1994, LANGUAGE INSTINCT; PREMACK D, 1985, COGNITION, V19, P207, DOI 10.1016/0010-0277(85)90036-8; Szathmary E, 1995, MAJOR TRANSITIONS EV; von Frisch K., 1967, DANCE LANGUAGE ORIEN; VONHUMBOLDT W, 1972, LINGUISTIC VARIABILI; WILSON EO, 1972, SCI AM, V227, P52, DOI 10.1038/scientificamerican0972-52; Zipf GK, 1935, PSYCHOBIOLOGY LANGUA	24	196	202	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					495	498		10.1038/35006635	http://dx.doi.org/10.1038/35006635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761917				2022-12-28	WOS:000086257700048
J	Wilczek, F				Wilczek, F			Particle physics - Backyard exotica	NATURE			English	Editorial Material									Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Wilczek, F (corresponding author), Inst Adv Study, Sch Nat Sci, Olden Lane, Princeton, NJ 08540 USA.							Black D, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.074026; DEGRAND T, 1975, PHYS REV D, V12, P2060, DOI 10.1103/PhysRevD.12.2060; DERUJULA A, 1977, PHYS REV D, V15, P281; ELIOT TS, 1974, LITTLE GIDDING 4 QUA; KOKKEDDEE J, 1968, QUARK MODEL; Wilczek F, 1999, NATURE, V397, P303, DOI 10.1038/16818	6	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					452	453		10.1038/35006549	http://dx.doi.org/10.1038/35006549			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761901				2022-12-28	WOS:000086257700032
J	Schiller, J; Major, G; Koester, HJ; Schiller, Y				Schiller, J; Major, G; Koester, HJ; Schiller, Y			NMDA spikes in basal dendrites of cortical pyramidal neurons	NATURE			English	Article							RAT HIPPOCAMPAL SLICES; ACTION-POTENTIALS; CELLS; ACTIVATION; COMPONENTS; SPINES; MODEL	Basal dendrites are a major target for synaptic inputs innervating cortical pyramidal neurons(1). At present little is known about signal processing in these fine dendrites. Here we show that coactivation of clustered neighbouring basal inputs initiated local dendritic spikes, which resulted in a 5.9 +/- 1.5 mV (peak) and 64.4 +/- 19.8 ms (half-width) cable-filtered voltage change at the soma that amplified the somatic voltage response by 226 +/- 46%. These spikes were accompanied by large calcium transients restricted to the activated dendritic segment. In contrast to conventional sodium or calcium spikes, these spikes were mediated mostly by NMDA (N-methyl-D-aspartate) receptor channels, which contributed at least 80% of the total charge. The ionic mechanism of these NMDA spikes may allow 'dynamic spike-initiation zones', set by the spatial distribution of glutamate pre-bound to NMDA receptors, which in turn would depend on recent and ongoing activity in the cortical network. In addition, NMDA spikes may serve as a powerful mechanism for modification of the cortical network by inducing long-term strengthening of co-activated neighbouring inputs.	Technion Med Sch, Dept Physiol, IL-31096 Haifa, Israel; Technion Med Sch, Dept Biophys, IL-31096 Haifa, Israel; Lucent Technol, Biol Computat Res Bell Labs, Murray Hill, NJ USA; Univ Lab Physiol, Oxford, England; Max Planck Inst Med Res, Dept Cell Physiol, Heidelberg, Germany; Rambam Med Ctr, Dept Neurol, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Alcatel-Lucent; Lucent Technologies; University of Oxford; Max Planck Society; Rambam Health Care Campus; Technion Israel Institute of Technology	Schiller, J (corresponding author), Technion Med Sch, Dept Physiol, Bat Galim, IL-31096 Haifa, Israel.	Jackie@tx.technion.ac.il	Major, Guy/A-4335-2010					ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRODIN L, 1991, J NEUROPHYSIOL, V66, P473, DOI 10.1152/jn.1991.66.2.473; BROWN AM, 1993, J NEUROPHYSIOL, V70, P1530, DOI 10.1152/jn.1993.70.4.1530; Cash S, 1998, J NEUROSCI, V18, P10; Cash S, 1999, NEURON, V22, P383, DOI 10.1016/S0896-6273(00)81098-3; Destexhe A, 1998, J NEUROSCI, V18, P3574, DOI 10.1523/jneurosci.18-10-03574.1998; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Koester HJ, 1998, P NATL ACAD SCI USA, V95, P9596, DOI 10.1073/pnas.95.16.9596; LARKMAN AU, 1991, J COMP NEUROL, V306, P332, DOI 10.1002/cne.903060209; MAJOR G, 1994, J NEUROSCI, V14, P4613; Martina M, 1997, J PHYSIOL-LONDON, V505, P593, DOI 10.1111/j.1469-7793.1997.593ba.x; Schiller J, 1998, NAT NEUROSCI, V1, P114, DOI 10.1038/363; Schiller J, 1997, J PHYSIOL-LONDON, V505, P605, DOI 10.1111/j.1469-7793.1997.605ba.x; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949	17	459	466	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					285	289		10.1038/35005094	http://dx.doi.org/10.1038/35005094			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749211				2022-12-28	WOS:000086022200049
J	Wei, M; Gibbons, LW; Kampert, JB; Nichaman, MZ; Blair, SN				Wei, M; Gibbons, LW; Kampert, JB; Nichaman, MZ; Blair, SN			Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, non-insulin-dependent; exercise; exercise tolerance; oxygen uptake	ALL-CAUSE MORTALITY; INSULIN SENSITIVITY; GLUCOSE-TOLERANCE; EXERCISE; WOMEN; DISEASE; HEALTHY; PROGRAM; CANCER; NIDDM	Background: Although physical activity is recommended as a basic treatment for patients with diabetes, its longterm association with mortality in these patients is unknown. Objective: To evaluate the association of low cardiorespiratory fitness and physical inactivity with mortality in men with type 2 diabetes. Design: Prospective cohort study. Setting: Preventive medicine clinic. Patients: 1263 men (50 +/- 10 years of age) with type 2 diabetes who received a thorough medical examination between 1970 and 1993 and were followed for mortality up to 31 December 1994. Measurements: Cardiorespiratory fitness measured by a maximal exercise test, self-reported physical inactivity at baseline, and subsequent death determined by using the National Death Index. Results: During an average follow-up of 12 years, 180 patients died. After adjustment for age, baseline cardiovascular disease, fasting plasma glucose level, high cholesterol level, overweight, current smoking, high blood pressure, and parental history of cardiovascular disease, men in the low-fitness group had an adjusted risk for all-cause mortality of 2.1 (95% Cl, 1.5 to 2.9) compared with fit men. Men who reported being physically inactive had an adjusted risk for mortality that was 1.7-fold (Cl, 1.2-fold to 2.3-fold) higher than that in men who reported being physically active. Conclusions: Low cardiorespiratory fitness and physical inactivity are independent predictors of all-cause mortality in men with type 2 diabetes. Physicians should encourage patients with type 2 diabetes to participate in regular physical activity and improve cardiorespiratory fitness.	Cooper Inst, Dallas, TX 75230 USA; Cooper Clin, Dallas, TX USA; Westat Corp, Rockville, MD USA	Cooper Institute; Cooper Institute; Westat	Wei, M (corresponding author), Cooper Inst, 12330 Preston Rd, Dallas, TX 75230 USA.	mwei@cooperinst.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG006945, R01AG006945] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62508] Funding Source: Medline; NIA NIH HHS [AG06945] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS49; [Anonymous], 1996, JAMA, V276, P241; BAKTH S, 1986, J CLIN INVEST, V77, P382, DOI 10.1172/JCI112316; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1989, AM J EPIDEMIOL, V129, P1145, DOI 10.1093/oxfordjournals.aje.a115236; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BURCHFIEL CM, 1995, AM J EPIDEMIOL, V141, P360, DOI 10.1093/aje/141.4.360; Chalmers J, 1999, J HYPERTENS, V17, P151; Coupland CAC, 1999, INT J EPIDEMIOL, V28, P241, DOI 10.1093/ije/28.2.241; Cowie CC, 1995, NIH PUBLICATION, V95-1468, P117; DEVLIN JT, 1987, DIABETES, V36, P434, DOI 10.2337/diabetes.36.4.434; Erikssen G, 1998, LANCET, V352, P759, DOI 10.1016/S0140-6736(98)02268-5; Eriksson J, 1997, DIABETOLOGIA, V40, P125; GARBER AJ, 1998, INTERNAL MED, P1850; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gu K, 1999, JAMA-J AM MED ASSOC, V281, P1291, DOI 10.1001/jama.281.14.1291; Kampert JB, 1996, ANN EPIDEMIOL, V6, P452, DOI 10.1016/S1047-2797(96)00059-2; Kiningham RB, 1998, PRIMARY CARE, V25, P515, DOI 10.1016/S0095-4543(05)70080-4; KOHL HW, 1992, DIABETES CARE, V15, P184, DOI 10.2337/diacare.15.2.184; KUUSISTO J, 1994, STROKE, V25, P1157, DOI 10.1161/01.STR.25.6.1157; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; Martynenko OG, 1997, INT J HEAT MASS TRAN, V40, P1; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; *NIH, 1988, LIP RES CLIN POP STU; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; REWERS M, 1995, NIH PUBLICATION, P179; ROGERS MA, 1988, DIABETES CARE, V11, P613, DOI 10.2337/diacare.11.8.613; ROGERS MA, 1989, MED SCI SPORT EXER, V21, P362; *SAS I, 1989, SAS STAT US GUID VER; SCHNEIDER SH, 1992, DIABETES CARE, V15, P1800, DOI 10.2337/diacare.15.11.1800; SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stofan JR, 1998, AM J PUBLIC HEALTH, V88, P1807, DOI 10.2105/AJPH.88.12.1807; Wei M, 1999, ANN INTERN MED, V130, P89, DOI 10.7326/0003-4819-130-2-199901190-00002; Wei M, 1999, JAMA-J AM MED ASSOC, V282, P1547, DOI 10.1001/jama.282.16.1547; Wei M, 1997, J CLIN EPIDEMIOL, V50, P1137, DOI 10.1016/S0895-4356(97)00150-9; 1981, CANADA FITNESS SURVE	43	440	452	1	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					605	+		10.7326/0003-4819-132-8-200004180-00002	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766678				2022-12-28	WOS:000086497500001
J	Baleta, A				Baleta, A			South Africa's medicines control council contradicts health minister	LANCET			English	News Item																			0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1342	1342		10.1016/S0140-6736(05)72580-0	http://dx.doi.org/10.1016/S0140-6736(05)72580-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776757				2022-12-28	WOS:000086829400032
J	Berge, E; Abdelnoor, M; Nakstad, PH; Sandset, PM				Berge, E; Abdelnoor, M; Nakstad, PH; Sandset, PM		HAEST Study Grp	Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study	LANCET			English	Article							ACUTE ISCHEMIC STROKE; DEEP VENOUS THROMBOSIS; CEREBROVASCULAR-DISEASE; UNFRACTIONATED HEPARIN; SIMPLE QUESTIONS; ASSOCIATION; SAFETY	Background Patients with acute ischaemic stroke and atrial fibrillation have an increased risk of early stroke recurrence, and anticoagulant treatment with heparins has ben widely advocated, despite missing data on the balance of risk and benefit. Methods Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation. The primary aim was to test whether treatment with LMWH, started within 30 h of stroke onset, is superior to aspirin for the prevention of recurrent stroke during the first 14 days. Findings The frequency of recurrent ischaemic stroke during the first 14 days was 19/244 (8.5%) in dalteparin-allocated patients versus 17/225 (7.5%) in aspirin-allocated patients (odds ratio=1.13, 95% CI 0.57-2.24). The secondary events during the first 14 days also revealed no benefit of dalteparin compared with aspirin: symptomatic cerebral haemorrhage 6/224 versus 4/225; symptomatic and asymptomatic cerebral haemorrhage 26/224 versus 32/225; progression of symptoms within the first 48 hours 24/224 versus 17/225; and death 21/224 versus 16/225. There were no significant differences in functional outcome or death at 14 days or 3 months. Interpretation The present data do not provide any evidence that LMWH is superior to aspirin for the treatment of acute ischaemic stroke in patients with atrial fibrillation. However, the study could not exclude the possibility of smaller, but still worthwhile, effects of either of the trial drugs.	Ullevaal Univ Hosp, Dept Haematol, Haematol Res Lab, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Epidemiol Sect, Res Forum, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Dept Neuroradiol, N-0407 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Berge, E (corresponding author), Ullevaal Univ Hosp, Dept Haematol, Haematol Res Lab, N-0407 Oslo, Norway.	eivind.berge@ulleval.no	Sandset, Per Morten/J-8141-2019; abdelnoor, michael/K-4248-2019	Sandset, Per Morten/0000-0001-5556-8099; 				ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; [Anonymous], 1998, JAMA, V279, P1265; [Anonymous], 1985, Stroke, V16, P885; [Anonymous], 1984, Stroke, V15, P779; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; ASPLUND K, 1993, THROMBOLYTIC THERAPY, V2, P119; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; Castillo J, 1999, CEREBROVASC DIS, V9, P1, DOI 10.1159/000047548; *CER EMB TASK FORC, 1989, ARCH NEUROL-CHICAGO, V46, P1079; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; CHEN ZM, 1995, CEREBROVASC DIS, V5, P228; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Dahl T, 1997, CEREBROVASC DIS, V7, P28, DOI 10.1159/000108160; Dennis M, 1997, CEREBROVASC DIS, V7, P22, DOI 10.1159/000108159; Dennis M, 1997, CEREBROVASC DIS, V7, P19, DOI 10.1159/000108158; GUBITZ GJ, 1999, COCHRANE LIB; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HAKIM AM, 1983, STROKE, V14, P668; HART RG, 1987, ARCH INTERN MED, V147, P636; HIRSH J, 1992, BLOOD, V79, P1; Hommel M, 1998, CEREBROVASC DIS, V8, P19; Jorgensen HS, 1996, STROKE, V27, P1765, DOI 10.1161/01.STR.27.10.1765; JORGENSEN L, 1969, J NEUROL SCI, V9, P285, DOI 10.1016/0022-510X(69)90078-1; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KENT J, 1994, POSTGRAD MED J, V70, P185, DOI 10.1136/pgmj.70.821.185; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; Lindley RI, 1995, J ROY COLL PHYS LOND, V29, P479; MAHONEY F I, 1965, Md State Med J, V14, P61; MARSH EE, 1989, NEUROLOGY, V39, P1631, DOI 10.1212/WNL.39.12.1631; Pocock SJ, 1990, CLIN TRIALS PRACTICA; PRINS MH, 1989, HAEMOSTASIS, V19, P245; SANDERCOCK P, 1992, BRIT MED J, V305, P1460, DOI 10.1136/bmj.305.6867.1460; Sandercock P, 1997, LANCET, V349, P1569; SANDSET PM, 1990, SEMIN THROMB HEMOST, V16, P25; Turpie AGG, 1996, CAN FAM PHYSICIAN, V42, P1341; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wallentin L, 1996, LANCET, V347, P561; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	41	293	307	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2000	355	9211					1205	1210		10.1016/S0140-6736(00)02085-7	http://dx.doi.org/10.1016/S0140-6736(00)02085-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770301				2022-12-28	WOS:000086448000008
J	Dreger, DS; Tkalcic, H; Johnston, M				Dreger, DS; Tkalcic, H; Johnston, M			Dilational processes accompanying earthquakes in the Long Valley Caldera	SCIENCE			English	Article							1980 MAMMOTH LAKES; ISOTROPIC COMPONENT; MOMENT TENSOR; MECHANISMS; CALIFORNIA; INVERSION	Regional distance seismic moment tensor determinations and broadband wave-forms of moment magnitude 4.6 to 4.9 earthquakes from a November 1997 Long Valley Caldera swarm, during an inflation episode, display evidence of anomalous seismic radiation characterized by non-double couple (NDC) moment tensors with significant volumetric components. Observed coseismic dilation suggests that hydrothermal or magmatic processes are directly triggering some of the seismicity in the region. Similarity in the NDC solutions implies a common source process, and the anomalous events may have been triggered by net fault-normal stress reduction due to high-pressure fluid injection or pressurization of fluid-saturated faults due to magmatic heating.	Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA; US Geol Survey, Menlo Park, CA 94025 USA	University of California System; University of California Berkeley; United States Department of the Interior; United States Geological Survey	Dreger, DS (corresponding author), Univ Calif Berkeley, Berkeley Seismol Lab, 281 McCone Hall, Berkeley, CA 94720 USA.		Dreger, Douglas/AAK-6067-2021; Tkalcic, Hrvoje/E-8465-2013	Tkalcic, Hrvoje/0000-0001-7072-490X				Aki K., 1980, QUANTITATIVE SEISMOL, P932; BARKER JS, 1983, B SEISMOL SOC AM, V73, P419; Campus P, 1996, TECTONOPHYSICS, V261, P147, DOI 10.1016/0040-1951(96)00063-7; DREGER DS, 1993, J GEOPHYS RES-SOL EA, V98, P8107, DOI 10.1029/93JB00023; Dufumier H, 1997, GEOPHYS J INT, V131, P595, DOI 10.1111/j.1365-246X.1997.tb06601.x; EKSTROM G, 1983, EOS T AGU, V64, P769; EKSTROM G, 1983, EOS T AGU, V64, P262; FROHLICH C, 1994, SCIENCE, V264, P804, DOI 10.1126/science.264.5160.804; GIVEN JW, 1982, B SEISMOL SOC AM, V72, P1093; Hara T, 1996, GEOPHYS J INT, V127, P515, DOI 10.1111/j.1365-246X.1996.tb04737.x; HILL DP, 1985, J GEOPHYS RES-SOLID, V90, P1111, DOI 10.1029/JB090iB13p11111; HILL DP, 1998, EOS, V79, pE949; JOHNSTON MJS, 1987, TECTONOPHYSICS, V144, P189, DOI 10.1016/0040-1951(87)90017-5; Jost M. L., 1989, Seismological Research Letters, V60, P37; JULIAN BR, 1983, NATURE, V303, P323, DOI 10.1038/303323a0; JULIAN BR, 1985, J GEOPHYS RES-SOLID, V90, P1155, DOI 10.1029/JB090iB13p11155; KANAMORI H, 1975, B SEISMOL SOC AM, V65, P1073; Kawakatsu H, 1996, GEOPHYS J INT, V126, P525, DOI 10.1111/j.1365-246X.1996.tb05308.x; KNOPOFF L, 1970, J GEOPHYS RES, V75, P4957, DOI 10.1029/JB075i026p04957; KUGE K, 1994, J GEOPHYS RES-SOL EA, V99, P15457, DOI 10.1029/94JB00140; LANGBEIN J, 1998, EOS, V79, pE963; Menke W., 1989, GEOPHYS DATA ANAL DI, P96; Miller AD, 1998, REV GEOPHYS, V36, P551, DOI 10.1029/98RG00717; Pasyanos ME, 1996, B SEISMOL SOC AM, V86, P1255; *US GEOL SURV VOLC, 1997, LONG VALL CALD MON R; WALLACE T, 1982, GEOPHYS RES LETT, V9, P1131, DOI 10.1029/GL009i010p01131; WALLACE TC, 1985, J GEOPHYS RES-SOLID, V90, P1171, DOI 10.1029/JB090iB13p11171; ZHENG TY, 1995, PHYS EARTH PLANET IN, V91, P285, DOI 10.1016/0031-9201(95)03019-S	28	121	122	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					122	125		10.1126/science.288.5463.122	http://dx.doi.org/10.1126/science.288.5463.122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753113				2022-12-28	WOS:000086387700047
J	Sharp, PA; Zamore, PD				Sharp, PA; Zamore, PD			Molecular biology - RNA interference	SCIENCE			English	Editorial Material									MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA	Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Worcester	Sharp, PA (corresponding author), MIT, Ctr Canc Res, Cambridge, MA 02139 USA.		Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618				Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hunter CP, 2000, CURR BIOL, V10, pR137, DOI 10.1016/S0960-9822(00)00325-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Schmidt A, 1999, GENETICS, V151, P749; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; ZAMORE PD, IN PRESS CELL	12	91	173	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2431	+		10.1126/science.287.5462.2431	http://dx.doi.org/10.1126/science.287.5462.2431			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10766620				2022-12-28	WOS:000086202200030
J	Reichhardt, T				Reichhardt, T			Software error 'caused Mars lander crash'	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					423	423		10.1038/35006700	http://dx.doi.org/10.1038/35006700			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761881	Bronze			2022-12-28	WOS:000086257700003
J	Bergh, J				Bergh, J			Where next with stem-cell-supported high-dose therapy for breast cancer?	LANCET			English	Editorial Material							CHEMOTHERAPY		Karolinska Hosp & Inst, Radiumhemmet, S-17176 Stockholm, Sweden; Karolinska Hosp & Inst, Canc Ctr Karolinska, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Bergh, J (corresponding author), Karolinska Hosp & Inst, Radiumhemmet, S-17176 Stockholm, Sweden.			Bergh, Jonas/0000-0001-5526-1847				Abe O, 1998, LANCET, V352, P930; Antman KH, 1999, J CLIN ONCOL, V17, P30; Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; Clarke M, 1996, LANCET, V348, P1189; Clarke M, 1998, LANCET, V351, P1451; Fossati R, 1998, J CLIN ONCOL, V16, P3439, DOI 10.1200/JCO.1998.16.10.3439; Hortobagyi GN, 1999, J CLIN ONCOL, V17, P25; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; Quinn MJ, 1998, EUR J CANCER, V34, P2204, DOI 10.1016/S0959-8049(98)00323-2; Rahman ZU, 1997, J CLIN ONCOL, V15, P3171, DOI 10.1200/JCO.1997.15.10.3171	11	22	22	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					944	945		10.1016/S0140-6736(00)90007-2	http://dx.doi.org/10.1016/S0140-6736(00)90007-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768427				2022-12-28	WOS:000086054000003
J	Park, BK				Park, BK			Cytochrome P450 enzymes in the heart	LANCET			English	Editorial Material									Univ Liverpool, Dept Pharmacol, Liverpool L69 3GE, Merseyside, England	University of Liverpool	Park, BK (corresponding author), Univ Liverpool, Dept Pharmacol, Liverpool L69 3GE, Merseyside, England.							BROLY F, 1991, DNA CELL BIOL, V10, P545, DOI 10.1089/dna.1991.10.545; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Kilian JG, 1999, LANCET, V354, P1841, DOI 10.1016/S0140-6736(99)10385-4; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Park BK, 1995, PHARMACOL THERAPEUT, V68, P385, DOI 10.1016/0163-7258(95)02013-6; REIDLE AG, 1999, BRAIN RES, V822, P175; Voirol P, 2000, BRAIN RES, V855, P235, DOI 10.1016/S0006-8993(99)02354-9; Watkins PB, 1997, ADV DRUG DELIVER REV, V27, P161, DOI 10.1016/S0169-409X(97)00041-0	8	16	23	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					945	946		10.1016/S0140-6736(00)90008-4	http://dx.doi.org/10.1016/S0140-6736(00)90008-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768428				2022-12-28	WOS:000086054000004
J	Adler, E; Hoon, MA; Mueller, KL; Chandrashekar, J; Ryba, NJP; Zuker, CS				Adler, E; Hoon, MA; Mueller, KL; Chandrashekar, J; Ryba, NJP; Zuker, CS			A novel family of mammalian taste receptors	CELL			English	Article							ALPHA-GUSTDUCIN; CHORDA TYMPANI; G-PROTEIN; RAT; TRANSDUCTION; CELLS; AMILORIDE; GENES; NERVE; MICE	In mammals, taste perception is a major mode of sensory input. We have identified a novel family of 40-80 human and rodent G protein-coupled receptors expressed in subsets of taste receptor cells of the tongue and palate epithelia. These candidate taste receptors (T2Rs) are organized in the genome in clusters and are genetically linked to loci that influence bitter perception in mice and humans. Notably, a single taste receptor cell expresses a large repertoire of T2Rs, suggesting that each cell may be capable of recognizing multiple tastants. T2Rs are exclusively expressed in taste receptor cells that contain the G protein alpha subunit gustducin, implying that they function as gustducin-linked receptors. In the accompanying paper, we demonstrate that T2Rs couple to gustducin in vitro, and respond to bitter tastants in a functional expression assay.	NIH, Natl Inst Dent & Craniofacial Res, Bethesda, MD 20892 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, Dept Neurosci, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Ryba, NJP (corresponding author), NIH, Natl Inst Dent & Craniofacial Res, Bldg 10, Bethesda, MD 20892 USA.	nr13k@nih.gov; czucker@flyeye.ucsd.edu		Chandrashekar, jayaram/0000-0001-6412-0114; Ryba, Nicholas/0000-0002-2060-8393	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000561] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AVENET P, 1988, J MEMBRANE BIOL, V105, P245, DOI 10.1007/BF01871001; AZEN EA, 1986, TRENDS GENET, V2, P199, DOI 10.1016/0168-9525(86)90228-3; Boughter JD, 1997, J NEUROSCI, V17, P2852; BRAND JG, 1985, BRAIN RES, V334, P207, DOI 10.1016/0006-8993(85)90212-4; CAPELESS CG, 1992, BEHAV GENET, V22, P655, DOI 10.1007/BF01066636; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Chaudhari N, 2000, NAT NEUROSCI, V3, P113, DOI 10.1038/72053; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; CONNEALLY PM, 1976, HUM HERED, V26, P267, DOI 10.1159/000152813; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FRANK ME, 1991, J NEUROPHYSIOL, V65, P1452, DOI 10.1152/jn.1991.65.6.1452; FRANK ME, 1983, J NEUROPHYSIOL, V50, P941, DOI 10.1152/jn.1983.50.4.941; FULLER JL, 1974, J HERED, V65, P33, DOI 10.1093/oxfordjournals.jhered.a108452; GILBERTSON TA, 1992, J GEN PHYSIOL, V100, P803, DOI 10.1085/jgp.100.5.803; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; Hofer D, 1996, P NATL ACAD SCI USA, V93, P6631, DOI 10.1073/pnas.93.13.6631; Hofer D, 1998, HISTOCHEM CELL BIOL, V110, P303, DOI 10.1007/s004180050292; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1992, ANNU REV PHYSIOL, V54, P715, DOI 10.1146/annurev.physiol.54.1.715; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; LUSH IE, 1986, GENET RES, V47, P117, DOI 10.1017/S0016672300022941; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MCBURNEY DH, 1972, PERCEPT PSYCHOPHYS, V11, P228, DOI 10.3758/BF03206255; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MILLER IJ, 1974, J COMP NEUROL, V158, P155, DOI 10.1002/cne.901580204; Ming D, 1998, P NATL ACAD SCI USA, V95, P8933, DOI 10.1073/pnas.95.15.8933; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; NEJAD MS, 1986, CHEM SENSES, V11, P283, DOI 10.1093/chemse/11.3.283; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Reed DR, 1999, AM J HUM GENET, V64, P1478, DOI 10.1086/302367; Rouquier S, 1998, NAT GENET, V18, P243, DOI 10.1038/ng0398-243; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; Stewart RE, 1997, AM J PHYSIOL-CELL PH, V272, pC1, DOI 10.1152/ajpcell.1997.272.1.C1; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WARREN RP, 1970, NATURE, V227, P77, DOI 10.1038/227077a0; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0	40	972	1082	4	225	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 17	2000	100	6					693	702		10.1016/S0092-8674(00)80705-9	http://dx.doi.org/10.1016/S0092-8674(00)80705-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761934	Bronze			2022-12-28	WOS:000085983800011
J	Abbott, A				Abbott, A			Art imitating high-energy physics	NATURE			English	News Item																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					219	219		10.1038/35005257	http://dx.doi.org/10.1038/35005257			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749182	Bronze			2022-12-28	WOS:000086022200013
J	Bignami, GF				Bignami, GF			A 1,000-year chain of thinkers - ... Kant is connected to Abel, Abel's connected to Maxwell	NATURE			English	Editorial Material									Italian Space Agcy, I-00161 Rome, Italy	Agenzia Spaziale Italiana (ASI)	Bignami, GF (corresponding author), Italian Space Agcy, Via Villa Patrizi 13, I-00161 Rome, Italy.			Bignami, Giovanni/0000-0001-9582-2450					0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					227	227		10.1038/35005178	http://dx.doi.org/10.1038/35005178			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749188	Bronze			2022-12-28	WOS:000086022200024
J	Doll, R; Peto, R; Boreham, J; Sutherland, I				Doll, R; Peto, R; Boreham, J; Sutherland, I			Smoking and dementia in male British doctors: prospective study	BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; RISK-FACTORS; POPULATION; COHORT	Objective To assess the possible association between smoking and dementia. Design Prospective study Setting Cohort of British male doctors followed up since 1951. Subjects 34 439 male British doctors, with 24 133 deaths recorded. Results For all types of dementia combined the relative risk was 0.96 (95% confidence interval 0.78 to 1.18), based on 473 deaths at a mean age of 81 years. For probable or definite Alzheimer's disease, the relative risk in continuing smokers was 0.99 (0.78 to 1.25), based on 370 deaths at a mean age of 82 years. In aggregate, however, the other prospective studies indicate a direct, although not clearly significant, association between smoking and the onset of dementia in general and of Alzheimer's disease in particular. Conclusions Contrary to previous suggestions persistent smoking does not substantially reduce the age specific onset rate of Alzheimer's disease or of dementia in general. If anything, it might increase rather than decrease the rate, but any net effect on severe dementia cannot be large in either direction.	Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Doll, R (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.							Baron JA, 1996, BRIT MED BULL, V52, P58, DOI 10.1093/oxfordjournals.bmb.a011533; Braak H, 1996, J NEURAL TRANSM, V103, P455, DOI 10.1007/BF01276421; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; Graves A.B, 1994, J SMOKING RELATED S1, V5, P79; HEBERT LE, 1992, AM J EPIDEMIOL, V135, P347, DOI 10.1093/oxfordjournals.aje.a116296; Hirayama T, 1992, TOB CONTROL, V1, P176; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P736, DOI 10.1093/ije/20.3.736; Jellinger K. A., 1997, Journal of Neural Transmission Supplement, V51, P57; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; LEE PN, 1994, NEUROEPIDEMIOL, V13, P44; McKahnn G., 1984, NEUROLOGY, V34, P939; Merchant C, 1999, NEUROLOGY, V52, P1408, DOI 10.1212/WNL.52.7.1408; *OFF POP CENS SURV, 1995, 1993 MORT STAT ENGL, pR11; Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7; PRINCE M, 1994, NEUROLOGY, V44, P97; Wang HX, 1999, AM J EPIDEMIOL, V149, P640; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	19	80	86	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1097	1102		10.1136/bmj.320.7242.1097	http://dx.doi.org/10.1136/bmj.320.7242.1097			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775216	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086782800014
J	Ulrich, S; Hingorani, AD; Martin, J; Vallance, P				Ulrich, S; Hingorani, AD; Martin, J; Vallance, P			What is the optimal age for starting lipid lowering treatment? A mathematical model	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; PRIMARY PREVENTION; BLOOD-PRESSURE; RISK; PRAVASTATIN; FRAMINGHAM; MANAGEMENT; REDUCTION; MORTALITY		UCL, Ctr Clin Pharmacol & Therapeut, London WC1 6JJ, England; UCL, Ctr Cardiovasc Biol & Med, London WC1 6JJ, England	University of London; University College London; University of London; University College London	Vallance, P (corresponding author), UCL, Ctr Clin Pharmacol & Therapeut, London WC1 6JJ, England.	patrick.vallance@ucl.ac.uk		Ulrich, Silvia/0000-0002-5250-5022; Hingorani, Aroon/0000-0001-8365-0081				ANDERSEN HJ, 1990, Z LEBENSM UNTERS FOR, V191, P293, DOI 10.1007/BF01202429; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Betteridge J, 1997, BRIT MED J, V315, P1619; BRAND RJ, 1976, CIRCULATION, V53, P348, DOI 10.1161/01.CIR.53.2.348; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Gould AL, 1998, CIRCULATION, V97, P946; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; Haq IU, 1999, HEART, V81, P40, DOI 10.1136/hrt.81.1.40; Hingorani AD, 1999, BMJ-BRIT MED J, V318, P101, DOI 10.1136/bmj.318.7176.101; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; KEECH A, 1994, EUR HEART J, V15, P255, DOI 10.1093/oxfordjournals.eurheartj.a060485; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; Lloyd-Jones DM, 1999, LANCET, V353, P89, DOI 10.1016/S0140-6736(98)10279-9; *OFF NAT STAT, 1996, MORT STAT 1996 CAUS; PEDERSEN TR, 1994, LANCET, V344, P1383; Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443; PYORALA K, 1994, EUR HEART J, V15, P1300; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHONFELD G, 1979, ARTERY, V5, P305; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Ulrich S, 1999, LANCET, V353, P925, DOI 10.1016/S0140-6736(05)75030-3	24	32	32	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	2000	320	7242					1134	1140		10.1136/bmj.320.7242.1134	http://dx.doi.org/10.1136/bmj.320.7242.1134			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775228	Green Published			2022-12-28	WOS:000086782800025
J	Fratiglioni, L; Wang, HX; Ericsson, K; Maytan, M; Winblad, B				Fratiglioni, L; Wang, HX; Ericsson, K; Maytan, M; Winblad, B			Influence of social network on occurrence of dementia: a community-based longitudinal study	LANCET			English	Article							ALZHEIMERS-DISEASE; LEISURE ACTIVITIES; FOLLOW-UP; MORTALITY; HEALTH; DEPRESSION; QUALITY; SUPPORT; WOMEN; ONSET	Background Few data are available on the effect of social ties on dementia development. This study explored whether single social network components and different degrees of the social connections affect dementia incidence. Methods A community-based cohort of 1203 non-demented people, living at home in the Kungsholmen district of Stockholm, Sweden, and who had good cognition, was followed for an average period of 3 years. On the basis of medical and psychological data, 176 patients were diagnosed with dementia according to the criteria of the third edition revision of the Diagnostic and Statistical Manual of Mental Disorders. Information on social network was obtained by personal interview by trained nurses at baseline. The covariates included in the analysis were age, sex, education, cognitive and functional status, depressive symptoms, and vascular diseases. Findings Those individuals living alone, and those without any close social ties, both had an adjusted relative risk for developing dementia of 1.5 (95% CI 1.0-2.1 and 1.0-2.4, respectively). Compared with married people living with someone, single people and those living alone had an adjusted relative risk of 1.9 (95% CI 1.2-3.1). Infrequent contacts with network resources did not increase the risk of the disease if such contacts were experienced as satisfying. When all components were combined in an index, a poor or limited social network increased the risk of dementia by 60% (95% CI 1.2-2.1), and a significant gradient was found for the four degrees of social connections (p=0.0009). Interpretation An extensive social network seems to protect against dementia. Confirmation of this finding and further investigation to clarify the mechanisms are worthwhile due to the implications for prevention.	Stockholm Gerontol Res Ctr, S-11382 Stockholm, Sweden; Karolinska Inst, Div Geriatr Med, NEUROTEC, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Fratiglioni, L (corresponding author), Stockholm Gerontol Res Ctr, Box 6401, S-11382 Stockholm, Sweden.			Wang, Hui-Xin/0000-0002-5051-4929				Aguero-Torres H, 1999, J CLIN EPIDEMIOL, V52, P737, DOI 10.1016/S0895-4356(99)00067-0; *AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P97; Becker T, 1998, SOC PSYCH PSYCH EPID, V33, P299, DOI 10.1007/s001270050058; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cervilla JA, 1997, INT J GERIATR PSYCH, V12, P995; FABRIGOULE C, 1995, J AM GERIATR SOC, V43, P485, DOI 10.1111/j.1532-5415.1995.tb06093.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; FRATIGLIONI L, 1997, NEUROBIOL AGING, V46, pS214; Grundy A, 1998, REV CLIN GERONTOLOGY, V8, P353, DOI [10.1017/S095925989800848X, DOI 10.1017/S095925989800848X]; HENDERSON AS, 1986, PSYCHOL MED, V16, P379, DOI 10.1017/S0033291700009211; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; JOHNSON TP, 1991, J HEALTH SOC BEHAV, V32, P408, DOI 10.2307/2137107; KASPER J, 1995, J MENTAL HLTH AGING, V0001; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZMAN R, 1995, J AM GERIATR SOC, V43, P583, DOI 10.1111/j.1532-5415.1995.tb06112.x; Kawachi I, 1996, J EPIDEMIOL COMMUN H, V50, P245, DOI 10.1136/jech.50.3.245; KONDO K, 1990, PSYCHOGERIATRICS BIO, P49; Litwin H, 1998, SOC SCI MED, V46, P599, DOI 10.1016/S0277-9536(97)00207-4; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Ren XS, 1997, SOC SCI MED, V44, P241, DOI 10.1016/S0277-9536(96)00158-X; Seeman T E, 1993, Ann Epidemiol, V3, P325; Seeman TE, 1996, ANN EPIDEMIOL, V6, P442, DOI 10.1016/S1047-2797(96)00095-6; Seeman TE, 1996, J GERONTOL B-PSYCHOL, V51, pS191, DOI 10.1093/geronb/51B.4.S191; SHYE D, 1995, SOC SCI MED, V41, P935, DOI 10.1016/0277-9536(94)00404-H; Small BJ, 1997, J GERONTOL MED SCI, V52, P299; WELIN L, 1992, J EPIDEMIOL COMMUN H, V46, P127, DOI 10.1136/jech.46.2.127; *WHO, 1967, INT CLASS DIS MAN IN, V1; Yasuda N, 1997, AM J EPIDEMIOL, V145, P516	30	866	882	3	147	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1315	1319		10.1016/S0140-6736(00)02113-9	http://dx.doi.org/10.1016/S0140-6736(00)02113-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310LJ	10776744				2022-12-28	WOS:000086829400011
J	Matthews, SB; Campbell, AK				Matthews, SB; Campbell, AK			When sugar is not so sweet	LANCET			English	Article									Llandough Hosp NHS Trust, Dept Biochem Med, Penarth CF64 1XX, S Glam, Wales; Cardiff Univ, Dept Biochem Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Matthews, SB (corresponding author), Llandough Hosp NHS Trust, Dept Biochem Med, Penarth CF64 1XX, S Glam, Wales.		Campbell, Anthony K/N-5855-2014	Campbell, Anthony K/0000-0002-2506-5500				BOND JH, 1976, GASTROENTEROLOGY, V70, P1058; Campbell AK, 1983, INTRACELLULAR CALCIU, P135; FABRIZIS L, 1997, FOOD TECHNOL, V51, P74; Lee MF, 1998, NUTR REV, V56, P1; SAHI T, 1994, SCAND J GASTROENTERO, V29, P7, DOI 10.3109/00365529409091740	5	22	23	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	2000	355	9212					1330	1330		10.1016/S0140-6736(00)02116-4	http://dx.doi.org/10.1016/S0140-6736(00)02116-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776747				2022-12-28	WOS:000086829400014
J	Shum, C; Humphreys, A; Wheeler, D; Cochrane, MA; Skoda, S; Clement, S				Shum, C; Humphreys, A; Wheeler, D; Cochrane, MA; Skoda, S; Clement, S			Nurse management of patients with minor illnesses in general practice: multicentre, randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							PATIENTS SATISFACTION; QUESTIONNAIRE	Objective To assess the acceptability and safety of a minor illness service led by practice nurses in general practice. Design Multicentre, randomised controlled trial. Setting 5 general practices in south east London and Kent representing semi-rural, suburban, and urban settings. Participants 1815 patients requesting and offered same day appointments by receptionists. Intervention Patients were assigned to treatment by either a specially trained nurse or a general practitioner. Patients seen by a nurse were referred to a general practitioner when appropriate. Main outcome measures The general satisfaction of the patients as measured by the consultation satisfaction questionnaire. Other outcome measures included the length of the consultation, number of prescriptions written, rates of referral to general practitioners, patient's reported health status, patient's anticipated behaviour in seeking health care in future, and number of patients who returned to the surgery, visits to accident and emergency, and out of hours calls to doctors. Results Patients were very satisfied with both nurses and doctors, but they were significantly more satisfied with their consultations with nurses (mean (SD) score of satisfaction 78.6 (16.0) of 100 points for nurses v 76.4 (17.8) for doctors; 95% confidence interval for difference between means -4.07 to -0.38). Consultations with nurses took about 10 minutes compared with about 8 minutes for consultations with doctors. Nurses and doctors wrote prescriptions for a similar proportion of patients (nurses 481/736 (65.4%) v doctors 518/816 (63.5%)). 577/790 (73%) patients seen by nurses were managed without any input from doctors. Conclusion Practice nurses seem to offer an effective service for patients with minor illnesses who request same day appointments.	Walderslade Village Surg, Walderslade ME5 9LD, England; Lordswood Hlth Ctr, Chatham ME5 8TJ, Kent, England; Gallions Reach Med Ctr, London SE28 5BE, England; Medway Doctors Call, Chatham ME4 4TE, Kent, England; Guys Kings Coll & St Thomass Hosp Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England	University of London; King's College London	Shum, C (corresponding author), Walderslade Village Surg, Walderslade ME5 9LD, England.		Clement, Sarah/E-9601-2010; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				BAKER R, 1990, BRIT J GEN PRACT, V40, P487; CAMPBELL A, 1995, BRIT MED J, V310, P1404, DOI 10.1136/bmj.310.6991.1404b; MARSH GN, 1995, BRIT MED J, V310, P778, DOI 10.1136/bmj.310.6982.778; Murphy AW, 1996, BRIT MED J, V312, P1135; Poulton BC, 1996, BRIT J GEN PRACT, V46, P26; REES M, 1992, NURS TIMES, V6, P32; *SEC STAT HLTH, 1997, CM3807	7	146	147	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1038	1043		10.1136/bmj.320.7241.1038	http://dx.doi.org/10.1136/bmj.320.7241.1038			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764365	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000086675700024
J	Wynia, MK; Cummins, DS; VanGeest, JB; Wilson, IB				Wynia, MK; Cummins, DS; VanGeest, JB; Wilson, IB			Physician manipulation of reimbursement rules for patients - Between a rock and a hard place	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	16th Annual Meeting of the Association-for-Health-Services-Research	JUN 27-29, 1999	CHICAGO, ILLINOIS	Assoc Heart Serv Res			MANAGED CARE; HEALTH-CARE; ATTITUDES; MALPRACTICE; DECEPTION	Context Health plan utilization review rules are intended to enforce insurance contracts and can alter and constrain the services that physicians provide to their patients. Physicians can manipulate these rules, but how often they do so is unknown. Objective To determine the frequency with which physicians manipulate reimbursement rules to obtain coverage for services they perceive as necessary, and the physician attitudes and personal and practice characteristics associated with these manipulations. Design, Setting, and Participants A random national sample of 1124 practicing physicians was surveyed by mail in 1998; the response rate was 64% (n = 720). Main Outcome Measure Use of 3 different tactics "sometimes" or more often in the last year: (1) exaggerating the severity of patients' conditions; (2) changing patients' billing diagnoses; and/or (3) reporting signs or symptoms that patients did not have to help the patients secure coverage for needed care. Results Thirty-nine percent of physicians reported using at least 1 tactic "sometimes" or more often in the last year. In multivariate models comparing these physicians with physicians who "never" or "rarely" used any of these tactics, physicians using these tactics were more likely to (1) believe that "gaming the system" is necessary to provide high-quality care today (odds ratio [OR], 3.67; 95% confidence interval [CI], 2.54-5.29); (2) have received requests from patients to deceive insurers (OR, 2.44; 95% CI, 1.72-3.45); (3) feel pressed for time during patient visits (OR, 1.69; 95% CI, 1.21-2.37); and (4) have more than 25% of their patients covered by Medicaid (OR, 1.60; 95% CI, 1.08-2.38). Notably, greater worry about prosecution for fraud did not affect physicians' use of these tactics (P =.34). Of those reporting using these tactics, 54% reported doing so more often now than 5 years ago. Conclusions A sizable minority of physicians report manipulating reimbursement rules so patients can receive care that physicians perceive is necessary. Unless novel strategies are developed to address this, greater utilization restrictions in the health care system are likely to increase physicians' use of such manipulative "covert advocacy" tactics.	Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA; New England Med Ctr, Div Clin Care Res, Boston, MA 02111 USA	American Medical Association; Tufts Medical Center	Wynia, MK (corresponding author), Amer Med Assoc, Inst Eth, 515 N State St, Chicago, IL 60610 USA.		Wilson, Ira/F-9190-2016; Wynia, Matthew/T-2210-2019	Wilson, Ira/0000-0002-0246-738X; 				*AM COLL OBST GYN, 1992, INT J GYNECOL OBSTET, V37, P63; *AM MED ASS, 1997, HLTH CAR FRAUD AB RE; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Bernat JL, 1997, NEUROLOGY, V49, P4, DOI 10.1212/WNL.49.1.4; BURDA D, 1993, MOD HEALTHCARE, V23, P17; CAIN JM, 1993, OBSTET GYNECOL, V82, P475; *CTR STUD HLTH SYS, 1999, PHYS ORG ARE RESP MA; EISENBERG J, 1986, DOCTORS DECISIONS CO; Freeman VG, 1999, ARCH INTERN MED, V159, P2263, DOI 10.1001/archinte.159.19.2263; GLASSON J, 1994, JAMA-J AM MED ASSOC, V272, P1056, DOI 10.1001/jama.1994.03520130094039; GOOLD SD, 1994, J GEN INTERN MED, V9, P544, DOI 10.1007/BF02599278; GRUMET GW, 1989, NEW ENGL J MED, V321, P607, DOI 10.1056/NEJM198908313210909; HALL RCW, 1994, PSYCHOSOMATICS, V35, P105, DOI 10.1016/S0033-3182(94)71783-7; HIBBARD JH, 1987, MED CARE, V25, P1019, DOI 10.1097/00005650-198711000-00001; Hibbard JH, 1997, MILBANK Q, V75, P395, DOI 10.1111/1468-0009.00061; HILZENRATH D, 1998, WASHINGTON POST 0315, pH6; Kalb PE, 1999, JAMA-J AM MED ASSOC, V282, P1163, DOI 10.1001/jama.282.12.1163; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LO B, 1995, RESOLVING ETHICAL DI, P223; Manuel B M, 1995, Bull Am Coll Surg, V80, P23; MORREIM E, 1998, AM MED NEWS     0223, P25; Morreim E. Haavi, 1995, BALANCING ACT NEW ME; MORREIM EH, 1991, ARCH INTERN MED, V151, P443, DOI 10.1001/archinte.151.3.443; Nemes J, 1993, Mod Healthc, V23, P44; Nemes J, 1993, Mod Healthc, V23, P39; NEMES J, 1993, MOD HEALTHCARE, V23, P44; NOVACK DH, 1989, JAMA-J AM MED ASSOC, V261, P2980, DOI 10.1001/jama.261.20.2980; RANDOLPH L, 1997, PHYSICIAN CHARACTERI; Rost K, 1994, Arch Fam Med, V3, P333, DOI 10.1001/archfami.3.4.333; Schlesinger MJ, 1997, HEALTH AFFAIR, V16, P106, DOI 10.1377/hlthaff.16.1.106; Sparrow Malcolm, 1996, LICENSE STEAL WHY FR, P1, DOI [10.4324/9780429039577, DOI 10.4324/9780429039577]; Veatch R M, 1972, Hastings Cent Rep, V2, P5, DOI 10.2307/3560825	34	145	148	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1858	1865		10.1001/jama.283.14.1858	http://dx.doi.org/10.1001/jama.283.14.1858			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770148	Bronze			2022-12-28	WOS:000086248600032
J	Talbot, M				Talbot, M			Video casebook: Medicine - The toy boy and the burgundy car	BRITISH MEDICAL JOURNAL			English	Software Review									Cent Sheffield Univ Hosp, Sheffield, S Yorkshire, England		Talbot, M (corresponding author), Cent Sheffield Univ Hosp, Sheffield, S Yorkshire, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					1015	1015						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753171				2022-12-28	WOS:000086453100073
J	Mahadevan, L; Matsudaira, P				Mahadevan, L; Matsudaira, P			Motility powered by supramolecular springs and ratchets	SCIENCE			English	Review							ACROSOMAL PROCESS; ACTIN-FILAMENTS; LIMULUS SPERM; LISTERIA-MONOCYTOGENES; THYONE SPERM; PROTEIN; POLYMERIZATION; MICROTUBULE; MOVEMENT; FORCE	Not all biological movements are caused by molecular motors sliding along filaments or tubules, Just as springs and ratchets can store or release energy and rectify motion in physical systems, their analogs can perform similar functions, in biological systems. The energy of biological springs is derived from hydrolysis of a nucleotide or the binding of a Ligand, whereas biological ratchets are powered by Brownian movements of polymerizing filaments, However, the viscous and fluctuating cellular environment and the mechanochemistry of soft biological systems constrain the modes of motion generated and the mechanisms for energy storage, control,and release.	MIT, Dept Biol, Cambridge, MA 02142 USA; MIT, Dept Mech Engn, Cambridge, MA 02142 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02142 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Matsudaira, P (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02142 USA.	matsu@wi.mit.edu	Matsudaira, Paul/H-1475-2012	Matsudaira, Paul/0000-0002-8399-3276	NIGMS NIH HHS [GM52703] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052703] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham VC, 1999, BIOPHYS J, V77, P1721, DOI 10.1016/S0006-3495(99)77018-9; AMOS WB, 1971, NATURE, V229, P127, DOI 10.1038/229127a0; ARISAKA F, 1990, BIOCHEMISTRY-US, V29, P5057, DOI 10.1021/bi00473a009; Berry RM, 1999, ADV MICROB PHYSIOL, V41, P291, DOI 10.1016/S0065-2911(08)60169-1; Block SM, 1998, CELL, V93, P5, DOI 10.1016/S0092-8674(00)81138-1; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; CASPAR DLD, 1980, BIOPHYS J, V32, P103, DOI 10.1016/S0006-3495(80)84929-0; DEROSIER D, 1980, J MOL BIOL, V137, P375, DOI 10.1016/0022-2836(80)90163-1; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; DEROSIER DJ, 1982, J CELL BIOL, V93, P324, DOI 10.1083/jcb.93.2.324; Dogterom M, 1997, SCIENCE, V278, P856, DOI 10.1126/science.278.5339.856; FEYNMAN R, 1963, FEYMAN LECT PHYSICS, V1; HILL TL, 1982, INT REV CYTOL, V78, P1, DOI 10.1016/S0074-7696(08)60105-9; HOFFMANNBERLING H, 1958, BIOCHIM BIOPHYS ACTA, V27, P247, DOI 10.1016/0006-3002(58)90331-7; INOUE S, 1964, PRIMITIVE MOTILE SYS, P498; Italiano JE, 1996, CELL, V84, P105, DOI 10.1016/S0092-8674(00)80997-6; Janosi IM, 1998, EUR BIOPHYS J BIOPHY, V27, P501, DOI 10.1007/s002490050160; KATCHALSKY A, 1960, CONTRACTILE POLYMERS, P1; LI Y, 1992, ANNU REV MATER SCI, V22, P243; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Maciejewski JJ, 1999, J EUKARYOT MICROBIOL, V46, P165, DOI 10.1111/j.1550-7408.1999.tb04601.x; MARGOLIS RL, 1981, NATURE, V293, P705, DOI 10.1038/293705a0; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Mogilner A, 1999, EUR BIOPHYS J BIOPHY, V28, P235, DOI 10.1007/s002490050204; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Moriyama Y, 1999, BIOPHYS J, V76, P993, DOI 10.1016/S0006-3495(99)77263-2; Moriyama Y, 1998, BIOPHYS J, V74, P487, DOI 10.1016/S0006-3495(98)77806-3; MULLER M, 1994, J STRUCT BIOL, V112, P11, DOI 10.1006/jsbi.1994.1003; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Noireaux V, 2000, BIOPHYS J, V78, P1643, DOI 10.1016/S0006-3495(00)76716-6; Olbris DJ, 1999, BIOPHYS J, V77, P3407, DOI 10.1016/S0006-3495(99)77172-9; OSTER GF, 1982, J MATH BIOL, V15, P259, DOI 10.1007/BF00275078; Paoletti A, 1996, J CELL SCI, V109, P3089; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; ROBERTS TM, IN PRESS INT REV CYT; Salisbury JL, 1998, J EUKARYOT MICROBIOL, V45, P28, DOI 10.1111/j.1550-7408.1998.tb05064.x; Shahinpoor M, 1998, SMART MATER STRUCT, V7, pR15, DOI 10.1088/0964-1726/7/6/001; Shaw MK, 1999, P NATL ACAD SCI USA, V96, P9095, DOI 10.1073/pnas.96.16.9095; Sherman MB, 1999, J MOL BIOL, V294, P139, DOI 10.1006/jmbi.1999.3222; Stebbings H., 1979, CELL MOTILITY; STEWART M, 1994, J MOL BIOL, V243, P60, DOI 10.1006/jmbi.1994.1630; Sullivan DS, 1998, J CELL BIOL, V143, P751, DOI 10.1083/jcb.143.3.751; Sun SJ, 1997, MOL BIOL CELL, V8, P421, DOI 10.1091/mbc.8.3.421; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1979, J CELL BIOL, V81, P608, DOI 10.1083/jcb.81.3.608; TILNEY LG, 1973, J CELL BIOL, V59, P109, DOI 10.1083/jcb.59.1.109; TILNEY LG, 1982, J CELL BIOL, V93, P820, DOI 10.1083/jcb.93.3.820; TILNEY LG, 1975, J CELL BIOL, V64, P289, DOI 10.1083/jcb.64.2.289; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VANLEEUWENHOEK A, 1976, PHILOS T R SOC LON B, V12, P133; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3	54	168	172	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	2000	288	5463					95	99		10.1126/science.288.5463.95	http://dx.doi.org/10.1126/science.288.5463.95			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753126				2022-12-28	WOS:000086387700041
J	Zhitenev, NB; Fulton, TA; Yacoby, A; Hess, HF; Pfeiffer, LN; West, KW				Zhitenev, NB; Fulton, TA; Yacoby, A; Hess, HF; Pfeiffer, LN; West, KW			Imaging of localized electronic states in the quantum Hall regime	NATURE			English	Article							DENSITY; GAS	The concept of electron localization has long been accepted to be essential to the physics of the quantum Hall effect(1,2) in a two-dimensional electron gas. The exact quantization of the Ball resistance and the zero of the diagonal resistance over a range of filling factors close to integral are attributed to the localization of electronic states at the Fermi level in the interior of the gas. As the electron density is changed, charging of the individual localized states may occur by single-electron jumps(3,4), causing associated oscillations in the local electrostatic potential. Here we search for such a manifestation of localized states in the quantum Hall regime, using a scanning electrometer probe(5,6). We observe localized potential signals, at numerous locations, that oscillate with changing electron density. In general, the corresponding spatial patterns are complex, but well-defined objects are often seen which evidently arise from individual localized states. These objects interact, and at times form a lattice-like arrangement.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Weizmann Inst Sci, IL-76100 Rehovot, Israel; Phasemetr Inc, San Diego, CA 92121 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Weizmann Institute of Science	Zhitenev, NB (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Zhitenev, Nikolai/N-1780-2014	Zhitenev, Nikolai/0000-0002-7477-6341				EFROS AL, 1988, SOLID STATE COMMUN, V65, P1281, DOI 10.1016/0038-1098(88)90077-4; EFROS AL, 1988, SOLID STATE COMMUN, V67, P1019, DOI 10.1016/0038-1098(88)91177-5; FULTON TA, 1987, PHYS REV LETT, V59, P109, DOI 10.1103/PhysRevLett.59.109; KASTNER MA, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881393; LAUGHLIN RB, 1981, PHYS REV B, V23, P5632, DOI 10.1103/PhysRevB.23.5632; McCormick KL, 1999, PHYS REV B, V59, P4654, DOI 10.1103/PhysRevB.59.4654; Prange R. E., 1990, QUANTUM HALL EFFECT; SHKLOVSKII BI, 1985, ELECT PROPERTIES DOP; SMITH TP, 1985, PHYS REV B, V32, P2696, DOI 10.1103/PhysRevB.32.2696; Tessmer SH, 1998, NATURE, V392, P51, DOI 10.1038/32112; Yacoby A, 1999, SOLID STATE COMMUN, V111, P1, DOI 10.1016/S0038-1098(99)00139-8; Yoo MJ, 1997, SCIENCE, V276, P579, DOI 10.1126/science.276.5312.579	12	84	84	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					473	476		10.1038/35006591	http://dx.doi.org/10.1038/35006591			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761909				2022-12-28	WOS:000086257700040
J	Nassif, X				Nassif, X			Microbiology - A furtive pathogen revealed	SCIENCE			English	Editorial Material									Fac Med Necker Enfants Malad, INSERM, U411, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Nassif, X (corresponding author), Fac Med Necker Enfants Malad, INSERM, U411, 156 Rue Vaugirard, F-75015 Paris, France.			Nassif, Xavier/0000-0003-2855-3240				Nassif X, 1999, MOL MICROBIOL, V32, P1124, DOI 10.1046/j.1365-2958.1999.01416.x; Naumann M, 1999, CURR OPIN MICROBIOL, V2, P62, DOI 10.1016/S1369-5274(99)80011-3; Perrin A, 1999, INFECT IMMUN, V67, P6119, DOI 10.1128/IAI.67.11.6119-6129.1999; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Vogel U, 1999, MOL MICROBIOL, V32, P1133, DOI 10.1046/j.1365-2958.1999.01469.x	7	16	36	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2000	287	5459					1767	1768		10.1126/science.287.5459.1767	http://dx.doi.org/10.1126/science.287.5459.1767			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BY	10755929				2022-12-28	WOS:000085775300028
J	Anderson, PW				Anderson, PW			Sources of quantum protection in high-T-c superconductivity	SCIENCE			English	Article							RESONATING-VALENCE-BOND	The layer-structure cuprates with high superconducting transition temperatures T-c exhibit a number of anomalous electronic properties in both superconducting and normal states. These anomalies are ascribed to the existence of independent spectra of excitations for charge and for spin, signaling a collective state, a "quantum protectorate."	Princeton Univ, Joseph Henry Labs Phys, Princeton, NJ 08544 USA	Princeton University	Anderson, PW (corresponding author), Princeton Univ, Joseph Henry Labs Phys, Princeton, NJ 08544 USA.							Anderson P. W., 1997, THEORY SUPERCONDUCTI; ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; Anderson PW, 1995, PHYS REV B, V52, P16415, DOI 10.1103/PhysRevB.52.16415; JOHNSON PD, IN PRESS P 11 SYNCHR; KALMEYER V, 1987, PHYS REV LETT, V59, P2095, DOI 10.1103/PhysRevLett.59.2095; KRISHANA K, 1995, PHYS REV LETT, V75, P3529, DOI 10.1103/PhysRevLett.75.3529; Laughlin RB, 2000, P NATL ACAD SCI USA, V97, P28, DOI 10.1073/pnas.97.1.28; Lieb E, 1968, PHYS REV LETT, V20, P1444; Senthil T, 1999, PHYS REV B, V60, P6893, DOI 10.1103/PhysRevB.60.6893; Wen XG, 1998, PHYS REV LETT, V80, P2193, DOI 10.1103/PhysRevLett.80.2193	10	112	112	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					480	482		10.1126/science.288.5465.480	http://dx.doi.org/10.1126/science.288.5465.480			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775101				2022-12-28	WOS:000086626000036
J	Schenfeld, LA				Schenfeld, LA			Staphylococcal scalded skin syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Conemaugh Mem Med Ctr, Johnstown, PA 15905 USA		Schenfeld, LA (corresponding author), Conemaugh Mem Med Ctr, Johnstown, PA 15905 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	2000	342	16					1178	1178		10.1056/NEJM200004203421605	http://dx.doi.org/10.1056/NEJM200004203421605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305DG	10770983	Bronze			2022-12-28	WOS:000086523700005
J	Stadtmauer, EA; O'Neill, A; Goldstein, LJ; Crilley, PA; Mangan, KF; Ingle, JN; Brodsky, I; Martino, S; Lazarus, HM; Erban, JK; Sickles, C; Glick, JH				Stadtmauer, EA; O'Neill, A; Goldstein, LJ; Crilley, PA; Mangan, KF; Ingle, JN; Brodsky, I; Martino, S; Lazarus, HM; Erban, JK; Sickles, C; Glick, JH		Philadelphia Bone Marrow Transplan	Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CONSOLIDATION THERAPY; FOLLOW-UP; SUPPORT; RESCUE; CYCLOPHOSPHAMIDE; CARBOPLATIN; REMISSION; SELECTION; THIOTEPA	Background: We conducted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell rescue with a prolonged course of monthly conventional-dose chemotherapy in women with metastatic breast cancer. Methods: Women 18 to 60 years of age who had metastatic breast cancer received four to six cycles of standard combination chemotherapy. Patients who had a complete or partial response to induction chemotherapy were then randomly assigned to receive either a single course of high doses of carboplatin, thiotepa, and cyclophosphamide plus transplantation of autologous hematopoietic stem cells or up to 24 cycles of cyclophosphamide, methotrexate, and fluorouracil in conventional doses. The primary end point was survival. Results: The median follow-up was 37 months. Of 553 patients who enrolled in the study, 58 had a complete response to induction chemotherapy and 252 had a partial response. Of these, 110 patients were assigned to receive high-dose chemotherapy plus hematopoietic stem cells and 89 were assigned to receive conventional-dose chemotherapy. In an intention-to-treat analysis, we found no significant difference in survival overall at three years between the two treatment groups (32 percent in the transplantation group and 38 percent in the conventional-chemotherapy group). There was no significant difference between the two treatments in the median time to progression of the disease (9.6 months for high-dose chemotherapy plus hematopoietic stem cells and 9.0 months for conventional-dose chemotherapy). Conclusions: As compared with maintenance chemotherapy in conventional doses, high-dose chemotherapy plus autologous stem-cell transplantation soon after the induction of a complete or partial remission with conventional-dose chemotherapy does not improve survival in women with metastatic breast cancer. (N Engl J Med 2000;342:1069-76.) (C) 2000, Massachusetts Medical Society.	Univ Penn, Ctr Canc, Bone Marrow & Stem Cell Transplant Program, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Med Coll Penn & Hahnemann Univ, Philadelphia, PA USA; Temple Univ, Philadelphia, PA 19122 USA; Mayo Clin, Rochester, MN USA; John Wayne Canc Inst, Santa Monica, CA USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Tufts Univ, New England Med Ctr, Boston, MA 02111 USA	University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center; Drexel University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Mayo Clinic; John Wayne Cancer Institute; University Hospitals of Cleveland; Tufts Medical Center; Tufts University	Stadtmauer, EA (corresponding author), Univ Penn, Ctr Canc, Bone Marrow & Stem Cell Transplant Program, 16 Penn Tower,3400 Spruce St, Philadelphia, PA 19104 USA.	stadtmau@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [P30CA016520, U10CA023318, U10CA015488] Funding Source: NIH RePORTER; NCI NIH HHS [CA16520, CA23318, CA15488] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; Cassileth PA, 1998, NEW ENGL J MED, V339, P1649, DOI 10.1056/NEJM199812033392301; Crump M, 1996, J CLIN ONCOL, V14, P66, DOI 10.1200/JCO.1996.14.1.66; EDER JP, 1990, J CLIN ONCOL, V8, P1239, DOI 10.1200/JCO.1990.8.7.1239; GarciaCarbonero R, 1997, J CLIN ONCOL, V15, P3178, DOI 10.1200/JCO.1997.15.10.3178; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; JENNISON C, 1989, J R STAT SOC B, V51, P305; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; LOTZ JP, 1999, P AN M AM SOC CLIN, V18, pA43; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; Rahman ZU, 1997, J CLIN ONCOL, V15, P3171, DOI 10.1200/JCO.1997.15.10.3171; THOMAS ED, 1970, BLOOD-J HEMATOL, V36, P507, DOI 10.1182/blood.V36.4.507.507; WILLIAMS SF, 1992, J CLIN ONCOL, V10, P1743, DOI 10.1200/JCO.1992.10.11.1743; WILLIAMS SF, 1989, J CLIN ONCOL, V7, P1824, DOI 10.1200/JCO.1989.7.12.1824; 1998, ABMTR NEWSLETTER DEC, V5	18	339	342	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1069	1076		10.1056/NEJM200004133421501	http://dx.doi.org/10.1056/NEJM200004133421501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10760307	Green Submitted			2022-12-28	WOS:000086406700001
J	Firstenberg, MS; Thomas, JD				Firstenberg, MS; Thomas, JD			Stroke-distance measurement after acute myocardial infarction	LANCET			English	Editorial Material									Cleveland Clin Fdn, Cardiovasc Imaging Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Thomas, JD (corresponding author), Cleveland Clin Fdn, Cardiovasc Imaging Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.							Trent RJ, 1999, HEART, V82, P187, DOI 10.1136/hrt.82.2.187	1	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1204	1204		10.1016/S0140-6736(00)02084-5	http://dx.doi.org/10.1016/S0140-6736(00)02084-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770300				2022-12-28	WOS:000086448000007
J	Detre, KM; Lombardero, MS; Brooks, MM; Hardison, RM; Holubkov, R; Sopko, G; Frye, RL; Chaitman, BR				Detre, KM; Lombardero, MS; Brooks, MM; Hardison, RM; Holubkov, R; Sopko, G; Frye, RL; Chaitman, BR		Bypass Angioplasty Revascularizati	The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN-TREATMENT; CLINICAL COURSE; MORTALITY; MELLITUS; SURVIVAL	Background: Acute myocardial infarction in patients with diabetes is associated with high mortality. We studied whether previous revascularization by coronary-artery bypass grafting (CABG), as compared with percutaneous transluminal coronary angioplasty (PTCA), influences the prognosis in such patients. Methods: We classified all patients eligible for the Bypass Angioplasty Revascularization Investigation who underwent coronary revascularization within three months after entry into the study according to whether they had diabetes and whether they had undergone CABG, either initially or after PTCA. The protective effect of CABG with regard to mortality in the presence and in the absence of subsequent spontaneous Q-wave myocardial infarction was estimated with the use of Cox regression models. Results: Among the 641 patients with diabetes and the 2962 without diabetes, the cumulative five-year rates of death were 20 percent and 8 percent, respectively (P<0.001), and the five-year rates of spontaneous Q-wave myocardial infarction were 8 percent and 4 percent (P<0.001). CABG greatly reduced the risk of death after spontaneous Q-wave myocardial infarction in the patients with diabetes (relative risk, 0.09; 95 percent confidence interval, 0.03 to 0.29). Among patients with diabetes who had undergone CABG but did not have spontaneous Q-wave myocardial infarction, the corresponding relative risk of death was 0.65 (95 percent confidence interval, 0.45 to 0.94). Among the patients without diabetes, no protective effect of CABG was evident. Conclusions: Among patients with diabetes, previous coronary bypass surgery, as compared with coronary angioplasty, has a highly favorable influence on prognosis after acute myocardial infarction and a smaller beneficial effect among patients who do not have infarction. These findings should influence the type of coronary revascularization procedure selected for patients with diabetes who have multivessel coronary artery disease. (N Engl J Med 2000;342:989-97.) (C) 2000, Massachusetts Medical Society.	Univ Pittsburgh, Grad Sch Publ Hlth, BARI Coordinating Ctr, Pittsburgh, PA 15261 USA; NIH, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; St Louis Univ, Hlth Sci Ctr, St Louis, MO 63103 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; Mayo Clinic; Saint Louis University	Detre, KM (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, BARI Coordinating Ctr, 130 DeSoto St,127 Parran Hall, Pittsburgh, PA 15261 USA.			Brooks, Maria/0000-0002-2030-7873				Abaci A, 1999, CIRCULATION, V99, P2239, DOI 10.1161/01.CIR.99.17.2239; Alderman E, 1997, CIRCULATION, V96, P1761, DOI 10.1161/01.CIR.96.6.1761; Alderman EL, 1996, NEW ENGL J MED, V335, P217; ALDERMAN EL, 1991, CIRCULATION, V83, P1087, DOI 10.1161/01.CIR.83.3.1087; BOURASSA MG, 1995, AM J CARDIOL, V75, pC3, DOI 10.1016/S0002-9149(99)80389-0; *BYP ANG REV INV B, 1997, NEW ENGL J MED, V336, P147; Chaitman BR, 1996, J ELECTROCARDIOL, V29, P265, DOI 10.1016/S0022-0736(96)80091-4; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, ANAL SURVIVAL DATA, P112; CZYZK A, 1980, DIABETES CARE, V3, P526, DOI 10.2337/diacare.3.4.526; DAVIS KB, 1992, CIRCULATION, V85, P2100, DOI 10.1161/01.CIR.85.6.2100; HERLITZ J, 1988, ACTA MED SCAND, V224, P31; JACOBY RM, 1992, J AM COLL CARDIOL, V20, P736, DOI 10.1016/0735-1097(92)90033-J; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARLSON BW, 1993, DIABETIC MED, V10, P449, DOI 10.1111/j.1464-5491.1993.tb00097.x; KING SB, IN PRESS J AM COLL C; LOOP FD, 1990, ANN THORAC SURG, V49, P179, DOI 10.1016/0003-4975(90)90136-T; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Mak KH, 1997, J AM COLL CARDIOL, V30, P171, DOI 10.1016/S0735-1097(97)00118-6; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; MALMBERG K, 1988, EUR HEART J, V9, P259, DOI 10.1093/oxfordjournals.eurheartj.a062494; MANTEL N, 1974, J AM STAT ASSOC, V69, P81, DOI 10.2307/2285503; PEDUZZI P, 1991, CIRCULATION, V83, P747, DOI 10.1161/01.CIR.83.3.747; SINGER DE, 1989, DIABETES, V38, P350, DOI 10.2337/diabetes.38.3.350; SOLER NG, 1975, Q J MED, V44, P125; Whitlow PL, 1999, J AM COLL CARDIOL, V34, P1750, DOI 10.1016/S0735-1097(99)00406-4; 1991, CIRCULATION S5, V84, P1	29	129	137	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	2000	342	14					989	997		10.1056/NEJM200004063421401	http://dx.doi.org/10.1056/NEJM200004063421401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300JB	10749960				2022-12-28	WOS:000086248900001
J	Fonseca, V; Rosenstock, J; Patwardhan, R; Salzman, A				Fonseca, V; Rosenstock, J; Patwardhan, R; Salzman, A			Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; HOMEOSTASIS MODEL ASSESSMENT; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; FATTY-ACIDS; BETA-CELL; GLYCEMIC CONTROL; DRUG-THERAPY; PLASMA; TROGLITAZONE	Context Most antidiabetic agents target only 1 of several underlying causes of diabetes. The complementary actions of the antidiabetic agents metformin hydrochloride and rosiglitazone maleate may maintain optimal glycemic control in patients with type 2 diabetes; therefore, their combined use may be indicated for patients whose diabetes is poorly controlled by metformin alone. Objective To evaluate the efficacy of metformin-rosiglitazone therapy in patients whose type 2 diabetes is inadequately controlled with metformin alone. Design Randomized, double-blind, placebo-controlled trial from April 1997 and March 1998. Setting Thirty-six outpatient centers in the United States. Patients Three hundred forty-eight patients aged 40 to 80 years with a mean fasting plasma glucose level of 12.0 mmol/L (216 mg/dL), a mean glycosylated hemoglobin level of 8.8%, and a mean body mass index of 30.1 kg/m(2) were randomized. Interventions Patients were assigned to receive 2.5 g/d of metformin plus placebo (n = 116); 2.5 g/d of metformin plus 4 mg/d of rosiglitazone (n = 119); or 2.5 g/d of metformin and 8 mg/d of rosiglitazone (n = 113) for 26 weeks. Main Outcome Measures Glycosylated hemoglobin levels, fasting plasma glucose levels, insulin sensitivity, and beta-cell function, compared between baseline and week 26, by treatment group. Results Glycosylated hemoglobin levels, fasting plasma glucose levels, insulin sensitivity, and p-cell function improved significantly with metformin-rosiglitazone therapy in a dose-dependent manner. The mean levels of glycosylated hemoglobin decreased by 1.0% in the 4 mg/d metformin-rosiglitazone group and by 1.2% in the 8 mg/d metformin-rosiglitazone group and fasting plasma glucose levels by 2.2 mmol/L (39.8 mg/dL) and 2.9 mmol/L (52.9 mg/dL) compared with the metformin-placebo group (P<.001 for all). Of patients receiving 8 mg/d of metformin-rosiglitazone, 28.1% achieved a glycosylated hemoglobin level of less than 7%. Dose-dependent increases in body weight and total and low-density lipoprotein cholesterol levels were observed (P<.001 for both rosiglitazone groups vs placebo). The proportion of patients reporting adverse experiences was comparable across all groups. Conclusions Our data suggest that combination treatment with once-daily metformin-rosiglitazone improves glycemic control, insulin sensitivity, and beta-cell function more effectively than treatment with metformin alone.	Tulane Univ, Dept Med, Endocrinol Sect, 1430 Tulane Ave,POB SL53, New Orleans, LA 70112 USA; Dallas Diabet Ctr, Dallas, TX USA; SmithKline Beecham Pharmaceut, Dept Biometr, Collegeville, PA USA; SmithKline Beecham Pharmaceut, Dept Clin Res & Dev, Collegeville, PA USA	Tulane University; Diabetes & Endocrine Center; GlaxoSmithKline; GlaxoSmithKline	Fonseca, V (corresponding author), Tulane Univ, Dept Med, Endocrinol Sect, 1430 Tulane Ave,POB SL53, New Orleans, LA 70112 USA.							Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; Bergman Richard N., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P205; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; Criqui Michael H., 1998, American Journal of Medicine, V105, p48S, DOI 10.1016/S0002-9343(98)00212-5; Cusi K, 1996, J CLIN ENDOCR METAB, V81, P4059, DOI 10.1210/jc.81.11.4059; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Dogterom P, 1999, DIABETES, V48, pA98; Emoto M, 1999, DIABETES CARE, V22, P818, DOI 10.2337/diacare.22.5.818; Fagot-Campagna A, 1998, INT J EPIDEMIOL, V27, P808, DOI 10.1093/ije/27.5.808; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gavin JR, 1999, DIABETES CARE, V22, pS5; Haffner SM, 1997, DIABETES CARE, V20, P1087, DOI 10.2337/diacare.20.7.1087; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; HARRIS M, 1979, DIABETES, V28, P1039; Hermann LS, 1992, INT TXB DIABETES MEL, V1, P773; Hermans MP, 1999, DIABETES, V48, P1779, DOI 10.2337/diabetes.48.9.1779; Hermans MP, 1999, DIABETOLOGIA, V42, P678, DOI 10.1007/s001250051215; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MIKHAILIDIS DP, 1983, THROMB RES, V32, P641, DOI 10.1016/0049-3848(83)90067-1; MIMURA K, 1994, DIABETIC MED, V11, P685, DOI 10.1111/j.1464-5491.1994.tb00333.x; MITROPOULOS KA, 1992, ATHEROSCLEROSIS, V95, P119, DOI 10.1016/0021-9150(92)90015-9; Mooradian AD, 1999, DRUGS, V57, P19, DOI 10.2165/00003495-199957010-00003; Paolisso G, 1998, DIABETIC MED, V15, P360, DOI 10.1002/(SICI)1096-9136(199805)15:5<360::AID-DIA568>3.0.CO;2-W; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; RASKIN P, IN PRESS DIABETOLOGI; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; SEIDELL JC, 1989, INFUSIONSTHERAPIE, V16, P276; Shimizu H, 1998, DIABETES CARE, V21, P1470, DOI 10.2337/diacare.21.9.1470; SMITH SA, 1993, DIABETOLOGIA, V36, pA184; Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001; Yamasaki Y, 1997, TOHOKU J EXP MED, V183, P173, DOI 10.1620/tjem.183.173; Young MMR, 1999, EUR J CLIN PHARMACOL, V55, P101, DOI 10.1007/s002280050602	44	407	427	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1695	1702		10.1001/jama.283.13.1695	http://dx.doi.org/10.1001/jama.283.13.1695			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BK	10755495	Bronze			2022-12-28	WOS:000086119300029
J	Horton, R				Horton, R			After Bezwoda	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							Buyse M, 1999, STAT MED, V18, P3435, DOI 10.1002/(SICI)1097-0258(19991230)18:24<3435::AID-SIM365>3.3.CO;2-F; *GEN MED COUNC, 1999, GOOD PRACT MED RES; GRADY D, 2000, NY TIMES        0205, pA7; Horton R, 1999, LANCET, V354, P1138, DOI 10.1016/S0140-6736(99)00328-1; Horton R, 1999, LANCET, V354, P7, DOI 10.1016/S0140-6736(99)00227-5; Nylenna M, 1999, LANCET, V354, P57, DOI 10.1016/S0140-6736(98)07133-5; Office of Research Integrity, 2000, MAN ALL SCI MISC GUI; PETO R, 2000, P R COLL PHYSICIA S7, V30, P25; Snyderman R, 2000, SCIENCE, V287, P595, DOI 10.1126/science.287.5453.595; 2000, NY TIMES        0220, P12	10	16	16	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					942	943		10.1016/S0140-6736(00)90006-0	http://dx.doi.org/10.1016/S0140-6736(00)90006-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768426				2022-12-28	WOS:000086054000002
J	Weiss, RB; Rifkin, RM; Stewart, FM; Theriault, RL; Williams, LA; Herman, AA; Beveridge, RA				Weiss, RB; Rifkin, RM; Stewart, FM; Theriault, RL; Williams, LA; Herman, AA; Beveridge, RA			High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study	LANCET			English	Article							BONE-MARROW SUPPORT; RANDOMIZED TRIAL; CELL SUPPORT	Background The efficacy of high-dose chemotherapy with progenitor-cell rescue for women with breast cancer is a controversial issue. Although historically controlled trials have suggested a survival advantage for high-dose chemotherapy, several randomised studies have yet to confirm this advantage. Two studies, however, by Bezwoda, of patients with high-risk and metastatic disease, seemed to show a significant survival advantage for high-dose compared with conventional-dose chemotherapy for metastatic and high-risk primary breast cancer. Methods To corroborate the study results before starting a large international confirmatory study, a US team did an onsite review of records for patients in the high-risk study. Limited numbers of records were made available for review, all of which were for patients who received the high-dose-chemotherapy regimen. Findings There was much disparity between the reviewed records and the data presented at two international meetings. In addition, the reviewers saw no signed informed consent, and the institutional review committee had no record of approval for the investigational therapy. After the site visit, Bezwoda admitted scientific misconduct by using a different control chemotherapy regimen from that described in presented data. Interpretation The Bezwoda study should not be used as the basis for further trials to test the efficacy of the cyclophosphamide, mitoxantrone, etoposide regimen for high-dose chemotherapy in women with high-risk primacy breast cancer. This review validates the essential nature of on-site audits, especially in single-institution studies.	US Oncol Inc, Houston, TX 77060 USA; Rockville, Washington, DC USA; Univ Massachusetts, Med Ctr, Dept Med, Worcester, MA USA; Univ Texas, MD Anderson Canc Ctr, Med Breast Canc Serv, Houston, TX 77030 USA; Med Univ Southern Africa, Natl Sch Publ Hlth, Pretoria, South Africa	University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; UTMD Anderson Cancer Center; Sefako Makgatho Health Sciences University	Beveridge, RA (corresponding author), US Oncol Inc, 16825 Northchase Dr,Suite 1300, Houston, TX 77060 USA.	roy.beveridge@usoncology.com						Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; Bezwoda WR, 1999, EUR J CANCER, V35, pS230, DOI 10.1016/S0959-8049(99)81322-7; BEZWODA WR, 1999, P ASCO, V18, P2; BEZWODA WR, 1998, P AN M AM SOC CLIN, V17, P115; Gianni AM, 1997, J CLIN ONCOL, V15, P2312, DOI 10.1200/JCO.1997.15.6.2312; Hortobagyi GN, 2000, JNCI-J NATL CANCER I, V92, P225, DOI 10.1093/jnci/92.3.225; Nylenna M, 1999, LANCET, V354, P57, DOI 10.1016/S0140-6736(98)07133-5; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; PETERS WP, 1999, P ASCO, V18, P1; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6; STADTMAUER EA, 1999, P AN M AM SOC CLIN, V18, pA1; Weiss R B, 1999, Oncologist, V4, P450; Weiss RB, 1998, CANCER CHEMOTH PHARM, V42, pS88, DOI 10.1007/s002800051087; WEISS RB, 1993, JAMA-J AM MED ASSOC, V270, P459, DOI 10.1001/jama.270.4.459; 2000, CANC LETT, V26, P1	17	99	101	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					999	1003		10.1016/S0140-6736(00)90024-2	http://dx.doi.org/10.1016/S0140-6736(00)90024-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768448				2022-12-28	WOS:000086054000039
J	Schoof, H; Lenhard, M; Haecker, A; Mayer, KFX; Jurgens, G; Laux, T				Schoof, H; Lenhard, M; Haecker, A; Mayer, KFX; Jurgens, G; Laux, T			The stem cell population of Arabidopsis shoot meristems is maintained by a regulatory loop between the CLAVATA and WUSCHEL genes	CELL			English	Article							FLORAL MERISTEMS; EXPRESSION; PROTEIN; ZWILLE; FATE	The higher-plant shoot meristem is a dynamic structure whose maintenance depends on the coordination of two antagonistic processes, organ initiation and self-renewal of the stem cell population. In Arabidopsis shoot and floral meristems, the WUSCHEL (WUS) gene is required for stem cell identity, whereas the CLAVATA1, 2, and 3 (CLV) genes promote organ initiation. Our analysis of the interactions between these key regulators indicates that (1) the CLV genes repress WUS at the transcript level and that (2) WUS expression is sufficient to induce meristem cell identity and the expression of the stem cell marker CLV3. Our data suggest that the shoot meristem has properties of a self-regulatory system in which WUS/CLV interactions establish a feedback loop between the stem cells and the underlying organizing center.	Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Laux, T (corresponding author), Zentrum Mol Biol Pflanzen, Morgenstelle 1, D-72076 Tubingen, Germany.	thomas.laux@uni-tuebingen.de	Mayer, Klaus FX/M-7941-2015; Schoof, Heiko/Y-7073-2018; Lenhard, Michael/J-1554-2015	Mayer, Klaus FX/0000-0001-6484-1077; Schoof, Heiko/0000-0002-1527-3752; 				BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Bowman J., 1994, ARABIDOPSIS ATLAS MO, V102, P117; CLARK SE, 1993, DEVELOPMENT, V119, P397; Clark SE, 1996, DEVELOPMENT, V122, P1567; CLARK SE, 1995, DEVELOPMENT, V121, P2057; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Elliott RC, 1996, PLANT CELL, V8, P155, DOI 10.1105/tpc.8.2.155; Endrizzi K, 1996, PLANT J, V10, P967, DOI 10.1046/j.1365-313X.1996.10060967.x; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Jeong S, 1999, PLANT CELL, V11, P1925, DOI 10.1105/tpc.11.10.1925; Kayes JM, 1998, DEVELOPMENT, V125, P3843; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Laufs P, 1998, PLANT CELL, V10, P1375, DOI 10.1105/tpc.10.8.1375; Laufs P, 1998, DEVELOPMENT, V125, P1253; Laux T, 1996, DEVELOPMENT, V122, P87; Lenhard M, 1999, CURR OPIN PLANT BIOL, V2, P44, DOI 10.1016/S1369-5266(99)80009-0; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Lynn K, 1999, DEVELOPMENT, V126, P469; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; Moore I, 1998, P NATL ACAD SCI USA, V95, P376, DOI 10.1073/pnas.95.1.376; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; STEWART RN, 1970, AM J BOT, V57, P816, DOI 10.2307/2441339; VANDERKROL AR, 1991, PLANT CELL, V3, P667, DOI 10.1105/tpc.3.7.667; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	25	1171	1269	18	244	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 17	2000	100	6					635	644		10.1016/S0092-8674(00)80700-X	http://dx.doi.org/10.1016/S0092-8674(00)80700-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761929	Bronze			2022-12-28	WOS:000085983800006
J	Hsueh, YP; Wang, TF; Yang, FC; Sheng, M				Hsueh, YP; Wang, TF; Yang, FC; Sheng, M			Nuclear translocation and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2	NATURE			English	Article							EPITHELIAL-CELLS; BASOLATERAL MEMBRANE; PROTEIN COMPLEX; BETA-CATENIN; IDENTIFICATION; LOCALIZATION; BRACHYURY; HOMOLOG; DOMAIN	Membrane-associated guanylate kinases (MAGUKs) contain multiple protein-binding domains that allow them to assemble specific multiprotein complexes in particular regions of the cell(1,2). CASK/LIN-2, a MAGUK required for EGF receptor localization and signalling in Caenorhabditis elegans, contains a calmodulin-dependent protein kinase-like domain followed by PDZ, SH3 and guanylate kinase-like domains(3-5). In adult rat brain, CASK is concentrated at neuronal synapses and binds to the cell-surface proteins neurexin and syndecan(6-8) and the cytoplasmic proteins Mint/LIN-10 and Veli/LIN-7 (refs 4, 9, 10). Here we report that, through its guanylate kinase domain, CASK interacts with Tbr-1, a T-box transcription factor that is involved in forebrain development(11,12). CASK enters the nucleus and binds to a specific DNA sequence (the T-element) in a complex with Tbr-1. CASK acts as a coactivator of Tbr-1 to induce transcription of T-element containing genes, including reelin, a gene that is essential for cerebrocortical development. Our findings show that a MAGUK which is usually associated with cell junctions has a transcription regulation function.	Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurobiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Sheng, M (corresponding author), Howard Hughes Med Inst, Boston, MA 02114 USA.	sheng@helix.mgh.harvard.edu	Hsueh, Yi-Ping/ABH-5052-2020; Wang, Ting-Fang/ABI-3818-2020	Hsueh, Yi-Ping/0000-0002-0866-6275; Wang, Ting-Fang/0000-0001-6306-9505; Sheng, Morgan/0000-0002-8703-5366				Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Hata Y, 1996, J NEUROSCI, V16, P2488; Hevner R. F., 1999, Society for Neuroscience Abstracts, V25, P502; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; HSUEH YP, 1995, J IMMUNOL, V154, P5675; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Niethammer M, 1998, METHOD ENZYMOL, V293, P104; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752	22	278	288	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					298	302		10.1038/35005118	http://dx.doi.org/10.1038/35005118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749215				2022-12-28	WOS:000086022200053
J	Mira-Perez, J				Mira-Perez, J			Spanish university study ignores research	NATURE			English	Letter									Univ Santiago de Compostela, Dept Appl Phys, E-15706 Santiago De Compostela, Spain	Universidade de Santiago de Compostela	Mira-Perez, J (corresponding author), Univ Santiago de Compostela, Dept Appl Phys, E-15706 Santiago De Compostela, Spain.		Mira, Jorge/F-9077-2016	Mira, Jorge/0000-0002-6024-6294				Bosch X, 1999, NATURE, V402, P848, DOI 10.1038/47167	1	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					222	222		10.1038/35005266	http://dx.doi.org/10.1038/35005266			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749185	Green Published, Bronze			2022-12-28	WOS:000086022200016
J	Ellertson, C; Elul, B; Ambardekar, S; Wood, L; Carroll, J; Coyaji, K				Ellertson, C; Elul, B; Ambardekar, S; Wood, L; Carroll, J; Coyaji, K			Accuracy of assessment of pregnancy duration by women seeking early abortions	LANCET			English	Article							MIFEPRISTONE-MISOPROSTOL; GESTATIONAL-AGE; UNITED-STATES; TERMINATION; ACCEPTABILITY; TRIAL	Background Advances in medical abortion might allow women seeking early abortions to terminate their pregnancies safely and effectively without medical supervision. We investigated whether such women can calculate pregnancy duration accurately, a key step in unsupervised use. Methods 422 women seeking first-trimester abortions in two clinics (Pune, India, and Atlanta, USA) used a simple worksheet and calendar to calculate the duration of gestation from the date of last menstrual period (LMP) and/or of unprotected intercourse. Clinicians then used standard clinic practices to estimate pregnancy duration. We compared the two sets of estimates, focusing on women who fell into the "caution zone" (ie, had pregnancy durations >8 weeks according to providers, but less than or equal to 8 weeks by their own estimates). Findings The participants were generally representative of the women seeking abortion at the two clinics. 217 (97.7%) of 222 women in Atlanta and 173 (86.5%) of 200 in Pune could produce an estimate of pregnancy duration. Most (85.4% in Atlanta; 93.6% in Pune) of these estimates were within 2 weeks of those made by providers. For estimates based on LMP, only 10.0% (exact 95% CI 6.2-15.0) of women in Atlanta and 9.8% (5.8-15.3) in Pune fell into the caution zone. For estimates based on a date of intercourse, just 7.7% (4.0-13.1) of women in Atlanta and 3.4% (0-17.8) in Pune fell into the caution zone, although fewer women could use this method. Interpretation The vast majority of women seeking first-trimester abortion in this study could accurately calculate pregnancy duration within a margin of error clinically inconsequential for safe use of unsupervised medical abortion.	Populat Council, Mexico City 11560, DF, Mexico; Populat Council, New York, NY 10021 USA; KEM Hosp, Pune, Maharashtra, India; Feminist Womens Hlth Ctr, Atlanta, GA USA; Univ Calif Berkeley, Berkeley, CA 94720 USA	Population Council; University of California System; University of California Berkeley	Ellertson, C (corresponding author), Populat Council, Apartado Postal 105-152, Mexico City 11560, DF, Mexico.							Adatto-Levy R, 1998, CONTRACEPTION, V58, P257; Ashok PW, 1999, BRIT J OBSTET GYNAEC, V106, P706, DOI 10.1111/j.1471-0528.1999.tb08371.x; Ashok PW, 1998, LANCET, V352, P542, DOI 10.1016/S0140-6736(05)79250-3; Aubeny E, 1995, Int J Fertil Menopausal Stud, V40 Suppl 2, P85; DICKEY RP, 1993, HUM REPROD, V8, P331, DOI 10.1093/oxfordjournals.humrep.a138046; ELLERTSON C, 1997, REPROD HEALTH MATTER, V9, P149; Guengant JP, 1999, CONTRACEPTION, V60, P167, DOI 10.1016/S0010-7824(99)00074-8; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; Robillard P Y, 1992, J Perinatol, V12, P115; SAYERS SM, 1992, J PAEDIATR CHILD H, V28, P312, DOI 10.1111/j.1440-1754.1992.tb02675.x; Schaff EA, 1997, J FAM PRACTICE, V44, P353; Spitz IM, 1998, NEW ENGL J MED, V338, P1241, DOI 10.1056/NEJM199804303381801; TSUI AO, 1997, REPROD HLTH DEV COUN, P116; Waldenstrom U, 1991, ACTA OBSTET GYN SCAN, V70, P17, DOI 10.3109/00016349109006171; Winikoff B, 1998, ARCH FAM MED, V7, P360, DOI 10.1001/archfami.7.4.360; Winikoff B, 1997, AM J OBSTET GYNECOL, V176, P431, DOI 10.1016/S0002-9378(97)70511-8	16	37	37	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					877	881		10.1016/S0140-6736(99)10170-3	http://dx.doi.org/10.1016/S0140-6736(99)10170-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752703				2022-12-28	WOS:000085896000009
J	Kent, JM				Kent, JM			SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; MAJOR DEPRESSION; DOUBLE-BLIND; CLINICAL EFFICACY; NEFAZODONE; VENLAFAXINE; OUTPATIENTS; MIRTAZAPINE; ANTIDEPRESSANT	A major goal of antidepressant development is to improve on preceding drug classes with agents with greater specificity (and therefore fewer unwanted side-effects) and with more rapid onset of antidepressant action. To this end, four antidepressants with significantly distinct pharmacological characteristics have been recently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine. Venlafaxine is the first antidepressant in a new drug class referred to as the serotonin noradrenergic reuptake inhibitors (SNaRIs). Nefazodone is a weaker serotonin and norepinephrine reuptake inhibitor, but a potent serotonin 5-HT2 receptor antagonist. Mirtazapine is a potent antagonist of central 2 alpha-adrenergic autoreceptors, and heteroreceptors and is an antagonist of serotonin 5-HT2 and 5-HT3 receptors. The result of these actions is to increase both noradrenergic and specific (5-HT1) serotonergic transmission, and mirtazapine has therefore been termed a noradrenergic and specific serotonergic antidepressant (NaSSA). Reboxetine is the first selective noradrenaline reuptake inhibitor (NaRI) to be introduced since the tricyclics, and lacks immediate serotonergic effects.	New York State Psychiat Inst, Unit 41, New York, NY 10032 USA	New York State Psychiatry Institute	Kent, JM (corresponding author), New York State Psychiat Inst, Unit 41, 1051 Riverside Dr, New York, NY 10032 USA.							Anderson I M, 1998, Depress Anxiety, V7 Suppl 1, P11, DOI 10.1002/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3.3.CO;2-O; ANSSEAU M, 1994, PSYCHOPHARMACOLOGY, V115, P254, DOI 10.1007/BF02244780; ANTON SF, 1994, PSYCHOPHARMACOL BULL, V30, P165; Aranda-Michel J, 1999, ANN INTERN MED, V130, P285, DOI 10.7326/0003-4819-130-4-199902160-00013; Baldwin DS, 1996, J CLIN PSYCHIAT, V57, P46; Ball SE, 1997, BRIT J CLIN PHARMACO, V43, P619, DOI 10.1046/j.1365-2125.1997.00591.x; BOLDENWATSON C, 1993, LIFE SCI, V52, P1023, DOI 10.1016/0024-3205(93)90194-8; BREMNER JD, 1995, J CLIN PSYCHIAT, V56, P519; *BRIST MYERS SQUIB, 1999, NEF  US PACK INS; Burrows GD, 1998, J CLIN PSYCHIAT, V59, P4; CLAGHORN JL, 1995, J AFFECT DISORDERS, V34, P165, DOI 10.1016/0165-0327(95)00014-E; CLERC GE, 1994, INT CLIN PSYCHOPHARM, V9, P139, DOI 10.1097/00004850-199409000-00001; Cohn CK, 1996, J CLIN PSYCHIAT, V57, P15; CUNNINGHAM LA, 1997, ANN CLIN PSYCHIAT, V14, P99; Davis R, 1996, CNS DRUGS, V5, P389, DOI 10.2165/00023210-199605050-00007; Davis R, 1997, DRUGS, V53, P608, DOI 10.2165/00003495-199753040-00006; DEBOER T, 1988, NEUROPHARMACOLOGY, V27, P399, DOI 10.1016/0028-3908(88)90149-9; deBoer T, 1996, J CLIN PSYCHIAT, V57, P19; deBoer T, 1995, INT CLIN PSYCHOPHARM, V10, P19, DOI 10.1097/00004850-199512004-00004; Dierick M, 1996, PROG NEURO-PSYCHOPH, V20, P57, DOI 10.1016/0278-5846(95)00292-8; Dostert P, 1997, EUR NEUROPSYCHOPHARM, V7, pS23, DOI 10.1016/S0924-977X(97)00417-3; Dubini A, 1997, J PSYCHOPHARMACOL, V11, pS17; EISON AS, 1990, PSYCHOPHARMACOL BULL, V26, P311; Entsuah AR, 1996, INT CLIN PSYCHOPHARM, V11, P137, DOI 10.1097/00004850-199611020-00008; Fawcett J, 1998, J AFFECT DISORDERS, V51, P267, DOI 10.1016/S0165-0327(98)00224-9; Feiger A, 1996, J CLIN PSYCHIAT, V57, P53; Feiger AD, 1999, INT CLIN PSYCHOPHARM, V14, P19, DOI 10.1097/00004850-199901000-00002; Feighner J, 1998, J CLIN PSYCHIAT, V59, P246, DOI 10.4088/JCP.v59n0508; FEIGHNER JP, 1989, PSYCHOPHARMACOL BULL, V25, P219; FEIGHNER JP, 1993, PERSPECTIVES PSYCHIA, V1; FONTAINE R, 1994, J CLIN PSYCHIAT, V55, P234; Gillin JC, 1997, J CLIN PSYCHIAT, V58, P185, DOI 10.4088/JCP.v58n0502; GREENE DS, 1995, J CLIN PSYCHOPHARM, V15, P409, DOI 10.1097/00004714-199512000-00004; GUELFI JD, 1995, J CLIN PSYCHIAT, V56, P450; HALIKAS JA, 1995, HUM PSYCHOPHARM CLIN, V10, pS125, DOI 10.1002/hup.470100807; HALL H, 1981, EUR J PHARMACOL, V70, P393, DOI 10.1016/0014-2999(81)90172-2; HERMAN BD, IN PRESS CLIN PHARM; Hoyberg OJ, 1996, ACTA PSYCHIAT SCAND, V93, P184; HYTTEL J, 1994, INT CLIN PSYCHOPHARM, V9, P19, DOI 10.1097/00004850-199403001-00004; Kasper S, 1997, DRUG SAFETY, V17, P251, DOI 10.2165/00002018-199717040-00005; Kasper S, 1995, INT CLIN PSYCHOPHARM, V10, P25, DOI 10.1097/00004850-199512004-00005; Katona C, 1999, J AFFECT DISORDERS, V55, P203, DOI 10.1016/S0165-0327(99)00073-7; KHAN A, 1991, PSYCHOPHARMACOL BULL, V27, P141; KLAMERUS KJ, 1992, J CLIN PHARMACOL, V32, P716, DOI 10.1002/j.1552-4604.1992.tb03875.x; KROBOTH PD, 1995, J CLIN PSYCHOPHARM, V15, P306, DOI 10.1097/00004714-199510000-00002; KUITUNEN T, 1994, PHARMACOL TOXICOL, V75, P91, DOI 10.1111/j.1600-0773.1994.tb00329.x; MASSANA J, 1998, P ANN M AM PSYCH ASS, V129; MENDELS J, 1995, J CLIN PSYCHIAT, V56, P30; MENDELS J, 1993, PSYCHOPHARMACOL BULL, V29, P169; MENDLEWICZ J, 1995, INT CLIN PSYCHOPHARM, V10, P5, DOI 10.1097/00004850-199503002-00003; MONGOMERY SA, 1995, INT J CLIN PSYCHO S4, V10, P37; Montgomery SA, 1997, J PSYCHOPHARMACOL, V11, pS9; Montgomery SA, 1998, INT CLIN PSYCHOPHARM, V13, P63, DOI 10.1097/00004850-199803000-00002; Montgomery SA, 1996, J PSYCHOPHARMACOL, V10, P5; Mucci M, 1997, J PSYCHOPHARMACOL, V11, pS33; MUTH EA, 1986, BIOCHEM PHARMACOL, V35, P4493, DOI 10.1016/0006-2952(86)90769-0; *ORG, 1998, MIRT US PACK INS; Owen J R, 1998, Depress Anxiety, V7 Suppl 1, P24, DOI 10.1002/(SICI)1520-6394(1998)7:1+<24::AID-DA7>3.0.CO;2-F; *PHARM UPJ, 1997, REB EUR PACK INS; Richelson E, 1997, MAYO CLIN PROC, V72, P835, DOI 10.4065/72.9.835; RICHOU H, 1995, HUM PSYCHOPHARM CLIN, V10, P263, DOI 10.1002/hup.470100403; RICKELS K, 1994, BRIT J PSYCHIAT, V164, P802, DOI 10.1192/bjp.164.6.802; RICKELS K, 1995, J CLIN PSYCHIAT, V56, P43; RIVA M, 1989, Journal of Drug Development, V1, P243; Robinson DS, 1996, J CLIN PSYCHIAT, V57, P31; SCHWEIZER E, 1991, J CLIN PSYCHOPHARM, V11, P233; SCHWEIZER E, 1994, J CLIN PSYCHIAT, V55, P104; Silva JCE, 1998, J CLIN PSYCHIAT, V59, P352; SISTEN JMA, 1995, CNS DRUGS S1, V4, P39; SMITH WT, 1990, PSYCHOPHARMACOL BULL, V26, P191; TAYLOR DP, 1995, J CLIN PSYCHIAT, V56, P3; Taylor DP, 1986, RECEPTOR BINDING DRU, P151; Thase ME, 1997, J CLIN PSYCHIAT, V58, P393, DOI 10.4088/JCP.v58n0904; Versiani M, 1999, J CLIN PSYCHIAT, V60, P400, DOI 10.4088/JCP.v60n0610; Wheatley DP, 1998, J CLIN PSYCHIAT, V59, P306, DOI 10.4088/JCP.v59n0606; WIENKERS LC, IN PRESS CYTOCHROME; WONG EHF, 1997, P ANN M AM COLL NEUR; *WYETH AYERST, 1999, VENL US PACK INS; ZIKOV M, 1995, HUM PSYCHOPHARMACO S, V10, pS135; ZIVKOV M, 1995, HUM PSYCHOPHARM CLIN, V10, P173, DOI 10.1002/hup.470100302	80	239	256	3	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					911	918		10.1016/S0140-6736(99)11381-3	http://dx.doi.org/10.1016/S0140-6736(99)11381-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752718				2022-12-28	WOS:000085896000041
J	Musters, CJM; de Graaf, HJ; ter Keurs, WJ				Musters, CJM; de Graaf, HJ; ter Keurs, WJ			Ecology - Can protected areas be expanded in Africa?	SCIENCE			English	Article									Leiden Univ, Dept Environm Biol, Inst Evolutionary & Ecol Sci, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Musters, CJM (corresponding author), Leiden Univ, Dept Environm Biol, Inst Evolutionary & Ecol Sci, POB 9516, NL-2300 RA Leiden, Netherlands.	musters@rulsfb.leidenuniv.nl	Musters, Cornelis/K-7828-2013	Musters, C.J.M./0000-0003-1321-6786				Daily G, 1998, SCIENCE, V281, P1291, DOI 10.1126/science.281.5381.1291; *FAO UN, 1997, STAT FOOD AGR 1997; FORD WR, 1999, 2 INT CULT C AFR AFR; Goklany IM, 1998, BIOSCIENCE, V48, P941, DOI 10.2307/1313298; Helmuth L, 1999, SCIENCE, V286, P1283, DOI 10.1126/science.286.5443.1283; Inamdar A, 1999, SCIENCE, V283, P1856, DOI 10.1126/science.283.5409.1856; James AN, 1999, NATURE, V401, P323, DOI 10.1038/43774; Kramer R, 1997, LAST STAND PROTECTED; Kramer Randall A., 1997, P3; LUYTEN JC, 1995, 37 RES I AGR SOIL FE; *POP DIV DEP EC SO, 1999, WOLF; *S AFR RES DOC CTR, 1994, STAT ENV SO AFR; Soule ME, 1998, SCIENCE, V279, P2060, DOI 10.1126/science.279.5359.2060; *UN ENV PROGR, 1991, STAT DES IMPL US NAT; *UN ENV PROGR, 1991, WORLD RESOURCES 1994; van Schaik Carel P., 1997, P212; Western D., 1994, NATURAL CONNECTIONS; WOLF EC, 1987, BRINK EXTEINCTION CO; *WORLD RES I, 1994, WORLD RESOURCES 1994; [No title captured]	20	33	34	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2000	287	5459					1759	1760		10.1126/science.287.5459.1759	http://dx.doi.org/10.1126/science.287.5459.1759			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BY	10755927				2022-12-28	WOS:000085775300023
J	Tromans, A				Tromans, A			Entomology - Love is not puffed up	NATURE			English	Editorial Material																		Funk DH, 2000, ANIM BEHAV, V59, P411, DOI 10.1006/anbe.1999.1310	1	0	0	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					138	138		10.1038/35004700	http://dx.doi.org/10.1038/35004700			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10755907	Bronze			2022-12-28	WOS:000085870900032
J	Fisher, PE; Russell, DA; Stoskopf, MK; Barrick, RE; Hammer, M; Kuzmitz, AA				Fisher, PE; Russell, DA; Stoskopf, MK; Barrick, RE; Hammer, M; Kuzmitz, AA			Cardiovascular evidence for an intermediate or higher metabolic rate in an ornithischian dinosaur	SCIENCE			English	Article							SOFT	Computerized tomography scans of a ferruginous concretion within the chest region of an ornithischian dinosaur reveal structures that are suggestive of a four-chambered heart and a single systemic aorta. The apparently derived condition of the cardiovascular system in turn suggests the existence of intermediate-to-high metabolic rates among dinosaurs.	N Carolina State Univ, Biomed Imaging Facil, Raleigh, NC 27606 USA; N Carolina State Univ, N Carolina State Museum Nat Sci, Raleigh, NC 27696 USA; N Carolina State Univ, Dept Marine Earth & Atmospher Sci, Raleigh, NC 27696 USA; N Carolina State Univ, Coll Vet Med, Dept Marine Earth & Atmospher Sci, Raleigh, NC 27696 USA; N Carolina State Univ, Environm Med Consortium, Raleigh, NC 27696 USA; N Carolina State Univ, Dept Marine Earth & Atmospher Sci, Raleigh, NC 27696 USA; Hammer & Hammer Paleotek, Jacksonville, OR 97530 USA	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Fisher, PE (corresponding author), N Carolina State Univ, Biomed Imaging Facil, 4700 Hillsborough St, Raleigh, NC 27606 USA.							ANDERSON JF, 1985, J ZOOL, V207, P53, DOI 10.1111/j.1469-7998.1985.tb04915.x; [Anonymous], [No title captured]; Barrick Reese E., 1997, P474; Benton MJ, 1998, TRENDS ECOL EVOL, V13, P303, DOI 10.1016/S0169-5347(98)01420-7; BURGGREN WW, 1994, CARDIOSCIENCE, V5, P183; Butler H., 1987, ATLAS STAGING MAMMAL; Dal Sasso C, 1998, NATURE, V392, P383; Farlow J.O., 1990, P43; Feduccia A, 1991, TORREYS MORPHOGENESI; Galton Peter M., 1997, Revue de Paleobiologie, V16, P231; HICKS JW, 1998, REPTILES MECHANISMS, V19, P425; Padian K, 1998, NATURE, V393, P729, DOI 10.1038/31576; PALADINO FV, 1977, COMPLETE DINOSAUR, P491; Paul Gregory S., 1997, P129; Reid R.E.H., 1997, P449; Sereno PC, 1999, SCIENCE, V284, P2137, DOI 10.1126/science.284.5423.2137; Thrall D. E., 1998, TXB VET DIAGNOSTIC R; Weigelt Johannes, 1989, RECENT VERTEBRATE CA, DOI DOI 10.7208/CHICAGO/9780226881683.001.0001	18	40	42	0	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					503	505		10.1126/science.288.5465.503	http://dx.doi.org/10.1126/science.288.5465.503			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775107				2022-12-28	WOS:000086626000042
J	Dyck, PJ; Dyck, PJB				Dyck, PJ; Dyck, PJB			Atypical varieties of chronic inflammatory demyelinating neuropathies	LANCET			English	Editorial Material							MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; FOLLOW-UP; POLYRADICULONEUROPATHY		Mayo Clin & Mayo Fdn, Peripheral Neuropathy Res Ctr, Rochester, MN 55905 USA	Mayo Clinic	Dyck, PJ (corresponding author), Mayo Clin & Mayo Fdn, Peripheral Neuropathy Res Ctr, 200 1st St SW, Rochester, MN 55905 USA.							Dyck P.J., 1990, CHARCOT MARIE TOOTH, P1; DYCK PJ, 1975, MAYO CLIN PROC, V50, P621; DYCK PJ, 1991, NEW ENGL J MED, V325, P1482, DOI 10.1056/NEJM199111213252105; Dyck PJB, 1999, NEUROLOGY, V53, P2113, DOI 10.1212/WNL.53.9.2113; GOSSELIN S, 1991, ANN NEUROL, V30, P54, DOI 10.1002/ana.410300111; Katz JS, 2000, NEUROLOGY, V54, P615, DOI 10.1212/WNL.54.3.615; KYLE RA, 1993, MAYO CLIN PROC, V68, P26, DOI 10.1016/S0025-6196(12)60015-9; KYLE RA, 1993, PERIPHERAL NEUROPATH, P1275; Midroni G, 1996, NEUROLOGY, V46, P1206, DOI 10.1212/WNL.46.5.1206; PARRY GJ, 1988, MUSCLE NERVE, V11, P103, DOI 10.1002/mus.880110203; SIMMONS Z, 1995, BRAIN, V118, P359, DOI 10.1093/brain/118.2.359; Van den Berg-Vos RM, 2000, NEUROLOGY, V54, P26, DOI 10.1212/WNL.54.1.26	12	31	32	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1293	1294		10.1016/S0140-6736(00)02109-7	http://dx.doi.org/10.1016/S0140-6736(00)02109-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776740				2022-12-28	WOS:000086829400007
J	Mackie, E; Hill, J; Kondryn, H; McNally, R				Mackie, E; Hill, J; Kondryn, H; McNally, R			Adult psychosocial outcomes in long-term survivors of acute lymphoblastic leukaemia and Wilms' tumour: a controlled study	LANCET			English	Article							CHILDHOOD-CANCER SURVIVORS; PSYCHOLOGICAL ADJUSTMENT; LEUKEMIA; LIFE; PSYCHOPATHOLOGY; CONSEQUENCES; ADAPTATION; ADOLESCENT; CHILDREN; DISEASE	Background Variability in methods and deficits in design have contributed to conflicting findings about adult psychosocial functioning after childhood cancer. We did a controlled study of psychosocial outcomes in adult survivors of childhood acute lymphoblastic leukaemia (ALL) and Wilms' tumour to address previous methods limitations. Methods We assessed 102 survivors of childhood ALL and Wilms' tumour, who had been free from relapse for 5 years and were aged 19-30 years, and 102 unrelated healthy controls. We used standard measures of adult psychiatric disorder, interpersonal and social-role performance, and intellectual ability to assess past and current functioning. Findings Cancer survivors had no increased rates of psychiatric disorder. Mean scores of cancer survivors were significantly higher (indicating poorer functioning) than those of controls for love/sex relationships (mean difference 0.87 [95% CI 0.53-1.22]), friendships (0.37 [0.07-0.67]), non-specific social contacts (0.40 [0.20-0.60]), and day-to-day coping (0.35 [0.14-0.57]). Cancer survivors were more likely than controls to have a combination of deficits in love/sex relationships and friendships (ALL survivors odds ratio 10.83 [95% CI 3.87-30.82], Wilms' tumour survivors 4.85 [1.43-16.47]), which was associated with more recent treatment (p=0.005). Poor coping was associated with lower intellectual ability scores (p=0.018). Interpretation Childhood ALL and Wilms' tumour have longterm effects on interpersonal functioning and coping, probably mediated by different mechanisms. Prospective studies with each of these tumour groups are needed with similar adolescent and adult outcome measures.	Royal Manchester Childrens Hosp, Paediat Oncol Unit, Manchester M27 1HA, Lancs, England; Alder Hey Childrens Hosp, Dept Psychiat, Liverpool L12 2AP, Merseyside, England; Univ Manchester, Dept Child Hlth, CRC Paediat & Familial Canc Res Grp, Manchester, Lancs, England	Royal Manchester Children's Hospital; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Manchester	Mackie, E (corresponding author), Southampton Gen Hosp, Dept Child Hlth, Southampton SO16 6YD, Hants, England.			McNally, Richard/0000-0001-6685-6467				BIRCH JM, 1988, IARC SCI PUBL, V87, P299; BROWN RT, 1993, J AM ACAD CHILD PSY, V32, P554, DOI 10.1097/00004583-199305000-00010; BYRNE J, 1989, JAMA-J AM MED ASSOC, V262, P2683; CELLA DF, 1986, J CONSULT CLIN PSYCH, V54, P616, DOI 10.1037/0022-006X.54.5.616; CHANG P-N, 1991, Pediatrician, V18, P20; CLARE AW, 1978, PSYCHOL MED, V8, P589, DOI 10.1017/S0033291700018808; EISER C, 1991, ARCH DIS CHILD, V66, P164, DOI 10.1136/adc.66.1.164; Everitt B.S., 1992, ANAL CONTINGENCY TAB; *GOV STAT SER, 1990, STAND OCC CLASS, V1; GRAY RE, 1992, CANCER-AM CANCER SOC, V70, P2713, DOI 10.1002/1097-0142(19921201)70:11<2713::AID-CNCR2820701124>3.0.CO;2-T; GREEN DM, 1991, CANCER, V67, P206, DOI 10.1002/1097-0142(19910101)67:1<206::AID-CNCR2820670134>3.0.CO;2-2; GUDJONSSON GH, 1995, PERSON INDIVIDUAL DI, V3, P441; HARRINGTON R, 1988, PSYCHOL MED, V18, P487, DOI 10.1017/S0033291700008023; HAUPT R, 1994, JAMA-J AM MED ASSOC, V272, P1427, DOI 10.1001/jama.272.18.1427; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; HAYS DM, 1992, J CLIN ONCOL, V10, P1397, DOI 10.1200/JCO.1992.10.9.1397; HILL J, 1989, BRIT J PSYCHIAT, P15524; Hill JM, 1998, CANCER-AM CANCER SOC, V82, P208; JANKOVIC M, 1994, LANCET, V344, P224, DOI 10.1016/S0140-6736(94)92997-1; KELAGHAN J, 1988, MED PEDIATR ONCOL, V16, P320, DOI 10.1002/mpo.2950160506; KOOCHER GP, 1980, J CHILD PSYCHOL PSYC, V21, P163, DOI 10.1111/j.1469-7610.1980.tb00028.x; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; Naughton M, 1996, BRIT J PSYCHIAT, V168, P33, DOI 10.1192/bjp.168.1.33; QUINTON D, 1995, BRIT J PSYCHIAT, V167, P315, DOI 10.1192/bjp.167.3.315; Rauck AM, 1999, MED PEDIATR ONCOL, V33, P60, DOI 10.1002/(SICI)1096-911X(199907)33:1<60::AID-MPO11>3.0.CO;2-H; Raven J, 2003, STANDARD PROGR MATRI; SAHLER OJZ, 1994, J DEV BEHAV PEDIATR, V15, P353; SHALET SM, 1989, ARCH DIS CHILD, V64, P1635, DOI 10.1136/adc.64.11.1635; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; TETA MJ, 1986, J CHRON DIS, V39, P751, DOI 10.1016/0021-9681(86)90158-X; Zeltzer LK, 1997, J CLIN ONCOL, V15, P547, DOI 10.1200/JCO.1997.15.2.547	31	105	106	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1310	1314		10.1016/S0140-6736(00)02112-7	http://dx.doi.org/10.1016/S0140-6736(00)02112-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310LJ	10776743				2022-12-28	WOS:000086829400010
J	Rembacken, BJ; Fujii, T; Cairns, A; Dixon, MF; Yoshida, S; Chalmers, DM; Axon, ATR				Rembacken, BJ; Fujii, T; Cairns, A; Dixon, MF; Yoshida, S; Chalmers, DM; Axon, ATR			Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK	LANCET			English	Article							EARLY COLORECTAL-CARCINOMA; LARGE-BOWEL; LARGE-INTESTINE; ADENOMA; CANCER; POLYPECTOMY; PREVENTION; SEQUENCE; REMOVAL	Background Flat and depressed colorectal tumours were originally thought to be unique to the Japanese population. Recently there have been reports of flat and depressed lesions in western countries but they have been thought to be uncommon. Methods In this prospective study, 1000 consecutive patients attending for routine colonoscopy were examined for flat or depressed lesions. The examinations were done by one European colonoscopist using methods developed in Japan. Finding 321 adenomas were found: 202 (63%) were polypoid, 36% (117) were flat and 2 (0.6%) appeared depressed. Most adenomas contained areas of mild or moderate dysplasia but 10% (31) were severely dysplastic. Six Dukes' A adenocarcinomas were identified together with 25 more advanced adenocarcinomas. The likelihood of Dukes' A cancer or severe dysplasia increased from 4% (3/70) in small flat lesions, to 6% (9/154) in small polyps, 16% (8/50) in larger polyps, 29% (14/49) in large flat lesions, and 75% (3/4) in depressed lesions. 54% (20/37) lesions containing severe dysplasia or Dukes' A carcinoma were flat or depressed. Interpretation The polyp-carcinoma hypothesis prompts colonoscopists to search only for polypoid lesions when screening for cancer, and many early colorectal neoplasms may therefore be missed. Colonoscopists require training in the recognition of flat and depressed lesions to detect colorectal tumours in the early stages.	Gen Infirm, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England; Natl Canc Ctr, Tokyo 104, Japan	Leeds General Infirmary; University of Leeds; National Cancer Center - Japan	Rembacken, BJ (corresponding author), Gen Infirm, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England.	BJR@firstnet.co.uk						ADACHI M, 1988, DIS COLON RECTUM, V31, P236, DOI 10.1007/BF02552553; BEDENNE L, 1992, CANCER, V69, P883, DOI 10.1002/1097-0142(19920215)69:4<883::AID-CNCR2820690408>3.0.CO;2-B; Cairns A, 1999, GUT, V44, pA142; CRAWFORD BE, 1983, CANCER, V51, P1760, DOI 10.1002/1097-0142(19830501)51:9<1760::AID-CNCR2820510933>3.0.CO;2-N; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; Fujii T, 1998, ENDOSCOPY, V30, P437, DOI 10.1055/s-2007-1001304; HACHISU T, 1991, SURG ENDOSC-ULTRAS, V5, P70, DOI 10.1007/BF00316840; Hachisu T, 1988, Surg Endosc, V2, P13, DOI 10.1007/BF00591392; *JAP RES SOC CANC, 1983, GEN RUL CLIN PATH ST; JARAMILLO E, 1994, GASTROINTEST ENDOSC, V40, P369, DOI 10.1016/S0016-5107(94)70077-X; Jass JR, 1989, WHO INT HISTOLOGICAL, V2nd; KASUMI A, 1995, SURG ENDOSC-ULTRAS, V9, P690; KUDO S, 1993, ENDOSCOPY, V25, P455, DOI 10.1055/s-2007-1010367; KUDO S, 1995, EUR J CANCER, V31A, P1118, DOI 10.1016/0959-8049(95)00251-D; KUDO S, 1986, GASTROINTEST ENDOSC, V28, P2811; KUDO S, 1989, GASTROENTEROL ENDOSC, V31, P2845; KURAMOTO S, 1989, CANCER, V64, P950, DOI 10.1002/1097-0142(19890815)64:4<950::AID-CNCR2820640430>3.0.CO;2-O; LANSPA SJ, 1992, DIS COLON RECTUM, V35, P543, DOI 10.1007/BF02050533; LYNCH HT, 1992, DIS COLON RECTUM, V35, P411, DOI 10.1007/BF02049396; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; MORSON BC, 1968, BRIT J SURG, V55, P725, DOI 10.1002/bjs.1800551003; MULLER AD, 1995, ANN INTERN MED, V123, P904, DOI 10.7326/0003-4819-123-12-199512150-00002; MUTO T, 1991, DIS COLON RECTUM, V34, P696, DOI 10.1007/BF02050353; MUTO T, 1985, DIS COLON RECTUM, V28, P847, DOI 10.1007/BF02555490; SAWADA T, 1989, BAILLIERE CLIN GASTR, V3, P627, DOI 10.1016/0950-3528(89)90021-3; SHIMODA T, 1989, CANCER, V64, P1138, DOI 10.1002/1097-0142(19890901)64:5<1138::AID-CNCR2820640529>3.0.CO;2-A; SPRATT JS, 1962, JAMA-J AM MED ASSOC, V179, P337, DOI 10.1001/jama.1962.03050050027005; STOLTE M, 1995, ENDOSCOPY, V27, P286, DOI 10.1055/s-2007-1005694; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WOLBER RA, 1991, HUM PATHOL, V34, P981	30	522	538	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2000	355	9211					1211	1214		10.1016/S0140-6736(00)02086-9	http://dx.doi.org/10.1016/S0140-6736(00)02086-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770302				2022-12-28	WOS:000086448000009
J	Morita, YS; Paul, KS; Englund, PT				Morita, YS; Paul, KS; Englund, PT			Specialized fatty acid synthesis in African trypanosomes: Myristate for GPI anchors	SCIENCE			English	Article							VARIANT SURFACE GLYCOPROTEIN; BIOLOGICAL PROPERTIES; CULTURE FORMS; BRUCEI; BIOSYNTHESIS; BLOOD; THIOLACTOMYCIN; RHODESIENSE; METABOLISM; LEWISI	African trypanosomes, the cause of sleeping sickness, need massive amounts of myristate to remodel glycosyl phosphatidylinositol (GPI) anchors on their surface glycoproteins. However, it has been believed that the parasite is unable to synthesize any fatty acids, and myristate is not abundant in the hosts' bloodstreams. Thus, it has been unclear how trypanosomes meet their myristate requirement. Here we found that they could indeed synthesize fatty acids. The synthetic pathway was unique in that the major product, myristate, was preferentially incorporated into GPIs and not into other lipids. The antibiotic thiolactomycin inhibited myristate synthesis and killed the parasite, making this pathway a potential chemotherapeutic target.	Johns Hopkins Med Sch, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Englund, PT (corresponding author), Johns Hopkins Med Sch, Dept Biol Chem, Baltimore, MD 21205 USA.	penglund@jhmi.edu	Paul, Kimberly/AAO-4275-2020	Morita, Yasu/0000-0002-4514-9242	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21334] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DIXON H, 1970, COMP BIOCHEM PHYSIOL, V33, P111, DOI 10.1016/0010-406X(70)90487-1; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; DOERING TL, 1994, BIOCHEM J, V299, P741, DOI 10.1042/bj2990741; DOERING TL, 1993, J BIOL CHEM, V268, P9215; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; Edelstein C., 1986, BIOCH BIOL PLASMA LI, P495; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FOSBROOKE AS, 1968, CLIN CHIM ACTA, V20, P517, DOI 10.1016/0009-8981(68)90311-2; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Ilgoutz SC, 1999, EMBO J, V18, P3643, DOI 10.1093/emboj/18.13.3643; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KLEIN RA, 1976, BIOCHEM SOC T, V4, P48, DOI 10.1042/bst0040048; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MIYAKAWA S, 1982, J ANTIBIOT, V35, P411, DOI 10.7164/antibiotics.35.411; OISHI H, 1982, J ANTIBIOT, V35, P391, DOI 10.7164/antibiotics.35.391; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Werbovetz KA, 1997, MOL BIOCHEM PARASIT, V85, P1, DOI 10.1016/S0166-6851(96)02820-4	21	100	104	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	2000	288	5463					140	143		10.1126/science.288.5463.140	http://dx.doi.org/10.1126/science.288.5463.140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753118				2022-12-28	WOS:000086387700052
J	Hawker, GA; Wright, JG; Coyte, PC; Williams, JI; Harvey, B; Glazier, R; Badley, EM				Hawker, GA; Wright, JG; Coyte, PC; Williams, JI; Harvey, B; Glazier, R; Badley, EM			Differences between men and women in the rate of use of hip and knee arthroplasty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; GENDER DIFFERENCES; COST-EFFECTIVENESS; OSTEO-ARTHRITIS; HEALTH SURVEY; REPLACEMENT; SURGERY; CARE; DISABILITY; COMMUNITY	Background: Previous studies suggest that, for some conditions, women receive fewer health care interventions than men. We estimated the potential need for arthroplasty and the willingness to undergo the procedure in both men and women and examined whether there were differences between the sexes. Methods: All 48,218 persons 55 years of age or older in two areas of Ontario, Canada, were surveyed by mail and telephone to identify those with hip or knee problems. In these subjects, we assessed the severity of arthritis and the presence of coexisting conditions by questionnaire, documented arthritis by examination and radiography, and conducted interviews to evaluate the subjects' willingness to undergo arthroplasty. The potential need for arthroplasty was defined by the presence of severe symptoms and disability, the absence of any absolute contraindications to surgery, and clinical and radiographic evidence of arthritis. The estimates of need were then adjusted for the subjects' willingness to undergo arthroplasty. Results: The overall response rates were at least 72 percent for the questionnaires and interviews. As compared with men, women had a higher prevalence of arthritis of the hip or knee (age-adjusted odds ratio, 1.76; P<0.001) and had worse symptoms and greater disability, but women were less likely to have undergone arthroplasty (adjusted odds ratio, 0.78; P<0.001). Despite their equal willingness to have the surgery, fewer women than men had discussed the possibility of arthroplasty with a physician (adjusted odds ratio, 0.63). The numbers of people with a potential need for hip or knee arthroplasty were 44.9 per 1000 among women and 20.8 per 1000 among men. After adjustment for willingness to undergo the procedure, the numbers were 5.3 per 1000 for women and 1.6 per 1000 for men. Conclusions: There is underuse of arthroplasty for severe arthritis in both sexes, but the degree of underuse is more than three times as great in women as in men. (N Engl J Med 2000;342:1016-22.) (C) 2000, Massachusetts Medical Society.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M5S 1B2, Canada; Univ Toronto, Fac Med, Dept Med, Div Rheumatol, Toronto, ON, Canada; Hosp Sick Children, Clin Epidemiol & Hlth Care Res Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; St Michaels Hosp, Dept Family & Community Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Hlth Adm, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Wellesley Hosp, Res Inst, Arthrit Community Res & Evaluat Unit, Toronto, ON M4Y 1J3, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Hawker, GA (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Womens Coll Hosp Campus,76 Grenville St, Toronto, ON M5S 1B2, Canada.		Glazier, Richard H/E-5255-2012	Badley, Elizabeth/0000-0002-6045-2549				BADLEY EM, 1994, J RHEUMATOL, V21, P505; BELL MR, 1995, J AM COLL CARDIOL, V25, P1650, DOI 10.1016/0735-1097(95)00044-5; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bergelson BA, 1996, CATHETER CARDIO DIAG, V37, P1, DOI 10.1002/(SICI)1097-0304(199601)37:1<1::AID-CCD1>3.0.CO;2-I; BERGELSON BA, 1995, CHEST, V108, P1510, DOI 10.1378/chest.108.6.1510; Bloembergen WE, 1997, AM J KIDNEY DIS, V30, P733, DOI 10.1016/S0272-6386(97)90076-7; BOMBARDIER C, 1988, CANADIAN CLIN EPIDEM; BUNKER JP, 1994, MILBANK Q, V72, P225, DOI 10.2307/3350295; CALLAHAN CM, 1994, JAMA-J AM MED ASSOC, V271, P1349, DOI 10.1001/jama.271.17.1349; Chang RW, 1996, JAMA-J AM MED ASSOC, V275, P858, DOI 10.1001/jama.275.11.858; COYTE PC, 1994, NEW ENGL J MED, V331, P1068, DOI 10.1056/NEJM199410203311607; DeBoer D, 1998, PATTERNS HLTH CARE O, P121; Giacomini MK, 1996, ARCH INTERN MED, V156, P1217, DOI 10.1001/archinte.156.11.1217; HADLER NM, 1985, CLIN RHEUM DIS, V11, P175; HARVEY B, 1994, P 160 NAT M AM ASS A; Hawker G, 1998, J BONE JOINT SURG AM, V80A, P163, DOI 10.2106/00004623-199802000-00003; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; Karlson EW, 1997, AM J MED, V102, P524; Katz BP, 1996, HEALTH SERV RES, V31, P125; KATZ JN, 1994, ARTHRITIS RHEUM, V37, P687, DOI 10.1002/art.1780370512; KRAMER JS, 1983, ARTHRITIS RHEUM, V26, P901, DOI 10.1002/art.1780260712; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MASSEY JT, 1989, VITAL HLTH STATISTIC, V2, P1; MCALINDON TE, 1992, BRIT J RHEUMATOL, V31, P189; MIKKELSEN WM, 1970, J CHRON DIS, V23, P151, DOI 10.1016/0021-9681(70)90092-5; National Institutes of Health, 1994, NIH TECHN ASS STAT, P1; NAYLOR CD, 1994, ICES PRACTICE ATLAS, V1, P69; PEYRON JG, 1992, OSTEOARTHRITIS DIAGN, P15; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; *STAT CAN, 1997, 1996 CENS NAT SER TA; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; vanWijk CMTG, 1996, SOC SCI MED, V43, P707, DOI 10.1016/0277-9536(96)00115-3; Ware JE, 1993, SF36 HLTH SURVEY MAN; Weitzman S, 1997, AM J CARDIOL, V79, P722, DOI 10.1016/S0002-9149(96)00857-0; WRIGHT JG, 1995, CAN MED ASSOC J, V152, P687; Wright JG, 1997, J BONE JOINT SURG AM, V79A, P974, DOI 10.2106/00004623-199707000-00003	36	444	448	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	2000	342	14					1016	1022		10.1056/NEJM200004063421405	http://dx.doi.org/10.1056/NEJM200004063421405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300JB	10749964				2022-12-28	WOS:000086248900005
J	Jones, GH; Balogh, A; Horbury, TS				Jones, GH; Balogh, A; Horbury, TS			Identification of comet Hyakutake's extremely long ion tail from magnetic field signatures	NATURE			English	Article							SOLAR-WIND	Observations of the varying orientations of comet tails led to the suggestion of the existence of the solar wind-a continuous outflow of ionized material from the Sun(1). It is now well established that gas from comets is ionized by several processes and joins the solar wind(2), forming an ion (plasma) tail that points away from the Sun. The plasma environments of three comets have been measured in situ, but only in the upstream direction or less than 8,000 km downstream of the nucleus. Here we report a fortuitous crossing by a spacecraft of the plasma tail of comet Hyakutake (C/1996 B2), at a distance of more than 3.8 astronomical units (550 million kilometres) from its nucleus. This surpasses the tail length of 2 AU determined for the Great March Comet of 1843 (C/1843 D1)(3). Our measurements reveal that, at this distance, the tail of comet Hyakutake was a structured entity at least 7 million kilometres in diameter.	Imperial Coll, Blackett Lab, Space & Atmospher Phys Grp, London SW7 2BW, England; Univ London Queen Mary & Westfield Coll, Astron Unit, London E1 4NS, England	Imperial College London; University of London; Queen Mary University London	Jones, GH (corresponding author), Imperial Coll, Blackett Lab, Space & Atmospher Phys Grp, London SW7 2BW, England.		Balogh, Andre/GZK-2076-2022; Jones, Geraint H./C-1682-2008; Horbury, Tim/E-9486-2010	Jones, Geraint H./0000-0002-5859-1136; 				ALFVEN H, 1957, TELLUS, V9, P92, DOI 10.1111/j.2153-3490.1957.tb01855.x; BALOGH A, 1992, ASTRON ASTROPHYS SUP, V92, P221; BAME SJ, 1992, ASTRON ASTROPHYS SUP, V92, P237; Bertaux JL, 1998, PLANET SPACE SCI, V46, P555, DOI 10.1016/S0032-0633(97)00179-7; BIERMANN L, 1951, Z ASTROPHYS, V29, P274; Brandt JC, 1999, ICARUS, V137, P69, DOI 10.1006/icar.1998.6030; Coates AJ, 1997, ADV SPACE RES-SERIES, V20, P255, DOI 10.1016/S0273-1177(97)00543-7; Gloeckler G, 2000, NATURE, V404, P576, DOI 10.1038/35007015; GLOECKLER G, 1992, ASTRON ASTROPHYS SUP, V92, P267; GREEN DWE, 1996, 6388 IAU; HUDDLESTON DE, 1992, GEOPHYS RES LETT, V8, P837; IP WH, 1982, COMETS, P588; JOCKERS K, 1991, COMETARY PLASMA PROC, P139; JOHNSTONE AD, 1993, NATURE, V321, P344; JONES GH, 1997, THESIS U LONDON; Jorda L., 1992, ASTEROIDS COMETS MET, P285; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; Lisse CM, 1999, ICARUS, V140, P189, DOI 10.1006/icar.1999.6131; RAEDER J, 1987, ASTRON ASTROPHYS, V187, P61; RAUER H, 1995, ASTRON ASTROPHYS, V295, P529; Riley P, 1998, J GEOPHYS RES-SPACE, V103, P1933, DOI 10.1029/97JA02142; RUSSELL CT, 1983, NATURE, V305, P612, DOI 10.1038/305612a0; SLAVIN JA, 1986, GEOPHYS RES LETT, V13, P283, DOI 10.1029/GL013i003p00283; SONNERUP BU, 1967, J GEOPHYS RES, V72, P171, DOI 10.1029/JZ072i001p00171	24	33	33	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					574	+		10.1038/35007011	http://dx.doi.org/10.1038/35007011			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766233				2022-12-28	WOS:000086400100044
J	Smocovitis, VB				Smocovitis, VB			George Ledyard Stebbins (1906-2000) - Obituary	NATURE			English	Biographical-Item									Univ Florida, Dept Hist, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Smocovitis, VB (corresponding author), Univ Florida, Dept Hist, 4131 Turlington Hall, Gainesville, FL 32611 USA.							STEBBINS GL, PUBLICATION LIST	1	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					562	562		10.1038/35007195	http://dx.doi.org/10.1038/35007195			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766227				2022-12-28	WOS:000086400100038
J	Haig, D; Pierce, NE; Wilson, EO				Haig, D; Pierce, NE; Wilson, EO			William Hamilton (1936-2000)	SCIENCE			English	Biographical-Item									Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA	Harvard University	Haig, D (corresponding author), Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA.							HAMILTON WG, PUBLICATION LIST	1	1	1	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2438	2438		10.1126/science.287.5462.2438	http://dx.doi.org/10.1126/science.287.5462.2438			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10766623				2022-12-28	WOS:000086202200034
J	Ho, PKH; Kim, JS; Burroughes, JH; Becker, H; Li, SFY; Brown, TM; Cacialli, F; Friend, RH				Ho, PKH; Kim, JS; Burroughes, JH; Becker, H; Li, SFY; Brown, TM; Cacialli, F; Friend, RH			Molecular-scale interface engineering for polymer light-emitting diodes	NATURE			English	Article							POLY(P-PHENYLENE VINYLENE); CONJUGATED POLYMER; CHARGE INJECTION; STABILITY; DEVICES	Achieving balanced electron-hole injection and perfect recombination of the charge carriers is central to the design of efficient polymer light-emitting diodes(1,2) (LEDs). A number of approaches have focused on modification of the injection contacts, for example by incorporating an additional conducting-polymer layer at the indium-tin oxide (ITO) anode(3,4). Recently, the layer-by-layer polyelectrolyte deposition route has been developed for the fabrication of ultrathin polymer layers(5,6). Using this route, we previously incorporated ultrathin (<100 Angstrom) charge-injection interfacial layers in polymer LEDs(7). Here we show how molecular-scale engineering of these interlayers to form stepped and graded electronic profiles can lead to remarkably efficient singlelayer polymer LEDs. These devices exhibit nearly balanced injection, near-perfect recombination, and greatly reduced pre-turn-on leakage currents. A green-emitting LED comprising a poly(p-phenylene vinylene) derivative sandwiched between a calcium cathode and the modified ITO anode yields an external forward efficiency of 6.0 per cent (estimated internal efficiency, 15-20 per cent) at a luminance of 1,600 candelas per m(2) at 5 V.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; Cambridge Display Technol, Cambridge CB3 0HJ, England; Cov Org Semicond, D-65926 Frankfurt, Germany; Natl Univ Singapore, Dept Chem, S-119260 Singapore, Singapore; Inst Mat Res & Engn, S-119260 Singapore, Singapore	University of Cambridge; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Materials Research & Engineering (IMRE)	Friend, RH (corresponding author), Univ Cambridge, Cavendish Lab, Madingley Rd, Cambridge CB3 0HE, England.		Brown, Thomas M/R-1829-2016; Li, Sam F Y/J-3113-2013; Cacialli, Franco/B-4222-2010; Kim, Ji-Seon/Y-3301-2018	Brown, Thomas M/0000-0003-2141-3587; Li, Sam F Y/0000-0002-2092-9226; Cacialli, Franco/0000-0001-6821-6578; Kim, Ji-Seon/0000-0003-4715-3656; Friend, Richard Henry/0000-0001-6565-6308				Arkhipov VI, 1998, J APPL PHYS, V84, P848, DOI 10.1063/1.368146; Baldo MA, 1999, PHYS REV B, V60, P14422, DOI 10.1103/PhysRevB.60.14422; Brown TM, 1999, APPL PHYS LETT, V75, P1679, DOI 10.1063/1.124789; Campbell IH, 1996, PHYS REV LETT, V76, P1900, DOI 10.1103/PhysRevLett.76.1900; Cao Y, 1999, NATURE, V397, P414, DOI 10.1038/17087; Carter JC, 1997, APPL PHYS LETT, V71, P34, DOI 10.1063/1.119483; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; DIETRICH M, 1994, J ELECTROANAL CHEM, V369, P87, DOI 10.1016/0022-0728(94)87085-3; Friend RH, 1999, NATURE, V397, P121, DOI 10.1038/16393; Harrison NT, 1996, PHYS REV LETT, V77, P1881, DOI 10.1103/PhysRevLett.77.1881; He Y, 1999, APPL PHYS LETT, V74, P2265, DOI 10.1063/1.123862; Ho PKH, 1998, ADV MATER, V10, P769, DOI 10.1002/(SICI)1521-4095(199807)10:10<769::AID-ADMA769>3.0.CO;2-3; Hung LS, 1997, APPL PHYS LETT, V70, P152, DOI 10.1063/1.118344; Karg S, 1996, SYNTHETIC MET, V80, P111, DOI 10.1016/S0379-6779(96)03690-9; Kim JS, 1999, J APPL PHYS, V86, P2774, DOI 10.1063/1.371124; KIM JS, IN PRESS J APPL PHYS; LOGDLUND M, 1989, PHYS REV LETT, V63, P1841, DOI 10.1103/PhysRevLett.63.1841; Losche M, 1998, MACROMOLECULES, V31, P8893, DOI 10.1021/ma980910p; Onitsuka O, 1996, J APPL PHYS, V80, P4067, DOI 10.1063/1.363369; Spreitzer H, 1998, ADV MATER, V10, P1340, DOI 10.1002/(SICI)1521-4095(199811)10:16<1340::AID-ADMA1340>3.0.CO;2-G; TAI K, 1990, APPL PHYS LETT, V56, P2496, DOI 10.1063/1.102869; VanSlyke SA, 1996, APPL PHYS LETT, V69, P2160, DOI 10.1063/1.117151; Wiberley, 1964, INTRO INFRARED RAMAN; Xing KZ, 1997, SYNTHETIC MET, V89, P161, DOI 10.1016/S0379-6779(97)81212-X; Yoo D, 1998, MACROMOLECULES, V31, P4309, DOI 10.1021/ma9800360	25	744	767	4	210	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					481	484		10.1038/35006610	http://dx.doi.org/10.1038/35006610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761912				2022-12-28	WOS:000086257700043
J	Vukusic, P; Sambles, JR; Lawrence, CR				Vukusic, P; Sambles, JR; Lawrence, CR			Structural colour - Colour mixing in wing scales of a butterfly	NATURE			English	Article									Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England; DERA, Mech Sci Sector, Farnborough GU14 0LX, Hants, England	University of Exeter	Vukusic, P (corresponding author), Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England.	P.Vukusic@ex.ac.uk	Sambles, John Roy/X-8675-2019	SAMBLES, John/0000-0003-2721-0692				BURNHAM RW, 1963, COLOR; Fox DL, 1976, ANIMAL BIOCHROMES ST, V2d; Ghiradella H, 1998, MICROSCOPIC ANATOMY OF INVERTEBRATES, VOL 11 A-C, P257; HUXLEY J, 1975, J ENTOMOL SER A, V50, P9; Kelber A, 1999, NATURE, V402, P251, DOI 10.1038/46204; SCHULTZ TD, 1989, NATURE, V337, P72, DOI 10.1038/337072a0; Vukusic P, 1999, P ROY SOC B-BIOL SCI, V266, P1403, DOI 10.1098/rspb.1999.0794	7	320	342	12	230	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	2000	404	6777					457	457		10.1038/35006561	http://dx.doi.org/10.1038/35006561			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761905				2022-12-28	WOS:000086257700036
J	Feany, MB; Bender, WW				Feany, MB; Bender, WW			A Drosophila model of Parkinson's disease	NATURE			English	Article							CATECHOLAMINE-CONTAINING NEURONS; ALPHA-SYNUCLEIN; LEWY BODIES; CELL-DEATH; MELANOGASTER; MUTANT; DEGENERATION; EXPRESSION; INCLUSIONS; PATHOLOGY	Parkinson's disease is a common neurodegenerative syndrome characterized by loss of dopaminergic neurons in the substantia nigra, formation of filamentous intraneuronal inclusions (Lewy bodies) and an extrapyramidal movement disorder. Mutations in the alpha-synuclein gene are linked to familial Parkinson's disease(1,2) and alpha-synuclein accumulates in Lewy bodies and Lewy neurites(3-5). Here we express normal and mutant forms of alpha-synuclein in Drosophila and produce adult-onset loss of dopaminergic neurons, filamentous intraneuronal inclusions containing alpha-synuclein and locomotor dysfunction. Our Drosophila model thus recapitulates the essential features of the human disorder, and makes possible a powerful genetic approach to Parkinson's disease.	Brigham & Womens Hosp, Dept Pathol, Div Neuropathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Feany, MB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Div Neuropathol, 75 Francis St, Boston, MA 02115 USA.			Feany, Mel/0000-0003-0315-7970				Baba M, 1998, AM J PATHOL, V152, P879; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUCHANAN RL, 1993, NEURON, V10, P839, DOI 10.1016/0896-6273(93)90200-B; BUDNIK V, 1988, J COMP NEUROL, V268, P400, DOI 10.1002/cne.902680309; BUDNIK V, 1986, J NEUROSCI, V6, P3682; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; COOMBE PE, 1986, J NEUROGENET, V3, P135, DOI 10.3109/01677068609106845; DICKSON DW, 1989, ACTA NEUROPATHOL, V78, P572, DOI 10.1007/BF00691284; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Franceschini N., 1972, INFORMATION PROCESSI, P75; GANETZKY B, 1978, EXP GERONTOL, V13, P189, DOI 10.1016/0531-5565(78)90012-8; GIBB WRG, 1991, J NEUROL NEUROSUR PS, V54, P388, DOI 10.1136/jnnp.54.5.388; Hong L, 1998, NEUROREPORT, V9, P1239, DOI 10.1097/00001756-199804200-00051; JELLINGER KA, 1991, MOL CHEM NEUROPATHOL, V14, P153, DOI 10.1007/BF03159935; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; LEBOURG E, 1992, GERONTOLOGY, V38, P59; LI H, IN PRESS CURR BIOL; LUNDELL MJ, 1994, DEV BIOL, V165, P385, DOI 10.1006/dbio.1994.1261; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; VALLES AM, 1988, J COMP NEUROL, V268, P414, DOI 10.1002/cne.902680310; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3	30	1573	1660	7	171	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					394	398		10.1038/35006074	http://dx.doi.org/10.1038/35006074			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746727				2022-12-28	WOS:000086119000052
J	Czech, MP				Czech, MP			PIP2 and PIP3: Complex roles at the cell surface	CELL			English	Review							PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOINOSITIDE; PROTEIN; BINDING		Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.							Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Loyet KM, 1998, J BIOL CHEM, V273, P8337, DOI 10.1074/jbc.273.14.8337; OTAEY PB, 1999, BIOCHEM J, V344, P511; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; SHEETZ MP, 2000, CELL, P221; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Venkateswarlu K, 1999, BIOCHEM J, V340, P359, DOI 10.1042/0264-6021:3400359	21	420	438	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 17	2000	100	6					603	606		10.1016/S0092-8674(00)80696-0	http://dx.doi.org/10.1016/S0092-8674(00)80696-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761925	Bronze			2022-12-28	WOS:000085983800002
J	Aldhous, P				Aldhous, P			Protests force primate farm to close	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					215	215		10.1038/35005241	http://dx.doi.org/10.1038/35005241			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10766598	Bronze			2022-12-28	WOS:000086022200007
J	Werker, JF; Vouloumanos, A				Werker, JF; Vouloumanos, A			Language - Who's got rhythm?	SCIENCE			English	Article							VOICED-VOICELESS DISTINCTION; SPEECH-PERCEPTION		Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Werker, JF (corresponding author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.			Werker, Janet F./0000-0002-1168-9013				DOOLING RJ, 1989, PERCEPT PSYCHOPHYS, V46, P65, DOI 10.3758/BF03208075; Hauser, 1996, EVOL COMMUN; HIRSHPASEK K, 1987, COGNITION, V26, P269, DOI 10.1016/S0010-0277(87)80002-1; KLUENDER KR, 1987, SCIENCE, V237, P1195, DOI 10.1126/science.3629235; KUHL PK, 1975, SCIENCE, V190, P69, DOI 10.1126/science.1166301; Mehler J, 1996, SIGNAL TO SYNTAX: BOOTSTRAPPING FROM SPEECH TO GRAMMAR IN EARLY ACQUISITION, P101; MORGAN JL, 1995, CHILD DEV, V66, P911, DOI 10.2307/1131789; Ramus F, 2000, SCIENCE, V288, P349, DOI 10.1126/science.288.5464.349	8	12	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					280	281		10.1126/science.288.5464.280	http://dx.doi.org/10.1126/science.288.5464.280			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	303YA	10777409				2022-12-28	WOS:000086454300023
J	Beach, R				Beach, R			Minimally invasive approach to management of irritable hip in children	LANCET			English	Editorial Material							HOSPITAL ADMISSION; ULTRASOUND		Norfolk & Norwich Hlth Care NHS Trust, Dept Paediat, Norwich NR1 3SR, Norfolk, England	Norfolk & Norwich University Hospitals NHS Foundation Trust	Beach, R (corresponding author), Norfolk & Norwich Hlth Care NHS Trust, Dept Paediat, Norwich NR1 3SR, Norfolk, England.							BENNETT OM, 1992, CLIN ORTHOP RELAT R, P123; Eich GF, 1999, EUR J PEDIATR, V158, P923, DOI 10.1007/s004310051243; FINK AM, 1995, ARCH DIS CHILD, V72, P110, DOI 10.1136/adc.72.2.110; Fischer SU, 1999, J BONE JOINT SURG BR, V81B, P1029, DOI 10.1302/0301-620X.81B6.9607; GOPAKUMAR TS, 1992, EUR J RADIOL, V15, P113, DOI 10.1016/0720-048X(92)90134-U; Loder RT, 1996, CLIN ORTHOP RELAT R, P8; MAH ET, 1994, PEDIATR RADIOL, V24, P484, DOI 10.1007/BF02015005; Mattick A, 1999, J ACCID EMERG MED, V16, P345; TAYLOR GR, 1994, ARCH DIS CHILD, V71, P59, DOI 10.1136/adc.71.1.59	9	11	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1202	1203		10.1016/S0140-6736(00)02082-1	http://dx.doi.org/10.1016/S0140-6736(00)02082-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770298				2022-12-28	WOS:000086448000005
J	Arico, M; Valsecchi, MG; Camitta, B; Schrappe, M; Chessells, J; Baruchel, A; Gaynon, P; Silverman, L; Janka-Schaub, G; Kamps, W; Pui, CH; Masera, G				Arico, M; Valsecchi, MG; Camitta, B; Schrappe, M; Chessells, J; Baruchel, A; Gaynon, P; Silverman, L; Janka-Schaub, G; Kamps, W; Pui, CH; Masera, G			Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; PEDIATRIC-ONCOLOGY-GROUP; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS; PROSPECTIVE METAANALYSIS; INTENSIVE CHEMOTHERAPY; INTERIM ANALYSIS; CANCER GROUP; CHILDHOOD; THERAPY	Background: Children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) have a poor prognosis, and there is no consensus on the optimal treatment for this variant of ALL. Methods: We reviewed the medical records of patients with Ph-positive ALL who were treated with intensive chemotherapy, with or without bone marrow transplantation, by 10 study groups or large single institutions from 1986 to 1996. Data on 326 children and young adults, who ranged in age from 0.4 to 19.9 years (median, 8.1), were analyzed to determine the rate of complete remission and the probability of event-free, disease-free, and overall survival according to standard prognostic factors and type of treatment. Results: The 267 patients who had a complete remission after induction chemotherapy (82 percent) were stratified into three subgroups according to the age and leukocyte count at the time of diagnosis: those with the best prognosis (a leukocyte count of less than 50,000 per cubic millimeter and an age of less than 10 years; 95 patients); those with an intermediate prognosis (intermediate-risk features; 92 patients); and those with the worst prognosis (a leukocyte count of more than 100,000 per cubic millimeter; 80 patients). The estimates of disease-free survival at five years (+/-SE) were 49+/-5 percent (for patients with the best prognosis), 30+/-5 percent (for those with an intermediate prognosis), and 20+/-5 percent (for those with the worst prognosis) (P<0.001 for the overall comparison). We also found that transplantation of bone marrow from an HLA-matched related donor offered significantly greater benefit than intensive chemotherapy alone in terms of protecting patients from relapse or other adverse events (relative risk, 0.3; 95 percent confidence interval, 0.2 to 0.5; P<0.001). This finding was consistent in all three subgroups. Conclusions: Unlike the usual type of ALL, Ph-positive ALL is associated with a poor prognosis. Nevertheless, in some patients with favorable prognostic features, the disease can be controlled by intensive chemotherapy. Transplantation of bone marrow from an HLA-matched related donor is superior to other types of transplantation and to intensive chemotherapy alone in prolonging initial complete remissions. (N Engl J Med 2000;342:998-1006.) (C) 2000, Massachusetts Medical Society.	Policlin San Matteo, IRCCS, Pediat Clin, Dept Pediat, I-27100 Pavia, Italy; Univ Verona, Dept Publ Hlth, I-37100 Verona, Italy; Med Coll Wisconsin, Midw Childrens Canc Ctr, Dept Pediat, Milwaukee, WI 53226 USA; Med Hsch Hannover, Dept Pediat Hematol Oncol, Hannover, Germany; Inst Child Hlth, Leukemia Res Fund, London, England; Hop St Louis, Serv Pediat Hematol, Paris, France; Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Univ So Calif, Los Angeles, CA USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Hamburg, Dept Pediat Hematol & Oncol, Hamburg, Germany; Beatrix Children Hosp, Dept Pediat Oncol, Groningen, Netherlands; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA; Univ Milan, Dept Pediat, Monza, Italy; Osped San Gerardo, Monza, Italy	IRCCS Fondazione San Matteo; University of Pavia; University of Verona; Medical College of Wisconsin; Hannover Medical School; University of London; University College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Children's Hospital Los Angeles; University of Southern California; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Hamburg; University of Groningen; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Milan; San Gerardo Hospital	Arico, M (corresponding author), Policlin San Matteo, IRCCS, Pediat Clin, Dept Pediat, I-27100 Pavia, Italy.		Schrappe, Martin/A-8109-2010; Pui, Ching-Hon/N-8076-2018; Arico, Maurizio/S-3039-2019; Valsecchi, Maria Grazia/K-8891-2016; SESM, SESM/C-1440-2008; Schrappe, Martin/ABA-6144-2020	Pui, Ching-Hon/0000-0003-0303-5658; Arico, Maurizio/0000-0002-1908-6671; Valsecchi, Maria Grazia/0000-0001-5574-3504; 	NATIONAL CANCER INSTITUTE [R37CA036401, R29CA051001, R01CA036401, R01CA051001, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA 51001, CA 36401] Funding Source: Medline; Telethon [E.0755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon)		BARRETT AJ, 1992, BLOOD, V79, P3067; Bassan R, 1999, ADV EXP MED BIOL, V457, P489; CASPER J, 1992, BLOOD S, V80, pA65; CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; Conter V, 1998, HAEMATOLOGICA, V83, P791; CONTER V, 1995, J CLIN ONCOL, V13, P2497, DOI 10.1200/JCO.1995.13.10.2497; CRIST W, 1990, BLOOD, V76, P489; FLETCHER JA, 1991, BLOOD, V77, P435; GAJJAR A, 1995, BLOOD, V86, P1292, DOI 10.1182/blood.V86.4.1292.bloodjournal8641292; GAYNON PS, 1990, MED PEDIATR ONCOL, V18, P273, DOI 10.1002/mpo.2950180403; Harbott J, 1993, Recent Results Cancer Res, V131, P123; JankaSchaub GE, 1996, EUR J PEDIATR, V155, P640; KANTARJIAN HM, 1991, BLOOD, V78, P2411, DOI 10.1182/blood.V78.9.2411.bloodjournal7892411; Marks DI, 1998, J CLIN ONCOL, V16, P931, DOI 10.1200/JCO.1998.16.3.931; MARUBINI E, 1995, ANAL SURVIVAL DATA C, P171; MASTRANGELO R, 1986, MED PEDIATR ONCOL, V14, P191, DOI 10.1002/mpo.2950140317; MAURER J, 1991, LANCET, V337, P1055, DOI 10.1016/0140-6736(91)91706-Z; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1994, J PEDIATR-US, V124, P491, DOI 10.1016/S0022-3476(05)83125-7; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; RAIMONDI SC, 1999, CHILDHOOD LEUKEMIAS, P168; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; RIBEIRO RC, 1987, BLOOD, V70, P948; Ribeiro RC, 1997, LEUKEMIA, V11, P1493, DOI 10.1038/sj.leu.2400749; RIEHM H, 1987, KLIN PADIATR, V199, P151, DOI 10.1055/s-2008-1026781; ROBERTS WM, 1994, LANCET, V343, P331, DOI 10.1016/S0140-6736(94)91166-5; RUSSO C, 1991, BLOOD, V77, P1050; Schlieben S, 1996, LEUKEMIA, V10, P957; Schrappe M, 1998, BLOOD, V92, P2730; SCHRAPPE M, 1994, KLIN PADIATR, V206, P208, DOI 10.1055/s-2008-1046607; Shuster JJ, 1996, ANN ONCOL, V7, P1009; Silverman LB, 1999, CANCER-AM CANCER SOC, V85, P1395, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1395::AID-CNCR25>3.0.CO;2-2; SIMON R, 1984, STAT MED, V3, P35, DOI 10.1002/sim.4780030106; Smith M, 1996, J CLIN ONCOL, V14, P680, DOI 10.1200/JCO.1996.14.2.680; Steinherz PG, 1996, J CLIN ONCOL, V14, P389, DOI 10.1200/JCO.1996.14.2.389; Stram DO, 1996, BIOMETRICS, V52, P1079, DOI 10.2307/2533069; SURYANARAYAN K, 1991, BLOOD, V77, P324; Thomas X, 1998, HEMATOL CELL THER, V40, P119; Uckun FM, 1998, CANCER-AM CANCER SOC, V83, P2030, DOI 10.1002/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q; Uderzo C, 1997, BRIT J HAEMATOL, V96, P387, DOI 10.1046/j.1365-2141.1997.d01-2033.x; Valsecchi MG, 1996, ANN ONCOL, V7, P1005	42	415	442	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	2000	342	14					998	1006		10.1056/NEJM200004063421402	http://dx.doi.org/10.1056/NEJM200004063421402			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300JB	10749961	Bronze			2022-12-28	WOS:000086248900002
J	DiTullio, GR; Grebmeier, JM; Arrigo, KR; Lizotte, MP; Robinson, DH; Leventer, A; Barry, JB; VanWoert, ML; Dunbar, RB				DiTullio, GR; Grebmeier, JM; Arrigo, KR; Lizotte, MP; Robinson, DH; Leventer, A; Barry, JB; VanWoert, ML; Dunbar, RB			Rapid and early export of Phaeocystis antarctica blooms in the Ross Sea, Antarctica	NATURE			English	Article							PHYTOPLANKTON; CARBON; DIMETHYLSULFIDE; POUCHETII; PRYMNESIOPHYCEAE; POLYNYA; OCEAN; CYCLE	The Southern Ocean is very important for the potential sequestration of carbon dioxide in the oceans(1) and is expected to be vulnerable to changes in carbon export forced by anthropogenic climate warming(2). Annual phytoplankton blooms in seasonal ice zones are highly productive and are thought to contribute significantly to pCO(2) drawdown in the Southern Ocean. Diatoms are assumed to be the most important phytoplankton class with respect to export production in the Southern Ocean; however, the colonial prymnesiophyte Phaeocystis antarctica regularly forms huge blooms in seasonal ice zones and coastal Antarctic waters(3). There is little evidence regarding the fate of carbon produced by P. antarctica in the Southern Ocean, although remineralization in the upper water column has been proposed to be the main pathway in polar waters(4,5). Here we present evidence for early and rapid carbon export from P. antarctica blooms to deep water and sediments in the Ross Sea. Carbon sequestration from P. antarctica blooms may influence the carbon cycle in the Southern Ocean, especially if projected climatic changes lead to an alteration in the structure of the phytoplankton community(6,7).	Univ Charleston, Grice Marine Lab, Charleston, SC 29412 USA; Univ Tennessee, Knoxville, TN 37996 USA; Stanford Univ, Dept Geophys, Stanford, CA 94305 USA; Univ Wisconsin, Dept Biol & Microbiol, Oshkosh, WI 54901 USA; San Francisco State Univ, Romberg Tiburon Ctr, Tiburon, CA 94920 USA; Colgate Univ, Dept Geol, Hamilton, NY 13346 USA; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; NOAA, NESDIS, Off Res & Applicat, Camp Springs, MD 20746 USA; Natl Ice Ctr, Washington, DC 20395 USA; Stanford Univ, Stanford, CA 94305 USA	College of Charleston; University of Tennessee System; University of Tennessee Knoxville; Stanford University; University of Wisconsin System; California State University System; San Francisco State University; Colgate University; Monterey Bay Aquarium Research Institute; National Oceanic Atmospheric Admin (NOAA) - USA; Stanford University	DiTullio, GR (corresponding author), Univ Charleston, Grice Marine Lab, 205 Ft Johnson, Charleston, SC 29412 USA.	ditullioj@cofc.edu	Grebmeier, Jacqueline/L-9805-2013	Grebmeier, Jacqueline/0000-0001-7624-3568; Leventer, Amy/0000-0001-9401-0987; Arrigo, Kevin/0000-0002-7364-876X; Dunbar, Robert/0000-0002-9728-5609				Accornero A, 1999, OCEANOGRAPHY OF THE ROSS SEA, P177; Arrigo KR, 1999, SCIENCE, V283, P365, DOI 10.1126/science.283.5400.365; ARRIGO KR, IN PRESS J GEOPHYS R; Asper VL, 1999, J GEOPHYS RES-OCEANS, V104, P5345, DOI 10.1029/1998JC900067; CANTONI GL, 1956, J BIOL CHEM, V222, P171; Carlson CA, 1998, LIMNOL OCEANOGR, V43, P375, DOI 10.4319/lo.1998.43.3.0375; DACEY JWH, 1986, SCIENCE, V233, P1314, DOI 10.1126/science.233.4770.1314; De La Rocha CL, 1998, NATURE, V395, P680, DOI 10.1038/27174; DITULLIO GR, 1995, DEEP-SEA RES PT I, V42, P873, DOI 10.1016/0967-0637(95)00051-7; Dunbar R., 1985, ANTARCT RES SER, P291, DOI [DOI 10.1029/AR043P0291), 10.1029/AR043p0291, DOI 10.1029/AR043P0291]; ELSAYED SZ, 1983, DEEP-SEA RES, V30, P871, DOI 10.1016/0198-0149(83)90005-5; HANSEN FC, 1991, MAR ECOL PROG SER, V78, P123, DOI 10.3354/meps078123; KUMAR N, 1995, NATURE, V378, P675, DOI 10.1038/378675a0; LEGRAND M, 1991, NATURE, V350, P144, DOI 10.1038/350144a0; MARTIN JH, 1992, ENVIR SCI R, V43, P123; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; MATRAI PA, 1995, MAR BIOL, V124, P157, DOI 10.1007/BF00349157; MOORE JK, IN PRESS GLOB BIOGEO; PASSOW U, 1994, MAR ECOL PROG SER, V104, P153, DOI 10.3354/meps104153; Sarmiento JL, 1996, SCIENCE, V274, P1346, DOI 10.1126/science.274.5291.1346; Sarmiento JL, 1998, NATURE, V393, P245, DOI 10.1038/30455; SEDWICK PN, IN PRESS J GEOPHYS R; Smith WO, 1997, GEOPHYS RES LETT, V24, P233, DOI 10.1029/96GL03926; Stefels J, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P305; Stefels J, 1998, J PHYCOL, V34, P486, DOI 10.1046/j.1529-8817.1998.340486.x; SWEENEY C, IN PRESS DEEP SEA RE; VERITY PG, 1989, MAR BIOL, V100, P161, DOI 10.1007/BF00391955; WASSMANN P, 1990, MAR ECOL PROG SER, V66, P183, DOI 10.3354/meps066183	28	237	245	2	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					595	598		10.1038/35007061	http://dx.doi.org/10.1038/35007061			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766240				2022-12-28	WOS:000086400100051
J	Ma, H; dePamphilis, C				Ma, H; dePamphilis, C			The ABCs of floral evolution	CELL			English	Review							FLOWER DEVELOPMENT; GENE LINEAGES; MADS; DIVERSIFICATION; ARABIDOPSIS; ORIGIN; MAIZE		Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Penn State Univ, Life Sci Consortium, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ma, H (corresponding author), Penn State Univ, Dept Biol, 208 Mueller Lab, University Pk, PA 16802 USA.		dePamphilis, Claude W/P-6652-2016					Ambrose BA, 2000, MOL CELL, V5, P569, DOI 10.1016/S1097-2765(00)80450-5; BOWE LM, 2000, IN PRESS P NATL ACAD, V97; Bowman JL, 1997, J BIOSCIENCE, V22, P515, DOI 10.1007/BF02703197; CHAW SM, 2000, IN PRESS P NATL ACAD, V97; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; DARWON C, 1903, UNPUB MORE LETT C DA, V2; Flanagan CA, 1996, PLANT J, V10, P343, DOI 10.1046/j.1365-313X.1996.10020343.x; Kang HG, 1998, PLANT MOL BIOL, V38, P1021, DOI 10.1023/A:1006051911291; Kramer EM, 1998, GENETICS, V149, P765; Kramer EM, 1999, NATURE, V399, P144, DOI 10.1038/20172; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; Mena M, 1996, SCIENCE, V274, P1537, DOI 10.1126/science.274.5292.1537; Mena M, 1995, PLANT J, V8, P845, DOI 10.1046/j.1365-313X.1995.8060845.x; Purugganan MD, 1997, J MOL EVOL, V45, P392, DOI 10.1007/PL00006244; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; Riechmann JL, 1997, BIOL CHEM, V378, P1079; Rutledge R, 1998, PLANT J, V15, P625, DOI 10.1046/j.1365-313x.1998.00250.x; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; Winter KU, 1999, P NATL ACAD SCI USA, V96, P7342, DOI 10.1073/pnas.96.13.7342	20	151	179	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 31	2000	101	1					5	8		10.1016/S0092-8674(00)80618-2	http://dx.doi.org/10.1016/S0092-8674(00)80618-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778850	Bronze			2022-12-28	WOS:000086249900002
J	Blatt, R				Blatt, R			Push-button entanglement	NATURE			English	Editorial Material									Univ Innsbruck, Inst Expt Phys, A-6020 Innsbruck, Austria	University of Innsbruck	Blatt, R (corresponding author), Univ Innsbruck, Inst Expt Phys, Tech Str 25, A-6020 Innsbruck, Austria.	rainer.blatt@uibk.ac.at	Blatt, Rainer/H-9527-2014					Bouwmeester D, 1999, PHYS REV LETT, V82, P1345, DOI 10.1103/PhysRevLett.82.1345; Hagley E, 1997, PHYS REV LETT, V79, P1, DOI 10.1103/PhysRevLett.79.1; Molmer K, 1999, PHYS REV LETT, V82, P1835, DOI 10.1103/PhysRevLett.82.1835; Monroe C, 1996, SCIENCE, V272, P1131, DOI 10.1126/science.272.5265.1131; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P844, DOI 10.1007/BF01491987; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; Schroedinger E., 1935, NATURWISSENSCHAFTEN, V23, P823, DOI [DOI 10.1007/BF01491914, 10.1007/BF01491914]; Turchette QA, 1998, PHYS REV LETT, V81, P3631, DOI 10.1103/PhysRevLett.81.3631	10	18	18	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					231	232		10.1038/35005185	http://dx.doi.org/10.1038/35005185			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749190				2022-12-28	WOS:000086022200026
J	Mendez, R; Hake, LE; Andresson, T; Littlepage, LE; Ruderman, JV; Richter, JD				Mendez, R; Hake, LE; Andresson, T; Littlepage, LE; Ruderman, JV; Richter, JD			Phosphorylation of CPE binding factor by Eg2 regulates translation of c-mos mRNA	NATURE			English	Article							XENOPUS OOCYTE MATURATION; CYTOPLASMIC POLYADENYLATION; RNA-BINDING; KINASE; PATHWAY; PROTEIN; SPECIFICITY; ACTIVATION; SEPARATION; ELEMENTS	Full-grown Xenopus oocytes arrest at the G2/M border of meiosis. I. Progesterone breaks this arrest, leading to the resumption of the meiotic cell cycles and maturation of the oocyte into a fertilizable egg. In these oocytes, progesterone interacts with an unidentified surface-associated receptor, which induces a non-transcriptional signalling pathway that stimulates the translation of dormant c-mos messenger RNA. Mos, a mitogen-activated protein (MAP) kinase kinase kinase, indirectly activates MAP kinase, which in turn leads to oocyte maturation. The translational recruitment of c-mos and several other mRNAs is regulated by cytoplasmic polyadenylation, a process that requires two 3' untranslated regions, the cytoplasmic polyadenylation element (CPE) and the polyadenylation hexanucleotide AAUAAA(1-4). Although the signalling events that trigger c-mos mRNA polyadenylation and translation are unclear, they probably involve the activation of CPEB, the CPE binding factor(5,6), Here we show that an early site-specific phosphorylation of CPEB is essential for the polyadenylation of c-mos mRNA and its subsequent translation, and for oocyte maturation. In addition, we show that this selective, early phosphorylation of CPEB is catalysed by Eg2, a member of the Aurora family of serine/threonine protein kinases.	Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School	Richter, JD (corresponding author), Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA.	joel.richter@umassmed.edu		Mendez, Raul/0000-0002-1952-6905				Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Ballantyne S, 1997, MOL BIOL CELL, V8, P1633, DOI 10.1091/mbc.8.8.1633; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; Dickson KS, 1999, MOL CELL BIOL, V19, P5707; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hake LE, 1997, BBA-REV CANCER, V1332, pM31, DOI 10.1016/S0304-419X(96)00039-X; Hake LE, 1998, MOL CELL BIOL, V18, P685, DOI 10.1128/MCB.18.2.685; Katsu Y, 1999, DEV BIOL, V209, P186, DOI 10.1006/dbio.1999.9247; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Tatsuka M, 1998, CANCER RES, V58, P4811; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	24	284	290	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					302	307		10.1038/35005126	http://dx.doi.org/10.1038/35005126			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749216				2022-12-28	WOS:000086022200054
J	Halliday, G; Banerjee, S; Philpot, M; Macdonald, A				Halliday, G; Banerjee, S; Philpot, M; Macdonald, A			Community study of people who live in squalor	LANCET			English	Article							DIOGENES-SYNDROME; NEGLECT	Background The reasons why people live in squalor have been the subject of much debate but little systematic research other than reports of case series from secondary health-care services. We did a study in the community using standardised instruments to investigate the relation between squalor and mental and physical disorders. Methods We did a cross-sectional study of the clients of a local-authority special cleaning service. Levels of domestic squalor and self neglect were measured with the living conditions rating scale, and diagnoses of mental disorder were made by use of WHO's schedules for clinical assessment in neuropsychiatry (SCAN). Findings 91 individuals were eligible for inclusion; 81 from 76 households consented and were interviewed (a response rate of 89%). 41 (51%) were younger than 65 years of age. 57 individuals (70%) were diagnosed as having a mental disorder at interview, as defined by the SCAN, and 21 participants (26%) had a physical health problem which contributed significantly to the unclean state of their living environment. Those with a contributory physical disorder had a lower severity of domestic squalor. People older than 65 years were less likely to have a mental disorder than those younger than 65 years, but a contributory physical disorder was not associated with the presence of active mental disorder. Only 30 (53%) of the 57 individuals with active mental disorder had had any contact with mental-health services in the previous year. Interpretation People who live in squalor and who receive special cleaning services have high rates of mental disorder, and squalor affects younger as well as older people. Living in squalid conditions in the group was generally associated with a mental or physical disorder. and there were possible deficits in the health care received. The extent to which these disorders might respond to more assertive treatment from health services requires further study, but questions are raised about the adequacy of their current health care.	Univ London Kings Coll, Inst Psychiat, Sect Epidemiol & Gen Practice, London SE5 8AF, England; Univ London Kings Coll, Inst Psychiat, Old Age Psychiat Sect, London SE5 8AF, England; S London & Maudsley NHS Trust, London, England; Lewisham Hosp, Guys Kings & St Thomass Med Sch, London SE13 6LH, England	University of London; King's College London; University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London	Banerjee, S (corresponding author), Univ London Kings Coll, Inst Psychiat, Sect Epidemiol & Gen Practice, London SE5 8AF, England.		Banerjee, Sube/E-3757-2010	Banerjee, Sube/0000-0002-8083-7649				Beveridge W, 1942, CMND6404 HMSO; BURVILL PW, 1990, INT J GERIATR PSYCH, V5, P161, DOI 10.1002/gps.930050304; CLARK ANG, 1975, LANCET, V1, P366; Drummond LM, 1997, IRISH J PSYCHOL MED, V14, P99, DOI 10.1017/S0790966700003190; MACMILLAN D, 1966, BMJ-BRIT MED J, V2, P1032, DOI 10.1136/bmj.2.5521.1032; MANN AH, 1981, PSYCHOL MED, V11, P839, DOI 10.1017/S0033291700041337; ORRELL MW, 1989, BRIT J PSYCHIAT, V155, P101, DOI 10.1192/bjp.155.1.101; Reifler BV, 1996, J AM GERIATR SOC, V44, P1484, DOI 10.1111/j.1532-5415.1996.tb04079.x; Samios K., 1996, THESIS ROYAL AUSTR N; SNOWDON J, 1987, HOSP COMMUNITY PSYCH, V38, P491; Snowdon J, 1997, J AM GERIATR SOC, V45, P1539; WHITEHEAD T, 1975, LANCET, V1, P627; World Health Organization, 1992, SCHED CLIN ASS NEUR; WRIGLEY M, 1992, IRISH J PSYCHOL MED, V9, P37, DOI 10.1017/S0790966700013896	14	65	70	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					882	886		10.1016/S0140-6736(99)06250-9	http://dx.doi.org/10.1016/S0140-6736(99)06250-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	294DM	10752704				2022-12-28	WOS:000085896000010
J	Cavelaars, AEJM; Kunst, AE; Geurts, JJM; Crialesi, R; Grotvedt, L; Helmert, U; Lahelma, E; Lundberg, O; Matheson, J; Mielck, A; Rasmussen, NK; Regidor, E; do Rosario-Giraldes, M; Spuhler, T; Mackenbach, JP				Cavelaars, AEJM; Kunst, AE; Geurts, JJM; Crialesi, R; Grotvedt, L; Helmert, U; Lahelma, E; Lundberg, O; Matheson, J; Mielck, A; Rasmussen, NK; Regidor, E; do Rosario-Giraldes, M; Spuhler, T; Mackenbach, JP			Educational differences in smoking: international comparison	BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMIC INEQUALITIES; MORTALITY; HEALTH; MISCLASSIFICATION; POPULATION; PREVALENCE; COUNTRIES; DISEASE; EUROPE; ADULT	Objective To investigate international variations in smoking associated with educational level, Design International comparison of national health, or similar, surveys. Subjects Men and women aged 20 to 44 years and 45 to 74 years. Setting 12 European countries, around 1990. Main outcome measures Relative differences (odds ratios) and absolute differences in the prevalence of ever smoking and current smoking for men and women in each age group by educational level. Results In the 45 to 74 year age group, higher rates of current and ever smoking among lower educated subjects were found in some countries only. Among women this was found in Great Britain, Norway, and Sweden, whereas an opposite pattern, with higher educated women smoking more, was found in southern Europe. Among men a similar north-south pattern was found but it was less noticeable than among women. In the 20 to 44 year age group, educational differences in smoking were generally greater than in the older age group, and smoking rates were higher among lower educated people in most countries. Among younger women, a similar north-south pattern was found as among older women. Among younger men, large educational differences in smoking were found for northern European as well as for southern European countries, except for Portugal. Conclusions These international variations in social gradients in smoking, which are likely to be related to differences between countries in their stage of the smoking epidemic, may have contributed to the socioeconomic differences in mortality from ischaemic heart disease being greater in northern European countries. The observed age patterns suggest that socioeconomic differences in diseases related to smoking will increase in the coming decades hi many European countries.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Stat Netherlands, NL-6401 CZ Heerlen, Netherlands; Natl Inst Stat, Serv Studi Metodol, I-00198 Rome, Italy; Stat Norway, Div Hlth, N-0033 Oslo 1, Norway; Univ Bremen, Ctr Social Policy Res, D-28209 Bremen, Germany; Univ Helsinki, Dept Publ Hlth, Helsinki 00014, Finland; Univ Stockholm, Swedish Inst Social Res, S-10691 Stockholm, Sweden; Off Natl Stat, Social Surv Div, Lonson SW1V 2QQ, England; GSF, Inst Med Informat & Hlth Serv Res, D-85758 Neuherberg, Germany; Natl Publ Hlth Inst, DK-2100 Copenhagen, Denmark; Minist Hlth, Dept Epidemiol, Madrid 28071, Spain; Natl Sch Publ Hlth, P-1699 Lisbon, Portugal; Swiss Fed Stat Off, CH-2010 Neuchatel, Switzerland	Erasmus University Rotterdam; Statistics Norway; University of Bremen; University of Helsinki; Stockholm University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mackenbach, JP (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Lahelma, Eero/ABC-8716-2020; Cavelaars, Adrienne/O-4085-2014	Lahelma, Eero/0000-0002-1064-1333; Kunst, Anton/0000-0002-3313-5273; Regidor, Enrique/0000-0002-2374-9861				BERRINO F, 1988, REV EPIDEMIOL SANTE, V36, P166; BOSTROM G, 1993, SCAND J SOC MED, V21, P77, DOI 10.1177/140349489302100204; Cavelaars A E, 1997, J Health Psychol, V2, P353, DOI 10.1177/135910539700200306; FERRARONI M, 1989, TUMORI, V75, P521, DOI 10.1177/030089168907500601; Graham H, 1996, SOC SCI MED, V43, P243, DOI 10.1016/0277-9536(95)00369-X; HELMERT U, 1992, SOC SCI MED, V35, P1283, DOI 10.1016/0277-9536(92)90181-O; Kunst AE, 1998, BMJ-BRIT MED J, V316, P1636, DOI 10.1136/bmj.316.7145.1636; Kunst AE, 1994, MEASURING SOCIOECONO; KUNST AE, 1996, SOCIOECONOMIC INEQUA; LAVECCHIA C, 1987, INT J EPIDEMIOL, V16, P624; Mackenbach JP, 1997, LANCET, V349, P1655, DOI 10.1016/S0140-6736(96)07226-1; Mackenbach JP, 1997, SOC SCI MED, V44, P757, DOI 10.1016/S0277-9536(96)00073-1; *ORG EC COOP DEV, 1990, ED OECD COUNTR 1987; PAMUK ER, 1985, POP STUD-J DEMOG, V39, P17, DOI 10.1080/0032472031000141256; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PETO R, 1994, MORTALITY SMOKING; PIERCE JP, 1989, AM J PUBLIC HEALTH, V79, P152, DOI 10.2105/AJPH.79.2.152; PIERCE JP, 1991, ANNU REV PUBL HEALTH, V12, P383; SASCO AJ, 1994, B CANCER, V81, P355; SUADICANI P, 1994, INT J EPIDEMIOL, V23, P293, DOI 10.1093/ije/23.2.293; TODD GF, 1978, J EPIDEMIOL COMMUN H, V32, P289, DOI 10.1136/jech.32.4.289; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3; vanDoorslaer E, 1997, J HEALTH ECON, V16, P93, DOI 10.1016/S0167-6296(96)00532-2; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WEWERS ME, 1995, AM J RESP CRIT CARE, V152, P1917, DOI 10.1164/ajrccm.152.6.8520755	25	440	447	1	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1102	1107		10.1136/bmj.320.7242.1102	http://dx.doi.org/10.1136/bmj.320.7242.1102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	309RJ	10775217	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086782800015
J	Donnelly, R; Emslie-Smith, AM; Gardner, ID; Morris, AD				Donnelly, R; Emslie-Smith, AM; Gardner, ID; Morris, AD			ABC of arterial and venous disease - Vascular complications of diabetes	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Nottingham NG7 2RD, England; Derbyshire Royal Infirm, Derby DE1 2QY, England; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Tayside Ctr Gen Practice, Dundee, Scotland	University of Nottingham; University of Dundee; University of Dundee	Donnelly, R (corresponding author), Univ Nottingham, Nottingham NG7 2RD, England.		Morris, Andrew D/C-2837-2009						0	163	185	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1062	1066		10.1136/bmj.320.7241.1062	http://dx.doi.org/10.1136/bmj.320.7241.1062			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764371	Green Published			2022-12-28	WOS:000086675700029
J	Caterina, MJ; Leffler, A; Malmberg, AB; Martin, WJ; Trafton, J; Petersen-Zeitz, KR; Koltzenburg, M; Basbaum, AI; Julius, D				Caterina, MJ; Leffler, A; Malmberg, AB; Martin, WJ; Trafton, J; Petersen-Zeitz, KR; Koltzenburg, M; Basbaum, AI; Julius, D			Impaired nociception and pain sensation in mice lacking the capsaicin receptor	SCIENCE			English	Article							RAT SENSORY NEURONS; CATION CHANNEL; ION-CHANNEL; RESPONSES; PROTONS; SENSITIZATION; SENSITIVITY; INVITRO; SKIN	The capsaicin (vanilloid) receptor VR1 is a cation channel expressed by primary sensory neurons of the "pain" pathway. Heterologously expressed VR1 can be activated by vanilloid compounds, protons, or heat (>43 degrees C), but whether this channel contributes to chemical or thermal sensitivity in vivo is not known. Here, we demonstrate that sensory neurons from mice lacking VR1 are severely deficient in their responses to each of these noxious stimuli. VR1(-/-) mice showed normal responses to noxious mechanical stimuli but exhibited no vanilloid-evoked pain behavior, were impaired in the detection of painful heat, and showed little thermal hypersensitivity in the setting of inflammation. Thus, VR1 is essential for selective modalities of pain sensation and for tissue injury-induced thermal hyperalgesia.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Ctr Neurosci, San Francisco, CA 94143 USA; Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wurzburg	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	julius@socrates.ucsf.edu	Leffler, Andreas/C-6552-2009; Martin, William J/L-9033-2017; Leffler, Andreas/K-1191-2012; Koltzenburg, Martin/C-1349-2008	Martin, William J/0000-0002-2749-3365; Leffler, Andreas/0000-0003-1121-6387; Koltzenburg, Martin/0000-0001-9181-5966	NINDS NIH HHS [NS07265] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benson CJ, 1999, CIRC RES, V84, P921; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; de Castro F, 1998, EUR J NEUROSCI, V10, P146, DOI 10.1046/j.1460-9568.1998.00037.x; DOUCETTE R, 1987, J COMP NEUROL, V261, P583, DOI 10.1002/cne.902610409; DUBNER R, 1977, PAIN TRIGEMINAL REGI, P57; FEIGIN AM, 1995, NEUROREPORT, V6, P2134, DOI 10.1097/00001756-199511000-00009; Fields H. L., 1987, PAIN; GARCIAHIRSCHFELD J, 1995, NEUROSCIENCE, V67, P235, DOI 10.1016/0306-4522(95)00055-N; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; HANDWERKER HO, 1991, PAIN RES CL, V4, P59; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Helliwell RJA, 1998, NEUROSCI LETT, V250, P177, DOI 10.1016/S0304-3940(98)00475-3; HOLZER P, 1991, PHARMACOL REV, V43, P143; JANCSOGABOR A, 1970, J PHYSIOL-LONDON, V206, P495, DOI 10.1113/jphysiol.1970.sp009027; JANIG W, 1986, PROG BRAIN RES, V67, P87; Kirschstein T, 1999, J NEUROPHYSIOL, V82, P2853, DOI 10.1152/jn.1999.82.6.2853; Koltzenburg M, 1997, J NEUROPHYSIOL, V78, P1841, DOI 10.1152/jn.1997.78.4.1841; KRESS M, 1992, J NEUROPHYSIOL, V68, P581, DOI 10.1152/jn.1992.68.2.581; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; Levine J.D., 1994, TXB PAIN, P45; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; MARTENSON ME, 1994, BRAIN RES, V651, P143, DOI 10.1016/0006-8993(94)90690-4; MARTIN WJ, UNPUB; McCleskey EW, 1999, ANNU REV PHYSIOL, V61, P835, DOI 10.1146/annurev.physiol.61.1.835; Nagy I, 1999, J NEUROSCI, V19, P10647, DOI 10.1523/JNEUROSCI.19-24-10647.1999; Nagy I, 1999, NEUROSCIENCE, V88, P995, DOI 10.1016/S0306-4522(98)00535-1; Petersen M, 1996, NEUROSCIENCE, V75, P495, DOI 10.1016/0306-4522(96)00259-X; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; RAJA SN, 1999, TXB PAIN, P00011; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; STEEN KH, 1992, J NEUROSCI, V12, P86; SZALLASI A, 1990, BRAIN RES, V524, P106, DOI 10.1016/0006-8993(90)90498-Z; Szallasi A, 1999, PHARMACOL REV, V51, P159; SZOLCSANYI J, 1975, ARZNEIMITTEL-FORSCH, V25, P1877; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Yeomans DC, 1996, PAIN, V68, P133, DOI 10.1016/S0304-3959(96)03176-4; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	44	2647	2801	14	279	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	2000	288	5464					306	313		10.1126/science.288.5464.306	http://dx.doi.org/10.1126/science.288.5464.306			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764638				2022-12-28	WOS:000086454300029
J	Ramus, F; Hauser, MD; Miller, C; Morris, D; Mehler, J				Ramus, F; Hauser, MD; Miller, C; Morris, D; Mehler, J			Language discrimination by human newborns and by cotton-top tamarin monkeys	SCIENCE			English	Article							SPEECH-PERCEPTION; CATEGORICAL PERCEPTION; INFANTS; ACQUISITION; SYLLABLES	Humans, but no other animal, make meaningful use of spoken Language. What is unclear, however, is whether this capacity depends on a unique constellation of perceptual and neurobiological mechanisms or whether a subset of such mechanisms is shared with other organisms, To explore this problem, parallel experiments were conducted on human newborns and cotton-top tamarin monkeys to assess their ability to discriminate unfamiliar Languages. A habituation-dishabituation procedure was used to show that human newborns and tamarins can discriminate sentences from Dutch and Japanese but not if the sentences are played backward. Moreover, the cues for discrimination are not present in backward speech. This suggests that the human newborns' tuning to certain properties of speech relies on general processes of the primate auditory system.	Ecole Hautes Etud Sci Sociales, CNRS, Lab Sci Cognit & Psycholinguist, F-75006 Paris, France; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Centre National de la Recherche Scientifique (CNRS); Harvard University	Ramus, F (corresponding author), Inst Cognit Neurosci, 17 Queen Sq, London WC1N 3AR, England.		Ramus, Franck/A-1755-2009	Ramus, Franck/0000-0002-1122-5913	NCRR NIH HHS [P51RR00168-37] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bertoncini J, 1995, LANG SPEECH, V38, P311, DOI 10.1177/002383099503800401; BERTONCINI J, 1981, INFANT BEHAV DEV, V4, P247, DOI 10.1016/S0163-6383(81)80027-6; BIJELJACBABIC R, 1993, DEV PSYCHOL, V29, P711, DOI 10.1037/0012-1649.29.4.711; Chomsky Noam, 1988, LANGUAGE PROBLEMS KN; CHRISTOPHE A, 1994, J ACOUST SOC AM, V95, P1570, DOI 10.1121/1.408544; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; DUTOIT T, 1996, MBROLA PROJECT SET H; EHRET G, 1981, NATURWISSENSCHAFTEN, V68, P208, DOI 10.1007/BF01047208; EIMAS PD, 1971, SCIENCE, V171, P303, DOI 10.1126/science.171.3968.303; FLOCCIA C, 1996, THESIS ECOLE HAUTES; Ghazanfar AA, 1999, TRENDS COGN SCI, V3, P377, DOI 10.1016/S1364-6613(99)01379-0; Hauser, 1996, EVOL COMMUN; JUSCZYK PW, 1992, COGNITION, V43, P253, DOI 10.1016/0010-0277(92)90014-9; Kuhl P. K., 1987, CATEGORICAL PERCEPTI, P355; KUHL PK, 1975, SCIENCE, V190, P69, DOI 10.1126/science.1166301; MEHLER J, 1988, COGNITION, V29, P143, DOI 10.1016/0010-0277(88)90035-2; Nazzi T, 1998, J EXP PSYCHOL HUMAN, V24, P756, DOI 10.1037/0096-1523.24.3.756; Neville HJ, 1997, MENT RETARD DEV D R, V3, P282; Perani D, 1996, NEUROREPORT, V7, P2439, DOI 10.1097/00001756-199611040-00007; Pinker Steven, 1994, LANGUAGE INSTINCT; Ramus F, 1999, J ACOUST SOC AM, V105, P512, DOI 10.1121/1.424522; Spelke E.S., 1998, HDB CHILD PSYCHOL, P275; Wyttenbach RA, 1996, SCIENCE, V273, P1542, DOI 10.1126/science.273.5281.1542	23	293	299	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					349	351		10.1126/science.288.5464.349	http://dx.doi.org/10.1126/science.288.5464.349			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	303YA	10764650	Green Accepted			2022-12-28	WOS:000086454300041
J	Choi, DMA; Yate, P; Coats, T; Kalinda, P; Paul, EA				Choi, DMA; Yate, P; Coats, T; Kalinda, P; Paul, EA			Ethnicity and prescription of analgesia in an accident and emergency department: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Royal London Hosp, Barts & London NHS Trust, Dept Anaesthet, London E1 1BB, England; Royal London Hosp, Dept Accid & Emergency, London, England; Royal London Hosp, Clin Effectiveness Unit, London, England; St Bartholomews & Royal London Sch Med & Dent, Dept Environm & Prevent Med, London E1 2AD, England	Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Yate, P (corresponding author), Royal London Hosp, Barts & London NHS Trust, Dept Anaesthet, London E1 1BB, England.		Coats, Timothy/AAW-1254-2021	Coats, Timothy/0000-0003-2736-2784				GREENWALD HP, 1991, PAIN, V44, P157, DOI 10.1016/0304-3959(91)90130-P; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; ZATZICK DF, 1990, PSYCHOSOM MED, V52, P544, DOI 10.1097/00006842-199009000-00007	3	26	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					980	981		10.1136/bmj.320.7240.980	http://dx.doi.org/10.1136/bmj.320.7240.980			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753150	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086453100023
J	Kivimaki, M; Vahtera, J; Pentti, J; Ferrie, JE				Kivimaki, M; Vahtera, J; Pentti, J; Ferrie, JE			Factors underlying the effect of organisational downsizing on health of employees: longitudinal cohort study	BRITISH MEDICAL JOURNAL			English	Article							PSYCHOSOCIAL WORK-ENVIRONMENT; SICKNESS ABSENCE; WHITEHALL-II; MORTALITY; DISEASE; ALCOHOL; MEN	Objective To explore the underlying mechanisms between organisational downsizing and deterioration of health of employees. Design Longitudinal cohort study. Data were assembled from before downsizing (time 1); during major downsizing affecting some job categories (time 2); and after downsizing (time 3), Contributions of changes in work, support, and health related behaviours between time 1 and rime 2 to the relation between downsizing and sickness absence at time 3 were assessed by multilevel modelling. Mean length of follow up was 4.9 years. Setting Raisio, a town in Finland. Subjects 764 municipal employees who remained in employment after downsizing. Main outcome measures Records of absences from work from all causes with medical certificate. Results Downsizing was associated with negative changes in work, impaired support from spouse, and increased prevalence of smoking. Sickness absence rate from all causes was 2.17 (95% confidence inter-val 1.54 to 3.07) times higher after major downsizing than after minor downsizing. Adjustment for changes in work (for instance, physical demands,job control, and job insecurity) diminished the relation between downsizing and sickness absence by 49%. Adjustments for impaired social support or increased smoking did not alter. the relation between downsizing and sickness absence. The findings were unaffected by sex and income. Conclusions The exploration of potential mediating factors provides new information about the possible of Applied causal pathways linking organisational do downsizing Psychology, and health. Downsizing results in changes in work, social relationships, and health related behaviours. The observed increase in certificated sickness absence was partially explained by concomitant increases in physical demands and job insecurity and a reduction in job control, A considerable proportion of the increase, however, remained unexplained by the factors measured.	Univ Helsinki, Dept Psychol, Div Appl Psychol, FIN-00014 Helsinki, Finland; Finnish Inst Occupat Hlth, FIN-20500 Turku, Finland; UCL, Sch Med, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of Helsinki; Finnish Institute of Occupational Health; University of London; University College London; UCL Medical School	Kivimaki, M (corresponding author), Univ Helsinki, Dept Psychol, Div Appl Psychol, POB 13, FIN-00014 Helsinki, Finland.	mika.kivimaki@occuphealth.fi	Ferrie, Jane/AAZ-2009-2020; Vahtera, Jussi/J-3271-2013; Kivimaki, Mika/B-3607-2012	Kivimaki, Mika/0000-0002-4699-5627				BEALE N, 1988, BRIT MED J, V296, P1508, DOI 10.1136/bmj.296.6635.1508; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; Cobb S, 1977, TERMINATION CONSEQUE; Cohen J., 2013, APPL MULTIPLE REGRES; Diez-Roux AV, 1998, AM J PUBLIC HEALTH, V88, P216, DOI 10.2105/AJPH.88.2.216; Ferrie JE, 1998, AM J PUBLIC HEALTH, V88, P1030, DOI 10.2105/AJPH.88.7.1030; Hurrell JJ, 1998, AM J PUBLIC HEALTH, V88, P1012, DOI 10.2105/AJPH.88.7.1012; Johnson JV, 1996, AM J PUBLIC HEALTH, V86, P324, DOI 10.2105/AJPH.86.3.324; KAPRIO J, 1987, ALCOHOL CLIN EXP RES, V11, P349, DOI 10.1111/j.1530-0277.1987.tb01324.x; Kivimaki M, 1997, J APPL PSYCHOL, V82, P858, DOI 10.1037/0021-9010.82.6.858; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; LITTELL RC, 1998, SAS SYSTEM MIXED MOD; MARMOT M, 1995, J EPIDEMIOL COMMUN H, V49, P124, DOI 10.1136/jech.49.2.124; MARMOT MG, 1993, ADDICTION, V88, P369, DOI 10.1111/j.1360-0443.1993.tb00824.x; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; North FM, 1996, AM J PUBLIC HEALTH, V86, P332, DOI 10.2105/AJPH.86.3.332; Parker S K, 1997, J Occup Health Psychol, V2, P289, DOI 10.1037/1076-8998.2.4.289; RAEL EGS, 1995, J EPIDEMIOL COMMUN H, V49, P474, DOI 10.1136/jech.49.5.474; *SAS I, 1993, P243 SAS I; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; *STAT FINL, 1998, STAT YB FINL; Vahtera J, 1997, LANCET, V350, P1124, DOI 10.1016/S0140-6736(97)03216-9; Vahtera J, 1996, WORK STRESS, V10, P286, DOI 10.1080/02678379608256809; VAHTERA J, 1999, EMPLOYEES STORM EC D	24	276	280	0	28	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					971	975		10.1136/bmj.320.7240.971	http://dx.doi.org/10.1136/bmj.320.7240.971			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303XP	10753148	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086453100021
J	Loots, GG; Locksley, RM; Blakespoor, CM; Wang, ZE; Miller, W; Rubin, EM; Frazer, KA				Loots, GG; Locksley, RM; Blakespoor, CM; Wang, ZE; Miller, W; Rubin, EM; Frazer, KA			Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons	SCIENCE			English	Article							MOUSE	Long-range regulatory elements are difficult to discover experimentally; how-ever, they tend to be conserved among mammals, suggesting that cross-species sequence comparisons should identify them. To search for regulatory sequences, we examined about 1 megabase of orthologous human and mouse sequences for conserved noncoding elements with greater than or equal to 70% identity over at Least 100 base pairs. Ninety noncoding sequences meeting these criteria were discovered, and the analysis of 15 of these elements found that about 70% were conserved across mammals. Characterization of the Largest element in yeast artificial chromosome transgenic mice revealed it to be a coordinate regulator of three genes, interleukin-4, interleukin-13, and interleukin-5, spread over 120 kilobases.	Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Genome Sci Dept, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Penn State Univ, Dept Comp Sci & Engn, University Pk, PA 16802 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Frazer, KA (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Genome Sci Dept, Berkeley, CA 94720 USA.		Loots, Gabriela G/AGA-4868-2022	Loots, Gabriela G/0000-0001-9546-5561; Frazer, Kelly/0000-0002-6060-8902	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, P01HL056385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057482] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56385] Funding Source: Medline; NIAID NIH HHS [AI30663] Funding Source: Medline; NIGMS NIH HHS [GM-5748202] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; DUFF K, 1993, GENE THER, V1, P1; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; FRAZER KA, UNPUB; GREEN ED, 1999, GENOME ANAL LAB MANU, P303; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; LEWIS BC, 1992, GENET ANAL-BIOMOL E, V9, P86, DOI 10.1016/1050-3862(92)90003-N; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; LOCKSLEY RM, UNPUB; LOOTS GG, UNPUB; OSBORNE CS, 1995, J IMMUNOL, V155, P226; Symula DJ, 1999, NAT GENET, V23, P241, DOI 10.1038/13880; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323	16	624	645	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					136	140		10.1126/science.288.5463.136	http://dx.doi.org/10.1126/science.288.5463.136			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753117				2022-12-28	WOS:000086387700051
J	Nishitani, H; Lygerou, Z; Nishimoto, T; Nurse, P				Nishitani, H; Lygerou, Z; Nishimoto, T; Nurse, P			The Cdt1 protein is required to license DNA for replication in fission yeast	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; S-PHASE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; MCM PROTEINS; SACCHAROMYCES-CEREVISIAE; INITIATION; COMPONENT; XENOPUS; MITOSIS	To maintain genome stability in eukaryotic cells, DNA is licensed for replication only after the cell has completed mitosis, ensuring that DNA synthesis (S phase) occurs once every cell cycle(1). This licensing control is thought to require the protein Cdc6 (Cdc18 in fission yeast) as a mediator for association of minichromosome maintenance (MCM) proteins with chromatin(2-10). The control is overridden in fission yeast by overexpressing Cdc18 (ref. 11) which leads to continued DNA synthesis in the absence of mitosis(12). Other factors acting in this control have been postulated(13) and we have used a re-replication assay to identify Cdt1 (ref. 14) as one such factor. Cdt1 cooperates with Cdc18 to promote DNA replication, interacts with Cdc18, is located in the nucleus, and its concentration peaks as cells finish mitosis and proceed to S phase. Both Cdc18 and Cdt1 are required to load the MCM protein Cdc21 onto chromatin at the end of mitosis and this is necessary to initiate DNA replication. Genes related to Cdt1 have been found in Metazoa and plants (A. Whitaker, I. Roysman and T. Orr-Weaver, personal communication), suggesting that the cooperation of Cdc6/Cdc18 with Cdt1 to load MCM proteins onto chromatin may be a generally conserved feature of DNA licensing in eukaryotes.	Imperial Canc Res Fund, London WC2A 3PX, England; Kyushu Univ, Grad Sch Med Sci, Fukuoka 8128582, Japan	Cancer Research UK; Kyushu University	Lygerou, Z (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.	z_lygerou@yahoo.com		Nishitani, Hideo/0000-0001-5907-9380				Alfa C, 1993, EXPT FISSION YEAST L; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; Greenwood E, 1998, J CELL SCI, V111, P3101; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lygerou Z, 1999, J CELL SCI, V112, P3703; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; Tada S, 1999, CURR BIOL, V9, P211, DOI 10.1016/S0960-9822(99)80092-X; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7	25	365	369	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					625	+		10.1038/35007110	http://dx.doi.org/10.1038/35007110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766248				2022-12-28	WOS:000086400100059
J	Phair, RD; Misteli, T				Phair, RD; Misteli, T			High mobility of proteins in the mammalian cell nucleus	NATURE			English	Article							RNA SPLICING FACTORS; LIVING CELLS; LOCALIZATION; DIFFUSION	The mammalian cell nucleus contains numerous sub-compartments, which have been implicated in essential processes such as transcription and splicing(1,2). The mechanisms by which nuclear compartments are formed and maintained are unclear. More fundamentally, it is not known how proteins move within the cell nucleus. We have measured the kinetic properties of proteins in the nucleus of living cells using photobleaching techniques. Here we show that proteins involved in diverse nuclear processes move rapidly throughout the entire nucleus. Protein movement is independent of energy, which indicates that proteins may use a passive mechanism of movement. Proteins rapidly associate and dissociate with nuclear compartments. Using kinetic modelling, we determined residence times and steady-state fluxes of molecules in two main nuclear compartments. These data show that many nuclear proteins roam the cell nucleus in vivo and that nuclear compartments are the reflection of the steady-state association/dissociation of its 'residents' with the nucleoplasmic space. Our observations have conceptual implications for understanding nuclear architecture and how nuclear processes are organized in vivo.	NCI, NIH, Bethesda, MD 20892 USA; BioInformat Serv, Rockville, MD 20854 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Misteli, T (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.	mistelit@mail.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010309] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Bell BM, 1996, COMPUT STAT DATA AN, V22, P119, DOI 10.1016/0167-9473(95)00043-7; Boudonck K, 1999, MOL BIOL CELL, V10, P2297, DOI 10.1091/mbc.10.7.2297; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Daneholt B, 1999, CURR BIOL, V9, pR412, DOI 10.1016/S0960-9822(99)80256-5; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; FOSTER DM, 1994, P SIM HLTH SCI C SOC, P87; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Hanamura A, 1998, RNA, V4, P430; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; OLSON MOJ, IN PRESS TRENDS CELL; Politz JC, 1998, P NATL ACAD SCI USA, V95, P6043, DOI 10.1073/pnas.95.11.6043; Politz JC, 1999, CURR BIOL, V9, P285, DOI 10.1016/S0960-9822(99)80136-5; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Singh OP, 1999, EXP CELL RES, V251, P135, DOI 10.1006/excr.1999.4490; Sleeman J, 1998, EXP CELL RES, V243, P290, DOI 10.1006/excr.1998.4135; White J, 1999, TRENDS CELL BIOL, V9, P61, DOI 10.1016/S0962-8924(98)01433-0; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	30	937	961	2	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					604	+		10.1038/35007077	http://dx.doi.org/10.1038/35007077			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766243				2022-12-28	WOS:000086400100054
J	Dennis, MS; Eigenbrot, C; Skelton, NJ; Ultsch, MH; Santell, L; Dwyer, MA; O'Connell, MP; Lazarus, RA				Dennis, MS; Eigenbrot, C; Skelton, NJ; Ultsch, MH; Santell, L; Dwyer, MA; O'Connell, MP; Lazarus, RA			Peptide exosite inhibitors of factor VIIa as anticoagulants	NATURE			English	Article							TISSUE FACTOR PATHWAY; COAGULATION-FACTOR VIIA; SERINE PROTEASES; ALPHA-THROMBIN; PROTEINASES; LIBRARIES; DISCOVERY; COMPLEX; DISPLAY; DOMAIN	Potent anticoagulants have been derived by targeting the tissue factor-factor VIIa complex with naive peptide libraries displayed on M13 phage, The peptides specifically block the activation of factor X with a median inhibitory concentration of 1 nM and selectively inhibit tissue-factor-dependent clotting, The peptides do not bind to the active site of factor VIIa; rather, they work by binding to an exosite on the factor VIIa protease domain, and non-competitively inhibit activation of factor X and amidolytic activity. One such peptide (E-76) has a well defined structure in solution determined by NMR spectroscopy that is similar to the X-ray crystal structure when complexed with factor VIIa, These structural and functional studies indicate an allosteric 'switch' mechanism of inhibition involving an activation loop of factor VIIa and represent a new framework for developing inhibitors of serine proteases.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Lazarus, RA (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.							Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1986, MOL CELLULAR BASIS D, P213; BROZE GJ, 1993, BLOOD, V82, P1679; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Higashi S, 1998, INT J HEMATOL, V67, P229; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; Hirsh J, 1999, LANCET, V353, P1431, DOI 10.1016/S0140-6736(98)09233-2; HIRSH J, 1994, HEMOSTASIS THROMBOSI, P1567; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Johnson K, 1998, CORONARY ARTERY DIS, V9, P83, DOI 10.1097/00019501-199809020-00004; Kelley RF, 1997, BLOOD, V89, P3219, DOI 10.1182/blood.V89.9.3219; Kemball-Cook G, 1999, J STRUCT BIOL, V127, P213, DOI 10.1006/jsbi.1999.4158; Kirchhofer D, 1997, TRENDS CARDIOVAS MED, V7, P316, DOI 10.1016/S1050-1738(97)00094-7; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Lowman HB, 1997, ANNU REV BIOPH BIOM, V26, P401, DOI 10.1146/annurev.biophys.26.1.401; MANN KG, 1993, BLOOD, V82, P1680; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; POLGAR L, 1989, MECHANISMS PROTEASE, P87; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; Sanderson PEJ, 1999, MED RES REV, V19, P179, DOI 10.1002/(SICI)1098-1128(199903)19:2<179::AID-MED4>3.0.CO;2-5; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; Shobe J, 1999, BIOCHEMISTRY-US, V38, P2745, DOI 10.1021/bi981951g; SKELTON NJ, 1994, BIOCHEMISTRY-US, V33, P13581, DOI 10.1021/bi00250a010; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; STUBBS MT, 1994, CURR OPIN STRUC BIOL, V4, P823, DOI 10.1016/0959-440X(94)90263-1; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; Vlasuk GP, 1998, ARCH PATHOL LAB MED, V122, P812; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	45	192	217	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					465	470		10.1038/35006574	http://dx.doi.org/10.1038/35006574			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761907				2022-12-28	WOS:000086257700038
J	Higgins, AM; Jones, RAL				Higgins, AM; Jones, RAL			Anisotropic spinodal dewetting as a route to self-assembly of patterned surfaces	NATURE			English	Article							THIN POLYMER-FILMS; INTERFACE	The ability to pattern surfaces on a microscopic length scale is of importance for technological applications such as the fabrication of microelectronic circuits and digital storage media. Devices fabricated entirely from polymers are now available, opening up the possibility of adapting polymer processing technologies to fabricate cheap, large-area devices using non-lithographic techniques(1,2)-for example, by exploiting dewetting(3) and phase separation(4-6) in thin films. But the final pattern adopted by the polymer film using such approaches requires a template printed onto the substrate by optical lithography, microcontact printing(4,5) or vapour deposition(3). Here we describe a simple process for patterning surfaces that does not require a template. Our method involves the spinodal dewetting of a polymer surface by a thin polymer film, in which a liquid film breaks up owing to the amplification of thermal fluctuations in film thickness induced by dispersion forces(7-14). A preferred orientation is imposed on the dewetting process simply by rubbing the substrate, and this gives rise to patterns of remarkably well-aligned polymer lines. The width of these lines is well-defined, and is controlled by the magnitude of the dispersion forces at the interface, which in turn can be varied by varying the thickness of the polymer substrate. We expect that further work will make it possible to optimize the degree of order in the final morphology.	Univ Sheffield, Dept Phys & Astron, Sheffield S3 7RH, S Yorkshire, England	University of Sheffield	Jones, RAL (corresponding author), Univ Sheffield, Dept Phys & Astron, Hicks Bldg, Sheffield S3 7RH, S Yorkshire, England.	R.A.L.Jones@Sheffield.ac.uk		Jones, Richard/0000-0001-5400-6369				[Anonymous], 1992, INTERMOLECULAR SURFA; Boltau M, 1998, NATURE, V391, P877, DOI 10.1038/36075; FRIEND RH, 1999, ELECTROLUMINESCENCE, V397, P121; Gau H, 1999, SCIENCE, V283, P46, DOI 10.1126/science.283.5398.46; Heier J, 1997, MACROMOLECULES, V30, P6610, DOI 10.1021/ma961686b; Herminghaus S, 1998, SCIENCE, V282, P916, DOI 10.1126/science.282.5390.916; JONES RAL, 1991, PHYS REV LETT, V66, P1326, DOI 10.1103/PhysRevLett.66.1326; Krausch G, 1997, J PHYS-CONDENS MAT, V9, P7741, DOI 10.1088/0953-8984/9/37/007; Lambooy P, 1996, PHYS REV LETT, V76, P1110, DOI 10.1103/PhysRevLett.76.1110; Nisato G, 1999, MACROMOLECULES, V32, P2356, DOI 10.1021/ma981546x; REITER G, 1992, PHYS REV LETT, V68, P75, DOI 10.1103/PhysRevLett.68.75; Service RF, 1997, SCIENCE, V278, P383, DOI 10.1126/science.278.5337.383; Sferrazza M, 1998, PHYS REV LETT, V81, P5173, DOI 10.1103/PhysRevLett.81.5173; Stange TG, 1997, LANGMUIR, V13, P4459, DOI 10.1021/la962090k; WYART FB, 1990, CAN J PHYS, V68, P1084, DOI 10.1139/p90-151; Xie R, 1998, PHYS REV LETT, V81, P1251, DOI 10.1103/PhysRevLett.81.1251	16	346	360	5	171	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	2000	404	6777					476	478		10.1038/35006597	http://dx.doi.org/10.1038/35006597			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761910				2022-12-28	WOS:000086257700041
J	Bock, H; Gharagozloo-Hubmann, K; Sievert, M; Prisner, T; Havlas, Z				Bock, H; Gharagozloo-Hubmann, K; Sievert, M; Prisner, T; Havlas, Z			Single crystals of an ionic anthracene aggregate with a triplet ground state	NATURE			English	Article							ANIONS; CRYSTALLIZATION; TETRAANION; CHARGE; SPIN	Crystalline supramolecular aggregates consisting of charged organic molecules, held together through metal-duster-mediated Coulomb interactions, have attracted interest owing to their unusual structural, chemical and electronic properties(1-3). Aggregates containing metal cation dusters 'wrapped' by lipophilic molecular anions have, for example, been shown(4,5) to be kinetically stable and soluble in nonpolar liquids such as saturated hydrocarbons. The formation of supramolecular aggregates can even be exploited to generate aromatic hydrocarbons that carry four negative charges and crystallize in the form of organic poly(metal cation) clusters(6,7) or helical polymers(8). Here we report the anaerobic crystallization of an ionic organic aggregate-a contact ion septuple consisting of a fourfold negatively charged 'tripledecker' of three anthracene molecules bridged by four solvated potassium cations, Its electronic ground state is shown experimentally, using temperature-dependent electron paramagnetic resonance spectroscopy, to be a triplet, Although the spins in this biradical ionic solid are separated by a considerable distance, density functional theory calculations(9) indicate that the triplet ground state is 84 kJ mol(-1) more stable than the first excited singlet state. We expect that the successful crystallization of the ionic solid we report here, and that of a covalent organic compound with a triplet ground state(10) at room temperature, will stimulate further attempts to develop new triplet-ground-state materials for practical use.	Univ Frankfurt, Dept Chem, D-60439 Frankfurt, Germany; Acad Sci Czech Republ, Inst Organ Chem & Biochem, CZ-16610 Prague, Czech Republic	Goethe University Frankfurt; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences	Bock, H (corresponding author), Univ Frankfurt, Dept Chem, Marie Curie Str 11, D-60439 Frankfurt, Germany.		Havlas, Zdenek/B-2164-2012	Havlas, Zdenek/0000-0002-8369-7303				BECKER J, 1995, MG CLIN PED, V8, P117; BOCK H, 1992, J AM CHEM SOC, V114, P6907, DOI 10.1021/ja00043a041; BOCK H, 1993, ANGEW CHEM INT EDIT, V32, P416, DOI 10.1002/anie.199304161; BOCK H, 1995, ANGEW CHEM INT EDIT, V34, P1353, DOI 10.1002/anie.199513531; Bock H, 1999, ANGEW CHEM INT EDIT, V38, P952, DOI 10.1002/(SICI)1521-3773(19990401)38:7<952::AID-ANIE952>3.0.CO;2-#; BOCK H, 1995, J CHEM SOC CHEM COMM, P2393, DOI 10.1039/C39950002393; Bock H, 1996, ANGEW CHEM INT EDIT, V35, P631, DOI 10.1002/anie.199606311; BOCK H, 1992, ANGEW CHEM INT EDIT, V31, P550, DOI 10.1002/anie.199205501; BOCK H, 1994, ANGEW CHEM INT EDIT, V33, P875, DOI 10.1002/anie.199408751; BOCK H, UNPUB ANGEW CHEM INT; Havlas Z, 1998, COLLECT CZECH CHEM C, V63, P1245, DOI 10.1135/cccc19981245; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Muller A, 1999, NATURE, V397, P48, DOI 10.1038/16215; MULLER A, 1995, ANGEW CHEM INT EDIT, V34, P2326; RHINE WE, 1975, J AM CHEM SOC, V97, P2079, DOI 10.1021/ja00841a014; Sekiguchi A, 1997, ANGEW CHEM INT EDIT, V36, P2462, DOI 10.1002/anie.199724621; Stoll S, 1998, J MAGN RESON, V130, P86, DOI 10.1006/jmre.1997.1285	17	54	54	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					267	269		10.1038/35005048	http://dx.doi.org/10.1038/35005048			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749205				2022-12-28	WOS:000086022200043
J	Dear, P; Newell, S				Dear, P; Newell, S			Establishing probable cause in cerebral palsy - How much certainty is enough?	BRITISH MEDICAL JOURNAL			English	Letter									St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Dear, P (corresponding author), St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England.							Little WJ., 1861, T OBSTET SOC LOND, P293; MacLennan A, 1999, BMJ-BRIT MED J, V319, P1054, DOI 10.1136/bmj.319.7216.1054	2	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1075	1076						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764378				2022-12-28	WOS:000086675700044
J	Porte, RJ; Molenaar, IQ; Begliomini, B; Groenland, THN; Januszkiewicz, A; Lindgren, L; Palareti, G; Hermans, J; Terpstra, OT				Porte, RJ; Molenaar, IQ; Begliomini, B; Groenland, THN; Januszkiewicz, A; Lindgren, L; Palareti, G; Hermans, J; Terpstra, OT		EMSALT Study Grp	Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study	LANCET			English	Article							HIGH-DOSE APROTININ; BLOOD-LOSS; FIBRINOLYSIS; PRESERVATION; COAGULATION; HEMOSTASIS; BYPASS; INHIBITORS; REDUCTION; INJURY	Background Intraoperative hyperfibrinolysis contributes to bleeding during adult orthotopic liver transplantation. We aimed to find out whether aprotinin, a potent antifibrinolytic agent, reduces blood loss and transfusion requirements. Methods We did a randomised, double-blind placebo-controlled trial in which six liver-transplant centres participated. Patients undergoing primary liver transplantation were randomly assigned intraoperative high-dose aprotinin, regular-dose aprotinin, or placebo. Primary endpoints were intraoperative blood loss and transfusion requirements. Secondary endpoints were perioperative fluid requirements, postoperative blood transfusions, complications, and mortality. Findings 137 patients received high-dose aprotinin (n=46), regular-dose aprotinin (n=43), or placebo (n=48), Intraoperative blood loss was significantly lower in the aprotinin-treated patients, with a reduction of 60% in the high-dose group and 44% in the regular-dose group, compared with the placebo group (p=0.03). Total amount of red blood cell (homologous and autologous) transfusion requirements was 37% lower in the high-dose group and 20% lower in the regular-dose group, than in the placebo group (p=0.02). Thromboembolic events occurred in two patients in the high-dose group, none in the regular-dose group, and in two patients in the placebo group (p=0.39). Mortality at 30 days did not differ between the three groups (6.5%, 4.7%, and 8.3%; p=0.79). Interpretation Intraoperative use of aprotinin in adult patients undergoing orthotopic liver transplantation significantly reduces blood-transfusion requirements and should be routinely used in patients without contraindications.	Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands; Univ Hosp S Orsola, Dept Anesthesiol, Bologna, Italy; Univ Hosp S Orsola, Dept Angiol & Blood Coagulat, Bologna, Italy; Univ Hosp Dijkzigt, Dept Anesthesiol, NL-3015 GD Rotterdam, Netherlands; Univ Hosp, Dept Anesthesiol, Huddinge, Sweden; Univ Hosp, Dept Anesthesiol, Helsinki, Finland	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Erasmus University Rotterdam; Erasmus MC; University of Helsinki; Helsinki University Central Hospital	Porte, RJ (corresponding author), Univ Groningen Hosp, Dept Surg, POB 30-001, NL-9700 RB Groningen, Netherlands.							BAUBILLIER E, 1994, TRANSPLANTATION, V57, P1664; Bechstein W O, 1997, Liver Transpl Surg, V3, P653; BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364; Bilbao I, 1998, CLIN TRANSPLANT, V12, P123; CALMUS Y, 1995, GASTROENTEROLOGY, V108, P1510, DOI 10.1016/0016-5085(95)90701-7; DEAKIN M, 1993, ANN ROY COLL SURG, V75, P339; Dietrich W, 1992, J Cardiothorac Vasc Anesth, V6, P324, DOI 10.1016/1053-0770(92)90150-6; GOLDSMITH MF, 1983, JAMA-J AM MED ASSOC, V250, P2904, DOI 10.1001/jama.250.21.2904; GROH J, 1992, LANCET, V340, P173, DOI 10.1016/0140-6736(92)93246-J; GROSSE H, 1993, SEMIN THROMB HEMOST, V19, P302, DOI 10.1055/s-2007-994047; HUETE LG, 1997, HEPATOLOGY, V26, P1143; Kang Y, 1997, Liver Transpl Surg, V3, P655, DOI 10.1002/lt.500030621; KANG YG, 1985, ANESTH ANALG, V64, P888; KINDSCHER J, 1993, TRANSPLANT P, V25, P1823; KOZEKLANGENECKER SA, 1995, INFUSIONSTHERAPIE, V22, P296; LEGNANI C, 1993, TRANSPLANTATION, V56, P568, DOI 10.1097/00007890-199309000-00014; LEMMER JH, 1995, ANN THORAC SURG, V59, P132, DOI 10.1016/0003-4975(94)00813-M; LEWIS JH, 1987, TRANSFUSION, V27, P222, DOI 10.1046/j.1537-2995.1987.27387235624.x; MALLETT SV, 1990, LANCET, V336, P886, DOI 10.1016/0140-6736(90)92404-6; Miki C, 1997, ARCH SURG-CHICAGO, V132, P136; MOR E, 1993, SURG GYNECOL OBSTET, V176, P219; NEUHAUS P, 1989, LANCET, V2, P924; OLDHAFER KJ, 1991, TRANSPLANT P, V23, P2380; Porte RJ, 1998, HEPATOLOGY, V27, P1169; PORTE RJ, 1989, TRANSPLANTATION, V47, P978, DOI 10.1097/00007890-198906000-00012; PORTE RJ, 1993, SEMIN THROMB HEMOST, V19, P191, DOI 10.1055/s-2007-994025; PORTE RJ, 1989, GASTROENTEROLOGY, V97, P488, DOI 10.1016/0016-5085(89)90090-5; Rich JB, 1998, ANN THORAC SURG, V66, pS6, DOI 10.1016/S0003-4975(98)00964-3; RIESS H, 1991, TRANSPLANTATION, V52, P482, DOI 10.1097/00007890-199109000-00018; Roberts RF, 1998, ANN THORAC SURG, V66, P225, DOI 10.1016/S0003-4975(98)00323-3; SHAW BW, 1985, SEMIN LIVER DIS, V5, P344, DOI 10.1055/s-2008-1040631; TAKEI Y, 1990, TRANSPLANTATION, V50, P14, DOI 10.1097/00007890-199007000-00003; VERSTRAETE M, 1985, DRUGS, V29, P236, DOI 10.2165/00003495-198529030-00003; WESTABY S, 1993, ANN THORAC SURG, V55, P1033, DOI 10.1016/0003-4975(93)90149-C	34	205	220	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1303	1309		10.1016/S0140-6736(00)02111-5	http://dx.doi.org/10.1016/S0140-6736(00)02111-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776742				2022-12-28	WOS:000086829400009
J	Price, BH; Richardson, EP				Price, BH; Richardson, EP			The neurologic illness of Eugene O'Neill - A clinicopathological report.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TREMOR; ATAXIA		McLean Hosp, Dept Neurol, Belmont, MA 02478 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; McLean Hospital; Harvard University; Massachusetts General Hospital	Price, BH (corresponding author), McLean Hosp, Dept Neurol, 115 Mill St, Belmont, MA 02478 USA.							Adams RD, 1997, PRINCIPLES NEUROLOGY; BAIN PG, 1994, BRAIN, V117, P805, DOI 10.1093/brain/117.4.805; CANBY V, 1997, NY TIMES        1019, P37; CHARNESS ME, 1993, ALCOHOL CLIN EXP RES, V17, P2, DOI 10.1111/j.1530-0277.1993.tb00718.x; DRUKMAN S, 1997, NY TIMES        1005, P18; Geschwind DH, 1999, ARCH NEUROL-CHICAGO, V56, P20, DOI 10.1001/archneur.56.1.20; HARDING A, 1984, HEREDITARY ATAXIAS R; HARDING AE, 1981, J NEUROL SCI, V51, P259, DOI 10.1016/0022-510X(81)90104-0; HARDING AE, 1993, ADV NEUROL, V61, P1; HENSON RA, 1982, CANCER NERVOUS SYSTE, P346; Holmes G, 1907, BRAIN, V30, P466; Holmes G, 1907, BRAIN, V30, P545; KOLLER W, 1985, NEUROLOGY, V35, P1660, DOI 10.1212/WNL.35.11.1660; Marie P., 1893, SEM MED PARIS, V13, P444; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; *MASS GEN HOSP, 1953, NECR REP; Matsuura T, 1999, ANN NEUROL, V45, P407, DOI 10.1002/1531-8249(199903)45:3<407::AID-ANA21>3.0.CO;2-D; Moseley ML, 1998, NEUROLOGY, V51, P1666, DOI 10.1212/WNL.51.6.1666; ONEILL E, 1981, WORK DIARY 1924 1943, V2; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; SCOVELL J, 1998, ONA LIVING SHADOWS B; Sheaffer L., 1973, ONEILL SON ARTIST; STEVENSON S, 1994, AM REPERTORY THEATRE, V15, P4; Storey E, 1999, ARCH NEUROL-CHICAGO, V56, P43, DOI 10.1001/archneur.56.1.43; VICTOR M, 1959, ARCH NEUROL-CHICAGO, V1, P579, DOI 10.1001/archneur.1959.03840060001001; YOUNG AB, 1998, MOL NEUROLOGY; YOUNG RR, 1992, DIS NERVOUS SYSTEM C, V1, P353	28	5	6	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1126	1133		10.1056/NEJM200004133421511	http://dx.doi.org/10.1056/NEJM200004133421511			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10760316				2022-12-28	WOS:000086406700011
J	Williams, TM; Davis, RW; Fuiman, LA; Francis, J; Le Boeuf, BL; Horning, M; Calambokidis, J; Croll, DA				Williams, TM; Davis, RW; Fuiman, LA; Francis, J; Le Boeuf, BL; Horning, M; Calambokidis, J; Croll, DA			Sink or swim: Strategies for cost-efficient diving by marine mammals	SCIENCE			English	Article							CONFLICTING METABOLIC DEMANDS; NORTHERN ELEPHANT SEALS; DOLPHINS; KINEMATICS; EXERCISE; ENERGY; BIRDS	Locomotor activity by diving marine mammals is accomplished while breath-holding and often exceeds predicted aerobic capacities. Video sequences of freely diving seals and whales wearing submersible cameras reveal a behavioral strategy that improves energetic efficiency in these animals. Prolonged gliding (greater than 78% descent duration) occurred during dives exceeding 80 meters in depth. Gliding was attributed to buoyancy changes with Lung compression at depth. By modifying locomotor patterns to take advantage of these physical changes, Weddell seals realized a 9.2 to 59.6% reduction in diving energetic costs. This energy-conserving strategy allows marine mammals to increase aerobic dive duration and achieve remarkable depths despite Limited,oxygen availability when submerged.	Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA; Texas A&M Univ, Dept Marine Biol, Galveston, TX 77553 USA; Univ Texas, Dept Marine Sci, Port Aransas, TX 78373 USA; Natl Geog Soc, Comm Res & Explorat, Washington, DC 20036 USA; Cascadia Res, Olympia, WA USA; Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; Texas A&M University System; University of Texas System; National Geographic Society; University of California System; University of California Santa Cruz	Williams, TM (corresponding author), Univ Calif Santa Cruz, Dept Biol, EMS-A316, Santa Cruz, CA 95064 USA.		Horning, Markus/I-3019-2015; Fuiman, Lee A/L-9514-2017	Horning, Markus/0000-0001-6178-4935; Fuiman, Lee A/0000-0003-2667-2684				AU D, 1980, NATURE, V284, P548, DOI 10.1038/284548a0; Butler PJ, 1997, PHYSIOL REV, V77, P837, DOI 10.1152/physrev.1997.77.3.837; CASTELLINI MA, 1992, J EXP BIOL, V165, P181; CASTELLINI MA, 1985, J APPL PHYSIOL, V58, P392, DOI 10.1152/jappl.1985.58.2.392; Crocker DE, 1997, CAN J ZOOL, V75, P27, DOI 10.1139/z97-004; Davis RW, 1999, SCIENCE, V283, P993, DOI 10.1126/science.283.5404.993; DAVIS RW, 1985, PHYSIOL ZOOL, V58, P590, DOI 10.1086/physzool.58.5.30158585; Fish FE, 1998, J EXP BIOL, V201, P2867; FISH FE, 1988, J EXP BIOL, V137, P157; HADRICH Y, 1997, NATURE, V388, P64; HOCHACHKA PW, 1986, FASEB J, V45, P2948; KOOYMAN GL, 1970, SCIENCE, V169, P82, DOI 10.1126/science.169.3940.82; Kooyman GL, 1998, ANNU REV PHYSIOL, V60, P19, DOI 10.1146/annurev.physiol.60.1.19; Lovvorn JR, 1999, J EXP BIOL, V202, P1741; Marshall GJ, 1998, MAR TECHNOL SOC J, V32, P11; PONGANIS PJ, 1990, CAN J ZOOL, V68, P2105, DOI 10.1139/z90-293; RIDGWAY SH, 1969, SCIENCE, V166, P1651, DOI 10.1126/science.166.3913.1651; RIDGWAY SH, 1979, SCIENCE, V206, P1182, DOI 10.1126/science.505001; SCHMIDTNIELSEN K, 1972, SCIENCE, V177, P222, DOI 10.1126/science.177.4045.222; Skrovan RC, 1999, J EXP BIOL, V202, P2749; STEPHENSON R, 1994, J EXP BIOL, V190, P155; Thompson D., 1993, Symposia of the Zoological Society of London, V66, P349; VIDELER J, 1985, J EXP BIOL, V119, P265; Webb PM, 1998, J EXP BIOL, V201, P2349; WEBB PW, 1999, THESIS U CALIFORNIA; WEIHS D, 1974, J THEOR BIOL, V48, P215, DOI 10.1016/0022-5193(74)90192-1; Williams T.M., 1993, Symposia of the Zoological Society of London, V66, P383; Williams TM, 1999, J EXP BIOL, V202, P2739; WILLIAMS TM, 1992, NATURE, V355, P821, DOI 10.1038/355821a0; Williams TM, 1999, PHILOS T R SOC B, V354, P193, DOI 10.1098/rstb.1999.0371	30	311	319	2	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					133	136		10.1126/science.288.5463.133	http://dx.doi.org/10.1126/science.288.5463.133			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753116				2022-12-28	WOS:000086387700050
J	Zeki, S				Zeki, S			Abstraction and idealism - From Plato to Einstein: how do we acquire knowledge?	NATURE			English	Editorial Material									UCL, Wellcome Dept Cognit Neurol, London WC1E 6BT, England	University of London; University College London	Zeki, S (corresponding author), UCL, Wellcome Dept Cognit Neurol, Gower St, London WC1E 6BT, England.								0	6	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					547	547		10.1038/35007158	http://dx.doi.org/10.1038/35007158			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	303BC	10766218	Bronze			2022-12-28	WOS:000086400100027
J	Geiderman, JM				Geiderman, JM			Faith and doubt	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1661	1662		10.1001/jama.283.13.1661	http://dx.doi.org/10.1001/jama.283.13.1661			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BK	10755477				2022-12-28	WOS:000086119300001
J	Buc, H				Buc, H			Molecular biology - Running the red light	SCIENCE			English	Editorial Material							RNA-POLYMERASE; TERMINATION EFFICIENCY; SINGLE MOLECULES; TRANSCRIPTION; FORCE		Inst Pasteur, Unite Physicochim Macromol Biol, CNRS, URA 1773, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Buc, H (corresponding author), Inst Pasteur, Unite Physicochim Macromol Biol, CNRS, URA 1773, F-75724 Paris 15, France.							Chamberlin M.J., 1994, HARVEY LECT, V88, P1; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; DEMERCOYROL L, 1990, BIOCHEM J, V269, P651, DOI 10.1042/bj2690651; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; JOB D, 1988, J THEOR BIOL, V134, P273, DOI 10.1016/S0022-5193(88)80059-6; Landick R, 1999, SCIENCE, V284, P598, DOI 10.1126/science.284.5414.598; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124	15	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2437	2438		10.1126/science.287.5462.2437	http://dx.doi.org/10.1126/science.287.5462.2437			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10766622				2022-12-28	WOS:000086202200033
J	Emery, P; Stanewsky, R; Hall, JC; Rosbash, M				Emery, P; Stanewsky, R; Hall, JC; Rosbash, M			Drosophila cryptochromes - A unique circadian-rhythm photoreceptor	NATURE			English	Article							CLOCK; PHOTOSENSITIVITY		Brandeis Univ, NSF Ctr Biol Timing, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA; Univ Regensburg, Inst Zool, D-93040 Regensburg, Germany	Brandeis University; National Science Foundation (NSF); Brandeis University; Howard Hughes Medical Institute; University of Regensburg	Emery, P (corresponding author), Brandeis Univ, NSF Ctr Biol Timing, Dept Biol, Waltham, MA 02454 USA.		Stanewsky, Ralf/ABB-9193-2021	Stanewsky, Ralf/0000-0001-8238-6864				ASCHOFF J, 1979, Z TIERPSYCHOL, V49, P225; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; EWER J, 1992, J NEUROSCI, V12, P3321; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; OHATA K, 1999, BIOL CLOCKS MECHANIS, P167; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114	10	197	204	6	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					456	457		10.1038/35006558	http://dx.doi.org/10.1038/35006558			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761904				2022-12-28	WOS:000086257700035
J	[Anonymous]				[Anonymous]			A squandered opportunity	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	2000	404	6777					421	421						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761880				2022-12-28	WOS:000086257700001
J	Sun, ZM; Arendt, CW; Ellmeier, W; Schaeffer, EM; Sunshine, MJ; Gandhi, L; Annes, J; Petrzilka, D; Kupfer, A; Schwartzberg, PL; Littman, DR				Sun, ZM; Arendt, CW; Ellmeier, W; Schaeffer, EM; Sunshine, MJ; Gandhi, L; Annes, J; Petrzilka, D; Kupfer, A; Schwartzberg, PL; Littman, DR			PKC-theta is required for TCR-induced NF-kappa B activation in mature but not immature T lymphocytes	NATURE			English	Article							PROTEIN-KINASE-C; CELL ACTIVATION; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; IL-2 PROMOTER; RECEPTOR; INTERLEUKIN-2; VAV; THYMOCYTES; EPSILON	Productive interaction of a T lymphocyte with an antigen-presenting cell results in the clustering of the T-cell antigen receptor (TCR) and the recruitment of a large signalling complex to the site of cell-cell contact(1,2). Subsequent signal transduction resulting in cytokine gene expression requires the activation of one or more of the multiple isoenzymes of serine/threonine-specific protein kinase C (PKC)(3). Among the several PKC isoenzymes expressed in T cells, PKC-theta is unique in being rapidly recruited to the site of TCR clustering(4). Here we show that PKC-theta is essential for TCR-mediated T-cell activation, but is dispensable during TCR-dependent thymocyte development. TCR-initiated NF-kappa B activation was absent from PKC-theta(-/-) mature T lymphocytes, but was intact in thymocytes. Activation of NF-kappa B by tumour-necrosis factor alpha and interleukin-1 was unaffected in the mutant mice. Although studies in T-cell lines had suggested that PKC-B regulates activation of the JNK signalling pathway(5,6), induction of JNK was normal in T cells from mutant mice. These results indicate that PKC-theta functions in a unique pathway that links the TCR signalling, complex to the activation of NF-kappa B in mature T lymphocytes.	NYU, Sch Med, Mol Pathogenesis Program, Sjirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80262 USA	New York University; Howard Hughes Medical Institute; New York University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Chicago; National Jewish Health	Littman, DR (corresponding author), NYU, Sch Med, Mol Pathogenesis Program, Sjirball Inst Biomol Med, New York, NY 10016 USA.			Ellmeier, Wilfried/0000-0001-8192-8481; Sunshine, Mary Jean/0000-0002-2188-7881; Annes, Justin/0000-0001-8431-3589; Gandhi, Leena/0000-0002-2398-9179				Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Esslinger CW, 1998, MOL IMMUNOL, V35, P847, DOI 10.1016/S0161-5890(98)00071-6; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JAMIESON C, 1991, J IMMUNOL, V147, P416; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Meller N, 1998, STEM CELLS, V16, P178, DOI 10.1002/stem.160178; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Zandi E, 1999, MOL CELL BIOL, V19, P4547	28	762	802	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					402	407		10.1038/35006090	http://dx.doi.org/10.1038/35006090			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746729				2022-12-28	WOS:000086119000054
J	Gebo, DL; Dagosto, M; Beard, KC; Qi, T; Wang, JW				Gebo, DL; Dagosto, M; Beard, KC; Qi, T; Wang, JW			The oldest known anthropoid postcranial fossils and the early evolution of higher primates	NATURE			English	Article							EOCENE FISSURE-FILLINGS; MIDDLE EOCENE; ORIGINS; CHINA; FOOT; MORPHOLOGY; PROVINCE; SKULLS	The middle Eocene primate family Eosimiidae, which is known from sites in central and eastern China(1,2) and Myanmar(3), is central to efforts to reconstruct the origin and early evolution of anthropoid or 'higher' primates (monkeys, apes and humans)(1-6). Previous knowledge of eosimiid anatomy has been restricted to the dentition(3-3,7) and an isolated petrosal bone(5), and this limited anatomical information has led to conflicting interpretations of early anthropoid phylogeny(1-6,8,9). Here we describe foot bones of Eosimias from the same middle Eocene sites in China that yield abundant dental remains of this primate. Tarsals of Eosimias show derived anatomical traits that are otherwise restricted to living and fossil anthropoids. These new fossils substantiate the anthropoid status of Eosimias and clarify the phylogenetic position of anthropoids with respect to other major primate clades. Early anthropoids possessed a mosaic of primitive and derived traits in their postcranial skeletons, reflecting their derivation from haplorhine ancestors that retained marry prosimian-like features.	No Illinois Univ, Dept Anthropol, De Kalb, IL 60115 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA; Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China	Northern Illinois University; Northwestern University; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	Gebo, DL (corresponding author), No Illinois Univ, Dept Anthropol, De Kalb, IL 60115 USA.		Beard, K. Christopher/AAQ-4438-2021	Beard, K. Christopher/0000-0002-6279-9837				Beard K. Christopher, 1994, P55; Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BEARD KC, 1988, NATURE, V331, P712, DOI 10.1038/331712a0; BEARD KC, 1991, NATURE, V349, P64, DOI 10.1038/349064a0; BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; Cartmill M., 1980, P243; Cartmill M., 1978, RECENT ADV PRIMATOL, P205; DAGOSTO M, 1992, INT J PRIMATOL, V13, P307, DOI 10.1007/BF02547818; DAGOSTO M, 1988, J HUM EVOL, V17, P35, DOI 10.1016/0047-2484(88)90048-6; Dagosto Marian, 1994, P567; Decker R.L., 1974, P261; FLEAGIE JG, 1999, PRIMATE ADAPTATION E; GEBO DL, 1986, J HUM EVOL, V15, P421, DOI 10.1016/S0047-2484(86)80025-2; GEBO DL, 1988, FOLIA PRIMATOL, V50, P3, DOI 10.1159/000156332; Gingerich P.D., 1980, P123; Godinot Marc, 1994, P235; Jaeger JJ, 1999, SCIENCE, V286, P528, DOI 10.1126/science.286.5439.528; Kay RF, 1997, SCIENCE, V275, P797, DOI 10.1126/science.275.5301.797; LEWIS OJ, 1980, J ANAT, V131, P275; MacPhee RDE, 1995, J HUM EVOL, V29, P501, DOI 10.1006/jhev.1995.1073; Martin R.D., 1990, PRIMATE ORIGINS EVOL; Rasmussen D. Tab, 1994, P335; RASMUSSEN DT, 1990, INT J PRIMATOL, V11, P439, DOI 10.1007/BF02196131; Rosenberger A.L., 1980, P139; Ross C, 1998, J HUM EVOL, V35, P221, DOI 10.1006/jhev.1998.0254; Ross Callum, 1994, P469; SIMONS EL, 1989, AM J PHYS ANTHROPOL, V79, P1, DOI 10.1002/ajpa.1330790103; SIMONS EL, 1995, SCIENCE, V268, P1885, DOI 10.1126/science.7604261; Swofford DL, 1998, PHYLOGENETIC ANAL US; TONG Y, 1997, PALEONTOLOGIA SINICA, V26, P1	30	54	57	2	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					276	278		10.1038/35005066	http://dx.doi.org/10.1038/35005066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	296JX	10749208				2022-12-28	WOS:000086022200046
J	Ramsaransing, G; Zwanikken, C; De Keyser, J				Ramsaransing, G; Zwanikken, C; De Keyser, J			Drug points - Worsening of symptoms of multiple sclerosis associated with carbamazepine	BRITISH MEDICAL JOURNAL			English	Article									Acad Ziekenhuis, Dept Neurol, NL-9700 RB Groningen, Netherlands	University of Groningen	De Keyser, J (corresponding author), Acad Ziekenhuis, Dept Neurol, Hanzeplein 1, NL-9700 RB Groningen, Netherlands.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				SEDGWICK EM, 1997, MULTIPLE SCLEROSIS C, P195	1	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1113	1113		10.1136/bmj.320.7242.1113	http://dx.doi.org/10.1136/bmj.320.7242.1113			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775221	Green Submitted, Bronze			2022-12-28	WOS:000086782800018
J	Cassidy, JD; Carroll, LJ; Cote, P; Lemstra, M; Berglund, A; Nygren, A				Cassidy, JD; Carroll, LJ; Cote, P; Lemstra, M; Berglund, A; Nygren, A			Effect of eliminating compensation for pain and suffering on the outcome of insurance claims for whiplash injury.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH SURVEY SF-36; CES-D; DEPRESSION; VALIDITY; WORKERS; SCALE; POPULATIONS; SYMPTOMS; NECK	Background and Methods: The incidence and prognosis of whiplash injury from motor vehicle collisions may be related to eligibility for compensation for pain and suffering. On January 1, 1995, the tort-compensation system for traffic injuries, which included payments for pain and suffering, in Saskatchewan, Canada, was changed to a no-fault system, which did not include such payments. To determine whether this change was associated with a decrease in claims and improved recovery after whiplash injury, we studied a population-based cohort of persons who filed insurance claims for traffic injuries between July 1, 1994, and December 31, 1995. Results: Of 9006 potentially eligible claimants, 7462 (83 percent) met our criteria for whiplash injury. The six-month cumulative incidence of claims was 417 per 100,000 persons in the last six months of the tort system, as compared with 302 and 296 per 100,000, respectively, in the first and second six-month periods of the no-fault system. The incidence of claims was higher for women than for men in each period; the incidence decreased by 43 percent for men and by 15 percent for women between the tort period and the two no-fault periods combined. The median time from the date of injury to the closure of a claim decreased from 433 days (95 percent confidence interval, 409 to 457) to 194 days (95 percent confidence interval, 182 to 206) and 203 days (95 percent confidence interval, 193 to 213), respectively. The intensity of neck pain, the level of physical functioning, and the presence or absence of depressive symptoms were strongly associated with the time to claim closure in both systems. Conclusions: The elimination of compensation for pain and suffering is associated with a decreased incidence and improved prognosis of whiplash injury. (N Engl J Med 2000;342:1179-86.) (C) 2000, Massachusetts Medical Society.	Univ Alberta, Alberta Ctr Injury Control & Res, Dept Publ Hlth Sci, Edmonton, AB T6G 2V2, Canada; Univ Toronto, Inst Work & Hlth, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Saskatchewan, Dept Phys Med & Rehabil, Saskatoon, SK, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden	University of Alberta; Institute for Work & Health; University of Toronto; University of Toronto; University of Saskatchewan; Karolinska Institutet	Cassidy, JD (corresponding author), Univ Alberta, Alberta Ctr Injury Control & Res, Dept Publ Hlth Sci, 4075 EDC,8308-114 St, Edmonton, AB T6G 2V2, Canada.		Côté, Pierre/AAG-5358-2021	Côté, Pierre/0000-0002-6986-6676				Allison P. D., 1995, SURVIVAL ANAL USING; BALLA JI, 1982, CULT MED PSYCHIAT, V6, P191, DOI 10.1007/BF00051428; Beaton DE, 1997, J CLIN EPIDEMIOL, V50, P79, DOI 10.1016/S0895-4356(96)00296-X; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLALOCK SJ, 1989, ARTHRITIS RHEUM, V32, P991, DOI 10.1002/anr.1780320808; Borchgrevink GE, 1998, SPINE, V23, P25, DOI 10.1097/00007632-199801010-00006; BOYD JH, 1982, ARCH GEN PSYCHIAT, V39, P1195; Butterfield PG, 1998, AM J IND MED, V34, P559, DOI 10.1002/(SICI)1097-0274(199812)34:6<559::AID-AJIM3>3.0.CO;2-3; CARROLL S, 1995, COSTS EXCESSIVE MED; Collett D, 1994, MODELLING SURVIVAL D; COTE P, 1999, 94 I WORK HLTH; Devins G.M., 1988, PSYCHOL HLTH, V2, P139, DOI [10.1080/08870448808400349, DOI 10.1080/08870448808400349]; EVANS RW, 1992, NEUROL CLIN, V10, P975, DOI 10.1016/S0733-8619(18)30191-9; Ferrari R, 1997, J RHEUMATOL, V24, P618; Ferrari R, 1999, ANN RHEUM DIS, V58, P1, DOI 10.1136/ard.58.1.1; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GORE SM, 1984, APPL STAT-J ROY ST C, V33, P176; HALEY SM, 1994, J CLIN EPIDEMIOL, V47, P671, DOI 10.1016/0895-4356(94)90215-1; Harder S, 1998, J CLIN EPIDEMIOL, V51, P377, DOI 10.1016/S0895-4356(98)00011-0; Hosmer D. W., 1999, APPL SURVIVAL ANAL; *ISR RES COUNC, 1994, AUT INJ CLAIM BEH IT; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; MACNAB I, 1964, J BONE JOINT SURG AM, V46, P1797, DOI 10.2106/00004623-196446080-00021; MARGOLIS RB, 1986, PAIN, V24, P57, DOI 10.1016/0304-3959(86)90026-6; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCKINNEY LA, 1989, BRIT MED J, V299, P1006, DOI 10.1136/bmj.299.6706.1006; ORME JG, 1986, J CLIN PSYCHOL, V42, P28, DOI 10.1002/1097-4679(198601)42:1<28::AID-JCLP2270420104>3.0.CO;2-T; RADANOV BP, 1994, BRIT J RHEUMATOL, V33, P442; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REILLY PA, 1991, J RHEUMATOL, V18, P1448; ROSSIGNOL M, 1988, J OCCUP ENVIRON MED, V30, P502, DOI 10.1097/00043764-198806000-00012; Rothman K., 1998, MODERN EPIDEMIOLOGY, P253; *SAS I, 1996, VERS 6 12; *SASK GOV INS, 1996, SASK TRAFF ACC FACTS; *SASK HLTH, 1995, HLTHINS REG COV POP; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; Sinclair SJ, 1997, SPINE, V22, P2919, DOI 10.1097/00007632-199712150-00015; SPITZER WO, 1995, SPINE, V20, P2372; *SPSS, 1998, VERS 8 0; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware Jr JE, 1993, SF 36 HEALTH SURVEY; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; ZICH JM, 1990, INT J PSYCHIAT MED, V20, P259, DOI 10.2190/LYKR-7VHP-YJEM-MKM2	44	493	510	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	2000	342	16					1179	1186		10.1056/NEJM200004203421606	http://dx.doi.org/10.1056/NEJM200004203421606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305DG	10770984				2022-12-28	WOS:000086523700006
J	Fritz, J; Baller, MK; Lang, HP; Rothuizen, H; Vettiger, P; Meyer, E; Guntherodt, HJ; Gerber, C; Gimzewski, JK				Fritz, J; Baller, MK; Lang, HP; Rothuizen, H; Vettiger, P; Meyer, E; Guntherodt, HJ; Gerber, C; Gimzewski, JK			Translating biomolecular recognition into nanomechanics	SCIENCE			English	Article							ATOMIC-FORCE MICROSCOPY; INDUCED SURFACE STRESS; DNA; OLIGONUCLEOTIDES; MOLECULES; GOLD	We report the specific transduction, via surface stress changes, of DNA hybridization and receptor-ligand binding into a direct nanomechanical response of microfabricated cantilevers. Cantilevers in an array were functionalized with a selection of biomolecules. The differential deflection of the cantilevers was found to provide a true molecular recognition signal despite Large nonspecific responses of individual cantilevers. Hybridization of complementary oligonucleotides shows that a single base mismatch between two 12-mer oligonucleotides is clearly detectable. Similar experiments on protein A-immunoglobulin interactions demonstrate the wide-ranging applicability of nanomechanical transduction to detect biomolecular recognition.	IBM Res, Zurich Res Lab, CH-8803 Ruschlikon, Switzerland; Univ Basel, Inst Phys, CH-4056 Basel, Switzerland	International Business Machines (IBM); University of Basel	Gerber, C (corresponding author), IBM Res, Zurich Res Lab, Saumerstr 4, CH-8803 Ruschlikon, Switzerland.		Gerber, Christoph E/G-4851-2011; Meyer, Ernst/L-3873-2016; Lang, Hans Peter/G-3884-2011	Meyer, Ernst/0000-0001-6385-3412; Lang, Hans Peter/0000-0002-0012-2564; gimzewski, james/0000-0003-4333-6957				Abel AP, 1996, ANAL CHEM, V68, P2905, DOI 10.1021/ac960071+; Baller MK, 2000, ULTRAMICROSCOPY, V82, P1, DOI 10.1016/S0304-3991(99)00123-0; Berger R, 1997, SCIENCE, V276, P2021, DOI 10.1126/science.276.5321.2021; Butt HJ, 1996, J COLLOID INTERF SCI, V180, P251, DOI 10.1006/jcis.1996.0297; CHEN GY, 1995, J APPL PHYS, V77, P3618, DOI 10.1063/1.359562; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; IBACH H, 1994, J VAC SCI TECHNOL A, V12, P2240, DOI 10.1116/1.579122; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; Lundbaek JA, 1997, BIOCHEMISTRY-US, V36, P5695, DOI 10.1021/bi9619841; Miyatani T, 1997, J APPL PHYS, V81, P7099, DOI 10.1063/1.365306; Moulin AM, 1999, LANGMUIR, V15, P8776, DOI 10.1021/la990416u; Okahata Y, 1998, ANAL CHEM, V70, P1288, DOI 10.1021/ac970584w; Rekesh D, 1996, BIOPHYS J, V71, P1079, DOI 10.1016/S0006-3495(96)79308-6; RICHMAN DD, 1982, J IMMUNOL, V128, P2300; Safran SA, 1999, ADV PHYS, V48, P395, DOI 10.1080/000187399243428; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Vettiger P, 1999, MICROELECTRON ENG, V46, P11, DOI 10.1016/S0167-9317(99)00006-4; Viani MB, 1999, J APPL PHYS, V86, P2258, DOI 10.1063/1.371039	20	1396	1504	4	269	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					316	318		10.1126/science.288.5464.316	http://dx.doi.org/10.1126/science.288.5464.316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764640				2022-12-28	WOS:000086454300031
J	Lebestky, T; Chang, T; Hartenstein, V; Banerjee, U				Lebestky, T; Chang, T; Hartenstein, V; Banerjee, U			Specification of Drosophila hematopoietic lineage by conserved transcription factors	SCIENCE			English	Article							CHROMOSOMAL TRANSLOCATIONS; CELL LINEAGE; DIFFERENTIATION; LEUKEMIA; LOZENGE; SWITCH; BLOOD; AML1; EYE	Two major classes of cells observed within the Drosophila hematopoietic repertoire are plasmatocytes/macrophages and crystal cells. The transcription factor Lz (Lozenge), which resembles human AML1 (acute myeloid leukemia-1) protein, is necessary for the development of crystal cells during embryonic and larval hematopoiesis. Another transcription factor, Gcm (glial cells missing), has previously been shown to be required for plasmatocyte development. Misexpression of Gcm causes crystal cells to be transformed into plasmatocytes. The Drosophila GATA protein Srp (Serpent) is required for both Lz and Gcm expression and is necessary for the development of both classes of hemocytes, whereas Lz and Gcm are required in a lineage-specific manner. Given the similarities of Srp and Lz to; mammalian GATA and AML1 proteins, observations in Drosophila are Likely to have broad implications for understanding mammalian hematopoiesis and leukemias.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lebestky, T (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.	banerjee@mbi.ucla.edu			NATIONAL EYE INSTITUTE [R01EY008152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029367, R56NS029367] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY08152] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline; NINDS NIH HHS [NS29367] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Bae SC, 1999, HISTOL HISTOPATHOL, V14, P1213, DOI 10.14670/HH-14.1213; Bernardoni R, 1997, DEV BIOL, V191, P118; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Dearolf CR, 1998, BBA-REV CANCER, V1377, pM13, DOI 10.1016/S0304-419X(97)00031-0; Flores GV, 1998, DEVELOPMENT, V125, P3681; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Mathey-Prevot B, 1998, CELL, V92, P697, DOI 10.1016/S0092-8674(00)81396-3; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Orkin SH, 1998, INT J DEV BIOL, V42, P927; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Riechmann V, 1998, DEVELOPMENT, V125, P713; RIZKI T M, 1981, Genetics, V97, pS90; RIZKI TM, 1980, ROUX ARCH DEV BIOL, V188, P91, DOI 10.1007/BF00848799; RIZKI TM, 1978, GENETICS BIOL DROS B, V2, P398; RUGENDORFF A, 1994, ROUX ARCH DEV BIOL, V203, P266, DOI 10.1007/BF00360522; SHRESTHA R, 1982, DEV GROWTH DIFFER, V24, P65; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Speck NA, 1999, CANCER RES, V59, p1789S; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	29	361	376	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	2000	288	5463					146	149		10.1126/science.288.5463.146	http://dx.doi.org/10.1126/science.288.5463.146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753120				2022-12-28	WOS:000086387700054
J	Cuffey, KM; Marshall, SJ				Cuffey, KM; Marshall, SJ			Substantial contribution to sea-level rise during the last interglacial from the Greenland ice sheet	NATURE			English	Article							CORE PROJECT; CLIMATE; RECORD; TEMPERATURES; ACCUMULATION; DELTA-O-18; TRANSITION; ELEVATION; INTERVAL; PERIOD	During the last interglacial period (the Eemian), global sea level was at least three metres, and probably more than five metres, higher than at present(1,2). Complete melting of either the West Antarctic ice sheet or the Greenland ice sheet would today raise sea levels by 6-7 metres. But the high sea levels during the last interglacial period have been proposed to result mainly from disintegration of the West Antarctic ice sheet(3), with model studies attributing only 1-2 m of sea-level rise to meltwater from Greenland(4,5). This result was considered consistent with ice core evidence(4), although earlier work had suggested a much reduced Greenland ice sheet during the last interglacial period(6). Here we reconsider the Eemian evolution of the Greenland ice sheet by combining numerical modelling with insights obtained from recent central Greenland ice-core analyses. Our results suggest that the Greenland ice sheet was considerably smaller and steeper during the Eemian, and plausibly contributed 4-5.5 m to the sealevel highstand during that period. We conclude that the high sea level during the last interglacial period most probably included a large contribution from Greenland meltwater and therefore should not be interpreted as evidence for a significant reduction of the West Antarctic ice sheet.	Univ Calif Berkeley, Dept Geog, Berkeley, CA 94720 USA; Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada	University of California System; University of California Berkeley; University of British Columbia	Cuffey, KM (corresponding author), Univ Calif Berkeley, Dept Geog, Berkeley, CA 94720 USA.							Adkins JF, 1997, NATURE, V390, P154, DOI 10.1038/36540; ALLEY RB, IN PRSS MECHANISMS M; Boyle EA, 1997, GEOPHYS RES LETT, V24, P273, DOI 10.1029/97GL00081; Chappellaz J, 1997, J GEOPHYS RES-OCEANS, V102, P26547, DOI 10.1029/97JC00164; CUFFEY KM, 1994, J GLACIOL, V40, P341, DOI 10.3189/S0022143000007425; Cuffey KM, 1997, J GEOPHYS RES-OCEANS, V102, P26383, DOI 10.1029/96JC03981; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; DahlJensen D, 1998, SCIENCE, V282, P268, DOI 10.1126/science.282.5387.268; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Fawcett PJ, 1997, PALEOCEANOGRAPHY, V12, P23, DOI 10.1029/96PA02711; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HUYBRECHTS P, 1991, GLOBAL PLANET CHANGE, V89, P399, DOI 10.1016/0921-8181(91)90119-H; Johnsen SJ, 1989, TELLUS B, V41, P452, DOI 10.1111/j.1600-0889.1989.tb00321.x; JOUZEL J, 1993, NATURE, V364, P407, DOI 10.1038/364407a0; KOERNER RM, 1989, SCIENCE, V244, P964, DOI 10.1126/science.244.4907.964; LETREGUILLY A, 1991, J GLACIOL, V37, P149; LETREGUILLY A, 1991, GLOBAL PLANET CHANGE, V90, P385, DOI 10.1016/0921-8181(91)90004-G; MACAYEAL DR, 1992, NATURE, V359, P29, DOI 10.1038/359029a0; Marshall SJ, 1997, J GEOPHYS RES-SOL EA, V102, P20599, DOI 10.1029/97JB01188; MERCER JH, 1978, NATURE, V271, P321, DOI 10.1038/271321a0; *NAT GEOPH DAT CTR, 1997, GREENL SUMM IC COR C; OHMURA A, 1991, J GLACIOL, V37, P140; Oppenheimer M, 1998, NATURE, V393, P325, DOI 10.1038/30661; Raynaud D, 1997, J GEOPHYS RES-OCEANS, V102, P26607, DOI 10.1029/97JC01908; Ritz C., 1997, CLIM DYNAM, V13, P11, DOI DOI 10.1007/S003820050149; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3; Vezina J, 1999, J SEDIMENT RES, V69, P317, DOI 10.2110/jsr.69.317; Wang XL, 1999, J CLIMATE, V12, P71, DOI 10.1175/1520-0442-12.1.71; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255	30	191	194	3	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					591	594		10.1038/35007053	http://dx.doi.org/10.1038/35007053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766239				2022-12-28	WOS:000086400100050
J	Murtagh, GJ; Dyer, PS; Crittenden, PD				Murtagh, GJ; Dyer, PS; Crittenden, PD			Reproductive systems - Sex and the single lichen	NATURE			English	Article							EVOLUTION; ISLAND; PLANTS		Univ Nottingham, Sch Biol Sci, Nottingham NG7 2RD, England	University of Nottingham	Murtagh, GJ (corresponding author), Univ Nottingham, Sch Biol Sci, Univ Pk, Nottingham NG7 2RD, England.			Dyer, Paul/0000-0003-0237-026X				BURNETT JH, 1975, MYCOGENETICS INTRO G; FAHSELT D, 1989, LICHENOLOGIST, V21, P343, DOI 10.1017/S0024282989000587; HESTMARK G, 1992, OECOLOGIA, V92, P305, DOI 10.1007/BF00317455; JAHNS H. M., 1997, BIBLIOTHECA LICHENOL, V67, P49; JAIN SK, 1976, ANNU REV ECOL SYST, V7, P469, DOI 10.1146/annurev.es.07.110176.002345; JARNE P, 1993, ANNU REV ECOL SYST, V24, P441, DOI 10.1146/annurev.es.24.110193.002301; Kershaw K.A., 1985, PHYSL ECOLOGY LICHEN, DOI 10.2307/3243300; MAYNARD SMITH J., 1978, EVOLUTION SEX; Murtagh GJ, 1999, LICHENOLOGIST, V31, P257; PURVIS OW, 1992, LICHEN FLORA GREAT B; Richards A.J, 1997, PLANT BREEDING SYSTE; SANCHO LG, 1993, POLAR BIOL, V13, P227; WEISING K, 1995, FINGERPRINTING PLANT	13	83	86	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					564	564		10.1038/35007142	http://dx.doi.org/10.1038/35007142			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766229				2022-12-28	WOS:000086400100040
J	Peabody, JW; Luck, J; Glassman, P; Dresselhaus, TR; Lee, M				Peabody, JW; Luck, J; Glassman, P; Dresselhaus, TR; Lee, M			Comparison of vignettes, standardized patients, and chart abstraction - A prospective validation study of 3 methods for measuring quality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL DECISION-MAKING; SIMULATED PATIENTS; GENERAL-PRACTICE; PHYSICIAN JUDGMENTS; CONTROLLED TRIAL; CARE; PERFORMANCE; OUTCOMES; CONSULTATION; ASSOCIATION	Context Better health care quality is a universal goal, yet measuring quality has proven to be difficult and problematic. A central problem has been isolating physician practices from other effects of the health care system, Objective To validate clinical vignettes as a method for measuring the competence of physicians and the quality of their actual practice. Design Prospective trial conducted in 1997 comparing 3 methods for measuring the quality of care for 4 common outpatient conditions: (1) structured reports by standardized patients (SPs), trained actors who presented unannounced to physicians' clinics (the gold standard); (2) abstraction of medical records for those same visits; and (3) physicians' responses to clinical vignettes that exactly corresponded to the SPs' presentations. Setting Outpatient primary care clinics at 2 Veterans Affairs medical centers. Participants Ninety-eight (97%) of 101 general internal medicine staff physicians, faculty, and second- and third-year residents consented to be randomized for the study. From this group, 10 physicians at each site were randomly selected for inclusion. Main Outcome Measures A total of 160 quality scores (8 cases x 20 physicians) were generated for each method using identical explicit criteria based on national guidelines and local expert panels, Scores were defined as the percentage of process criteria correctly met and were compared among the 3 methods. Results The quality of care, as measured by all 3 methods, ranged from 76.2% (SPs) to 71.0% (vignettes) to 65.6% (chart abstraction). Measuring quality using vignettes consistently produced scores closer to the gold standard of SP scores than using chart abstraction, This pattern was robust when the scores were disaggregated by the 4 conditions (P<.001 to <.05), by case complexity (P<.001), by site (P<.001), and by level of physician training (P values from <.001 to <.05). The pattern persisted, although less dominantly, when we assessed the component domains of the clinical encounter-history, physical examination, diagnosis, and treatment, Vignettes were responsive to expected directions of variation in quality between sites and levels of training. The vignette responses did not appear to be sensitive to physicians' having seen an SP presenting with the same case. Conclusions Our data indicate that quality of health care can be measured in an outpatient setting by using clinical vignettes. Vignettes appear to be a valid and comprehensive method that directly focuses on the process of care provided in actual clinical practice. Vignettes show promise as an inexpensive case-mix adjusted method for measuring the quality of care provided by a group of physicians.	Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Inst Global Hlth, San Francisco, CA 94105 USA; RAND Corp, Santa Monica, CA USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA; Univ Calif San Diego, San Diego Vet Affairs Med Ctr, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California San Diego	Peabody, JW (corresponding author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Inst Global Hlth, Suite 508,74 New Montgomery St, San Francisco, CA 94105 USA.							ARONOW DB, 1995, P ANN S COMP APPL ME, P303; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; Badger L W, 1995, Fam Med, V27, P126; Beullens J, 1997, FAM PRACT, V14, P58, DOI 10.1093/fampra/14.1.58; Beyth RJ, 1996, J GEN INTERN MED, V11, P721, DOI 10.1007/BF02598985; BROOK RH, 1985, MED CARE, V23, P710, DOI 10.1097/00005650-198505000-00030; Carey TS, 1996, ANN INTERN MED, V125, P807, DOI 10.7326/0003-4819-125-10-199611150-00004; Carney P A, 1998, Nurse Pract, V23, P56; CARNEY PA, 1993, ANN INTERN MED, V119, P129, DOI 10.7326/0003-4819-119-2-199307150-00007; Carroll Robert G., 1993, American Journal of Physiology, V264, pS11; Colenda CC, 1996, J AM GERIATR SOC, V44, P1375, DOI 10.1111/j.1532-5415.1996.tb01411.x; Colliver J A, 1997, JAMA, V278, P790, DOI 10.1001/jama.278.9.790; COLLIVER JA, 1993, ACAD MED, V68, P153, DOI 10.1097/00001888-199302000-00013; Cooper GS, 1997, ARCH INTERN MED, V157, P1946, DOI 10.1001/archinte.157.17.1946; DeChamplain AE, 1997, ACAD MED, V72, pS85, DOI 10.1097/00001888-199710001-00029; DONABEDIAN A, 1980, DEFINITION QUALITY A; EVERITT DE, 1990, AM J MED, V89, P357, DOI 10.1016/0002-9343(90)90349-I; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Glassman PA, 1997, ARCH INTERN MED, V157, P506, DOI 10.1001/archinte.157.5.506; Glassman PA, 1996, J HEALTH POLIT POLIC, V21, P219, DOI 10.1215/03616878-21-2-219; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KANTEN DN, 1993, J AM GERIATR SOC, V41, P662, DOI 10.1111/j.1532-5415.1993.tb06741.x; Katz JN, 1996, MED CARE, V34, P73, DOI 10.1097/00005650-199601000-00006; KOPELOW ML, 1992, ACAD MED, V67, pS19, DOI 10.1097/00001888-199210000-00026; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; Lawthers A G, 1995, J Ambul Care Manage, V18, P56; Lawthers A G, 1993, Jt Comm J Qual Improv, V19, P552; Lohr KN, 1990, MEDICARE STRATEGY QU; LUCK J, IN PRESS AM J MED; LUCK J, 1999, 22 ANN M SOC GEN INT; McDonald CJ, 1997, ANN INTERN MED, V127, P675, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00049; McLeod PJ, 1997, JAMA-J AM MED ASSOC, V278, P1164, DOI 10.1001/jama.278.14.1164; NORMAN GR, 1993, JAMA-J AM MED ASSOC, V270, P1046; NORMAN GR, 1985, J MED EDUC, V60, P925; ONEILL D, 1995, AGE AGEING, V24, P242, DOI 10.1093/ageing/24.3.242; PALMER RH, 1985, MED CARE, V23, P751, DOI 10.1097/00005650-198506000-00001; Peabody J W, 1994, Bull Pan Am Health Organ, V28, P122; Peabody John W., 1999, POLICY HLTH IMPLICAT; Peabody JW, 1998, HEALTH POLICY, V43, P1, DOI 10.1016/S0168-8510(97)00085-7; Peabody JW, 1998, ARCH INTERN MED, V158, P2291, DOI 10.1001/archinte.158.21.2291; PIETERS HM, 1994, MED EDUC, V28, P226, DOI 10.1111/j.1365-2923.1994.tb02703.x; RETHANS JJ, 1991, BRIT MED J, V303, P1377, DOI 10.1136/bmj.303.6814.1377; RETHANS JJ, 1994, BRIT J GEN PRACT, V44, P153; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; ROSEN AK, 1995, J CLIN EPIDEMIOL, V48, P631, DOI 10.1016/0895-4356(94)00165-M; RUBENSTEIN L, 1977, ANN INTERN MED, V86, P617, DOI 10.7326/0003-4819-86-5-617; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; Ryynanen OP, 1997, FAM PRACT, V14, P216, DOI 10.1093/fampra/14.3.216; Safran DG, 1998, MED CARE, V36, P728, DOI 10.1097/00005650-199805000-00012; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; Sandvik H, 1995, Fam Med, V27, P388; Socolar RRS, 1998, PEDIATRICS, V101, P817, DOI 10.1542/peds.101.5.817; SRIRAM TG, 1990, ACTA PSYCHIAT SCAND, V82, P174, DOI 10.1111/j.1600-0447.1990.tb01377.x; Swartz MH, 1996, MT SINAI J MED, V63, P241; Tait RC, 1997, SOC SCI MED, V45, P1199, DOI 10.1016/S0277-9536(97)00033-6; Tamblyn R, 1998, JAMA-J AM MED ASSOC, V280, P989, DOI 10.1001/jama.280.11.989; *US C OFF TECHN AS, 1994, ID HLTH TECHN WORK S; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009; Wu L, 1997, EVAL HEALTH PROF, V20, P146, DOI 10.1177/016327879702000203; YAGER J, 1986, GEN HOSP PSYCHIAT, V8, P145, DOI 10.1016/0163-8343(86)90072-1	61	879	882	3	58	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1715	1722		10.1001/jama.283.13.1715	http://dx.doi.org/10.1001/jama.283.13.1715			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	298BK	10755498	Bronze			2022-12-28	WOS:000086119300032
J	Treasure, T				Treasure, T			Rational decision-making about paediatric cardiac surgery	LANCET			English	Editorial Material									Univ London St Georges Hosp, Sch Med, Cardiothorac Unit, London SW17 0QT, England	St Georges University London	Treasure, T (corresponding author), Univ London St Georges Hosp, Sch Med, Cardiothorac Unit, London SW17 0QT, England.							DOBSON R, 2000, BRIT MED J, V320, P468; GARDINER K, 1998, BRIT MED J, V317, P811	2	4	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					948	948		10.1016/S0140-6736(00)90010-2	http://dx.doi.org/10.1016/S0140-6736(00)90010-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768431				2022-12-28	WOS:000086054000007
J	Buck, LB				Buck, LB			The molecular architecture of odor and pheromone sensing in mammals	CELL			English	Review							OLFACTORY RECEPTOR NEURONS; MULTIGENE FAMILY; VOMERONASAL SYSTEM; GENE-EXPRESSION; EPITHELIUM; RESPONSES; RAT; TRANSDUCTION; ORGANIZATION; PROJECTION		Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Buck, LB (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA.							Alenius M, 1997, J BIOL CHEM, V272, P26083, DOI 10.1074/jbc.272.42.26083; Barth AL, 1996, NEURON, V16, P23, DOI 10.1016/S0896-6273(00)80020-3; BEETS MGJ, 1970, PHARMACOL REV, V22, P1; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Belluscio L, 1999, CELL, V97, P209, DOI 10.1016/S0092-8674(00)80731-X; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Berghard A, 1996, J NEUROSCI, V16, P909; Bozza TC, 1998, J NEUROSCI, V18, P4560; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; Cao YX, 1998, P NATL ACAD SCI USA, V95, P11987, DOI 10.1073/pnas.95.20.11987; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CINELLI AR, 1992, ANNU REV NEUROSCI, V15, P321, DOI 10.1146/annurev.neuro.15.1.321; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Dorries KM, 1997, BRAIN BEHAV EVOLUT, V49, P53, DOI 10.1159/000112981; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; Firestein S, 1992, Curr Opin Neurobiol, V2, P444, DOI 10.1016/0959-4388(92)90178-N; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Horowitz LF, 1999, P NATL ACAD SCI USA, V96, P3194, DOI 10.1073/pnas.96.6.3194; Inamura K, 1997, NEUROSCI LETT, V233, P129, DOI 10.1016/S0304-3940(97)00655-1; Kandel E., 2000, PRINCIPLES NEURAL SC; Kauer J.S., 1987, P205; Keverne EB, 1999, SCIENCE, V286, P716, DOI 10.1126/science.286.5440.716; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Krieger J, 1999, J BIOL CHEM, V274, P4655, DOI 10.1074/jbc.274.8.4655; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; NOVOTNY M, 1990, CHEM RODENT PHEROMON, V5; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Qasba P, 1998, J NEUROSCI, V18, P227; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sasaki K, 1999, BRAIN RES, V823, P161, DOI 10.1016/S0006-8993(99)01164-6; SATO T, 1994, J NEUROPHYSIOL, V72, P2980, DOI 10.1152/jn.1994.72.6.2980; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Shepherd G. M., 1988, NEUROBIOLOGY; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; Sorensen Peter W., 1998, P375; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STROTMANN J, 1995, EUR J NEUROSCI, V7, P492, DOI 10.1111/j.1460-9568.1995.tb00345.x; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TAKAMI S, 1991, J COMP NEUROL, V311, P65, DOI 10.1002/cne.903110106; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; WILSON EO, 1963, SCI AM, V208, P100, DOI 10.1038/scientificamerican0563-100; Wysocki C.J., 1987, P125; Yoshihara Y, 1997, J NEUROSCI, V17, P5830; Yoshihara Y, 1999, NEURON, V22, P33, DOI 10.1016/S0896-6273(00)80676-5; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	83	312	328	3	59	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 17	2000	100	6					611	618		10.1016/S0092-8674(00)80698-4	http://dx.doi.org/10.1016/S0092-8674(00)80698-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761927	Bronze			2022-12-28	WOS:000085983800004
J	Fagon, JY; Chastre, J; Wolff, M; Gervais, C; Parer-Aubas, S; Stephan, F; Similowski, T; Mercat, A; Diehl, JL; Sollet, JP; Tenaillon, A				Fagon, JY; Chastre, J; Wolff, M; Gervais, C; Parer-Aubas, S; Stephan, F; Similowski, T; Mercat, A; Diehl, JL; Sollet, JP; Tenaillon, A		VAP Trial Grp	Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article						ventilators, mechanical; pneumonia; cross infection; bronchoalveolar lavage; diagnosis	RESPIRATORY-DISTRESS SYNDROME; INTENSIVE-CARE UNIT; NOSOCOMIAL PNEUMONIA; BRONCHOSCOPIC TECHNIQUES; CLINICAL JUDGMENT; ORGAN FAILURE; DIAGNOSIS; IMPACT; SEPSIS; INFECTION	Background: Optimal management of patients who are clinically suspected of having ventilator-associated pneumonia remains open to debate. Objective: To evaluate the effect on clinical outcome and antibiotic use of two strategies to diagnose ventilator-associated pneumonia and select initial treatment for this condition. Design: Multicenter, randomized, uncontrolled trial. Setting: 31 intensive care units in France. Patients: 413 patients suspected of having ventilator-associated pneumonia. Intervention: The invasive management strategy was based on direct examination of bronchoscopic protected specimen brush samples or bronchoalveolar lavage samples and their quantitative cultures. The noninvasive ("clinical") management strategy was based on clinical criteria, isolation of microorganisms by nonquantitative analysis of endotracheal aspirates, and clinical practice guidelines. Measurements: Death from any cause, quantification of organ failure, and antibiotic use at 14 and 28 days. Results: Compared with patients who received clinical management, patients who received invasive management had reduced mortality at day 14(16.2% and 25.8%; difference, -9.6 percentage points [95% CI, -17.4 to -1.8 percentage points]; P = 0.022), decreased mean Sepsis-related Organ Failure Assessment scores at day 3 (6.1 +/- 4.0 and 7.0 +/- 4.3; P = 0.033) and day 7 (4.9 +/- 4.0 and 5.8 +/- 4.4; P = 0.043), and decreased antibiotic use (mean number of antibiotic-free days, 5.0 +/- 5.1 and 2.2 +/- 3.5; P < 0.001). At 28 days, the invasive management group had significantly more antibiotic-free days (11.5 +/- 9.0 compared with 7.5 +/- 7.6; P < 0.001), and only multivariate analysis showed a significant difference in mortality (hazard ratio, 1.54 [CI, 1.10 to 2.16]; P = 0.01). Conclusions: Compared with a noninvasive management strategy, an invasive management strategy was significantly associated with fewer deaths at 14 days, earlier attenuation of organ dysfunction, and less antibiotic use in patients suspected of having ventilator-associated pneumonia.	Hop Broussais, Serv Reanimat Med, F-75674 Paris 14, France; Hop Bichat Claude Bernard, F-75877 Paris 18, France; Hop Tenon, F-75970 Paris, France; Hop La Pitie Salpetriere, Paris, France; Hop Boucicault, Paris, France; Ctr Hosp Univ Nimes, Nimes, France; CHU Montpellier, Montpellier, France; Hop Bicetre, Le Kremlin Bicetre, France; Ctr Hosp Victor Dupouy, Argenteuil, France; Ctr Hosp Louise Michel, Evry, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Fagon, JY (corresponding author), Hop Broussais, Serv Reanimat Med, 96 Rue Didot, F-75674 Paris 14, France.		Mercat, Alain/AFU-4426-2022					AlvarezLerma F, 1996, INTENS CARE MED, V22, P387, DOI 10.1007/BF01712153; Baker AM, 1996, AM J RESP CRIT CARE, V153, P343, DOI 10.1164/ajrccm.153.1.8542141; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bonten MJM, 1997, AM J RESP CRIT CARE, V156, P1820, DOI 10.1164/ajrccm.156.6.9610117; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; Chastre J, 1995, CLIN INFECT DIS, V21, pS226, DOI 10.1093/clind/21.Supplement_3.S226; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; CHASTRE J, 1988, AM J MED, V85, P499; Chastre J, 1998, AM J RESP CRIT CARE, V157, P1165, DOI 10.1164/ajrccm.157.4.9708057; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; CROCE MA, 1994, J TRAUMA, V37, P721, DOI 10.1097/00005373-199411000-00005; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; Helling TS, 1996, AM J SURG, V171, P570, DOI 10.1016/S0002-9610(96)00040-2; Heyland DK, 1999, CHEST, V115, P1076, DOI 10.1378/chest.115.4.1076; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378/chest.113.2.412; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378/chest.111.3.676; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; Pittet D, 1998, LANCET, V352, P83, DOI 10.1016/S0140-6736(98)85005-8; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Sanchez-Nieto JM, 1998, AM J RESP CRIT CARE, V157, P371, DOI 10.1164/ajrccm.157.2.97-02039; Sterling TR, 1996, CHEST, V110, P1025, DOI 10.1378/chest.110.4.1025; Tenover FC, 1996, JAMA-J AM MED ASSOC, V275, P300, DOI 10.1001/jama.275.4.300; TORRES A, 1994, AM J RESP CRIT CARE, V149, P324, DOI 10.1164/ajrccm.149.2.8306025; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; WEINBERG PF, 1984, AM REV RESPIR DIS, V130, P791; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9; 1996, AM J RESP CIRT CARE, V153, P1711	37	544	570	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					621	+		10.7326/0003-4819-132-8-200004180-00004	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766680				2022-12-28	WOS:000086497500003
J	Rudolph, RE; Vaughan, TL; Storer, BE; Haggitt, RC; Rabinovitch, PS; Levine, DS; Reid, BJ				Rudolph, RE; Vaughan, TL; Storer, BE; Haggitt, RC; Rabinovitch, PS; Levine, DS; Reid, BJ			Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus	ANNALS OF INTERNAL MEDICINE			English	Article						aneuploidy; Barrett esophagus; adenocarcinoma; esophageal neoplasms; endoscopy	COLUMNAR-LINED ESOPHAGUS; HIGH-GRADE DYSPLASIA; INTESTINAL METAPLASIA; ESOPHAGOGASTRIC JUNCTION; GASTROESOPHAGEAL JUNCTION; ENDOSCOPIC SURVEILLANCE; FOLLOW-UP; ADENOCARCINOMA; PREVALENCE; MANAGEMENT	Background: The increased risk for esophageal adenocarcinoma associated with long-segment (greater than or equal to 3 cm) Barrett esophagus is well recognized. Recent studies suggest that short-segment (<3 cm) Barrett esophagus is substantially more common; however, the risk for neoplastic progression in patients with this disorder is largely unknown. Objective: To examine the relation between segment length and risk for aneuploidy and esophageal adenocarcinoma in patients with Barrett esophagus. Design: Prospective cohort study. Setting: University medical center in Seattle, Washington. Patients: 309 patients with Barrett esophagus. Measurements: Patients were monitored for progression to aneuploidy and adenocarcinoma by repeated endoscopy with biopsy for an average of 3.8 years. Cox proportional hazards analysis was used to calculate adjusted relative risks and 95% Cls. Results: After adjustment for histologic diagnosis at study entry, segment length was not related to risk for cancer in the full cohort (P > 0.2 for trend). When patients with high-grade dysplasia at baseline were excluded, however, a nonsignificant trend was observed; based on a linear model, a 5-cm difference in segment length was associated with a 1.7-fold (95% CI, 0.8-fold to 3.8-fold) increase in cancer risk. Among all eligible patients, a 5-cm difference in segment length was associated with a small increase in the risk for aneuploidy (relative risk, 1.4 [CI, 1.0 to 2.1]; P = 0.06 far trend). A similar trend was observed among patients without high-grade dysplasia at baseline. Conclusions: The risk for esophageal adenocarcinoma in patients with short-segment Barrett esophagus was not substantially lower than that in patients with longer segments. Although our results suggest a small increase in risk for neoplastic progression with increasing segment length, additional follow-up is needed to determine whether the patterns of risk occurred by chance or represent true differences. Until more data are available, the frequency of endoscopic surveillance should be selected without regard to segment length.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Rudolph, RE (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,MP-474,Box 19024, Seattle, WA 98109 USA.		Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X	NATIONAL CANCER INSTITUTE [R01CA061202, R25CA057734] Funding Source: NIH RePORTER; NCI NIH HHS [R25 CA57734, R01 CA61202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHKAR E, 1988, AM J GASTROENTEROL, V83, P291; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BANERJEE B, 1994, GASTROENTEROLOGY, V106, pA45; Beck I T, 1997, Can J Gastroenterol, V11 Suppl B, p7B; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; Cameron AJ, 1998, MAYO CLIN PROC, V73, P457; Chalasani N, 1997, DIGEST DIS SCI, V42, P603, DOI 10.1023/A:1018863529777; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; Farrow DC, 1996, CANCER CAUSE CONTROL, V7, P322, DOI 10.1007/BF00052937; Fitzgerald RC, 1998, DIGEST DIS, V16, P63, DOI 10.1159/000016850; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HARLE IA, 1985, ANN THORAC SURG, V40, P330, DOI 10.1016/S0003-4975(10)60062-8; Hirota WK, 1999, GASTROENTEROLOGY, V116, P277, DOI 10.1016/S0016-5085(99)70123-X; HONG MK, 1995, CANCER, V75, P423, DOI 10.1002/1097-0142(19950115)75:2<423::AID-CNCR2820750202>3.0.CO;2-5; IFTIKHAR SY, 1992, GUT, V33, P1155, DOI 10.1136/gut.33.9.1155; Johnston MH, 1996, AM J GASTROENTEROL, V91, P1507; KIM SL, 1994, GASTROENTEROLOGY, V107, P945, DOI 10.1016/0016-5085(94)90217-8; KINGSNORTH AN, 1983, CANCER RES, V43, P2545; LERUT T, 1994, J THORAC CARDIOV SUR, V107, P1059, DOI 10.1016/S0022-5223(94)70381-7; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; LEVINE DS, 1991, GASTROINTEST ENDOSC, V37, P332, DOI 10.1016/S0016-5107(91)70726-8; MENKEPLUYMERS MBE, 1994, GUT, V35, P1348, DOI 10.1136/gut.35.10.1348; MENKEPLUYMERS MBE, 1993, CANCER, V72, P1155, DOI 10.1002/1097-0142(19930815)72:4<1155::AID-CNCR2820720404>3.0.CO;2-C; MIROS M, 1991, GUT, V32, P1441, DOI 10.1136/gut.32.12.1441; Morales TG, 1997, AM J GASTROENTEROL, V92, P414; PROVENZALE D, 1994, AM J GASTROENTEROL, V89, P670; RANSOM JM, 1982, ANN THORAC SURG, V33, P19, DOI 10.1016/S0003-4975(10)63192-X; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; REID BJ, 1993, GASTROENTEROLOGY, V105, P119, DOI 10.1016/0016-5085(93)90017-7; Reid BJ, 1996, EUR J CANCER PREV, V5, P57, DOI 10.1097/00008469-199612002-00009; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; Riddell RH, 1996, AM J GASTROENTEROL, V91, P853; RUSCH VW, 1994, CANCER, V74, P1225, DOI 10.1002/1097-0142(19940815)74:4<1225::AID-CNCR2820740408>3.0.CO;2-Q; Sampliner RE, 1998, AM J GASTROENTEROL, V93, P1028; SCHNELL TG, 1992, DIGEST DIS SCI, V37, P137, DOI 10.1007/BF01308357; Sharma P, 1997, AM J GASTROENTEROL, V92, P2012; Spechler SJ, 1996, GASTROENTEROLOGY, V110, P614, DOI 10.1053/gast.1996.v110.agast960614; SPECHLER SJ, 1994, LANCET, V344, P1533, DOI 10.1016/S0140-6736(94)90349-2; *STAT CORP, 1997, STAT STAT SOFTW REL; STREITZ JM, 1993, J THORAC CARDIOV SUR, V105, P383; STREITZ JM, 1991, ANN SURG, V213, P122, DOI 10.1097/00000658-199102000-00005; TERPSTRA OT, 1981, GASTROENTEROLOGY, V81, P475; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Weston AP, 1996, AM J GASTROENTEROL, V91, P981; Weston AP, 1997, AM J GASTROENTEROL, V92, P407; WILLIAMSON WA, 1991, ARCH INTERN MED, V151, P2212, DOI 10.1001/archinte.151.11.2212	48	201	204	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					612	+		10.7326/0003-4819-132-8-200004180-00003	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766679				2022-12-28	WOS:000086497500002
J	Verdejo, A; de Cos, MA; Zubimendi, JA				Verdejo, A; de Cos, MA; Zubimendi, JA			Drug points - Probable interaction between cyclosporin A and low dose ticlopidine	BRITISH MEDICAL JOURNAL			English	Article							HEART-TRANSPLANT RECIPIENTS		Marques de Valdecilla Univ, Serv Clin Pharmacol, E-39008 Santander, Spain; Marques de Valdecilla Univ, Serv Nephrol, E-39008 Santander, Spain; San Carlos Hosp, Clin Pharmacol Serv, E-28040 Madrid, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); San Paolo-Polo Universitaria Hospital	Verdejo, A (corresponding author), Marques de Valdecilla Univ, Serv Clin Pharmacol, E-39008 Santander, Spain.		Verdejo, Asuncion/FCC-0537-2022	Lopez Lazaro, Luis/0000-0003-0620-6133				BIRMELE B, 1991, NEPHROL DIAL TRANSPL, V6, P150, DOI 10.1093/ndt/6.2.150-a; Boissonnat P, 1997, EUR J CLIN PHARMACOL, V53, P39, DOI 10.1007/s002280050334; DELORGERIL M, 1993, TRANSPLANTATION, V55, P1195, DOI 10.1097/00007890-199305000-00050	3	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1037	1037		10.1136/bmj.320.7241.1037	http://dx.doi.org/10.1136/bmj.320.7241.1037			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764363	Green Submitted, Bronze			2022-12-28	WOS:000086675700022
J	Forrest, EH; McMahon, A; Danesh, BJ				Forrest, EH; McMahon, A; Danesh, BJ			A man with a leaky drain	LANCET			English	Article									Stobhill Hosp, Med Off, Dept Med, Glasgow G21 3UW, Lanark, Scotland; Stobhill Hosp, Dept Surg, Glasgow G21 3UW, Lanark, Scotland		Forrest, EH (corresponding author), Stobhill Hosp, Med Off, Dept Med, Glasgow G21 3UW, Lanark, Scotland.							Atwater JS, 1943, ANN SURG, V117, P414, DOI 10.1097/00000658-194303000-00008; LOWDON AGR, 1953, BRIT J SURG, V41, P113, DOI 10.1002/bjs.18004116602; MARSHALL SF, 1957, ANN SURG, V145, P770, DOI 10.1097/00000658-195705000-00019; THOENY RH, 1960, AMER J ROENTGENOL RA, V83, P876	4	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1238	1238		10.1016/S0140-6736(00)02091-2	http://dx.doi.org/10.1016/S0140-6736(00)02091-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770307				2022-12-28	WOS:000086448000014
J	Velicer, GJ; Kroos, L; Lenski, RE				Velicer, GJ; Kroos, L; Lenski, RE			Developmental cheating in the social bacterium Myxococcus xanthus	NATURE			English	Article							CELL; EVOLUTION; DICTYOSTELIUM; MUTANTS; LOCUS; GENES	Cheating is a potential problem in any social system that depends on cooperation and in which actions that benefit a group are costly to individuals that perform them(1-5). Genetic mutants that fail to perform a group-beneficial function but that reap the benefits of belonging to the group should have a within-group selective advantage, provided that the mutants are not too common. Here we show that social cheating exists even among prokaryotes. The bacterium Myxococcus xanthus exhibits several social behaviours, including aggregation of cells into spore-producing fruiting bodies during starvation. We examined a number of M. xanthus genotypes that were defective for fruiting-body development, including several lines that evolved for 1,000 generations under asocial conditions(6) and others carrying defined mutations in developmental pathways(7-10), to determine whether they behaved as cheaters when mixed with their developmentally proficient progenitor. Clones from several evolved lines and two defined mutants exhibited cheating during development, being overrepresented among resulting spores relative to their initial frequency in the mixture. The ease of finding anti-social behaviours suggests that cheaters may be common in natural populations of M. xanthus.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Velicer, GJ (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	velicerg@pilot.msu.edu		Lenski, Richard/0000-0002-1064-8375				Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BONNER JT, 1967, CELLULAR SLIME MOLDS; Buss LW, 1999, P NATL ACAD SCI USA, V96, P8801, DOI 10.1073/pnas.96.16.8801; DOWNARD J, 1993, J BACTERIOL, V175, P7762, DOI 10.1128/JB.175.24.7762-7770.1993; DWORKIN M, 1993, MYCOBACTERIA, V2; Frank, 1998, FDN SOCIAL EVOLUTION; FRANK SA, 1995, NATURE, V377, P520, DOI 10.1038/377520a0; Garza AG, 2000, MOL MICROBIOL, V35, P812, DOI 10.1046/j.1365-2958.2000.01753.x; Grosberg RK, 1998, TRENDS ECOL EVOL, V13, P112, DOI 10.1016/S0169-5347(97)01313-X; HAGEN DC, 1978, DEV BIOL, V64, P284, DOI 10.1016/0012-1606(78)90079-9; HODGKIN J, 1977, P NATL ACAD SCI USA, V74, P2938, DOI 10.1073/pnas.74.7.2938; KAISER D, 1979, P NATL ACAD SCI USA, V76, P5952, DOI 10.1073/pnas.76.11.5952; KAISER D, 1986, ANNU REV GENET, V20, P539; KROOS L, 1986, DEV BIOL, V117, P252, DOI 10.1016/0012-1606(86)90368-4; KUSPA A, 1989, J BACTERIOL, V171, P2762, DOI 10.1128/jb.171.5.2762-2772.1989; KUSPA A, 1986, DEV BIOL, V117, P267, DOI 10.1016/0012-1606(86)90369-6; LAUE BE, 1995, J BACTERIOL, V177, P4089, DOI 10.1128/jb.177.14.4089-4096.1995; Matapurkar AK, 1997, AM NAT, V150, P790, DOI 10.1086/286094; Maynard Smith J., 1982, pi; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Pellmyr O, 1996, NATURE, V380, P155, DOI 10.1038/380155a0; Reichenbach H, 1993, MYXOBACTERIA, P13; Rosenberg E, 1984, MYXOBACTERIA DEV CEL, P109; SHIMKETS LJ, 1988, MOL GEN GENET, V211, P63, DOI 10.1007/BF00338394; Stoner DS, 1999, P NATL ACAD SCI USA, V96, P9148, DOI 10.1073/pnas.96.16.9148; Szathmary E, 1995, MAJOR TRANSITIONS EV; Turner PE, 1999, NATURE, V398, P441, DOI 10.1038/18913; Velicer GJ, 1998, P NATL ACAD SCI USA, V95, P12376, DOI 10.1073/pnas.95.21.12376; Wall D, 1999, J BACTERIOL, V181, P24, DOI 10.1128/JB.181.1.24-33.1999	30	234	238	1	47	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					598	+		10.1038/35007066	http://dx.doi.org/10.1038/35007066			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766241				2022-12-28	WOS:000086400100052
J	Emsley, J; Knight, CG; Farndale, RW; Barnes, MJ; Liddington, RC				Emsley, J; Knight, CG; Farndale, RW; Barnes, MJ; Liddington, RC			Structural basis of collagen recognition by integrin alpha 2 beta 1	CELL			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-1; CATION-INDEPENDENT ADHESION; I-DOMAIN; DIVALENT-CATION; LIGAND-BINDING; PLATELET-ADHESION; CRYSTAL-STRUCTURE; A-DOMAIN; ALPHA(2)BETA(1) INTEGRIN	We have determined the crystal structure of a complex between the I domain of integrin alpha 2 beta 1 and a triple helical collagen peptide containing a critical GFOGER motif. Three loops on the upper surface of the I domain that coordinate a metal ion also engage the collagen, with a collagen glutamate completing the coordination sphere of the metal. Comparison with the unliganded I domain reveals a change in metal coordination linked to a reorganization of the upper surface that together create a complementary surface for binding collagen. Conformational changes propagate from the upper surface to the opposite pole of the domain, suggesting both a basis for affinity regulation and a pathway for signal transduction. The structural features observed here may represent a general mechanism for integrin-ligand recognition.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Burnham Inst, La Jolla, CA 92037 USA	University of Leicester; University of Cambridge; Sanford Burnham Prebys Medical Discovery Institute	Liddington, RC (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.		emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BILSLAND CAG, 1994, J LEUKOCYTE BIOL, V55, P501, DOI 10.1002/jlb.55.4.501; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Erb EM, 1997, BIOCHEMISTRY-US, V36, P7395, DOI 10.1021/bi9702187; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kadler KE, 1996, BIOCHEM J, V316, P1; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; KERN A, 1994, J BIOL CHEM, V269, P22811; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Liddington R, 1998, STRUCT FOLD DES, V6, P937, DOI 10.1016/S0969-2126(98)00094-X; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; SADLER JE, 1995, THROMB HAEMOSTASIS, V74, P161; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; ZIJENAH LS, 1990, BIOCHEM J, V268, P481, DOI 10.1042/bj2680481	61	809	834	5	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 31	2000	101	1					47	56		10.1016/S0092-8674(00)80622-4	http://dx.doi.org/10.1016/S0092-8674(00)80622-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778855	Bronze			2022-12-28	WOS:000086249900007
J	Difilippantonio, MJ; Zhu, J; Chen, HT; Meffre, E; Nussenzweig, MC; Max, EE; Ried, T; Nussenzweig, A				Difilippantonio, MJ; Zhu, J; Chen, HT; Meffre, E; Nussenzweig, MC; Max, EE; Ried, T; Nussenzweig, A			DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation	NATURE			English	Article							V(D)J RECOMBINATION; MICE; P53; TRANSPOSITION; GROWTH; RAG1; GENE	Cancer susceptibility genes have been classified into two groups: gatekeepers and caretakers(1). Gatekeepers are genes that control cell proliferation and death, whereas caretakers are DNA repair genes whose inactivation leads to genetic instability. Abrogation of both caretaker and gatekeeper function markedly increases cancer susceptibility. Although the importance of Ku80 in DNA double-strand break repair is well established, neither Ku80 nor other components of the non-homologous end-joining pathway are known to have a caretaker role in maintaining genomic stability. Here we show that mouse cells deficient for Ku80 display a marked increase in chromosomal aberrations, including breakage, translocations and aneuploidy. Despite the observed chromosome instabilities, Ku80(-/-) mice have only a slightly earlier onset of cancer(2,3). Loss of p53 synergizes with Ku80 to promote tumorigenesis such that all Ku80(-/-) p53(-/-) mice succumb to disseminated pro-B-cell lymphoma before three months of age. Tumours result from a specific set of chromosomal translocations and gene amplications involving IgH and c-Myc, reminiscent of Burkitt's lymphoma. We conclude that Ku80 is a caretaker gene that maintains the integrity of the genome by a mechanism involving the suppression of chromosomal rearrangements.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Genet, NIH, Bethesda, MD 20892 USA; Rockefeller Inst, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Inst, Howard Hughes Med Inst, New York, NY 10021 USA; US FDA, Lab Cell Regulat, Ctr Biol Evaluat & Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Nussenzweig, A (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.		Difilippantonio, Michael/AAF-2839-2021; Nussenzweig, Michel/AAE-7292-2019	Difilippantonio, Michael/0000-0002-4676-7034; 	Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010298, Z01SC010299] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Chen C, 1998, MOL CELL, V2, P9, DOI 10.1016/S1097-2765(00)80109-4; CHU CC, 1992, P NATL ACAD SCI USA, V89, P6978, DOI 10.1073/pnas.89.15.6978; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GU Y, 1997, IMMUNITY, V7, P367; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TIMME TL, 1994, BIOTECHNIQUES, V17, P462; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	30	440	451	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					510	514		10.1038/35006670	http://dx.doi.org/10.1038/35006670			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761921	Green Accepted			2022-12-28	WOS:000086257700052
J	Bell, S; Kamm, MA				Bell, S; Kamm, MA			Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease	LANCET			English	Editorial Material							INFLAMMATORY BOWEL-DISEASE; AZATHIOPRINE; TERM; CA2		St Marks Hosp, Dept Gastroenterol, Harrow HA1 3UJ, Middx, England	Imperial College London	Bell, S (corresponding author), St Marks Hosp, Dept Gastroenterol, Harrow HA1 3UJ, Middx, England.							Baert FJ, 1999, INT J COLORECTAL DIS, V14, P47, DOI 10.1007/s003840050182; Bickston SJ, 1999, GASTROENTEROLOGY, V117, P1433, DOI 10.1016/S0016-5085(99)70294-5; CONNELL WR, 1994, GUT, V35, P347, DOI 10.1136/gut.35.3.347; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; CONNELL WR, 1993, GUT, V34, P1081, DOI 10.1136/gut.34.8.1081; D'Haens G, 1999, GASTROENTEROLOGY, V116, P1029, DOI 10.1016/S0016-5085(99)70005-3; Dalum I, 1999, NAT BIOTECHNOL, V17, P666, DOI 10.1038/10878; GREENSTEIN AJ, 1992, CANCER-AM CANCER SOC, V69, P1119; Hanauer SB, 1999, GASTROENTEROLOGY, V116, pA731; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Rutgeerts P, 1999, GASTROENTEROLOGY, V117, P761, DOI 10.1016/S0016-5085(99)70332-X; SANDBORN WJ, 1999, GUT, V45, pA133; SCALLON BJ, 1995, CYTOKINE, V7, P251, DOI 10.1006/cyto.1995.0029; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502	15	79	81	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					858	860		10.1016/S0140-6736(99)00442-0	http://dx.doi.org/10.1016/S0140-6736(99)00442-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752696				2022-12-28	WOS:000085896000002
J	Tang, XP; Kleinhammes, A; Shimoda, H; Fleming, L; Bennoune, KY; Sinha, S; Bower, C; Zhou, O; Wu, Y				Tang, XP; Kleinhammes, A; Shimoda, H; Fleming, L; Bennoune, KY; Sinha, S; Bower, C; Zhou, O; Wu, Y			Electronic structures of single-walled carbon nanotubes determined by NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SUPERCONDUCTORS; TUBULES	Single-walled carbon nanotubes were studied by C-13 nuclear magnetic resonance (NMR). Two types of C-13 nuclear spins were identified with different spin-lattice relaxation rates. The fast-relaxing component, assigned to metallic tubes, followed the relaxation behavior expected in metals, and the density-of-states at the Fermi level increased with decreasing tube diameter. The slow-relaxing component has a significantly lower density-of-states at the Fermi level Exposure to oxygen has a substantial effect on relaxation rates of both components.	Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Appl & Mat Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wu, Y (corresponding author), Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA.			Zhou, Otto/0000-0003-1476-5517				ANTROPOV VP, 1993, PHYS REV B, V47, P12373, DOI 10.1103/PhysRevB.47.12373; Kane CL, 1997, PHYS REV LETT, V78, P1932, DOI 10.1103/PhysRevLett.78.1932; Kataura H, 1998, JPN J APPL PHYS 2, V37, pL616, DOI 10.1143/JJAP.37.L616; MINTMIRE JW, 1992, PHYS REV LETT, V68, P631, DOI 10.1103/PhysRevLett.68.631; Mintmire JW, 1998, APPL PHYS A-MATER, V67, P65, DOI 10.1007/s003390050738; Mintmire JW, 1998, PHYS REV LETT, V81, P2506, DOI 10.1103/PhysRevLett.81.2506; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; Pennington CH, 1996, PHYS REV B, V53, pR2967, DOI 10.1103/PhysRevB.53.R2967; Pennington CH, 1996, REV MOD PHYS, V68, P855, DOI 10.1103/RevModPhys.68.855; SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; TYCKO R, 1992, PHYS REV LETT, V68, P1912, DOI 10.1103/PhysRevLett.68.1912; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Winter J., 1971, MAGNETIC RESONANCE M; YILDIRIM T, IN PRESS FULLERENE B; ZHOU O, IN PRESS MOL CRYST L	16	198	220	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					492	494		10.1126/science.288.5465.492	http://dx.doi.org/10.1126/science.288.5465.492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775103				2022-12-28	WOS:000086626000038
J	Segal, H; Hunt, BJ				Segal, H; Hunt, BJ			Aprotinin: pharmacological reduction of perioperative bleeding	LANCET			English	Editorial Material							BLOOD-LOSS; LIVER-TRANSPLANTATION; CARDIAC-SURGERY; TRANSFUSION; NEED		Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England; Guys & St Thomass Trust, Dept Haematol, London SE1 7EH, England; Guys & St Thomass Trust, Dept Rheumatol, London SE1 7EH, England	University of Oxford; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Segal, H (corresponding author), Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England.							CARSON JL, 1988, LANCET, V1, P727; DAVIS R, 1995, DRUGS, V49, P954, DOI 10.2165/00003495-199549060-00008; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; GARCIAHUETE L, 1997, HYEPATOLOGY, V25, P1143; Levi M, 1999, LANCET, V354, P1940, DOI 10.1016/S0140-6736(99)01264-7; MALLETT SV, 1990, LANCET, V336, P886, DOI 10.1016/0140-6736(90)92404-6; ROYSTON D, 1987, LANCET, V2, P1289; SCUDAMORE CH, 1995, AM J SURG, V169, P546, DOI 10.1016/S0002-9610(99)80215-3; WESTABY S, 1993, ANN THORAC SURG, V55, P1033, DOI 10.1016/0003-4975(93)90149-C	9	24	26	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1289	1290		10.1016/S0140-6736(00)02105-X	http://dx.doi.org/10.1016/S0140-6736(00)02105-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776736				2022-12-28	WOS:000086829400003
J	Molinari, M; Helenius, A				Molinari, M; Helenius, A			Chaperone selection during glycoprotein translocation into the endoplasmic reticulum	SCIENCE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; CHAIN BINDING-PROTEIN; SEQUENTIAL INTERACTION; BIP; ASSOCIATION; CALNEXIN; TRANSPORT; SECRETION; GLYCOSYLATION; MATURATION	A variety of molecular chaperones and folding enzymes assist the folding of newly synthesized proteins in the endoplasmic reticulum. Here we investigated why some glycoproteins interact with the molecular chaperone sip, and others with the calnexin/calreticulin pathway. The folding of Semliki forest virus glycoproteins and influenza hemagglutinin was studied in Living cells. The initial choice of chaperone depended on the Location of N-linked glycans in the growing nascent chain. Direct interaction with calnexin and calreticulin without prior interaction with BiP occurred if glycans were present within about 50 residues of the protein's NH2-terminus.	ETH Zurich, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Helenius, A (corresponding author), ETH Zurich, Univ Str 16, CH-8092 Zurich, Switzerland.		Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829				BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; MULVEY M, 1995, J VIROL, V69, P1621, DOI 10.1128/JVI.69.3.1621-1627.1995; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; SU K, 1993, J BIOL CHEM, V268, P14301; Xu AM, 1998, J VIROL, V72, P9865, DOI 10.1128/JVI.72.12.9865-9872.1998; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	21	273	282	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					331	333		10.1126/science.288.5464.331	http://dx.doi.org/10.1126/science.288.5464.331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764645				2022-12-28	WOS:000086454300036
J	Purvis, A; Agapow, PM; Gittleman, JL; Mace, GM				Purvis, A; Agapow, PM; Gittleman, JL; Mace, GM			Nonrandom extinction and the loss of evolutionary history	SCIENCE			English	Article							DIVERSITY; PHYLOGENY; FUTURE	The hierarchical nature of phylogenies means that random extinction of species affects a smaller fraction of higher taxa, and so the total amount of evolutionary history lost may be comparatively slight. However, current extinction risk is not phylogenetically random. We show the potentially severe implications of the clumped nature of threat for the loss of biodiversity. An additional 120 avian and mammalian genera are at risk compared with the number predicted under random extinction. We estimate that the prospective extra Loss of mammalian evolutionary history alone would be equivalent to Losing a monotypic phylum.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, Ascot SL5 7PY, Berks, England; Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA; Zool Soc London, Inst Zool, London NW1 4RY, England	Imperial College London; University of Virginia; Zoological Society of London	Purvis, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.		Mace, Georgina M/I-3072-2016; Purvis, Andy/A-7529-2008	Mace, Georgina M/0000-0001-8965-5211; Purvis, Andy/0000-0002-8609-6204				[Anonymous], 1995, GLOBAL BIODIVERSITY; AVISE JC, 1982, EVOL BIOL, V15, P151; Bennett PM, 1997, P ROY SOC B-BIOL SCI, V264, P401, DOI 10.1098/rspb.1997.0057; Bininda-Emonds ORP, 1999, BIOL REV, V74, P143, DOI 10.1017/S0006323199005307; Crozier RH, 1997, ANNU REV ECOL SYST, V28, P243, DOI 10.1146/annurev.ecolsys.28.1.243; Faith Daniel P., 1994, V50, P251; FAITH DP, 1992, BIOL CONSERV, V61, P1, DOI 10.1016/0006-3207(92)91201-3; Gaston KJ, 1997, EVOL ECOL, V11, P557, DOI 10.1007/s10682-997-1511-4; Heard SB, 2000, P ROY SOC B-BIOL SCI, V267, P613, DOI 10.1098/rspb.2000.1046; IUCN, 1994, IUCN RED LIST CAT; IUCN (International Union for Conservation of Nature), 2021, THE IUCN RED LIST TH, DOI [10.2305/IUCN.UK.2015-2.RLTS.T2446A22156678.en, DOI 10.2305/IUCN.UK.2015-2.RLTS.T2446A22156678.EN]; MACE GM, 1999, FUTURE PRIORITIES CO; MacPhee R.D.E., 1999, P333; MAY RM, 1990, NATURE, V347, P129, DOI 10.1038/347129a0; May Robert M., 1995, P1; Morony JJ, 1975, REFERENCE LIST BIRDS; Musser G G, 1993, MAMMAL SPECIES WORLD; Nee S, 1997, SCIENCE, V278, P692, DOI 10.1126/science.278.5338.692; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; PURVIS A, 1995, PHILOS T ROY SOC B, V348, P405, DOI 10.1098/rstb.1995.0078; Russell GJ, 1998, CONSERV BIOL, V12, P1365, DOI 10.1046/j.1523-1739.1998.96332.x; Rylands Anthony B., 1995, Neotropical Primates, V3, P113; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; Williams Paul H., 1996, P261; Williams Paul H., 1996, P54	25	396	403	3	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 14	2000	288	5464					328	330		10.1126/science.288.5464.328	http://dx.doi.org/10.1126/science.288.5464.328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764644				2022-12-28	WOS:000086454300035
J	Marshall, MN; Shekelle, PG; Leatherman, S; Brook, RH				Marshall, MN; Shekelle, PG; Leatherman, S; Brook, RH			The public release of performance data - What do we expect to gain? A review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NEW-YORK-STATE; BYPASS GRAFT-SURGERY; CARDIAC-SURGERY; QUALITY IMPROVEMENT; OUTCOMES DATA; HEALTH-CARE; MORTALITY; INFORMATION; INDICATORS; CONSUMERS	Context information about the performance of hospitals, health professionals, and health care organizations has been made public in the United States for more than a decade. The expected gains of public disclosure have not been made clear, and both the benefits and potential risks have received minimal empirical investigation. Objective To summarize the empirical evidence concerning public disclosure of performance data, relate the results to the potential gains, and identify areas requiring further research. Data Sources A literature search was conducted on MEDLINE and EMBASE databases for articles published between January 1986 and October 1999 in peer-reviewed journals. Review of citations, public documents, and expert advice was conducted to identify studies not found in the electronic databases. Study Selection Descriptive, observational, or experimental evaluations of CIS reporting systems were selected for inclusion. Data Extraction Included studies were organized based on use of public data by consumers, purchasers, physicians, and hospitals; impact on quality of care outcomes; and costs. Data Synthesis Seven US reporting systems have been the subject of published empirical evaluations. Descriptive and observational methods predominate, Consumers and purchasers rarely search out the information and do not understand or trust it; it has a small, although increasing, impact on their decision making. Physicians are skeptical about such data and only a small proportion makes use of it, Hospitals appear to be most responsive to the data. In a limited number of studies, the publication of performance data has been associated with an improvement in health outcomes. Conclusions There are several potential gains from the public disclosure of performance data, but use of the information by provider organizations for quality improvement may be the most productive area for further research.	Univ Exeter, Sch Postgrad Med & Hlth Sci, Exeter, Devon, England; RAND Hlth Program, Santa Monica, CA USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA; Ctr Hlth Care Policy & Evaluat, United Hlth Grp, Minnetonka, MN USA; Univ Cambridge, Judge Inst Management, Cambridge, England; Univ Calif Los Angeles, Ctr Hlth Serv, Los Angeles, CA USA	University of Exeter; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; UnitedHealth Group Incorporated; University of Cambridge; University of California System; University of California Los Angeles	Marshall, MN (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, 5th Floor,Williamson Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.							Bentley J M, 1998, Jt Comm J Qual Improv, V24, P40; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BROOK RH, 1994, ANN INTERN MED, V120, P84, DOI 10.7326/0003-4819-120-1-199401010-00015; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Davies HTO, 1999, LANCET, V353, P1639, DOI 10.1016/S0140-6736(99)90047-8; Davies HTO, 1998, QUAL HEALTH CARE, V7, P159, DOI 10.1136/qshc.7.3.159; DZIUBAN SW, 1994, ANN THORAC SURG, V58, P1871, DOI 10.1016/0003-4975(94)91730-2; EdgmanLevitan S, 1996, HEALTH AFFAIR, V15, P42, DOI 10.1377/hlthaff.15.4.42; Epstein AM, 1998, JAMA-J AM MED ASSOC, V279, P1691, DOI 10.1001/jama.279.21.1691; GABEL JR, 1998, 293 COMM FUND; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; Goddard M, 1998, NHS PERFORMANCE FRAM; GOLDFIELD N, 1999, JOINT COMM J QUAL IM, V25, P423; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Hannan EL, 1997, MED CARE, V35, P49, DOI 10.1097/00005650-199701000-00004; Hannan EL, 1997, AM HEART J, V134, P55, DOI 10.1016/S0002-8703(97)70106-6; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HIBBARD JH, 1989, MED CARE, V27, P1167, DOI 10.1097/00005650-198912000-00008; Hibbard JH, 1997, HEALTH AFFAIR, V16, P172, DOI 10.1377/hlthaff.16.6.172; Hibbard JH, 1998, HEALTH AFFAIR, V17, P181, DOI 10.1377/hlthaff.17.6.181; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; Jewett JJ, 1996, HEALTH CARE FINANC R, V18, P75; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; Lansky D, 1998, HEALTH AFFAIR, V17, P40, DOI 10.1377/hlthaff.17.4.40; Lansky D, 1996, JOINT COMM J QUAL IM, V22, P439, DOI 10.1016/S1070-3241(16)30246-2; Longo DR, 1997, JAMA-J AM MED ASSOC, V278, P1579, DOI 10.1001/jama.278.19.1579; Luce JM, 1996, WESTERN J MED, V164, P410; MARSHALL MN, PUBLICATION PERFORMA; Mennemeyer ST, 1997, INQUIRY-J HEALTH CAR, V34, P117; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Omoigui NA, 1996, CIRCULATION, V93, P27, DOI 10.1161/01.CIR.93.1.27; Peterson ED, 1998, J AM COLL CARDIOL, V32, P993, DOI 10.1016/S0735-1097(98)00332-5; Rainwater J A, 1998, Jt Comm J Qual Improv, V24, P31; Robinson S, 1997, JOINT COMM J QUAL IM, V23, P239, DOI 10.1016/S1070-3241(16)30313-3; Romano PS, 1999, MED CARE, V37, P295, DOI 10.1097/00005650-199903000-00009; Rosenthal G E, 1998, Jt Comm J Qual Improv, V24, P347; Rosenthal G E, 1997, Am J Med Qual, V12, P103, DOI 10.1177/0885713X9701200204; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; SCHOEN C, 1998, EROSION EMPLOYER SPO; Sirio C A, 1996, Am J Med Qual, V11, pS78; Smith P., 1995, INT J PUBLIC ADMIN, V18, P277, DOI DOI 10.1080/01900699508525011; Thomson R, 1998, QUAL HEALTH CARE, V7, P122, DOI 10.1136/qshc.7.3.122; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011; *US GEN ACC OFF, 1994, US GEN ACC OFF PUBL; VLADECK BC, 1988, HEALTH AFFAIR, V7, P122, DOI 10.1377/hlthaff.7.1.122	50	615	617	0	44	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1866	1874		10.1001/jama.283.14.1866	http://dx.doi.org/10.1001/jama.283.14.1866			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770149				2022-12-28	WOS:000086248600033
J	Yusuf, HR; Akhter, HH; Rahman, MH; Chowdhury, MEEK; Rochat, RW				Yusuf, HR; Akhter, HH; Rahman, MH; Chowdhury, MEEK; Rochat, RW			Injury-related deaths among women aged 10-50 years in Bangladesh, 1996-97	LANCET			English	Article							RURAL BANGLADESH; EPIDEMIOLOGY; DELHI; INDIA	Background Few studies have examined injury-related deaths among women in Bangladesh. We did a case-finding study to identify causes and the impact of intentional and unintentional injury-related deaths among women aged 10-50 years in Bangladesh. Methods Between 1996 and 1997, health care and other service providers at 4751 health facilities throughout Bangladesh were interviewed about their knowledge of deaths among women aged 10-50 years. In addition, at all public facilities providing inpatient service. medical records of women who died during the study period were reviewed. The reported circumstances surrounding each death were carefully reviewed to attribute the most likely cause of death. Findings 28 998 deaths among women aged 10-50 years were identified in our study, and, of these, 6610 (23%) were thought to be caused by intentional or unintentional injuries. About half (3317) of the injury deaths were attributable to suicide, 352 (5%) to homicide, 1100 (17%) to accidental injuries, and the intent was unknown for 1841 (28%) deaths. The unadjusted rate of suicides were higher in the Khulna administrative division (27.0 per 100 000) than the other four administrative divisions of Bangladesh (range 3.5-11.3 per 100 000). Poisoning (n=3971) was the commonest cause of injury-related death-60% of all injury deaths (6610) and 14% of all deaths (28 998). Other common causes of injury deaths in order of frequency were hanging or suffocation, road traffic accidents, bums, drowning, physical assault, firearm or sharp instrument injury, and snake or animal bite. Interpretation Intentional and unintentional injuries are a major cause of death among women aged 10-50 years in Bangladesh. Strategies to reduce injury-related deaths among women need to be devised.	Ctr Dis Control & Prevent, Immunisat Serv Div, Hlth Serv Res & Evaluat Branch, Atlanta, GA 30333 USA; Bangladesh Inst Res & Promot Essential & Reprod H, Dhaka, Bangladesh; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Yusuf, HR (corresponding author), Ctr Dis Control & Prevent, Immunisat Serv Div, Hlth Serv Res & Evaluat Branch, Atlanta, GA 30333 USA.		Rochat, Roger/J-9802-2012					Adityanjee D R, 1986, Int J Soc Psychiatry, V32, P64, DOI 10.1177/002076408603200208; *BANGL BUR STAT, 1994, HDSPUB004 BANGL BUR; *BANGL BUR STAT, 1994, BANGL POP CENS 1991, V1, P98; Bhattacharjee JB, 1996, MED SCI LAW, V36, P194, DOI 10.1177/002580249603600303; FAUVEAU V, 1989, INT J EPIDEMIOL, V18, P139, DOI 10.1093/ije/18.1.139; FAUVEAU V, 1988, B WORLD HEALTH ORGAN, V66, P643; ISLAM S, 1985, WOMEN VICTIMS VIOLEN; KUMAR P, 1994, BURNS, V20, P236, DOI 10.1016/0305-4179(94)90189-9; Latha KS, 1996, ACTA PSYCHIAT SCAND, V94, P26, DOI 10.1111/j.1600-0447.1996.tb09820.x; MAHLER H, 1987, LANCET, V1, P668; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1, P117; NAGPAUL H, 1985, INT J OFFENDER THER, V29, P147, DOI 10.1177/0306624X8502900207; PANDEY R, 1985, INDIAN J SOC WORK, V45, P429; PANDEY R, 1986, SOCIAL DEFENSE, V21, P5; PRASAD BD, 1994, J COMP FAM STUD, V25, P71, DOI 10.3138/jcfs.25.1.71; ROCHAT R W, 1981, International Journal of Gynecology and Obstetrics, V19, P155, DOI 10.1016/0020-7292(81)90056-4; SAHDEV P, 1994, ACCIDENT ANAL PREV, V26, P377, DOI 10.1016/0001-4575(94)90011-6; SHIQING Z, 1994, CRISIS, V15, P44; SMITH GS, 1991, EPIDEMIOL REV, V13, P228, DOI 10.1093/oxfordjournals.epirev.a036070; STEIN S, 1986, INT J EPIDEMIOL, V15, P303; *WHO, 1978, LAY REP HLTH INF; *WHO, 1993, WHO2 REG OFF SE AS	22	41	42	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1220	1224		10.1016/S0140-6736(00)02088-2	http://dx.doi.org/10.1016/S0140-6736(00)02088-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303VX	10770304				2022-12-28	WOS:000086448000011
J	Chong, L; Culotta, E; Sugden, A				Chong, L; Culotta, E; Sugden, A			On the move	SCIENCE			English	Editorial Material																			0	15	16	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					79	79		10.1126/science.288.5463.79	http://dx.doi.org/10.1126/science.288.5463.79			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10766639				2022-12-28	WOS:000086387700033
J	Dalton, R; Cyranoski, D				Dalton, R; Cyranoski, D			Baja peninsula claims five victims in tragic accident	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					533	533		10.1038/35007221	http://dx.doi.org/10.1038/35007221			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766204	Bronze			2022-12-28	WOS:000086400100010
J	Gardin, JM; Schumacher, D; Constantine, G; Davis, KD; Leung, C; Reid, CL				Gardin, JM; Schumacher, D; Constantine, G; Davis, KD; Leung, C; Reid, CL			Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	71st Scientific Session of the American-Heart-Association Meeting	NOV 08-12, 1998	DALLAS, TEXAS	Amer Heart Assoc			APPETITE-SUPPRESSANT DRUGS; STRUCTURALLY NORMAL HEARTS; DOPPLER ECHOCARDIOGRAPHY; FENFLURAMINE-PHENTERMINE; MITRAL REGURGITATION; OBESE PATIENTS; COLOR-DOPPLER; PREVALENCE; INSUFFICIENCY; POPULATION	Context Fenfluramine and dexfenfluramine were voluntarily withdrawn from the market in September 1997 because of reports of an association with heart valve abnormalities. Studies have been limited by lack of comparison with untreated controls. Objective To evaluate cardiovascular status and the prevalence of valvular abnormalities, as assessed by clinical cardiovascular parameters and echocardiography, in patients treated for obesity with dexfenfluramine or phentermine/fenfluramine. Design Reader-blinded controlled study completed in February 1998. Setting and Participants Twenty-five clinical centers in the United States. Of 1640 enrolled subjects, 1473 were eligible (479 and 455 had taken dexfenfluramine and phentermine/fenfluramine, respectively, continuously for 30 days or more in the previous 14 months, and 539 were untreated matched controls) and provided clinical and echocardiographic data. Mean (SD) age was 47.4 (11.4) years, mean body mass index was 35.0 (7.4) kg/m(2), and 74% were women. Mean (SD) duration of therapy was 6.0 (3.3) months (range, 1 - 18.4 months) in the dexfenfluramine group, and 11.9 (10.4) months (range, 1.4-63 months) in the phentermine/fenfluramine group, while the untreated group had no anorexigen use during the previous 5 years. Main Outcome Measures Cardiovascular signs and symptoms; echocardiographic evidence of aortic (AR) or mitral (MR) regurgitation according to US Food and Drug Administration (FDA) criteria (AR greater than or equal to mild or MR greater than or equal to moderate) and by grade; tricuspid and pulmonic valve regurgitation; and aortic, mitral, and tricuspid valve leaflet mobility and thickness, for treated vs untreated subjects. Results Cardiovascular signs and symptoms were similar among anorexigen-treated and untreated subjects. Prevalence rates and relative risk (RR) of AR were significantly increased in anorexigen-treated patients and were 8.9% in the dexfenfluramine group (RR, 2.18; 95% confidence interval [CI], 1.32-3.59), 13.7% in the phentermine/fenfluramine group (RR, 3.34; 95% CI, 2.09-5.35), and 4.1% in the untreated group (P<.001). No statistically significant differences in prevalence were observed for MR, thickening or decreased mobility of any valve leaflet, calculated pulmonary artery systolic pressure, or left ventricular ejection fraction. Serious cardiac events (including myocardial infarction, congestive heart failure, or ventricular arrhythmia) occurring at any time were not statistically different in treated and untreated subjects (dexfenfluramine, 9.0%; phentermine/fenfluramine, 4.0%; and untreated, 8.4%); and following anorexigen treatment were uncommon (dexfenfluramine, 2.3%; phentermine/fenfluramine, 2.4%,and untreated, 3.3%, when adjusted for the median start date of anorexigen use). Conclusions Our data indicate that use of dexfenfluramine and phentermine/ fenfluramine is associated with an increase in the prevalence of AR using FDA echocardiographic criteria, but was not associated with an increase in the prevalence of MR using FDA criteria or with serious cardiac events.	Univ Calif Irvine, Med Ctr, Div Cardiol, Orange, CA 92868 USA; Ctr Nutr & Prevent Med, Charlotte, NC USA; Wyeth Ayerst Res, Philadelphia, PA USA	University of California System; University of California Irvine; Pfizer	Gardin, JM (corresponding author), Univ Calif Irvine, Med Ctr, Div Cardiol, Bldg 53,Rte 81,Room 100,101 City Dr S, Orange, CA 92868 USA.							AKASAKA T, 1987, CIRCULATION, V76, P262, DOI 10.1161/01.CIR.76.2.262; Aronow WS, 1997, AM J CARDIOL, V79, P379, DOI 10.1016/S0002-9149(96)00769-2; Biava G, 1997, CORONARY ARTERY DIS, V8, P559; BONOW RO, 1985, CIRCULATION, V72, P1244, DOI 10.1161/01.CIR.72.6.1244; Burger AJ, 1999, J AM COLL CARDIOL, V34, P1153, DOI 10.1016/S0735-1097(99)00321-6; Cannistra LB, 1997, NEW ENGL J MED, V337, P636, DOI 10.1056/NEJM199708283370912; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1061; CHOONG CY, 1989, AM HEART J, V117, P636, DOI 10.1016/0002-8703(89)90739-4; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; *FDA, 1998, FDA AN CARD VALV DYS; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; Graham DJ, 1997, NEW ENGL J MED, V337, P635, DOI 10.1056/NEJM199708283370911; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; Khan MA, 1998, NEW ENGL J MED, V339, P713, DOI 10.1056/NEJM199809103391101; Klein A L, 1990, J Am Soc Echocardiogr, V3, P54; Kurz X, 1997, NEW ENGL J MED, V337, P1772; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; Rasmussen S, 1997, NEW ENGL J MED, V337, P1773; REID CL, 1994, CIRCULATION, V90, P282; SHIVELY B K, 1990, Journal of the American College of Cardiology, V15, p187A; SINGH JP, 1998, J AM SOC ECHOCARDIOG, V11, P509; Weissman NJ, 1998, NEW ENGL J MED, V339, P725, DOI 10.1056/NEJM199809103391103; *WYETH LAB, 1998, RED PACK INS; *WYETH LAB, 1998, POND PACK INS; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657	26	120	121	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1703	1709		10.1001/jama.283.13.1703	http://dx.doi.org/10.1001/jama.283.13.1703			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BK	10755496	Bronze			2022-12-28	WOS:000086119300030
J	El-Omar, EM; Carrington, M; Chow, WH; McColl, KEL; Bream, JH; Young, HA; Herrera, J; Lissowska, J; Yuan, CC; Rothman, N; Lanyon, G; Martin, M; Fraumeni, JF; Rabkin, CS				El-Omar, EM; Carrington, M; Chow, WH; McColl, KEL; Bream, JH; Young, HA; Herrera, J; Lissowska, J; Yuan, CC; Rothman, N; Lanyon, G; Martin, M; Fraumeni, JF; Rabkin, CS			Interleukin-1 polymorphisms associated with increased risk of gastric cancer	NATURE			English	Article							HELICOBACTER-PYLORI INFECTION; NECROSIS-FACTOR-ALPHA; DUODENAL-ULCER DISEASE; ACID-SECRETION; RECEPTOR; CELLS; PATHWAYS	Helicobacter pylori infection is associated with a variety of clinical outcomes including gastric cancer and duodenal ulcer disease(1). The reasons for this variation are not clear, but the gastric physiological response is influenced by the severity and anatomical distribution of gastritis induced by H. pylori. Thus, individuals with gastritis predominantly localized to the antrum retain normal (or even high) acid secretion(2), whereas individuals with extensive corpus gastritis develop hypochlorhydria and gastric atrophy(3), which are presumptive precursors of gastric cancer(4). Here we report that interleukin-1 gene cluster polymorphisms suspected of enhancing production of interleukin-1-beta are associated with an increased risk of both hypochlorhydria induced by H. pylori and gastric cancer. Two of these polymorphism are hi near-complete linkage disequilibrium and one is a TATA-box polymorphism that markedly affects DNA-protein interactions in vitro. The association with disease may be explained by the biological properties of interleukin-1-beta, which is an important pro-inflammatory cytokine(5) and a powerful inhibitor of gastric acid secretion(6,7). Host genetic factors that affect interleukin-1-beta may determine why some individuals infected with H. pylori develop gastric cancer while others do not.	NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland; NCI, Intramural Res Support Program, Sci Applicat Int Corp Frederick, Frederick Canc Res & Dev Ctr, Bethesda, MD 20892 USA; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; NCI, Div Basic Sci, Frederick Canc Res & Dev Ctr, Bethesda, MD 20892 USA; M Sklodowska Curie Inst Oncol, Warsaw, Poland; Ctr Canc, Div Canc Epidemiol & Prevent, Warsaw, Poland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Aberdeen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Glasgow; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Maria Sklodowska-Curie National Research Institute of Oncology	El-Omar, EM (corresponding author), NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.	elomare@mail.nih.gov	Lissowska, Jolanta/AAH-3252-2020; Garza-González, Elvira/B-7569-2009; El-Omar, Emad/AAT-7780-2021; Young, Howard/A-6350-2008	Lissowska, Jolanta/0000-0003-2695-5799; El-Omar, Emad/0000-0002-0011-3924; Young, Howard/0000-0002-3118-5111; Bream, Jay/0000-0002-9149-7643	NATIONAL CANCER INSTITUTE [Z01CP010136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000732] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andus T, 1997, GUT, V41, P651, DOI 10.1136/gut.41.5.651; Basso D, 1996, INT J CLIN LAB RES, V26, P207, DOI 10.1007/BF02592984; Beales ILP, 1998, GUT, V42, P227, DOI 10.1136/gut.42.2.227; BIDWELL JL, CYTOKINE GENE POLYM; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; CARRINGTON M, 1992, HUM IMMUNOL, V33, P208, DOI 10.1016/0198-8859(92)90073-V; Chow WH, 1999, INT J CANCER, V81, P871, DOI 10.1002/(SICI)1097-0215(19990611)81:6&lt;871::AID-IJC6&gt;3.0.CO;2-#; CORREA P, 1992, CANCER RES, V52, P6735; Cox A, 1998, AM J HUM GENET, V62, P1180, DOI 10.1086/301817; DANIS VA, 1995, CLIN EXP IMMUNOL, V99, P303; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; El-Omar EM, 2000, GASTROENTEROLOGY, V118, P22, DOI 10.1016/S0016-5085(00)70410-0; ElOmar EM, 1997, GASTROENTEROLOGY, V113, P15, DOI 10.1016/S0016-5085(97)70075-1; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; Jung HC, 1997, J GASTROEN HEPATOL, V12, P473, DOI 10.1111/j.1440-1746.1997.tb00469.x; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; NOACH LA, 1994, SCAND J GASTROENTERO, V29, P425, DOI 10.3109/00365529409096833; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; ROYALL RM, 1986, INT STAT REV, V54, P221, DOI 10.2307/1403146; RUIZ B, 1994, AM J GASTROENTEROL, V89, P533; SANTODONATO J, 1981, J ENVIRON PATHOL TOX, V5, P1; SIPPONEN P, 1994, SCAND J GASTROENTERO, V29, P24, DOI 10.3109/00365529409105356; STOCKBRUEGGER RW, 1984, SCAND J GASTROENTERO, V19, P355, DOI 10.1080/00365521.1984.12005735; Tountas NA, 1999, GASTROENTEROLOGY, V117, P806, DOI 10.1016/S0016-5085(99)70338-0; WALLACE JL, 1991, AM J PHYSIOL, V261, pG559, DOI 10.1152/ajpgi.1991.261.4.G559; Wolfe M M, 1992, Gastroenterology, V102, P2177; Yamaoka Y, 1999, J CLIN MICROBIOL, V37, P2274, DOI 10.1128/JCM.37.7.2274-2279.1999; Yu CR, 1996, J IMMUNOL, V157, P126	30	1801	1914	2	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					398	402		10.1038/35006081	http://dx.doi.org/10.1038/35006081			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746728	Green Published, Green Accepted			2022-12-28	WOS:000086119000053
J	Gu, L; Tseng, S; Horner, RM; Tam, C; Loda, M; Rollins, BJ				Gu, L; Tseng, S; Horner, RM; Tam, C; Loda, M; Rollins, BJ			Control of T(H)2 polarization by the chemokine monocyte chemoattractant protein-1	NATURE			English	Article							T-LYMPHOCYTES; CHEMOTACTIC RESPONSIVENESS; TRANSGENIC MICE; CELL-LINE; EXPRESSION; RECEPTOR; INDUCTION; CLONING; PURIFICATION; RECRUITMENT	Activated T lymphocytes differentiate into effector cells tailored to meet disparate challenges to host integrity(1). For example, type 1 and type 2 helper (T(H)1 and T(H)2) cells secrete cytokines that enhance cell-mediated and humoral immunity, respectively. The chemokine monocyte chemoattractant protein-1 (MCP-1) can stimulate interleukin-4 production(2) and its overexpression is associated with defects in cell-mediated immunity(3), indicating that it might be involved in T(H)2 polarization. Here we show that MCP-1-deficient mice are unable to mount T(H)2 responses. Lymph node cells from immunized MCP-1(-/-) mice synthesize extremely low levels of interleukin-4, interleukin-5 and interleukin-10, but normal amounts of interferon-gamma and interleukin-2. Consequently, these mice do not accomplish the immunoglobulin subclass switch that is characteristic of T(H)2 responses and are resistant to Leishmania major. These effects are direct rather than due to abnormal cell migration, because the trafficking of naive T cells is undisturbed in MCP-1(-/-) mice despite the presence of MCP-1-expressing cells in secondary lymphoid organs of wild-type mice. Thus, MCP-1 influences both innate immunity, through effects on monocytes, and adaptive immunity, through control of T helper cell polarization.	Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Rollins, BJ (corresponding author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.			Tam-Amersdorfer, Carmen/0000-0003-3123-6342				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHENSUE SW, 1995, AM J PATHOL, V146, P130; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; FUENTES ME, 1995, J IMMUNOL, V155, P5769; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Gunn MD, 1997, J IMMUNOL, V158, P376; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Karpus WJ, 1997, J IMMUNOL, V158, P4129; Karpus WJ, 1998, J EXP MED, V187, P733, DOI 10.1084/jem.187.5.733; Kelder W, 1998, ANN NEUROL, V44, P831, DOI 10.1002/ana.410440521; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; MAGHAZACHI AA, 1994, J IMMUNOL, V153, P4969; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; NAKAMURA K, 1995, J INVEST DERMATOL, V105, P635, DOI 10.1111/1523-1747.ep12324061; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; RUTLEDGE BJ, 1995, J IMMUNOL, V155, P4838; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Schecter AD, 1997, J BIOL CHEM, V272, P28568, DOI 10.1074/jbc.272.45.28568; Warmington KS, 1999, AM J PATHOL, V154, P1407, DOI 10.1016/S0002-9440(10)65394-1; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449	30	691	719	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					407	411		10.1038/35006097	http://dx.doi.org/10.1038/35006097			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746730				2022-12-28	WOS:000086119000055
J	Thanassi, WT; Schoen, RT				Thanassi, WT; Schoen, RT			The Lyme disease vaccine: Conception, development, and implementation	ANNALS OF INTERNAL MEDICINE			English	Review							OUTER-SURFACE PROTEIN; BORRELIA-BURGDORFERI OSPA; IMMUNOGLOBULIN-G RESPONSE; EXPERIMENTAL-INFECTION; TREATMENT-RESISTANT; RECOMBINANT OSPA; RHESUS-MONKEY; UNITED-STATES; A OSPA; ARTHRITIS	In the past 20 years, remarkable strides have been made toward understanding and preventing Lyme disease in humans. In December 1998, the U.S. Food and Drug Administration approved a recombinant outer surface protein A vaccine against Lyme disease (LYMErix. SmithKline Beecham, Philadelphia, Pennsylvania). The vaccine, which is derived from a lipidated outer surface protein of the causative spirochete Borrelia burgdorferi, is important because it may decrease the morbidity and financial costs associated with Lyme disease. Its mechanism is unique because it works inside the tick vector itself, preventing the human from becoming infected.	Yale Univ, Sch Med, Sect Emergency Med, New Haven, CT 06519 USA	Yale University	Thanassi, WT (corresponding author), Yale Univ, Sch Med, Sect Emergency Med, 464 Congress Ave, New Haven, CT 06519 USA.			Todaro Thanassi, Wendy/0000-0003-4187-0777				ABERER E, 1989, ANN NEUROL, V26, P732, DOI 10.1002/ana.410260608; Afzelius A., 1910, ARCH DERM SYPH-BERL, P405; [Anonymous], 1999, MED LETT DRUGS THER, V41, P29; AYDINTUG MK, 1994, INFECT IMMUN, V62, P4929, DOI 10.1128/IAI.62.11.4929-4937.1994; Barbour AG, 1996, J INFECT DIS, V173, P403, DOI 10.1093/infdis/173.2.403; BARTHOLD SW, 1990, J INFECT DIS, V162, P133, DOI 10.1093/infdis/162.1.133; BARTHOLD SW, 1991, AM J PATHOL, V139, P263; BARTHOLD SW, 1995, INFECT IMMUN, V63, P2255, DOI 10.1128/IAI.63.6.2255-2261.1995; BERAN J, 1998, INFECT DIS SOC AM, P75; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Busch U, 1996, J CLIN MICROBIOL, V34, P1072, DOI 10.1128/JCM.34.5.1072-1078.1996; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; CHANG YF, 1995, INFECT IMMUN, V63, P3543, DOI 10.1128/IAI.63.9.3543-3549.1995; CHU HJ, 1992, J AM VET MED ASSOC, V201, P403; CLARK JR, 1985, LARYNGOSCOPE, V95, P1341; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; deSilva AM, 1996, J EXP MED, V183, P271, DOI 10.1084/jem.183.1.271; Dotevall L, 1996, INFECTION, V24, P125, DOI 10.1007/BF01713316; EDELMAN R, 1991, VACCINE, V9, P531, DOI 10.1016/0264-410X(91)90236-Y; ERDILE LF, 1993, INFECT IMMUN, V61, P81, DOI 10.1128/IAI.61.1.81-90.1993; Evans Janine, 1996, Current Opinion in Rheumatology, V8, P327, DOI 10.1097/00002281-199607000-00009; FIKRIG E, 1992, J IMMUNOL, V148, P2256; FIKRIG E, 1992, INFECT IMMUN, V60, P773, DOI 10.1128/IAI.60.3.773-777.1992; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; GERN L, 1993, J INFECT DIS, V167, P971, DOI 10.1093/infdis/167.4.971; GREENE RT, 1988, J CLIN MICROBIOL, V26, P648, DOI 10.1128/JCM.26.4.648-653.1988; JOHNSON RC, 1986, INFECT IMMUN, V54, P897, DOI 10.1128/IAI.54.3.897-898.1986; JOHNSON RC, 1986, INFECT IMMUN, V53, P713, DOI 10.1128/IAI.53.3.713-714.1986; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; KELLER D, 1994, JAMA-J AM MED ASSOC, V271, P1764, DOI 10.1001/jama.271.22.1764; Lane RS, 1998, J PARASITOL, V84, P29, DOI 10.2307/3284524; LENGLJANSSEN B, 1994, J EXP MED, V180, P2069, DOI 10.1084/jem.180.6.2069; LISSMAN BA, 1984, J AM VET MED ASSOC, V185, P219; LOVRICH SD, 1995, INFECT IMMUN, V63, P2113, DOI 10.1128/IAI.63.6.2113-2119.1995; Maes E, 1998, CLIN THER, V20, P993, DOI 10.1016/S0149-2918(98)80081-7; MARKS D, 1994, 6 INT C LYM BORR; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; Mathiesen DA, 1997, J INFECT DIS, V175, P98, DOI 10.1093/infdis/175.1.98; Matuschka FR, 1996, J INFECT DIS, V174, P424, DOI 10.1093/infdis/174.2.424; MONTGOMERY RR, 1994, J INFECT DIS, V170, P890, DOI 10.1093/infdis/170.4.890; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; PARENTI D, 1998, INFECT DIS SOC AM, P705; PARENTI D, 1998, INFECT DIS SOC AM, P704; PAVIA CS, 1991, J INFECT DIS, V163, P656, DOI 10.1093/infdis/163.3.656; Pham TN, 1998, J BIOMOL NMR, V11, P407, DOI 10.1023/A:1008246908142; Philipp MT, 1997, VACCINE, V15, P1872, DOI 10.1016/S0264-410X(97)00133-3; ROEHRIG JT, 1992, J IMMUNOL, V149, P3648; SCHAIBLE UE, 1990, P NATL ACAD SCI USA, V87, P3768, DOI 10.1073/pnas.87.10.3768; SCHOEN RT, 1995, J INFECT DIS, V172, P1324, DOI 10.1093/infdis/172.5.1324; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; Seiler KP, 1996, CURR OPIN IMMUNOL, V8, P503, DOI 10.1016/S0952-7915(96)80038-0; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SIGAL LH, 1993, J INFECT DIS, V167, P1372, DOI 10.1093/infdis/167.6.1372; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; *SO CONN DEP HLTH, 1995, CONN EP, V15, P13; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; SZCZEPANSKI A, 1991, MICROBIOL REV, V55, P21, DOI 10.1128/MMBR.55.1.21-34.1991; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; Tsai T F, 1989, Conn Med, V53, P324; Van Hoecke C, 1999, CLIN INFECT DIS, V28, P1260, DOI 10.1086/514779; VANHOECKE C, 1994, 34 INT C ANT AG CHEM; VANHOECKE C, 1994, 6 INT C LYM BORR; Vasiliu V, 1998, MED MICROBIOL IMMUN, V187, P97, DOI 10.1007/s004300050079; Wallich R, 1996, INFECTION, V24, P396, DOI 10.1007/BF01716093; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042; Young JD, 1998, NEW ENGL J MED, V338, P1629, DOI 10.1056/NEJM199805283382216; 1997, MMWR MORB MORTAL WKL, V45, P1; 1999, MMWR MORB MORTAL WKL, V48, P1	74	36	39	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					661	668		10.7326/0003-4819-132-8-200004180-00009	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766685				2022-12-28	WOS:000086497500008
J	Buchan, J; Edwards, N				Buchan, J; Edwards, N			Nursing numbers in Britain: the argument for workforce planning	BRITISH MEDICAL JOURNAL			English	Article									Queen Margaret Univ, Fac Social Sci & Hlth Care, Edinburgh EH12 8TS, Midlothian, Scotland; NHS Confederat, Policy, London SW1P 4ND, England	Queen Margaret University	Buchan, J (corresponding author), Queen Margaret Univ, Fac Social Sci & Hlth Care, Edinburgh EH12 8TS, Midlothian, Scotland.							BUCHAN J, 1998, NURSES WORK ANAL UK; BUCHAN J, 2000, HLTH SERVICE J  0106, P20; *DEP HLTH, 1999, GUID INT NURS RECR; *DEP HLTH, 1999, STAT B; *HOUS COMM SEL COM, 1999, 3 HOUS COMM SEL COMM	5	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1067	1070		10.1136/bmj.320.7241.1067	http://dx.doi.org/10.1136/bmj.320.7241.1067			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764372	Green Published, Green Submitted			2022-12-28	WOS:000086675700030
J	Vella, K; Goldfrad, C; Rowan, K; Bion, J; Black, N				Vella, K; Goldfrad, C; Rowan, K; Bion, J; Black, N			Use of consensus development to establish national research priorities in critical care	BRITISH MEDICAL JOURNAL			English	Article							DELPHI	Objectives To test the Feasibility of using a nominal group technique to establish clinical and health services research priorities in critical care and to test the representativeness of the group's views. Design Generation of topics by means of a national survey a nominal group technique to establish the level of consensus: a survey to test the representativeness of the results. Setting United Kingdom and Republic of Ireland. Subjects Nominal group composed of 10 doctors (8 consultants, 2 trainees) and 2 nurses. Main outcome measure Level of support (median) and level of agreement (mean absolute deviation from the median) derived from a 9 point Likert scale. Results Of the 325 intensive care units approached. 187 (58%) responded, providing about 1000 suggestions for research Of the 106 most frequently suggested topics considered by the nominal group. 37 attracted strong support. 48 moderate support and 21 weak support. There was more agreement after the group had met-overall mean of the mean absolute deviations from the median fell from 1.41 to 1.26. The group's views represented the views of the wider community of critical care staff (r = 0.73, P < 0.01). There was no significant difference in the views of staff from teaching or from non-teaching hospitals. Of the 37 topics that attracted the strongest support, 24 were concerned with organisational aspects of critical care and only 13 with technology assessment or clinical research. Conclusions A nominal group technique is feasible and reliable for determining research priorities among clinicians. This approach is more democratic and transparent than the traditional methods used by research funding bodies. The results suggest that clinicians perceive research into the best ways of delivering and organising services as a high priority.	London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England; Intens Care & Natl Audit & Res Ctr, London WC1H 9HR, England; Univ Birmingham, Dept Anaesthesia & Intens Care, Birmingham B15 2TH, W Midlands, England	University of London; London School of Hygiene & Tropical Medicine; Intensive Care National Audit & Research Centre; University of Birmingham	Black, N (corresponding author), London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.			Bion, Julian/0000-0003-0344-5403				Ayanian JZ, 1998, NEW ENGL J MED, V338, P1896, DOI 10.1056/NEJM199806253382608; Black N, 1999, J Health Serv Res Policy, V4, P236; BOND S, 1982, J ADV NURS, V7, P565, DOI 10.1111/j.1365-2648.1982.tb00277.x; Brittenham GM, 1998, ANN INTERN MED, V129, P993, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00011; Harrington JM, 1996, OCCUP ENVIRON MED, V53, P642, DOI 10.1136/oem.53.9.642; LINDEMAN CA, 1975, NURS RES, V24, P434, DOI 10.1097/00006199-197511000-00006; Mootz RD, 1997, J MANIP PHYSIOL THER, V20, P201; Rudy S F, 1996, ORL Head Neck Nurs, V14, P16; Schmidt K, 1997, J Pediatr Nurs, V12, P201, DOI 10.1016/S0882-5963(97)80002-4; Sedlak C, 1998, Orthop Nurs, V17, P51; THOMAS B, 1983, J NURS EDUC, V22, P335; vanderBeek AJ, 1997, OCCUP ENVIRON MED, V54, P504, DOI 10.1136/oem.54.7.504	12	123	124	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					976	980		10.1136/bmj.320.7240.976	http://dx.doi.org/10.1136/bmj.320.7240.976			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303XP	10753149	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000086453100022
J	Kim, S; Wadsworth, WG				Kim, S; Wadsworth, WG			Positioning of longitudinal nerves in C-elegans by nidogen	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GLR-1 GLUTAMATE-RECEPTOR; EPITHELIAL MORPHOGENESIS; BASEMENT-MEMBRANES; AXON GUIDANCE; IN-VITRO; LAMININ; COLLAGEN; BINDING; MIGRATIONS	Basement membranes can help determine pathways of migrating axons. Although members of the nidogen (entactin) protein family are structural components of basement membranes, we find that nidogen is not required for basement membrane assembly in the nematode Caenorhabditis elegans. Nidogen is Localized to body wall basement membranes and is required to direct longitudinal nerves dorsoventrally and to direct axons at the midlines. By examining migration of a single axon in vivo, we show that nidogen is required for the axon to switch from circumferential to Longitudinal migration. Specialized basement membranes may thus regulate nerve position.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wadsworth, WG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol, Piscataway, NJ 08854 USA.		Wadsworth, William G/N-7866-2014	Wadsworth, William G/0000-0003-3824-2948				Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colavita A, 1998, SCIENCE, V281, P706, DOI 10.1126/science.281.5377.706; EKBLOM P, 1994, DEVELOPMENT, V120, P2003; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Kadoya Y, 1997, DEVELOPMENT, V124, P683; Kim S, 1999, DEVELOPMENT, V126, P3881; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; Mayer U, 1998, ANN NY ACAD SCI, V857, P130, DOI 10.1111/j.1749-6632.1998.tb10113.x; Mello C, 1995, METHOD CELL BIOL, V48, P451; Moerman DG, 1996, DEV BIOL, V173, P228, DOI 10.1006/dbio.1996.0019; NICOSIA RF, 1994, DEV BIOL, V164, P197, DOI 10.1006/dbio.1994.1191; Ren XC, 1999, J NEUROBIOL, V39, P107, DOI 10.1002/(SICI)1097-4695(199904)39:1&lt;107::AID-NEU9&gt;3.0.CO;2-7; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; Seydoux G, 1995, METHOD CELL BIOL, V48, P323; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YELIAN FD, 1993, J CELL BIOL, V121, P923, DOI 10.1083/jcb.121.4.923; [No title captured]	30	84	95	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					150	154		10.1126/science.288.5463.150	http://dx.doi.org/10.1126/science.288.5463.150			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753123				2022-12-28	WOS:000086387700055
J	Porter, EA; Wang, XF; Lee, HS; Weisblum, B; Gellman, SH				Porter, EA; Wang, XF; Lee, HS; Weisblum, B; Gellman, SH			Antibiotics - Non-haemolytic beta-amino-acid oligomers	NATURE			English	Article							PEPTIDES		Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Porter, EA (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.		Lee, Hee-Seung/C-1627-2011					Appella DH, 1997, NATURE, V387, P381, DOI 10.1038/387381a0; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; DeGrado WF, 1999, J PEPT RES, V54, P206, DOI 10.1034/j.1399-3011.1999.00131.x; Gellman SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/ar960298r; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; Hamuro Y, 1999, J AM CHEM SOC, V121, P12200, DOI 10.1021/ja992728p; Hintermann T, 1997, CHIMIA, V51, P244; Oren Z, 1998, BIOPOLYMERS, V47, P451; SABERWAL G, 1994, BBA-REV BIOMEMBRANES, V1197, P109, DOI 10.1016/0304-4157(94)90002-7; SEEBACH D, 1997, J CHEM SOC CHEM COMM, P2015, DOI DOI 10.1039/A704933A; Werder M, 1999, HELV CHIM ACTA, V82, P1774; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	14	621	642	1	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					565	565		10.1038/35007145	http://dx.doi.org/10.1038/35007145			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766230	Bronze			2022-12-28	WOS:000086400100041
J	Albarede, F; Blichert-Toft, J; Vervoort, JD; Gleason, JD; Rosing, M				Albarede, F; Blichert-Toft, J; Vervoort, JD; Gleason, JD; Rosing, M			Hf-Nd isotope evidence for a transient dynamic regime in the early terrestrial mantle	NATURE			English	Article							EARLY EARTH DIFFERENTIATION; ARCHEAN MANTLE; EVOLUTION; CRUST; SYSTEMATICS; CONSTRAINTS; CHONDRITES; BASALTS; MODELS; LU-176	Modern basalts have seemingly lost all 'memory' of the primitive Earth's mantle except for an ambiguous isotopic signal observed in some rare gases(1,2). Although the Earth is expected to have reached a thermal steady state within several hundred million years (refs 3, 4) of accretion, it is not known how and when the initial chemical fractionations left over from planetary accretion (and perhaps a stage involving a magma ocean) were overshadowed by fractionations imposed by modern-style geodynamics. Because of the lack of samples older than 4 Gyr, this early dynamic regime of the Earth is poorly understood. Here we compare published Hf-Nd isotope data on supracrustals from Isua, Greenland, with similar data on lunar rocks and the SNC (martian) meteorites, and show that, about 3.8 Gyr ago, the geochemical signature of the Archaean mantle was partly inherited from the initial differentiation of the Earth. The observed features seem to indicate that the planet at that time was still losing a substantial amount of primordial heat. The survival of remnants from an early layering in the modern deep mantle may account for some unexplained seismological, thermal and geochemical characteristics of the Earth as observed today.	Ecole Normale Super Lyon, F-69364 Lyon 7, France; Univ Arizona, Tucson, AZ 85721 USA; Geol Museum, DK-1350 Copenhagen K, Denmark	Ecole Normale Superieure de Lyon (ENS de LYON); University of Arizona	Albarede, F (corresponding author), Ecole Normale Super Lyon, 46 Allee Italie, F-69364 Lyon 7, France.		Blichert-Toft, Janne/C-8280-2012; Albarede, Francis/A-8871-2011; Vervoort, Jeff/AAJ-6234-2020; Rosing, Minik/A-9977-2013	Blichert-Toft, Janne/0000-0002-4932-4079; Albarede, Francis/0000-0003-1994-1428; Rosing, Minik/0000-0001-7559-661X; Vervoort, Jeff/0000-0002-1138-4527				Beard BL, 1998, GEOCHIM COSMOCHIM AC, V62, P525, DOI 10.1016/S0016-7037(97)00373-6; BENNETT VC, 1993, EARTH PLANET SC LETT, V119, P299, DOI 10.1016/0012-821X(93)90140-5; Blichert-Toft J, 1999, GEOCHIM COSMOCHIM AC, V63, P3901, DOI 10.1016/S0016-7037(99)00183-0; Blichert-Toft J, 1999, EARTH PLANET SC LETT, V173, P25, DOI 10.1016/S0012-821X(99)00222-8; Blichert-Toft J, 1999, EARTH PLANET SC LETT, V171, P439, DOI 10.1016/S0012-821X(99)00151-X; BLICHERTTOFT J, 1994, SCIENCE, V263, P1593, DOI 10.1126/science.263.5153.1593; BlichertToft J, 1997, EARTH PLANET SC LETT, V148, P243, DOI 10.1016/S0012-821X(97)00040-X; BOWRING SA, 1995, SCIENCE, V269, P1535, DOI 10.1126/science.7667634; CHASE CG, 1988, EARTH PLANET SC LETT, V91, P66, DOI 10.1016/0012-821X(88)90151-3; CHRISTENSEN UR, 1985, J GEOPHYS RES-SOLID, V90, P2995, DOI 10.1029/JB090iB04p02995; DALMASSO J, 1992, APPL RADIAT ISOTOPES, V43, P69, DOI 10.1016/0883-2889(92)90078-S; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; Gruau G, 1996, CHEM GEOL, V133, P225, DOI 10.1016/S0009-2541(96)00092-7; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; HONDA M, 1991, NATURE, V349, P149, DOI 10.1038/349149a0; Ishii M, 1999, SCIENCE, V285, P1231, DOI 10.1126/science.285.5431.1231; JACOBSEN SB, 1980, EARTH PLANET SC LETT, V50, P139, DOI 10.1016/0012-821X(80)90125-9; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Lee DC, 1997, NATURE, V388, P854, DOI 10.1038/42206; MCDONOUGH WF, 1991, PHILOS T ROY SOC A, V335, P407, DOI 10.1098/rsta.1991.0055; Nir-El Y, 1998, APPL RADIAT ISOTOPES, V49, P1653, DOI 10.1016/S0969-8043(97)10007-0; Nutman AP, 1996, PRECAMBRIAN RES, V78, P1, DOI 10.1016/0301-9268(95)00066-6; NYQUIST LE, 1992, GEOCHIM COSMOCHIM AC, V56, P2213, DOI 10.1016/0016-7037(92)90185-L; ROSING MT, 1990, GEOCHIM COSMOCHIM AC, V54, P1337, DOI 10.1016/0016-7037(90)90158-H; Salters VJM, 1998, CHEM GEOL, V145, P447, DOI 10.1016/S0009-2541(97)00154-X; SCHUBERT G, 1980, J GEOPHYS RES, V85, P2531, DOI 10.1029/JB085iB05p02531; SHIREY SB, 1986, GEOCHIM COSMOCHIM AC, V50, P2631, DOI 10.1016/0016-7037(86)90215-2; STAUDACHER T, 1982, EARTH PLANET SC LETT, V60, P389, DOI 10.1016/0012-821X(82)90075-9; Unruh D. M., 1984, Journal of Geophysical Research, V89, P459, DOI 10.1029/JB089iS02p0B459; Vervoort JD, 1999, EARTH PLANET SC LETT, V168, P79, DOI 10.1016/S0012-821X(99)00047-3; Vervoort JD, 1999, GEOCHIM COSMOCHIM AC, V63, P533, DOI 10.1016/S0016-7037(98)00274-9; Vervoort JD, 1996, NATURE, V379, P624, DOI 10.1038/379624a0; [No title captured]	34	50	50	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					488	490		10.1038/35006621	http://dx.doi.org/10.1038/35006621			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761914				2022-12-28	WOS:000086257700045
J	Hasinger, G				Hasinger, G			X-ray astronomy - Peeking into the obscured Universe	NATURE			English	Editorial Material									Astrophys Inst Potsdam, D-14482 Potsdam, Germany		Hasinger, G (corresponding author), Astrophys Inst Potsdam, Sternwarte 16, D-14482 Potsdam, Germany.							COMASTRI A, 1995, ASTRON ASTROPHYS, V296, P1; HASINGER G, IN PRESS SPRINGER LE; Mushotzky RF, 2000, NATURE, V404, P459, DOI 10.1038/35006564; Olbers HWM., 1823, ASTRONOMISCHES JB 18, P110; Poe Edgar Allan, 1848, EUREKA PROSE POEM, P15; Schmidt M, 1998, ASTRON ASTROPHYS, V329, P495; SETTI G, 1989, ASTRON ASTROPHYS, V224, P21	7	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					443	+		10.1038/35006529	http://dx.doi.org/10.1038/35006529			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761895				2022-12-28	WOS:000086257700026
J	Young, S; Bom, S; Lightman, S				Young, S; Bom, S; Lightman, S			An unusual case of retinitis	LANCET			English	Article							SYPHILITIC UVEITIS; OCULAR SYPHILIS; IMMUNODEFICIENCY		Moorfields Eye Hosp, London EC1V 2PD, England; Inst Ophthalmol, Dept Clin Ophthalmol, London WC1H 9QS, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London	Young, S (corresponding author), Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.							BECERRA LI, 1989, OPHTHALMOLOGY, V96, P1727; MCLEISH WM, 1990, OPHTHALMOLOGY, V97, P196; PASSO MS, 1988, AM J OPHTHALMOL, V106, P1; Shalaby IA, 1997, ARCH OPHTHALMOL-CHIC, V115, P469, DOI 10.1001/archopht.1997.01100150471003; TAMESIS RR, 1990, OPHTHALMOLOGY, V97, P1281	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					984	984		10.1016/S0140-6736(00)90017-5	http://dx.doi.org/10.1016/S0140-6736(00)90017-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768438				2022-12-28	WOS:000086054000014
J	Doncaster, CP; Pound, GE; Cox, SJ				Doncaster, CP; Pound, GE; Cox, SJ			The ecological cost of sex	NATURE			English	Article							COEXISTENCE; COEVOLUTION; DIVERSITY; SELECTION; CLONES; MODEL	Why sex prevails in nature remains one of the great puzzles of evolution(1,2). Sexual reproduction has an immediate cost relative to asexual reproduction, as males only express their contribution to population growth through females. With no males to sustain, an asexual mutant can double its relative representation in the population in successive generations. This is the widely accepted 'twofold cost of males'(1-3). Many studies(4-7) have attempted to explain how sex can recoup this cost from fitness benefits associated with the recombination of parental genotypes, but these require complex biological environments that cycle over evolutionary timescales. In contrast, we have considered the ecological dynamics that govern asexual invasion. Here we show the existence of a threshold growth rate for the sexual population, above which the invasion is halted by intraspecific competition. The asexual population then exerts a weaker inhibitory effect on the carrying capacity of the sexual population than on its own carrying capacity. The stable outcome of this is coexistence on a depleted resource base. Under these ecological circumstances, longer-term benefits of sex may eventually drive out the asexual competitor.	Univ Southampton, Sch Biol Sci, Div Biodivers & Ecol, Southampton SO16 7PX, Hants, England; Univ Southampton, Dept Elect & Comp Sci, Southampton SO17 1BJ, Hants, England	University of Southampton; University of Southampton	Doncaster, CP (corresponding author), Univ Southampton, Sch Biol Sci, Div Biodivers & Ecol, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	cpd@soton.ac.uk	Doncaster, C. Patrick/AAT-7621-2020	Doncaster, C. Patrick/0000-0001-9406-0693				Begon M., 1996, ECOLOGY; Bell G., 1982, MASTERPIECE NATURE; BOLGER DT, 1994, OECOLOGIA, V100, P397, DOI 10.1007/BF00317861; BROWNE RA, 1990, EVOLUTION, V44, P1035, DOI 10.1111/j.1558-5646.1990.tb03824.x; BULEMR M, 1994, THEORETICAL EVOLUTIO; CASE TJ, 1986, EVOLUTION, V40, P366, DOI 10.1111/j.1558-5646.1986.tb00478.x; CASE TJ, 1990, OECOLOGIA, V83, P220, DOI 10.1007/BF00317756; Connolly SR, 1999, ECOL MONOGR, V69, P277, DOI 10.1890/0012-9615(1999)069[0277:TOMCCP]2.0.CO;2; Doebeli M, 1996, ECOLOGY, V77, P510, DOI 10.2307/2265626; Futuyama D.J., 1998, EVOLUTIONARY BIOL; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; Hurst Laurence D., 1996, Trends in Ecology and Evolution, V11, P46, DOI 10.1016/0169-5347(96)81041-X; Jokela J, 1997, EVOLUTION, V51, P1120, DOI 10.1111/j.1558-5646.1997.tb03959.x; Judson Olivia P., 1996, Trends in Ecology and Evolution, V11, P41, DOI 10.1016/0169-5347(96)81040-8; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; Levins R., 1970, SOME MATH PROBLEMS B, P75; Lively CM, 1996, BIOSCIENCE, V46, P107, DOI 10.2307/1312813; LOTKA ALFRED J., 1932, JOUR WASHINGTON ACAD SCI, V22, P461; Maynard Smith, 1998, EVOL GENET; MAYNARD SMITH J., 1978, EVOLUTION SEX; Ridley M., 1996, EVOLUTION; Semlitsch RD, 1997, EVOLUTION, V51, P1249, DOI 10.1111/j.1558-5646.1997.tb03972.x; Skelton P., 1993, EVOLUTION BIOL PALAE; Stearns S.C., 2000, EVOLUTION INTRO; VJIJENHOEK RC, 1997, EVOLUTION, V51, P1593; Volterra V, 1931, ANIMAL ECOLOGY, P409; VRIJENHOEK RC, 1979, AM ZOOL, V19, P787; Weeks AR, 1998, EVOLUTION, V52, P1325, DOI [10.2307/2411302, 10.1111/j.1558-5646.1998.tb02014.x]; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi	29	111	114	0	68	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					281	285		10.1038/35005078	http://dx.doi.org/10.1038/35005078			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749210				2022-12-28	WOS:000086022200048
J	Umstadter, D				Umstadter, D			Photonuclear physics - Laser light splits atom	NATURE			English	Editorial Material									Univ Michigan, Ctr Ultrafast Opt Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Nucl Engn & Radiol Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Umstadter, D (corresponding author), Univ Michigan, Ctr Ultrafast Opt Sci, Ann Arbor, MI 48109 USA.		Umstadter, Donald P/A-1581-2016	Umstadter, Donald P/0000-0002-2182-4346				BOYER K, 1988, PHYS REV LETT, V60, P557, DOI 10.1103/PhysRevLett.60.557; Chen SY, 1998, NATURE, V396, P653, DOI 10.1038/25303; Cowan TE, 2000, PHYS REV LETT, V84, P903, DOI 10.1103/PhysRevLett.84.903; Krushelnick K, 1999, PHYS REV LETT, V83, P737, DOI 10.1103/PhysRevLett.83.737; Ledingham KWD, 2000, PHYS REV LETT, V84, P899, DOI 10.1103/PhysRevLett.84.899; Sarkisov GS, 1999, PHYS REV E, V59, P7042, DOI 10.1103/PhysRevE.59.7042; STRICKLAND D, 1985, OPT COMMUN, V56, P219, DOI 10.1016/0030-4018(85)90120-8	7	18	19	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					239	239		10.1038/35005202	http://dx.doi.org/10.1038/35005202			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749194				2022-12-28	WOS:000086022200031
J	Yudkin, JS				Yudkin, JS			Insulin for the world's poorest countries	LANCET			English	Article							AFRICA	In the industrialised world, type 1 diabetes rarely results in death from ketoacidosis. The same is not true in many countries in the developing world where insulin availability is intermittent, and insulin may not even be included on national formularies of essential drugs. The life expectancy for a newly diagnosed patient with type 1 diabetes in some parts of Africa may be as short as 1 year. The World Bank has identified 40 highly indebted poor countries (HIPCs) whose national debt substantially exceeds any possibility of repayment without heavy impact on health and social programmes. Incidence and prognosis of type 1 diabetes in HIPCs are lower than in most industrialised countries, and 0.48% of the world's current use of insulin is estimated to be sufficient to treat all type 1 diabetic patients in these countries. A proposal is made for the major insulin manufacturers to donate insulin, at an estimated cost of US$3-5 million per year, as part of a distribution and education initiative for type 1 diabetic patients in the HIPCs. No type 1 diabetic patient in the world's poorest countries need then die because they, or their government, cannot afford insulin.	Royal Free & UCL Sch Med, Whittington Hosp, London N19 3UA, England	University of London; University College London	Yudkin, JS (corresponding author), Royal Free & UCL Sch Med, Whittington Hosp, London N19 3UA, England.	j.yudkin@ucl.ac.uk	Yudkin, John S/C-1988-2008					Abbasi K, 1999, BMJ-BRIT MED J, V318, P1003, DOI 10.1136/bmj.318.7189.1003; Abbasi K, 1999, BRIT MED J, V318, P865, DOI 10.1136/bmj.318.7187.865; Abbasi K, 1999, BMJ-BRIT MED J, V318, P1568, DOI 10.1136/bmj.318.7198.1568; ALBERTI KGM, 1994, WORLD HEALTH FORUM, V15, P6; Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1; CASTLE WM, 1980, DIABETOLOGIA, V18, P121, DOI 10.1007/BF00290487; CHALE SS, 1992, BRIT MED J, V304, P1215, DOI 10.1136/bmj.304.6836.1215; CHANTELAU E, 1993, LANCET, V342, P620, DOI 10.1016/0140-6736(93)91447-T; Decosas J, 1999, LANCET, V353, P143, DOI 10.1016/S0140-6736(98)11454-X; DEEB LC, 1994, DIABETES CARE, V17, P220, DOI 10.2337/diacare.17.3.220; Gill G. V., 1997, DIABETES AFRICA, P65; MAKAME MH, 1992, DIABETIC MED, V9, P571, DOI 10.1111/j.1464-5491.1992.tb01841.x; McLarty D. G., 1994, International Diabetes Digest, V5, P15; RAAB R, 1999, PRACT DIABETES INT, V16, P58; SAVAGE A, 1994, INT DIABETES DIGEST, V5, P19; United Nations Development Programme, 1997, HUM DEV REP; *WORLD BANK, 1993, WORLD DEV REP 1993 I; Yudkin JS, 1999, LANCET, V353, P1519, DOI 10.1016/S0140-6736(98)09440-9; Zaffran M, 1996, DEV BIOL STAND, V87, P9; 1996, JUBILEE 2000 DEBT CU; 1999, LYMPHATIC FILARIASIS	21	45	46	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	2000	355	9207					919	+		10.1016/S0140-6736(99)09225-9	http://dx.doi.org/10.1016/S0140-6736(99)09225-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752719				2022-12-28	WOS:000085896000042
J	Costedoat-Chalumeau, N; Amoura, Z; Aymard, G; Sevin, O; Wechsler, B; Cacoub, P; Du, LTH; Diquet, B; Ankri, A; Piette, JC				Costedoat-Chalumeau, N; Amoura, Z; Aymard, G; Sevin, O; Wechsler, B; Cacoub, P; Du, LTH; Diquet, B; Ankri, A; Piette, JC			Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone	ANNALS OF INTERNAL MEDICINE			English	Article							WARFARIN; ANTICOAGULATION; FLUINDIONE; POPULATION; AUDIT	Background: Oral anticoagulants and pulse high-dose intravenous methylprednisolone are often administered concomitantly, but no data on potential interactions are available. Objective: To assess possible potentiation of oral anticoagulation by high-dose intravenous methylprednisolone. Design: Prospective cohort study. Setting: University hospital in Paris, France. Patients: 10 consecutive patients concomitantly receiving methylprednisolone and oral anticoagulants (fluindione and acenocoumarol) and 5 consecutive controls receiving methylprednisolone alone. Measurements: Serial determinations of the international normalized ratio (INR) and clotting factors during administration of pulse methylprednisolone. The total plasma fluindione concentration was determined in 3 patients. Results: The mean INR was 2.75 (range, 2.02 to 3.81) at baseline and increased to 8.04 (range, 5.32 to 20.0) after methylprednisolone administration. Plasma fluindione concentrations and the INR increased after methylprednisolone administration. Methylprednisolone alone did not increase prothrombin time. Conclusions: The action of oral anticoagulants is potentiated by intravenous high-dose methylprednisolone. The INR should be monitored daily during concomitant administration of these medications.	Grp Hosp Univ Pitie Salpetriere, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Costedoat-Chalumeau, N (corresponding author), Hop La Pitie Salpetriere, Serv Med Interne, 47-83 Blvd Hop, F-75013 Paris, France.		AMOURA, Zahir/P-5324-2017; Amoura, Zahir/P-5325-2017	AMOURA, Zahir/0000-0003-0292-9043; , nathalie/0000-0002-1555-9021; Cacoub, Patrice/0000-0002-6727-4992				Aymard G, 1998, J CHROMATOGR B, V707, P169, DOI 10.1016/S0378-4347(97)00587-2; Brigden ML, 1998, AM J HEMATOL, V59, P22, DOI 10.1002/(SICI)1096-8652(199809)59:1<22::AID-AJH5>3.3.CO;2-J; BROZOVIC M, 1973, BRIT J HAEMATOL, V24, P579, DOI 10.1111/j.1365-2141.1973.tb01684.x; CHATTERJEA JB, 1954, BRIT MED J, V2, P790, DOI 10.1136/bmj.2.4891.790; COSGRIFF SW, 1950, AM J MED, V9, P752, DOI 10.1016/0002-9343(50)90290-7; GOODMAN BW, 1979, AM J MED, V67, P839, DOI 10.1016/0002-9343(79)90744-7; Hirsh J, 1998, CHEST, V114, p445S, DOI 10.1378/chest.114.5_Supplement.445S; Hylek EM, 1998, JAMA-J AM MED ASSOC, V279, P657, DOI 10.1001/jama.279.9.657; Kaminsky LS, 1997, PHARMACOL THERAPEUT, V73, P67, DOI 10.1016/S0163-7258(96)00140-4; Kaufman M, 1997, MULT SCLER, V3, P248, DOI 10.1177/135245859700300406; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Mentre F, 1998, CLIN PHARMACOL THER, V63, P64, DOI 10.1016/S0009-9236(98)90122-9; Murphy PT, 1998, CLIN LAB HAEMATOL, V20, P253, DOI 10.1046/j.1365-2257.1998.00142.x; PATEL PM, 1993, HEMATOL ONCOL, V11, P89, DOI 10.1002/hon.2900110206; PICHARD L, 1990, DRUG METAB DISPOS, V18, P595; Roujeau JC, 1996, ARCH DERMATOL, V132, P1499, DOI 10.1001/archderm.132.12.1499; Wechsler B, 1992, Eur J Med, V1, P387	17	36	39	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					631	635		10.7326/0003-4819-132-8-200004180-00005	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766681				2022-12-28	WOS:000086497500004
J	Farci, P; Shimoda, A; Coiana, A; Diaz, G; Peddis, G; Melpolder, JC; Strazzera, A; Chien, DY; Munoz, SJ; Balestrieri, A; Purcell, RH; Alter, HJ				Farci, P; Shimoda, A; Coiana, A; Diaz, G; Peddis, G; Melpolder, JC; Strazzera, A; Chien, DY; Munoz, SJ; Balestrieri, A; Purcell, RH; Alter, HJ			The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies	SCIENCE			English	Article							NON-B-HEPATITIS; HYPERVARIABLE REGION-1; VIRUS-INFECTION; LONG-TERM; NON-A; HYPERIMMUNE SERUM; IMMUNE-RESPONSE; ENVELOPE; GLYCOPROTEIN; ANTIBODY	The mechanisms by which hepatitis C virus (HCV) induces chronic infection in the vast majority of infected individuals are unknown. Sequences within the HCV E1 and E2 envelope genes were analyzed during the acute phase of hepatitis C in 12 patients with different clinical outcomes. Acute resolving hepatitis was associated with relative evolutionary stasis of the heterogeneous viral population (quasispecies), whereas progressing hepatitis correlated with genetic evolution of HCV. Consistent with the hypothesis of selective pressure by the host immune system, the sequence changes occurred almost exclusively within the hypervariable region 1 of the E2 gene and were temporally correlated with antibody seroconversion. These data indicate that the evolutionary dynamics of the HCV quasispecies during the acute phase of hepatitis C predict whether the infection will resolve or become chronic.	Univ Cagliari, Dept Med Sci, I-09124 Cagliari, Italy; NIAID, Hepatitis Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Kanazawa Univ, Dept Internal Med, Kanazawa, Ishikawa 9208641, Japan; Univ Cagliari, Dept Cytomorphol, I-09124 Cagliari, Italy; NIH, Dept Transfus Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Chiron Corp, Emeryville, CA 94507 USA; Albert Einstein Med Ctr, Philadelphia, PA 19141 USA	University of Cagliari; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Kanazawa University; University of Cagliari; National Institutes of Health (NIH) - USA; Novartis; Yeshiva University	Farci, P (corresponding author), Univ Cagliari, Dept Med Sci, Via San Giorgio 12, I-09124 Cagliari, Italy.	farcip@pacs.unica.it-		Coiana, Alessandra/0000-0002-1039-5486				Alter H, 1997, VIRAL HEPATITIS, P467; ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; [Anonymous], 1997, HEPATOLOGY, V26, pS2; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHISARI V, 1997, VIRAL HEPATITIS LIVE, P405; COFFIN M, 1992, CURR TOP MICROBIOL I, V176, P181; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Eigen M., 1988, RNA GENETICS, V3, P211; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; Farci P, 1999, J INFECT DIS, V179, P1007, DOI 10.1086/314653; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FARCI P, 1999, P 6 INT S HEP C REL, P80; FELSENSTEIN J, 1993, PHYLIP VERSION 3 573; FERRARI C, 1994, HEPATOLOGY, V19, P286; HAMMING RW, 1986, CODING INFORMATION T; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; KATO N, 1993, J VIROL, V67, P3923, DOI 10.1128/JVI.67.7.3923-3930.1993; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUMAR S, MOL EVOLUTIONARY GEN; KUMAR U, 1994, GASTROENTEROLOGY, V106, P1072, DOI 10.1016/0016-5085(94)90770-6; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; Manzin A, 1998, J VIROL, V72, P6271, DOI 10.1128/JVI.72.7.6271-6276.1998; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842; Mondelli MU, 1999, HEPATOLOGY, V30, P537, DOI 10.1002/hep.510300233; MUNOZ SJ, UNPUB; NEI M, 1986, MOL BIOL EVOL, V3, P418; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; PRINCE AM, 1992, J INFECT DIS, V165, P438, DOI 10.1093/infdis/165.3.438; Ray SC, 1999, J VIROL, V73, P2938, DOI 10.1128/JVI.73.4.2938-2946.1999; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Seeff LB, 1997, HEPATOLOGY, V26, pS21, DOI 10.1002/hep.510260704; Shimizu YK, 1996, VIROLOGY, V223, P409, DOI 10.1006/viro.1996.0497; STEINHAUER DA, 1987, ANNU REV MICROBIOL, V41, P409, DOI 10.1146/annurev.mi.41.100187.002205; TANIGUCHI S, 1993, VIROLOGY, V195, P297, DOI 10.1006/viro.1993.1378; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; Welch BL, 1938, BIOMETRIKA, V29, P350, DOI 10.1093/biomet/29.3-4.350; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; WRIGHT S, 1982, EVOLUTION, V36, P427, DOI 10.1111/j.1558-5646.1982.tb05065.x; WRIGHT S, 1977, EVOLUTION GENETICS P, V1; ZIBERT A, 1995, VIROLOGY, V208, P653, DOI 10.1006/viro.1995.1196	50	719	758	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	2000	288	5464					339	344		10.1126/science.288.5464.339	http://dx.doi.org/10.1126/science.288.5464.339			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303YA	10764648				2022-12-28	WOS:000086454300039
J	Canto, JG; Allison, JJ; Kiefe, CI; Fincher, C; Farmer, R; Sekar, P; Person, S; Weissman, NW				Canto, JG; Allison, JJ; Kiefe, CI; Fincher, C; Farmer, R; Sekar, P; Person, S; Weissman, NW			Relation of race and sex to the use of reperfusion therapy in medicare beneficiaries with acute myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THROMBOLYTIC THERAPY; NATIONAL REGISTRY; UNITED-STATES; IMMEDIATE ANGIOPLASTY; GENDER DIFFERENCES; MANAGEMENT; WOMEN; PERSPECTIVE; GUIDELINES; MORTALITY	Background: There are few reports describing the combined influence of the race and sex of a patient on the use of reperfusion therapy for acute myocardial infarction. Methods: To determine the relation of race and sex to the receipt of reperfusion therapy for myocardial infarction in the United States, we reviewed the medical records of 234,769 Medicare patients with myocardial infarction. From these records we identified 26,575 white or black patients who met strict eligibility criteria for reperfusion therapy. We then performed bivariate and multivariate analyses of prevalence ratios to determine predictors of the use of reperfusion therapy in four subgroups of patients categorized according to race and sex: white men, white women, black men, and black women. Results: Among eligible patients, white men received reperfusion therapy with the highest frequency (59 percent), followed by white women (56 percent), black men (50 percent), and black women (44 percent). After adjustment for differences in demographic and clinical characteristics, white women were as likely as white men to receive reperfusion therapy (prevalence ratio, 1.00; 95 percent confidence interval, 0.98 to 1.03). Likewise, black women were as likely as black men to receive reperfusion therapy (prevalence ratio, 1.00; 95 percent confidence interval, 0.89 to 1.13). However, black women were significantly less likely to receive reperfusion therapy than white men (prevalence ratio, 0.90; 95 percent confidence interval, 0.82 to 0.98), as were black men (prevalence ratio, 0.85; 95 percent confidence interval, 0.78 to 0.93). Conclusions: After adjustment for differences in clinical and demographic characteristics and clinical presentation, differences according to sex in the use of reperfusion therapy are minimal. However, blacks, regardless of sex, are significantly less likely than whites to receive this potentially lifesaving therapy. (N Engl J Med 2000;342:1094-100.) (C) 2000, Massachusetts Medical Society.	Univ Alabama, Ctr Outcomes & Effect Res & Educ, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Canto, JG (corresponding author), Univ Alabama, Ctr Outcomes & Effect Res & Educ, 363 BDB,1808 7th Ave S, Birmingham, AL 35294 USA.			Allison, Jeroan/0000-0003-4472-2112	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008843, U18HS009446] Funding Source: NIH RePORTER; AHRQ HHS [HS09446, HS08843] Funding Source: Medline; NCRR NIH HHS [RR00032] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Allison JJ, 1996, J GEN INTERN MED, V11, P736, DOI 10.1007/BF02598987; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BEHAR S, 1994, AM J CARDIOL, V73, P438, DOI 10.1016/0002-9149(94)90672-6; Borzak S, 1999, AM HEART J, V137, P338, DOI 10.1053/hj.1999.v137.92523; *CDCP, 1993, CARD DIS SURV ISCH H; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; Dellborg M, 1993, Qual Assur Health Care, V5, P261; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; *ICD, 1980, ICD9CM; JOHNSON N, 1988, ENCY STAT, P646; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; Lauderdale DS, 1996, AM J PUBLIC HEALTH, V86, P712, DOI 10.2105/AJPH.86.5.712; MAYNARD C, 1991, AM J CARDIOL, V68, P529, DOI 10.1016/0002-9149(91)90791-I; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; MCLAUGHLIN TJ, 1996, ARCH INTERN MED, V156, P1920; *NAT CTR HLTH STAT, 1998, HLTH US 1998 SOC STA; PAGLEY PR, 1993, ARCH INTERN MED, V153, P625, DOI 10.1001/archinte.153.5.625; Pan CX, 1999, J AM GERIATR SOC, V47, P730, DOI 10.1111/j.1532-5415.1999.tb01599.x; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SCHULMAN K, 1918, NEW ENGL J MED, V340, P1130; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Taylor HA, 1998, AM J CARDIOL, V82, P1019, DOI 10.1016/S0002-9149(98)00547-5; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; Yarzebski J, 1996, AM HEART J, V131, P43, DOI 10.1016/S0002-8703(96)90049-6; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; Zocchetti C, 1997, INT J EPIDEMIOL, V26, P220, DOI 10.1093/ije/26.1.220	32	176	178	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1094	1100		10.1056/NEJM200004133421505	http://dx.doi.org/10.1056/NEJM200004133421505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10760310	Bronze			2022-12-28	WOS:000086406700005
J	El-Sadr, WM; Burman, WJ; Grant, LB; Matts, JP; Hafner, R; Crane, L; Zeh, D; Gallagher, B; Mannheimer, SB; Martinez, A; Gordin, F				El-Sadr, WM; Burman, WJ; Grant, LB; Matts, JP; Hafner, R; Crane, L; Zeh, D; Gallagher, B; Mannheimer, SB; Martinez, A; Gordin, F		Terry Beirn Community Programs Cli	Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STREPTOCOCCUS-PNEUMONIAE; CYTOMEGALOVIRUS DISEASE; WEEKLY AZITHROMYCIN; ORAL GANCICLOVIR; CONTROLLED TRIAL; PREVENTION; AIDS; BACTEREMIA; ILLNESSES	Background: Several agents are effective in preventing Mycobacterium avium complex disease in patients with advanced human immunodeficiency virus (HIV) infection. However, there is uncertainty about whether prophylaxis should be continued in patients whose CD4+ cell counts have increased substantially with antiviral therapy. Methods: We conducted a multicenter, double-blind, randomized trial of treatment with azithromycin (1200 mg weekly) as compared with placebo in HIV-infected patients whose CD4+ cell counts had increased from less than 50 to more than 100 per cubic millimeter in response to antiretroviral therapy. The primary end point was M. avium complex disease or bacterial pneumonia. Results: A total of 520 patients entered the study; the median CD4+ cell count at entry was 230 per cubic millimeter. In 48 percent of the patients, the HIV RNA value was below the level of quantification. The median prior nadir CD4+ cell count was 23 per cubic millimeter, and 65 percent of the patients had had an acquired immunodeficiency syndrome-defining illness. During follow-up over a median period of 12 months, there were no episodes of confirmed M. avium complex disease in either group (95 percent confidence interval for the rate of disease in each group, 0 to 1.5 episodes per 100 person-years). Three patients in the azithromycin group (1.2 percent) and five in the placebo group (1.9 percent) had bacterial pneumonia (relative risk in the azithromycin group, 0.60; 95 percent confidence interval, 0.14 to 2.50; P=0.48). Neither the rate of progression of HIV disease nor the mortality rate differed significantly between the two groups. Adverse effects led to discontinuation of the study drug in 19 patients assigned to receive azithromycin (7.4 percent) and in 3 assigned to receive placebo (1.1 percent; relative risk, 6.6; P=0.002). Conclusions: Azithromycin prophylaxis can safely be withheld in HIV-infected patients whose CD4+ cell counts have increased to more than 100 cells per cubic millimeter in response to antiretroviral therapy. (N Engl J Med 2000;342:1085-92.) (C) 2000, Massachusetts Medical Society.	Harlem Hosp Med Ctr, Div Infect Dis, New York, NY 10037 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Denver Publ Hlth Dept, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; NIAID, Div Aids, Bethesda, MD 20892 USA; Wayne State Univ, Detroit, MI USA; Res & Educ Grp, Portland, OR USA; Philadelphia FIGHT, Philadelphia, PA USA; Dept Vet Affairs Med Ctr, Washington, DC USA	Columbia University; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Wayne State University	El-Sadr, WM (corresponding author), Harlem Hosp Med Ctr, Div Infect Dis, 506 Lenox Ave,Rm 3107, New York, NY 10037 USA.	wne1@columbia.edu			NCRR NIH HHS [RR00032] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABERG JA, 1999, 39 INT C ANT AG CHEM, P1164; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Benson C. A., 1996, P91; Brosgart CL, 1998, AIDS, V12, P269, DOI 10.1097/00002030-199803000-00004; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CreweBrown HH, 1997, CLIN INFECT DIS, V25, P1165, DOI 10.1086/516104; Dunne MW, 1999, LANCET, V354, P891, DOI 10.1016/S0140-6736(98)10328-8; DWORKIN M, 1999, 6 C RETR OPP INF CHI, P198; El-Sadr WM, 1999, CLIN INFECT DIS, V29, P775, DOI 10.1086/520433; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; KEDREE MA, 1996, 11 INT C AIDS VANC B, P232; LOPEZ JC, 1999, 6 C RETR OPP INF CHI, P206; Meynard JL, 1996, CLIN INFECT DIS, V22, P437, DOI 10.1093/clinids/22.3.437; Mocroft A, 1998, ARCH INTERN MED, V158, P491, DOI 10.1001/archinte.158.5.491; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; Oldfield EC, 1998, CLIN INFECT DIS, V26, P611, DOI 10.1086/514566; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0	32	106	109	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	2000	342	15					1085	1092		10.1056/NEJM200004133421503	http://dx.doi.org/10.1056/NEJM200004133421503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303DZ	10766581	Green Published			2022-12-28	WOS:000086406700003
J	Anbar, AD; Roe, JE; Barling, J; Nealson, KH				Anbar, AD; Roe, JE; Barling, J; Nealson, KH			Nonbiological fractionation of iron isotopes	SCIENCE			English	Article							CHLORIDE SOLUTIONS; COMPLEXES	Laboratory experiments demonstrate that iron isotopes can be chemically fractionated in the absence of biology. Isotopic variations comparable to those seen during microbially mediated reduction of ferrihydrite are observed. Fractionation may occur in aqueous solution during equilibration between inorganic iron complexes. These findings provide insight into the mechanisms of iron isotope fractionation and suggest that nonbiological processes may contribute to iron isotope variations observed in sediments.	Univ Rochester, Dept Earth & Environm Sci, Rochester, NY 14627 USA; Univ Rochester, Dept Chem, Rochester, NY 14627 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91106 USA	University of Rochester; University of Rochester; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Anbar, AD (corresponding author), Univ Rochester, Dept Earth & Environm Sci, Rochester, NY 14627 USA.		Barling, Jane/F-9443-2015	Barling, Jane/0000-0001-8535-5262				ANBAR AD, 1998, MINERAL MAG A, V62, P53; APTED MJ, 1985, GEOCHIM COSMOCHIM AC, V49, P2081, DOI 10.1016/0016-7037(85)90065-1; Beard BL, 1999, SCIENCE, V285, P1889, DOI 10.1126/science.285.5435.1889; Beard BL, 1999, GEOCHIM COSMOCHIM AC, V63, P1653, DOI 10.1016/S0016-7037(99)00089-7; BIGELEISEN J, 1947, J CHEM PHYS, V15, P261, DOI 10.1063/1.1746492; BJERRUM J, 1986, ACTA CHEM SCAND A, V40, P31, DOI 10.3891/acta.chem.scand.40a-0031; Bullen T.D., 1998, MINERAL MAG A, V62, P255; BULLEN TD, 1999, EOS, V80, P479; Criss R. E., 1999, PRINCIPLES STABLE IS; GLUECKAUF E, 1958, T FARADAY SOC, V54, P1203, DOI 10.1039/tf9585401203; HALLIDAY AN, 1995, INT J MASS SPECTROM, V146, P21, DOI 10.1016/0168-1176(95)04200-5; MAGINI M, 1979, J CHEM PHYS, V71, P4255, DOI 10.1063/1.438233; Mandernack KW, 1999, SCIENCE, V285, P1892, DOI 10.1126/science.285.5435.1892; Marechal CN, 1999, CHEM GEOL, V156, P251, DOI 10.1016/S0009-2541(98)00191-0; MOORE GE, 1959, J AM CHEM SOC, V72, P5792; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Polyakov VB, 2000, GEOCHIM COSMOCHIM AC, V64, P849, DOI 10.1016/S0016-7037(99)00329-4; RUSSELL WA, 1978, ANAL CHEM, V50, P1151, DOI 10.1021/ac50030a036; SKOOG DA, 1998, INSTRUMENTAL ANAL, P675; Taylor TI, 1938, J CHEM PHYS, V6, P429, DOI 10.1063/1.1750288; UREY HC, 1947, J CHEM SOC, P562, DOI 10.1039/jr9470000562; VANDERWALT TN, 1985, SOLVENT EXTR ION EXC, V3, P723, DOI 10.1080/07366298508918536; Zhu XK, 2000, CHEM GEOL, V163, P139, DOI 10.1016/S0009-2541(99)00076-5	23	224	248	1	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					126	128		10.1126/science.288.5463.126	http://dx.doi.org/10.1126/science.288.5463.126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10753114				2022-12-28	WOS:000086387700048
J	Smith, O				Smith, O			Nota bene: Development - Awakening aurora	SCIENCE			English	Editorial Material																		Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					69	69		10.1126/science.288.5463.69	http://dx.doi.org/10.1126/science.288.5463.69			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10766638				2022-12-28	WOS:000086387700032
J	Cirac, JI; Zoller, P				Cirac, JI; Zoller, P			A scalable quantum computer with ions in an array of microtraps	NATURE			English	Article							TRAPPED IONS; COMPUTATION; UNIVERSAL; CAVITY; GATES; LOGIC	Quantum computers require the storage of quantum information in a set of two-level systems (called qubits), the processing of this information using quantum gates and a means of final readout(1). So far, only a few systems have been identified as potentially viable quantum computer models-accurate quantum control of the coherent evolution is required in order to realize gate operations, while at the same time decoherence must be avoided. Examples include quantum optical systems (such as those utilizing trapped ions(2-9) or neutral atoms(10-12), cavity quantum electrodynamics(13-15) and nuclear magnetic resonance(16,17)) and solid state systems (using nuclear spins(1,18), quantum dots(19) and Josephson junctions(20)). The most advanced candidates are the quantum optical and nuclear magnetic resonance systems, and we expect that they will allow quantum computing with about ten qubits within the next few years. This is still far from the numbers required for useful applications: for example, the factorization of a 200-digit number requires about 3,500 qubits(21), rising to 100,000 if error correction(22) is implemented. Scalability of proposed quantum computer architectures to many qubits is thus of central importance. Here we propose a model for an ion trap quantum computer that combines scalability (a feature usually associated with solid state proposals) with the advantages of quantum optical systems (in particular, quantum control and long decoherence times).	Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria	University of Innsbruck	Zoller, P (corresponding author), Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria.	peter.zoller@uibk.ac.at	Cirac, J. Ignacio/A-9105-2017; Zoller, Peter/O-1639-2014	Cirac, J. Ignacio/0000-0003-3359-1743; Zoller, Peter/0000-0003-4014-1505				Beckman D, 1996, PHYS REV A, V54, P1034, DOI 10.1103/PhysRevA.54.1034; Brennen GK, 1999, PHYS REV LETT, V82, P1060, DOI 10.1103/PhysRevLett.82.1060; CALARCO T, 1999, QUANTPH9905013; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; Cory DG, 1997, P NATL ACAD SCI USA, V94, P1634, DOI 10.1073/pnas.94.5.1634; DeVoe RG, 1998, PHYS REV A, V58, P910, DOI 10.1103/PhysRevA.58.910; DIVINCENZO DP, 1995, PHYS REV A, V51, P1015, DOI 10.1103/PhysRevA.51.1015; Friebel S, 1998, PHYS REV A, V57, pR20, DOI 10.1103/PhysRevA.57.R20; Gershenfeld NA, 1997, SCIENCE, V275, P350, DOI 10.1126/science.275.5298.350; Jaksch D, 1999, PHYS REV LETT, V82, P1975, DOI 10.1103/PhysRevLett.82.1975; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Lloyd S, 1996, SCIENCE, V273, P1073, DOI 10.1126/science.273.5278.1073; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Maitre X, 1997, PHYS REV LETT, V79, P769, DOI 10.1103/PhysRevLett.79.769; Makhlin Y, 1999, NATURE, V398, P305, DOI 10.1038/18613; PELLIZZARI T, 1995, PHYS REV LETT, V75, P3788, DOI 10.1103/PhysRevLett.75.3788; Poyatos JF, 1998, PHYS REV LETT, V81, P1322, DOI 10.1103/PhysRevLett.81.1322; ROOS C, 1999, QUANTPH9909038; Steane A, 1997, APPL PHYS B-LASERS O, V64, P623, DOI 10.1007/s003400050225; STEANE AM, 1998, QUANTPH9809054; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; Turchette QA, 1998, PHYS REV LETT, V81, P3631, DOI 10.1103/PhysRevLett.81.3631	25	422	430	1	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					579	581		10.1038/35007021	http://dx.doi.org/10.1038/35007021			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766235				2022-12-28	WOS:000086400100046
J	van Jaarsveld, BC; Krijnen, P; Pieterman, H; Derkx, FHM; Deinum, J; Postma, CT; Dees, A; Woittiez, AJJ; Bartelink, AKM; Man in 't Veld, AJ; Schalekamp, MADH				van Jaarsveld, BC; Krijnen, P; Pieterman, H; Derkx, FHM; Deinum, J; Postma, CT; Dees, A; Woittiez, AJJ; Bartelink, AKM; Man in 't Veld, AJ; Schalekamp, MADH		Dutch Renal Artery Stenosis Invert	The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENOVASCULAR HYPERTENSION; CAPTOPRIL RENOGRAPHY; DIAGNOSIS; DISEASE	Background: Patients with hypertension and renal-artery stenosis are often treated with percutaneous transluminal renal angioplasty. However, the long-term effects of this procedure on blood pressure are not well understood. Methods: We randomly assigned 106 patients with hypertension who had atherosclerotic renal-artery stenosis (defined as a decrease in luminal diameter of 50 percent or more) and a serum creatinine concentration of 2.3 mg per deciliter (200 mu mol per liter) or less to undergo percutaneous transluminal renal angioplasty or to receive drug therapy. To be included, patients also had to have a diastolic blood pressure of 95 mm Hg or higher despite treatment with two antihypertensive drugs or an increase of at least 0.2 mg per deciliter (20 mu mol per liter) in the serum creatinine concentration during treatment with an angiotensin-converting-enzyme inhibitor. Blood pressure, doses of antihypertensive drugs, and renal function were assessed at 3 and 12 months, and patency of the renal artery was assessed at 12 months. Results: At base line, the mean (+/-SD) systolic and diastolic blood pressures were 179+/-25 and 104+/-10 mm Hg, respectively, in the angioplasty group and 180+/-23 and 103+/-8 mm Hg, respectively, in the drug-therapy group. At three months, the blood pressures were similar in the two groups (169+/-28 and 99+/-12 mm Hg, respectively, in the 56 patients in the angioplasty group and 176+/-31 and 101+/-14 mm Hg, respectively, in the 50 patients in the drug-therapy group; P=0.25 for the comparison of systolic pressure and P=0.36 for the comparison of diastolic pressure between the two groups); at the time, patients in the angioplasty group were taking 2.1+/-1.3 defined daily doses of medication and those in the drug-therapy group were taking 3.2+/-1.5 daily doses (P<0.001). In the drug-therapy group, 22 patients underwent balloon angioplasty after three months because of persistent hypertension despite treatment with three or more drugs or because of a deterioration in renal function. According to intention-to-treat analysis, at 12 months, there were no significant differences between the angioplasty and drug-therapy groups in systolic and diastolic blood pressures, daily drug doses, or renal function. Conclusions: In the treatment of patients with hypertension and renal-artery stenosis, angioplasty has little advantage over antihypertensive-drug therapy. (N Engl J Med 2000;342:1007-14.) (C) 2000, Massachusetts Medical Society.	Erasmus Univ Hosp, Dept Internal Med, Rotterdam, Netherlands; Erasmus Univ Hosp, Dept Radiol, Rotterdam, Netherlands; Erasmus Univ, Dept Publ Hlth, Ctr Clin Decis Sci, Rotterdam, Netherlands; Univ Nijmegen Hosp, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands; Ikazia Hosp, Dept Internal Med, Rotterdam, Netherlands; Twenteborg Hosp, Dept Internal Med, Almelo, Netherlands; Eemland Hosp, Dept Internal Med, Amersfoort, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Radboud University Nijmegen; Ikazia Hospital	van Jaarsveld, BC (corresponding author), Stichting Dianet, Brennerbaan 130, NL-3524 BN Utrecht, Netherlands.	b.v.jaarsveld@utr.dianet.nl	Postma, C.T./L-4585-2015; Deinum, J./L-4261-2015	Deinum, J./0000-0003-2465-1986; van Jaarsveld, Brigit/0000-0001-5871-4952; Dees, Adriaan/0000-0001-9164-4538				[Anonymous], 1992, AM J HYPERTENS, V5, P207; Blum U, 1997, NEW ENGL J MED, V336, P459, DOI 10.1056/NEJM199702133360702; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; FOMMEI E, 1993, EUR J NUCL MED, V20, P617; FOSTER JH, 1975, JAMA-J AM MED ASSOC, V231, P1043, DOI 10.1001/jama.231.10.1043; Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; GRUNTZIG A, 1978, LANCET, V1, P801; HANSEN KJ, 1990, J VASC SURG, V12, P227, DOI 10.1067/mva.1990.22791; HOFFMANN U, 1991, KIDNEY INT, V39, P1232, DOI 10.1038/ki.1991.156; HOVINGA TKK, 1986, NEPHRON, V44, P64, DOI 10.1159/000184050; HUNT JC, 1974, ARCH INTERN MED, V133, P988, DOI 10.1001/archinte.133.6.988; JENSEN G, 1995, KIDNEY INT, V48, P1936, DOI 10.1038/ki.1995.494; MANN SJ, 1991, AM J MED, V90, P30, DOI 10.1016/0002-9343(91)90503-P; NALLY JV, 1991, AM J HYPERTENS, V4, pS749, DOI 10.1093/ajh/4.12.749S; PICKERING TG, 1991, KIDNEY, V2, P1940; Plouin PF, 1998, HYPERTENSION, V31, P823, DOI 10.1161/01.HYP.31.3.823; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; van de Ven PJG, 1999, LANCET, V353, P282, DOI 10.1016/S0140-6736(98)04432-8; van Jaarsveld B, 1998, J HYPERTENS, V16, pS21; vanJaarsveld BC, 1997, ARCH INTERN MED, V157, P1226, DOI 10.1001/archinte.157.11.1226; Webster J, 1998, J HUM HYPERTENS, V12, P329, DOI 10.1038/sj.jhh.1000599; *WHO COLL CTR DRUG, 1995, GUID ATC CLASS DDD A, P22; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	24	624	642	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 6	2000	342	14					1007	1014		10.1056/NEJM200004063421403	http://dx.doi.org/10.1056/NEJM200004063421403			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300JB	10749962				2022-12-28	WOS:000086248900003
J	Angus, DC; Birmingham, MC; Balk, RA; Scannon, PJ; Collins, D; Kruse, JA; Graham, DR; Dedhia, HV; Homann, S; MacIntyre, N				Angus, DC; Birmingham, MC; Balk, RA; Scannon, PJ; Collins, D; Kruse, JA; Graham, DR; Dedhia, HV; Homann, S; MacIntyre, N		E5 Study Investigators	E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIPID-A; SEPTIC SHOCK; DOUBLE-BLIND; ENDOTOXIN; BINDING; LIPOPOLYSACCHARIDES; PATHOGENESIS; REACTIVITY; THERAPIES; BACTERIA	Context Knowledge and understanding of gram-negative sepsis have grown over the past 20 years, but the ability to treat severe sepsis successfully has not. Objective To assess the efficacy and safety of E5 in the treatment of patients with severe gram-negative sepsis. Design A multicenter, double-blind, randomized, placebo-controlled trial conducted at 136 US medical centers from April 1993 to April 1997, designed with 90% power to detect a 25% relative risk reduction, incorporating 2 planned interim analyses. Setting Intensive care units at university medical centers, Veterans Affairs medical centers, and community hospitals. Patients Adults aged 18 years or older, with signs and symptoms consistent with severe sepsis and documented or probable gram-negative infection. Intervention Patients were assigned to receive 2 doses of either E5, a murine monoclonal antibody directed against endotoxin (n = 550; 2 mg/kg per day by intravenous infusion 24 hours apart) or placebo (n = 552), Main Outcome Measures The primary end point was mortality at day 14; secondary end points were mortality at day 28, adverse event rates, and 14-day and 28-day mortality in the subgroup without shock at presentation. Results The trial was stopped after the second interim analysis. A total of 1090 patients received study medication and 915 had gram-negative infection confirmed by culture. There were no statistically significant differences in mortality between the E5 and placebo groups at either day 14 (29.7% vs 31.1%; P = .67) or day 28 (38.5% vs 40.3%; P = .56), Patients presenting without shock had a slightly lower mortality when treated with E5 but the difference was not significant (28.9% vs 33.0% for the E5 and placebo groups, respectively, at day 28; P = .32). There was a similar profile of adverse event rates between E5 and placebo. Conclusions Despite adequate sample size and high enrollment of patients with confirmed gram-negative sepsis, E5 did not improve short-term survival. Current study rationale and designs should be carefully reviewed before further large-scale studies of patients with sepsis are conducted.	Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Crit Care Med Div, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA; Millard Fillmore Hosp, Kaleida Hlth, Buffalo, NY USA; SUNY Buffalo, Buffalo, NY 14260 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; XOMA Corp, Berkeley, CA USA; Detroit Receiving Hosp & Univ Hlth Ctr, Detroit, MI USA; St Johns Hosp, Springfield Clin, Springfield, IL USA; W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA; Swedish Amer Hosp, Rockford, IL USA; Duke Univ, Med Ctr, Durham, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kaleida Health; State University of New York (SUNY) System; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Rush University; Detroit Receiving Hospital & University Health Center; West Virginia University; Duke University	Angus, DC (corresponding author), Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Crit Care Med Div, Room 604,Scaife Hall,200 Lothrop St, Pittsburgh, PA 15213 USA.	angusdc@anes.upmc.edu	Angus, Derek C/E-9671-2012					ANGUS DC, 1998, YB INTENSIVE CARE EM, P263; Bermudez LE, 1989, REV INFECT DIS    S7, V11, pS1564; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BOUTER AS, 1994, INT J ANTIMICROB AG, V4, P191, DOI 10.1016/0924-8579(94)90008-6; Brade H, 1988, Prog Clin Biol Res, V272, P17; CDC, 1990, JAMA-J AM MED ASSOC, V263, P937; CHEN TY, 1993, J APPL PHYSIOL, V75, P233, DOI 10.1152/jappl.1993.75.1.233; *COUNC INT ORG MED, 1990, INT REP ADV DRUG REA; Dellinger RP, 1997, CHEST, V111, P744; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GORELICK KJ, 1993, 2 INT C IMM CONS TRA, P1212; GREENBERG RN, 1992, CRIT CARE MED, V20, P730, DOI 10.1097/00003246-199206000-00005; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HARKONEN S, 1988, ANTIMICROB AGENTS CH, V32, P710, DOI 10.1128/AAC.32.5.710; Inada K, 1993, Kansenshogaku Zasshi, V67, P1108; INADA K, 1993, J JPN ASS INFECT DIS, V67, P1108; Kobayashi H, 1994, Kansenshogaku Zasshi, V68, P314; LAN KKG, 1984, COMMUN STAT-THEOR M, V13, P2339, DOI 10.1080/03610928408828830; Linde-Zwirble WT, 1999, CRIT CARE MED, V27, pA33, DOI 10.1097/00003246-199901001-00023; LUNDBLAD R, 1993, BIOL RESPONSE MODIFI; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Natanson C, 1998, CRIT CARE MED, V26, P1927, DOI 10.1097/00003246-199812000-00001; PARENT JB, 1992, CIRC SHOCK, V38, P63; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; ROMULO RLC, 1993, J INFECT DIS, V167, P126, DOI 10.1093/infdis/167.1.126; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; SEELEN MA, 1995, IMMUNOLOGY, V84, P653; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; WILLATTS SM, 1995, CRIT CARE MED, V23, P1033, DOI 10.1097/00003246-199506000-00007; WOOD DM, 1992, CIRC SHOCK, V38, P55; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	35	168	181	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1723	1730		10.1001/jama.283.13.1723	http://dx.doi.org/10.1001/jama.283.13.1723			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BK	10755499	Bronze			2022-12-28	WOS:000086119300033
J	Whelan, G				Whelan, G			High-stakes medical performance testing: The Clinical Skills Assessment program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Educ Commiss Foreign Med Grad, Clin Skills Assessment Program, Philadelphia, PA USA		Whelan, G (corresponding author), Educ Commiss Foreign Med Grad, Clin Skills Assessment Program, Philadelphia, PA USA.							*I MED, 1996, NAT PHYS WORKF OPT B; SUTRICK AI, 1993, JAMA-J AM MED ASSOC, V270, P1041	2	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1748	1748		10.1001/jama.283.13.1748	http://dx.doi.org/10.1001/jama.283.13.1748			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BK	10755506	hybrid			2022-12-28	WOS:000086119300040
J	Katz, HE; Lovinger, AJ; Johnson, J; Kloc, C; Siegrist, T; Li, W; Lin, YY; Dodabalapur, A				Katz, HE; Lovinger, AJ; Johnson, J; Kloc, C; Siegrist, T; Li, W; Lin, YY; Dodabalapur, A			A soluble and air-stable organic semiconductor with high electron mobility	NATURE			English	Article							THIN-FILM TRANSISTORS; CIRCUITS; CRYSTAL; GROWTH	Electronic devices based on organic semiconductors offer an attractive alternative to conventional inorganic devices due to potentially lower costs, simpler packaging and compatibility with flexible substrates(1,2). As is the case for silicon-based microelectronics, the use of complementary logic elements-requiring n- and p-type semiconductors whose majority charge carriers are electrons and holes, respectively-is expected to be crucial to achieving low-power, high-speed performance. Similarly, the electron-segregating domains of photovoltaic assemblies require both n- and p-type semiconductors(3-5). Stable organic p-type semiconductors are known(6), but practically useful n-type semiconductor materials have proved difficult to develop, reflecting the unfavourable electrochemical properties of known, electron-demanding polymers(7). Although high electron mobilities have been obtained for organic materials, these values are usually obtained for single crystals at low temperatures, whereas practically useful field-effect transistors (FETs) will have to be made of polycrystalline films that remain functional at room temperature. A few organic n-type semiconductors that can be used in FETs are known, but these suffer from low electron mobility, poor stability in air and/or demanding processing conditions(8-10). Here we report a crystallographically engineered naphthalenetetracarboxylic diimide derivative that allows us to fabricate solution-cast n-channel FETs with promising performance at ambient conditions. By integrating our n-channel FETs with solution-deposited p-channel FETs, we are able to produce a complementary inverter circuit whose active layers are deposited entirely from the liquid phase. We expect that other complementary circuit designs(11) can be realized by this approach as well.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Katz, HE (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Siegrist, Theo/R-3855-2019; Kloc, Christian/A-2255-2011; Katz, Howard E/A-3352-2010; Dodabalapur, Ananth/H-3043-2012	Siegrist, Theo/0000-0001-5368-1442; 				Bao ZA, 1998, J AM CHEM SOC, V120, P207, DOI 10.1021/ja9727629; Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530; deLeeuw DM, 1997, SYNTHETIC MET, V87, P53, DOI 10.1016/S0379-6779(97)80097-5; Dodabalapur A, 1996, APPL PHYS LETT, V69, P4227, DOI 10.1063/1.116953; Drury CJ, 1998, APPL PHYS LETT, V73, P108, DOI 10.1063/1.121783; Fichou D, 1996, ADV MATER, V8, P500, DOI 10.1002/adma.19960080610; FOX MA, 1992, ACCOUNTS CHEM RES, V25, P569, DOI 10.1021/ar00024a004; HADDON RC, 1995, APPL PHYS LETT, V67, P121, DOI 10.1063/1.115503; Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U; HOROWITZ G, 1995, CHEM MATER, V7, P1337, DOI 10.1021/cm00055a010; KATZ HE, IN PRESS P MAT RES S; Laquindanum JG, 1996, J AM CHEM SOC, V118, P11331, DOI 10.1021/ja962461j; Li WJ, 1999, CHEM MATER, V11, P458, DOI 10.1021/cm980672c; Matters M, 1999, OPT MATER, V12, P189, DOI 10.1016/S0925-3467(99)00064-6; PANAYOTATOS P, 1987, IEEE PHOT SPEC C, V19, P889; RADEMACHER A, 1982, CHEM BER-RECL, V115, P2927, DOI 10.1002/cber.19821150823; SIEGRIST T, 1995, J MATER RES, V10, P2170, DOI 10.1557/JMR.1995.2170; Wiederrecht GP, 1999, CHEM MATER, V11, P1409, DOI 10.1021/cm9901008; YAMAGUCHI Y, 1991, J APPL PHYS, V70, P855, DOI 10.1063/1.349646	19	978	1003	12	478	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					478	481		10.1038/35006603	http://dx.doi.org/10.1038/35006603			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761911				2022-12-28	WOS:000086257700042
J	Pignon, JP; Bourhis, J; Domenge, C; Designe, L				Pignon, JP; Bourhis, J; Domenge, C; Designe, L		MACH NC Collaborative Grp	Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data	LANCET			English	Article							PATIENT DATA; CANCER; TRIAL	Background Despite more than 70 randomised trials, the effect of chemotherapy on non-metastatic head and neck squamous-cell carcinoma remains uncertain. We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment. Methods We updated data on all patients in randomised trials between 1965 and 1993, We included patients with carcinoma of the oropharynx, oral cavity, larynx, or hypopharynx. Findings The main meta-analysis of 63 trials (10 741 patients) of locoregional treatment with or without chemotherapy yielded a pooled hazard ratio of death of 0.90 (95% CI 0.85-0.94, p<0.0001), corresponding to an absolute survival benefit of 4% at 2 and 5 years in favour of chemotherapy. There was no significant benefit associated with adjuvant or neoadjuvant chemotherapy. Chemotherapy given concomitantly to radiotherapy gave significant benefits, but heterogeneity of the results prohibits firm conclusions. Meta-analysis of six trials (861 patients) comparing neoadjuvant chemotherapy plus radiotherapy with concomitant or alternating radiochemotherapy yielded a hazard ratio of 0.91 (0.79-1.06) in favour of concomitant or alternating radiochemotherapy, Three larynx-preservation trials (602 patients) compared radical surgery plus radiotherapy with neoadjuvant chemotherapy plus radiotherapy in responders or radical surgery and radiotherapy in non-responders. The hazard ratio of death in the chemotherapy arm as compared with the control arm was 1.19 (0.97-1.46). Interpretation Because the main meta-analysis showed only a small significant survival benefit in favour of chemotherapy, the routine use of chemotherapy is debatable. For larynx preservation, the non-significant negative effect of chemotherapy in the organ-preservation strategy indicates that this procedure must remain investigational.	Inst Gustave Roussy, Dept Biostat & Epidemiol, F-94805 Villejuif, France	UNICANCER; Gustave Roussy	Pignon, JP (corresponding author), Inst Gustave Roussy, Dept Biostat & Epidemiol, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Simes, Robert John/P-1497-2014; Kowalski, Luiz P/D-1701-2012	Kowalski, Luiz P/0000-0002-0481-156X; Stewart, Lesley/0000-0003-0287-4724; PIGNON, Jean-Pierre/0000-0003-2047-1582; Bourhis, Jean/0000-0001-5162-1171				ALBERTI W, 1995, BRIT MED J, V311, P899; Bourhis J, 1999, HEMATOL ONCOL CLIN N, V13, P769, DOI 10.1016/S0889-8588(05)70091-5; HAHARI P, 1997, J CLIN ONCOL, V15, P2050; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; OXMAN AD, 1995, JAMA-J AM MED ASSOC, V274, P845, DOI 10.1001/jama.274.10.845; Parker S. L., 1996, CA CANC J CLIN, V65, P5; Parkin DM, 1992, CANC INCIDENCE 5 CON, VVI; Richard JM, 1998, ORAL ONCOL, V34, P224, DOI 10.1016/S1368-8375(97)00090-0; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	13	1884	1950	1	92	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					949	955		10.1016/S0140-6736(00)90011-4	http://dx.doi.org/10.1016/S0140-6736(00)90011-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768432				2022-12-28	WOS:000086054000008
J	Thomson, R; Parkin, D; Eccles, M; Sudlow, M; Robinson, A				Thomson, R; Parkin, D; Eccles, M; Sudlow, M; Robinson, A			Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation	LANCET			English	Article							COST-EFFECTIVENESS; MEDICAL LITERATURE; USERS GUIDES; WARFARIN; ASPIRIN; COMMUNITY; COMPLICATIONS; PROPHYLAXIS; POPULATION; PREVALENCE	Background Clinical guidelines are needed on whether or not to use anticoagulant therapy to prevent stroke in patients with non-valvular atrial fibrillation. We did a Markov decision analysis to model decision-making with regard to warfarin treatment in patients with atrial fibrillation, and used the model to develop evaluative guidelines. Methods The decision analysis involved a systematic literature review supplemented by patients' estimates of the quality of life associated with different states of health, secondary analysis of stroke-registry data, and estimation of service costs; it also incorporated a sensitivity analysis. The derived guidelines were subsequently applied to a cohort of patients with atrial fibrillation, Findings We constructed decision tables for 12 age and sex groups. For most risk combinations, warfarin treatment would have decreased healthcare costs and increased quality-of-life years, although the clinical decision was sensitive to patients' preferences and to the estimate of warfarin's effectiveness. 97% of women with atrial fibrillation older than 75 years, and 69% aged 65-74 would have been recommended for treatment; for men, the corresponding figures would have been 75% and 53%, With the upper quartile for the loss of quality of life associated with being on warfarin treatment (1.00), all but two of the 116 patients without contraindications would have been treated, whereas with the lower quartile (0.92), only 27 of 116 would have been treated. Interpretation Decision analysis is useful in the incorporation of complex probabilistic data into informed decision-making, the identification of factors influencing such decisions, and the subsequent development of evaluative guidelines.	Med Sch Newcastle Upon Tyne, Sch Hlth Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Med Sch Newcastle Upon Tyne, Sch Hlth Sci, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Thomson, R (corresponding author), Med Sch Newcastle Upon Tyne, Sch Hlth Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	richard.thomson@ncl.ac.uk	Eccles, Martin P/AAD-4029-2020					[Anonymous], 1997, ARCH INTERN MED, V157, P1237; *ATR FIBR INV, 1994, ARCH INTERN MED, V15, P1449; BERTAKIS KD, 1977, J FAM PRACTICE, V5, P217; *COCHR COLL, 1997, COCHR STROK GROUP SE; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; *CTR REV DISS, 1996, MAK COST EFF INF ACC; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; ECKMAN MH, 1995, CHEST, V108, pS457, DOI 10.1378/chest.108.4_Supplement.457S; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FORBES JF, 1995, COSTS HLTH OUTCOMES; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gage BF, 1998, STROKE, V29, P1083, DOI 10.1161/01.STR.29.6.1083; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; HUTCHINSON A, 1995, DEV IMPLEMENTATION C; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; KING D, 1995, BRIT J CLIN PRACT, V49, P123; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; Lilford R, 1998, J Health Serv Res Policy, V3, P159; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; *OFF NAT STAT, 1997, ANN ABSTR STAT; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PETERSEN P, 1989, LANCET, V1, P175; Rodgers H, 1997, BRIT J GEN PRACT, V47, P309; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; SANDERCOCK P, 1992, BRIT MED J, V305, P1460, DOI 10.1136/bmj.305.6867.1460; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P153; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Ubel PA, 1997, SOC SCI MED, V44, P647, DOI 10.1016/S0277-9536(96)00217-1; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; 1994, EFFECTIVE HLTH CARE	45	142	143	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					956	962		10.1016/S0140-6736(00)90012-6	http://dx.doi.org/10.1016/S0140-6736(00)90012-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YH	10768433				2022-12-28	WOS:000086054000009
J	Chi, TH; Crabtree, GR				Chi, TH; Crabtree, GR			Signal transduction - Inositol phosphates in the nucleus	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; ARGININE		Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University	Chi, TH (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.							Cocco L, 1998, ADV ENZYME REGUL, V38, P351, DOI 10.1016/S0065-2571(97)00014-9; CRABEEL M, 1995, YEAST, V11, P1367, DOI 10.1002/yea.320111405; DUBOIS E, 1994, MOL GEN GENET, V243, P315, DOI 10.1007/BF00301067; El Bakkoury M, 2000, MOL MICROBIOL, V35, P15, DOI 10.1046/j.1365-2958.2000.01665.x; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Helliwell SB, 1998, GENETICS, V148, P99; Maraldi NM, 1999, J CELL PHYSIOL, V181, P203, DOI 10.1002/(SICI)1097-4652(199911)181:2<203::AID-JCP3>3.0.CO;2-O; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; Wu C., COMMUNICATION; York JD, 1998, ADV ENZYME REGUL, V38, P365, DOI 10.1016/S0065-2571(97)00018-6; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YORK JW, COMMUNICATION; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	15	34	35	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1937	+		10.1126/science.287.5460.1937	http://dx.doi.org/10.1126/science.287.5460.1937			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10755944				2022-12-28	WOS:000085902800031
J	Greene, HW; Cundall, D				Greene, HW; Cundall, D			Evolutionary biology - Limbless tetrapods and snakes with legs	SCIENCE			English	Editorial Material									Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14850 USA; Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18015 USA	Cornell University; Lehigh University	Greene, HW (corresponding author), Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14850 USA.		Cundall, David/AAO-7496-2021					Caldwell MW, 1997, NATURE, V386, P705, DOI 10.1038/386705a0; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; CUNDALL D, 1993, ZOOL J LINN SOC-LOND, V109, P275, DOI 10.1006/zjls.1993.1039; CUNDALL D, 1995, J ZOOL, V237, P353, DOI 10.1111/j.1469-7998.1995.tb02767.x; GANS C, 1986, HERPETOLOGICA, V42, P33; Greene H. W., 1997, SNAKES EVOLUTION MYS; Kley NJ, 1999, NATURE, V402, P369, DOI 10.1038/46460; Lee MSY, 1999, NATURE, V400, P655, DOI 10.1038/23236; Lee MSY, 1998, EVOLUTION, V52, P1441, DOI 10.1111/j.1558-5646.1998.tb02025.x; Lee MSY, 1998, PHILOS T ROY SOC B, V353, P1521, DOI 10.1098/rstb.1998.0308; List J. C., 1966, Illinois Biological Monographs, VNo. 36, P1; RIEPPEL O, 1988, EVOL BIOL, V22, P37; Rodriguez-Robles JA, 1999, J ZOOL, V248, P49; Scanlon J.D., 1999, Historical Biology, V13, P127; Tchernov E, 2000, SCIENCE, V287, P2010, DOI 10.1126/science.287.5460.2010; Wake D B, 1999, Novartis Found Symp, V222, P24; Zaher H, 1999, CR ACAD SCI II A, V329, P831, DOI 10.1016/S1251-8050(00)88639-5	17	46	49	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1939	1941		10.1126/science.287.5460.1939	http://dx.doi.org/10.1126/science.287.5460.1939			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10755945				2022-12-28	WOS:000085902800032
J	Jan, YN; Jan, LY				Jan, YN; Jan, LY			Polarity in cell division: What frames thy fearful asymmetry?	CELL			English	Review							DROSOPHILA; ELEGANS; PAR-3		Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Jan, YN (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Gho M, 1999, DEVELOPMENT, V126, P3573; Hung TJ, 1999, DEVELOPMENT, V126, P127; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Lu BW, 2000, ANNU REV NEUROSCI, V23, P531, DOI 10.1146/annurev.neuro.23.1.531; Lu BW, 1999, CURR BIOL, V9, P1247, DOI 10.1016/S0960-9822(99)80505-3; Lu BW, 1999, MOL CELL, V4, P883, DOI 10.1016/S1097-2765(00)80218-X; SCHAEFER M, 2000, IN PRESS CURR BIOL; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	19	69	70	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 17	2000	100	6					599	602		10.1016/S0092-8674(00)80695-9	http://dx.doi.org/10.1016/S0092-8674(00)80695-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761924	Bronze			2022-12-28	WOS:000085983800001
J	Koster, JC; Marshall, BA; Ensor, N; Corbett, JA; Nichols, CG				Koster, JC; Marshall, BA; Ensor, N; Corbett, JA; Nichols, CG			Targeted overactivity of beta cell K-ATP channels induces profound neonatal diabetes	CELL			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; SENSITIVE POTASSIUM CHANNELS; DEFECTIVE INSULIN-SECRETION; SULFONYLUREA RECEPTOR GENE; PORE-FORMING SUBUNIT; TRANSGENIC MICE; GLUCOKINASE GENE; FAMILIAL HYPERINSULINISM; NONSENSE MUTATION; KIR6.2	A paradigm for control of insulin secretion is that glucose metabolism elevates cytoplasmic [ATP]/[ADP] in beta cells, closing K-ATP channels and causing depolarization, Ca2+ entry, and insulin release. Decreased responsiveness of K-ATP channels to elevated [ATP]/[ADP] should therefore lead to decreased insulin secretion and diabetes. To test this critical prediction, we generated transgenic mice expressing beta cell K-ATP channels with reduced ATP sensitivity. Animals develop severe hyperglycemia, hypoinsulinemia, and ketoacidosis within 2 days and typically die within 5. Nevertheless, islet morphology, insulin localization, and alpha and beta cell distributions were normal (before day 3), pointing to reduced insulin secretion as causal. The data indicate that normal K-ATP channel activity is critical for maintenance of euglycemia and that overactivity can cause diabetes by inhibiting insulin secretion.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Saint Louis University	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.		Nichols, Colin/D-6336-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, R01DK055282, K08DK002339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55282, DK20579, DK02339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; BAETENS D, 1978, DIABETES, V27, P1, DOI 10.2337/diabetes.27.1.1; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BONNERWEIR S, 1983, J CLIN INVEST, V71, P44; Bosch F, 1998, ANNU REV NUTR, V18, P207, DOI 10.1146/annurev.nutr.18.1.207; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; CESAR LA, 1994, VIRCHOWS ARCH, V425, P73; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; Dobie KW, 1996, P NATL ACAD SCI USA, V93, P6659, DOI 10.1073/pnas.93.13.6659; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Hani EH, 1998, DIABETOLOGIA, V41, P1511, DOI 10.1007/s001250051098; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hogan B, 1994, MANIPULATING MOUSE E; HUMASON GL, 1997, HUMASONS ANIMAL TISS, P361; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Koster JC, 1999, J GEN PHYSIOL, V114, P203, DOI 10.1085/jgp.114.2.203; Koster JC, 1999, J PHYSIOL-LONDON, V515, P19, DOI 10.1111/j.1469-7793.1999.019ad.x; Lalli MJ, 1998, PFLUG ARCH EUR J PHY, V436, P957, DOI 10.1007/s004240050729; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MARSHALL BA, 1994, AM J PHYSIOL-ENDOC M, V267, pE738, DOI 10.1152/ajpendo.1994.267.5.E738; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; MISLER S, 1992, DIABETES, V41, P1211; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; OVERBEEK P, 1994, TRANSGENIC ANIMAL TE, P96; PHILIPSON LH, 1994, J BIOL CHEM, V269, P27787; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; PRAVTCHEVA DD, 1991, DEVELOPMENT, V111, P1109; Proks P, 1999, J PHYSIOL-LONDON, V514, P19, DOI 10.1111/j.1469-7793.1999.019af.x; RAHIER J, 1983, DIABETOLOGIA, V24, P366; Reimann F, 1999, J PHYSIOL-LONDON, V518, P325, DOI 10.1111/j.1469-7793.1999.0325p.x; Sakura H, 1998, DIABETOLOGIA, V41, P654, DOI 10.1007/s001250050964; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; ZHOU YP, 1995, ENDOCRINOLOGY, V136, P3546, DOI 10.1210/en.136.8.3546	72	233	243	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 17	2000	100	6					645	654		10.1016/S0092-8674(00)80701-1	http://dx.doi.org/10.1016/S0092-8674(00)80701-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761930	Bronze			2022-12-28	WOS:000085983800007
J	Hammond, SM; Bernstein, E; Beach, D; Hannon, GJ				Hammond, SM; Bernstein, E; Beach, D; Hannon, GJ			An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells	NATURE			English	Article							MESSENGER-RNA; EXPRESSION; PLANTS; VIRUS	In a diverse group of organisms that includes Caenorhabditis elegans, Drosophila, planaria, hydra, trypanosomes, fungi and plants, the introduction of double-stranded RNAs inhibits gene expression in a sequence-specific manner(1-7). These responses, called RNA interference or post-transcriptional gene silencing, may provide anti-viral defence, modulate transposition or regulate gene expression(1,6,8-10). We have taken a biochemical approach towards elucidating the mechanisms underlying this genetic phenomenon. Here we show that 'loss-of-function' phenotypes can be created in cultured Drosophila cells by transfection with specific double-stranded RNAs. This coincides with a marked reduction in the level of cognate cellular messenger RNAs. Extracts of transfected cells contain a nuclease activity that specifically degrades exogenous transcripts homologous to transfected double-stranded RNA. This enzyme contains an essential RNA component. After partial purification, the sequence-specific nuclease co-fractionates with a discrete, similar to 25-nucleotide RNA species which may confer specificity to the enzyme through homology to the substrate mRNAs.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Genet Inc, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA; UCL, Wolfson Inst Biol Sci, London WC1E 6BT, England	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of London; University College London	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.org	Hannon, Gregory/AAB-3568-2019					Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Bosher JM, 1999, GENETICS, V153, P1245; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Jones AL, 1998, EMBO J, V17, P6385, DOI 10.1093/emboj/17.21.6385; Jones L, 1999, PLANT CELL, V11, P2291, DOI 10.1105/tpc.11.12.2291; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Lohmann JU, 1999, DEV BIOL, V214, P211, DOI 10.1006/dbio.1999.9407; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; SHUTTLEWORTH J, 1988, EMBO J, V7, P427, DOI 10.1002/j.1460-2075.1988.tb02830.x; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wolf DA, 1998, CURR BIOL, V8, pR636, DOI 10.1016/S0960-9822(07)00410-1	23	2183	2688	10	224	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					293	296		10.1038/35005107	http://dx.doi.org/10.1038/35005107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749213				2022-12-28	WOS:000086022200051
J	Corper, AL; Stratmann, T; Apostolopoulos, V; Scott, CA; Garcia, KC; Kang, AS; Wilson, IA; Teyton, L				Corper, AL; Stratmann, T; Apostolopoulos, V; Scott, CA; Garcia, KC; Kang, AS; Wilson, IA; Teyton, L			A structural framework for deciphering the link between I-A(g7) and autoimmune diabetes	SCIENCE			English	Article							BIOZZI AB/H MICE; A BETA-CHAIN; CRYSTAL-STRUCTURE; PEPTIDE; PROTEIN; COMPLEX; MELLITUS; MOLECULES; EPITOPE; DRA-ASTERISK-0101	Susceptibility to murine and human insulin-dependent diabetes mellitus correlates strongly with major histocompatibility complex (MHC) class II I-A or HLA-DQ alleles that lack an aspartic acid at position beta 57. I-A(g7) lacks this aspartate and is the only class II allele expressed by the nonobese diabetic mouse. The crystal structure of I-A(g7) was determined at 2.6 angstrom resolution as a complex with a high-affinity peptide from the autoantigen glutamic acid decarboxylase (CAD) 65. I-A(g7) has a substantially wider peptide-binding groove around beta 57, which accounts for distinct peptide preferences compared with other MHC class II alleles. Loss of Asp(beta 57) Leads to an oxyanion hole in I-A(g7) that can be filled by peptide carboxyl residues or, perhaps, through interaction with the T cell receptor.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu; lteyton@scripps.edu	Apostolopoulos, Vasso/Q-4525-2019	Stratmann, Thomas/0000-0001-6196-1487; Apostolopoulos, Vasso/0000-0001-6788-2771; Kang, Angray/0000-0002-4672-4114	NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055037] Funding Source: NIH RePORTER; NCI NIH HHS [CA58896] Funding Source: Medline; NIDDK NIH HHS [DK55037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; AMOR S, 1993, J IMMUNOL, V150, P5666; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartnes K, 1997, INT IMMUNOL, V9, P1185, DOI 10.1093/intimm/9.8.1185; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrasco-Marin E, 1999, P NATL ACAD SCI USA, V96, P8621, DOI 10.1073/pnas.96.15.8621; CarrascoMarin E, 1996, J IMMUNOL, V156, P450; Chao CC, 1997, IMMUNOGENETICS, V46, P29, DOI 10.1007/s002510050238; Chao CC, 1999, P NATL ACAD SCI USA, V96, P9299, DOI 10.1073/pnas.96.16.9299; CORPER A, UNPUB; Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; Harrison LC, 1997, J EXP MED, V185, P1013, DOI 10.1084/jem.185.6.1013; Hausmann DHF, 1999, J EXP MED, V189, P1723, DOI 10.1084/jem.189.11.1723; HURTENBACH U, 1993, J EXP MED, V177, P1499, DOI 10.1084/jem.177.5.1499; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU GY, 1993, IMMUNOGENETICS, V37, P296, DOI 10.1007/BF00187458; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; NALEFSKI EA, 1995, J BIOL CHEM, V270, P22351, DOI 10.1074/jbc.270.38.22351; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUARTEYPAPAFIO R, 1995, J IMMUNOL, V154, P5567; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Read RJ, 1997, METHOD ENZYMOL, V277, P110, DOI 10.1016/S0076-6879(97)77009-5; REICH EP, 1994, J IMMUNOL, V152, P2279; Reizis B, 1997, INT IMMUNOL, V9, P43, DOI 10.1093/intimm/9.1.43; Ridgway WM, 1999, CURR OPIN IMMUNOL, V11, P638, DOI 10.1016/S0952-7915(99)00030-8; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3; SINGER SM, 1993, P NATL ACAD SCI USA, V90, P9566, DOI 10.1073/pnas.90.20.9566; SMILEK DE, 1990, IMMUNOL REV, V118, P37, DOI 10.1111/j.1600-065X.1990.tb00813.x; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; STIFFEL C, 1987, IMMUNOL LETT, V16, P205, DOI 10.1016/0165-2478(87)90149-0; STURA EA, 1991, J CRYST GROWTH, V110, P270, DOI 10.1016/0022-0248(91)90896-D; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	47	221	233	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					505	511		10.1126/science.288.5465.505	http://dx.doi.org/10.1126/science.288.5465.505			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775108				2022-12-28	WOS:000086626000043
J	Sachdev, S				Sachdev, S			Quantum criticality: Competing ground states in low dimensions	SCIENCE			English	Review							HIGH-TEMPERATURE SUPERCONDUCTORS; HEISENBERG-ANTIFERROMAGNET; NONZERO-TEMPERATURE; TRANSVERSE FIELD; CRITICAL-POINTS; HUBBARD-MODEL; PHASE-DIAGRAM; GAUGE-THEORY; DYNAMICS; SYSTEMS	Small changes in an external parameter can often lead to dramatic qualitative changes in the Lowest energy quantum mechanical ground state of a correlated electron system. In anisotropic crystals, such as the high-temperature superconductors where electron motion occurs primarily on a two-dimensional square Lattice, the quantum critical point between two such Lowest energy states has nontrivial emergent excitations that control the physics over a significant portion of the phase diagram. Nonzero temperature dynamic properties near quantum critical points are described, using simple theoretical models. Possible quantum phases and transitions in the two-dimensional electron gas on a square Lattice are discussed.	Yale Univ, Dept Phys, New Haven, CT 06520 USA	Yale University	Sachdev, S (corresponding author), Yale Univ, Dept Phys, POB 208120, New Haven, CT 06520 USA.	subir.sachdev@yale.edu	Sachdev, Subir/A-8781-2013; Sachdev, Subir/Y-3037-2019	Sachdev, Subir/0000-0002-2432-7070; Sachdev, Subir/0000-0002-2432-7070				Aeppli G, 1997, SCIENCE, V278, P1432, DOI 10.1126/science.278.5342.1432; Bailey DB, 1997, PHYS REV B, V55, P15239, DOI 10.1103/PhysRevB.55.15239; Balents L, 1999, PHYS REV B, V60, P1654, DOI 10.1103/PhysRevB.60.1654; BASKARAN G, 1988, PHYS REV B, V37, P580, DOI 10.1103/PhysRevB.37.580; Bobroff J, 1999, PHYS REV LETT, V83, P4381, DOI 10.1103/PhysRevLett.83.4381; Bourges P, 1998, NATO ADV SCI I B-PHY, V371, P349; CHAKRAVARTY S, 1989, PHYS REV B, V39, P2344, DOI 10.1103/PhysRevB.39.2344; CHUBUKOV AV, 1993, PHYS REV LETT, V71, P169, DOI 10.1103/PhysRevLett.71.169; CHUBUKOV AV, 1994, PHYS REV B, V49, P11919, DOI 10.1103/PhysRevB.49.11919; Damle K, 1997, PHYS REV B, V56, P8714, DOI 10.1103/PhysRevB.56.8714; FISHER MPA, 1990, PHYS REV LETT, V64, P587, DOI 10.1103/PhysRevLett.64.587; Fong HF, 1999, PHYS REV LETT, V82, P1939, DOI 10.1103/PhysRevLett.82.1939; Fujiyama S, 1999, PHYS REV B, V60, P9801, DOI 10.1103/PhysRevB.60.9801; HERTZ JA, 1976, PHYS REV B, V14, P1165, DOI 10.1103/PhysRevB.14.1165; Hunt AW, 1999, PHYS REV LETT, V82, P4300, DOI 10.1103/PhysRevLett.82.4300; IMAI T, 1993, PHYS REV LETT, V70, P1002, DOI 10.1103/PhysRevLett.70.1002; KATOH N, 1994, J PHYS SOC JPN, V63, P4529, DOI 10.1143/JPSJ.63.4529; KIVELSON SA, 1987, PHYS REV B, V35, P8865, DOI 10.1103/PhysRevB.35.8865; KOTLIAR G, 1988, PHYS REV B, V37, P3664, DOI 10.1103/PhysRevB.37.3664; LANDAU LD, 1980, STAT PHYSICS; Lee HL, 2000, SCIENCE, V287, P633, DOI 10.1126/science.287.5453.633; Lee YS, 1999, PHYS REV B, V60, P3643, DOI 10.1103/PhysRevB.60.3643; MARSTON JB, 1989, PHYS REV B, V39, P11538, DOI 10.1103/PhysRevB.39.11538; MILLIS AJ, 1993, PHYS REV B, V48, P7183, DOI 10.1103/PhysRevB.48.7183; READ N, 1990, PHYS REV B, V42, P4568, DOI 10.1103/PhysRevB.42.4568; READ N, 1991, PHYS REV LETT, V66, P1773, DOI 10.1103/PhysRevLett.66.1773; Sachdev S, 1997, PHYS REV LETT, V78, P2220, DOI 10.1103/PhysRevLett.78.2220; SACHDEV S, 1992, PHYS REV LETT, V69, P2411, DOI 10.1103/PhysRevLett.69.2411; Sachdev S, 1999, SCIENCE, V286, P2479, DOI 10.1126/science.286.5449.2479; Sachdev S., 1999, QUANTUM PHASE TRANSI; SCHULZ HJ, 1989, J PHYS-PARIS, V50, P2833, DOI 10.1051/jphys:0198900500180283300; SCHULZ HJ, 1989, PHYS REV B, V39, P2940, DOI 10.1103/PhysRevB.39.2940; Singh RRP, 1999, PHYS REV B, V60, P7278, DOI 10.1103/PhysRevB.60.7278; SOKOL A, 1993, PHYS REV LETT, V71, P2813, DOI 10.1103/PhysRevLett.71.2813; Sondhi SL, 1997, REV MOD PHYS, V69, P315, DOI 10.1103/RevModPhys.69.315; Tranquada JM, 1997, PHYS REV LETT, V78, P338, DOI 10.1103/PhysRevLett.78.338; Tranquada JM, 1999, PHYS REV B, V59, P14712, DOI 10.1103/PhysRevB.59.14712; TYC S, 1990, PHYS REV B, V42, P2096, DOI 10.1103/PhysRevB.42.2096; Valla T, 1999, SCIENCE, V285, P2110, DOI 10.1126/science.285.5436.2110; Vojta M, 1999, PHYS REV LETT, V83, P3916, DOI 10.1103/PhysRevLett.83.3916; WEN XG, 1991, PHYS REV B, V44, P2664, DOI 10.1103/PhysRevB.44.2664; White SR, 1999, PHYS REV B, V60, pR753, DOI 10.1103/PhysRevB.60.R753; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391	48	348	350	0	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					475	480		10.1126/science.288.5465.475	http://dx.doi.org/10.1126/science.288.5465.475			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775100	Green Submitted			2022-12-28	WOS:000086626000035
J	Alberts, DS; Martinez, ME; Roe, DJ; Guillen-Rodriguez, JM; Marshall, JR; van Leeuwen, JB; Reid, ME; Ritenbaugh, C; Vargas, PA; Bhattacharyya, AB; Earnest, DL; Sampliner, RE; Parish, D; Koonce, K; Fales, L				Alberts, DS; Martinez, ME; Roe, DJ; Guillen-Rodriguez, JM; Marshall, JR; van Leeuwen, JB; Reid, ME; Ritenbaugh, C; Vargas, PA; Bhattacharyya, AB; Earnest, DL; Sampliner, RE; Parish, D; Koonce, K; Fales, L		Phoenix Colon Canc Prevention Phys	Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WHEAT BRAN FIBER; COLON-CANCER; DIETARY FIBER; RANDOMIZED TRIAL; RISK-FACTORS; BILE-ACIDS; POLYPS; MEN; FAT; EPIDEMIOLOGY	Background: The risks of colorectal cancer and adenoma, the precursor lesion, are believed to be influenced by dietary factors. Epidemiologic evidence that cereal fiber protects against colorectal cancer is equivocal. We conducted a randomized trial to determine whether dietary supplementation with wheat-bran fiber reduces the rate of recurrence of colorectal adenomas. Methods: We randomly assigned 1429 men and women who were 40 to 80 years of age and who had had one or more histologically confirmed colorectal adenomas removed within three months before recruitment to a supervised program of dietary supplementation with either high amounts (13.5 g per day) or low amounts (2 g per day) of wheat-bran fiber. The primary end point was the presence or absence of new adenomas at the time of follow-up colonoscopy. Subjects and physicians, including colonoscopists, were unaware of the group assignments. Results: Of the 1303 subjects who completed the study, 719 had been randomly assigned to the high-fiber group and 584 to the low-fiber group. The median times from randomization to the last follow-up colonoscopy were 34 months in the high-fiber group and 36 months in the low-fiber group. By the time of the last follow-up colonoscopy, at least one adenoma had been identified in 338 subjects in the high-fiber group (47.0 percent) and in 299 subjects in the low-fiber group (51.2 percent). The multivariate adjusted odds ratio for recurrent adenoma in the high-fiber group, as compared with the low-fiber group, was 0.88 (95 percent confidence interval, 0.70 to 1.11; P=0.28), and the relative risk of recurrence according to the number of adenomas, in the high-fiber group as compared with the low-fiber group, was 0.99 (95 percent confidence interval, 0.71 to 1.36; P=0.93). Conclusions: As used in this study, a dietary supplement of wheat-bran fiber does not protect against recurrent colorectal adenomas. (N Engl J Med 2000;342:1156-62.) (C) 2000, Massachusetts Medical Society.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Coll Publ Hlth, Tucson, AZ USA; Univ Arizona, Dept Pathol, Tucson, AZ USA; Univ Arizona, Dept Med, Tucson, AZ USA; Ctr Hlth Res, Portland, OR USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Vet Affairs Med Ctr, Tucson, AZ USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	Alberts, DS (corresponding author), Univ Arizona, Arizona Canc Ctr, POB 245024, Tucson, AZ 85724 USA.	dalberts@azcc.arizona.edu		Ritenbaugh, Cheryl/0000-0002-3307-2727; Vargas, Perla/0000-0003-2852-3922	NCI NIH HHS [KO1CA79069-10, CA-41108, CA-23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074, K01CA079069, P01CA041108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts DS, 1997, CANCER EPIDEM BIOMAR, V6, P161; Alberts DS, 1996, JNCI-J NATL CANCER I, V88, P81, DOI 10.1093/jnci/88.2.81; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; BIDOLI E, 1992, INT J CANCER, V50, P223, DOI 10.1002/ijc.2910500211; BURKITT DP, 1971, CANCER, V28, P3, DOI 10.1002/1097-0142(197107)28:1<3::AID-CNCR2820280104>3.0.CO;2-N; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Diggle PJ, 1995, J AM STAT ASSOC; EASTWOOD MA, 1992, ANNU REV NUTR, V12, P19, DOI 10.1146/annurev.nu.12.070192.000315; EMERSON SS, 1993, STAT MED, V12, P339, DOI 10.1002/sim.4780120316; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GREEN S, 1992, INVEST NEW DRUG, V10, P239, DOI 10.1007/BF00944177; HILL MJ, 1991, EUROPEAN JOURNAL OF CANCER PREVENTION, VOL 1, SUPPLEMENT 2, OCTOBER 1991, P69, DOI 10.1097/00008469-199110002-00012; LAMPE JW, 1992, CANCER EPIDEM BIOMAR, V1, P207; LAVECCHIA C, 1988, INT J CANCER, V41, P492, DOI 10.1002/ijc.2910410404; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P813; Martinez ME, 1999, CANCER EPIDEM BIOMAR, V8, P941; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; MCKEOWNEYSSEN GE, 1995, J CLIN EPIDEMIOL, V48, pR1; *NAT AC SCI, 1989, DIET NUTR CANC; PETERS RK, 1989, CANCER RES, V49, P5459; Platz EA, 1997, CANCER EPIDEM BIOMAR, V6, P661; POTTER JD, 1997, FOOD NUTR PREVENTION; REDDY BS, 1977, CANCER RES, V37, P3238; REDDY BS, 1994, GASTROENTEROLOGY, V106, P883, DOI 10.1016/0016-5085(94)90746-3; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; Ritenbaugh C, 1997, CANCER EPIDEM BIOMAR, V6, P347; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; *WHO STUD GROUP DI, 1990, DIET NUTR PREV CHRON; Winawer SJ, 1998, GASTROENTEROLOGY, V114, P625; Wolk A, 1999, JAMA-J AM MED ASSOC, V281, P1998, DOI 10.1001/jama.281.21.1998	36	596	615	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 20	2000	342	16					1156	1162		10.1056/NEJM200004203421602	http://dx.doi.org/10.1056/NEJM200004203421602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305DG	10770980				2022-12-28	WOS:000086523700002
J	Schatzkin, A; Lanza, E; Corle, D; Lance, P; Iber, F; Caan, B; Shike, M; Weissfeld, J; Burt, R; Cooper, MR; Kikendall, JW; Cahill, J; Freedman, L; Marshall, J; Schoen, RE; Slattery, M				Schatzkin, A; Lanza, E; Corle, D; Lance, P; Iber, F; Caan, B; Shike, M; Weissfeld, J; Burt, R; Cooper, MR; Kikendall, JW; Cahill, J; Freedman, L; Marshall, J; Schoen, RE; Slattery, M		Polyp Prevention Trial Study Grp	Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; COLON-CANCER; ANTIOXIDANT VITAMINS; CLINICAL-TRIAL; NURSES HEALTH; LARGE-BOWEL; PREVENTION; RISK; WOMEN; EPIDEMIOLOGY	Background: We tested the hypothesis that dietary intervention can inhibit the development of recurrent colorectal adenomas, which are precursors of most large-bowel cancers. Methods: We randomly assigned 2079 men and women who were 35 years of age or older and who had had one or more histologically confirmed colorectal adenomas removed within six months before randomization to one of two groups: an intervention group given intensive counseling and assigned to follow a diet that was low in fat (20 percent of total calories) and high in fiber (18 g of dietary fiber per 1000 kcal) and fruits and vegetables (3.5 servings per 1000 kcal), and a control group given a standard brochure on healthy eating and assigned to follow their usual diet. Subjects entered the study after undergoing complete colonoscopy and removal of adenomatous polyps; they remained in the study for approximately four years, undergoing colonoscopy one and four years after randomization. Results: A total of 1905 of the randomized subjects (91.6 percent) completed the study. Of the 958 subjects in the intervention group and the 947 in the control group who completed the study, 39.7 percent and 39.5 percent, respectively, had at least one recurrent adenoma; the unadjusted risk ratio was 1.00 (95 percent confidence interval, 0.90 to 1.12). Among subjects with recurrent adenomas, the mean (+/-SE) number of such lesions was 1.85+/-0.08 in the intervention group and 1.84+/-0.07 in the control group. The rate of recurrence of large adenomas (with a maximal diameter of at least 1 cm) and advanced adenomas (defined as lesions that had a maximal diameter of at least 1 cm or at least 25 percent villous elements or evidence of high-grade dysplasia, including carcinoma) did not differ significantly between the two groups. Conclusions: Adopting a diet that is low in fat and high in fiber, fruits, and vegetables does not influence the risk of recurrence of colorectal adenomas. (N Engl J Med 2000;342:1149-55.) (C) 2000, Massachusetts Medical Society.	NCI, Bethesda, MD 20892 USA; SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA; Vet Affairs Edward Hines Jr Hosp, Vet Affairs Med Ctr, Hines, IL USA; Kaiser Fdn Res Inst, Oakland, CA USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Utah, Salt Lake City, UT USA; Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; WESTAT Corp, Rockville, MD 20850 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Arizona, Tucson, AZ USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utah System of Higher Education; University of Utah; Wake Forest University; Wake Forest Baptist Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Westat; Memorial Sloan Kettering Cancer Center; University of Arizona	Schatzkin, A (corresponding author), NCI, Bethesda, MD 20892 USA.			Caan, Bette/0000-0002-5803-310X				Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BUSSEY HJR, 1982, CANCER, V50, P1434, DOI 10.1002/1097-0142(19821001)50:7<1434::AID-CNCR2820500733>3.0.CO;2-F; DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290; Friedman LM., 1981, FUNDAMENTALS CLIN TR; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; HILL MJ, 1978, LANCET, V1, P245, DOI 10.1016/S0140-6736(78)90487-7; Ji BT, 1998, CANCER EPIDEM BIOMAR, V7, P661; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Kritchevsky David, 1999, American Journal of Medicine, V106, p28S, DOI 10.1016/S0002-9343(98)00344-1; Lanza E, 1996, CANCER EPIDEM BIOMAR, V5, P584; Little R. J. A., 1987, STAT ANAL MISSING DA; Liu SM, 1999, AM J CLIN NUTR, V70, P412; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; MARESPERLMAN JA, 1993, J NUTR, V123, P489, DOI 10.1093/jn/123.3.489; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; MCKEOWNEYSSEN GE, 1995, J CLIN EPIDEMIOL, V48, pR1; MCMICHAEL AJ, 1988, CANCER RES, V48, P751; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; RONCUCCI L, 1993, DIS COLON RECTUM, V36, P227, DOI 10.1007/BF02053502; SCHATZKIN A, 1994, JNCI-J NATL CANCER I, V86, P1053, DOI 10.1093/jnci/86.14.1053; Schatzkin A, 1996, CANCER EPIDEM BIOMAR, V5, P375; TOMINAGA S, 1994, CANC MORTALITY MORBI; WAKABAYASHI K, 1992, CANCER RES, V52, pS2092; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; ZHAO LP, 1991, NUTR CANCER, V15, P169, DOI 10.1080/01635589109514124; [No title captured]	37	683	704	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 20	2000	342	16					1149	1155		10.1056/NEJM200004203421601	http://dx.doi.org/10.1056/NEJM200004203421601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305DG	10770979				2022-12-28	WOS:000086523700001
J	Kinnersley, P; Anderson, E; Parry, K; Clement, J; Archard, L; Turton, P; Stainthorpe, A; Fraser, A; Butler, CC; Rogers, C				Kinnersley, P; Anderson, E; Parry, K; Clement, J; Archard, L; Turton, P; Stainthorpe, A; Fraser, A; Butler, CC; Rogers, C			Randomised controlled trial of nurse practitioner versus general practitioner care for patients requesting "same day" consultations in primary care	BRITISH MEDICAL JOURNAL			English	Article							PATIENTS SATISFACTION; QUESTIONNAIRE	Objective To ascertain any differences between care from nurse practitioners and that from general practitioners for patients seeking "same day" consultations in primary care. Design Randomised controlled trial with patients allocated by one of two randomisation schemes (by day or within day). Setting 10 general practices in south Wales and south west England. Subjects 1368 patients requesting same dap consultations. Main outcome measures Patient satisfaction, resolution of symptoms and concerns, care provided (prescriptions, investigations, referrals, recall, and length of consultation), information provided to patients, and patients' intentions for seeking care in the future. Results Generally patients consulting nurse practitioners were significantly more satisfied with their care, although for adults this difference was not observed in all practices. For children, the mean difference between general and nurse practitioner in percentage satisfaction score was -4.8 (95% confidence interval -6.8 to -2.8), and for adults the differences ranged from -8.8 (-13.6 to -3.9) to 3.8 (-3.3 to 10.8) across the practices. Resolution of symptoms and concerns did not differ between the two groups (odds ratio 1.2 (95% confidence interval 0.8 to 1.8) for symptoms and 1.03 (0.8 to 1.4) for concerns). The number of prescriptions issued, investigations ordered, referrals to secondary care, and reattendances were similar between the two groups. However, patients managed by nurse practitioners reported receiving significantly more information about their illnesses and, in all but one practice, their consultations were significantly longer. Conclusion This study supports the wider acceptance of the role of nurse practitioners in providing care to patients requesting same day consultations.	Univ Wales Coll Med, Dept Gen Practice, Llanedeyrn Hlth Ctr, Cardiff CF3 7PN, S Glam, Wales; Southmead Gen Hosp, Res & Dev Support Unit, Trust Headquarters, Bristol BS10 5NB, Avon, England; Gloucester Rd Med Ctr, Bristol BS7 8SA, Avon, England; London Sch Econ Hlth, London WC2A 2AE, England; Bristol Canc Help Ctr, Bristol BS8 4PG, Avon, England	Cardiff University; Southmead Hospital; University of London; London School Economics & Political Science	Kinnersley, P (corresponding author), Univ Wales Coll Med, Dept Gen Practice, Llanedeyrn Hlth Ctr, Cardiff CF3 7PN, S Glam, Wales.		Butler, Christopher C/B-5048-2009	Butler, Christopher/0000-0002-0102-3453				BAKER R, 1990, BRIT J GEN PRACT, V40, P487; BECKMAN H, 1989, COMMUNICATING MED PA; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CLEMENT MJ, 1999, RANDOMISED CONTROLLE; Gill D, 1998, BRIT J GEN PRACT, V48, P1856; Helman C., 1984, CULTURE HLTH ILLNESS; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; Kinnersley P, 1999, BRIT J GEN PRACT, V49, P711; KINNERSLEY P, 1997, THESIS U BRISTOL BRI; LEWIS CC, 1986, MED CARE, V24, P209, DOI 10.1097/00005650-198603000-00003; MARSH GN, 1995, BRIT MED J, V310, P778, DOI 10.1136/bmj.310.6982.778; Myers PC, 1997, FAM PRACT, V14, P492, DOI 10.1093/fampra/14.6.492; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS, V1-3; Poulton BC, 1996, BRIT J GEN PRACT, V46, P26; Rees M, 1996, Nurs Times, V92, P32; Royal College of General Practitioners, 1986, MORB STAT GEN PRACT; SALISBURY CJ, 1988, J ROY COLL GEN PRACT, V38, P314; Stewart M, 1995, PATIENT CTR MED TRAN	18	244	247	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1043	1048		10.1136/bmj.320.7241.1043	http://dx.doi.org/10.1136/bmj.320.7241.1043			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764366	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086675700025
J	Bishop, RA; Litch, JA				Bishop, RA; Litch, JA			Medical tourism can do harm	BRITISH MEDICAL JOURNAL			English	Editorial Material														Litch, James/0000-0003-0570-0308					0	38	38	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					1017	1017		10.1136/bmj.320.7240.1017	http://dx.doi.org/10.1136/bmj.320.7240.1017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753174	Green Published			2022-12-28	WOS:000086453100074
J	Provan, D; Weatherall, D				Provan, D; Weatherall, D			Red cells II: acquired anaemias and polycythaemia	LANCET			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; BONE-MARROW TRANSPLANTATION; SEVERE APLASTIC-ANEMIA; COBALAMIN DEFICIENCY; TRANSFERRIN RECEPTOR; PERNICIOUS-ANEMIA; MYELODYSPLASIA; PATHOGENESIS; DISEASE; POLYCYTHEMIA	Iron deficiency affects 30% of the world's population. Iron metabolism is tightly regulated, with both gut transport and storage being coordinated. Hereditary haemochromatosis due to mutations in the HFE gene loads to increased absorption of iron and multiple end-organ damage. Myelodysplastic disorders are acquired clonal stem-cell disorders that cause ineffective erythropoiesis. Aplastic anaemia is caused by an intrinsic defect of haemopoietic stem cells; both inherited and acquired forms occur. Primary polycythaemia is a myeloproliferative disorder, a non-malignant stem-cell disease.	Southampton Univ Hosp NHS Trust, Dept Haematol, Southampton SO16 6UY, Hants, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Oxford	Provan, D (corresponding author), Southampton Univ Hosp NHS Trust, Dept Haematol, Southampton SO16 6UY, Hants, England.		Provan, Drew/AAF-2766-2021	Provan, Drew/0000-0002-5110-8455				Anderson JE, 1996, BRIT J HAEMATOL, V93, P59, DOI 10.1046/j.1365-2141.1996.4811022.x; BAER AN, 1990, SEMIN ARTHRITIS RHEU, V19, P209, DOI 10.1016/0049-0172(90)90001-V; BENCH AJ, 2000, MOL HAEMATOLOGY; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Berlin NI, 1997, SEMIN HEMATOL, V34, P1; BOULTWOOD J, 1994, BLOOD, V84, P3253; CALLENDER ST, 1966, BRIT J HAEMATOL, V12, P276, DOI 10.1111/j.1365-2141.1966.tb05634.x; CAMITTA BM, 1979, BLOOD, V53, P504; CHAMPLIN RE, 1984, BRIT J HAEMATOL, V56, P455, DOI 10.1111/j.1365-2141.1984.tb03975.x; Chanarin I, 1997, BRIT J HAEMATOL, V97, P695, DOI 10.1046/j.1365-2141.1997.00124.x; COOK JD, 1994, ADV EXP MED BIOL, V356, P219; Dacie J., 1992, AUTOIMMUNE HAEMOLYTI; Department of Health Expert Advisory Group, 1992, FOL AC PREV NEUR TUB; DEPLANQUE MM, 1988, BRIT J HAEMATOL, V70, P55; FAIRBANKS VF, 1983, MAYO CLIN PROC, V58, P541; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Gordon-Smith EC, 1999, POSTGRADUATE HAEMATO, P68; GORDONSMITH EC, 1999, POSTGRADUATE HAEMATO, P144; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hallberg L, 1984, Acta Med Scand, V216, P147; HOFFBRAND AV, 1999, POSTGRADUATE HAEMATO, P47; HUSSEIN S, 1978, SCAND J HAEMATOL, V20, P241; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KOHGO Y, 1988, JAPANESE J MED, V27, P67; MEANS RT, 1992, BLOOD, V80, P1639; Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; PASSMORE SJ, 1995, BLOOD, V85, P1742, DOI 10.1182/blood.V85.7.1742.bloodjournal8571742; PEARSON TC, 1991, BLOOD REV, V5, P205, DOI 10.1016/0268-960X(91)90010-A; Petz Lawrence D., 1993, Transfusion Medicine Reviews, V7, P242, DOI 10.1016/S0887-7963(93)70144-3; PIPPARD MJ, 1999, POSTGRADUATE HAEMATO, P23; Provan D, 1999, BRIT J HAEMATOL, V105, P19; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; SAVAGE DG, 1995, BAILLIERE CLIN HAEM, V8, P657, DOI 10.1016/S0950-3536(05)80225-2; SELIGMAN PA, 1979, J BIOL CHEM, V254, P9943; Socie G, 1996, LANCET, V348, P573, DOI 10.1016/S0140-6736(95)12360-1; SPIVAK JL, 1982, ARCH INTERN MED, V142, P2111, DOI 10.1001/archinte.142.12.2111; Toh BH, 1997, NEW ENGL J MED, V337, P1441, DOI 10.1056/NEJM199711133372007; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579; WICKRAMASINGHE SN, 1995, BAILLIERE CLIN HAEM, V8, P441, DOI 10.1016/S0950-3536(05)80215-X; WINSTON RM, 1970, BRIT J HAEMATOL, V19, P587, DOI 10.1111/j.1365-2141.1970.tb01642.x; Zoller H, 1999, LANCET, V353, P2120, DOI 10.1016/S0140-6736(98)11179-0	43	22	22	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 8	2000	355	9211					1260	1268		10.1016/S0140-6736(00)02099-7	http://dx.doi.org/10.1016/S0140-6736(00)02099-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770319				2022-12-28	WOS:000086448000040
J	Kopelman, PG				Kopelman, PG			Obesity as a medical problem	NATURE			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; LEFT-VENTRICULAR FUNCTION; WEIGHT-GAIN; INSULIN-RESISTANCE; SLEEP-APNEA; WAIST CIRCUMFERENCE; ENERGY-EXPENDITURE; BODY-WEIGHT; WOMEN	Obesity is now so common within the world's population that it is beginning to replace undernutrition and infectious diseases as the mast significant contributor to ill health. In particular, obesity is associated with diabetes mellitus, coronary heart disease, certain forms of cancer, and sleep-breathing disorders. Obesity is defined by a body-mass index (weight divided by square of the height) of 30 kg m(-2) or greater, but this does not take into account the morbidity and mortality associated with more modest degrees of overweight, nor the detrimental effect of intra-abdominal fat. The global epidemic of obesity results from a combination of genetic susceptibility, increased availability of high-energy foods and decreased requirement for physical activity in modern society. Obesity should no longer be regarded simply as a cosmetic problem affecting certain individuals, but an epidemic that threatens global well being.	St Bartholomews & Royal London Sch Med, Univ London Queen Mary & Westfield Coll, London E1 2AD, England	University of London; Queen Mary University London	Kopelman, PG (corresponding author), St Bartholomews & Royal London Sch Med, Univ London Queen Mary & Westfield Coll, London E1 2AD, England.		Duarte, Graziela Biude Silva/Q-7728-2016					[Anonymous], 1980, SOC ACT BUILD STUD 1; [Anonymous], 1995, WHO TECH REP SER; Barker D. J., 1989, BMJ-BRIT MED J, V298, P654; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Bennett N, 1995, HLTH SURVEY ENGLAND; Blundell JE, 1997, ANN NY ACAD SCI, V827, P392, DOI 10.1111/j.1749-6632.1997.tb51850.x; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; DEDIVITIIS O, 1981, CIRCULATION, V64, P477, DOI 10.1161/01.CIR.64.3.477; DELAMAZA MP, 1994, INT J OBESITY, V18, P193; DIETZ WH, 1994, AM J CLIN NUTR, V59, P829; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; FERROLUZZI A, 1996, ORIGINS CONSEQUENCES, P207; FORRESTER T, 1996, ORIGINS CONSEQUENCES, P17; Frayn KN, 1996, CLIN SCI, V90, P243, DOI 10.1042/cs0900243; GARAVAGLIA GE, 1988, AM J CARDIOL, V62, P594, DOI 10.1016/0002-9149(88)90662-5; GORMAKER S, 1996, ARCH PEDIAT ADOLESC, V150, P356; Grunstein RR, 1998, CLINICAL OBESITY-BOOK, P248; GRUNSTEIN RR, 1995, INT J OBESITY, V19, P410; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HAN TS, 1995, BRIT MED J, V311, P1401, DOI 10.1136/bmj.311.7017.1401; HODGE AM, 1995, OBES RES, V3, pS77, DOI 10.1002/j.1550-8528.1995.tb00450.x; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; HUBERT HB, 1986, ANNU REV PUBL HEALTH, V7, P493, DOI 10.1146/annurev.pu.07.050186.002425; JAME SW, 1996, ORIGINS CONSEQUENCES, P1; KOLTERMAN OG, 1980, J CLIN INVEST, V65, P1272, DOI 10.1172/JCI109790; KOPELMAN PG, 1986, INT J OBESITY, V10, P211; KOPELMAN PG, 1985, J ROY COLL PHYS LOND, V19, P243; KOPELMAN PG, 1992, INT J OBESITY, V16, pS37; KOPELMAN PG, 1994, MED INT, V22, P385; Kotani K, 1997, INT J OBESITY, V21, P912, DOI 10.1038/sj.ijo.0800492; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; LAWTON JH, 1993, TRENDS ECOL EVOL, V8, P409, DOI 10.1016/0169-5347(93)90043-O; Lean MEJ, 1998, LANCET, V351, P853, DOI 10.1016/S0140-6736(97)10004-6; LEW EA, 1985, ANN INTERN MED, V103, P1024, DOI 10.7326/0003-4819-103-6-1024; LICATA G, 1991, INT J OBESITY, V15, P295; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MASSERLI FH, 1982, CIRCULATION, V66, P55; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MUSAIGER AO, 1996, DIET RELATED NONCOMM, P99; PALOMAKI H, 1992, NEUROLOGY, V42, P75; POPKIN BM, 1994, NUTR REV, V52, P285, DOI 10.1111/j.1753-4887.1994.tb01460.x; Poppitt SD, 1998, INT J OBESITY, V22, P303, DOI 10.1038/sj.ijo.0800584; Prentice AM, 1996, EUR J CLIN NUTR, V50, P93; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PRESCOTTCLARKE P, 1988, HLTH SURVEY ENGLAND; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; RAVUSSIN E, 1995, METABOLISM S3, V9, P12; REYNISDOTTIR S, 1994, J CLIN INVEST, V93, P2590, DOI 10.1172/JCI117271; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; ROCHESTER DF, 1974, AM J MED, V57, P402, DOI 10.1016/0002-9343(74)90135-1; Rose G., 1991, NUTR METAB CARDIOVAS, V1, P37; SEIDELL JC, 1992, INT J OBESITY, V16, P667; SEIDELL JC, 1995, INT J OBESITY, V19, pS13; SNIDERMAN AD, 1995, INT J OBESITY, V19, pS27; *WHO MONICA PROJ, 1988, WORLD HLTH STAT Q, V41, P115; WILKS R, 1996, ORIGINS CONSEQUENCES, P37; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607; World Health Organization, 1997, OB PREV MAN GLOB EP; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	68	3250	3461	8	454	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					635	643		10.1038/35007508	http://dx.doi.org/10.1038/35007508			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766250				2022-12-28	WOS:000086400100063
J	Morrison, RS; Wallenstein, S; Natale, DK; Senzel, RS; Huang, LL				Morrison, RS; Wallenstein, S; Natale, DK; Senzel, RS; Huang, LL			"We don't carry that" - Failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE-ONCOLOGY-GROUP; CANCER PAIN; SURGERY; MANAGEMENT; MEDICATION; ATTITUDES; RELIEF	Background: We have observed that many black and Hispanic patients receiving palliative care at a major urban teaching hospital are unable to obtain prescribed opioids from their neighborhood pharmacies. In this study, we investigated the availability of commonly prescribed opioids in New York City pharmacies. Methods: We surveyed a randomly selected sample of 30 percent of New York City pharmacies to obtain information about their stock of opioids. For each pharmacy, U.S. Census estimates for 1997 were used to determine the racial and ethnic composition of the neighborhood (defined as the area within a 0.4-km [0.25-mile] radius of the pharmacy) and the proportion of residents who were more than 65 years old. Data on robberies, burglaries, and arrests involving illicit drugs in 1997 were obtained for the precinct in which each pharmacy was located. We used a generalized linear model to examine the relation between the racial or ethnic composition of neighborhoods and the opioid supplies of pharmacies, while controlling for the proportion of elderly persons at the census-block level and for crime rates at the precinct level. Results: Pharmacists representing 347 of 431 eligible pharmacies (81 percent) responded to the survey. A total of 176 pharmacies (51 percent) did not have sufficient supplies of opioids to treat patients with severe pain. Only 25 percent of pharmacies in predominantly nonwhite neighborhoods (those in which less than 40 percent of residents were white) had opioid supplies that were sufficient to treat patients in severe pain, as compared with 72 percent of pharmacies in predominantly white neighborhoods (those in which at least 80 percent of residents were white) (P<0.001). Conclusions: Pharmacies in predominantly nonwhite neighborhoods of New York City do not stock sufficient medications to treat patients with severe pain adequately. (N Engl J Med 2000;342:1023-6.) (C) 2000, Massachusetts Medical Society.	Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Hertzberg Palliat Care Inst, New York, NY USA; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Morrison, RS (corresponding author), CUNY Mt Sinai Sch Med, Dept Geriatr, Box 1070,1 Gustave L Levy Pl, New York, NY 10029 USA.			Natale, Dana/0000-0003-4976-0310	NATIONAL INSTITUTE ON AGING [K08AG000833] Funding Source: NIH RePORTER; NIA NIH HHS [K08AG00833-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Breitbart W, 1996, PAIN, V68, P315, DOI 10.1016/S0304-3959(96)03215-0; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; CLOSS SJ, 1990, J ADV NURS, V15, P42, DOI 10.1111/j.1365-2648.1990.tb01671.x; COHEN FL, 1980, PAIN, V9, P265, DOI 10.1016/0304-3959(80)90013-5; FAHERTY BS, 1984, NURS RES, V33, P369, DOI 10.1097/00006199-198411000-00013; JACOX A, 1994, CLIN PRACTICE GUIDEL, V9, P257; KANNER RM, 1986, J PAIN SYMPTOM MANAG, V1, P187; KELSEN DP, 1995, J CLIN ONCOL, V13, P748, DOI 10.1200/JCO.1995.13.3.748; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LARUE F, 1995, BRIT MED J, V310, P1034, DOI 10.1136/bmj.310.6986.1034; Lynch EP, 1997, ANESTH ANALG, V85, P117, DOI 10.1097/00000539-199707000-00021; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; *MED EC, 1998, PHYS DESK REF; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; MORRISON RS, IN PRESS J PAIN SYMP; *NYNEX INF RES, 1998, NYNEX YELL PAG; OATES JDL, 1994, ANAESTHESIA, V49, P755; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; Tay W. K. J., 1994, Annals Academy of Medicine Singapore, V23, P191; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; ZENZ M, 1995, J PAIN SYMPTOM MANAG, V10, P187, DOI 10.1016/0885-3924(94)00122-2	25	282	284	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	2000	342	14					1023	1026		10.1056/NEJM200004063421406	http://dx.doi.org/10.1056/NEJM200004063421406			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	300JB	10749965	Bronze			2022-12-28	WOS:000086248900006
J	[Anonymous]				[Anonymous]			Don't blame NASA alone for Mars mission failures	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					527	527						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766199				2022-12-28	WOS:000086400100001
J	Joranson, DE; Ryan, KM; Gilson, AM; Dahl, JL				Joranson, DE; Ryan, KM; Gilson, AM; Dahl, JL			Trends in medical use and abuse of opioid analgesics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PAIN MANAGEMENT; ADDICTION; BARRIERS; SYSTEM	Context Pain often is inadequately treated due in part to reluctance about using opioid analgesics and fear that they will be abused. Although international and national expert groups have determined that opioid analgesics are essential for the relief of pain, little information has been available about the health consequences of the abuse of these drugs. Objective To evaluate the proportion of drug abuse related to opioid analgesics and the trends in medical use and abuse of 5 opioid analgesics used to treat severe pain: fentanyl, hydromorphone, meperidine, morphine, and oxycodone. Design and Setting Retrospective survey of medical records from 1990 to 1996 stored in the databases of the Drug Abuse Warning Network (source of abuse data)and the Automation of Reports and Consolidated Orders System (source of medical use data). Patients Nationally representative sample of hospital emergency department admissions resulting from drug abuse. Main Outcome Measures Medical use in grams and grams per 100 000 population and mentions of drug abuse by number and percentage of the population. Results From 1990 to 1996, there were increases in medical use of morphine (59%; 2.2 to 3.5 million g), fentanyl (1168%; 3263 to 41 371 g), oxycodone (23%; 1.6 to 2.0 million g), and hydromorphone (19%; 118 455 to 141 325 g), and a decrease in the medical use of meperidine (35%; 5.2 to 3.4 million g). During the same period, the total number of drug abuse mentions per year due to opioid analgesics increased from 32 430 to 34 563 (6.6%), although the proportion of mentions for opioid abuse relative to total drug abuse mentions decreased from 5.1% to 3.8%. Reports of abuse decreased for meperidine (39%; 1335 to 806), oxycodone (29%; 4526 to 3190), fentanyl (59%; 59 to 24), and hydromorphone (15%; 718 to 609), and increased for morphine (3%; 838 to 865). Conclusions The trend of increasing medical use of opioid analgesics to treat pain does not appear to contribute to increases in the health consequences of opioid analgesic abuse.	Univ Wisconsin, Sch Med, Pain & Policy Studies Grp, Ctr Comprehens Canc, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Joranson, DE (corresponding author), Univ Wisconsin, Sch Med, Pain & Policy Studies Grp, Ctr Comprehens Canc, 1900 Univ Ave, Madison, WI 53705 USA.							*AC PAIN MAN GUID, 1992, CLIN PRACT GUID; ADAMS EH, 1991, NEW YORK STATE J MED, V91, pS32; *ALC DRUG AB MENT, 1990, DAT DRUG AB WARN NET; American Academy of Pain Medicine and American Pain Society, 1997, US OP TREATM CHRON P; [Anonymous], [No title captured]; Doyle D., 1993, OXFORD TXB PALLIATIV; *DRUG ENF ADM, 1997, ARCOS DAT SEL OP AN; *DRUG ENF ADM, 1984, ARCOS DADS STATE LOC; Federation of State Medical Boards of the United States, 1998, MOD GUID US CONTR SU; Field MJ, 1997, APPROACHING DEATH IM; HILL CS, 1993, SEMIN ONCOL, V20, P1; Jacox A, 1994, CLIN PRACTICE GUIDEL; Joranson D E, 1998, Semin Oncol Nurs, V14, P158, DOI 10.1016/S0749-2081(98)80022-3; JORANSON DE, 1993, MONOGRAPH NATL I DRU, V131, P18; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lebovits AH, 1997, CLIN J PAIN, V13, P237, DOI 10.1097/00002508-199709000-00009; Litovitz TL, 1998, AM J EMERG MED, V16, P443, DOI 10.1016/S0735-6757(98)90000-6; MCCAFFERY M, 1995, AM J NURS, V95, P61; *OFF INSP GEN US D, 1991, AUD REP DRUG ENF ADM; Paice JA, 1998, J PAIN SYMPTOM MANAG, V16, P1, DOI 10.1016/S0885-3924(98)00025-6; *SUBST AB MENT HLT, 1996, DAT DRUG AB WARN NET; *SUBST AB MENT HLT, 1997, NATL HOUSEHOLD SURVE; *UN, 1977, SINGL CONV NARC DRUG; Ward SE, 1996, RES NURS HEALTH, V19, P205, DOI 10.1002/(SICI)1098-240X(199606)19:3<205::AID-NUR4>3.0.CO;2-O; WEISSMAN DE, 1993, SEMIN ONCOL, V20, P53; World Health Organization, 1996, CANC PAIN REL GUID O	27	354	370	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1710	1714		10.1001/jama.283.13.1710	http://dx.doi.org/10.1001/jama.283.13.1710			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	298BK	10755497				2022-12-28	WOS:000086119300031
J	Salsberg, E; Nolan, J				Salsberg, E; Nolan, J			The posttraining plans of international medical graduates and US medical graduates in New York State	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									SUNY Albany, Sch Publ Hlth, Ctr Workforce Studies, Rensselaer, NY 12144 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany	Salsberg, E (corresponding author), SUNY Albany, Sch Publ Hlth, Ctr Workforce Studies, Rensselaer, NY 12144 USA.							Baer LD, 1998, MED CARE, V36, P1534, DOI 10.1097/00005650-199811000-00003; *COUNC GRAD MED ED, 1999, 14 US DHHS COUNC GRA; *COUNC GRAD MED ED, 1998, 11 US DHHS COUNC GRA; *I MED, 1996, NAT PHYS WORKF OPT B; *MED PAYM ADV COMM, 1998, REP C MED PAYM POL; Politzer RM, 1998, MED CARE RES REV, V55, P116, DOI 10.1177/107755879805500107; 1999, JAMA, V282, P897	7	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1749	1750		10.1001/jama.283.13.1749	http://dx.doi.org/10.1001/jama.283.13.1749			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298BK	10755507				2022-12-28	WOS:000086119300041
J	Zamore, PD; Tuschl, T; Sharp, PA; Bartel, DP				Zamore, PD; Tuschl, T; Sharp, PA; Bartel, DP			RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals	CELL			English	Article							CAENORHABDITIS-ELEGANS; TOMATO LEAVES; GENE; INTERFERENCE; NEUROSPORA; POLYMERASE	Double-stranded RNA (dsRNA) directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). Using a recently developed Drosophila in vitro system, we examined the molecular mechanism underlying RNAi. We find that RNAi is ATP dependent yet uncoupled from mRNA translation. During the RNAi reaction, both strands of the dsRNA are processed to RNA segments 21-23 nucleotides in length. Processing of the dsRNA to the small RNA fragments does not require the targeted mRNA. The mRNA is cleaved only within the region of identity with the dsRNA. Cleavage occurs at sites 21-23 nucleotides apart, the same interval observed for the dsRNA itself, suggesting that the 21-23 nucleotide fragments from the dsRNA are guiding mRNA cleavage.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA; Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37077 Gottingen, Germany; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of Massachusetts System; University of Massachusetts Worcester; Max Planck Society; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Zamore, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA.	phillip.zamore@umassmed.edu; ttuschl@mpibpc.gwdg.de	Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618				Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; BASS BL, 1997, TRENDS BIOCHEM SCI, V22, P278; Baulcombe DC, 1999, CURR OPIN PLANT BIOL, V2, P109, DOI 10.1016/S1369-5266(99)80022-3; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Cundliffe E., 1981, MOL BASIS ANTIBIOTIC, V2nd, P402; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gebauer F, 1999, EMBO J, V18, P6146, DOI 10.1093/emboj/18.21.6146; Grant SR, 1999, CELL, V96, P303, DOI 10.1016/S0092-8674(00)80541-3; GRISHOK A, 2000, IN PRESS SCIENCE; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hunter CP, 2000, CURR BIOL, V10, pR137, DOI 10.1016/S0960-9822(00)00325-0; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lohmann JU, 1999, DEV BIOL, V214, P211, DOI 10.1006/dbio.1999.9407; Merrick WC., 1996, TRANSLATION CONTROL, P31; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Page AW, 1997, DEV BIOL, V183, P195, DOI 10.1006/dbio.1997.8506; QIAO L, 1995, GENETICS, V141, P551; Ratcliff FG, 1999, PLANT CELL, V11, P1207, DOI 10.1105/tpc.11.7.1207; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11851; Schiebel W, 1998, PLANT CELL, V10, P2087, DOI 10.1105/tpc.10.12.2087; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11858; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Silberklang M, 1979, Methods Enzymol, V59, P58; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Wagner RW, 1998, NATURE, V391, P744, DOI 10.1038/35750; Wargelius A, 1999, BIOCHEM BIOPH RES CO, V263, P156, DOI 10.1006/bbrc.1999.1343; Waterhouse PM, 1999, TRENDS PLANT SCI, V4, P452, DOI 10.1016/S1360-1385(99)01493-4; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016	46	1972	2604	11	341	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 31	2000	101	1					25	33		10.1016/S0092-8674(00)80620-0	http://dx.doi.org/10.1016/S0092-8674(00)80620-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778853	Bronze			2022-12-28	WOS:000086249900005
J	Quinn, JP; Rodvold, KA				Quinn, JP; Rodvold, KA			Antibiotic policies in neonatal intensive-care units	LANCET			English	Editorial Material							ANTIMICROBIAL RESISTANCE		Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm & Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Quinn, JP (corresponding author), Univ Illinois, Dept Med, Chicago, IL 60612 USA.							Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; Gould IM, 1999, J ANTIMICROB CHEMOTH, V43, P459, DOI 10.1093/jac/43.4.459; Itokazu GS, 1996, CLIN INFECT DIS, V23, P779, DOI 10.1093/clinids/23.4.779; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; Shlaes DM, 1997, CLIN INFECT DIS, V25, P584, DOI 10.1086/513766	7	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					946	947		10.1016/S0140-6736(00)90009-6	http://dx.doi.org/10.1016/S0140-6736(00)90009-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768429				2022-12-28	WOS:000086054000005
J	Thum, T; Borlak, J				Thum, T; Borlak, J			Gene expression in distinct regions of the heart	LANCET			English	Article							CONVERTING ENZYME-INHIBITORS; CYTOCHROME-P450; ACID; LIVER	Background Cytochrome P450 mono-oxygenases bring about metabolism of marry drugs, including verapamil, but no information is available on the metabolism of such drugs in the human heart. Methods We investigated the gene expression of major human cytochrome P450 monooxygenases in the various regions of explanted hearts from six patients with dilated cardiomyopathy and one with transposition of the arterial trunk. For comparison we also studied samples of liver and lung from three patients and two samples of normal heart. The biological significance of tissue-specific cytochrome monooxygenase gene expression was further investigated by study of the microsomal metabolism of verapamil in ventricular tissue. Findings mRNA for the cytochromes 1A1, 2B6/7, 2C8-19, 2D6, and 4B1 was predominantly expressed in the right ventricle, the unilateral expression of the 2D6 gene in right-venticular tissue is important because of its key role in the metabolism of beta-blockers. A strong correlation between tissue-specific gene expression and enzyme activity was found; microsomal metabolism of verapamil was confined to the right ventricle. By contrast, cytochrome P450 3A genes (which are the major drug-metabolising enzymes in the liver and the lung) were not expressed in any of the human heart tissues, and mRNA transcripts for epoxide hydrolase, cytochrome P450 2E1, and flavin-containing monooxygenases 2 and 5 were detected in all regions of the human heart and the great vessels. Interpretation These findings show that expression of genes for cytochrome P450 monooxygenases and verapamil metabolism are found predominantly in the right side of the heart. This finding may explain lack of efficacy of certain cardioselective drugs.	Fraunhofer Inst Toxicol & Aerosol Res, Dept Mol Toxicol & Pharmacokinet, D-30659 Hannover, Germany	Fraunhofer Gesellschaft	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Aerosol Res, Dept Mol Toxicol & Pharmacokinet, Nicolal Fuchs Str 1, D-30659 Hannover, Germany.			Thum, Thomas/0000-0003-4360-1511				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARISTIZABAL D, 1994, AM J CARDIOL, V73, P483, DOI 10.1016/0002-9149(94)90679-3; BORLAK JT, 1994, BIOCHEM PHARMACOL, V48, P1717, DOI 10.1016/0006-2952(94)90456-1; Cheng YF, 1998, J CHROMATOGR A, V828, P273, DOI 10.1016/S0021-9673(98)00823-1; Clarke SE, 1998, XENOBIOTICA, V28, P1167, DOI 10.1080/004982598238877; HAKKOLA J, 1994, BIOCHEM PHARMACOL, V48, P59, DOI 10.1016/0006-2952(94)90223-2; JURIMAROMET M, 1993, BIOCHEM PHARMACOL, V46, P2163, DOI 10.1016/0006-2952(93)90605-V; Kivisto KT, 1996, N-S ARCH PHARMACOL, V353, P207; MCCALLUM GP, 1993, CAN J PHYSIOL PHARM, V71, P151, DOI 10.1139/y93-021; Oldham HG, 1997, DRUG METAB DISPOS, V25, P970; PRICE T, 1992, J CLIN ENDOCR METAB, V74, P879, DOI 10.1210/jc.74.4.879; RAUNIO H, 1995, ADV DRUG METABOLISM, P233; Smith DA, 1998, XENOBIOTICA, V28, P1095, DOI 10.1080/004982598238859; Smith G, 1998, XENOBIOTICA, V28, P1129, DOI 10.1080/004982598238868; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEARNS RA, 1995, DRUG METAB DISPOS, V23, P207; Tracy TS, 1999, BRIT J CLIN PHARMACO, V47, P545, DOI 10.1046/j.1365-2125.1999.00923.x; Wu S, 1996, J BIOL CHEM, V271, P3460; Xiao YF, 1998, J PHYSIOL-LONDON, V508, P777, DOI 10.1111/j.1469-7793.1998.777bp.x; ZIERHUT W, 1990, J CARDIOVASC PHARM, V16, P480, DOI 10.1097/00005344-199009000-00019	20	159	167	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 18	2000	355	9208					979	983		10.1016/S0140-6736(00)99016-0	http://dx.doi.org/10.1016/S0140-6736(00)99016-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768437				2022-12-28	WOS:000086054000013
J	Dulac, C				Dulac, C			The physiology of taste, vintage 2000	CELL			English	Review							OLFACTORY-BULB; C-ELEGANS; GENETICS; MICE; RESPONSES; SUCROSE		Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Dulac, C (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	dulac@fas.harvard.edu		Dulac, Catherine/0000-0001-5024-5418				Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Belluscio L, 1999, CELL, V97, P209, DOI 10.1016/S0092-8674(00)80731-X; BRILLATSAVARIN J, 1826, PHYSL GOUT MEDITATIO, V8; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Herness MS, 1999, ANNU REV PHYSIOL, V61, P873, DOI 10.1146/annurev.physiol.61.1.873; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; LUSH IE, 1984, GENET RES, V44, P151, DOI 10.1017/S0016672300026355; LUSH IE, 1989, GENET RES, V53, P95, DOI 10.1017/S0016672300027968; LUSH IE, 1981, GENET RES, V38, P93, DOI 10.1017/S0016672300020425; Reed DR, 1999, AM J HUM GENET, V64, P1478, DOI 10.1086/302367; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0	18	34	36	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 17	2000	100	6					607	610		10.1016/S0092-8674(00)80697-2	http://dx.doi.org/10.1016/S0092-8674(00)80697-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761926	Bronze			2022-12-28	WOS:000085983800003
J	Szabo, SJ; Kim, ST; Costa, GL; Zhang, XK; Fathman, CG; Glimcher, LH				Szabo, SJ; Kim, ST; Costa, GL; Zhang, XK; Fathman, CG; Glimcher, LH			A novel transcription factor, T-bet, directs Th1 lineage commitment	CELL			English	Article							INTERFERON-GAMMA PROMOTER; CYTOKINE GENE-EXPRESSION; HELPER CELL SUBSETS; NATURAL-KILLER; IFN-GAMMA; IMMUNE-RESPONSES; TRANSGENIC MICE; FACTOR GATA-3; DNA-BINDING; T-HELPER-1	Naive T helper cells differentiate into two subsets, Th1 and Th2, each with distinct functions and cytokine profiles. Here, we report the isolation of T-bet, a Th1-specific T box transcription factor that controls the expression of the hallmark Th1 cytokine, IFN gamma. T-bet expression correlates with IFN gamma expression in Th1 and NK cells. Ectopic expression of T-bet both transactivates the IFN gamma gene and induces endogenous IFN gamma production. Remarkably, retroviral gene transduction of T-bet into polarized Th2 and Tc2 primary T cells redirects them into Th1 and Tc1 cells, respectively, as evidenced by the simultaneous induction of IFN gamma and repression of IL-4 and IL-5. Thus, T-bet initiates Th1 lineage development from naive Thp cells both by activating Th1 genetic programs and by repressing the opposing Th2 programs.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Stanford Univ, Sch Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Stanford University; Medical University of South Carolina	Glimcher, LH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	lglimche@hsph.harvard.edu			NIAID NIH HHS [AI/AG 37833, AI 39646, AI 36535] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037833, P01AI039646, P01AI036535] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; BROMBACHER F, 1994, INT IMMUNOL, V6, P189, DOI 10.1093/intimm/6.2.189; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; Coccia EM, 1999, J BIOL CHEM, V274, P6698, DOI 10.1074/jbc.274.10.6698; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Huang H, 1997, J IMMUNOL, V159, P3731; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; KORNBLUTH J, 1982, J IMMUNOL, V129, P2831; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; LEDERER JA, 1994, J IMMUNOL, V152, P77; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Nakamura T, 1997, J IMMUNOL, V158, P1085; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Papaioannou VE, 1997, TRENDS GENET, V13, P212, DOI 10.1016/S0168-9525(97)01144-X; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; Rodriguez-Esteban C, 1999, NATURE, V398, P814, DOI 10.1038/19769; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Takeuchi JK, 1999, NATURE, V398, P810, DOI 10.1038/19762; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TONY Y, 1995, CURR BIOL, V5, P1; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yasui DH, 1998, J IMMUNOL, V160, P4433; YODOI J, 1985, J IMMUNOL, V134, P1623; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	64	2605	2839	1	98	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 17	2000	100	6					655	669		10.1016/S0092-8674(00)80702-3	http://dx.doi.org/10.1016/S0092-8674(00)80702-3			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	295TK	10761931	Bronze			2022-12-28	WOS:000085983800008
J	Macilwain, C				Macilwain, C			US energy agency pulls plug on role in genome project	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					4	4		10.1038/35003706	http://dx.doi.org/10.1038/35003706			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10755905	Bronze			2022-12-28	WOS:000085775100005
J	Nieto, FJ; Young, TB; Lind, BK; Shahar, E; Samet, JM; Redline, S; D'Agostino, RB; Newman, AB; Lebowitz, MD; Pickering, TG				Nieto, FJ; Young, TB; Lind, BK; Shahar, E; Samet, JM; Redline, S; D'Agostino, RB; Newman, AB; Lebowitz, MD; Pickering, TG		Sleep Heart Hlth Study	Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE AIRWAY PRESSURE; BLOOD-PRESSURE; SYSTEMIC HYPERTENSION; RISK-FACTORS; RELATIVE RISK; PREVALENCE; POPULATION; MORTALITY; HEALTH; MEN	Context Sleep-disordered breathing (SDB) and sleep apnea have been linked to hypertension in previous studies, but most of these studies used surrogate information to define SDB (eg, snoring) and were based on small clinic populations, or both. Objective To assess the association between SDB and hypertension in a large cohort of middle-aged and older persons. Design and Setting Cross-sectional analyses of participants in the Sleep Heart Health Study, a community-based multicenter study conducted between November 1995 and January 1998. Participants A total of 6132 subjects recruited from ongoing population-based studies (aged greater than or equal to 40 years; 52.8% female). Main Outcome Measures Apnea-hypopnea index (AHI, the average number of apneas plus hypopneas per hour of sleep, with hypopnea defined as a greater than or equal to 30% reduction in airflow or thoracoabdominal excursion accompanied by a greater than or equal to 4% drop in oxyhemoglobin saturation), obtained by unattended home polysomnography. Other measures include arousal index; percentage of sleep time below 90% oxygen saturation; history of snoring; and presence of hypertension, defined as resting blood pressure of at least 140/90 mm Hg or use of antihypertensive medication. Results Mean systolic and diastolic blood pressure and prevalence of hypertension increased significantly with increasing SDB measures, although some of this association was explained by body mass index (BMI). After adjusting for demographics and anthropometric variables (including BMI, neck circumference, and waist-to-hip ratio), as well as for alcohol intake and smoking, the odds ratio for hypertension, comparing the highest category of AHI (greater than or equal to 30 per hour) with the lowest category (<1.5 per hour), was 1.37 (95% confidence interval [CI], 1.03-1.83; P for trend=.005). The corresponding estimate comparing the highest and lowest categories of percentage of sleep time below 90% oxygen saturation (greater than or equal to 12% vs <0.05%) was 1.46 (95% CI, 1.12-1.88; P for trend <.001). In stratified analyses, associations of hypertension with either measure of SDB were seen in both sexes, older and younger ages, all ethnic groups, and among normal-weight and overweight individuals. Weaker and nonsignificant associations were observed for the arousal index or self-reported history of habitual snoring. Conclusion Our findings from the largest cross-sectional study to date indicate that SDB is associated with systemic hypertension in middle-aged and older individuals of different sexes and ethnic backgrounds.	Johns Hopkins Univ, Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Univ Wisconsin, Madison, WI USA; Univ Minnesota, Minneapolis, MN USA; Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Div Clin Epidemiol, Cleveland, OH 44106 USA; Boston Univ, Dept Math, Boston, MA 02215 USA; Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA; Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ USA; Cornell Univ, New York Cornell Med Ctr, Ctr Cardiovasc, New York, NY USA	Johns Hopkins University; University of Wisconsin System; University of Wisconsin Madison; University of Minnesota System; University of Minnesota Twin Cities; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Boston University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Arizona; Cornell University	Nieto, FJ (corresponding author), Johns Hopkins Univ, Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Room W6009, Baltimore, MD 21205 USA.		Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150	NHLBI NIH HHS [U01HL53940, U01HL53938, U01HL53931] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL053940, U01HL053931, U01HL053938] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASKENASY JJM, 1995, ISRAEL J MED SCI, V31, P561; Bartel PR, 1995, AM J HYPERTENS, V8, P1200, DOI 10.1016/0895-7061(95)00387-8; BLIWISE DL, 1988, AM J PUBLIC HEALTH, V78, P544, DOI 10.2105/AJPH.78.5.544; BONNET MH, 1992, SLEEP, V15, P526; BONSIGNORE MR, 1994, EUR RESPIR J, V7, P786, DOI 10.1183/09031936.94.07040786; CARLSON JT, 1994, AM J RESP CRIT CARE, V150, P72, DOI 10.1164/ajrccm.150.1.8025776; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; FLETCHER EC, 1985, ANN INTERN MED, V103, P190, DOI 10.7326/0003-4819-103-2-190; FREEMAN J, 1980, AM J EPIDEMIOL, V112, P707, DOI 10.1093/oxfordjournals.aje.a113043; GISLASON T, 1987, ACTA MED SCAND, V222, P415; GISLASON T, 1993, CHEST, V103, P1147, DOI 10.1378/chest.103.4.1147; GRUNSTEIN R, 1993, INT J OBESITY, V17, P533; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; HOFFSTEIN V, 1991, AM J MED, V91, P190, DOI 10.1016/0002-9343(91)90014-O; Hu FB, 1999, AM J EPIDEMIOL, V150, P806; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; KALES A, 1984, LANCET, V2, P1005; LAVIE P, 1993, CHEST, V103, P717, DOI 10.1378/chest.103.3.717; LAVIE P, 1984, ARCH INTERN MED, V144, P2025, DOI 10.1001/archinte.144.10.2025; LEVINSON PD, 1991, ARCH INTERN MED, V151, P455, DOI 10.1001/archinte.151.3.455; Lindberg E, 1998, EUR RESPIR J, V11, P884, DOI 10.1183/09031936.98.11040884; Martorell R., 1988, ANTHROPOMETRIC STAND, P41; *MATHS INC, 1993, S PLUS 2000 GUID STA, V1; MILLMAN RP, 1991, CHEST, V99, P861, DOI 10.1378/chest.99.4.861; *NAT HIGH BLOOD PR, 1993, NAT I HLTH PUBL; NORTON PG, 1985, BRIT MED J, V291, P630, DOI 10.1136/bmj.291.6496.630; PARTINEN M, 1988, CHEST, V94, P1200, DOI 10.1378/chest.94.6.1200; Pickering T, 1996, AM J HYPERTENS, V9, P1, DOI 10.1016/0895-7061(95)00341-X; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; Quan SF, 1997, SLEEP, V20, P1077; Redline S, 1997, SLEEP, V20, P1209, DOI 10.1093/sleep/20.12.1209; Redline S, 1998, SLEEP, V21, P759; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; *SHHS RES GROP, 1996, SLEEP HEART HLTH STU; SILVERBERG DS, 1995, ISRAEL J MED SCI, V31, P527; Stradling J, 1997, SLEEP, V20, P789, DOI 10.1093/sleep/20.9.789a; STRADLING JR, 1990, BRIT MED J, V300, P75, DOI 10.1136/bmj.300.6717.75; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; SUZUKI M, 1993, SLEEP, V16, P545, DOI 10.1093/sleep/16.6.545; Szklo M., 2019, EPIDEMIOLOGY BASICS, V4; WALLER PC, 1989, LANCET, V1, P143; Whitney CW, 1998, SLEEP, V21, P749, DOI 10.1093/sleep/21.7.749; WIGGINS CL, 1990, SLEEP, V13, P245, DOI 10.1093/sleep/13.3.245; WILCOX I, 1993, SLEEP, V16, P539, DOI 10.1093/sleep/16.6.539; WILLIAMS AJ, 1985, AM J CARDIOL, V55, P1019, DOI 10.1016/0002-9149(85)90738-6; Worsnop CJ, 1998, AM J RESP CRIT CARE, V157, P111, DOI 10.1164/ajrccm.157.1.9609063; Wright J, 1997, BRIT MED J, V314, P851; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; Young T, 1996, SLEEP, V19, pS202, DOI 10.1093/sleep/19.suppl_10.S202; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zhao LP, 1996, AM J EPIDEMIOL, V144, P598	54	2247	2371	2	107	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1829	1836		10.1001/jama.283.14.1829	http://dx.doi.org/10.1001/jama.283.14.1829			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770144	Bronze			2022-12-28	WOS:000086248600028
J	Landray, MJ; Lehman, R; Arnold, I				Landray, MJ; Lehman, R; Arnold, I			Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study	BRITISH MEDICAL JOURNAL			English	Article									Hightown Surg, Banbury OX18 9DB, Oxon, England; Univ Birmingham, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Oxford Radcliffe Hosp NHS Trust, Horton Hosp, Dept Med, Banbury OX16 9AL, Oxon, England	University of Birmingham; Oxford University Hospitals NHS Foundation Trust	Lehman, R (corresponding author), Hightown Surg, Banbury OX18 9DB, Oxon, England.			Landray, Martin/0000-0001-6646-827X				Hoes A. W., 1998, European Heart Journal, V19, pL2; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; Struthers AD, 1999, EUR HEART J, V20, P712; WHEELDON NM, 1993, Q J MED, V86, P17	4	63	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 8	2000	320	7240					985	986		10.1136/bmj.320.7240.985	http://dx.doi.org/10.1136/bmj.320.7240.985			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753153	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086453100028
J	Forbes, JG; Lorimer, GH				Forbes, JG; Lorimer, GH			Structural biology - Unraveling a membrane protein	SCIENCE			English	Editorial Material							ATOMIC-FORCE MICROSCOPY; BACTERIORHODOPSIN; RESOLUTION; TITIN; MOLECULES		Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Forbes, JG (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.							Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; Heymann JB, 1999, J STRUCT BIOL, V128, P243, DOI 10.1006/jsbi.1999.4180; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15177, DOI 10.1021/bi970147b; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15156, DOI 10.1021/bi970146j; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Klimov DK, 1999, P NATL ACAD SCI USA, V96, P6166, DOI 10.1073/pnas.96.11.6166; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Marszalek PE, 1999, NATURE, V402, P100, DOI 10.1038/47083; Marti T, 1998, J BIOL CHEM, V273, P9312, DOI 10.1074/jbc.273.15.9312; Mou JX, 1996, BIOPHYS J, V71, P2213, DOI 10.1016/S0006-3495(96)79422-5; MULLER DJ, 1995, BIOPHYS J, V68, P1681, DOI 10.1016/S0006-3495(95)80345-0; Oberhauser AF, 1999, NAT STRUCT BIOL, V6, P1025; Oesterhelt F, 2000, SCIENCE, V288, P143, DOI 10.1126/science.288.5463.143; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Yang GL, 2000, P NATL ACAD SCI USA, V97, P139, DOI 10.1073/pnas.97.1.139	22	6	7	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					63	64		10.1126/science.288.5463.63	http://dx.doi.org/10.1126/science.288.5463.63			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10766636				2022-12-28	WOS:000086387700028
J	Gavaghan, H				Gavaghan, H			Companies of all sizes are prospecting for proteins	NATURE			English	Editorial Material																		Abbott A, 1999, NATURE, V402, P715, DOI 10.1038/45350; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Brent R, 2000, CELL, V100, P169, DOI 10.1016/S0092-8674(00)81693-1; Kell DB, 2000, TRENDS BIOTECHNOL, V18, P93, DOI 10.1016/S0167-7799(99)01407-9; 2000, NATURE, V403, P815; 1999, NATURE, V402, P715	6	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					684	+		10.1038/35007267	http://dx.doi.org/10.1038/35007267			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766256				2022-12-28	WOS:000086400100069
J	Gavaghan, H				Gavaghan, H			Training - Europe seeks solution to bioinformatics shortfall	NATURE			English	Editorial Material																			0	2	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					687	+		10.1038/35007279	http://dx.doi.org/10.1038/35007279			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766258				2022-12-28	WOS:000086400100071
J	McGlynn, P; Lloyd, RG				McGlynn, P; Lloyd, RG			Modulation of RNA polymerase by (p)ppGpp reveals a RecG-dependent mechanism for replication fork progression	CELL			English	Article							ESCHERICHIA-COLI K-12; HOLLIDAY JUNCTION RESOLVASE; DOUBLE-STRAND BREAKS; MEIOTIC RECOMBINATION; DNA-REPLICATION; HOMOLOGOUS RECOMBINATION; PROTEIN PRIA; TRANSCRIPTION; MUTANTS; REPAIR	We have discovered a correlation between the ability of Escherichia coli cells to survive damage to DNA and their ability to modulate RNA polymerase via the stringent response regulators, (p)ppGpp. Elevation of (p)ppGpp, or certain mutations in the beta subunit of RNA polymerase, dramatically improve survival of UV-irradiated strains lacking the RuvABC Holliday junction resolvase. Increased survival depends on excision and recombination proteins and relies on the ability of RecG helicase to form Holliday junctions from replication forks stalled at lesions in the DNA and of PriA to initiate replication restart. The role of RecG provides novel insights into the interplay between transcription, replication, and recombination, and suggests a general model in which recombination underpins genome duplication in the face of frequent obstacles to replication fork progression.	Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England	University of Nottingham	Lloyd, RG (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England.			McGlynn, Peter/0000-0001-8629-4713				AlDeib AA, 1996, J BACTERIOL, V178, P6782, DOI 10.1128/jb.178.23.6782-6789.1996; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; BACHMANN BJ, 1996, ESCHERICHIA COLI SAL, P2460; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Bolt EL, 1999, J MOL BIOL, V286, P403, DOI 10.1006/jmbi.1998.2499; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chan SN, 1998, NUCLEIC ACIDS RES, V26, P1560, DOI 10.1093/nar/26.7.1560; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; Gentry DR, 1996, MOL MICROBIOL, V19, P1373, DOI 10.1111/j.1365-2958.1996.tb02480.x; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Krasilnikova MM, 1998, EMBO J, V17, P5095, DOI 10.1093/emboj/17.17.5095; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; Lindahl T, 1996, PHILOS T ROY SOC B, V351, P1529, DOI 10.1098/rstb.1996.0139; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; Nicolas A, 1998, P NATL ACAD SCI USA, V95, P87, DOI 10.1073/pnas.95.1.87; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Prado F, 1997, EMBO J, V16, P2826, DOI 10.1093/emboj/16.10.2826; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 1996, GENETICS, V143, P5; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; XIAO H, 1991, J BIOL CHEM, V266, P5980; Xu F, 1996, GENETICS, V143, P1115; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; Zerbib D, 1998, J MOL BIOL, V281, P621, DOI 10.1006/jmbi.1998.1959; Zerbib D, 1997, J MOL BIOL, V270, P663, DOI 10.1006/jmbi.1997.1157; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	48	232	235	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 31	2000	101	1					35	45		10.1016/S0092-8674(00)80621-2	http://dx.doi.org/10.1016/S0092-8674(00)80621-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778854	Bronze			2022-12-28	WOS:000086249900006
J	Bosch, X				Bosch, X			Radical changes urged for Spanish universities	NATURE			English	News Item																		Weitzman JB, 1999, NATURE, V400, P401, DOI 10.1038/22637; 2000, NATURE, V404, P211; 1999, NATURE, V400, P203; 1999, NATURE, V400, P393	4	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					425	426		10.1038/35006711	http://dx.doi.org/10.1038/35006711			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761884	Bronze			2022-12-28	WOS:000086257700007
J	Williams, TJ; Pepitone, ME; Christensen, SE; Cooke, BM; Huberman, AD; Breedlove, NJ; Breedlove, TJ; Jordan, CL; Breedlove, SM				Williams, TJ; Pepitone, ME; Christensen, SE; Cooke, BM; Huberman, AD; Breedlove, NJ; Breedlove, TJ; Jordan, CL; Breedlove, SM			Finger-length ratios and sexual orientation	NATURE			English	Article									Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Grad Grp Neurosci Endocrinol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Williams, TJ (corresponding author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall,MC 1650, Berkeley, CA 94720 USA.		; Cooke, Bradley/E-4568-2013	Breedlove, S. Marc/0000-0003-4359-4315; Cooke, Bradley/0000-0003-0989-9684				BAILEY JM, 1991, ARCH GEN PSYCHIAT, V48, P1089; Blanchard R, 1997, Annu Rev Sex Res, V8, P27; Bogaert AF, 1999, ARCH SEX BEHAV, V28, P213, DOI 10.1023/A:1018780108597; Bogaert AF, 1997, BEHAV NEUROSCI, V111, P1395, DOI 10.1037/0735-7044.111.6.1395; Breedlove SM, 1999, BRAIN BEHAV EVOLUT, V54, P8, DOI 10.1159/000006607; BRODIE HK, 1974, AM J PSYCHIAT, V131, P82, DOI 10.1176/ajp.131.1.82; GORMAN MR, 1994, PERSPECT BIOL MED, V38, P61; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; JAMES WH, 1987, HUM BIOL, V59, P721; Manning JT, 1999, NATURE, V399, P214, DOI 10.1038/20341; Manning JT, 1998, HUM REPROD, V13, P3000, DOI 10.1093/humrep/13.11.3000; MAYERBAHLBURG HFL, 1984, PROGR BRAIN RES, V61, P375; McFadden D, 1998, P NATL ACAD SCI USA, V95, P2709, DOI 10.1073/pnas.95.5.2709; MCFADDEN D, IN PRESS J ASS RES O	14	314	336	6	84	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					455	456		10.1038/35006555	http://dx.doi.org/10.1038/35006555			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761903				2022-12-28	WOS:000086257700034
J	Yasutomo, K; Doyle, C; Miele, L; Germain, RN				Yasutomo, K; Doyle, C; Miele, L; Germain, RN			The duration of antigen receptor signalling determines CD4(+) versus CD8(+) T-cell lineage fate	NATURE			English	Article							CLASS-II INTERACTION; TRANSGENIC MICE; TYROSINE KINASE; THYMOCYTES; COMMITMENT; DIFFERENTIATION; SPECIFICITY; EXPRESSION; ACTIVATION; MECHANISM	Signals elicited by binding of the T-cell antigen receptor and the CD4/CD8 co-receptor to major histocompatibility complex (MHC) molecules control the generation of CD4(+) (helper) or CD8(+) (cytotoxic) T cells from thymic precursors that initially express both co-receptor proteins'. These precursors have unique, clonally distributed T-cell receptors with unpredictable specificity for the self-MHC molecules involved in this differentiation process', However, the mature T cells that emerge express only the CD4 (MHC class II-binding) or CD8 (MHC class I-binding) co-receptor that complements the MHC class-specificity of the T-cell receptor. How this matching of co-receptor-defined lineage and T-cell-receptor specificity is achieved remains unknown(1,3,4), as does whether signalling by the T-cell receptors, co-receptors and/ or general cell-fate regulators such as Notch-1 (refs 5, 6) contributes to initial lineage choice, to subsequent differentiation processes or to both. Here we show that the CD4 versus CD8 lineage fate of immature thymocytes is controlled by the co-receptor-influenced duration of initial T-cell receptor-dependent signalling. Notch-1 does not appear to be essential for this fate determination, but it is selectively required for CD8(+) T-cell maturation after commitment directed by T-cell receptors, This indicates that the signals constraining CD4 versus CD8 lineage decisions are distinct from those that support subsequent differentiation events such as silencing of co-receptor loci.	NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Maywood, IL 60153 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Duke University; Loyola University Chicago	Germain, RN (corresponding author), NIAID, Lymphocyte Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020	Yasutomo, Koji/0000-0003-0411-2037; Miele, Lucio/0000-0002-5853-7287	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000757] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; Basson MA, 1998, J EXP MED, V187, P1249; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bommhardt U, 1999, J IMMUNOL, V163, P715; CHAN TYK, 1995, PHARMACOEPIDEM DR S, V4, P165; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HOGQUIST KA, 1995, IMMUNITY, V3, P79, DOI 10.1016/1074-7613(95)90160-4; INABA M, 1991, J EXP MED, V173, P549, DOI 10.1084/jem.173.3.549; Iwata M, 1996, EUR J IMMUNOL, V26, P2081, DOI 10.1002/eji.1830260918; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; Merkenschlager M, 1997, J EXP MED, V186, P1149, DOI 10.1084/jem.186.7.1149; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Riberdy JM, 1998, P NATL ACAD SCI USA, V95, P4493, DOI 10.1073/pnas.95.8.4493; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; vonBoehmer H, 1996, J EXP MED, V183, P713, DOI 10.1084/jem.183.3.713; WIEST DL, 1993, J EXP MED, V178, P1701, DOI 10.1084/jem.178.5.1701	30	198	206	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					506	510		10.1038/35006664	http://dx.doi.org/10.1038/35006664			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761920				2022-12-28	WOS:000086257700051
J	Syntichaki, P; Topalidou, I; Thireos, G				Syntichaki, P; Topalidou, I; Thireos, G			The Gcn5 bromodomain co-ordinates nucleosome remodelling	NATURE			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; YEAST PHO5 PROMOTER; ADA-COMPLEX; IN-VIVO; CHROMATIN; TRANSCRIPTION; SAGA	The access of transcription factors to eukaryotic promoters often requires modification of their chromatin structure, which is accomplished by the action of two general classes of multiprotein complexes(1). One class contains histone acetyltransferases (HATs), such as Gcn5 in the SAGA complex(2), which acetylate nucleosomal histones. The second dass contains ATPases, such as Swi2 in the Swi/Snf complex(3), which provide the energy for nucleosome remodelling. In several promoters these two complexes cooperate but their functional linkage is unknown(4-8). A protein module that is present in, all, nuclear HATs, the bromodomain, could provide such a link(9). The recently reported in vitro binding of a HAT bromodomain with acetylated lysines within H3 and H4 aminoterminal peptides(10) indicates that this interaction may constitute a targeting step for events that follow histone acetylation. Here we use a suitable promoter to show that bromodomain residues essential for acetyl-lysine binding are not required in vivo for Gcn5-mediated histone acetylation but are fundamental for the subsequent Swi2-dependent nucleosome remodelling and consequent transcriptional activation. We show that the Gcn5 bromodomain stabilizes the Swi/Snf complex on this promoter.	FORTH, Inst Mol Biol & Biotechnol, Heraklion 71110, Crete, Greece; Univ Crete, Dept Biol, Heraklion 71409, Crete, Greece	Foundation for Research & Technology - Hellas (FORTH); University of Crete	Thireos, G (corresponding author), FORTH, Inst Mol Biol & Biotechnol, POB 1527, Heraklion 71110, Crete, Greece.		Topalidou, Irini/ABG-2833-2020; Syntichaki, Popi/ABA-7218-2020	Syntichaki, Popi/0000-0001-9536-8905				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Ornaghi P, 1999, J MOL BIOL, V287, P1, DOI 10.1006/jmbi.1999.2577; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Roberts SM, 1997, GENETICS, V147, P451; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Syntichaki P, 1998, J BIOL CHEM, V273, P24414, DOI 10.1074/jbc.273.38.24414; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640	26	163	165	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					414	417		10.1038/35006136	http://dx.doi.org/10.1038/35006136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746732				2022-12-28	WOS:000086119000057
J	Triendl, R				Triendl, R			Japan's cloning ban will still allow stem cell experiments	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					321	321		10.1038/35006223	http://dx.doi.org/10.1038/35006223			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10766599	Bronze			2022-12-28	WOS:000086119000006
J	Carr, AM				Carr, AM			Cell cycle - Piecing together the p53 puzzle	SCIENCE			English	Editorial Material							P53-DEPENDENT G(1) ARREST		Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England	University of Sussex	Carr, AM (corresponding author), Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England.			Carr, Antony Michael/0000-0002-2028-2389				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chehab NH, 2000, GENE DEV, V14, P278; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; Lohrum M, 1996, ONCOGENE, V13, P2527; Shieh SY, 2000, GENE DEV, V14, P289	13	96	97	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2000	287	5459					1765	1766		10.1126/science.287.5459.1765	http://dx.doi.org/10.1126/science.287.5459.1765			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BY	10755928				2022-12-28	WOS:000085775300027
J	Lipman, T; Price, D				Lipman, T; Price, D			Decision making, evidence, audit, and education: case study of antibiotic prescribing in general practice	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTIONS; WOMEN; 3-DAY; CYSTITIS	Objectives To describe a group general practice's implementation of a decision to prescribe 3 day courses of 200 mg trimethoprim twice daily for urinary tract infections in women and to compare 3 day courses with 5 and 7 day courses. Design Record review, audit of trimethoprim prescribing for urinary tract infections, and critical appraisal of evidence originally presented in support of 3 day course. Setting Group general practice in Newcastle upon Tyne. Data sources The records of all female patients aged 12 years and older who were prescribed trimethoprim for uncomplicated urinary tract infections during a 12 month period were reviewed. 271 valid records were identified. Data extraction Prescribing rates for different courses of trimethoprim, rates of patients returning for second consultations, rates of urine cultures, results of cultures, results of critical appraisal of evidence. Results 114 of 271 (42%) prescriptions written at the first visit were for 3 day courses. 16 of 114 (14%) patients who had had a 3 day course of treatment returned for a second consultation compared with 6/83 (7.2%) of those who had had a 5 day course and 8/74 (11%) who had had a 7 day course. The difference between 3 day and 5 day courses in rates of returning for second consultations was 6.8% (95% CI -1.7% to 12.6%) and between 3 day and 7 day courses was 3.2% (-3.6% to 10.0%). Appraisal of the original evidence on which the practice based its recommendations showed that it was flawed. Additional evidence was found in the Cochrane Library. Conclusions Our original decision, made by consensus at a meeting of the practice's partners, had not led to a consistent change in practice. We did not find a significant increase in treatment failures among patients treated with the 3 day regimen.	Westerhope Med Grp, Newcastle Upon Tyne NE5 2LH, Tyne & Wear, England; Blyth Valley Primary Care Grp, Blyth NE24 2JN, Northd, England	Westerhope Medical Group	Lipman, T (corresponding author), Westerhope Med Grp, Newcastle Upon Tyne NE5 2LH, Tyne & Wear, England.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				[Anonymous], 1995, DRUG THER B, V33, P92; Bailey R R, 1993, Drugs, V45 Suppl 3, P139; BRUMFITT W, 1995, J CHEMOTHERAPY, V7, P136, DOI 10.1179/joc.1995.7.2.136; Dunning M., 1999, EXPERIENCE EVIDENCE; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; Elwood M, 1998, CRITICAL APPRAISAL E; FAIR WR, 1980, J UROLOGY, V123, P717, DOI 10.1016/S0022-5347(17)56104-2; GORDIN A, 1987, SCAND J INFECT DIS, V19, P97, DOI 10.3109/00365548709032384; GREENBERG RN, 1986, J INFECT DIS, V153, P277, DOI 10.1093/infdis/153.2.277; GREENHALGH T, 1997, READ PAPER BASICS EV; Houghton G, 1997, J Eval Clin Pract, V3, P245, DOI 10.1046/j.1365-2753.1997.t01-1-00001.x; IRAVANI A, 1993, AM J MED, V94, P89; LEIBOVICI L, 1991, Q J MED, V78, P43; Lipman T, 1998, BRIT MED J, V317, P604, DOI 10.1136/bmj.317.7158.604; LIPMAN T, 1998, ROYAL COLL GEN PRACT; NEU HC, 1992, AM J MED, V92, pS63, DOI 10.1016/0002-9343(92)90312-Y; *NHS, 1994, NHS NO YORKSH REG DR, V5, P17; NORRBY SR, 1990, REV INFECT DIS, V12, P458; Onion CWR, 1998, FAM PRACT, V15, P99, DOI 10.1093/fampra/15.2.99; OSTERBERG E, 1990, J INFECT DIS, V161, P942, DOI 10.1093/infdis/161.5.942; POWERS RD, 1991, AM J OBSTET GYNECOL, V164, P1387, DOI 10.1016/0002-9378(91)91478-F; Sackett D. L., 1997, EVIDENCE BASED MED P; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAGINUR R, 1992, ARCH INTERN MED, V152, P1233, DOI 10.1001/archinte.152.6.1233; TRIENEKENS TAM, 1989, BRIT MED J, V299, P1319, DOI 10.1136/bmj.299.6711.1319; WINKENS RAG, 1995, FAM PRACT, V12, P290, DOI 10.1093/fampra/12.3.290; 1998, DRUG THER B, V36, P30	27	13	13	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1114	1118		10.1136/bmj.320.7242.1114	http://dx.doi.org/10.1136/bmj.320.7242.1114			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RJ	10775223	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086782800020
J	DeCelles, PG; Gehrels, GE; Quade, J; LaReau, B; Spurlin, M				DeCelles, PG; Gehrels, GE; Quade, J; LaReau, B; Spurlin, M			Tectonic implications of U-PL zircon ages of the Himalayan orogenic belt in Nepal	SCIENCE			English	Article							NORTHWESTERN HIMALAYA; STRUCTURAL EVOLUTION; GRANITE HIMALAYA; WESTERN NEPAL; HISTORY; INDIA; LESSER; TIBET; LEUCOGRANITES; METAMORPHISM	Metasedimentary rocks of the Greater Himalaya are traditionally viewed as Indian shield basement that has been thrust southward onto Lesser Himalayan sedimentary rocks during the Cenozoic collision of India and Eurasia, Ages determined from radioactive decay of uranium to lead in zircon grains from Nepal suggest that Greater Himalayan protoliths were shed from the northern end of the East African orogen during the Late Proterozoic pan-African orogenic event, These rocks were accreted onto northern Gondwana and intruded by crustal melts during Cambrian-Ordovician time. Our data suggest that the Main Central thrust may have a large amount of pre-Tertiary displacement, that structural restorations placing Greater Himalayan rocks below Lesser Himalayan rocks at the onset of Cenozoic orogenesis are flawed, and that some metamorphism of Greater Himalayan rocks may have occurred during early Paleozoic time.	Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA	University of Arizona	DeCelles, PG (corresponding author), Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA.	decelles@geo.arizona.edu						ARITA K, 1983, TECTONOPHYSICS, V95, P43, DOI 10.1016/0040-1951(83)90258-5; Bouquillon A., 1990, P OCEAN DRILL PROGRA, V116, P43; BROOKFIELD ME, 1993, SEDIMENT GEOL, V84, P1, DOI 10.1016/0037-0738(93)90042-4; BRUNEL M, 1986, CAN J EARTH SCI, V23, P1117, DOI 10.1139/e86-111; Dalziel IWD, 1997, GEOL SOC AM BULL, V109, P16, DOI 10.1130/0016-7606(1997)109<0016:ONPGAT>2.3.CO;2; DeCelles PG, 1998, TECTONICS, V17, P741, DOI 10.1029/98TC02598; DeCelles PG, 1998, GEOL SOC AM BULL, V110, P2, DOI 10.1130/0016-7606(1998)110<0002:NFBDEU>2.3.CO;2; DENIEL C, 1987, CONTRIB MINERAL PETR, V96, P78, DOI 10.1007/BF00375529; Derry LA, 1996, EARTH PLANET SC LETT, V142, P59, DOI 10.1016/0012-821X(96)00091-X; DEWEY JF, 1988, PHILOS T R SOC A, V327, P379, DOI 10.1098/rsta.1988.0135; DIPIETRO JA, 1993, GEOL SOC SPEC PUBL, V74, P207; FERRARA G, 1983, GEOL RUNDSCH, V72, P119, DOI 10.1007/BF01765903; France-Lanord C., 1988, T R SOC EDINBURGH EA, V79, P183; FRANK W, 1970, JB GEOL BUNDESANST, V18, P103; GAETANI M, 1991, AAPG BULL, V75, P1427; Gansser A., 1964, GEOLOGY HIMALAYA; GARZANTI E, 1986, SEDIMENT GEOL, V48, P237, DOI 10.1016/0037-0738(86)90032-1; GEHRELS GE, 1991, CAN J EARTH SCI, V28, P1285, DOI 10.1139/e91-114; Godin L, 1999, GEOLOGY, V27, P151, DOI 10.1130/0091-7613(1999)027<0151:BFITCO>2.3.CO;2; HARRISON TM, 1992, SCIENCE, V255, P1663, DOI 10.1126/science.255.5052.1663; Hauck ML, 1998, TECTONICS, V17, P481, DOI 10.1029/98TC01314; Hodges KV, 1996, TECTONICS, V15, P1264, DOI 10.1029/96TC01791; HODGES KV, 1988, TECTONICS, V7, P583, DOI 10.1029/TC007i003p00583; HOFFMAN PF, 1991, SCIENCE, V252, P1409, DOI 10.1126/science.252.5011.1409; Le Fort P., 1986, VOLUTION DOMAINESORO, P191; LEFORT P, 1981, J GEOPHYS RES, V86, P545, DOI 10.1029/JB086iB11p10545; MACFARLANE AM, 1993, TECTONICS, V12, P1004, DOI 10.1029/93TC00916; Manickavasagam R.M., 1999, GEOL S AM S, P179; Naqvi S.M., 1987, OXFORD MONOGR GEOL G; Parrish RR, 1996, GEOL SOC AM BULL, V108, P904, DOI 10.1130/0016-7606(1996)108<0904:ICOTAA>2.3.CO;2; PECHER A, 1989, J METAMORPH GEOL, V7, P31, DOI 10.1111/j.1525-1314.1989.tb00573.x; POGUE KR, 1999, GEOL S AM S, P257; RATSCHBACHER L, 1994, J GEOPHYS RES-SOL EA, V99, P19917, DOI 10.1029/94JB00932; ROBINSON DM, 1999, GEOL SOC AM ABSTR A, V96; RUPKE J, 1974, SEDIMENT GEOL, V11, P81, DOI 10.1016/0037-0738(74)90027-X; SAKAI H, 1983, Memoirs of the Faculty of Science Kyushu University Series D Geology, V25, P27; Sakai H., 1985, MEMOIRS FS KYUSHU D, V25, P337; SCHARER U, 1983, EARTH PLANET SC LETT, V63, P423, DOI 10.1016/0012-821X(83)90115-2; SCHARER U, 1986, EARTH PLANET SC LETT, V77, P35, DOI 10.1016/0012-821X(86)90130-5; SCHELLING D, 1992, TECTONICS, V11, P925, DOI 10.1029/92TC00213; SCOTESE CR, 1997, 90 PALEOMAP U TEX DE; SEARLE MP, 1986, J STRUCT GEOL, V8, P923, DOI 10.1016/0191-8141(86)90037-4; Sengor A. M. C., 1996, TECTONIC EVOLUTION A, P486; STERN RJ, 1994, ANNU REV EARTH PL SC, V22, P319, DOI 10.1146/annurev.ea.22.050194.001535; STOCKLIN J, 1980, J GEOL SOC LONDON, V137, P1, DOI 10.1144/gsjgs.137.1.0001; TRIVEDI JR, 1984, J GEOL SOC INDIA, V25, P641; UNRUG R, 1996, RODINIA GONDWANA GEO; Valdiya KS., 1980, GEOLOGY KUMAUN LESSE; Whittington A, 1999, GEOLOGY, V27, P585, DOI 10.1130/0091-7613(1999)027<0585:LCITWH>2.3.CO;2; Yin A., 1996, TECTONIC EVOLUTION A, P442	50	476	506	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	2000	288	5465					497	499		10.1126/science.288.5465.497	http://dx.doi.org/10.1126/science.288.5465.497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10775105				2022-12-28	WOS:000086626000040
J	Gotzsche, PC				Gotzsche, PC			Extracts from "Clinical Evidence" - Non-steroidal anti-inflammatory drugs	BRITISH MEDICAL JOURNAL			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; GASTROINTESTINAL COMPLICATIONS; CONTROLLED TRIAL; METAANALYSIS; MISOPROSTOL; ULCERS; OSTEOARTHRITIS; INDOMETHACIN		Rigshosp, Nord Cochrane Ctr, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, 9 Blegdamsvej, DK-2100 Copenhagen O, Denmark.							Cappelleri J., 1995, ONLINE J CURR CLIN T; CHALMERS TC, 1988, ALIMENT PHARM THERAP, V2, P9; DEANDRADE J R, 1965, Arthritis Rheum, V8, P302; Dieppe P., 1999, CLIN EVIDENCE, V2, P437; EISENBERG E, 1994, J CLIN ONCOL, V12, P2756, DOI 10.1200/JCO.1994.12.12.2756; GOTZSCHE PC, 1989, LANCET, V1, P88; GOTZSCHE PC, 1993, SCAND J RHEUMATOL, V22, P255, DOI 10.3109/03009749309095135; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GOTZSCHE PC, 1989, DAN MED BULL, V36, P395; GOTZSCHE PC, 1989, CONTROLLED CLIN TRIA, V10, P356; GREEN S, 1999, COCHRANE LIB; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; Koch M, 1996, ARCH INTERN MED, V156, P2321, DOI 10.1001/archinte.156.20.2321; LEUFKENS HG, 1990, PHARM WEEKBLAD, V12, P97, DOI 10.1007/BF01967602; McManus P, 1996, MED J AUSTRALIA, V164, P589, DOI 10.5694/j.1326-5377.1996.tb122200.x; Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333; OGILVIEHARRIS DJ, 1995, CLIN J SPORT MED, V5, P175, DOI 10.1097/00042752-199507000-00008; Raskin JB, 1996, AM J GASTROENTEROL, V91, P223; RIEDEMANN PJ, 1993, J RHEUMATOL, V20, P2095; Shackel NA, 1997, MED J AUSTRALIA, V167, P134, DOI 10.5694/j.1326-5377.1997.tb138811.x; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; SIMPSON J, 1989, BRIT J CLIN PRACT, V43, P328; SPEED C, 1999, CLIN EVIDENCE, V2, P463; TOWHEED TE, 1999, COCHRANE LIB; WATSON MC, 1999, COCHRANE LIB; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104	29	57	58	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 15	2000	320	7241					1058	1061		10.1136/bmj.320.7241.1058	http://dx.doi.org/10.1136/bmj.320.7241.1058			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307VW	10764369	Green Published			2022-12-28	WOS:000086675700028
J	Maccarrone, M; Valensise, H; Bari, M; Lazzarin, M; Romanini, C; Finazzi-Agro, A				Maccarrone, M; Valensise, H; Bari, M; Lazzarin, M; Romanini, C; Finazzi-Agro, A			Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage	LANCET			English	Article							MOUSE EMBRYO DEVELOPMENT; SPONTANEOUS-ABORTION; CANNABINOID RECEPTORS; EARLY-PREGNANCY; FIRST-TRIMESTER; T-CELLS; BRAIN; UTERUS; IMPLANTATION; DEATH	Background Endocannabinoids such as anandamide are thought to have adverse effects on pregnancy and embryonic development. The activity of the degradative enzyme anandamide hydrolase may therefore be crucial for prevention of excessive concentrations of anandamide in the uterus, and thus prevention of pregnancy failure or female infertility. We tested this hypothesis in a preliminary study, and then used the results to find out whether anandamide hydrolase activity could predict miscarriage in a group of pregnant women. Methods We assessed anandamide hydrolase activity in peripheral lymphocytes from 50 healthy, pregnant women at weeks 6-11 of gestation by a specific radiochromatographic method. The expression of the enzyme at the protein level was measured by ELISA with specific polyclonal antibodies. In a further study, we measured anandamide hydrolase concentration in 120 women who were 7-8 weeks pregnant and compared these findings with subsequent pregnancy outcome. Findings In the first study, seven of the 50 women had a miscarriage. Anandamide hydrolase activity was lower in the seven women who miscarried than in the 43 who did not (60.43 pmol/min per mg protein [SD 29.34] vs 169.60 pmol/min per mg protein [30.20]; difference 109.17 pmol/min per mg protein [95% CI 26.64-191.70]; p<0.0001 by the Mann-Whitney test). Enzyme activity correlated with enzyme concentration, and a threshold concentration represented by an optical density (after ELISA) of 0.15 absorbance units at 450 nm separated the women who had miscarriages from those who did not. In the second study, 15 women had anandamide hydrolase concentrations below the threshold, and 105 had concentrations at or above the threshold. All 15 women in the low anandamide hydrolase group had miscarriages, compared with one of the 105 women with high concentrations [p<0.0001 by Fisher's exact test). Interpretation Decreased anandamide hydrolase activity and expression in peripheral lymphocytes is an early (<8 weeks of gestation) marker of spontaneous abortion, and may prove useful as a diagnostic tool for large-scare, routine monitoring of gestation. Our results also suggest that endocannabinoids might be critical in regulating the lymphocyte-dependent cytokine network associated with human fertility and successful pregnancy.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tor Vergata, Div Obstet & Gynaecol, I-00133 Rome, Italy; San Giovanni Calibita Hosp, Fatebenefratelli Assoc Res, Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata	Finazzi-Agro, A (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy.		Valensise, Herbert/AAC-1345-2019	Valensise, Herbert/0000-0003-4764-544X				Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cole LA, 1997, FETAL DIAGN THER, V12, P336, DOI 10.1159/000264500; DAS SK, 1995, P NATL ACAD SCI USA, V92, P4332, DOI 10.1073/pnas.92.10.4332; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, NATURE, V396, P636, DOI 10.1038/25267; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; GOLDSTEIN SR, 1994, OBSTET GYNECOL, V84, P294; GOLDSTEIN SR, 1994, CLIN OBSTET GYNECOL, V37, P681, DOI 10.1097/00003081-199409000-00020; Kline J.S., 1989, CONCEPTION BIRTH EPI; Kovalevskaya G, 1999, CLIN CHEM, V45, P68; Maccarrone M, 1997, CELL DEATH DIFFER, V4, P396, DOI 10.1038/sj.cdd.4400255; Maccarrone M, 1998, J BIOL CHEM, V273, P32332, DOI 10.1074/jbc.273.48.32332; Molina-Holgado F, 1998, FEBS LETT, V433, P139, DOI 10.1016/S0014-5793(98)00851-5; Ness RB, 1999, NEW ENGL J MED, V340, P333, DOI 10.1056/NEJM199902043400501; Okon MA, 1998, FERTIL STERIL, V69, P682, DOI 10.1016/S0015-0282(98)00007-7; Ouyang YL, 1998, MOL PHARMACOL, V53, P676, DOI 10.1124/mol.53.4.676; Paria BC, 1998, BIOL REPROD, V58, P1490, DOI 10.1095/biolreprod58.6.1490; Paria BC, 1999, BIOL REPROD, V60, P1151, DOI 10.1095/biolreprod60.5.1151; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Piccinni MP, 1998, NAT MED, V4, P1020, DOI 10.1038/2006; Redline RW, 1999, HUM PATHOL, V30, P93, DOI 10.1016/S0046-8177(99)90307-6; Schmid PC, 1997, P NATL ACAD SCI USA, V94, P4188, DOI 10.1073/pnas.94.8.4188; Sozio J, 1998, Infect Dis Obstet Gynecol, V6, P8, DOI 10.1155/S1064744998000039; Spandidos DA, 1998, FERTIL STERIL, V70, P892, DOI 10.1016/S0015-0282(98)00279-9; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Stewart CL, 1997, DEV GENET, V21, P91, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;91::AID-DVG11&gt;3.0.CO;2-D; SzekeresBartho J, 1996, J REPROD IMMUNOL, V31, P81, DOI 10.1016/0165-0378(96)00964-3; WALSH RA, 1994, HUM BIOL, V66, P1059; Wang XB, 1998, EPIDEMIOLOGY, V9, P540, DOI 10.1097/00001648-199809000-00012; Yang ZM, 1996, BIOL REPROD, V55, P756, DOI 10.1095/biolreprod55.4.756	30	202	206	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 15	2000	355	9212					1326	1329		10.1016/S0140-6736(00)02115-2	http://dx.doi.org/10.1016/S0140-6736(00)02115-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LJ	10776746				2022-12-28	WOS:000086829400013
J	Brady, K; Pearlstein, T; Asnis, GM; Baker, D; Rothbaum, B; Sikes, CR; Farfel, GM				Brady, K; Pearlstein, T; Asnis, GM; Baker, D; Rothbaum, B; Sikes, CR; Farfel, GM			Efficacy and safety of sertraline treatment of posttraumatic stress disorder - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; PANIC DISORDER; MULTICENTER TRIAL; URBAN-POPULATION; VIETNAM VETERANS; MAJOR DEPRESSION; YOUNG-ADULTS; EVENT SCALE; PLACEBO; COMORBIDITY	Context Despite the high prevalence, chronicity, and associated comorbidity of posttraumatic stress disorder (PTSD) in the community, few placebo-controlled studies have evaluated the efficacy of pharmacotherapy for this disorder. Objective To determine if treatment with sertraline hydrochloride effectively diminishes symptoms of PTSD of moderate to marked severity. Design Twelve-week, double-blind, placebo-controlled trial preceded by a 2-week, single-blind placebo lead-in period, conducted between May 1996 and June 1997, Setting Outpatient psychiatric clinics in 8 academic medical centers and 6 clinical research centers. Patients A total of 187 outpatients with a Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition diagnosis of PTSD and a Clinician Administered PTSD Scale Part 2 (CAPS-2) minimum total severity score of at least 50 at baseline (mean age, 40 years; mean duration of illness, 12 years; 73% were women; and 61.5% experienced physical or sexual assault). Intervention Patients were randomized to acute treatment with sertraline hydrochloride in flexible daily dosages of 50 to 200 mg/d, following 1 week at 25 mg/d (n=94); or placebo (n=93). Main Outcome Measures Baseline-to-end-point changes in CAPS-2 total severity score, Impact of Event Scale total score (IES), and Clinical Global impression-Severity (CGI-S), and CGI-Improvement (CGI-I) ratings, compared by treatment vs placebo groups. Results Sertraline treatment yielded significantly greater improvement than placebo on 3 of the 4 primary outcome measures (mean change from baseline to end point for CAPS-2 total score, -33.0 vs -23.2 [P=.02], and for CGI-S, -1.2 vs -0.8 [P=.01]; mean CGI-I score at end point, 2.5 vs 3.0 [P=.02]), with the fourth measure, the IES total score, showing a trend toward significance (mean change from baseline to end point, -16.2 vs -12.1; P=.07). Using a conservative last-observation-carried-forward analysis, treatment with sertraline resulted in a responder rate of 53% at study end point compared with 32% for placebo (P=.008, with responder defined as >30% reduction from baseline in CAPS-2 total severity score and a CGI-I score of 1 [very much improved], or 2 [much improved]). Significant (P<.05) efficacy was evident for sertraline from week 2 on the CAPS-2 total severity score; Sertraline had significant efficacy vs placebo on the CAPS-2 PTSD symptom clusters of avoidance/numbing (P=.02) and increased arousal (P=.03) but not on reexperiencing/intrusion (P=.14). Sertraline was well tolerated, with insomnia the only adverse effect reported significantly more often than placebo (16.0% vs 4.3 %; P=.01). Conclusions Our data suggest that sertraline is a safe, well-tolerated, and effective treatment for PTSD.	Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA; Butler Hosp, Dept Psychiat, Providence, RI 02906 USA; Montefiore Med Ctr, Dept Psychiat, Bronx, NY 10467 USA; Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA; Cincinnati Vet Affairs Med Ctr, Posttraumat Stress Disorder Unit, Cincinnati, OH USA; Pfizer Inc, New York, NY USA	Medical University of South Carolina; Butler Hospital Rhode Island; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Pfizer	Brady, K (corresponding author), Med Univ S Carolina, Dept Psychiat, 67 President St,POB 250861, Charleston, SC 29425 USA.		Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838; Brady, Kathleen/0000-0002-3944-8051				Baker DG, 1995, PSYCHOPHARMACOLOGY, V122, P386, DOI 10.1007/BF02246271; Blake D. D., 1990, BEHAV THERAPIST, V18, P187, DOI DOI 10.1007/BF02105408; Brady KT, 1997, J CLIN PSYCHIAT, V58, P12; BRADY KT, 1995, J CLIN PSYCHIAT, V56, P502; BRAUN P, 1990, J CLIN PSYCHIAT, V51, P236; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BRESLAU N, 1992, AM J PSYCHIAT, V149, P671; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P81; DAVIDSON J, 1990, ARCH GEN PSYCHIAT, V47, P259; DAVIDSON JR, 1998, INT SOC TRAUM STRESS; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; DAVIDSON JRT, 1990, COMPR PSYCHIAT, V31, P162, DOI 10.1016/0010-440X(90)90020-S; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321; FABRE LF, 1995, BIOL PSYCHIAT, V38, P592, DOI 10.1016/0006-3223(95)00178-8; FOA EB, 1992, PSYCHOL BULL, V112, P218, DOI 10.1037/0033-2909.112.2.218; FRANK JB, 1988, AM J PSYCHIAT, V145, P1289; Friedman Matthew J., 1995, P507; GOLDING JM, 1988, AM J COMMUN PSYCHOL, V16, P625, DOI 10.1007/BF00930018; GREIST J, 1995, ARCH GEN PSYCHIAT, V52, P289; Grillon C, 1996, MOL PSYCHIATR, V1, P278; Guy W., 1976, DHEW PUBL; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HEYM J, 1988, J CLIN PSYCHIAT, V49, P40; HOEHNSARIC R, 1997, EUR NEUROPSYCHOPHARM, V7, pS180; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KATZ R, 1994, ANXIETY, V1, P169; Keller MB, 1998, JAMA-J AM MED ASSOC, V280, P1665, DOI 10.1001/jama.280.19.1665; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KIMERLING R, 1994, J CONSULT CLIN PSYCH, V62, P333, DOI 10.1037/0022-006X.62.2.333; Londborg PD, 1998, BRIT J PSYCHIAT, V173, P54, DOI 10.1192/bjp.173.1.54; MELLMAN TA, 1992, AM J PSYCHIAT, V149, P1568; Pohl RB, 1998, AM J PSYCHIAT, V155, P1189, DOI 10.1176/ajp.155.9.1189; Pollack MH, 1998, ARCH GEN PSYCHIAT, V55, P1010, DOI 10.1001/archpsyc.55.11.1010; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; REIST C, 1989, AM J PSYCHIAT, V146, P513; RESNICK HS, 1993, J CONSULT CLIN PSYCH, V61, P984, DOI 10.1037/0022-006X.61.6.984; RESNICK HS, 1991, J CONSULT CLIN PSYCH, V13, P561; Rothbaum BO, 1996, J TRAUMA STRESS, V9, P865; SHESTATZKY M, 1988, PSYCHIAT RES, V24, P149, DOI 10.1016/0165-1781(88)90057-1; Solomon SD, 1997, J CLIN PSYCHIAT, V58, P5; SOLOMON SD, 1992, JAMA-J AM MED ASSOC, V268, P633, DOI 10.1001/jama.268.5.633; VANDERKOLK BA, 1994, J CLIN PSYCHIAT, V55, P517; Weathers F. W., 1994, PTSD RES Q, V5, P2, DOI DOI 10.1037/E572192010-003; YEHUDA R, 1995, AM J PSYCHIAT, V152, P1705; YEHUDA R, 1993, BIOL PSYCHIAT, V33, P479, DOI 10.1016/0006-3223(93)90001-T; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690; ZILBERG NJ, 1982, J CONSULT CLIN PSYCH, V50, P407, DOI 10.1037/0022-006X.50.3.407; Zlotnick C, 1996, J NERV MENT DIS, V184, P255, DOI 10.1097/00005053-199604000-00010	49	468	478	1	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1837	1844		10.1001/jama.283.14.1837	http://dx.doi.org/10.1001/jama.283.14.1837			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	300HY	10770145	Bronze			2022-12-28	WOS:000086248600029
J	Harris, J				Harris, J			Essays on science and society - Intimations of immortality	SCIENCE			English	Editorial Material									Univ Manchester, Inst Med Law & Bioeth, Manchester M13 9PL, Lancs, England	University of Manchester	Harris, J (corresponding author), Univ Manchester, Inst Med Law & Bioeth, Manchester M13 9PL, Lancs, England.								0	43	43	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 7	2000	288	5463					59	59		10.1126/science.288.5463.59	http://dx.doi.org/10.1126/science.288.5463.59			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	302VT	10766635				2022-12-28	WOS:000086387700025
J	Lim, DS; Kim, ST; Xu, B; Maser, RS; Lin, JY; Petrini, JHJ; Kastan, MB				Lim, DS; Kim, ST; Xu, B; Maser, RS; Lin, JY; Petrini, JHJ; Kastan, MB			ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway	NATURE			English	Article							NIJMEGEN BREAKAGE SYNDROME; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; IONIZING-RADIATION; PROTEIN-KINASE; REPAIR; P53; LINKAGE	The rare diseases ataxia-telangiectasia (AT), caused by mutations in the ATM gene, and Nijmegen breakage syndrome (NBS), with mutations in the p95/nbs1 gene, share a variety of phenotypic abnormalities such as chromosomal instability, radiation sensitivity and defects in cell-cycle checkpoints in response to ionizing radiation(1-4). The ATM gene encodes a protein kinase that is activated by ionizing radiation or radiomimetic drugs(5,6), whereas p95/nbs1 is part of a protein complex that is involved in responses to DNA double-strand breaks(3,7). Here, because of the similarities between AT and NBS, we evaluated the functional interactions between ATM and p95/nbs1. Activation of the ATM kinase by ionizing radiation and induction of ATM-dependent responses in NBS cells indicated that p95/nbs1 may not be required for signalling to ATM after ionizing radiation. However, p95/nbs1 was phosphorylated on serine 343 in an ATM-dependent manner in vitro and in vivo after ionizing radiation. A p95/nbs1 construct mutated at the ATM phosphorylation site abrogated an S-phase checkpoint induced by ionizing radiation in normal cells and failed to compensate for this functional deficiency in NBS cells. These observations link ATM and p95/nbs1 in a common signalling pathway and provide an explanation for phenotypic similarities in these two diseases.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	St Jude Children's Research Hospital; University of Wisconsin System; University of Wisconsin Madison	Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale, Memphis, TN 38105 USA.	Michael.Kastan@stjude.org	Kim, Seong-Tae/A-9917-2013; Lim, Dae-Sik/C-1599-2011; Maser, Richard/B-2970-2012	Lim, Dae-Sik/0000-0003-2356-7555; 				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MASER RS, 1999, MRE11 RAD50 COMPLEX; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Yamazaki V, 1998, CANCER RES, V58, P2316; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	28	644	661	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	2000	404	6778					613	+		10.1038/35007091	http://dx.doi.org/10.1038/35007091			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10766245				2022-12-28	WOS:000086400100056
J	Mohr, JC				Mohr, JC			American medical malpractice litigation in historical perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE EVENTS; TECHNOLOGY; NEGLIGENT	Medical malpractice and the problems associated with it remain an important issue in the US medical community, Yet relatively little information regarding the long-term history of malpractice litigation can be found in the literature. This article addresses 2 questions: (1) when and why did medical malpractice litigation originate in the United States and (2) what historical factors best explain its subsequent perpetuation and growth? Medical malpractice litigation appeared in the United States around 1840 for reasons specific to that period. Those reasons are discussed in the context of marketplace professionalism, an environment that provided few quality controls over medical practitioners. Medical malpractice litigation has since been sustained for a century and a half by an interacting combination of 6 principal factors. Three of these factors are medical: the innovative pressures on American medicine, the spread of uniform standards, and the advent of medical malpractice liability insurance. Three are legal factors: contingent fees, citizen juries, and the nature of tort pleading in the United States. Knowledge of these historical factors may prove useful to those seeking to reform the current medical malpractice litigation system.	Univ Oregon, Dept Hist, Eugene, OR 97403 USA	University of Oregon	Mohr, JC (corresponding author), Univ Oregon, Dept Hist, Eugene, OR 97403 USA.	jmohr@oregon.uoregon.edu						*AM AC FAM PHYS, 2000, PHYS PAYM COMM 1996; BLACKSTONE W, 1768, COMMENTARIES LAWS EN, V3, P122; BOVBJERG RR, 1986, MED MALPRACTICE PRIV; Brennan TA, 1996, NEW ENGL J MED, V335, P1963, DOI 10.1056/NEJM199612263352606; BURNS C R, 1969, Bulletin of the History of Medicine, V43, P41; Channing W., 1860, BOSTON MED SURG J, V62, P259; Channing W, 1860, BOSTON MED SURG J, V62, P233; Channing W., 1860, BOSTON MED SURG J, V62, P300; Crossen H, 1940, FOREIGN BODIES LEFT; Culbertson HE, 1913, MED MEN LAW MODERN T; DANZON PM, 1985, MED MALPRACTICE THEO; De Ville K, 1998, INT J TECHNOL ASSESS, V14, P197; De Ville Kenneth Allen, 1990, MED MALPRACTICE 19 C; ELWELL JJ, 1860, MEDICO LEGAL TREATIS; EPSTEIN RA, 1976, AM BAR FOUND RES J, P87; Galanter Marc, 1998, ARIZ LAW REV, V40, P717; GRADY MF, 1988, NORTHWEST U LAW REV, V82, P293; GRADY MF, 1992, NORTHWEST U LAW REV, V86, P1068; GRIFFITH RE, 1834, AM J MED SCI, V15, P168; Horwitz Morton J, 1977, TRANSFORMATION AM LA; JORDAN LF, 1926, VA LAW REGISTER, V12, P88; Konold D. E., 1962, HIST AM MED ETHICS 1; *LAW DEP MED PROT, 1934, BRIEF MALPR LAW; LINOWITZ SM, 1936, CORNELL LAW Q, V22, P276; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOMBARDI T, 1987, MED MALPRACTICE INSU; MCCLELLAND M, 1873, CIVIL MALPRACTICE; MITCHELL EV, 1913, DOCTOR COURT; Mohr J C, 1992, Trans Stud Coll Physicians Phila, V14, P1; Mohr James C, 1993, DOCTORS LAW MED JURI; *NAT C STAT LEG GE, 1975, LEG GUID MED MALPR I; *NATL TECHN INF SE, 1987, MALPR TRIANGL MED LE; OPPENHEIMER BS, 1935, TREATISE MED JURISPR; Ordronaux John, 1869, JURISPRUDENCE MED IT; *PRES FELL HARV CO, 1990, PAT DOCT LAW MED INJ; REGAN LJ, 1943, MED MALPRACTICE; ROSENBLATT R, 1997, LAW AM HLTH CARE SYS; ROSENTHAL MM, 1988, DEALING MED MALPRACT; ROTHSTEIN W, 1972, AM PHYSICIANS 19 CEN; ROTTENBERG S, 1978, EC MED MALPRACTICE; SANDOR AA, 1957, JAMA-J AM MED ASSOC, V163, P459, DOI 10.1001/jama.1957.82970410010018; SANGER EF, 1878, T MAINE MED ASS, V6, P360; Sharpe VA, 1997, J MED PHILOS, V22, P373; SLOAN FA, 1991, INSURING MED MALPRAC; SLOAN FA, 1994, MED MALPRACTICE LAW; Smith HW, 1941, J AMER MED ASSOC, V116, P942, DOI 10.1001/jama.1941.62820100002009; SMITH HW, 1941, JAMA-J AM MED ASSOC, V116, P2490; Smith HW, 1941, JAMA-J AM MED ASSOC, V117, P23; SMITH HW, 1941, JAMA-J AM MED ASSOC, V116, P2755; SMITH HW, 1941, JAMA-J AM MED ASSOC, V116, P2670; Smith HW, 1941, JAMA-J AM MED ASSOC, V116, P2149; SMITH N, 1827, MED JURISPRUDENCE LE; Starr P, 1982, SOCIAL TRANSFORMATIO; Stewart GH, 1910, LEGAL MED; US Congress Office of Technology Assessment, 1994, DEF MED MED MALPR; *US JUST DEP, 1986, REP TORT POL WORK GR; VIDMAR N, 1995, MED MALPRACTICE AM J; WEILER PC, 1991, MED MALPRACTICE TRIA; Weiler PC, 1993, MEASURE MALPRACTICE; WHITE GE, 1977, YALE LAW J, V86, P671, DOI 10.2307/795640; Wilson LP, 1922, CORNELL LAW Q, V7, P334; WING KR, 1998, LAW AM HLTH CARE; WOOD W, 1849, AM J MED SCI, V18, P400; 1846, BOSTON MED SURG J, V35, P207; 1887, JAMA, V9, P839; 1850, BOSTON MED SURG J, V42, P67; 1940, VA LAW REV, V26, P919; 1853, BOSTON MED SURG J, V48, P506; 1848, AM LAW J, V1, P284	69	96	96	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	2000	283	13					1731	1737		10.1001/jama.283.13.1731	http://dx.doi.org/10.1001/jama.283.13.1731			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	298BK	10755500				2022-12-28	WOS:000086119300034
J	Ovchinnikov, IV; Gotherstrom, A; Romanova, GP; Kharitonov, VM; Liden, K; Goodwin, W				Ovchinnikov, IV; Gotherstrom, A; Romanova, GP; Kharitonov, VM; Liden, K; Goodwin, W			Molecular analysis of Neanderthal DNA from the northern Caucasus	NATURE			English	Article							SEQUENCE; HUMANS	The expansion of premodern humans into western and eastern Europe similar to 40,000 years before the present led to the eventual replacement of the Neanderthals by modern humans similar to 28,000 years ago(1). Here we report the second mitochondrial DNA (mtDNA) analysis of a Neanderthal, and the first such analysis on clearly dated Neanderthal remains. The specimen is from one of the eastern-most Neanderthal populations, recovered from Mezmaiskaya Cave in the northern Caucasus(2). Radiocarbon dating estimated the specimen to be similar to 29,000 years old and therefore from one of the latest living Neanderthals(3). The sequence shows 3.48% divergence from the Feldhofer Neanderthal(4). Phylogenetic analysis places the two Neanderthals from the Caucasus and western Germany together in a clade that is distinct from modern humans, suggesting that their mtDNA types have not contributed to the modern human mtDNA pool. Comparison with modern populations provides no evidence for the multiregional hypothesis of modern human evolution.	Univ Glasgow, Human Identificat Ctr, Glasgow G12 8QQ, Lanark, Scotland; Inst Gerontol, Moscow 129226, Russia; Stockholm Univ, Archaeol Res Lab, S-10691 Stockholm, Sweden; Archaeol Inst, Moscow 117036, Russia; Moscow MV Lomonosov State Univ, Inst Anthropol, Moscow 103009, Russia; Moscow MV Lomonosov State Univ, Museum Anthropol, Moscow 103009, Russia	University of Glasgow; Stockholm University; Lomonosov Moscow State University; Lomonosov Moscow State University	Goodwin, W (corresponding author), Univ Glasgow, Human Identificat Ctr, Glasgow G12 8QQ, Lanark, Scotland.			Liden, Kerstin/0000-0002-5911-9503; Gotherstrom, Anders/0000-0001-8579-1304; Goodwin, William/0000-0002-3632-3552				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BROWN TA, 1988, RADIOCARBON, V30, P171, DOI 10.1017/S0033822200044118; Burckhardt F, 1999, NUCLEIC ACIDS RES, V27, P138, DOI 10.1093/nar/27.1.138; Cooper A, 1997, SCIENCE, V277, P1021; DENIRO MJ, 1985, NATURE, V317, P806, DOI 10.1038/317806a0; Excoffier L, 1999, MOL BIOL EVOL, V16, P1357, DOI 10.1093/oxfordjournals.molbev.a026046; GABUNIA L, 1995, NATURE, V373, P509, DOI 10.1038/373509a0; Gagneux P, 1999, P NATL ACAD SCI USA, V96, P5077, DOI 10.1073/pnas.96.9.5077; Gamble C, 1998, PREHISTORIC EURPE, P5; Golovanova LV, 1999, CURR ANTHROPOL, V40, P77, DOI 10.1086/515805; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Kozlowski JK, 1998, NEANDERTALS AND MODERN HUMANS IN WESTERN ASIA, P461; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Krings M, 1999, P NATL ACAD SCI USA, V96, P5581, DOI 10.1073/pnas.96.10.5581; Liden K, 1997, ISKOS, V11, P158; Smith FH, 1999, P NATL ACAD SCI USA, V96, P12281, DOI 10.1073/pnas.96.22.12281; Stringer C., 1996, AFRICAN EXODUS ORIGI; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023	19	327	351	1	67	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					490	493		10.1038/35006625	http://dx.doi.org/10.1038/35006625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761915				2022-12-28	WOS:000086257700046
J	Pickett, G				Pickett, G			Superfluidity - A new twist to an old story	NATURE			English	Editorial Material									Univ Lancaster, Dept Phys, Lancaster LA1 4YB, England	Lancaster University	Pickett, G (corresponding author), Univ Lancaster, Dept Phys, Lancaster LA1 4YB, England.							Blaauwgeers R, 2000, NATURE, V404, P471, DOI 10.1038/35006583	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					450	451		10.1038/35006543	http://dx.doi.org/10.1038/35006543			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761899				2022-12-28	WOS:000086257700030
J	Gold, JI; Shadlen, MN				Gold, JI; Shadlen, MN			Representation of a perceptual decision in developing oculomotor commands	NATURE			English	Article							SACCADIC EYE-MOVEMENTS; SUPERIOR COLLICULUS; PSYCHOPHYSICAL PERFORMANCE; VISUAL-MOTION; NEURONS; RESPONSES; MONKEY; COMPUTATION; STIMULATION; DISCHARGE	Behaviour often depends on the ability to make categorical judgements about sensory information acquired over time. Such judgements require a comparison of the evidence favouring the alternatives(1-4), but how the brain forms these comparisons is unknown. Here we show that in a visual discrimination task, the accumulating balance of sensory evidence favouring one interpretation over another is evident in the neural circuits that generate the behavioural response. We trained monkeys to make a direction judgement about dynamic random-dot motion(5) and to indicate their judgement with an eye movement to a visual target We interrupted motion viewing with electrical microstimulation of the frontal eye field and analysed the resulting, evoked eye movements for evidence of ongoing activity associated with the oculomotor response(6-10). Evoked eye movements deviated in the direction of the monkey's judgement. The magnitude of the deviation depended on motion strength and viewing time. The oculomotor signals responsible for these deviations reflected the accumulated motion information that informed the monkey's choices on the discrimination task. Thus, for this task, decision formation and motor preparation appear to share a common level of neural organization.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Shadlen, MN (corresponding author), Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.		Shadlen, Michael Neil/AAL-1870-2020	Shadlen, Michael/0000-0002-2002-2210				BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CARPENTER RHS, 1995, NATURE, V377, P59, DOI 10.1038/377059a0; Geisler WS, 1997, VISUAL NEUROSCI, V14, P897, DOI 10.1017/S0952523800011627; Graham N.V.S, 1989, VISUAL PATTERN ANAL; GREEN DM, 1966, SIGNAL DETECTION THE; Horwitz GD, 1999, SCIENCE, V284, P1158, DOI 10.1126/science.284.5417.1158; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; Kim JN, 1999, NAT NEUROSCI, V2, P176, DOI 10.1038/5739; Kustov AA, 1996, NATURE, V384, P74, DOI 10.1038/384074a0; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; Leon MI, 1998, NEURON, V21, P669, DOI 10.1016/S0896-6273(00)80584-X; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; ROBINSON DA, 1989, ANNU REV NEUROSCI, V12, P33, DOI 10.1146/annurev.neuro.12.1.33; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; Schall JD, 1999, ANNU REV NEUROSCI, V22, P241, DOI 10.1146/annurev.neuro.22.1.241; SCHILLER PH, 1983, EXP BRAIN RES, V49, P381; SCHLAGREY M, 1989, EXP BRAIN RES, V76, P537, DOI 10.1007/BF00248910; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; Shadlen MN, 1996, J NEUROSCI, V16, P1486; Shadlen MN, 1998, J NEUROSCI, V18, P3870; SPARKS DL, 1990, COLD SH Q B, V55, P805; SPARKS DL, 1987, J NEUROPHYSIOL, V58, P300, DOI 10.1152/jn.1987.58.2.300; SPARKS DL, 1983, J NEUROPHYSIOL, V49, P45, DOI 10.1152/jn.1983.49.1.45; Tehovnik EJ, 1999, EUR J NEUROSCI, V11, P2431, DOI 10.1046/j.1460-9568.1999.00665.x; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575; ZOHARY E, 1994, NATURE, V370, P140, DOI 10.1038/370140a0	30	414	452	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					390	394		10.1038/35006062	http://dx.doi.org/10.1038/35006062			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746726				2022-12-28	WOS:000086119000051
J	de Man, P; Verhoeven, BAN; Verbrugh, HA; Vos, MC; van den Anker, JN				de Man, P; Verhoeven, BAN; Verbrugh, HA; Vos, MC; van den Anker, JN			An antibiotic policy to prevent emergence of resistant bacilli	LANCET			English	Article							INTENSIVE-CARE-UNIT; ENTEROBACTER-CLOACAE; INFECTION; COLONIZATION; AMPICILLIN; CEFUROXIME; CEFOTAXIME; OUTBREAK; RESTRICTION; IMPACT	Background Fear of infection in neonatal intensive care units (NICUs) often leads to early use of empiric broad-spectrum antibiotics, a strategy that selects for resistant bacteria. We investigated whether the emergence of resistant strains could be halted by modifying the empiric antibiotic regimens to remove the selective pressure that favours resistant bacteria. Methods Two identical NICUs were assigned to different empiric antibiotic regimens. On unit A, penicillin G and tobramycin were used for early-onset septicaemia, flucloxacillin and tobramycin were used for late-onset septicaemia, and no broad-spectrum beta-lactam antibiotics, such as amoxicillin and cefotaxime were used, In unit B, intravenous amoxicillin with cefotaxime was the empiric therapy. After 6 months of the study the units exchanged regimens. Rectal and respiratory cultures were taken on a weekly basis. Findings There were 436 admissions, divided equally between the two regimens (218 in each), Three neonates treated with the penicillin-tobramycin regimen became colonised with bacilli resistant to the empirical therapy used versus 41 neonates on the amoxicillin-cefotaxime regimen (p < 0.001). The relative risk for colonisation with strains resistant to the empirical therapy per 1000 patient days at risk was 18 times higher for the amoxicillin-cefotaxime regimen compared with the penicillin-tobramycin regimen (95% CI 5.6-58.0). Enterobacter cloacae was the predominant bacillus in neonates on the amoxicillin-cefotaxime regimen, whereas Escherichia coli predominated in neonates on the penicillin-tobramycin regimen. These colonisation patterns were also seen when the units exchanged regimens. Interpretation Policies regarding the empiric use of antibiotics do matter in the control of antimicrobial resistance, A regimen avoiding amoxicillin and cefotaxime restricts the resistance problem. of antimicrobial and cefotaxime.	St Franciscus Gasthuis, Dept Med Microbiol & Infect Control, NL-3004 BA Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Med Microbiol & Infect Control, Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Sophias Childrens Hosp, Dept Paediat, Rotterdam, Netherlands	Franciscus Gasthuis; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	de Man, P (corresponding author), St Franciscus Gasthuis, Dept Med Microbiol & Infect Control, POB 10900, NL-3004 BA Rotterdam, Netherlands.	peter_de_man@franciscus.nl						ACOLET D, 1994, J HOSP INFECT, V28, P273, DOI 10.1016/0195-6701(94)90091-4; ARREDONDO-GARCIA J L, 1992, Revista Latinoamericana de Microbiologia, V34, P11; BERKOWITZ FE, 1995, PEDIATR INFECT DIS J, V14, P97, DOI 10.1097/00006454-199502000-00003; BLAKEY JL, 1982, J MED MICROBIOL, V15, P519, DOI 10.1099/00222615-15-4-519; BRYAN CS, 1985, AM J DIS CHILD, V139, P1086, DOI 10.1001/archpedi.1985.02140130024022; BURMAN LG, 1993, J ANTIMICROB CHEMOTH, V31, P111, DOI 10.1093/jac/31.1.111; Gould IM, 1999, J ANTIMICROB CHEMOTH, V43, P459, DOI 10.1093/jac/43.4.459; HAERTL R, 1993, J HOSP INFECT, V25, P109, DOI 10.1016/0195-6701(93)90101-5; HAMMERSCHLAG MR, 1977, NEW ENGL J MED, V296, P1268, DOI 10.1056/NEJM197706022962206; KALENIC S, 1993, J HOSP INFECT, V23, P35, DOI 10.1016/0195-6701(93)90128-M; KAYYALI MZ, 1972, CLIN PEDIATR, V11, P422; KHADILKAR V, 1995, J PAEDIATR CHILD H, V31, P387, DOI 10.1111/j.1440-1754.1995.tb00843.x; LEDINGHAM IM, 1988, LANCET, V1, P785; MARKOWITZ SM, 1980, J INFECT DIS, V142, P106, DOI 10.1093/infdis/142.1.106; MAYHALL CG, 1980, INFECT CONT HOSP EP, V1, P239, DOI 10.1017/S019594170005308X; MODI N, 1987, ARCH DIS CHILD, V62, P148, DOI 10.1136/adc.62.2.148; NOY JH, 1974, J MED MICROBIOL, V7, P509, DOI 10.1099/00222615-7-4-509; PRICE DJE, 1970, LANCET, V2, P1213; Sanders WE, 1997, CLIN MICROBIOL REV, V10, P220, DOI 10.1128/CMR.10.2.220; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; SPRITZER R, 1990, PEDIATR INFECT DIS J, V9, P92, DOI 10.1097/00006454-199002000-00006; Toltzis P, 1998, CRIT CARE MED, V26, P1893, DOI 10.1097/00003246-199811000-00035; TULLUS K, 1989, LANCET, V1, P1405; TULLUS K, 1990, ANTIMICROB AGENTS CH, V34, P361, DOI 10.1128/AAC.34.2.361; VENEZIA RA, 1995, CLIN INFECT DIS, V21, P915, DOI 10.1093/clinids/21.4.915; VERWEIJ PE, 1995, INFECT CONT HOSP EP, V16, P25; White AC, 1997, CLIN INFECT DIS, V25, P230	27	268	274	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	2000	355	9208					973	978		10.1016/S0140-6736(00)90015-1	http://dx.doi.org/10.1016/S0140-6736(00)90015-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YH	10768436				2022-12-28	WOS:000086054000012
J	Cynader, M				Cynader, M			Neuroscience - Strengthening visual connections	SCIENCE			English	Editorial Material							CORTEX		Univ British Columbia, Brain Res Ctr, Vancouver, BC V5Z 3N9, Canada; Vancouver Hosp, Vancouver, BC V5Z 3N9, Canada	University of British Columbia; University of British Columbia	Cynader, M (corresponding author), Univ British Columbia, Brain Res Ctr, Vancouver, BC V5Z 3N9, Canada.							Bruer J. T., 1999, MYTH 1 3 YEARS; CYNADER M, 1977, NATURE, V270, P177, DOI 10.1038/270177a0; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; Trachtenberg JT, 2000, SCIENCE, V287, P2029, DOI 10.1126/science.287.5460.2029	5	6	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1943	1944		10.1126/science.287.5460.1943	http://dx.doi.org/10.1126/science.287.5460.1943			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10755946				2022-12-28	WOS:000085902800035
J	Catalanotto, C; Azzalin, G; Macino, G; Cogoni, C				Catalanotto, C; Azzalin, G; Macino, G; Cogoni, C			Transcription - Gene silencing in worms and fungi	NATURE			English	Article							PLANTS				Catalanotto, C (corresponding author), Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Sez Genet Mol, Viale Regina Elena 324, I-00161 Rome, Italy.	carlo@bce.med.uniroma1.it		CATALANOTTO, Caterina/0000-0001-6583-5170				Benfey PN, 1999, CURR BIOL, V9, pR171, DOI 10.1016/S0960-9822(99)80105-5; Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Elmayan T, 1998, PLANT CELL, V10, P1747, DOI 10.1105/tpc.10.10.1747; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; Zou C, 1998, GENE, V211, P187, DOI 10.1016/S0378-1119(98)00107-3	11	191	238	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					245	245		10.1038/35005169	http://dx.doi.org/10.1038/35005169			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749199	Bronze			2022-12-28	WOS:000086022200037
J	Packer, A; Clay, K				Packer, A; Clay, K			Soil pathogens and spatial patterns of seedling mortality in a temperate tree	NATURE			English	Article							JANZEN-CONNELL MODEL; RAIN-FOREST TREE; MOIST TROPICAL FOREST; NEOTROPICAL FOREST; SPECIES-DIVERSITY; DISTANCE; DENSITY; RECRUITMENT; MAINTENANCE; FEEDBACK	The Janzen-Connell hypothesis(1,2) proposes that host-specific, distance- and/or density-dependent predators and herbivores maintain high tree diversity in tropical forests. Negative feedback between plant and soil communities could be a more effective mechanism promoting species coexistence because soil pathogens can increase rapidly in the presence of their host(3), causing conditions unfavourable for local conspecific recruitment(4-6). Here we show that a soil pathogen leads to patterns of seedling mortality in a temperate tree (Prunus serotina) as predicted by the Janzen-Connell hypothesis. In the field, the mean distance to parent of seedling cohorts shifted away from maternal trees over a period of 3 years. Seedlings were gown in soil collected 0-5 m or 25-30 m from Prunus trees. Sterilization of soil collected beneath trees improved seedling survival relative to unsterilized soil, whereas sterilization of distant soil did not affect survival. Pythium spp., isolated from roots of dying seedlings and used to inoculate healthy seedlings, decreased survival by 65% relative to controls. Our results provide the most complete evidence that native pathogens influence tree distributions, as predicted by the Janzen-Connell hypothesis, and suggest that similar ecological mechanisms operate in tropical and temperate forests.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Packer, A (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		Clay, Keith/C-8730-2012					AUGSPURGER CK, 1984, OECOLOGIA, V61, P211, DOI 10.1007/BF00396763; AUGSPURGER CK, 1983, OIKOS, V40, P189, DOI 10.2307/3544582; Barone JA, 1998, J ANIM ECOL, V67, P400, DOI 10.1046/j.1365-2656.1998.00197.x; BECKER P, 1985, OIKOS, V44, P382, DOI 10.2307/3565778; Bever JD, 1997, J ECOL, V85, P561, DOI 10.2307/2960528; BEVER JD, 1994, ECOLOGY, V75, P1965, DOI 10.2307/1941601; BURDON JJ, 1982, ANNU REV PHYTOPATHOL, V20, P143, DOI 10.1146/annurev.py.20.090182.001043; Burdon JJ., 1987, DIS PLANT POPULATION; BURKEY TV, 1994, OECOLOGIA, V97, P533, DOI 10.1007/BF00325893; CARLISLE MJ, 1994, FUNGI; CHEN W, 1992, PHYTOPATHOLOGY, V82, P1234, DOI 10.1094/Phyto-82-1234; Cintra R, 1997, J TROP ECOL, V13, P641, DOI 10.1017/S0266467400010841; CLARK DA, 1984, AM NAT, V124, P769, DOI 10.1086/284316; CONDIT R, 1992, AM NAT, V140, P261, DOI 10.1086/285412; CONNELL J H, 1971, P298; CONNELL JH, 1984, ECOL MONOGR, V54, P141, DOI 10.2307/1942659; FLORENCE RG, 1965, ECOLOGY, V46, P52, DOI 10.2307/1935257; FOX JF, 1977, AM NAT, V111, P69, DOI 10.1086/283138; GILBERT GS, 1994, OECOLOGIA, V98, P100, DOI 10.1007/BF00326095; HUBBELL SP, 1980, OIKOS, V35, P214, DOI 10.2307/3544429; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; Mills KE, 1998, ECOLOGY, V79, P1595, DOI 10.1890/0012-9658(1998)079[1595:MODWPC]2.0.CO;2; Notman E, 1996, OECOLOGIA, V106, P221, DOI 10.1007/BF00328602; SCHUPP EW, 1992, AM NAT, V140, P526, DOI 10.1086/285426; VanderPutten WH, 1997, ECOLOGY, V78, P1785, DOI 10.1890/0012-9658(1997)078[1785:HSBPMA]2.0.CO;2; VANDERPUTTEN WH, 1993, NATURE, V362, P53; Wills C, 1997, P NATL ACAD SCI USA, V94, P1252, DOI 10.1073/pnas.94.4.1252; WOODS KD, 1979, OIKOS, V33, P31, DOI 10.2307/3544508	29	653	702	18	335	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 16	2000	404	6775					278	281		10.1038/35005072	http://dx.doi.org/10.1038/35005072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749209				2022-12-28	WOS:000086022200047
J	Sanders, J; Milne, S; Brown, P; Bell, AJ				Sanders, J; Milne, S; Brown, P; Bell, AJ			Assessment of aggression in psychiatric admissions: semistructured interview and case note survey	BRITISH MEDICAL JOURNAL			English	Article							RISK		St Lukes Hosp, Middlesbrough TS4 3AF, Cleveland, England		Milne, S (corresponding author), St Lukes Hosp, Middlesbrough TS4 3AF, Cleveland, England.							APPLEBY L, 1988, MED SCI LAW, V28, P291, DOI 10.1177/002580248802800405; Ferris LE, 1997, CAN J PSYCHIAT, V42, P1051, DOI 10.1177/070674379704201006; Reed J, 1997, BRIT J PSYCHIAT, V170, P4, DOI 10.1192/S0007125000298644; YRNE P, 1998, PSYCHIAT B, V22, P174	4	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 22	2000	320	7242					1112	1112		10.1136/bmj.320.7242.1112	http://dx.doi.org/10.1136/bmj.320.7242.1112			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	309RJ	10775220	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086782800017
J	Khatta, M; Alexander, BS; Krichten, CM; Fisher, ML; Freudenberger, R; Robinson, SW; Gottlieb, SS				Khatta, M; Alexander, BS; Krichten, CM; Fisher, ML; Freudenberger, R; Robinson, SW; Gottlieb, SS			The effect of coenzyme Q(10) in patients with congestive heart failure	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; THERAPY; UBIQUINONE	Background: Coenzyme Q(10) is commonly used to treat congestive heart failure on the basis of data from several unblinded, subjective studies. Few randomized, blinded, controlled studies have evaluated objective measures of cardiac performance. Objective: To determine the effect of coenzyme Q(10) on peak oxygen consumption, exercise duration, and ejection fraction. Design: Randomized, double-blind, controlled trial. Setting: University and Veterans Affairs hospitals. Patients: 55 patients who had congestive heart failure with New York Heart Association class ill and IV symptoms, ejection fraction less than 40%, and peak oxygen consumption less than 17.0 mL/kg per minute (or <50% of predicted) during standard therapy were randomly assigned. Forty-six patients completed the study. Intervention: Coenzyme Q(10), 200 mg/d, or placebo. Measurements: Left ventricular ejection fraction (measured by radionuclide ventriculography) and peak oxygen consumption and exercise duration (measured by a graded exercise evaluation using the Naughton protocol) with continuous metabolic monitoring. Results: Although the mean (+/-SD) serum concentration of coenzyme Q(10) increased from 0.95 +/- 0.62 mu g/mL to 2.2 +/- 1.2 mu g/mL in patients who received active treatment, ejection fraction, peak oxygen consumption, and exercise duration remained unchanged in both the coenzyme Q(10) and placebo groups. Conclusion: Coenzyme Q(10) does not affect ejection fraction, peak oxygen consumption, or exercise duration in patients with congestive heart failure receiving standard medical therapy.	Univ Maryland, Sch Med, Div Cardiol, Baltimore, MD 21201 USA; Vet Affairs Med Ctr, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gottlieb, SS (corresponding author), Univ Maryland, Sch Med, Div Cardiol, 22 S Greene St, Baltimore, MD 21201 USA.				NATIONAL INSTITUTE ON AGING [P60AG012583] Funding Source: NIH RePORTER; NIA NIH HHS [P60AG12583] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGGIO E, 1994, MOL ASPECTS MED, V15, P287, DOI 10.1016/0098-2997(94)90040-X; BLUMENTHAL JA, 1991, AM J CARDIOL, V67, P633, DOI 10.1016/0002-9149(91)90904-Y; CRANE FL, 1957, BIOCHIM BIOPHYS ACTA, V25, P220, DOI 10.1016/0006-3002(57)90457-2; EDLUND PO, 1988, J CHROMATOGR-BIOMED, V425, P87, DOI 10.1016/0378-4347(88)80009-4; FOLKERS K, 1985, P NATL ACAD SCI USA, V82, P901, DOI 10.1073/pnas.82.3.901; GREENBERG S, 1990, J CLIN PHARMACOL, V30, P596, DOI 10.1002/j.1552-4604.1990.tb01862.x; Hjalmarson A, 1999, LANCET, V353, P2001; Hofman-Bang C, 1995, J Card Fail, V1, P101, DOI 10.1016/1071-9164(95)90011-X; JUDY WV, 1986, BIOMEDICAL CLIN ASPE; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; LANGSJOEN PH, 1990, AM J CARDIOL, V65, P521, DOI 10.1016/0002-9149(90)90824-K; LANGSJOEN PH, 1985, P NATL ACAD SCI USA, V82, P4240, DOI 10.1073/pnas.82.12.4240; MARUBAYASHI S, 1984, BIOCHIM BIOPHYS ACTA, V797, P1; MORISCO C, 1993, CLIN INVESTIGATOR, V71, pS134; MORTENSEN SA, 1993, CLIN INVESTIGATOR, V71, pS116; PERMANETTER B, 1992, EUR HEART J, V13, P1528, DOI 10.1093/oxfordjournals.eurheartj.a060096; Soja AM, 1997, MOL ASPECTS MED, V18, pS159; TANAKA J, 1982, ANN THORAC SURG, V33, P145, DOI 10.1016/S0003-4975(10)61900-5; Watson PS, 1999, J AM COLL CARDIOL, V33, P1549, DOI 10.1016/S0735-1097(99)00064-9	19	105	114	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 18	2000	132	8					636	640		10.7326/0003-4819-132-8-200004180-00006	http://dx.doi.org/10.7326/0003-4819-132-8-200004180-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304RG	10766682				2022-12-28	WOS:000086497500005
J	Hunt, DL; Jaeschke, R; McKibbon, KA				Hunt, DL; Jaeschke, R; McKibbon, KA		Evidence Based Med Working Grp	Users' guides to the medical literature - XXI. Using electronic health information resources in evidence-based practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDLINE		McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Hlth Informat Res Unit, Hamilton, ON, Canada	McMaster University; McMaster University	Hunt, DL (corresponding author), Hamilton Hlth Sci Corp, Henderson Campus,711 Concess St, Hamilton, ON L8V 1C3, Canada.							FULLER J, 1999, COCHRANE LIB, P4; Greenhalgh T, 1997, BRIT MED J, V315, P180, DOI 10.1136/bmj.315.7101.180; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; HAYWARD R, 1995, JAMA-J AM MED ASSOC, V274, P70; McKibbon A., 1999, EVIDENCE BASED PRINC; MCKIBBON KA, 1999, EVIDENCE BASED MED, V6, P164; Richardson W S, 1995, ACP J Club, V123, pA12; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; WILCZYNSKI NL, 1994, P ANN S COMP APPL ME, V17, P601; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; 1997, ACP J CLUB, V126, P57	14	54	59	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1875	1879		10.1001/jama.283.14.1875	http://dx.doi.org/10.1001/jama.283.14.1875			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770150				2022-12-28	WOS:000086248600034
J	Krantz, DS; Sheps, DS; Carney, RM; Natelson, BH				Krantz, DS; Sheps, DS; Carney, RM; Natelson, BH			Effects of mental stress in patients with coronary artery disease - Evidence and clinical implications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; CARDIAC EVENTS; CARDIOVASCULAR-DISEASE; SUDDEN-DEATH; RISK FACTOR; DAILY-LIFE; ISCHEMIA; MECHANISMS; DEPRESSION; HOSTILITY		Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA; Univ Florida, Div Cardiovasc Med, Gainesville, FL USA; Washington Univ, Med Ctr, Dept Psychiat, St Louis, MO USA; Univ Med & Dent New Jersey, Dept Neurosci, Newark, NJ 07103 USA	Uniformed Services University of the Health Sciences - USA; State University System of Florida; University of Florida; Washington University (WUSTL); Rutgers State University New Brunswick; Rutgers State University Medical Center	Krantz, DS (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	dkrantz@usuhs.mil	Krantz, David S./L-5364-2015	Krantz, David/0000-0002-1671-1355	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047337] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47337] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAREFOOT JC, 1983, PSYCHOSOM MED, V45, P59, DOI 10.1097/00006842-198303000-00008; Berkman LF, 2000, AM HEART J, V139, P1; Blumenthal JA, 1997, ARCH INTERN MED, V157, P2213, DOI 10.1001/archinte.157.19.2213; BLUMENTHAL JA, 1995, CIRCULATION, V92, P2102, DOI 10.1161/01.CIR.92.8.2102; Burg MM, 1993, J AM COLL CARDIOL, V22, P440, DOI 10.1016/0735-1097(93)90048-6; CARNEY RM, 1995, ANN BEHAV MED, V17, P142, DOI 10.1007/BF02895063; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; CORDERO DL, 1995, CARDIOVASC RES, V29, P319, DOI 10.1016/S0008-6363(96)88587-7; DEMBROSKI TM, 1989, PSYCHOSOM MED, V51, P514, DOI 10.1097/00006842-198909000-00003; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; Gorkin L., 1994, SOCIAL SUPPORT CARDI, P281; Gullette ECD, 1997, JAMA-J AM MED ASSOC, V277, P1521, DOI 10.1001/jama.277.19.1521; IRONSON G, 1992, AM J CARDIOL, V70, P281, DOI 10.1016/0002-9149(92)90605-X; JAIN D, 1995, AM J CARDIOL, V76, P31, DOI 10.1016/S0002-9149(99)80796-6; Jiang W, 1996, JAMA-J AM MED ASSOC, V275, P1651, DOI 10.1001/jama.275.21.1651; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KOP WJ, 1994, PSYCHOSOM MED, V56, P281, DOI 10.1097/00006842-199407000-00001; Krantz David S., 1996, Cardiology Clinics, V14, P271; KRANTZ DS, 1984, PSYCHOL BULL, V96, P435, DOI 10.1037/0033-2909.96.3.435; Krantz DS, 1999, AM J CARDIOL, V84, P1292, DOI 10.1016/S0002-9149(99)00560-3; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; Linden W, 1996, ARCH INTERN MED, V156, P745, DOI 10.1001/archinte.156.7.745; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; *US DEP HHS, 2000, NATL HEART LUNG BLOO; VERRIER RL, 1984, ANNU REV PHYSIOL, V46, P155, DOI 10.1146/annurev.ph.46.030184.001103; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205	31	93	96	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1800	1802		10.1001/jama.283.14.1800	http://dx.doi.org/10.1001/jama.283.14.1800			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770129				2022-12-28	WOS:000086248600002
J	Shlipak, MG; Simon, JA; Vittinghoff, E; Lin, F; Barrett-Connor, E; Knopp, RH; Levy, RI; Hulley, SB				Shlipak, MG; Simon, JA; Vittinghoff, E; Lin, F; Barrett-Connor, E; Knopp, RH; Levy, RI; Hulley, SB			Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRE-BETA LIPOPROTEIN; POSTMENOPAUSAL WOMEN; LP(A) LIPOPROTEIN; ELEVATED LIPOPROTEIN(A); PLASMA LIPOPROTEIN(A); MYOCARDIAL-INFARCTION; REPLACEMENT THERAPY; LDL CHOLESTEROL; ARTERIAL-WALL; MEN	Context Lipoprotein(a) [Lp(a)] has been identified as an independent risk factor for coronary heart disease (CHD) events. However, few data exist on the clinical importance of Lp(a) lowering for CHD prevention. Hormone therapy with estrogen has been found to lower Lp(a) levels in women. Objective To determine the relationships among treatment with estrogen and progestin, serum Lp(a) levels, and subsequent CHD events in postmenopausal women. Design and Setting The Heart and Estrogen/progestin Replacement Study (HERS), a randomized, blinded, placebo-controlled secondary prevention trial conducted from January 1993 through July 1998 with a mean follow-up of 4.1 years at 20 centers. Participants A total of 2763 postmenopausal women younger than 80 years with coronary artery disease and an intact uterus. Mean age was 66.7 years. Intervention Participants were randomly assigned to receive either conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in 1 tablet daily (n = 1380), or identical placebo (n = 1383). Main Outcome Measures Lipoprotein(a) levels and CHD events (nonfatal myocardial infarction and CHD death). Results Increased baseline Lp(a) levels were associated with subsequent CHD events among women in the placebo arm. After multivariate adjustment, women in the second, third, and fourth quartiles of baseline Lp(a) level had relative hazards (RHs) (compared with the first quartile) of 1.01 (95% confidence interval [CI], 0.64-1.59), 1.31 (95% CI, 0.85-2.04), and 1.54 (95% CI, 0.99-2.39), respectively, compared with women in the lowest quartile (P for trend =.03). Treatment with estrogen and progestin reduced mean (SD) Lp(a) levels significantly (-5.8 [15] mg/dL) (-0.20 [0.53] mu mol/L) compared with placebo (0.3 [17] mg/dL) (0.01 [0.60] mu mol/L) (P<.001). In a randomized subgroup comparison, women with low baseline Lp(a) levels had less benefit from estrogen and progestin than women with high Lp(a) levels; the RH for women assigned to estrogen and progestin compared with placebo were 1.49 (95% CI, 0.97-2.26) in the lowest quartile and 1.05 (95% CI, 0.67-1.65), 0.78 (0.52-1.18), and 0.85 (0.58-1.25) in the second, third, and fourth quartiles, respectively (P for interaction trend =.03). Conclusions Our data suggest that Lp(a) is an independent risk factor for recurrent CHD in postmenopausal women and that treatment with estrogen and progestin lowers Lp(a) levels. Estrogen and progestin therapy appears to have a more favorable effect (relative to placebo) in women with high initial Lp(a) levels than in women with low levels. This apparent interaction needs confirmation in other trials.	Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; Univ Washington, Seattle, WA 98195 USA; NW Lipid Res Clin, Seattle, WA USA; Amer Home Prod, Madison, NJ USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Shlipak, MG (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	shlip@itsa.ucsf.edu						ALBERS JJ, 1975, METABOLISM, V24, P1047, DOI 10.1016/0026-0495(75)90098-0; Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; Berg K, 1997, CLIN GENET, V52, P254; BERG K, 1974, CLIN GENET, V6, P230; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; BROWN RL, 1989, APPL PSYCH MEAS, V13, P151, DOI 10.1177/014662168901300205; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; COLEMAN MP, 1992, ATHEROSCLEROSIS, V92, P177, DOI 10.1016/0021-9150(92)90276-M; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DAHLEN G, 1972, ACTA MED SCAND, P1; Darling GM, 1997, NEW ENGL J MED, V337, P595, DOI 10.1056/NEJM199708283370903; Espeland MA, 1998, CIRCULATION, V97, P979; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Haines C, 1996, ARCH INTERN MED, V156, P866, DOI 10.1001/archinte.156.8.866; Hulley S, 1999, JAMA-J AM MED ASSOC, V281, P796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; Kim CJ, 1996, ARCH INTERN MED, V156, P1693, DOI 10.1001/archinte.156.15.1693; Knopp RH, 1998, AM J CARDIOL, V82, p24U, DOI 10.1016/S0002-9149(98)00847-9; KOSTNER GM, 1989, CIRCULATION, V80, P1313, DOI 10.1161/01.CIR.80.5.1313; LOBO RA, 1994, OBSTET GYNECOL, V84, P987; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; Marcovina SM, 1998, AM J CARDIOL, V82, p57U, DOI 10.1016/S0002-9149(98)00954-0; NOMA A, 1990, ATHEROSCLEROSIS, V84, P213, DOI 10.1016/0021-9150(90)90093-X; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; REBLIN T, 1995, ATHEROSCLEROSIS, V113, P179, DOI 10.1016/0021-9150(94)05445-O; RHOADS GG, 1978, AM J EPIDEMIOL, V108, P350, DOI 10.1093/oxfordjournals.aje.a112631; RIDER AK, 1970, CIRCULATION, V42, pII10; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; SACKS FM, 1994, ARCH INTERN MED, V154, P1106, DOI 10.1001/archinte.154.10.1106; *SAS I, 1996, SAS COMP PROGR; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SOMA MR, 1993, ARCH INTERN MED, V153, P1462, DOI 10.1001/archinte.153.12.1462; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1	41	239	256	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2000	283	14					1845	1852		10.1001/jama.283.14.1845	http://dx.doi.org/10.1001/jama.283.14.1845			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300HY	10770146				2022-12-28	WOS:000086248600030
J	Ashcroft, DM; Po, ALW; Williams, HC; Griffiths, CEM				Ashcroft, DM; Po, ALW; Williams, HC; Griffiths, CEM			Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ONCE-DAILY TREATMENT; DOUBLE-BLIND; TOPICAL CALCIPOTRIOL; MC-903 OINTMENT; COMBINATION PHOTOTHERAPY; BETAMETHASONE VALERATE; CALCIUM HOMEOSTASIS; CLINICAL-TRIALS; VULGARIS; MULTICENTER	Objectives To evaluate the comparative efficacy and tolerability of topical calcipotriol in the treatment of mild to moderate chronic plaque psoriasis. Design Quantitative systematic review of randomised controlled trials. Subjects 6038 patients with plaque psoriasis reported in 37 trials. Main outcome measures Mean difference in percentage change in scores on psoriasis area and severity index, and response rate ratios for both patients' and investigators' overall assessments of marked improvement or better. Adverse effects were estimated with the rate ratio, rate difference, and number needed to treat. Results Calcipotriol was at least as effective as potent topical corticosteroids, calcitriol iol, short contact dithranol, tacalcitol, coal tar,and combined coal tar 5%, allantoin 2%, and hydrocortisone 0.5%. Calcipotriol caused significantly more skin irritation than potent topical corticosteroids (number needed to treat to harm for irritation 10, 95% confidence interval 6 to 34). Calcipotriol monotherapy also caused more irritation than calcipotriol combined with a potent topical corticosteroid (6, 4 to 8). However, the number needed to treat for dithranol to produce lesional or perilesional irritation was 4 (3 to 5). On average, treating 23 patients with short contact dithranol led to one more patient dropping out of treatment owing to adverse effects than if they were treated with calcipotriol. Conclusions Calcipotriol is an effective treatment for mild to moderate chronic plaque psoriasis, more so than calcitriol, tacalcitol, coal tar,and short contact dithranol. Only potent topical corticosteroids seem to have comparable efficacy at eight weeks. Although calcipotriol caused more skin irritation than topical corticosteroids this has to be balanced against the potential long term effects of corticosteroids, Skin irritation rarely led to withdrawal of calcipotriol treatment Longer term comparative trials of calcipotriol versus dithranol and topical corticosteroids are needed to see whether these short term benefits are mirrored by long term outcomes such as duration of remission and improvement in quality of life.	Aston Univ, Sch Life & Hlth Sci, Ctr Evidence Based Pharmacotherapy, Birmingham B4 7ET, W Midlands, England; Queens Med Ctr, Dept Dermatol, Nottingham NG7 2UH, England; Univ Manchester, Hope Hosp, Dermatol Sect, Salford M6 8HD, Lancs, England	Aston University; University of Nottingham; University of Manchester	Po, ALW (corresponding author), Aston Univ, Sch Life & Hlth Sci, Ctr Evidence Based Pharmacotherapy, Birmingham B4 7ET, W Midlands, England.	a.liwanpo@aston.ac.uk	Griffiths, Christopher E.M./P-5448-2014; Ashcroft, Darren M/G-3244-2015	Griffiths, Christopher E.M./0000-0001-5371-4427; Ashcroft, Darren M/0000-0002-2958-915X; williams, hywel/0000-0002-5646-3093				AREVALO A, 1995, J EUR ACAD DERMAT S1, V5, pS92; Ashcroft DM, 1999, BRIT J DERMATOL, V141, P185; AUSTAD J, 1997, AUST J DERMATOL S2, V38, P45; AUSTAD J, 1995, 27 NORD DERM C FINL; BAADSGAARD O, 1995, J DERMATOL TREAT, V6, P145, DOI 10.3109/09546639509097171; BAIOCCHI R, 1997, GIORN ITAL DERMAT V, V132, P139; BERARDESCA E, 1994, ACTA DERM-VENEREOL, V74, P302; BERTHJONES J, 1992, BRIT J DERMATOL, V127, P266, DOI 10.1111/j.1365-2133.1992.tb00126.x; Bourke JF, 1997, ACTA DERM-VENEREOL, V77, P228; Bourke JF, 1997, CLIN EXP DERMATOL, V22, P259, DOI 10.1046/j.1365-2230.1997.2830683.x; BOURKE JF, 1993, CLIN EXP DERMATOL, V18, P504, DOI 10.1111/j.1365-2230.1993.tb01018.x; Bourke JF, 1995, BR J DERMATOL S45, V133, P17; BRUCE S, 1994, J AM ACAD DERMATOL, V31, P755, DOI 10.1016/S0190-9622(94)70237-3; Crosti C, 1997, INT J DERMATOL, V36, P537; CUNLIFFE WJ, 1992, J AM ACAD DERMATOL, V26, P736, DOI 10.1016/0190-9622(92)70103-M; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESIMONE C, 1993, GIORN ITAL DERMAT V, V128, pRC1; DUBERTRET L, 1992, J AM ACAD DERMATOL, V27, P983, DOI 10.1016/0190-9622(92)70299-U; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Grattan CEH, 1997, J DERMATOL TREAT, V8, P11, DOI 10.3109/09546639709160502; GRIFFITHS WAD, 1991, DAIV CALC TOT NEW TR; Guzzo C, 1996, J AM ACAD DERMATOL, V34, P429, DOI 10.1016/S0190-9622(96)90434-X; Harrington CI, 1996, J EUR ACAD DERMATOL, V6, P152; HIGHTON A, 1995, J AM ACAD DERMATOL, V32, P67, DOI 10.1016/0190-9622(95)90186-8; HUTCHINSON PE, 1992, BR J DERMATOL S40, V127, P17; JURGENSEN HJ, 1991, 2 C EUR AC DERM VEN; Kang S, 1998, BRIT J DERMATOL, V138, P77; KATZ HI, 1996, 54 ANN M AM AC DERM, pP293; KERSCHER M, 1993, LANCET, V342, P923, DOI 10.1016/0140-6736(93)91968-R; KERSCHER M, 1996, J INVEST DERMATOL S, V1, P107; KERSCHER M, 1994, AKTUEL DERMATOL, V20, P151; KIM JY, 1994, KOREAN J DERMATOLOGY, V32, P1054; Kose O, 1997, J DERMATOL TREAT, V8, P287, DOI 10.3109/09546639709160537; Kragballe K, 1998, BRIT J DERMATOL, V139, P649; KRAGBALLE K, 1990, DERMATOLOGICA, V181, P211, DOI 10.1159/000247926; KRAGBALLE K, 1989, ARCH DERMATOL, V125, P1647, DOI 10.1001/archderm.125.12.1647; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; KRAGBALLE K, 1988, BRIT J DERMATOL, V119, P223, DOI 10.1111/j.1365-2133.1988.tb03204.x; Landi G, 1993, 3 C EUR AC DERM VEN, P199; LANDI G, 1993, GIORN ITAL DERMAT V, V128, pR89; Lebwohl M, 1996, J AM ACAD DERMATOL, V35, P268, DOI 10.1016/S0190-9622(96)90349-7; Lehmann P, 1997, J AM ACAD DERMATOL, V36, P501, DOI 10.1016/S0190-9622(97)80250-2; Lister RK, 1997, BR J DERMATOL S50, V137, P17; MALLETT R B, 1990, British Journal of Dermatology, V123, P837; Medansky RS, 1996, J GERIATRIC DERMATOL, V4, P20; MEYRAT R, 1996, ARS MED, V20, P1218; Molin L, 1997, BRIT J DERMATOL, V136, P89, DOI 10.1111/j.1365-2133.1997.tb08752.x; MOLIN L, 1993, 2 INT S CALC MON; MUNRO CS, 1996, J INVEST DERMATOL, V1, P111; Nevitt GJ, 1996, BRIT J DERMATOL, V135, P533, DOI 10.1046/j.1365-2133.1996.d01-1035.x; Oranje AP, 1997, J AM ACAD DERMATOL, V36, P203, DOI 10.1016/S0190-9622(97)70281-0; Ortonne J-P, 1995, NOUV DERMATOL, V14, P746; Pariser DM, 1996, ARCH DERMATOL, V132, P1527, DOI 10.1001/archderm.132.12.1527; Pinheiro N, 1997, BRIT J CLIN PRACT, V51, P16; PLOTT RT, 54 ANN M AM AC DERM, V996, pP317; Po ALW, 1997, BRIT MED J, V315, P1565, DOI 10.1136/bmj.315.7122.1565; Poyner T., 1997, J DERMATOLOGICAL TRE, V8, P27; REA JN, 1976, BRIT J PREV SOC MED, V30, P107; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P177; Ruzicka T, 1998, BRIT J DERMATOL, V138, P254; SCARPA C, 1994, ACTA DERM-VENEREOL, V74, P47; SCHWARTZEL E, 1996, 54 ANN M AM AC DERM, pP287; STABERG B, 1989, ACTA DERM-VENEREOL, V69, P147; THAM SN, 1994, BRIT J DERMATOL, V131, P673, DOI 10.1111/j.1365-2133.1994.tb04981.x; Van de Kerkhof PC, 1995, J EUR ACAD DERMAT S1, V5, pS184; VanderVleuten CJM, 1995, EUR J DERMATOL, V5, P676; Veien NK, 1997, BRIT J DERMATOL, V137, P581, DOI 10.1111/j.1365-2133.1997.tb03790.x; VLADIMIROV VV, 1994, SKIN THERAPY UPDATE, P219; Wall ARJ, 1998, BRIT J DERMATOL, V139, P1005; Wehr R., 1992, Skin Pharmacology, V5, P206; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105	71	79	88	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2000	320	7240					963	967		10.1136/bmj.320.7240.963	http://dx.doi.org/10.1136/bmj.320.7240.963			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10753146	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086453100019
J	Spence, SA; Crimlisk, HL; Cope, H; Ron, MA; Grasby, PM				Spence, SA; Crimlisk, HL; Cope, H; Ron, MA; Grasby, PM			Discrete neurophysiological correlates in prefrontal cortex during hysterical and feigned disorder of movement	LANCET			English	Article								The clinical distinction between hysterical symptoms and those that are feigned awaits objective validation. We used functional neuroimaging to examine the neural correlates of these two disorders.	Inst Neurol, London WC1N 3BG, England; Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England; New York Presbyterian Hosp, Cornell Med Ctr, Dept Psychiat, Funct Neuroimaging Lab, New York, NY 10021 USA	University of London; University College London; Imperial College London; Cornell University; NewYork-Presbyterian Hospital	Spence, SA (corresponding author), New York Presbyterian Hosp, Cornell Med Ctr, Dept Psychiat, Funct Neuroimaging Lab, Box 140, New York, NY 10021 USA.	sean@hanazono.med.cornell.edu	Spence, Sean A/A-6218-2008	Crimlisk, Helen/0000-0003-0448-4850	Multiple Sclerosis Society [491] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Merskey H., 1995, ANAL HYSTERIA; Spence S A, 1999, Cogn Neuropsychiatry, V4, P203; Spence SA, 1998, BRIT J PSYCHIAT, V172, P316, DOI 10.1192/bjp.172.4.316	4	195	196	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	2000	355	9211					1243	1244		10.1016/S0140-6736(00)02096-1	http://dx.doi.org/10.1016/S0140-6736(00)02096-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303VX	10770312				2022-12-28	WOS:000086448000019
J	Mushotzky, RF; Cowie, LL; Barger, AJ; Arnaud, KA				Mushotzky, RF; Cowie, LL; Barger, AJ; Arnaud, KA			Resolving the extragalactic hard X-ray background	NATURE			English	Article							ROSAT DEEP SURVEY; N-LOG S; FAINT GALAXIES; LOCKMAN FIELD; HIGH-REDSHIFT; RADIO-SOURCES; SPECTRUM; ASCA; IDENTIFICATION; SPECTROSCOPY	The origin of the hard (2-10 keV) X-ray background has been a mystery for over 35 years. Most of the soft X-ray background has been resolved into individual sources (mainly quasars), but these sources do not have the spectral energy distribution required to match the spectrum of the X-ray background as a whole. Here we report the results of a deep survey, using the Chandra satellite, in which the detected hard X-ray sources account for at least 75 per cent of the hard X-ray background. The mean X-ray spectral energy distribution of these sources is in good agreement with that of the background. Moreover, most of those hard X-ray sources are associated unambiguously with either the nuclei of otherwise normal bright galaxies, or with optically faint sources. The latter could be active nuclei in dust-enshrouded galaxies or a population of quasars at extremely high redshift.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Maryland, Dept Astron, College Pk, MD 20742 USA	University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University System of Maryland; University of Maryland College Park	Cowie, LL (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.		Mushotzky, Richard/AAW-9465-2021	Mushotzky, Richard/0000-0002-7962-5446; Cowie, Lennox/0000-0002-6319-1575; Barger, Amy/0000-0002-3306-1606				ALLEN SW, 1999, IN PRESS MON NOT R A; Almaini O, 1996, MON NOT R ASTRON SOC, V282, P295, DOI 10.1093/mnras/282.1.295; Barger AJ, 1999, ASTROPHYS J, V518, pL5, DOI 10.1086/312054; Barger AJ, 1998, NATURE, V394, P248, DOI 10.1038/28338; Cagnoni I, 1998, ASTROPHYS J, V493, P54, DOI 10.1086/305097; Chen LW, 1997, MON NOT R ASTRON SOC, V285, P449, DOI 10.1093/mnras/285.3.449; COMASTRI A, 1995, ASTRON ASTROPHYS, V296, P1; Cowie LL, 1996, ASTRON J, V112, P839, DOI 10.1086/118058; Di Matteo T, 1999, ASTROPHYS J, V527, pL21, DOI 10.1086/312387; Fiore F, 1999, MON NOT R ASTRON SOC, V306, pL55, DOI 10.1046/j.1365-8711.1999.02795.x; GENDREAU KC, 1995, PUBL ASTRON SOC JPN, V47, pL5; GIACCONI R, 1962, PHYS REV LETT, V9, P439, DOI 10.1103/PhysRevLett.9.439; Gilli R, 1999, ASTRON ASTROPHYS, V347, P424; Gunn K. F., 1999, ASTROPH9909089 ASTROPH9909089; GUNN KF, 1999, UNPUB MON NOT R ASTR; Haiman Z, 1999, ASTROPHYS J, V521, pL9, DOI 10.1086/312177; Hasinger G, 1998, ASTRON ASTROPHYS, V329, P482; Hughes DH, 1998, NATURE, V394, P241, DOI 10.1038/28328; ISHISAKI Y, UNPUB ASTROPHYS J; LILLY SJ, 1991, ASTROPHYS J, V369, P79, DOI 10.1086/169740; MADAU P, 1994, MON NOT R ASTRON SOC, V270, pL17, DOI 10.1093/mnras/270.1.L17; MARSHALL FE, 1980, ASTROPHYS J, V235, P4, DOI 10.1086/157601; MATHER JC, 1994, ASTROPHYS J, V420, P439, DOI 10.1086/173574; MATT G, 1994, MON NOT R ASTRON SOC, V267, P187, DOI 10.1093/mnras/267.1.187; Miyaji T, 1998, ASTRON ASTROPHYS, V334, pL13; MIYAJI T, 1999, IN PRESS ASTRON ASTR; Moran EC, 1996, ASTROPHYS J, V461, P127, DOI 10.1086/177042; MURDOCH HS, 1973, ASTROPHYS J, V183, P1, DOI 10.1086/152202; PICCINOTTI G, 1982, ASTROPHYS J, V253, P485, DOI 10.1086/159651; Schmidt M, 1998, ASTRON ASTROPHYS, V329, P495; SCHMIDT M, 1999, HIGHLIGHTS XRAY ASTR; SETTI G, 1989, ASTRON ASTROPHYS, V224, pL21; Smit MF, 1996, NEPHROLOGY, V2, P355, DOI 10.1111/j.1440-1797.1996.tb00113.x; SONGAILA A, 1994, ASTROPHYS J SUPPL S, V94, P461, DOI 10.1086/192080; Ueda Y, 1999, ASTROPHYS J, V524, pL11, DOI 10.1086/312300; Ueda Y, 1998, NATURE, V391, P866, DOI 10.1038/36047; Ueda Y, 1999, ASTROPHYS J, V518, P656, DOI 10.1086/307291; Vecchi A, 1999, ASTRON ASTROPHYS, V349, pL73; WEISSKOPF MC, 1999, P NATO ASI NEUTR STA; WILSON GW, UNPUB ASTROPHYS J; WINDHORST RA, 1995, NATURE, V375, P471, DOI 10.1038/375471a0; WRIGHT EL, 1994, ASTROPHYS J, V420, P450, DOI 10.1086/173576; ZDZIARSKI AA, 1995, ASTROPHYS J, V438, pL63, DOI 10.1086/187716	44	414	414	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					459	464		10.1038/35006564	http://dx.doi.org/10.1038/35006564			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10761906	Green Submitted			2022-12-28	WOS:000086257700037
J	Ketting, RF; Plasterk, RHA				Ketting, RF; Plasterk, RHA			A genetic link between co-suppression and RNA interference in C-elegans	NATURE			English	Article							CAENORHABDITIS-ELEGANS; TRANSGENIC PLANTS; EXPRESSION; PETUNIA; METHYLATION; GLD-1; VIRUS; DNA	Originally discovered in plants(1,2), the phenomenon of co-suppression by transgenic DNA has since been observed in many organisms from fungi(3) to animals(4-7): introduction of transgenic copies of a gene results in reduced expression of the transgene as well as the endogenous gene. The effect depends on sequence identity between transgene and endogenous gene. Some cases of cosuppression resemble RNA interference (the experimental silencing of genes by the introduction of double-stranded RNA)(8), as RNA seems to be both an important initiator and a target in these processes(9-13). Here we show that co-suppression in Caenorhabditis elegans is also probably mediated by RNA molecules. Both RNA interference(14,15) and co-suppression(16) have been implicated in the silencing of transposons. We now report that mutants of C. elegans that are defective in transposon silencing and RNA interference (mut-2, mut-7, mut-8 and mut-9) are in addition resistant to co-suppression. This indicates that RNA interference and co-suppression in C. elegans may be mediated at least in part by the same molecular machinery, possibly through RNA-guided degradation of messenger RNA molecules.	Netherlands Canc Inst, Div Mol Biol, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Plasterk, RHA (corresponding author), Ctr Biomed Genet, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	plasterk@niob.know.nl		Ketting, Rene/0000-0001-6161-5621				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRANCIS R, 1995, GENETICS, V139, P579; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Grant SR, 1999, CELL, V96, P303, DOI 10.1016/S0092-8674(00)80541-3; INGELBRECHT I, 1994, P NATL ACAD SCI USA, V91, P10502, DOI 10.1073/pnas.91.22.10502; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Jones AL, 1998, EMBO J, V17, P6385, DOI 10.1093/emboj/17.21.6385; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Jorgensen RA, 1999, TRENDS GENET, V15, P11, DOI 10.1016/S0168-9525(98)01651-5; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mette MF, 1999, EMBO J, V18, P241, DOI 10.1093/emboj/18.1.241; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; MORI I, 1988, GENETICS, V120, P397; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Pal-Bhadra M, 1999, CELL, V99, P35, DOI 10.1016/S0092-8674(00)80060-4; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481	30	163	199	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	2000	404	6775					296	298		10.1038/35005113	http://dx.doi.org/10.1038/35005113			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296JX	10749214				2022-12-28	WOS:000086022200052
J	Frank, C; Mohamed, MK; Strickland, GT; Lavanchy, D; Arthur, RR; Magder, LS; El Khoby, T; Abdel-Wahab, Y; Ohn, EA; Anwar, W; Sallam, I				Frank, C; Mohamed, MK; Strickland, GT; Lavanchy, D; Arthur, RR; Magder, LS; El Khoby, T; Abdel-Wahab, Y; Ohn, EA; Anwar, W; Sallam, I			The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt	LANCET			English	Article							HIGH SEROPREVALENCE; BLOOD-DONORS; B INFECTION; SCHISTOSOMIASIS; PREVALENCE; GENOTYPES; REGIONS	Background The population of Egypt has a heavy burden of liver disease, mostly due to chronic infection with hepatitis C virus (HCV). Overall prevalence of antibody to HCV in the general population is around 15-20%. The risk factor for HCV transmission that specifically sets Egypt apart from other countries is a personal history of parenteral antischistosomal therapy (PAT). A review of the Egyptian PAT mass-treatment campaigns, discontinued only in the 1980s, show a very high potential for transmission of blood-borne pathogens. We examine the relative importance of PAT in the spread of HCV in Egypt. Methods The degree of exposure to PAT by cohort was estimated from 1961-86 Ministry of Health data. A cohort-specific exposure index for PAT was calculated and compared with cohort-specific HCV prevalence rates in four regions. Findings HCV prevalence was calculated for 8499 Egyptians aged 10-50 years. A significant association between seroprevalence of antibodies to HCV and the exposure index (1.31 [95% CI 1.08-1.59]; p=0.007) was identified across four different regions. In all regions cohort-specific HCV prevalence was lowest in children and young adults than in older cohorts. These lower prevalence rates coincided with the gradual and final replacement of PAT with oral antischistosomal drugs at different points in time in the four regions. Interpretation The data suggest that PAT had a major role in the spread of HCV throughout Egypt. This intensive transmission established a large reservoir of chronic HCV infection, responsible for the high prevalence of HCV infection and current high rates of transmission. Egypt's mass campaigns of PAT may represent the world's largest iatrogenic transmission of blood-borne pathogens.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Ain Shams Univ, Fac Med, Dept Community Environm & Occupat Med, Cairo, Egypt; WHO, Div Communicable Dis Surveillance & Response, CH-1211 Geneva, Switzerland; Egyptian Minist Hlth & Populat, Cairo, Egypt	University System of Maryland; University of Maryland Baltimore; Egyptian Knowledge Bank (EKB); Ain Shams University; World Health Organization; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt	Strickland, GT (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA.		mohamed, mostafa/AFE-7371-2022	mohamed, mostafa/0000-0002-1421-2667; Frank, Christina/0000-0001-6776-8450				ABDALLAH A, 1972, SCHISTOWP7241 WHO; ABDELWAHAB MF, 1994, AM J TROP MED HYG, V51, P563, DOI 10.4269/ajtmh.1994.51.563; Arthur R. R., 1997, T R SOC TROP MED HYG, V91, P121; *CENTR AG PUBL MOB, 1993, AR REP EG STAT YB 19; DARWISH MA, 1993, AM J TROP MED HYG, V49, P440, DOI 10.4269/ajtmh.1993.49.440; Darwish MA, 1996, AM J TROP MED HYG, V54, P554, DOI 10.4269/ajtmh.1996.54.554; Davis A., 1993, Human schistosomiasis., P367; DEELDER AM, 1990, LANCET, V335, P724, DOI 10.1016/0140-6736(90)90838-V; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; ELGOHARY A, 1995, ACTA TROP, V59, P155, DOI 10.1016/0001-706X(95)00075-P; ELKHOBY T, IN PRESS AM J TROP M; ElSayed HF, 1997, ACTA TROP, V68, P229, DOI 10.1016/S0001-706X(97)00097-1; ElSayed NM, 1996, AM J TROP MED HYG, V55, P179, DOI 10.4269/ajtmh.1996.55.179; FARGHALY AG, 1993, EGYPT PUBL HLTH ASS, V68, P63; GHAFFAR YA, 1991, AM J TROP MED HYG, V45, P743, DOI 10.4269/ajtmh.1991.45.743; HYAMS KC, 1987, J MED VIROL, V23, P109, DOI 10.1002/jmv.1890230203; MADWAR MA, 1989, T ROY SOC TROP MED H, V83, P233, DOI 10.1016/0035-9203(89)90657-3; MAEGRAITH BG, 1964, TREATMENT BILHARZIAS; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; MELLOR J, 1995, J GEN VIROL, V76, P2493, DOI 10.1099/0022-1317-76-10-2493; MOHAMED MK, 1996, EGYPT PUBL HLTH ASS, V71, P79; MOHAMED MK, 1996, EGYPT PUBL HLTH ASS, V71, P113; Quinti I, 1995, ZBL BAKT-INT J MED M, V283, P239; Quinti I, 1997, DIGEST DIS SCI, V42, P2017, DOI 10.1023/A:1018897813268; SHERIF MM, 1985, J MED VIROL, V15, P129, DOI 10.1002/jmv.1890150205; World Health Organization, 1993, WHO TECHN REP SER	26	745	768	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					887	891		10.1016/S0140-6736(99)06527-7	http://dx.doi.org/10.1016/S0140-6736(99)06527-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752705				2022-12-28	WOS:000085896000011
J	Green, A; Brutti, G; Patterson, CC; Dahlquist, G; Soltesz, G; Green, A; Schober, E; Weets, I; Vandevalle, C; Gorus, F; Coeckelberghs, M; Du Caju, M; Christov, V; Tzaneva, V; Iotova, V; Roglic, G; Vavrinec, J; Olsen, BS; Svendsen, AJ; Kreutzfeldt, J; Lund, E; Poodar, T; Tuomilehto, J; Karvonen, M; Levy-Marchal, C; Czernichow, P; Doutreix, J; Giani, G; Neu, A; Bartsocas, C; Kassiou, K; Dacou-Voutetaki, C; Kafourou, AC; Al-Qadreh, A; Karagianni, C; Papazoglou, N; Soltesz, G; Thorsson, AV; Laron, Z; Gordon, O; Albag, Y; Shamis, I; Chiumello, G; Pozzilli, P; Visalli, N; Sebastiani, L; Marietti, G; Buzzetti, R; Songini, M; Casu, A; Marinaro, A; Ricciardi, R; Zedda, MA; Milia, A; Purrello, F; Arpi, M; Fichera, G; Mancuso, M; Lucenti, C; Brigis, G; Urbonaite, B; De Beaufort, C; Kocova, M; Reeser, M; Joner, G; Woznicka, D; Szybinski, Z; Jarosz-Chobot, P; Kinaiska, I; Abreu, S; Menezes, C; Pina, EA; Ionescu-Tirgoviste, C; Michalkova, D; Hlava, P; Mikulecky, M; Cernay, J; Krzisnik, C; Battelino, T; Bratina-Ursic, N; Goday, A; Dahlquist, G; Schonle, E; Patterson, C; Greenlees, R; Carson, D; Hadden, D; Bingley, P; Raymond, N; McKinney, P; Bodansky, H; Stephenson, C				Green, A; Brutti, G; Patterson, CC; Dahlquist, G; Soltesz, G; Green, A; Schober, E; Weets, I; Vandevalle, C; Gorus, F; Coeckelberghs, M; Du Caju, M; Christov, V; Tzaneva, V; Iotova, V; Roglic, G; Vavrinec, J; Olsen, BS; Svendsen, AJ; Kreutzfeldt, J; Lund, E; Poodar, T; Tuomilehto, J; Karvonen, M; Levy-Marchal, C; Czernichow, P; Doutreix, J; Giani, G; Neu, A; Bartsocas, C; Kassiou, K; Dacou-Voutetaki, C; Kafourou, AC; Al-Qadreh, A; Karagianni, C; Papazoglou, N; Soltesz, G; Thorsson, AV; Laron, Z; Gordon, O; Albag, Y; Shamis, I; Chiumello, G; Pozzilli, P; Visalli, N; Sebastiani, L; Marietti, G; Buzzetti, R; Songini, M; Casu, A; Marinaro, A; Ricciardi, R; Zedda, MA; Milia, A; Purrello, F; Arpi, M; Fichera, G; Mancuso, M; Lucenti, C; Brigis, G; Urbonaite, B; De Beaufort, C; Kocova, M; Reeser, M; Joner, G; Woznicka, D; Szybinski, Z; Jarosz-Chobot, P; Kinaiska, I; Abreu, S; Menezes, C; Pina, EA; Ionescu-Tirgoviste, C; Michalkova, D; Hlava, P; Mikulecky, M; Cernay, J; Krzisnik, C; Battelino, T; Bratina-Ursic, N; Goday, A; Dahlquist, G; Schonle, E; Patterson, C; Greenlees, R; Carson, D; Hadden, D; Bingley, P; Raymond, N; McKinney, P; Bodansky, H; Stephenson, C		EURODIAB ACE Study Grp	Variation and trends in incidence of childhood diabetes in Europe	LANCET			English	Article							RISING INCIDENCE; INCREASED RISK; MELLITUS; IDDM; CONCORDANCE; CHILDREN; FINLAND; EVENTS; TWINS	Background To study the epidemiology of childhood-onset type 1 insulin-dependent diabetes in Europe, the EURODIAB collaborative group established in 1988 prospective geographically-defined registers of new cases diagnosed under 15 years of age. This report is based on 16 362 cases registered during the period 1989-94 by 44 centres representing most European countries and Israel and covering a population of about 28 million children. Methods Multiple sources of ascertainment were used in most centres to Validate the completeness of registration by the capture-recapture method. Trends in incidence during the period were analysed by Poisson regression, the data from centres within each country being pooled. Findings The standardised average annual incidence rate during the period 1989-94 ranged from 3.2 cases per 100 000 per year in the Former Yugoslav Republic of Macedonia to 40.2 cases per 100 000 per year in two regions of Finland. By pooling over all centres, the annual rate of increase in incidence was 3.4% (95% CI 2.5-4.4%), but in some central European countries it was more rapid than this. Pooled over centres and sexes, the rates of increase were 6.3% (4.1-8.5%) for children aged 0-4 years, 3.1% (1.5-4.8%) for 5-9 years, and 2.4% (1.0-3.8%) for 10-14 years. Interpretation The results confirm a very wide range of incidence rates within Europe and show that the increase in incidence during the period varied from country to country. The rapid rate of increase in children aged under 5 years is of particular concern.	Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland; Umea Univ, Dept Clin Sci, S-90187 Umea, Sweden; Univ Pecs, Dept Pediat, Pecs, Hungary; Univ Aarhus, Dept Epidemiol & Social Med, DK-8000 Aarhus C, Denmark	Queens University Belfast; Umea University; University of Pecs; Aarhus University	Patterson, CC (corresponding author), Queens Univ Belfast, Royal Victoria Hosp, Dept Epidemiol & Publ Hlth, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.		Pozzilli, Paolo/A-5235-2010; de Beaufort, Carine/AAJ-8063-2021; Brigis, Girts/K-5435-2013; Christov, Valerij/P-6056-2019; Purrello, Francesco/K-9721-2016; Casu, Anna/S-1914-2017	de Beaufort, Carine/0000-0003-4310-6799; Brigis, Girts/0000-0003-3296-4173; Purrello, Francesco/0000-0003-3313-8543; Casu, Anna/0000-0001-6924-0617; Weets, Ilse/0000-0002-9007-5203; Gorus, Frans/0000-0002-9007-6177				BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BISHOP YMM, 1975, ESTIMATING SIZE CLOS; BLOM L, 1992, DIABETOLOGIA, V35, P528, DOI 10.1007/BF00400480; CAVALLISFORZA LL, 1993, EUR J HUM GENET, V1, P3; Dahlquist GG, 1997, ANN MED, V29, P413, DOI 10.3109/07853899708999371; DAHLQUIST GG, 1995, DIABETES, V44, P408, DOI 10.2337/diabetes.44.4.408; Gardner SG, 1997, BRIT MED J, V315, P713, DOI 10.1136/bmj.315.7110.713; GORSUCH AN, 1981, LANCET, V2, P1363; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; GREEN A, 1997, TXB DIABETES; HYOTY H, 1995, DIABETES, V44, P652, DOI 10.2337/diabetes.44.6.652; JOHANSSON C, 1994, DIABETOLOGIA, V37, P91; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; KYVIK KO, 1995, BRIT MED J, V311, P913; LESLIE RDG, 1994, DIABETES, V43, P843, DOI 10.2337/diabetes.43.7.843; LESLIE RDG, 1992, EPIDEMIOLOGY ETIOLOG; LEVYMARCHAL C, 1995, DIABETOLOGIA, V38, P823, DOI 10.1007/s001250050359; STONE RA, 1990, DIABETES, V39, P858; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984	20	571	583	0	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					873	876						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294DM	10752702				2022-12-28	WOS:000085896000008
J	Hicks, D				Hicks, D			Is there a case for school-based screening for sexually transmitted diseases?	LANCET			English	Editorial Material									Royal Hallamshire Hosp, Dept Genitourinary Med, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield	Hicks, D (corresponding author), Royal Hallamshire Hosp, Dept Genitourinary Med, Sheffield S10 2JF, S Yorkshire, England.							Cohen DA, 1999, PEDIATRICS, V104, P1281, DOI 10.1542/peds.104.6.1281; GARLICK R, 1993, PUBLIC HEALTH, V107, P135, DOI 10.1016/S0033-3506(05)80411-1; Lacey CJN, 1997, BRIT MED J, V314, P1715, DOI 10.1136/bmj.314.7096.1715; *OFF NAT STAT, 1999, AB STAT 1998; *SOC EXCL UN, 1999, CN4342 SOC EXCL UN	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 11	2000	355	9207					864	864		10.1016/S0140-6736(00)90030-8	http://dx.doi.org/10.1016/S0140-6736(00)90030-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	294DM	10752700				2022-12-28	WOS:000085896000006
J	Richards, LJ; Wall, SN				Richards, LJ; Wall, SN			Iraqi medical education under the intellectual embargo	LANCET			English	Editorial Material									Univ Chicago, Pritzker Sch Med, Dept Pediat, Chicago, IL 60637 USA	University of Chicago	Richards, LJ (corresponding author), 1 Main St,Apt 7L, Brooklyn, NY 11201 USA.							Hoskins E., 2000, WAR PUBLIC HLTH, P254; RICHARDS L, 1999, LIVING SANCTIONS INT; RICHARDS L, 1999, CHILD MATERNAL HLTH; *UN, 1999, S1999356 UN; *UN COORD HUM ASS, 1999, SPEC TOP SOC COND IR; *UN SEC COUNC, 1999, S1999896 UN SEC COUN; *UNICEF, 1998, SIT AN CHILDR WOM IR; United Nations Development Program, 1990, HUM DEV REP 1990, P10; 2000, US POST OFFICE INT M, P581	9	24	24	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1093	1094		10.1016/S0140-6736(00)02049-3	http://dx.doi.org/10.1016/S0140-6736(00)02049-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10752738				2022-12-28	WOS:000086380800042
